item: #1 of 1356
          id: skin-100
      author: Weber, T M; Arrowitz, C E; Jiang, L I; Qian, K; Filbry, A
       title: Efficacy of an Ointment Body Spray to Improve the Appearance of Dry, Ashy Skin and Alleviate Moderate to Severe Dryness on the Heel
        date: 2017-10-27
       words: 603
      flesch: 50
     summary: Wk 2 Treated Untreated N=31 C o rn eo m et er U n it s Skin Hydration a,c b,c OBS=Ointment Body Spray ap<0.05 vs Baseline bp<0.001 vs Baseline cp<0.05 vs Control 5.7 4.3 3.4 5.8 5.8 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 Ashen Appearance M ea n C lin ic al G ra d in g S co re s a,b a,b a,b a,b 5.7 4.8 4.1 5.7 5.9 5.9 a,b a,b Dryness 5.5 4.1 3.1 5.5 5.6 5.6 Flaking N=31 ap<0.001 vs Baseline bp<0.001 vs Control Treated Untreated 0 1 2 3 4 5 6 7 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 M ea n C lin ic al G ra d in g S co re 0 1 2 3 4 5 6 7 Scaling Dryness Cracking 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 OBS AHO a a a a a a a a a a a a a a a a a a a a a a a a Roughness N=18ap=0.001 OBS Significantly Improved Skin Hydration of Dry Skin Compared with Baseline and Untreated Skin 19.6 23.5 24.9 20.4 20.1
    keywords: baseline; day
       cache: skin-100.pdf
  plain text: skin-100.txt

        item: #2 of 1356
          id: skin-1000
      author: Del Rosso, James Q; Gold, Linda Stein; Kircik, Leon; Bhatia, Neal D; Sadick, Neil; Zirwas, Matthew; Lain, Edward; Stuart, Iain
       title: Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies
        date: 2020-09-02
       words: 3476
      flesch: 42
     summary: Summary Efficacy Summary • FMX103 1.5% demonstrated efficacy over vehicle foam in treating papulopustular rosacea in a pooled population of ~1500 subjects, with effects being observed as early as 4 weeks into treatment • Sub-analyses were performed on the integrated data set to characterize the efficacy of FMX103 1.5% in treating papulopustular rosacea in predefined subgroups of subjects – FMX103 1.5% demonstrated significant efficacy benefits in treating papulopustular rosacea in subgroups of subjects that had either moderate (IGA=3) or severe (IGA=4) disease severity at baseline, with a more pronounced effect in the severe subpopulation • Findings from this integrated efficacy analysis are thus consistent with those from the individual phase 3 studies, both of which achieved statistically significant differences for all primary efficacy endpoints and further demonstrated significant differences as early as 4 weeks into treatment Safety Summary • FMX103 1.5% was generally safe and well tolerated • 341 (22.4%) subjects reported a TEAE during the 2 identical double-blind Phase 3 studies – In general, no differences were observed between treatment groups in the incidence of TEAEs – The most frequently reported TEAEs for FMX103 1.5% vs vehicle, respectively, were viral upper respiratory tract infection (2.4% vs 2.3%), upper respiratory tract infection (1.9% vs 2.5%), and headache (1.4% vs 1.9%) – The majority of TEAEs reported were mild in severity (overall 68%) – 7 subjects reported severe TEAEs; all were considered to be unrelated to treatment, and were similar between treatment groups • 219 (21.7) 122 (23.8) 341 (22.4) Number of TEAEs 350 184 534 Subjects with any serious TEAE, n(%) 3 (0.3) 5 (1.0) 8 (0.5) Number of serious TEAEs 8a 9b 17 Subjects with any treatment-related TEAE, n(%) 3 (0.3) 5 (1.0) 8 (0.5) Number of treatment-related TEAEs 24c 17d 41 Subjects with any TEAE leading to discontinuation, n(%) 7 (0.7) 2 (0.4) 9 (0.6) Number of TEAEs leading to study discontinuation 8e 2f 10 aNausea, chest discomfort, fatigue, seasonal allergy, dehydration, syncope, dyspnea, hypertension bGastrointestinal hemorrhage, chest pain, pyrexia, dyspnea, asthma, hypertension, myocardial infarction, tachycardia cPruritis, rash, dermatitis, dermatitis contact, hair color changes, nail discoloration, skin hyperpigmentation, application site pain, application site erythema, facial pain, nodule, migraine, dizziness, dysgeusia, aphthous ulcer, cheilitis, eye irritation, ophthalmic herpes simplex, sunburn dNail discoloration, rosacea, skin exfoliation, application site pain, facial pain, application site pruritis, headache, cellulitis, skin cancer, urine odor abnormal ePruritis, dermal cyst, dermatitis, telangiectasia, influenza, urinary tract infection, bladder mass fRash pustular, myocardial infarction • The incidence rate of the most frequently reported TEAEs (≥1% in any group) was similar between treatment groups (Table 3)
    keywords: baseline; efficacy; figure; fmx103; foam; subjects; teaes; treatment; vehicle; week
       cache: skin-1000.pdf
  plain text: skin-1000.txt

        item: #3 of 1356
          id: skin-1001
      author: Del Rosso, James Q; Jackson, Mark; Johnson, Sandra; Harvey, Alison; Chavda, Rajeev
       title: Effect of Combination Therapy on Visible/Non-Visible Symptoms, and Disease Burden Associated with Severe Rosacea: Results from A Post-Hoc Analysis of A Randomized Controlled Trial
        date: 2020-09-02
       words: 1684
      flesch: 52
     summary: [Figure 2] • Impact of baseline lesion count, previous oral and/or topical treatment, and disease duration on efficacy of combination therapy • At week 12, there was a significant and strong correlation (-0.727; P=.000) between lesion counts at baseline and absolute change in lesion counts for the combined treatment arms. • Impact of changes in the visible and nonvisible symptoms of rosacea on Dermatology Life Quality Index (DLQI) • Impact of baseline lesion count, prior rosacea treatment, and disease duration on efficacy of combination therapy METHODS
    keywords: baseline; change; dlqi; lesion; treatment
       cache: skin-1001.pdf
  plain text: skin-1001.txt

        item: #4 of 1356
          id: skin-1002
      author: Tan, Jerry; Del Rosso, James; Weiss, Jonathan; Gold, Linda Stein; Cook-Bolden, Fran; Eichenfeld, Lawrence; Tanghetti, Emil; Saenz, Alessandra Ali?; Ahmad, Faiz
       title: Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study
        date: 2020-09-02
       words: 1829
      flesch: 42
     summary: Medical writing supported by Galderma Laboratories, L.P. ALT.P-RD18250-08 INTRODUCTION Introduction to trifarotene 50 μg/g cream:1 • Retinoid receptor agonist that selectively targets retinoic acid receptor gamma • Low systemic exposure after topical administration • Once-daily cream developed for treatment of acne vulgaris on the face and trunk Objectives: • Study 1 and Study 2: Assess safety and efficacy of trifarotene 50 μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris • Long-term Safety and Efficacy Study: Evaluate long-term safety and efficacy of trifarotene 50 μg/g cream use over a period of 52 weeks TRIFAROTENE 50 μg/g CREAM FOR TREATMENT OF ACNE VULGARIS – A SUMMARY OF TWO RANDOMIZED TRIALS AND A LONG-TERM SAFETY STUDY Jerry Tan, MD1; James Del Rosso, DO2; Jonathan Weiss, MD3; Linda Stein Gold, MD4; Fran Cook-Bolden, MD5; Lawrence Eichenfield, MD6; Emil Tanghetti, MD7; Michael Graeber, MD8; Allesandra Alió Saenz, MD8; Faiz Ahmad8 1Department of Medicine, University of Western Ontario, Windsor ON, Canada, 2JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV; 3Gwinnett Dermatology, Snellville, GA; 4Henry Ford Medical Center Department of Dermatology, Detroit, MI; 5Mount Sinai Hospital, New York, NY; 6Department of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, University of California, San Diego, CA; 7Center for Dermatology and Laser Surgery Sacramento, CA; 8Galderma R&D, LLC, Fort Worth, TX METHODS Study 1 and 2 • Two identical multi-center, double-blind, randomized 12-week studies of subjects with moderate facial and truncal acne comparing vehicle with once-daily trifarotene 50 μg/g cream; N = 2,420 • Study 1: conducted at 109 sites, majority United States • Study 2: conducted at 80 sites, majority Europe • Primary efficacy endpoints (face) measured at Baseline and Weeks 1, 2, 4, 8, and 12: - Success rate: percentage of subjects with Investigator Global Assessment (IGA) of clear (0) or almost clear (1) and at least a 2-grade improvement - Absolute change in facial inflammatory/non-inflammatory lesion count • Secondary efficacy endpoints (trunk) measured at Baseline and Weeks 1, 2, 4, 8, and 12: - Success rate: percentage of subjects with Physician Global Assessment (PGA) of clear (0) or almost clear (1) and at least a 2-grade improvement - Absolute change in truncal inflammatory/non-inflammatory lesion count • Safety endpoints: - Incidence of adverse events and local tolerability1 Long-term Efficacy and Safety Study • A long-term safety and efficacy study conducted over 52 weeks for once-daily use of trifarotene 50 μg/g cream in patients with moderate facial and truncal acne; N = 455 • Efficacy and tolerability measured at Baseline and Weeks 12, 20, 26, 38, and 52 • Primary endpoints (safety) included: - Local tolerability (erythema, scaling, dryness, stinging/burning) on face and trunk - Adverse events • Secondary endpoints (efficacy) included: - Success rate: IGA/PGA score of clear (0) or almost clear (1) and at least a 2-grade IGA/PGA improvement from Baseline - Grade change from baseline of IGA and PGA - Subject’s assessment of facial acne improvement2 RESULTS Study 1 and 2 Efficacy: Results of all efficacy assessments at Week 12 significant (P <.001) in favor of trifarotene 50 μg/g cream versus vehicle • Study 1: Primary efficacy endpoints (MI) - 29.4% IGA success rate in trifarotene 50 μg/g cream compared with 19.5% for vehicle - Mean percent change of -54.4% in facial inflammatory lesion count from Baseline to Week 12 for trifarotene 50 μg/g cream, compared with -44.8% for vehicle - Mean percent change of -49.7% in facial non-inflammatory lesion count from Baseline to Week 12 for trifarotene 50 μg/g cream, compared with -35.7% for vehicle (multiple imputation values used) • Study 2: Primary efficacy endpoints - 42.3% trifarotene 50 μg/g cream IGA success rate compared with 25.7% for vehicle - Mean percent change of -66.2% in facial inflammatory lesion count from Baseline to Week 12 for trifarotene 50 μg/g cream, compared with -51.2% for vehicle - Mean percent change of -57.7% in facial non-inflammatory lesion count from Baseline to Week 12 for trifarotene 50 μg/g cream, compared with -43.9% for vehicle (multiple imputation values used) Safety: • Skin irritation related to trifarotene 50 μg/g cream was transient, and consistent with known patterns of topical retinoid dermatitis - Most common related AEs included irritation, pruritus, and sunburn (incidence ≥1%) - Severe AEs related to trifarotene 50 μg/g cream reported in nine subjects versus none in the vehicle group, with no serious AEs reported - Severe related AEs led to subject discontinuation in 1.9% of the trifarotene 50 μg/g cream group in Study 1, and in 1.2% of the trifarotene 50 μg/g cream group in Study 2 • Tolerability signs related to trifarotene 50 μg/g cream assessed as mostly mild to moderate by investigator Long-term Efficacy and Safety Study Efficacy: • Both IGA and PGA success rates improved over time - IGA success rates increased from 26.6% at Week 12 to 65.1% at Week 52 - PGA success rates increased from 38.6% at Week 12 to 66.9% at Week 52 - At Week 52, 57.9% of patients had both IGA and PGA success2 Safety: • Majority of treatment emergent adverse events (TEAEs) occurred during the first three months of the study • Most common TEAEs included pruritus, irritation, and sunburn • No serious TEAEs were related to trifarotene 50 μg/g cream2 REFERENCES We wish to thank our colleagues in Galderma International, Galderma R&D in Sophia Antipolis, and Galderma Laboratories and the trifarotene study group, as well as all investigators in the United States, Canada, Europe, and Russia who participated in these clinical trials. Local tolerability of trifarotene 50 µg/g cream
    keywords: cream; study; trifarotene
       cache: skin-1002.pdf
  plain text: skin-1002.txt

        item: #5 of 1356
          id: skin-1003
      author: Del Rosso, James Q; Hartman, Corey L; Lewis, Caitlin; Schreiber, Rhonda
       title: Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris
        date: 2020-09-02
       words: 2151
      flesch: 56
     summary: Foam vehicle formulations received the highest ranking by far, with 56% of respondents rating it as “most preferred”. It is well known that topical vehicle formulation can significantly alter drug delivery and therefore impact safety, efficacy and tolerability.3 In recent years aqueous-based foam formulations have become a preferred vehicle in treating skin disease as their favorable tolerability and cosmetic elegance have led to positive patient preference, increasing the likelihood that adherence to treatment regimens including these foam vehicles will also improve.
    keywords: foam; satisfaction; tazarotene; treatment; use; week
       cache: skin-1003.pdf
  plain text: skin-1003.txt

        item: #6 of 1356
          id: skin-1004
      author: Gold, Linda Stein; Pariser, David M; Levy, Marci; Guenin, Eric
       title: Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability
        date: 2020-09-02
       words: 1560
      flesch: 61
     summary: In�ammatory Lesions -27.4% -28.1% -24.1% -34.6% -36.3%Vehicle: -44.6% Week 8 -37.9% -46.7% -36.4% -50.3% -49.7% #( -55.3% Week 12 -45.2% -55.8% -46.6% -63.5% -56.7% 13-19 y (n=173) 20-29 y (n=163) 30+ y (n=80) #( -70% -50% -30% -10% -21.3% Week 4 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e B. Nonin�ammatory Lesions -17.0% -25.6% -18.2% -27.6% -20.3%Vehicle: -36.0% Week 8 -22.1% -39.2% -29.9% -45.2% -36.4% #( -47.1% Week 12 -27.6% -55.2% -39.3% -59.0% -45.4% 13-19 y (n=173) 20-29 y (n=163) 30+ y (n=80) 0% 0% *P<0.05 vs vehicle; **P<0.01 vs vehicle; ***P<0.001 vs vehicle. LS Mean Percent Reduction from Baseline in Inflammatory and Noninflammatory Lesion Counts by Age Group and Visit (ITT Population, Pooled) #( -70% -50% -30% -10% -30.5% Week 4 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e A.
    keywords: age; vehicle; week
       cache: skin-1004.pdf
  plain text: skin-1004.txt

        item: #7 of 1356
          id: skin-1005
      author: Baldwin, Hilary E; Green, Lawrence; Kircik, Leon; Caronia, Ashlie M; Guenin, Eric
       title: Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males With Moderate-to-Severe Acne
        date: 2020-09-02
       words: 1536
      flesch: 66
     summary: -70% -60% -50% -40% -30% -20% -10% 0% # * ) ( ' & % -70% -60% -50% -40% -30% -20% -10% 0% # * )
    keywords: lotion; tazarotene; week
       cache: skin-1005.pdf
  plain text: skin-1005.txt

        item: #8 of 1356
          id: skin-1006
      author: Silverberg, Jonathan I; Soong, Weily; Lockshin, Benjamin; Gadkari, Abhijit; Chen, Zhen; Bansal, Ashish
       title: Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL)
        date: 2020-09-02
       words: 2984
      flesch: 62
     summary: METHODS Study design • Detailed descriptions of the study populations and methodologies have been previously published,9,10 and are summarized below and in Figure 1 – ADOL adolescent patients received 200/300 mg dupilumab q2w (patients with body weight < CONCLUSIONS • A large proportion of adult and adolescent patients with AD had symptoms of anxiety or depression at baseline, indicative of a high burden of AD • Dupilumab monotherapy improved symptoms of anxiety and depression in adult and adolescent patients with AD, and was well tolerated with an acceptable safety profile METHODS (cont.)
    keywords: dupilumab
       cache: skin-1006.pdf
  plain text: skin-1006.txt

        item: #9 of 1356
          id: skin-1007
      author: Simpson, Eric L; Fujita, Hiroyuki; Arima, Kazuhiko; Hamilton, Jennifer; Lu, Yufang; Rossi, Ana B; Bansal, Ashish
       title: Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)
        date: 2020-09-02
       words: 2634
      flesch: 67
     summary: Eichenfield LF, et al. Thijs JL, et al.
    keywords: baseline; dupilumab; placebo
       cache: skin-1007.pdf
  plain text: skin-1007.txt

        item: #10 of 1356
          id: skin-1008
      author: Silverberg, Jonathan I; Lockshin, Benjamin; Gooderham, Melinda; Chen, Zhen; Gadkan, Abhijit; Rossi, Ana B
       title: Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial
        date: 2020-09-02
       words: 2493
      flesch: 63
     summary: In the 52-week, phase 3, randomized, double-blinded LIBERTY AD CHRONOS trial (NCT02260986), dupilumab with concomitant topical corticosteroids (TCS) vs placebo with TCS signifi cantly improved AD signs, symptoms, and patient quality of life with an acceptable safety profi le8 Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: Categorical change in AD severity according to total POEM score in (A) placebo + TCS group and (B) dupilumab 300 mg q2w group.
    keywords: n o; p o; tcs; week
       cache: skin-1008.pdf
  plain text: skin-1008.txt

        item: #11 of 1356
          id: skin-1009
      author: Sher, Lawrence; Soong, Weily; Prescilla, Randy; Chen, Zhen; Bansal, Ashish
       title: Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL)
        date: 2020-09-02
       words: 2272
      flesch: 62
     summary: Safety was assessed among patients who received ≥ 1 dose of any study drug RESULTS Patients • Of the 251 patients randomized, 166 had a history of AR and 85 did not have a history of AR • Baseline disease characteristics were similar among treatment groups and between subgroups with a history of AR and no history of AR (Table 1) OBJECTIVE • To determine if a history of AR impacts the effi cacy of dupilumab treatment in adolescent patients with moderate-to-severe AD enrolled in a phase 3 trial A P ro p o rt io n o f p a ti e n ts a c h ie vi n g IG A 0 o r 1 a t W e e k 1 6 ( % ) Placebo 0 n = 28 n = 50 22.0 18.5 (6.06, 30.93) This analysis includes the subpopulation of patients who reported a history of AR at baseline and the complementary subpopulation without a history of AR • Effi cacy outcomes were analyzed among randomized patients (full analysis set) among the 2 subgroups •
    keywords: dupilumab; patients
       cache: skin-1009.pdf
  plain text: skin-1009.txt

        item: #12 of 1356
          id: skin-101
      author: Weber, T M; Arrowitz, C E; Scherdin, U; Schoelermann, A M; Filbry, A
       title: A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis
        date: 2017-10-27
       words: 311
      flesch: -14
     summary: Figure 4. Figure 5. 55% 6% 35% 2% Atopic Eczema Xerosis Psoriasis Ichthyosis N=80 2.29 1.61 0.34 0.86 0.51 0.13 0 0.5 1.0 1.5 2.0 2.5 Dryness Scaling Cracks M ea n C lin ic al G ra d in g S co re * * * OBS=Aquaphor Ointment Body Spray *p<0.0001 vs Baseline N=80 Baseline End of Study 0 20 40 60 Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None 0 20 40 60 0 25 50 75 Reduction in Dryness Reduction in Scaling Reduction in Cracks N=70 N=20 End of Study 0.59 1.39 1.39 1.1 0.15 0.81 0.41 0.39 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Burning Erythema Itching Tightness M ea n C lin ic al G ra d in g S co re * * * * OBS=Aquaphor Ointment Body Spray *p<0.0001 vs Baseline N=80 Baseline End of Study Reduction in Itching Reduction in Erythema 0 20 40 60 0 20 40 60 % o f Su b je ct s % o f Su b je ct s N=62 N=57 Reduction in Burning Reduction in Tightness OBS=Aquaphor Ointment Body Spray Mean Duration of Treatment=16.2 days % o f Su b je ct s % o f Su b je ct s 0 20 40 60 0 20 40 60 80 N=35 N=52 Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Progression to Reduced Symptom Severity Baseline End of Study p p FC17PosterBeiersdorfWeberMoisturizingSpray.pdf INTRODUCTION RESULTS CONCLUSIONS METHODS OBJECTIVE Subjects Study design Assessments TM Weber,1 CE Arrowitz,1 U Scherdin,2 AM Schoelermann,2 A Filbry2 1Beiersdorf Inc, Wilton, CT, USA; 2Beiersdorf AG, Hamburg, Germany A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis Figure 1.
    keywords: reduction; severe/
       cache: skin-101.pdf
  plain text: skin-101.txt

        item: #13 of 1356
          id: skin-1010
      author: Eichenfield, Lawrence F; Elewski, Boni; Sugarman, Jeffrey L; Rosen, Ted; Gupta, Aditya; Cantrell, Wendy; Pillai, Radhakrishnan; Jacobson, Abby
       title: Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients
        date: 2020-09-02
       words: 1505
      flesch: 55
     summary: Participants were aged 6 – 16 years with culture-positive mild-to-severe onychomycosis affecting ≥20% of at least 1 great toenail ◾ ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC | 2020
    keywords: cure; dermatologics; efinaconazole; population
       cache: skin-1010.pdf
  plain text: skin-1010.txt

        item: #14 of 1356
          id: skin-1011
      author: Pr?stegaard, Morten; Vestbjerg, Birgitte; Selmer, Johan; Holm-Larsen, Tove
       title: Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension
        date: 2020-09-02
       words: 1188
      flesch: 57
     summary: The secondary endpoint assessing patient treatment convenience (PTCS) at Week 8 demonstrated superiority of MC2-01 cream compared to CAL/BDP TS (41.5 vs. 37.5, p<0.0001) PowerPoint-præsentation © mc2 therapeutics  1 Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension Adults mild to moderate psoriasis R MC2-01 cream (n=343) MC2-01 cream vehicle (n=115)
    keywords: cal; cream; mc2
       cache: skin-1011.pdf
  plain text: skin-1011.txt

        item: #15 of 1356
          id: skin-1012
      author: Blauvelt, Andrew; Kempers, Steven; Forman, Seth; Lain, Edward; Bruce, Suzanne
       title: Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies
        date: 2020-09-02
       words: 1667
      flesch: 51
     summary: Complete (100%) and partial (≥75%) clearance rates of AK lesions (ITT population) KX01-AK-003 (n=351) KX01-AK-004 (n=351) Tirbanibulin (n=175) Vehicle (n=176) p-value Tirbanibulin (n=178) Vehicle (n=173) p-value 100% clearance, n (%) 77 (44%) 8 (5%) <0.0001 97 (54%) 22 (13%) <0.0001 Face 50% 6% <0.0001 61% 14% <0.0001 Scalp 30% 2% <0.0001 41% 11% 0.0003 ≥75% clearance, n (%) 119 (68%) 29 (16%) <0.0001 136 (76%) 34 (20%) ACKNOWLEDGMENTS ‒ KX01-AK-003: 44% vs 5% (complete clearance); 68% vs 16% (partial clearance), respectively ‒ KX01-AK-004: 54% vs 13% (complete clearance); 76% vs 20% (partial clearance), respectively • Significantly higher complete and partial clearance rates for tirbanibulin compared with vehicle were also demonstrated in subgroup analyses for age, baseline AK lesion count, gender, skin type, and treatment location (face or scalp) in both studies (p<0.001) • To assess the efficacy and safety of tirbanibulin compared with vehicle in participants with AK lesions on the face or scalp OBJECTIVE • Adult participants with 4–8 typical, visible AK lesions in a 25 cm2 treatment area on the face or scalp were enrolled (2:1) in the study • Participants were randomized to receive either tirbanibulin ointment 1% or vehicle (1:1); treatment was self-applied once-daily for 5 consecutive days and left in place for ~12 hours •
    keywords: kx01; study; tirbanibulin; treatment; usa; vehicle
       cache: skin-1012.pdf
  plain text: skin-1012.txt

        item: #16 of 1356
          id: skin-1013
      author: Litchman, Graham H; Fitzgerald, Alison L; Kurley, Sarah J; Cook, Robert W; Rigel, Darrell S
       title: Impact of a Prognostic 40-Gene Expression Profiling Test on Clinical Management Decisions for High-Risk Cutaneous Squamous Cell Carcinoma
        date: 2020-09-02
       words: 1331
      flesch: 51
     summary: 25 19 0 118 Nodal Imaging 35 4 12 20 2 103 44 4 26 13 1 89 Adjuvant Radiation 53 1 11 25 1 133 71 2 27 17 2 117 Adjuvant Chemotherapy 34 1 9 26 4 112 53 2 17 15 1 104 *Fisher’s exact test with Freeman-Halton extension indicated that each row had statistically significant differences p<0.0001 when comparing Class 1, 2A, and 2B for a given modality. ns <.0001 <.05 ns Class 1 SLNB F/U, chemo, imaging, RT ---- SLNB, RT F/U, imaging, chemo ---- Class 2A ----
    keywords: class; gep; risk; test; vignette
       cache: skin-1013.pdf
  plain text: skin-1013.txt

        item: #17 of 1356
          id: skin-1014
      author: Freeman, Scott; Bettencourt, Miriam; Corliss, Meg; Dunkelly-Allen, Nikeshia; Veverka, Karen A
       title: Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis
        date: 2020-09-02
       words: 2443
      flesch: 46
     summary: Neri L et al, 2017 • Neri L et al, conducted an observational, multicenter, longitudinal cohort study in 1136 adult patients with multiple grade I/II AKs10 • LSRs were assessed at 2 follow-up visits: – T1: 8 days after initiation of AK treatment – T2: 25-30 days after initiation of AK treatment • Approximately 37% of patients received treatment for LSRs at T1 – 53% received topical antibiotics – 47% received emollient creams • Roughly 14% received treatment at T2 – 70% received emollient creams – 29% received antibiotics • There was a steep decrease in average LSR score (scale=0-4) from the first follow-up visit (2.6±1.5) to the second follow-up visit (0.9+1.0), which was seen in both LSR-treated and untreated groups Bettencourt MS, 2016 • Bettencourt MS conducted a study at a community dermatology practice in 78 male patients with recurring and relapsed scalp AK2 • All patients exhibited LSRs on the first day of treatment – Erythema (100%) – Flaking/Scaling (97%) – Crusting (66%) – Swelling (6%) – Vesiculation/Pustulation (32%) – Erosion/Ulceration (13%) • 44% of the patients treated their LSRs with a topical product (Figure 3) • LSRs were resolved in 10-14 days regardless of the use of a topical product – In 1 patient, LSRs were resolved at day 20 Bettencourt MS, 2014 • Bettencourt MS conducted a retrospective chart review of 135 patients who had a prolonged history of AKs treated with IMB7 • Regardless of body area or use of LSR treatment, most patients had developed LSRs by day 2 of treatment (Table 2) •
    keywords: dermatol; imb; lsrs; patients; treatment
       cache: skin-1014.pdf
  plain text: skin-1014.txt

        item: #18 of 1356
          id: skin-1015
      author: Berman, Brian; Bhatia, Neal; Piacquadio, Daniel; Houlihan, Anna; Siegel, Daniel
       title: Efficacy of ALA–PDT in the Treatment of Actinic Keratoses on the Upper Extremities: A Post Hoc Analysis of a Phase 3, Randomized, Vehicle-Controlled Trial
        date: 2020-09-02
       words: 1826
      flesch: 46
     summary: In a phase 3, randomized, evaluator-blinded, vehicle-controlled trial (NCT02137785), ALA 20% solution–PDT at baseline and week 8 using lesion-targeted treatment and a 3-hour occluded incubation was superior to vehicle (VEH)–PDT for AK clearance of the upper extremities3 — The study assessed response of the entire field to treatment, including new AKs present at follow-up, in calculations of clearance rates OBJECTIVE • To assess clearance rate relative to baseline, cumulative disease area clearance, and complete clearance rate by lesion size in treated lesions only in patients treated with ALA-PDT for AKs on the upper extremities METHODS Study design • Efficacy of ALA–PDT in the treatment of actinic keratoses on the upper extremities: A post hoc analysis of a phase 3, randomized, vehicle-controlled trial Brian Berman,1,2 Neal Bhatia,3 Daniel Piacquadio,4 Anna Houlihan,5 and Daniel Siegel6,7 1Center for Clinical and Cosmetic Research, Aventura, FL, USA; 2Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 3Therapeutics Clinical Research, San Diego, CA, USA; 4Therapeutics, Inc., San Diego, CA, USA; 5DUSA Pharmaceuticals, Inc., Wilmington, MA, USA; 6Department of Dermatology, The State University of New York Downstate Health Sciences University, Brooklyn, NY, USA; 7Dermatology Service, Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY, USA BACKGROUND • Actinic keratoses (AKs) are precancerous, dysplastic epidermal lesions that may progress to squamous cell carcinoma (SCC)1 • Aminolevulinic acid (ALA) 20% solution photodynamic therapy (PDT) is indicated for targeted treatment of AK on the face, scalp, and upper extremities2 •
    keywords: ala; clearance; pdt; treatment; veh
       cache: skin-1015.pdf
  plain text: skin-1015.txt

        item: #19 of 1356
          id: skin-1016
      author: Guminski, Alexander; Squittieri, Nicholas; Lear, John T
       title: Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study
        date: 2020-09-02
       words: 2207
      flesch: 47
     summary: Adverse events reported in ≥30% of patients receiving 200 mg daily N = 79. AE, adverse event; CK, creatine kinase. Adverse events of special interest reported in ≥30% of patients receiving sonidegib 200 mg daily N
    keywords: patients; response; sonidegib
       cache: skin-1016.pdf
  plain text: skin-1016.txt

        item: #20 of 1356
          id: skin-1017
      author: Migden, Michael; Lear, John; Squittieri, Nicholas; Liu, Li; Guminski, Alexander; Dummer, Reinhard
       title: Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind
        date: 2020-09-02
       words: 2149
      flesch: 33
     summary: • Tumor response was evaluated by central review using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for patients with laBCC (Figure 2 and 3) — Includes assessment by magnetic resonance imaging complemented by color photography and histology of multiple biopsy samples; complete response was defined as negative histology with complete disappearance of target lesions by all image modalities11,14 Figure 3. CONCLUSIONS • Patients with laBCC receiving sonidegib 200 mg/day experienced durable tumor response until disease progression or start of new antineoplastic therapy • Safety and tolerability of sonidegib 200 mg/day at 42 months was consistent with earlier data REFERENCES 1) Xiang F, et al.
    keywords: cell; labcc; patients; response; sonidegib
       cache: skin-1017.pdf
  plain text: skin-1017.txt

        item: #21 of 1356
          id: skin-1018
      author: Dummer, Richard; Migden, Michael; Squittieri, Nicholas; Liu, Li; Guminski, Alexander; Lear, John
       title: Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study
        date: 2020-09-02
       words: 2039
      flesch: 33
     summary: Efficacy outcomes per central review in patients with laBCC receiving sonidegib 200 mg daily IaBCC (n = 66) ORR, % (95% CI) 56.1 (43.3, 68.3) CR, % (95% CI) 4.5 (0.9, 12.7) DCR, % 90.9 DOR, median, months (95% CI) 26.1 (NE) PFS, median, months (95% CI) 22.1 (NE) TTR, median, months (95% CI) 4.0 (3.8, 5.6) BCC, basal cell carcinoma; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; laBCC, locally advanced BCC; mBCC, metastatic BCC; NE, not estimable; ORR, objective response rate; PFS, progression-free survival; TTR, time to tumor response. AE, adverse event; BOLT, Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment; CR, complete response; DOR, duration of response; HHI, hedgehog inhibitor; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Q8W, every 8 weeks; Q12W, every 12 weeks; TTR, time to tumor response.
    keywords: labcc; patients; response; sonidegib
       cache: skin-1018.pdf
  plain text: skin-1018.txt

        item: #22 of 1356
          id: skin-1019
      author: Eversman, Anna; Fatima, Sakeena; Honda, Kord; Beveridge, Mara
       title: Imatinib-Induced Acquired Dermal Melanocytosis 
        date: 2021-01-01
       words: 1156
      flesch: 43
     summary: While the histologic appearance of imatinib- induced hyperpigmentation varies, intradermal hemosiderosis is the most common finding.4 We report a rare case of hyperpigmented patches secondary to dermal melanocytosis following imatinib treatment in an African American patient with acute lymphoblastic leukemia (ALL). Although dermal melanocytosis is evidence of melanocyte activation, there are only 5 reported cases of primary cutaneous DISCUSSION A. B. C. SKIN January 2021 Volume 5 Issue 1 Copyright 2021 The National Society for Cutaneous Medicine 77 Figure 2.
    keywords: case; dermal; imatinib; melanocytosis
       cache: skin-1019.pdf
  plain text: skin-1019.txt

        item: #23 of 1356
          id: skin-102
      author: Dirschka, T; Ekanayake-Bohlig, S; Dominicus, R; Aschoff, R; Herrera-Ceballos, E; Botella-Estrada, R; Hunfeld, A; Schmitz, B; Lubbert, H; Puig, S
       title: Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL
        date: 2017-10-27
       words: 46
      flesch: 55
     summary: � � � � � � � � � � � � � � � � � � � 1 ≥ ≥ ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± • • • • • ≤ • > • < • • FC17PosterBiofronteraDirschkaDaylightPhotodynamic.pdf
    keywords: ± ±
       cache: skin-102.pdf
  plain text: skin-102.txt

        item: #24 of 1356
          id: skin-1020
      author: Beard, Cassandra; Mojica, Rafael; Ferrer-Bruker, Sarah; Krishnamurthy, Karthik
       title: Coexisting Pediatric Acute Generalized Exanthematous Pustulosis and Staphylococcal Scalded Skin Syndrome
        date: 2021-03-06
       words: 1348
      flesch: 44
     summary: SKIN March 2021 Volume 5 Issue 2 Copyright 2021 The National Society for Cutaneous Medicine 185 BRIEF ARTICLE Coexisting Pediatric Acute Generalized Exanthematous Pustulosis and Staphylococcal Scalded Skin Syndrome Cassandra Beard, DO, MPH1, Rafael Mojica, BS2, Sarah Ferrer-Bruker, DO1, Karthik Krishnamurthy, DO1 1Division of Dermatology, HCA Healthcare/Mercer University School of Medicine/Orange Park Medical Center Program, Orange Park, FL 2Edward Via College of Osteopathic Medicine, Spartanburg, SC Acute generalized exanthematous pustulosis (AGEP) is a disease of acute onset, typically following drug intake. The lesions quickly spread within hours to involve the trunk and limbs.1 Staphylococcal scalded skin syndrome (SSSS) presents in a similar distribution with swelling and erythema with subsequent bulla formation and exfoliation.2 Although rare, SSSS most commonly presents in the pediatric population with an annual incidence of 7.67 per million U.S. children.3 There are far fewer reported cases of AGEP in the pediatric population, which is highlighted by the paucity of such incidence reports.4
    keywords: acute; agep; skin; ssss; staphylococcal
       cache: skin-1020.pdf
  plain text: skin-1020.txt

        item: #25 of 1356
          id: skin-1021
      author: Domzalski, Colin; Wei, Nancy; Lebwohl, Mark
       title: A Systematic Review of Neurovascular Complications in Patients with Pseudoxanthoma Elasticum
        date: 2020-10-27
       words: 2394
      flesch: 53
     summary: Accordingly, individual cohort studies Van der Berg et al and Kauw et al found an 8% prevalence for ischemic CVAs in PXE patients, compared to the 3% prevalence for ischemic CVAs seen in the general population.9 Relative risk of developing ischemic strokes is estimated to be 3.6 in PXE patients less than 65 years compared with the general population (95 % confidence interval 3.3–4.0).23,21 As demonstrated in Bertamino et al and Araki et al, an ischemic stroke can be a rare presenting symptom in both pediatric and adult cases of PXE.14, 13 While an increased risk for neurovascular events in the general population warrants the initiation of prophylactic antiplatelet therapy, there is no current consensus on antiplatelet in PXE patients.5 Cardiovascular complications secondary to accelerated atherosclerosis are well-documented in published literature; however, there is a paucity of studies that reviews serious neurovascular complications including CVA(cerebral vascular accident), TIA(Transient ischemic attack), and intracranial aneurysm in PXE patients.
    keywords: aneurysm; complications; disease; elasticum; ischemic; patients; pseudoxanthoma; pxe
       cache: skin-1021.pdf
  plain text: skin-1021.txt

        item: #26 of 1356
          id: skin-1023
      author: Bissonnette, Robert; Gold, Linda Stein; Kircik, Leon; Tyring, Stephen; Tailman, Anna; Armstrong, April
       title: Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study
        date: 2020-08-29
       words: 1993
      flesch: 56
     summary: PGA Response Rates ■ Primary endpoint: PGA response rates (defined as PGA score 0 or 1 and ≥2-grade improvement) at Week 12 were significantly higher (at 0.05 significance level) in the tapinarof cream groups than the vehicle groups (65% [1% BID], 56% [1% QD], 46% [0.5% BID], and 36% [0.5% QD] vs 11% [vehicle BID] and 5% [vehicle QD]) and were maintained for 4 weeks after the end-of-study treatment in all active treatment groups, except for the 0.5% BID group3 Mean Change in PASI ■ Mean PASI improvements at Week 12 were significantly greater in all tapinarof groups vs vehicle groups (all P<0.001): – ■ Lower extremities: Mean PASI improvements in the lower extremities at Week 12 were significantly greater in all tapinarof groups vs vehicle groups (all P<0.001): –8.74 (1% BID), –8.19 (1% QD), –7.16 (0.5% BID), and –6.33 (0.5% QD) vs –2.47 (vehicle BID) and –2.0 (vehicle QD); significant improvements were maintained in all tapinarof groups for 4 weeks after the last application through Week 16 (Figure 4) Figure 4.
    keywords: bid; pasi; tapinarof; vehicle; week
       cache: skin-1023.pdf
  plain text: skin-1023.txt

        item: #27 of 1356
          id: skin-1024
      author: Lebwohl, Mark; Del Rosso, James Q; Hong, Chih-Ho; Tailman, Anna M; Kircik, Leon
       title: Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study
        date: 2020-08-29
       words: 2068
      flesch: 59
     summary: [vehicle BID] and 5% [vehicle QD]) and were maintained for 4 weeks after the end-of-study treatment in all active treatment groups except for the 0.5% BID group2 PGA Response Rates by Baseline % BSA Affected ■ PGA response rates at Week 12 were higher in tapinarof cream groups than vehicle groups, regardless of baseline % BSA affected (Figure 2) – 1 to <10% BSA affected (n=102): 67% (1% BID), 60% (1% QD), 33% (0.5% BID), and 35% (0.5% QD) vs 13% (vehicle BID) and 6% (vehicle QD) – ≥10% BSA affected (n=39): 64% (1% BID), 40% (1% QD), 75% (0.5% BID), and 38% (0.5% QD) vs 0% (vehicle BID) and 0% (vehicle QD) Figure 2. INTRODUCTION ■ Psoriasis is a chronic, immune-mediated disease characterized by scaly, erythematous, and pruritic plaques that can be painful and disfiguring1 ■ Although multiple options are available for the treatment of plaque psoriasis, there is a need for effective topical therapies that can be used without body surface area (BSA) restrictions or concerns for the duration of treatment ■ Tapinarof cream is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for the treatment of psoriasis (NCT03956355 & NCT03983980) and atopic dermatitis ■ This previously conducted phase 2b dose-finding study (NCT02564042) was designed to assess the efficacy and safety of tapinarof cream in subjects with plaque psoriasis2,3 ■ Factors related to disease characteristics and skin type may influence clinical outcomes in psoriasis4,5 ■ This post-hoc analysis was conducted to explore whether the efficacy and safety of tapinarof cream varied across subgroups by baseline disease characteristics and skin type OBJECTIVES ■ To evaluate the efficacy and safety of tapinarof through post-hoc analysis of a phase 2b study in subjects with plaque psoriasis stratified by baseline disease characteristics, including % BSA affected, duration of psoriasis, and Fitzpatrick skin type METHODS Study Design ■ In this multicenter (United States, Canada, and Japan), phase 2b, double-blind, vehicle-controlled, randomized study, adult subjects with psoriasis were randomized 1:1:1:1:1:1 to receive tapinarof cream 0.5% or 1% once (QD) or twice daily (BID) or vehicle QD or BID for 12 weeks and followed up for 4 more weeks (Figure 1) Figure 1.
    keywords: bid; pga; tapinarof; vehicle
       cache: skin-1024.pdf
  plain text: skin-1024.txt

        item: #28 of 1356
          id: skin-1025
      author: Heibel, Haley Danielle; Dhaliwal, Parneet; Cockerell, Clay J.
       title: New Cases of Syphilis and Molluscum Contagiosum in the COVID-19 Pandemic: A Sign That Social Distancing Guidelines Are Not Being Adhered to?
        date: 2021-01-01
       words: 1123
      flesch: 38
     summary: All medical providers must consider how we can better encourage individuals to abide by social distancing recommendations, optimize care for patients during the pandemic, and prevent the misallocation of valued health care resources. Dermatologists are experts in the recognition of the cutaneous manifestations of venereal diseases which is critical to appropriate diagnosis and management, and they should continue to provide care during this pandemic. Individuals who acquire STDs during this time may increase the strain on already limited health care resources by disregarding social distancing recommendations.
    keywords: care; distancing; health
       cache: skin-1025.pdf
  plain text: skin-1025.txt

        item: #29 of 1356
          id: skin-1028
      author: Snyder, Margaret; Lebwohl , Mark 
       title: Ixekizumab Overdose: A Case Report
        date: 2020-10-27
       words: 2218
      flesch: 39
     summary: Due to complex dosing schedules as well as increasing use of these agents, it is likely that healthcare providers will encounter cases of patients accidentally self- administering larger than recommended doses. Due to complex dosing schedules as well as increasing use of these agents, it is likely that healthcare providers will encounter cases of patients accidentally self-administering larger than recommended doses.
    keywords: case; insert; medicine; overdose; package; patients
       cache: skin-1028.pdf
  plain text: skin-1028.txt

        item: #30 of 1356
          id: skin-1029
      author: Garg, Jasmine; Cline, Abigail ; Pereira, Frederick 
       title: Increase in Google Trends Regarding Telogen Effluvium Due To COVID-19 
        date: 2021-03-06
       words: 913
      flesch: 58
     summary: Methods: We performed Google TrendsTM search for “COVID hair loss”, “telogen effluvium” and “hair loss” between 5/1/20 and 8/16/20. Conclusion: All three terms have increased in popularity for search terms since mid-March and were the most prevalent in the states that experienced the earliest increase in number of coronavirus cases. Date range 5/1/2020 to 8/16/2020 19 cases within their borders.4 New York and New Jersey topped the list both in terms of Google Trend searches and in COVID-19 infection rates per 100,000 (Table 1).5 TE secondary to COVID-19 may be on the rise.
    keywords: effluvium; hair; loss
       cache: skin-1029.pdf
  plain text: skin-1029.txt

        item: #31 of 1356
          id: skin-1030
      author: Conway, Jade; Roy, Bipasha; Barazani, Lauren; Wu, Albert; Cline, Abigail; Moy , Janet
       title: High Demand: Identification of Dermatology Visit Trends from 1991-2016 National Ambulatory Medical Care Surveys
        date: 2020-10-27
       words: 1127
      flesch: 49
     summary: Utilizing the National Summary Tables from the National Ambulatory Medical Care Survey from 1991-2016, we analyzed office data and identified trends relating to dermatology visits over time. Methods: Analysis of the 1991-2016 National Summary Tables from the National Ambulatory Medical Care Survey (NAMCS) was performed in order to identify several trends relating to dermatology visits.
    keywords: dermatology; drug; national; visits
       cache: skin-1030.pdf
  plain text: skin-1030.txt

        item: #32 of 1356
          id: skin-1031
      author: Kuraitis, Drew; Lee, Yong; Kadi, Abida; Murina, Andrea
       title: Eccrine Porocarcinoma Masquerading as Squamous Cell Carcinoma
        date: 2020-10-27
       words: 729
      flesch: 49
     summary: This squamous variant has been characterized in a retrospective study of 21 cases.1 Features that favor the diagnosis of squamous EPC include tumor cells within the dermis in anastomosing trabeculae and ductal structures lined by tumor cells. The National Society for Cutaneous Medicine 620 SHORT COMMUNICATIONS Eccrine Porocarcinoma Masquerading as Squamous Cell Carcinoma Drew Kuraitis, MD, PhD1, Yong Lee, BS2, Abida Kadi3, Andrea Murina, MD1 1Department of Dermatology, Tulane University, New Orleans, LA 2Tulane University School of Medicine, Tulane University, New Orleans, LA 3Department of Pathology, Tulane University, New Orleans, LA A squamoid variant of eccrine porocarcinoma (EPC) exists and is often misdiagnosed as squamous cell carcinoma (SCC) due to clinical and histopathologic similarities.
    keywords: scc; tumor
       cache: skin-1031.pdf
  plain text: skin-1031.txt

        item: #33 of 1356
          id: skin-1033
      author: none
       title: A Cross-Sectional Study on Herpes Zoster Diagnosis in the time of COVID-19
        date: 2020-10-27
       words: 1403
      flesch: 53
     summary: The total number of HZ cases to the total number of medical visits during the same six-month time frame (March to August) in 2019 and 2020 were also collected to assess if COVID-19 impacted the HZ incidence. To analyze whether there was an increase in the HZ condition rate during the pandemic, we compared the total number of HZ cases to the total number of medical visits during the same six-month time frame (March to August) in 2019 and 2020 using the general de-identified UC health data warehouse (UCHDW).
    keywords: cases; covid-19; patients
       cache: skin-1033.pdf
  plain text: skin-1033.txt

        item: #34 of 1356
          id: skin-1034
      author: Vu, Trang; Taher, Muba; Hung, Tawny
       title: A Case Report of a Primary Cutaneous Adenoid Carcinoma: A Diagnostic and Management Challenge 
        date: 2021-01-01
       words: 1343
      flesch: 28
     summary: Cutaneous adenoid cystic carcinoma with perineural invasion treated by mohs micrographic surgery-a case report with literature review. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.
    keywords: adenoid; carcinoma; http://paperpile.com/b/nzabld/9tza; http://paperpile.com/b/nzabld/nc1v; http://paperpile.com/b/nzabld/yu1b; pcacc
       cache: skin-1034.pdf
  plain text: skin-1034.txt

        item: #35 of 1356
          id: skin-1035
      author: Vittitow, Stephany; Kozak, Merrick; Daughtery, Reza; Zlotoff, Barrett
       title: A Rapidly Enlarging Solitary Infantile Myofibroma: A Case Report and a Review of Current Monitoring Guidelines
        date: 2020-10-27
       words: 1661
      flesch: 46
     summary: Larralde M, Ferrari B, Martinez JP, Barbieri MAF, Méndez JH, Casas J. Infantile myofibromatosis. Whole-body magnetic resonance imaging in the diagnosis and follow-up of multicentric infantile myofibromatosis: A case report.
    keywords: imaging; infantile; involvement; mri; myofibromatosis; skin; visceral
       cache: skin-1035.pdf
  plain text: skin-1035.txt

        item: #36 of 1356
          id: skin-1036
      author: Neville, Kayla; Obradovic, Aleksandar
       title: Verrucous Carcinoma Arising Secondary to Diabetic Foot Lesions: A Systematic Review of the Literature
        date: 2021-05-21
       words: 2550
      flesch: 45
     summary: Verrucous carcinoma is classically considered a variant of squamous cell carcinoma, which forms painful lesions marked by an exophytic appearance, with deep invasion into local underlying structures.6,7 Ackerman first described verrucous carcinoma in the oral cavity, associated with chewing tobacco,7 and verrucous carcinoma of the oral cavity has been so closely associated with the use of snuff and chewing tobacco that is has been ABSTRACT Verrucous carcinoma is classically considered a variant of squamous cell carcinoma, most commonly occurring in the oral cavity in association with snuff and chewed tobacco. Critically, we find that among 6 described cases of diabetic foot ulcer resulting in verrucous carcinoma, only a single patient reported pain in the area of the lesion.
    keywords: carcinoma; case; diabetes; foot; treatment; ulcers
       cache: skin-1036.pdf
  plain text: skin-1036.txt

        item: #37 of 1356
          id: skin-1037
      author: Jimenez, Antonio Roberto; Gleghorn, Kristyna ; Wagner, Richard 
       title: The Implementation of Educational Videos in Mohs Micrographic Surgery for Improved Patient Satisfaction and Comprehension: A Review of Literature
        date: 2021-05-21
       words: 3395
      flesch: 46
     summary: As per Migden’s article, patients who watched MMS videos asked more subjectively educated questions in comparison to patients who did not.4 Objective: To review published literature to determine if video education in MMS can improve patient satisfaction and comprehension of their procedure.
    keywords: education; mms; mohs; patients; satisfaction; video; wound
       cache: skin-1037.pdf
  plain text: skin-1037.txt

        item: #38 of 1356
          id: skin-1043
      author: Perez, Megan; Otto-Meyer, Sebastian; Nguyen, Cuong; Zheng, Lida; Choi, Jennnifer; Guggina, Lauren
       title: Atezolizumab Caused Pityriasis Lichenoides-Like Drug Eruption Treated with Narrowband Ultraviolet B 
        date: 2021-03-06
       words: 1562
      flesch: 40
     summary: Pityriasis lichenoides: clinical photograph of back drug-induced variant of pityriasis lichenoides, presenting with numerous erythematous slightly scaly papules coalescing into a large plaque in the central upper back with a second large plaque visible on the lower back. When considering treatments for drug induced pityriasis lichenoides, our patient presented unique therapeutic challenges given her complicated medical history.
    keywords: case; drug; eruption; lichenoides; nbuvb; pityriasis
       cache: skin-1043.pdf
  plain text: skin-1043.txt

        item: #39 of 1356
          id: skin-1046
      author: Carrillo, Brenda; Gallaga, Natalya; Hoyer, Paige; Ross, Lindy; Wilkerson, Michael
       title: A Case of Linagliptin-Induced Bullous Pemphigoid 
        date: 2021-03-06
       words: 1929
      flesch: 46
     summary: if refractory, followed by taper Corticosteroids PO prednisone >1mg/Kg (n = 22), adjuvant immunosuppressant (n=15), topical steroid (n = 4) High potency topical corticosteroid, systemic corticosteroid #BP Patients discontinued DPP4-I 19/28 27/31 19/36 48/106 DPP4-I Discontinuation Results Complete (11/19) or partial (7/19) remission Complete response (26/27), 1 death Complete remission off therapy (6/19), minimal therapy (9/19), partial remission (3/19). 7. Magdaleno-Tapial J, Valenzuela-Oñate C, Esteban Hurtado Á, et al. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
    keywords: bullous; dipeptidyl; inhibitors; linagliptin; patients; pemphigoid
       cache: skin-1046.pdf
  plain text: skin-1046.txt

        item: #40 of 1356
          id: skin-1050
      author: Litchman, Graham H; Schwartzberg, Lauren; Friedler, Suzanne; Sirota Rozenberg, Suzanne
       title: Elephantiasis Nostras Verrucosa: A Case Series
        date: 2020-10-27
       words: 1464
      flesch: 40
     summary: Physical examination revealed verrucous nodules and plaques scattered over bilateral lower legs down to the ankle (Figures 1A and 1B) with concomitant non-pitting edema of bilateral lower extremities and a positive Kaposi- Stemmer sign on bilateral 2nd toes. (A) Patient 1’s left lower leg; hyperpigmented verrucous plaques, scaling fissures, and significant xerosis.
    keywords: elephantiasis; env; nostras; patient; verrucosa; york
       cache: skin-1050.pdf
  plain text: skin-1050.txt

        item: #41 of 1356
          id: skin-1051
      author: Eichelberger, Ashley; Butt, Melissa; Silva, Colleen; Mosley, Aretha; Kirby, Joslyn
       title: Perceptions of Teledermatology among people with Hidradenitis Suppurativa
        date: 2021-01-01
       words: 1308
      flesch: 53
     summary: Teledermatology can be valuable for HS patients to decrease travel and wait times and improve patient access. Its benefits include reduced wait times and improved access, which support its ongoing use.1,2 Teledermatology can be valuable for people with hidradenitis suppurativa (HS) who may require maintenance therapy, as well as flare interventions, for the chronic and acute aspects of this inflammatory skin disease, respectively.3
    keywords: covid-19; patients; teledermatology
       cache: skin-1051.pdf
  plain text: skin-1051.txt

        item: #42 of 1356
          id: skin-1054
      author: Trigg, Joanna; Cubelli, Stefanie; Litchman, Graham; Cohen, Jason; Sirota Rozenberg, Suzanne
       title: An Uncommon Location for Granular Cell Tumor in a 10-year-old Caucasian Female: Granular Cell tumor in a Young Caucasian Female
        date: 2021-03-06
       words: 1408
      flesch: 59
     summary: Granular cell tumor on proximal left arm of the patient. There are three variants of granular cell tumors.
    keywords: case; cell; granular; skin; tumor
       cache: skin-1054.pdf
  plain text: skin-1054.txt

        item: #43 of 1356
          id: skin-1055
      author: E. Bax, Christina; J. Smith, Robert; L. Simpson, Cory
       title: Expanding Armor-Like Scales in a Middle-Aged Woman
        date: 2021-01-01
       words: 790
      flesch: 42
     summary: Over the following two months, her eruption worsened, and she developed painful oral mucosal erosions. Definitive diagnosis of PV depends on demonstration of typical suprabasal epidermal acantholysis along with detection of tissue-deposited or circulating auto-antibodies by immunofluorescence or ELISA, which measures antibodies recognizing Dsg1 and/or Dsg3.2 Treatment of PV is dictated by the extent of skin and/or mucosal involvement.
    keywords: disease; erosions; skin
       cache: skin-1055.pdf
  plain text: skin-1055.txt

        item: #44 of 1356
          id: skin-1056
      author: Moore, Angela; Green, Lawrence J.; Johnson, Jodi L.; Grada, Ayman
       title: Efficacy and Safety of Narrow-spectrum Oral Sarecycline for Moderate to Severe Acne Vulgaris
        date: 2020-10-27
       words: 828
      flesch: 62
     summary: Back: Significant improvements at week 12 in SC1401 (-32.9 vs -17.1%; p < 0.001) and SC1402 (-33.2 vs -25.7%; p < 0.05).  Significant improvements was seen at week 12in SC1401 (-29.5 vs -19.6%; p < 0.05) and SC1402 (-36.6 vs -21.6%;
    keywords: acne; sarecycline; week
       cache: skin-1056.pdf
  plain text: skin-1056.txt

        item: #45 of 1356
          id: skin-1057
      author: Pariser, David M; Green, Lawrence J.; Lain, Edward L.; Johnson, Jodi L.; Grada, Ayman
       title: Long-term Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
        date: 2020-10-27
       words: 822
      flesch: 46
     summary: Patterns of sarecycline use were a secondary assessment.  At three hours after administration of the study treatment, a previously unexposed area of each subject’s back was irradiated with 16J/cm2 of UVA, after which point, another area was irradiated with UVA/UVB at 50 percent of the subject’s minimum erythemal dose (MED)  UV-exposed skin was assessed visually at 24, 48, and 72 hours after irradiation, and UV-induced skin reaction was evaluated using dermal response score scale 
    keywords: acne; sarecycline
       cache: skin-1057.pdf
  plain text: skin-1057.txt

        item: #46 of 1356
          id: skin-1058
      author: Cook-Bolden, Fran E; Bhatia, Neal; Weiss, Jonathan S; Sadick, Neil; Tyring, Stephen K; Guenin, Eric; Loncaric, Anya; Harris, Susan
       title: Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race
        date: 2020-10-27
       words: 1666
      flesch: 47
     summary: % female: % Non-Hispanic/Latino: Mean in�ammatory lesion count: Mean nonin�ammatory lesion count: % EGSS distribution (moderate and severe): 63.2%78.2% 74.2%94.3% 90% 10% 95% 5% • Demographics and baseline characteristics were generally similar between subgroups, though: • Black participants were on average older and more likely to be female • A higher proportion of White participants had a baseline EGSS of 4 (“severe”) EGSS, Evaluator’s Global Severity Score; ITT, intent to treat. FIGURE 3. -70% -50% -30% -10% Black Participants White Participants Black Participants White Participants Black Participants White ParticipantsLS M e a n C h a n g e f ro m B a se lin e A.
    keywords: baseline; black; lotion; participants; tazarotene; vehicle; white
       cache: skin-1058.pdf
  plain text: skin-1058.txt

        item: #47 of 1356
          id: skin-1059
      author: Del Rosso, James ; Gold, Linda Stein; Kircik, Leon; Alexis, Andrew; Desai, Seemal R.; Stakias, Vassilis; Stuart, Iain
       title: Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients
        date: 2020-10-27
       words: 4011
      flesch: 35
     summary: ≥9 years • Moderate-to-severe acne (IGA score of 3 or 4) • 20-50 inflammatory lesions (papules, pustules, and nodules) • 25-100 non-inflammatory lesions (open and closed comedones) • Absolute change in the inflammatory lesion count at Week 12 compared with baseline • Absolute change in the inflammatory lesion count at Weeks 3, 6, and 9 compared with baseline Integrated efficacy population (N=2449) Vehicle foam (n=1071) FMX101 4% (n=1378) Included efficacy endpoints IGA, Investigator’s Global Assessment, based upon a 6-point scale in which 0 Absolute reduction from baseline in inflammatory lesions for the pooled population -16.0-16.0 -13.0 -13.0 -20 -15 -10 -5 0 0 3 6 9 12 A bs ol ut e ch an ge fr om b as el in e in in fla m m at or y le si on s Week -20 -15 -10 -5 0 A bs ol ut e ch an ge fr om b as el in e at W ee k 12 in in fla m m at or y le si on s P<0.0001, LSM Diff=3.43, CI=(2.40, 4.46) n=1378 n=1071 FMX101 4% A B Vehicle foam P<0.0001 P<0.0001 P<0.0001 P<0.0001 FMX101 4% Vehicle foam -16.0-16.0 -13.0 -13.0 -20 -15 -10 -5 0 0 3 6 9 12 A bs ol ut e ch an ge fr om b as el in e in in fla m m at or y le si on s Week -20 -15 -10 -5 0 A bs ol ut e ch an ge fr om b as el in e at W ee k 12 in in fla m m at or y le si on s P<0.0001, LSM Diff=3.43, CI=(2.40, 4.46) n=1378 n=1071 FMX101 4% A B Vehicle foam P<0.0001 P<0.0001 P<0.0001 P<0.0001 FMX101 4% Vehicle foam LSM Diff, least squares mean difference; CI, confidence interval; ITT population with multiple imputation; P values are based on LSM Diff from ANCOVA.
    keywords: e ch; fla; p<0.0001 p<0.0001; s p<0.0001; ut e
       cache: skin-1059.pdf
  plain text: skin-1059.txt

        item: #48 of 1356
          id: skin-106
      author: Jeong, Sinyoung; Hermsmeier, Maiko; Osseiran, Sam; Yamamoto, Akira; Nagavarapu, Usha; Chan, Kin F; Evans, Conor L
       title: Visualization of Cutaneous Distribution of Minocycline of a Topical Gel in Human Facial Skin with Two-Photon Excited Fluorescence Lifetime Imaging Microscopy (FLIM) and Phasor Analysis
        date: 2017-10-27
       words: 1500
      flesch: 44
     summary: Signals were acquired with photomultiplier tubes (PMT) to reconstruct FLIM images. FLIM analysis starting (from left to right column) bright field images, two-photon excitation fluorescence (2PEF) images, FLIM images, Phasor plots corresponding to FLIM images, and quantitative analysis of local minocycline concentration, in the epidermis, hair follicle and sebaceous gland by phasor analysis.
    keywords: analysis; flim; fluorescence; minocycline; phasor
       cache: skin-106.pdf
  plain text: skin-106.txt

        item: #49 of 1356
          id: skin-1060
      author: Del Rosso, James Q; Gold, Linda Stein; Draelos, Zoe; Raoof, Tooraj Joseph; Hooper, Deidre; Stuart, Iain
       title: A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne
        date: 2020-10-27
       words: 3396
      flesch: 54
     summary: The objectives of this study are: – To evaluate the safety, tolerability, and efficacy of the combination product FCD105 in the treatment of moderate-to-severe acne vulgaris with up to 12 weeks of daily treatment, in comparison with vehicle – To compare the efficacy and safety of FCD105 against the individual, active-drug components: minocycline 3% and adapalene 0.3% topical foam products Methods • Study FX2016-40 was a randomized, multicenter, double-blind, vehicle-controlled, Phase 2 study – The purpose was to evaluate the safety, tolerability, and efficacy over a 12-week treatment period of FCD105 as compared with vehicle foam and the individual active components of FCD105 in the treatment of subjects with moderate-to-severe acne vulgaris in a 2x2 factorial design (Figure 1) • Study drug administration – Subjects were randomized 5:3:4:4 to one of the following 4 color-matched foam treatments: FCD105 (minocycline 3% + adapalene 0.3%), vehicle, minocycline 3%, or adapalene 0.3% � Overall, there was high rate of study completion; 417 (93.3%) of the 447 subjects who were included in the ITT population completed the study, with comparable completion rates between treatment groups (Figure 1) – The assigned study treatment was applied once daily for 12 weeks • Co-primary efficacy endpoints – Absolute change in inflammatory and noninflammatory lesion counts from baseline to week 12 for FCD105 vs. vehicle – Percent of subjects achieving IGA treatment success at week 12, where success was defined as a score of 0 (clear) or 1 (minimal) and a ≥2-grade improvement (decrease) from baseline for FCD105 vs. vehicle • Secondary efficacy endpoints – Percentage change of inflammatory and noninflammatory lesion count for FCD105 vs vehicle at weeks 4, 8, and 12 – Absolute change of inflammatory and noninflammatory lesion count for FCD105 vs minocycline 3% and FCD105 vs. adapalene 0.3% from baseline to week 12 – Percent of patients achieving IGA treatment success at week 12 for FCD105 vs minocycline 3% and FCD105 vs. adapalene 0.3% • Safety evaluations – Treatment-emergent adverse events, local skin tolerability assessments, vital signs, and physical examinations • A subject satisfaction questionnaire was completed at baseline and week 12 Figure 1. A limitation of the study relates to the generalizability of the data to a larger population or to patients less than 12 years of age • Future studies are needed to confirm these findings and evaluate the safety profile of FCD105 over longer treatment durations Conclusions • Statistically significant improvement in disease burden was observed for FCD105 foam vs vehicle foam for the absolute change in inflammatory lesion count and IGA treatment success at week 12 • Numerical superiority was demonstrated for FCD105 over vehicle foam for the absolute change in noninflammatory lesions at week 12 • Numerical advantage of FCD105 foam over both minocycline 3% foam and adapalene 0.3% foam was observed at week 12, with the majority of comparisons being statistically significant • TEAEs were few in type and frequency.
    keywords: baseline; fcd105; inflammatory; subjects; treatment; vehicle; week
       cache: skin-1060.pdf
  plain text: skin-1060.txt

        item: #50 of 1356
          id: skin-1061
      author: Gold, Linda Stein; Del Rosso, James; Kircik, Leon; Bhatia, Neal D; Hooper, Deirdre; Nahm, Walter; Stuart, Iain
       title: Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea
        date: 2020-10-27
       words: 2618
      flesch: 47
     summary: Study 11 Randomized (N=751) Completed DB study (FMX103 1.5%) n=437 Completed DB study (Vehicle) n=232 Entered OL study n=140 (32%) Entered OL study n=77 (24%) Study 12 Randomized (N=771) Completed DB study (FMX103 1.5%) n=479 Completed DB study (Vehicle) n=239 Entered OL study n=192 (40%) Entered OL study n=95 (40%) Study design Week 52Baseline Key Inclusion Criteria for DB Study • Males and nonpregnant females ≥18 years • Moderate-to-severe facial papulopustular rosacea (IGA score of 3 or 4) • >15 to ≤75 facial papules and pustules, excluding lesions involving eyes and scalp; ≤2 nodules on the face • Presence or history of facial erythema or flushing Co-Primary Efficacy Endpoints • Absolute change in the inflammatory lesion count at Week 52 compared to DB baseline • IGA Success Rate (dichotomized as yes/no) at Week 52, where success was defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from DB baseline Secondary Efficacy Endpoints • The absolute and percent change from DB baseline in inflammatory lesion count at Weeks 16, 22, 28, 34, 40, 46, and 52 of the OL study • The dichotomized IGA Success Rate at Weeks 16, 22, 28, 34, 40, and 46 • The Subject Satisfaction Questionnaire (SSQ) at Week 52 Week 12 FMX103 1.5% (505 enrolled, 504 in safety population, 410 completed) Double-blind, vehicle-controlled (N=1522) Open-Label (FX2016-13) for subjects who completed the DB study Visit every 6 weeks Vehicle Foam (n=256) FMX103 1.5% (n=495) Vehicle Foam (n=257) FMX103 1.5% (n=514) S tu dy 1 1 S tu dy 1 2 IGA, Investigator’s Global Assessment; DB, double-blind study; OL, open-label study; OTC, over-the-counter. Results Subject Disposition and Double-Blind Baseline Demographics • As shown in Figure 2, 504 subjects who completed the DB study (Study 11: N=217; Study 12: N=287) comprised the All Treated (Safety) population in the OL extension study (Study 13) Figure 2.
    keywords: fmx103; rosacea; study; subjects; treatment; vehicle; week
       cache: skin-1061.pdf
  plain text: skin-1061.txt

        item: #51 of 1356
          id: skin-1062
      author: Del Rosso, James Q; Gold, Linda Stein; Kircik, Leon; Bhatia, Neal; Sadick, Neil; Zirwas, Matthew; Lain, Edward; Stuart, Iain
       title: Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies
        date: 2020-10-27
       words: 3476
      flesch: 42
     summary: Summary Efficacy Summary • FMX103 1.5% demonstrated efficacy over vehicle foam in treating papulopustular rosacea in a pooled population of ~1500 subjects, with effects being observed as early as 4 weeks into treatment • Sub-analyses were performed on the integrated data set to characterize the efficacy of FMX103 1.5% in treating papulopustular rosacea in predefined subgroups of subjects – FMX103 1.5% demonstrated significant efficacy benefits in treating papulopustular rosacea in subgroups of subjects that had either moderate (IGA=3) or severe (IGA=4) disease severity at baseline, with a more pronounced effect in the severe subpopulation • Findings from this integrated efficacy analysis are thus consistent with those from the individual phase 3 studies, both of which achieved statistically significant differences for all primary efficacy endpoints and further demonstrated significant differences as early as 4 weeks into treatment Safety Summary • FMX103 1.5% was generally safe and well tolerated • 341 (22.4%) subjects reported a TEAE during the 2 identical double-blind Phase 3 studies – In general, no differences were observed between treatment groups in the incidence of TEAEs – The most frequently reported TEAEs for FMX103 1.5% vs vehicle, respectively, were viral upper respiratory tract infection (2.4% vs 2.3%), upper respiratory tract infection (1.9% vs 2.5%), and headache (1.4% vs 1.9%) – The majority of TEAEs reported were mild in severity (overall 68%) – 7 subjects reported severe TEAEs; all were considered to be unrelated to treatment, and were similar between treatment groups • 219 (21.7) 122 (23.8) 341 (22.4) Number of TEAEs 350 184 534 Subjects with any serious TEAE, n(%) 3 (0.3) 5 (1.0) 8 (0.5) Number of serious TEAEs 8a 9b 17 Subjects with any treatment-related TEAE, n(%) 3 (0.3) 5 (1.0) 8 (0.5) Number of treatment-related TEAEs 24c 17d 41 Subjects with any TEAE leading to discontinuation, n(%) 7 (0.7) 2 (0.4) 9 (0.6) Number of TEAEs leading to study discontinuation 8e 2f 10 aNausea, chest discomfort, fatigue, seasonal allergy, dehydration, syncope, dyspnea, hypertension bGastrointestinal hemorrhage, chest pain, pyrexia, dyspnea, asthma, hypertension, myocardial infarction, tachycardia cPruritis, rash, dermatitis, dermatitis contact, hair color changes, nail discoloration, skin hyperpigmentation, application site pain, application site erythema, facial pain, nodule, migraine, dizziness, dysgeusia, aphthous ulcer, cheilitis, eye irritation, ophthalmic herpes simplex, sunburn dNail discoloration, rosacea, skin exfoliation, application site pain, facial pain, application site pruritis, headache, cellulitis, skin cancer, urine odor abnormal ePruritis, dermal cyst, dermatitis, telangiectasia, influenza, urinary tract infection, bladder mass fRash pustular, myocardial infarction • The incidence rate of the most frequently reported TEAEs (≥1% in any group) was similar between treatment groups (Table 3)
    keywords: baseline; efficacy; figure; fmx103; foam; subjects; teaes; treatment; vehicle; week
       cache: skin-1062.pdf
  plain text: skin-1062.txt

        item: #52 of 1356
          id: skin-1063
      author: Gooderham, Melinda J.; Kircik, Leon H.; Zirwas, Matthew; Lee, Mark; Kempers, Steven E.; Draelos, Zoe D.; Ferris, Laura; Jones, Terry M.; Saint-Cyr Proulx, Etienne; Bissonnette, Robert; Bhatia, Neal; Guenthner, Scott T.; Koppel, Robert A.; Welgus, Howard; Merritt, Charlotte; Elias, Meg; Navale, Lynn; Higham, Robert C.; Droege, Michael; Berk, David R.
       title: The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study
        date: 2020-10-27
       words: 2356
      flesch: 51
     summary: Phase 2 Proof-of-Concept Study Roflumilast cream 0.15% QD Roflumilast cream 0.05% QD Vehicle QD ENDPOINTS • Primary: EASI change from baseline • Secondary: – EASI % change from baseline – EASI-50 and EASI-75 – BSA – WI-NRS • Exploratory: – vIGA-AD “clear” or “almost clear” – vIGA-AD “clear” or “almost clear” + ≥2-grade improvement • Safety and tolerability 4 weeks Ra nd om iz at io n 1:1:1 N=136 ELIGIBILITY • Mild or moderate atopic dermatitis (vIGA-AD=2 or 3) • Week 1 Week 2 Week 4 LS M ea n Ch an ge F ro m B as el in e, % (9 5% C I) (A) 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 P=0.040 P=0.035 Vehicle (n=45)Roflumilast 0.15% (n=45) Roflumilast 0.05% (n=46) Melinda J. Gooderham,1 Leon H. Kircik,2 Matthew Zirwas,3 Mark Lee,4
    keywords: atopic; cream; dermatitis; easi; roflumilast; viga; week
       cache: skin-1063.pdf
  plain text: skin-1063.txt

        item: #53 of 1356
          id: skin-1064
      author: Guttman-Yassky, E; Blauvelt, A; Eichenfield, L; Paller, A; Armstrong, A; Drew, J; Gopalan, R; Simpson, E
       title: Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements
        date: 2020-10-27
       words: 2411
      flesch: 58
     summary: Patient-Reported Outcomes • LEB-treated patients showed a numerically greater reduction in pruritus NRS by Day 2 vs. placebo-treated patients, with further improvement across LEB arms vs. placebo to Week 16 as assessed by ≥4-point improvement or percent change from Baseline (Figure 3) – Differences in the proportions of patients achieving pruritus NRS change ≥4 points at Day 2: 6.3%, 5.6%, 15.3% of LEB 125 mg Q4W, 250 mg Q4W, 250 mg Q2W vs. 4.5% of placebo-treated patients, respectively Figure 3. SYNOPSIS • Atopic dermatitis (AD) is associated with higher rates of anxiety and depression, likely due to a number of contributing factors such as intense itching, disrupted sleep, stigma, increased healthcare costs, and a decreased quality of life1 • Lebrikizumab (LEB) is a novel, high-affinity monoclonal antibody targeting IL-13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex while leaving endogenous regulation of IL-13 intact • In a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study of LEB in patients with moderate-to-severe AD (NCT03443024),² LEB demonstrated dose-dependent, statistically significant improvement in the primary endpoint (percent change from Baseline to Week 16 in Eczema Area and Severity Index
    keywords: leb; mg q4w; q2w; q4w; week
       cache: skin-1064.pdf
  plain text: skin-1064.txt

        item: #54 of 1356
          id: skin-1065
      author: Papp, Kim; Szepietowski, Jacek C.; Kircik, Leon; Toth, Darryl; Kuligowski, Michael E.; Venturanza, May E.; Sun, Kang; Simpson, Eric L.
       title: Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
        date: 2020-10-27
       words: 2546
      flesch: 54
     summary: Kim Papp, MD, PhD,1 Jacek C. Szepietowski, MD, PhD,2 Leon Kircik, MD,3 Darryl Toth, MD,4 Michael E. Kuligowski, MD, PhD, MBA,5 May E. Venturanza, MD,5 Kang Sun, PhD,5 Eric L. Simpson, MD6 Background ● Atopic dermatitis (AD) is a chronic, inflammatory skin disease that greatly impacts patients’ quality of life1,2 ● Janus kinases (JAKs) modulate inflammatory cytokines involved in the pathogenesis of AD3 and may also directly modulate itch4 ● Ruxolitinib (RUX) is a potent, selective inhibitor of JAK1 and JAK25 ● In a phase 2 study (NCT03011892), RUX cream provided strength-dependent efficacy in patients with AD and a safety profile similar to vehicle6 Objectives ● To report efficacy and safety of RUX cream in patients with AD in two phase 3 studies (TRuE-AD1 [NCT03745638] and TRuE-AD2 [NCT03745651]) Methods Patients and Study Design ● Eligible patients were aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment (IGA) score of 2 or 3, and 3% to 20% affected body surface area ● Key exclusion criteria were unstable course of AD, other types of eczema, immunocompromised status, use of AD systemic therapies during the washout period and during the study, use of AD topical therapies (except bland emollients) during the washout period and during the study, and any serious illness/medical condition that could interfere with study conduct, interpretation of data, or patients’ well-being ● TRuE-AD1 and TRuE-AD2 had identical study designs (Figure 1) – In both studies, patients were randomized (2:2:1) to either of 2 RUX cream strength regimens (0.75% twice daily Efficacy ● Significantly more patients treated with RUX cream regimens vs vehicle demonstrated IGA-TS (primary endpoint); responses were time and strength dependent (Figure 2) ● Significantly more patients treated with RUX cream achieved EASI-75 vs vehicle; responses were time and strength dependent (Figure 3) ● Both strengths of RUX cream showed greater improvement in mean percentage change in EASI scores vs vehicle; statistical significance was observed at Week 2 and later (Figure 4) ● Significantly greater reductions in itch NRS scores were observed within 12 hours of the first application of RUX cream (1.5%; P<0.05; Figure 5) vs vehicle ● Significantly more patients treated with RUX cream demonstrated clinically meaningful reduction in itch (≥4-point improvement in itch NRS) vs vehicle (Figure 6)
    keywords: cream; patients; rux; treatment; vehicle; week
       cache: skin-1065.pdf
  plain text: skin-1065.txt

        item: #55 of 1356
          id: skin-1066
      author: Simpson, Eric; Blauvelt, Andrew; Guttman-Yassky, Emma; Worm, Margitta; Lynde, Charles; Saeki, Hidehisa; Poulin, Yves; Wollenberg, Andreas
       title: Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)
        date: 2020-10-27
       words: 2696
      flesch: 47
     summary: Frequent AEs (≥5% in any treatment group)a Table 2. Tralokinumab 300 mg q2w Placebo q2w Placebo q2w Tralokinumab 300 mg q4w Alternating with placebo Open-label treatment Tralokinumab 300 mg q2w � optional TCS 3:1 randomization Washout of TCS and other AD medication 300 mg q2w after initial loading dose (600 mg) Patients with clinical response of IGA-0/1 or EASI-75 2:2:1 randomization Screening Initial treatment Maintenance treatment Safety follow-up 66 weeks52 weeks16 weeks0-6 weeks Tralokinumab 300 mg q2w Placebo q2w ECZTRA 1 (n=603)
    keywords: ecztra; patients; placebo; q2w; rescue; tralokinumab; week
       cache: skin-1066.pdf
  plain text: skin-1066.txt

        item: #56 of 1356
          id: skin-1067
      author: Elewski, Boni E.; Zirwas, Matthew J.; Langley, Richard G.; Alexis, Andrew F.; Veverka, Karen A.; Zoidis, John; Kurbasic, Azra; Silverberg, Jonathan I.
       title: Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial
        date: 2020-10-27
       words: 2184
      flesch: 36
     summary: Efficacy and safety of tralokinumab with concomitant topical corticosteroids in North American adults with moderate-to-severe atopic dermatitis: a subanalysis of the ECZTRA 3 trial Boni E. Elewski,1 Matthew J. Zirwas,2 [SCORAD]) at week 16 — Cumulative TCS use in tralokinumab-treated patients was lower than that of those who received placebo at week 16, suggesting achievement of endpoints was not likely attributable to TCS use alone Objective • To evaluate the efficacy and safety of tralokinumab 300 mg q2w in combination with TCS in the ECZTRA 3 North American subpopulation at week 16 Methods Study design and patients • ECZTRA 3 was a randomized, double-blind, placebo-controlled, 32-week trial in adult patients with moderate-to-severe AD (Figure 1)
    keywords: american; north; placebo; q2w; tcs; tralokinumab; week
       cache: skin-1067.pdf
  plain text: skin-1067.txt

        item: #57 of 1356
          id: skin-1068
      author: Silverberg, Jonathan I.; Cork, Michael; Wollenberg, Andreas; Katoh, Norito; Steffensen, Louise Abildgaard; Kurbasic, Azra; Olsen, Christina Kurre; Kuznetsova, Alexandra; ?sterdal, Marie Louise; Vilsb?ll, Andreas Westh; Deleuran, Mette
       title: Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis
        date: 2020-10-27
       words: 2496
      flesch: 51
     summary: [bi-weekly to week 8, then at weeks 12 and 16] - Patient-Orientated Eczema Measure (POEM): consisting of seven items eac addressing a specific AD symptom over the last week (itching, sleep, bleeding, weeping, cracking, flaking, and dryness) – patients indicated the frequency of each experienced in the previous week to generate a total score (bi-weekly to week 8, then at weeks 12 and 16) - DLQI and POEM were answered electronically at the study site and all PRO measures were reported prior to clinician assessments 2020 Schedule of PRO assessments in ECZTRA 1-3 Patient-reported outcome measure DLQI POEM Eczema-related sleep NRS (weekly average) Assessed daily with eDiary Assessed daily with eDiary Worst daily pruritus NRS (weekly average) Baseline X X Week 1 Week 2 X X Week 3 Week 4 X X Week 5 Week 6 X X Week 7 Week 8 X X Week 9 Week 10 Visit 5a
    keywords: ecztra; placebo; q2w; tcs; tralokinumab; week
       cache: skin-1068.pdf
  plain text: skin-1068.txt

        item: #58 of 1356
          id: skin-1069
      author: Farberg, Aaron; Ahmed, Kelli; Bailey, Christine ; Russell, Brooke; Douglas, Kelly; Johnson, Clare; Zolochevska, Olga; Cook, Robert; Goldberg, Matthew
       title: A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists
        date: 2020-10-27
       words: 5027
      flesch: 50
     summary: As with the dermatopathologists, the lesion order and timing to which GEP results were presented was randomized for participants. While the head to head comparisons with other GEP tests for melanoma diagnosis do not exist, the cross study comparison of accuracy metrics, the substantially reduced intermediate-risk zone, and the inclusion of melanoma in situ lesions in the development and validation of the test position the 35-GEP test to provide superior diagnostic clarity when compared to existing GEPs for melanocytic neoplasms.21
    keywords: benign; dermatopathologists; diagnosis; gep; lesions; malignant; melanocytic; melanoma; result; study; test
       cache: skin-1069.pdf
  plain text: skin-1069.txt

        item: #59 of 1356
          id: skin-107
      author: Alexis, Andrew; Del Rosso, James; Desai, Seemal R; Downie, Jeanine; Draelos, Zoe D; Feser, Christina; Forconi, Rion; Fowler, Joseph; Gold, Michael; Kaufman-Janette, Joely; Lain, Edward; Lee, Mark; Ling, Mark; Shamban, Ava; Werschler, William; Daniels, AnnaMarie
       title: Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study
        date: 2017-10-27
       words: 1508
      flesch: 53
     summary: AnnaMarie Daniels16 Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 BPX-01 1% BPX-01 2% Vehicle Baseline 0.0% 0.0% 0.0% Week 2 -32.8% -27.6% -25.7% Week 4 -39.7% -43.3% -25.3% Week 8 -50.5% -49.5%
    keywords: acne; lesions; minocycline; reduction; treatment; week
       cache: skin-107.pdf
  plain text: skin-107.txt

        item: #60 of 1356
          id: skin-1070
      author: Estrada, Sarah; Shackelton, Jeffrey; Cleaver, Nathan; Depcik-Smith, Natalie; Cockerell, Clay; Lencioni, Stephen ; Martin, Howard; Wilkinson, Jeffrey; Meldi Sholl, Lauren; Berg, Michael; Russell, Brooke; Zolochevska, Olga; Covington, Kyle; Farberg, Aaron; Goldberg, Matthew; Gerami, Pedram; Hosler, Gregory
       title: Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions
        date: 2020-10-27
       words: 8713
      flesch: 53
     summary: The majority of malignant lesions were biopsied from arms and legs (extremities, 40% of cases in training and validation, p=0.812), while benign lesions were mainly located on patients’ backs (36.5% in training cohort and 41% in validation, p=0.863). The National Society for Cutaneous Medicine 513 diagnosis of pigmented lesions, yet there is a substantial amount of diagnostic discordance that may potentially lead to overtreatment of patients with benign lesions and undertreatment of patients with melanoma.80 The 35-GEP test to distinguish benign from malignant pigmented lesions was developed to improve diagnostic accuracy and reduce diagnostic uncertainty for difficult-to-diagnose cases.
    keywords: benign; cancer; cases; cutaneous; dermatol; diagnosis; doi:10.1016; expression; gene; gep; lesions; malignant; melanocytic; melanoma; nevi; nevus; pathol; protein; risk; samples; skin; spitz; study; test; training; validation
       cache: skin-1070.pdf
  plain text: skin-1070.txt

        item: #61 of 1356
          id: skin-1073
      author: Tamazian, Shant; Chu, Emily; Simpson, Cory L.
       title: Pruritic Rash and Oral Erosions During Nivolumab Treatment for Melanoma
        date: 2021-01-01
       words: 891
      flesch: 42
     summary: Only one case of non-bullous pemphigoid in association with anti-PD-1 therapy has been previously reported.6 Our case further supports that immunotherapy-related BP may present with non-bullous skin lesions and additionally emphasizes the need to monitor closely for oral erosions.2 Conflict of Interest Disclosures: None Funding: C.L.S. is supported by grant NIH K08- AR075846 Immunohistochemical (IHC) staining of the skin biopsy showed linear deposition of complement protein C3d along the dermal-epidermal junction (Figure 2) and enzyme-linked immunosorbent assay (ELISA) revealed anti-BP180 antibodies, confirming a diagnosis of bullous pemphigoid.
    keywords: figure; pemphigoid; skin
       cache: skin-1073.pdf
  plain text: skin-1073.txt

        item: #62 of 1356
          id: skin-1075
      author: Heibel, Haley Danielle; Dhaliwal, Parneet; Marks, Etan; Cockerell, Clay J.
       title: A Case of Metastatic Malignant Melanoma Simulating Granuloma Annulare
        date: 2021-05-21
       words: 1734
      flesch: 38
     summary: The etiology of a granulomatous process associated with metastatic melanoma is unclear, but theories include a cell-mediated immune response against an antigenic factor derived from tumor cells or that melanoma cells secrete cytokines which attract histiocytes and lead to granuloma formation.7 In the setting of granulomatous reactions occurring during the treatment of melanoma, Park et al6 suggested this may represent immune activation against tumor DISCUSSION SKIN May 2021 BRIEF ARTICLE A Case of Metastatic Malignant Melanoma Simulating Granuloma Annulare Haley D. Heibel, MD,1 Parneet Dhaliwal, DO,2 Etan Marks, DO,3 Clay J. Cockerell, MD, MBA1,4 1Cockerell Dermatopathology, Dallas, TX 2Department of Pathology, Baylor University Medical Center, Dallas, TX 3Advanced Dermatology and Cosmetic Surgery, Delray Beach, FL 4Departments of Dermatology and Pathology, UT Southwestern Medical Center, Dallas, TX Malignant melanoma is a complex malignancy that can present with a wide range of histological patterns, including mimicking other malignant tumors and benign entities, such as interstitial granulomatous processes.1,2 Similarly, metastatic melanoma has a wide variety of clinical presentations that may not be visible to the clinician and may not seem suspicious for melanoma.1 All of these factors contribute to the challenges with making an accurate diagnosis of metastatic melanoma.
    keywords: excision; history; melanoma; patient
       cache: skin-1075.pdf
  plain text: skin-1075.txt

        item: #63 of 1356
          id: skin-1076
      author: Silverberg, Jonathan; Pink, Andrew; Olsen, Christina; Weidinger, Stephan
       title: Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial
        date: 2020-10-27
       words: 2657
      flesch: 54
     summary: ● In patients who did not respond to tralokinumab q2w plus TCS at week 16 and then continued with tralokinumab q2w plus TCS treatment up to week 32, TCS use increased from 13.8 g at week 16 to 15.0 g at week 32 (data not shown) ● TCS use decreased from 25.4 g to 16.3 g between weeks 16 and 32 in placebo non-responders who were assigned to tralokinumab q2w plus TCS at week 16 (data not shown) Safety ● Tralokinumab in combination with TCS was well tolerated in patients with moderate-to-severe AD (Table 3) ● Tralokinumab 300 mg q2w plus TCS was significantly more efficacious than placebo plus TCS at treating moderate-to-severe AD ● The lower use of TCS by tralokinumab-treated patients compared to placebo-treated patients through the initial 16-week treatment period, and the lower use of rescue medication in the tralokinumab arm, demonstrated the potential steroid-sparing effects of tralokinumab — By week 16, TCS use was 50% higher for placebo compared to tralokinumab, suggesting the observed high placebo response could be attributed to high TCS use — For comparison, the level of TCS use (38.1 g/month)12 reported in a recent prescription database study in patients with moderate-to-severe AD was similar to that seen in the placebo-treated patients presented here ● The reduction in TCS use is important because prolonged use of TCS is associated with unwanted adverse events, especially in patients concomitantly receiving other forms of corticosteroids,8 reflecting the “real-world” setting Use of topical corticosteroids with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: results from the 32-week, Phase 3 ECZTRA 3 trial Jonathan I. Silverberg,1 Andrew E. Pink,2
    keywords: placebo; q2w; tcs; tralokinumab; treatment; week
       cache: skin-1076.pdf
  plain text: skin-1076.txt

        item: #64 of 1356
          id: skin-1077
      author: Weidinger, Stephan; Pink, Andrew; Francisco, Juan; Kurbasic, Azra; Olsen, Christina; Vilsb?ll, Andreas; de Bruin Weller, Marjolein
       title: Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis
        date: 2020-10-27
       words: 2235
      flesch: 28
     summary: John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK; 3Dermatology Department, Hospital General Universitario de Alicante, Alicante, Spain; 4LEO Pharma A/S, Ballerup, Denmark; 5Department of Dermatology and Allergology, University Medical Center Utrecht, National Expertise Center for Eczema, Utrecht, The Netherlands Patient characteristics ● Patients had a long duration of AD prior to being enrolled into the study; almost half of patients had severe AD (IGA-4) at baseline and mean body surface area (BSA) involvement was close to 50% (Table 2) ● Overall, 60% of patients had a worst PGI-B score of 4 (very much bothered by their AD) at baseline ● ECZTRA 3 included assessment of: - IGA and EASI assessed every 2 weeks - Patient Global Impression of Bother (PGI-B) and Numerical Rating Scale (NRS) for worst daily pruritus assessed daily and recorded as the worst weekly and daily score respectively - Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure (POEM) assessed bi-weekly until week 8, every 4 weeks until week 20, and then at week 28 and 32 Post hoc analysis ● Following HOME recommendations,8 outcomes were selected in the domains o clinician-assessed signs (EASI), patient-reported symptoms (pruritus NRS and POEM) quality of life (DLQI), and a patient global instrument (PGI-B) (Table 1) Conclusions ● Tralokinumab 300 mg every other week in combination with TCS as needed was associated with a high proportion of patients (91%) achieving a clinically meaningful improvement (minimal target) in at least one of the pre-defined disease domains (AD signs and symptoms and AD-related quality of life) 3 months after initiating treatment ● A high proportion of patients (82%) achieved an outcome equivalent to mild disease activity (ideal target) in at least one of the pre-defined disease domains (AD signs and symptoms and AD-related quality of life) during the maintenance treatment phase ● Using a holistic approach combining the achievement of the patients’ impression of burden target (PGI-B) in combination with one other initiation period target increased the proportion of patients who achieved EASI-50 and EASI-75 in the maintenance period ● This post hoc assessment is in line with previous data showing that IGA and EASI scores do not correlate perfectly with symptom outcome measures and suggest that jointly agreed treatment targets between patients and the clinician are important, as are holistic assessments References 1.
    keywords: patients; pgi; tcs; tralokinumab; treatment; week
       cache: skin-1077.pdf
  plain text: skin-1077.txt

        item: #65 of 1356
          id: skin-1078
      author: Simpson, Eric; Werfel, Thomas; Bieber, Thomas; Steffensen, Louise; Kuznetsova, Alexandra; ?sterdal, Marie; Saeki, Hidehisa
       title: Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials
        date: 2020-10-27
       words: 1940
      flesch: 49
     summary: In this post hoc analysis of the ECZTRA 1 and ECZTRA 2 studies, regional differences were observed in disease severity and prior AD treatment, despite identical inclusion criteria ● Japan and Australia enrolled a similarly high proportion of patients with severe AD (IGA-4); however, Australia had the highest levels of prior medication use, compared with low use of medications (including systemic immunosuppressants) in Japan, most likely due to regional differences in AD treatment guidelines ● Regional differences in standard of care, in addition to differential assessment of study outcomes may, in part, explain the differences in therapeutic responses observed between ECZTRA 1 and ECZTRA 2. Prior AD treatments in all randomized patients by region in (A) ECZTRA 1 and (B) ECZTRA 2 A B 0 20 40 60 80 100 P a ti e n ts , % 0 20 40 60 80 100 P a ti e n ts , % ECZTRA 2 ECZTRA 1 Topical corticosteroid potency Topical corticosteroid potency 37.4% 34.8% 15.2% 52.0% 45.7% 23.3% 50.1% 11.1% 12.8% 21.5% 49.6%
    keywords: ecztra; europe; patients
       cache: skin-1078.pdf
  plain text: skin-1078.txt

        item: #66 of 1356
          id: skin-1079
      author: Weidinger, Stephan; Silverberg, Jonathan; Toth, Darryl; Bieber, Thomas; Alexis, Andrew; Elewski, Boni; Pink, Andrew; Hignen, DirkJan
       title: Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial
        date: 2020-10-27
       words: 2734
      flesch: 47
     summary: ● Some patients who did not achieve IGA-0/1 or EASI-75 at week 16 were found to improve their IGA-0/1 or EASI-75 scores with continued tralokinumab q2w plus TCS treatment up to week 32 (Figure 6b) 2:1 randomization Washout of TCS and other AD medication 300 mg q2w after initial loading dose (600 mg) Clinical response defined as IGA-0/1 or EASI-75 Tralokinumab q2w  TCS (n=69) 16-week responders Tralokinumab q4w  TCS (n=69) 1:1 re-randomization Tralokinumab q2w  TCS (n=95) 16-week non-responders Placebo q2w  TCS (n=41) 16-week responders Tralokinumab q2w  TCS (n=79)
    keywords: patients; placebo; q2w; tcs; tralokinumab; week
       cache: skin-1079.pdf
  plain text: skin-1079.txt

        item: #67 of 1356
          id: skin-108
      author: Cook, Robert W; Oelschlager, Kristen; Poteet, Trisha; Maetzold, Derek; Stone, John; Monzon, Federico
       title: Clinical Reliability and Reproducibility of a Prognostic 31-Gene Expression Profile Test for Cutaneous Melanoma, and Association of the Test with Standard Clinicopathologic Factors
        date: 2017-10-27
       words: 773
      flesch: 43
     summary: Pathologic characteristics of all successfully reported samples according to GEP Class result; Stage IIB and above, Breslow >1mm, ulceration, and mitotic rate ≥1/mm2 were significantly associated with Class result (Fisher’s exact test, p<0.0001) Results Conclusions • The 31-GEP test demonstrates robust, reproducible and reliable performance in primary tumor FFPE specimens. Metastatic risk class was determined using a proprietary predictive modeling algorithm which provides two results: a binary classification of Class 1 (low risk) or Class 2 (high-risk) tumor biology, and a quantitative discriminant score from 0 to 1.0, for which 0.5 represents the cutoff score between the binary classes.
    keywords: class; risk; test
       cache: skin-108.pdf
  plain text: skin-108.txt

        item: #68 of 1356
          id: skin-1080
      author: Stein-Gold, Linda; Moore, Angela; Tanaka, S. Ken; Johnson, Jodi; Grada, Ayman
       title: Reduced Blood-brain Barrier Penetration of Sarecycline Relative to Minocycline in Rats Corresponds with Lipophilicity and Low Vestibular Side Effects
        date: 2020-10-27
       words: 709
      flesch: 55
     summary: Vestibular adverse events were low in Phase 3 efficacy and safety studies for sarecycline Time Mcn-pl Scn-pl Mcn-br Scn-br (hours) µg/mL µg/mL µg/g µg/g 1 0.333 0.460 0.074 BLQ 3 0.174 0.217 0.139 BLQ 6 0.077 0.049 0.068 BLQ Pl = plasma, Br = brain, Mcn = minocycline, Scn = sarecycline Limit of quantitation (LOQ) (plasma) = 0.025 µg/mL, LOQ (brain) = 0.05 µg/g; BLQ – Below the limit of quantitation Compound pH 5.5 pH 7.4 Sarecycline HCl -0.16 + 0.01 -0.26 + 0.01 Doxycycline HCl -0.00 + 0.02 -0.18 + 0.03 Minocycline HCl 0.09 + 0.02 0.12 + 0.02 Octanol/water distribution coefficients of sarecycline HCl, minocycline HCl, and doxycycline HCl at 25°C. Unlike minocycline, sarecycline was not detectable in the brain in rats Results - Table 2.
    keywords: brain; minocycline; sarecycline
       cache: skin-1080.pdf
  plain text: skin-1080.txt

        item: #69 of 1356
          id: skin-1081
      author: Chimalakonda, Anjaneya; Burke, James; Cheng, Lihong; Catlett, Ian; Patel, Aditya; Shen, Jun; Girgis, Ihab; Banerjee, Subhashis; Throup, John
       title: Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors
        date: 2020-10-27
       words: 1888
      flesch: 45
     summary: Tofacitinib 10 mg BID is approved for treating ulcerative colitis but not for rheumatoid arthritis.9 Tofacitinib, upadacitinib, and baricitinib: margins to TYK2 inhibitor IC50 are provided for the highest approved dose. BID, twice daily; IC50, half-maximal inhibitory concentration; JAK, Janus kinase; QD, once daily; TYK, tyrosine kinase 2. JAK 1−3 and TYK2 inhibitor pharmacokinetic parameters and whole blood IC50 • At clinically relevant doses, deucravacitinib Cmax, Cave, and Cmin were higher than or close to the TYK2 IC50 value, but were considerably lower than JAK 1/3 and JAK2 IC50 values (Figure 3) • Cmax, Cave, and Cmin values for tofacitinib, upadacitinib, and baricitinib were many-fold lower than TYK2 IC50 values, but were above or within range of JAK 1/3 and JAK2 IC50 values Figure 3.
    keywords: ic50; jak; tyk2
       cache: skin-1081.pdf
  plain text: skin-1081.txt

        item: #70 of 1356
          id: skin-1082
      author: Kirsch, Brandon; Armas, Danielle; Chadha, Deepak
       title: A Four-Way, Cross-Over Design, Randomized, Double-Blinded, Placebo-&Active-Controlled Study for the Evaluation of the Effect of a Supratherapeutic Dose of Sofpironium Bromide Gel, 15% Applied Topically on the QT/QTc Intervals in Adult Healthy Volunteers
        date: 2020-10-27
       words: 1011
      flesch: 65
     summary: (0%) 3 (5%) Table 1: Adverse Event Frequency by Treatment – Number of Subjects Reporting the Event (% of Subjects Dosed) (Safety Population) (≥5%) Results This was a randomized, double-blind (with respect to the supratherapeutic dose (6-fold) of sofpironium bromide gel, 15% and placebo gel only) and active-controlled (with respect to the moxifloxacin and therapeutic dose of sofpironium bromide gel, 15%), single-dose, 4-way crossover TQT study. In a study designed to mimic exposure that may occur under extreme circumstances in healthy subjects (BBI-4000-CL-109), a single 6-fold application of sofpironium bromide gel, 15% under occlusion showed a 3-fold increase in maximum sofpironium exposure compared to the intended therapeutic dose.
    keywords: bromide; dose; gel; sofpironium
       cache: skin-1082.pdf
  plain text: skin-1082.txt

        item: #71 of 1356
          id: skin-1083
      author: Kwong, Pearl; Baldwin, Hilary; Glaab, Debbie; Schreiber, Rhonda; Hignett, Emma
       title: Review of Mechanisms of Release of Commonly Prescribed Tetracyclines
        date: 2020-10-27
       words: 1153
      flesch: 44
     summary: The most common MORs used in dermatology are immediate release (IR), delayed release (DR), and extended release (ER). No Slide Title This review highlights the evolution of oral formulations of tetracyclines most prescribed in dermatology.
    keywords: doxycycline; information; minocycline; release
       cache: skin-1083.pdf
  plain text: skin-1083.txt

        item: #72 of 1356
          id: skin-1084
      author: Patel, Anisha; Seminario-Vidal, Lucia
       title: Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer
        date: 2020-10-27
       words: 1984
      flesch: 44
     summary: Characteristics of these 2 rash types are presented in Table 1.11 • Retrospective data from 2 patients who experienced alpelisib-associated rash showed histology consistent with a hypersensitivity reaction.11 • Laboratory assessment data showed that patients who developed rash had an increase in blood eosinophils after 2 weeks of alpelisib treatment compared with baseline (2.7% vs 4.4%, P<0.05); a trend toward elevated ALT was also observed.11 – No differences in lymphocyte, neutrophil, or monocyte counts were reported between patients who developed rash and those who did not. – Rash leading to alpelisib treatment discontinuation did not occur frequently in clinical studies and most patients were able to resume anticancer treatment upon rash resolution.
    keywords: alpelisib; cancer; grade; patients; rash; treatment
       cache: skin-1084.pdf
  plain text: skin-1084.txt

        item: #73 of 1356
          id: skin-1085
      author: Robert, Caroline; Grob, Jean; Stroyakovskiy, Daniil; Karaszewska, Boguslawa; Hauschild, Axel; Levchenko, Evgeny; Sileni, Vanna; Schachter, Jacob; Garbe, Claus; Bondarenko, Igor; Nathan, Paul; Ribas, Antoni; Davies, Michael; Flaherty, Keith; Burgess, Paul; Tan, Monique; Gasal, Eduard; Schadendorf, Dirk; Long, Georgina
       title: Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis
        date: 2020-10-27
       words: 2494
      flesch: 52
     summary: DOR in Patients Treated With D+T With CR or PR Patients With CR Patients With PR COMBI-d Patients, n Median DOR (95% CI), mo 39 NR (34.5-NR) 107 9.2 (7.2-10.5) COMBI-v Patients, n Median DOR (95% CI), mo 70 49.7 (27.6-NR) 167 10.8 (8.5-11.3) CR, complete response; D, dabrafenib; DOR, duration of response; NR, not reached; PR, partial response; T, trametinib. Baseline Characteristics in Patients With and Without CR • A higher proportion of patients who achieved CR had Eastern Cooperative Oncology Group performance status (ECOG PS) 0, normal LDH levels, and < 3 organ sites with metastases at baseline compared with patients who did not have a CR (Table 3)
    keywords: combi; disease; patients; response; years
       cache: skin-1085.pdf
  plain text: skin-1085.txt

        item: #74 of 1356
          id: skin-1086
      author: Draelos, Zoe; Tanghetti, Emil
       title: A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%
        date: 2020-10-27
       words: 797
      flesch: 50
     summary: The investigator applied the products with a gloved hand to obtain an even film, moving study product down the back until it would no longer spread ◾ These results are supported by the differences in the rheological profiles of the two products, in which tazarotene lotion exhibits lower yield stress and lower intrinsic viscosity versus trifarotene cream3 REFERENCES 1.
    keywords: lotion; trifarotene
       cache: skin-1086.pdf
  plain text: skin-1086.txt

        item: #75 of 1356
          id: skin-1087
      author: Melin, Matthew; Reinders, Jennifer; Wubben, Angie; Cecconi, Katie
       title: The Synergistic, Amplifying Use of Micronized Purified Flavanoid Fraction, Proprietary Ceramide Emulsion, and Dermal Microdeformation Fuzzy Wale Compression Under Inelastic Compression for the Management of Venous Leg Ulcers
        date: 2020-10-27
       words: 908
      flesch: 36
     summary: Initiation MPFF (diosmiplex 630mg), proprietary 3:1:1 ceramide dominant emulsion, fuzzy wale dermal compression under inelastic compres- sion, HOCL wound washes The Synergistic, amplifying use of Micronized Purified Flavanoid Fraction, proprietary ceramide emulsion, and dermal microdeformation fuzzy wale compression under inelastic compression for the management of Venous Leg Ulcers ■ Matthew M. Melin, MD, FACS, RPVI,FACCWS; Jennifer Reinders, WOCN; Angie Wubben, WOCN; Katie Cecconi, PA ■ Wound Healing Institute, M Health Fairview, Edina, MN OBJECTIVE Assess use of simultaneous treatment methods for accelerated wound healing and dermatitis improvement CONCLUSIONS Day 1 initiated MPFF (diosmiplex 630mg), proprietary 3:1:1 ceramide emulsion, fuzzy wale compression with inelastic compression (applied by husband)
    keywords: compression; day; venous; wound
       cache: skin-1087.pdf
  plain text: skin-1087.txt

        item: #76 of 1356
          id: skin-1088
      author: Anderson, Katlyn
       title: Step-up Therapy with Skin Barrier Repair Emulsion in Personal Protective Equipment (PPE) Associated Adverse Skin Reactions during the COVID-19 Pandemic
        date: 2020-10-27
       words: 700
      flesch: 50
     summary: Gloves CONCLUSIONS Step-up and maintenance therapy with a 3:1:1 skin barrier repair emulsion was associated with improved outcomes in PPE associated skin irritation on the hands. It is therefore important to re-evaluate and evolve approaches in the prevention, treatment, and maintenance of PPE associated ASRs.
    keywords: barrier; ppe; skin
       cache: skin-1088.pdf
  plain text: skin-1088.txt

        item: #77 of 1356
          id: skin-1089
      author: Kirsch, Brandon; Dubois, Janet; Zaiac, Martin; Ahuja, Sanjeev; Chadha, Deepak
       title: A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis
        date: 2020-10-27
       words: 1194
      flesch: 59
     summary: Approximately 2.1% of individuals <18 years of age have primary hyperhidrosis with ~65% having axillary [11] Table 2: Frequency of Anticholinergic TEAEs (≥5%) (n=21) Dry Eye 1 (4.8%)
    keywords: hyperhidrosis; severity; study; subjects
       cache: skin-1089.pdf
  plain text: skin-1089.txt

        item: #78 of 1356
          id: skin-109
      author: Fleming, Martin; Johnson, Clare; Covington, Kyle; Gadzia, Joseph; Dillon, Larry; Monzon, Frederico
       title: Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort
        date: 2017-10-27
       words: 1021
      flesch: 54
     summary: At the subsequent visit following receipt of GEP test result, follow-up recommendations were again collected to capture any changes in management. • Changes were categorized as increases, decreases or no change based on comparison of management plans pre- and post-receipt of GEP test result.
    keywords: class; gep; management; risk
       cache: skin-109.pdf
  plain text: skin-109.txt

        item: #79 of 1356
          id: skin-1090
      author: Rice, ZP; Pieretti, LJ; Wheeler, A; Payne, J; Gillard, KK; Hebert, AA
       title: Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents
        date: 2020-10-27
       words: 2839
      flesch: 51
     summary: In general, there is a lack of awareness of hyperhidrosis as a bona fide medical condition and an underappreciation for the extent of burden caused by the disease.3-7 Though primary focal hyperhidrosis typically has a childhood/adolescent onset, very few studies exist on the impact and burden of the disease in younger patients compared with adult patients. – Areas with excessive sweating were generally consistent with focal hyperhidrosis, including palmar (96%), axillary (86%), plantar (86%), craniofacial (61%), back (61%), and inguinal (18%) regions.
    keywords: age; children; figure; hyperhidrosis; impact; life; participants; quality; sweating
       cache: skin-1090.pdf
  plain text: skin-1090.txt

        item: #80 of 1356
          id: skin-1091
      author: Hull, M; Gillard, KK; Peterson-Brandt, J; Klein, SZ
       title: Depression, Anxiety, Health Care Costs, and Utilization among Patients with Hyperhidrosis in a Real‑World Database Analysis
        date: 2020-10-27
       words: 3568
      flesch: 4
     summary: The condition has reportedly been associated with impacts on health‑related quality of life, social and emotional stress, and a relatively high risk of concomitant depression and anxiety2‑5 • Real‑world observational data are limited in patients with hyperhidrosis, suggesting that additional research is warranted OBJECTIVES • To describe clinical characteristics and treatment patterns of patients with hyperhidrosis • To determine the prevalence of depression and anxiety among patients with hyperhidrosis relative to patients in a control cohort • To examine health care resource utilization (HCRU) and costs associated with concomitant depression and/or anxiety in patients with hyperhidrosis METHODS Patient Selection • Patients were identified from January 2010 through November 2017 from the Optum Research Database, a de‑identified database that contains medical and pharmacy information for commercial and Medicare Advantage claims • Inclusion criteria for patients newly diagnosed with hyperhidrosis were – Commercial health plan members with continuous enrollment with medical and pharmacy coverage for 12 months before (the baseline or pre‑index period) and ≥12 months after the index date (follow‑up period) – ≥2 hyperhidrosis diagnosis codes and/or prescription claims for extra‑ or prescription‑strength antiperspirant; the index date was the first observed claim indicating hyperhidrosis – No claims for medical procedures (botulinum toxin A, microwave thermolysis, suction curettage, iontophoresis, endoscopic thoracic sympathectomy) with codes specific to hyperhidrosis treatment during the baseline period – No claims for the above medical procedures or pharmacy claims for oral systemic therapies not specific to hyperhidrosis treatment within 7 days of the index date • Patients in the hyperhidrosis cohort were followed for a variable period of ≥12 months • A control cohort (CC) was constructed with comparable index year, age, gender, and health plan region to the hyperhidrosis cohort, and had the following key inclusion criteria – No evidence of hyperhidrosis based on medical claims or pharmacy claims for prescription‑strength antiperspirants – Continuous enrollment criteria identical to that of the hyperhidrosis cohort • The index date for control cohort patients was selected as a random date of health care resource utilization during the identification period, such as an office visit, inpatient admission, or a prescription claim; patients were followed for a fixed 12‑month period beginning on the index date Outcomes • Outcome variables were – Index year, age, gender, and geographic region – Baseline comorbid conditions, defined using indicator variables for specific disease conditions based on International Classification of Disease (ICD)‑9‑CM and ICD‑10 diagnoses employed by the Clinical Classifications Software, managed by the Agency for Healthcare Research and Quality – Hyperhidrosis treatments (hyperhidrosis cohort only, variable follow‑up period) P values were computed with clustering; Rao‑Scott test was used for binary measures Comorbidities were identified by Clinical Classification Software for ICD‑9‑CM/ICD‑10‑CM codes from the AHRQ AHRQ, Agency for Healthcare Research and Quality; ICD, International Classification of Disease Treatment Patterns • A slight majority of patients in the hyperhidrosis cohort (51.6%) received treatment with prescription antiperspirants, while 13.1% had prescription fills for oral systemic therapies; a very small percentage of the hyperhidrosis sample received procedures for hyperhidrosis treatment, including botulinum toxin A (Figure 1) • Prescription antiperspirants were the earliest initiated therapies in the hyperhidrosis cohort during the variable follow‑up period, with a mean ± SD time to first prescription fill of 1.4 ± 6.3 months (Table 2); this is consistent with the International Hyperhidrosis Society (IHhS) clinical treatment algorithm, which generally recommends antiperspirants as a first line of therapy for hyperhidrosis – While glycopyrronium cloth is also recommended by the IHhS as a first line treatment for primary axillary hyperhidrosis, the therapy was not available in the US until October 2018; since the study included data through November 2018, there were very few prescriptions made for glycopyrronium cloth (n=6) in this dataset, precluding meaningful analysis of the treatment option •
    keywords: anxiety; cohort; costs; depression; follow‑up; hyperhidrosis; patients; period; treatment
       cache: skin-1091.pdf
  plain text: skin-1091.txt

        item: #81 of 1356
          id: skin-1092
      author: Yavel, Regina; Overcash, J. Scott; Zhi, Jay; Cutler, Eva; Cutler, David; Fang, Jane
       title: Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis
        date: 2020-10-27
       words: 1225
      flesch: 64
     summary: • Mean (SD) dose applied was 137 (44.9) mg among the combined subject group (~55% of the full dose possible, 250 mg). • Secondary objectives were to evaluate the safety and tolerability of tirbanibulin ointment 1% and to determine the PK of tirbanibulin metabolites.
    keywords: mean; ointment; scalp; tirbanibulin
       cache: skin-1092.pdf
  plain text: skin-1092.txt

        item: #82 of 1356
          id: skin-1093
      author: Schlesinger, Todd; Bhatia, Neal; Berman, Brian; Grada, Ayman; Torra, Albert; Cutler, David; Lebwohl, Mark
       title: Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies
        date: 2020-10-27
       words: 1034
      flesch: 63
     summary: Pooled LSR composite scores (the sum of all 6 LSRs) by visit and treatment were analyzed. Regarding composite LSR scores, LSR peaked on D8 with tirbanibulin with a maximum mean composite LSR score of 4.1, decreased significantly by D15, and resolved by D29- D57.
    keywords: day; lsr; tirbanibulin; treatment
       cache: skin-1093.pdf
  plain text: skin-1093.txt

        item: #83 of 1356
          id: skin-1094
      author: Blauvelt, Andrew; Kempers, Steven; Schlesinger, Todd; Lain, Edward; Wang, Hui; Cutler, David; Lebwohl, Mark; Fang, Jane; Kwan, Rudolf
       title: Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies
        date: 2020-10-27
       words: 1089
      flesch: 68
     summary: PowerPoint Presentation • AK lesion count to Day 57 is shown in Figure 2. Reduction in AK lesion count to Day 57 was significantly greater than vehicle for all post-Baseline visits until Day 57 (Table 2). Complete and partial clearance rates of AK lesions (ITT population) • Primary and secondary endpoints were complete (100%) and partial (≥75%) clearance of AK lesions at Day (D) 57.
    keywords: day; tirbanibulin; vehicle
       cache: skin-1094.pdf
  plain text: skin-1094.txt

        item: #84 of 1356
          id: skin-1095
      author: Migden, Michael; Rischin, Danny; Sasane, Medha; Mastey, Vera; Pavlick, Anna; Schmults, Chrysalyne; Chen, Zhen; Guminski, Alexander; Hauschild, Axel; Bury, Denise; Chang, Anne Lynn; Rabinowits, Guilherme; Ibrahim, Sheriff; Lowy, Israel; Fury, Matthew; Li, Siyu; Chen, Chieh-I
       title: Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial
        date: 2020-10-27
       words: 3070
      flesch: 55
     summary: • At baseline and day 1 of each treatment cycle until progression, patients were administered the QLQ-C30.9 Group 1 – Adult patients with metastatic (nodal and/or distant) CSCC Cemiplimab 3 mg/kg Q2W IV, for up to 96 weeks Cemiplimab 350 mg/kg Q3W IV, for up to 54 weeks Tumor response assessment by ICR (RECIST v1.1 for scans; modified WHO criteria for photos) EORTC QLQ-C30 quality of life questionnaire administered at baseline and day 1 of each treatment cycle Tumor imaging every 8 weeks for the assessment of clinical activity Tumor imaging every 9 weeks for the assessment of clinical activity Group 3 – Adult patients with metastatic (nodal and/or distant) CSCC Group 2 – laCSCC Key inclusion criteria • ECOG performance status of 0 or 1 • Adequate organ function • Groups 1 and 3: - At least one lesion measurable by RECIST v1.1 • Synopsis • Cutaneous squamous cell carcinoma (CSCC) is considered the second most common malignancy in the US, although its exclusion from national cancer registries has presented a barrier to epidemiologic characterization.1 - Estimates suggest an incidence of around 1.5 million cases per year in the US.2 - The incidence of CSCC is increasing yearly in the US.3 • Most CSCC patients have a favorable prognosis, but for the patients who are not amenable to curative surgery, palliative systemic therapy has been administered.1 • Cemiplimab is a programmed cell death (PD)-1 inhibitor that is indicated for treatment of CSCC in patients with metastatic (mCSCC) or locally advanced (laCSCC) disease not amenable to curative surgery or curative radiation.4 - Cemiplimab demonstrated a robust durable clinical response and a safety profile consistent with other checkpoint inhibitors in a recent Phase 2 study (NCT02760498).5–8 - Longer follow-up data from the Phase 2 study of cemiplimab in patients with advanced CSCC is presented in the poster titled “Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC):
    keywords: baseline; cscc; cycle; hrql; inc; patients; pharmaceuticals; regeneron; treatment
       cache: skin-1095.pdf
  plain text: skin-1095.txt

        item: #85 of 1356
          id: skin-1096
      author: Jalbert, Jessica; Chen, Chieh-I; Wu, Ning; Fury, Matthew; Ge, Wenzhen; Ruiz, Emily
       title: Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice
        date: 2020-10-27
       words: 2257
      flesch: 57
     summary: Ning Wu,1 Matthew G Fury,1 Emily Ruiz,2 Wenzhen Ge1 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Brigham and Women’s Hospital, Boston, MA, USA • Among patients with HHI treatment discontinuation, the risk of 12-month HHI reinitiation, median time (95% CIs) to reinitiation, and the risk of treatment discontinuation following second HHI use at 12 months was estimated via Kaplan–Meier analysis and stratified by type of HHI use (i.e. potential adjuvant, neoadjuvant, or both neoadjuvant and adjuvant use) using a 60-day grace period. The risk of HHI treatment discontinuation at 12 months, and median time (95% confidence intervals [CIs]) to treatment discontinuation was estimated via Kaplan– Meier survival analysis using different grace periods and stratified by type of HHI use (i.e. potential adjuvant, neoadjuvant, or both neoadjuvant and adjuvant use) using a 60-day grace period.
    keywords: days; grace; hhi; period; treatment
       cache: skin-1096.pdf
  plain text: skin-1096.txt

        item: #86 of 1356
          id: skin-1097
      author: Rischin, Danny; Khushalani, Nikhil; Schmults, Chryslalyne; Guminski, Alexander; Chang, Anne Lynn; Lewis, Karl; Lim, Annette; Hernandez-Aya, Leonel; Hughes, Brett; Schadendorf, Dirk; Hauschild, Axel; Stankevich, Elizabeth; Booth, Jocelyn; Yoo, Suk-Young; Chen, Zhen; Okoye, Emmanuel; Lowy, Israel; Fury, Matthew; Migden, Micahel
       title: Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up
        date: 2020-10-27
       words: 3265
      flesch: 56
     summary: Maculopapular rash 23 (11.9) 1 (0.5) Anemia 22 (11.4) 8 (4.1) Hypothyroidism 22 (11.4) 0 Headache 21 (10.9) 0 Upper respiratory tract infection 20 (10.4) 0 †TEAEs reported in ≥10% of patients, ordered by frequency of any grade. Post hoc analysis of health-related quality of life in the same patient population is presented in the poster titled “Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial”, also available on the 2020 Fall Clinical Dermatology Conference platform.
    keywords: group; inc; merck; months; patients; pharmaceuticals; regeneron; response
       cache: skin-1097.pdf
  plain text: skin-1097.txt

        item: #87 of 1356
          id: skin-1098
      author: Rabinowits, Guilherme; Homsi, Jade; Nikanjam, Mina; Gentry, Rhonda; Strasswimmer, John; Venna, Suraj; Migden, Michael; Chandra, Sunandana; Ruiz, Emily; Zhang, Haixin; McGinniss, Jennifer; Seluzhytsky, Alex; Desai, Jigar
       title: Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma
        date: 2020-10-27
       words: 1656
      flesch: 46
     summary: This initial demographic analysis of patients with advanced CSCC receiving cemiplimab in real-world practice indicates that most patients were male and elderly, with ~20% being immunosuppressed or immunocompromised to varying degrees. However, a small percentage of patients develop locally advanced CSCC, that is not amenable to curative surgery or curative radiotherapy (RT).4 • Until recently, patients with advanced CSCC, who were not candidates for curative surgery or radiation, had poor prognosis.5,6 • Cemiplimab is a high-affinity, monoclonal antibody that blocks programmed cell death (PD)-1 binding to PD-ligand (L)1 and PD-L2 and has demonstrated substantial antitumor activity in patients with advanced CSCC.4, 7-9 • Cemiplimab (cemiplimab-rwlc in the US) is approved by the European Medicines Agency and is the first PD-1 inhibitor approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic CSCC who are not candidates for curative surgery or curative radiation.10,11 • Limited data exist on the clinical characteristics, management, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice.
    keywords: cemiplimab; cscc; inc; patients; pharmaceuticals; regeneron; usa
       cache: skin-1098.pdf
  plain text: skin-1098.txt

        item: #88 of 1356
          id: skin-1099
      author: Arrowitz, CE; Jiang, L; Hino, PD; Weber, TM
       title: Compatibility of a Colloidal Oatmeal Containing Body Wash for Pediatric Subjects with Atopic Dermatitis
        date: 2020-10-27
       words: 956
      flesch: 60
     summary: Baseline Week 1 Week 2 AGREE DISAGREE ** 62.9% 14.3% ** 71.4% 14.3% 28.6% 42.8% **Statistically significant compared to baseline (p!0.001) 100% 80% 60% 40% 20% 0% % S u b je c ts Baseline Week 1 Week 2 AGREE DISAGREE ** 45.7% 40.0% 14.3% ** 74.3% 20.0% 80.0% **Statistically significant compared to baseline (p!0.001) 100% 80% 60% 40% 20% 0% % S u b je c ts Baseline Week 1 Week 2 AGREE DISAGREE * 51.4% 34.3%37.2% * 62.9% 25.7% 50.0% *Statistically significant compared to baseline (p!0.05) 100% 80% 60% 40% 20% 0% % S u b je c ts Baseline Week 1 Week 2 AGREE DISAGREE * 60.0% 25.7% 31.4% * 65.8% 17.2% 51.4% *Statistically significant compared to baseline (p!0.05) The following clinical trial tested a specially formulated Mild Cream Body Wash (MCBW) containing 2% colloidal oatmeal (skin protectant), mild surfactants, Ceramide NP, and components of the natural moisturizing factor on children with AD.
    keywords: baseline; skin; week
       cache: skin-1099.pdf
  plain text: skin-1099.txt

        item: #89 of 1356
          id: skin-110
      author: Hsueh, Eddy C; DeBloom, James R; Lee, Jonathan; Sussman, Jeffrey J; Slingluff, Jr, Craig L; McMasters, Kelly M
       title: Interim Analysis of Survival Outcomes in a Prospective Multicenter Cohort Evaluating a Prognostic 31-Gene Expression Profile (GEP) Test for Melanoma
        date: 2017-10-27
       words: 1104
      flesch: 65
     summary: Physicians enrolled CM pts who were ≥16 years old and had successful GEP test results. This interim analysis of a prospective, multicenter study confirms the association between GEP class and outcomes (p<0.0001).
    keywords: analysis; class; gep; test
       cache: skin-110.pdf
  plain text: skin-110.txt

        item: #90 of 1356
          id: skin-1100
      author: Cork, Michael; Tha?i, Diamant; Eichenfield, Lawrence; Arkwright, Peter; Chen, Zhen; Kamal, Mohamed; O'Malley, John; Bansal, Ashish
       title: Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study
        date: 2020-10-27
       words: 3076
      flesch: 55
     summary: Here we present data from the patient population consisting of children who continued from the phase 2a study and received their original assigned regimen (2 mg/kg qw or 4 mg/kg qw, up to a maximum of 300 mg) in the OLE study Endpoints • Primary endpoints – Concentration–time profile (phase 2a study) of dupilumab, including PK parameters such as the area under the concentration time curve from 0 to the last measurable concentration (AUClast), maximal concentration (cmax), and time to cmax (tmax) – Incidence and rate of adverse events (phase 3 OLE study) Completion of Phase 2a study Baseline A B End of treatment End of study Screening period Screening visit between D –28 and D –1 Phone visits at W1, W2, W3 Weekly telephonic appraisalsc between in-clinic visitsd Treatment period Follow-up period W4 W260 W272W52D1 1st dose Part Aa Safety review of data up to 2 weeks from the first 8 patients in cohort 1A Cohort 1A (2 mg/kg in age group ≥ 12 to < 18 years) The second study is an ongoing, phase 3, OLE study (NCT02612454) enrolling pediatric patients who participated in previous dupilumab AD trials (Figure 1B) – Patients with a serious treatment-emergent adverse event (TEAE) deemed related to the study drug or with a TEAE related to study drug which led to discontinuation were not eligible to enroll in the OLE study – Patients continued on their original assigned regimen (2 mg/kg or 4 mg/kg qw) •
    keywords: dupilumab; ole; phase; study
       cache: skin-1100.pdf
  plain text: skin-1100.txt

        item: #91 of 1356
          id: skin-1101
      author: Nguyen, Tien; Lima, Hermenio; Finklea, Lindsey; Zhang, Haixin; Richman, Daniel; Korotzer, Andrew; Bansal, Shikha
       title: Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE)
        date: 2020-10-27
       words: 1133
      flesch: 51
     summary: We present baseline data from a real-world registry of adult AD patients, initiating commercial dupilumab treatment for AD per approved prescribing information OBJECTIVE • To report patient and family history of AD, and AD treatments taken before treatment initiation with dupilumab in patients from the PROSE registry Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE) Tien Q. Nguyen1, Hermenio Lima2, Lindsey Finklea3, Haixin Zhang4, Daniel Richman5, Andrew Korotzer4, Shikha Bansal4 1First OC Dermatology, Fountain Valley, CA, USA; 2McMaster University, Hamilton, ON, Canada; 3RFSA Dermatology, San Antonio, TX, USA; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 5Sanofi Genzyme, Cambridge, MA, USA CONCLUSIONS • Family history of AD was common in patients enrolled in this real-world registry • Comorbid ocular diseases were frequently reported, including one-fifth of patients reporting seasonal allergic conjunctivitis • AD treatment history (life-long recall).
    keywords: history; patients; table
       cache: skin-1101.pdf
  plain text: skin-1101.txt

        item: #92 of 1356
          id: skin-1102
      author: Shrager, Daniel; Guenthner, Scott; Cohen, David; Zhang, Haixin; Richman, Daniel; Korotzer, Andrew; Bansal, Shikha
       title: Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE)
        date: 2020-10-27
       words: 1328
      flesch: 54
     summary: We present baseline data from a real-world registry of adult AD patients, initiating commercial dupilumab treatment for AD per approved prescribing information OBJECTIVE • To report baseline disease severity and treatment burden of AD in patients initiating dupilumab using data from the PROSE registry Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE) Daniel I. Shrager1, Scott Guenthner2, David Cohen3, Haixin Zhang4, Daniel Richman5, Andrew Korotzer4, Shikha Bansal4 1Alpha Dermatology of PA, LLC, Sellersville, PA; 2The Indiana Clinical Trials Center, PC, Plainfield, IN; 3Skin Care Physicians of Georgia, Macon, GA; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY; 5Sanofi Genzyme, Cambridge, MA; USA CONCLUSIONS • Patients initiating dupilumab in routine clinical practice had significant burden of disease as determined by both patient- and clinician-assessed outcomes of AD lesions and quality of life • AD symptomology extended beyond itch and included skin sensitivity to touch and disturbances to sleep • More than half of the patients in PROSE were on ≥ 1 medication at study baseline, that included oral and topical corticosteroids and systemic AD treatments, signifying a high treatment burden References: Analysis • Data presented here are from the first interim analysis set of adult patients receiving dupilumab (data cutoff: July 2019) •
    keywords: disease; mean; patients
       cache: skin-1102.pdf
  plain text: skin-1102.txt

        item: #93 of 1356
          id: skin-1103
      author: Kircik, Leon; Lebwohl, Mark; Papp, Kim; Gooderham, Melinda; Stein Gold, Linda; Draelos, Zoe; Kempers, Steven; Tyring, Stephen; Albrecht, Lorne; Wiseman, Marni; Ferris, Laura; Smith, Kathleen; Higham, Robert; Navale, Lynn; Welgus, Howard; Berk, David
       title: Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study
        date: 2020-10-27
       words: 2453
      flesch: 53
     summary: For the primary endpoint, superior efficacy was demonstrated for both dose levels of roflumilast cream vs vehicle cream (Figure 1)4 CONCLUSIONS • Roflumilast once-daily cream 0.3% and 0.15% showed significant improvement of plaque psoriasis severity measured by achievement of IGA “clear” or “almost clear” • Roflumilast cream demonstrated improvement in patient-reported burden of psoriasis signs and symptoms and QoL • In a randomized, double-blind, phase 2b trial of 331 adults with chronic plaque psoriasis, roflumilast cream administered once daily was superior to vehicle cream and led to achievement of clear or almost clear skin based on Investigator Global Assessment (IGA) at Week 6 (Figure 1)4 •
    keywords: burden; cream; item; psd; psoriasis; roflumilast; vehicle; week
       cache: skin-1103.pdf
  plain text: skin-1103.txt

        item: #94 of 1356
          id: skin-1104
      author: Stein Gold, Linda; Lebwohl, Mark; Papp, Kim; Gooderham, Melinda; Kircik, Leon; Draelos, Zoe; Kempers, Steven; Pariser, David; Alonso-Llamazares, Javier; Toth, Darryl; Smith, Kathleen; Higham, Robert; Navale, Lynn; Welgus, Howard; Berk, David
       title: Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study
        date: 2020-10-27
       words: 2827
      flesch: 57
     summary: Here we report the effect of roflumilast cream on itch, a highly prevalent and frequently bothersome symptom of chronic plaque psoriasis that negatively impacts quality of life,3 assessed using patient-reported outcome (PRO) measures in this study OBJECTIVE • To assess the effect of roflumilast cream on various PROs related to itch METHODS • Design: parallel-group, randomized, double-blind, vehicle-controlled phase 2b study (ClinicalTrials.gov NCT03638258; Figure 1)2 • Location: 30 sites in the United States and Canada CONCLUSIONS • Once-daily roflumilast cream demonstrated significant improvement in reducing itch in patients with psoriasis compared with vehicle cream – Patients reported a rapid and clinically significant reduction in the severity and burden of itch – Significant itch reduction occurred by Week 2 and continued with further reductions through Week 12 – In a subgroup of patients with greater severity of itch at baseline (WI-NRS ≥6), more than half of the patients had a substantial (≥4-point) reduction in itch by Week 6, and the response rate continued to increase through Week 12 – Reduction in itch resulted in significant improvement in sleep loss by Week 6 • Roflumilast cream was well-tolerated and application site pain was uncommon and similar to vehicle Table 1. • Itch was assessed at baseline and Weeks 2, 4, 6, 8, and 12 using PRO measures: – Worst Itch Numeric Rating Scale (WI-NRS)3 assessed the worst itch – Psoriasis Symptom Diary (PSD) Items 1 and 24-6 assessed burden and severity of itch – Itch-Related Sleep Loss NRS assessed intensity of sleep loss – All PRO measures assessed itch over the previous 24 hours and were rated on a scale from 0 (no impact) to 10 (as bad as it can be) RESULTS •
    keywords: itch; nrs; psoriasis; roflumilast; score; vehicle; week
       cache: skin-1104.pdf
  plain text: skin-1104.txt

        item: #95 of 1356
          id: skin-1105
      author: Menter, Alan; Blauvelt, Andrew; Strober, Bruce; Colombo, Matthew; Kisa, Renata; Kundu, Sudeep; Banerjee, Subhashis; Leonardi, Craig
       title: Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis
        date: 2020-10-27
       words: 1419
      flesch: 53
     summary: DLQI at Week 12 according to level of BSA involvement • Mean DLQI at Week 12 was lower among patients with BSA ≤1% and ≤3% who received deucravacitinib compared with the placebo recipient with BSA ≤3% (Figure 3) — Mean DLQI at Week 12 was also numerically lower in those patients who received a daily dose of 12 mg deucravacitinib (ie, 6 mg BID and 12 mg QD groups) than in those who received 6 mg daily doses (ie, 3 mg BID; Figure 3) Figure 3. Percentage of patients who achieved BSA of ≤1% and ≤3% at Week 12 • BSA ≤1% was achieved by approximately one-third of patients receiving deucravacitinib vs 0% of those receiving placebo (Figure 2) — Additionally, BSA ≤3% was achieved by approximately one-half of patients receiving deucravacitinib vs 2.2% receiving placebo • Nearly 40% of patients achieved BSA ≤1 and nearly 60% achieved BSA ≤3 in the highest-responding deucravacitinib 12 mg QD group Figure 2.
    keywords: bid; bsa; patients; pharma
       cache: skin-1105.pdf
  plain text: skin-1105.txt

        item: #96 of 1356
          id: skin-1106
      author: none
       title: An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
        date: 2020-10-27
       words: 1887
      flesch: 34
     summary: Introduction • Plaque psoriasis is a debilitating, chronic, immune-mediated skin disorder that impairs patients’ health-related quality of life (HRQoL) and productivity1 • Treatment outcomes for plaque psoriasis based on the absolute Psoriasis Area and Severity Index (PASI) are indicative of an individual patient’s disease severity at the time of analysis2 — Absolute PASI may be more clinically meaningful than percentage change in PASI from baseline captured by scores such as PASI 75 (≥75% reduction from baseline PASI)2 — Although a consensus therapeutic target has yet to be defined, a recent analysis reported that attainment of an absolute PASI of ≤2 translates to meaningful improvements in clinical and HRQoL outcomes2 • Previous studies have demonstrated that an absolute PASI ≤2 correlates with PASI 90 (≥90% improvement from baseline PASI), static Physician’s Global Assessment (sPGA) score of 0/1 (range, 0–5; higher scores indicate greater disease severity), and Dermatology Life Quality Index (DLQI) of 0/1 (range, 0–30; higher scores indicate worse HRQoL)2 • Deucravacitinib (BMS-986165) is an oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2), an intracellular enzyme involved in key cytokine signaling pathways in plaque psoriasis pathogenesis3 — In a Phase 2, double-blind, randomized trial in patients with moderate to severe plaque psoriasis (NCT02931838), 67%–75% of patients treated with deucravacitinib at doses of 3 or 6 mg twice daily (BID) or 12 mg once daily (QD) achieved PASI 75 at Week 12 (primary endpoint) vs 7% with placebo (P<0.001)3 — Deucravacitinib had a favorable safety and tolerability profile, and was associated with low rates of treatment discontinuation3 Objective • This post hoc analysis of the Phase 2 trial compared the efficacy of deucravacitinib vs placebo based on absolute PASI over time up to Week 12 Materials and Methods Inclusion criteria • Adults with body mass index of 18–40 kg/m2 • Moderate to severe plaque psoriasis for ≥6 months affecting ≥10% of body surface area — PASI ≥12 (range, 0–72; higher scores indicate greater disease severity) — sPGA ≥3 • Eligible for phototherapy or systemic therapy Exclusion criteria • Diagnosis of nonplaque psoriasis or other immune-mediated condition requiring concomitant systemic immunosuppressant therapy • History or evidence of specific infections (eg, HIV or hepatitis B or C infection) or risk of tuberculosis • Previous lack of response to any therapeutic agent targeting the TYK2 pathway (eg, interleukin-12/-23 pathways) Absolute PASI at Week
    keywords: absolute; bid; deucravacitinib; pasi; psoriasis
       cache: skin-1106.pdf
  plain text: skin-1106.txt

        item: #97 of 1356
          id: skin-1107
      author: Jett, John; McLaughlin, Michael; Lee, Mark; Parish, Lawrence; Tabolt, Glenn; Wilson, Timothy; Somerville, Matthew; DellaMaestra, Wayne; Piscitelli, Stephen
       title: Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis
        date: 2020-10-27
       words: 1785
      flesch: 43
     summary: (36.8) BSA, body surface area; PASI, Psoriasis Area and Severity Index; PASI75, ≥75% improvement in PASI from baseline; PGA, Physician Global Assessment; QD, once daily; SD, standard deviation. Mean % change in PASI score from baseline to Day 29 (SD) –59.6 (29.0)
    keywords: patients; pga; psoriasis; tapinarof
       cache: skin-1107.pdf
  plain text: skin-1107.txt

        item: #98 of 1356
          id: skin-1108
      author: Lebwohl, Mark; Stein Gold, Linda; Strober, Bruce; Armstrong, April; Hong, H Chih-Ho; Kircik, Leon; Soung, Jennifer; Fromowitz, Jeff; Guenthner, Scott; Piscitelli, Stephen; Rubenstein, David; Brown, Philip; Tallman, Anna; Bissonnette, Robert
       title: Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials
        date: 2020-10-27
       words: 1809
      flesch: 58
     summary: Study Design Double-blind treatment (12 weeks) Adult subjects with stable plaque psoriasis ■ Aged 18–75 years ■ PGA score ≥2* ■ BSA ≥3%–≤20% 2:1 2:1 N=510 N=515 Tapinarof 1% QD (n=340) Tapinarof 1% QD (n=343) Vehicle QD (n=172) Vehicle QD (n=170) R R *PGA of 2 (mild) or 4 (severe) was limited to ~10% each of the total randomized population; ~80% of the randomized population had a PGA of 3 (moderate). PASI75 Response at Week 12 Δ 25.9% 36.1% 10.2% P<0.0001 M e a n P A S I7 5 r e sp o n se ra te , % ( S E M ) PSOARING 1 30 40 50 60 20 10 0 Tapinarof 1% QD (n=340) Vehicle QD (n=170) Δ 40.7% 47.6% 6.9% P<0.0001 PSOARING 2 Tapinarof 1% QD (n=343) Vehicle QD (n=172) ITT population.
    keywords: pga; tapinarof; vehicle
       cache: skin-1108.pdf
  plain text: skin-1108.txt

        item: #99 of 1356
          id: skin-1109
      author: Veverka, Karen; Hansen, Jes; Yaloumis, Maria; Kircik, Leon; Stein Gold, Linda
       title: Treatment Success in Mild Psoriasis Patients With Fixed-Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam: Results From the PSO-FAST Trial
        date: 2020-10-27
       words: 1361
      flesch: 47
     summary: Foam: Results From the PSO-FAST Trial Karen A. Veverka, PhD,1 Jes B. Hansen, PhD,1 Maria Yaloumis, PharmD,1 Leon Kircik, MD,2 and Linda Stein Gold, MD3 1LEO Pharma, Madison, NJ; 2Icahn School of Medicine at Mount Sinai, New York, NY; Indiana University School of Medicine, Indianapolis, IN; Physicians Skin Care, PLLC, Louisville, KY; 3Henry Ford Hospital, Detroit, MI Introduction • Psoriasis is a chronic skin disease affecting approximately 2% of the worldwide population characterized by sharply demarcated, scaling, and erythematous plaques that may be painful and often severely pruritic1 • While topical therapy is the regimen of choice for patients with less extensive disease,2 very few of these therapies have been demonstrated effective for mild psoriasis – Treatment success in this population requires that visible disease be completely cleared (i.e., improvement of Investigator’s Global Assessment (IGA) score from 2 to 0) • Corticosteroids and vitamin D analogues are among the most common treatments that are either used alone or in combination2,3 • Topical, fixed-combination calcipotriene (50 µg/g) plus betamethasone dipropionate (0.5 mg/g; Cal/BD) cutaneous foam is indicated for the treatment of plaque psoriasis in patients 12 years and older4 – In a Phase III, double-blind, randomized study that included patients with all severities of psoriasis (PSO-FAST), Cal/BD foam was efficacious and well tolerated, and also provided rapid treatment responses with significant itch relief3 Objective • To compare the efficacy of treatment with Cal/BD foam to that of treatment with vehicle for up to 4 weeks in patients with mild psoriasis vulgaris by performing a post hoc analysis of the PSO-FAST trial Materials and Methods Study Design • PSO-FAST was a Phase III, randomized, multicenter (US), double-blind, vehicle-controlled, 4-week study (NCT01866163) • 426 patients were randomized (3:1) to Cal/BD foam or foam vehicle once daily for up to 4 weeks Figure 1.  In this post hoc analysis, once-daily fixed-dose combination Cal/BD foam was efficacious in treating mild plaque psoriasis – Importantly, while numerous other topical and systemic therapies are available for psoriasis, very few have demonstrated efficacy in this subpopulation • These important results establish treatment success for Cal/BD foam in mild psoriasis, a population in which efficacy is difficult to demonstrate since the treatment must completely clear visible disease to be considered effective • The once-daily, Cal/BD foam may provide a valuable treatment option for patients with mild plaque psoriasis References 1.
    keywords: cal; foam; psoriasis; week
       cache: skin-1109.pdf
  plain text: skin-1109.txt

        item: #100 of 1356
          id: skin-111
      author: Armstrong, April; Levi, Eugenia
       title: A Retrospective Cohort Study of Real-World Experience with Apremilast in Patients with Plaque Psoriasis
        date: 2017-10-27
       words: 1125
      flesch: 46
     summary: Among patients who received APR monotherapy for ≥90 days and had ≥1 POTE assessment (n=160), the majority (n=138; 86%) somewhat agreed or strongly agreed that APR treatment was effective in clearing their skin of psoriasis (Figure 3). Pattern of Switching From Other Therapies to APR Treatment • Among the patients who changed from non-APR treatments to APR monotherapy during the study period, almost three-quarters (74.2%) changed from topical treatment alone to APR monotherapy (Figure 1).
    keywords: apr; monotherapy; patients; psoriasis
       cache: skin-111.pdf
  plain text: skin-111.txt

        item: #101 of 1356
          id: skin-1110
      author: Hebert, Adelaide; Schrieber, Rhonda; Glaab, Debbie; Eichenfield, Lawrence
       title: Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis
        date: 2020-10-27
       words: 2
      flesch: -6
     summary: PowerPoint Presentation
    keywords: powerpoint
       cache: skin-1110.pdf
  plain text: skin-1110.txt

        item: #102 of 1356
          id: skin-1111
      author: Leonardi, Craig; Stein Gold, Linda; Lain, Edward; Neimann, Andrea; Jacobson, Abby
       title: Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area
        date: 2020-10-27
       words: 1809
      flesch: 54
     summary: ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC • Presented at Fall Clinical 2020 • October 29 - November 1, 2020 • Virtual SYNOPSIS � In the treatment of psoriasis, combining tazarotene (TAZ) with a potent topical steroid, such as the superpotent corticosteroid halobetasol propionate (HP), is recommended for patients with mild-to-moderate disease1 � The TAZ + HP combination may provide synergistic efficacy, increase the duration of treatment effect and time of remission, and reduce side effects of both HP and TAZ1-3 � Topical psoriasis therapy has also been recommended for patients with lower levels of body surface area (BSA) involvement4; though these patients may be deemed more “mild,” they may nonetheless have disease characteristics that severely impact their quality of life (QoL) � A once-daily, fixed combination HP 0.01%/TAZ 0.045% lotion (Duobrii,® Ortho Dermatologics) was developed to address these unmet needs in the topical treatment of psoriasis OBJECTIVE � To evaluate the efficacy, impact on QoL, and safety of HP 0.01%/TAZ 0.045% lotion versus vehicle in patients with lower levels of BSA involvement (3–5%) at baseline METHODS FIGURE 1. BSA Reduction in 3–5% BSA Subgroup and Overall Populationa (ITT Population, Pooled) 0% -50% -40% -30% -20% -10% 10% M e a n P e rc e n t C h a n g e F ro m B a se lin e -60% 2 4 6 8 12 Study Visit (Weeks)
    keywords: baseline; bsa; lotion; taz; vehicle
       cache: skin-1111.pdf
  plain text: skin-1111.txt

        item: #103 of 1356
          id: skin-1112
      author: Stein Gold, Linda; Lebwohl, Mark; Bhatia, Neal ; DiRuggiero, Douglas; Jacobson, Abby; Pillai, Radhakrishnan
       title: Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
        date: 2020-10-27
       words: 1573
      flesch: 52
     summary: A fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion (Duobrii,® Ortho Dermatologics) was developed to address unmet needs in the topical treatment of psoriasis (see inset) • Topical corticosteroids—such as HP—are the mainstay of treatment, though long-term safety remains a concern, limiting use3 • The topical retinoid TAZ has demonstrated efficacy by modulating major causes of psoriasis and maintaining therapeutic effect, though TAZ may induce cutaneous irritation3-6 • Treating psoriasis by combining HP with TAZ may enhance efficacy, reduce side effects of both HP and TAZ, and sustain treatment response posttreatment3,6 OBJECTIVE ◾ To investigate maintenance of effect posttreatment following once-daily application of HP/TAZ lotion in patients with moderate-to-severe psoriasis who achieved clear skin METHODS ◾ These data indicate a long maintenance of therapeutic effect with HP 0.01%/ TAZ 0.045% lotion in participants who achieved clear skin, likely due to the role of TAZ in sustaining efficacy posttreatment (see inset) REFERENCES 1.
    keywords: participants; study; taz; treatment; weeks
       cache: skin-1112.pdf
  plain text: skin-1112.txt

        item: #104 of 1356
          id: skin-1113
      author: Blauvelt, A; Warren, RB; Reich, K; Brock, F; Fierens, F; Ciaravino, V; Lebwohl, M
       title: Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2020-10-27
       words: 2167
      flesch: 50
     summary: Author Disclosures: AB: Scientific adviser and/or clinical study investigator for AbbVie, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; paid speaker for AbbVie; RBW: Consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma; KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport; FB, FF, VC: Employees of UCB Pharma; ML: Employee of Mount Sinai which receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Pharma; consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi Pharma, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica.
    keywords: czp; dlqi; mg q2w; pharma; q2w
       cache: skin-1113.pdf
  plain text: skin-1113.txt

        item: #105 of 1356
          id: skin-1114
      author: Gordon, K; Warren, RB; Gottlieb, AB; Blauvelt, A; Tha?i, D; Poulin, Y; Boehnlein, M; Brock, F; Arendt, C; Reich, K
       title: Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
        date: 2020-10-27
       words: 2159
      flesch: 42
     summary: Author Disclosures: KG: Honoraria and/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira Inc., Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; RBW: Research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB Pharma; Consultant for AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma; ABG: Current consulting/advisory board agreements with AbbVie, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB Pharma, and XBiotech; Research and educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB Pharma, and XBiotech; AB: Served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira Inc., Eli Lilly, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho, Pfizer, Rapt, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie; DT: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Biogen-Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DS-Biopharma, Eli Lilly, Galapagos, Janssen, LEO Pharma, Morphosis, Novartis, Pfizer, Regeneron, Samsung, Sandoz-Hexal, Sanofi and UCB Pharma; Research grants received from Celgene, LEO Pharma and Novartis; YP: Investigator (research grants) from AbbVie, Baxter, Boehringer Ingelheim, Celgene, Centocor/Janssen, Eli Lilly, EMD Serono, GSK, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Takeda, and UCB Pharma; Speaker (honoraria) from AbbVie, Celgene, Janssen, Eli Lilly, LEO Pharma, Novartis, Regeneron, and Sanofi Genzyme; MB, FB, CA: Employees of UCB Pharma; KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport. UCB Pharma is the regulatory sponsor of certolizumab pegol in psoriasis.
    keywords: czp; pasi; patients; pharma; q2w; weeks
       cache: skin-1114.pdf
  plain text: skin-1114.txt

        item: #106 of 1356
          id: skin-1115
      author: Reich, K; Papp, K; Blauvelt, A; Langley, R; Armstrong, A; Warren, RB; Gordon, K; Merola, JF; Madden, C; Wang, M; Vanvoorden, V; Lebwohl, M
       title: Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study
        date: 2020-10-27
       words: 2652
      flesch: 35
     summary: Author Disclosures: KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermira Inc., Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Medac, Merck Sharp & Dohme, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant, and Xenoport. KAP: Honoraria and/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, Baxalta,Boehringer Ingelheim, Bristol-Myers Squibb, Canfite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, LEO Pharma, MedImmune, Merck Sharp & Dohme, Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Aventis/Genzyme, Sun Pharma, Takeda, UCB Pharma, and Valeant/Bausch Health; Consultant (no compensation) for AstraZeneca and Meiji Seika Pharma.
    keywords: bimekizumab; patients; pharma; placebo; ustekinumab; week
       cache: skin-1115.pdf
  plain text: skin-1115.txt

        item: #107 of 1356
          id: skin-1116
      author: Gordon, K; Foley, P; Krueger, JG; Pinter, A; Reich, K; Vender, R; Vanvoorden, V; Madden, C; Peterson, L; Blauvelt, A
       title: Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal
        date: 2020-10-27
       words: 2454
      flesch: 43
     summary: Received grant support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and Sanofi; served as an Investigator for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Celtaxsys, CSL, Cutanea, Dermira Inc., Eli Lilly, Galderma, Genentech, Geneseq, GSK, Hexima, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Reistone, Roche, Sanofi, Sun Pharma, UCB Pharma, and Valeant; served on the advisory board of AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Mayne Pharma, Merck, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Valeant; served as a consultant for Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, and Wintermute; received travel grants from AbbVie, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Roche, and Sanofi; served as a speaker for or received honoraria from AbbVie, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and Roche. Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermira Inc., Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Medac, Merck Sharp & Dohme, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant, and Xenoport.
    keywords: bimekizumab; pasi; patients; pharma; placebo; week
       cache: skin-1116.pdf
  plain text: skin-1116.txt

        item: #108 of 1356
          id: skin-1117
      author: Gottlieb, AB; Blauvelt, A; Tha?i, D; Poulin, Y; Brock, F; Arendt, C; Boehnlein, M; Reich, K
       title: Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2020-10-27
       words: 2010
      flesch: 51
     summary: Author Disclosures: ABG: Received honoraria as an advisory board member and consultant for Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb Co., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB Pharma, and Xbiotech (only stock options which she has not used); and has received research/educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharma, UCB Pharma, and Xbiotech; AB: Served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira Inc., Eli Lilly, Forte, Galderma, Janssen, LEO Pharma, Novartis, Ortho, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie; DT: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Biogen-Idec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DS-Biopharma, Eli Lilly, Galapagos, Janssen, LEO Pharma, Morphosis, Novartis, Pfizer, Regeneron, Samsung, Sandoz-Hexal, Sanofi and UCB Pharma; Research grants received from Celgene, LEO Pharma and Novartis; YP: Investigator (research grants) from AbbVie, Baxter, Boehringer Ingelheim, Celgene, Centocor/Janssen, Eli Lilly, EMD Serono, GSK, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Takeda, and UCB Pharma. Speaker (honoraria) from AbbVie, Celgene, Janssen, Eli Lilly, LEO Pharma, Novartis, Regeneron, and Sanofi Genzyme; FB, CA, MB: Employees of UCB Pharma; KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport.
    keywords: czp; mg q2w; pasi; q2w; week
       cache: skin-1117.pdf
  plain text: skin-1117.txt

        item: #109 of 1356
          id: skin-1118
      author: Blauvelt, A; Gottlieb, AB; Fierens, F; Brock, F; Wiegratz, S; Sofen, H
       title: Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT
        date: 2020-10-27
       words: 1524
      flesch: 51
     summary: Table 2 Percent improvement from baseline PASI at time of dose adjustment Median percentage change from baseline was assessed during the open-label extension period at the time of the first dose reduction (CZP 400 mg Q2W down to CZP 200 mg Q2W) and at the time of the second dose adjustment (CZP 200 mg Q2W back up to CZP 400 mg Q2W). CZP 400 mg Q2W Placebo Q2W CZP 200 mg Q2W CZP 400 mg Q2W LDa Maintenance period Initial treatment period (double-blinded) Open-label extensionb 1:2:2 randomization CIMPASI-1 and CIMPASI-2 1:3:3:3 randomization CIMPACT 3212Week 0 16 48 144 Dose adjustments: Mandatory Placebo Q2W CZP 200 mg Q2W CZP 400 mg Q2W LDa ETN 50 mg BW Washout Open-label escape CZP 400 mg Q2W <PASI 50 <PASI 50 <PASI 50 – withdrawn (Weeks 32–144) CZP 200 mg Q2W <PASI 50 ≥PASI 50 <PASI 75 ≥PASI 75 At the investigator’s discretion Week 16 48 CZP 400 mg Q2W escape arm 144 Open-label extension period with possible dose adjustment C Z P 2 0 0 m g Q 2 W C Z P 4 0 0 m g Q 2 W n=116 n=97 n=9 n=1 n=7 n=64 ≥PASI 75 in 44/64 (68.8%) dose non-adjusters at Week 144 7/9 (77.8%) dose re-adjusters regained PASI 75 within 12 weeks Dose non-adjusters Dose re-adjusters Dose adjusters 9/33 (27.3%) dose adjusters lost PASI 75 and increased dose 33/97 (34.0%) achieved ≥PASI 75 and reduced dose n=33 n=24 n=1n=2 Randomized to Placebo at Week 0 CZP 400 mg Q2W Escape Arm Open-label extension with possible dose adjustments: CZP 400 mg Q2W CZP 200 mg Q2W Non-adjusters: 68.8% were PASI 75 responders Dose adjustment to 200 mg: 27.3% of patients lost PASI 75 Dose re-adjustment to 400 mg: <PASI 50 77.8% of patients regained PASI 75
    keywords: czp; dose; pasi; q2w
       cache: skin-1118.pdf
  plain text: skin-1118.txt

        item: #110 of 1356
          id: skin-1119
      author: Hill, Sheena; Honda, Kord; Rohr, Bethany
       title: A Case of Shiitake Mushroom Dermatitis in a 21-year-old Female
        date: 2021-03-06
       words: 1468
      flesch: 46
     summary: Here we present a case of shiitake mushroom dermatitis with correlation of histologic findings. Although there have been cases of positive patch testing in shiitake mushroom dermatitis, patch tests are usually negative due to poor antigen penetration.10,11 Patch tests are also not consistently positive in delayed food reactions.12 Because lentinan is thermolabile – inactivated at temperatures between 130 and 145 degrees Celsius due to irreversible molecular structure changes – shiitake mushroom dermatitis is not seen with well-cooked mushrooms.5
    keywords: case; dermatitis; erythema; flagellate; infiltrate; mushroom; shiitake
       cache: skin-1119.pdf
  plain text: skin-1119.txt

        item: #111 of 1356
          id: skin-112
      author: Bagel, Jerry; Lebwohl, Mark; Stein Gold, Linda; Jackson, J Mark; Goncalves, Joana; Levi, Eugenia; Callis Duffin, Kristin; Strober, Bruce
       title: Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
        date: 2017-10-27
       words: 2640
      flesch: 64
     summary: Safety • The most common AEs reported with APR treatment from 0 to 52 weeks included diarrhea, nausea, headache, and nasopharyngitis; most AEs were mild or moderate in severity (Table 2). The benefi cial effects of APR on QOL and pruritus were consistent with those previously reported in patients with moderate to severe plaque psoriasis in randomized phase III trials.8,11 • Global treatment satisfaction was greater with APR than with PBO at Week 16, and satisfaction remained high over 52 weeks of APR treatment.
    keywords: apr; dlqi; patients; pbo; pruritus; satisfaction; treatment; week
       cache: skin-112.pdf
  plain text: skin-112.txt

        item: #112 of 1356
          id: skin-1123
      author: Farooq, Sahira; Frizzell, Madeline; Limmer, Emily; Swali, Ritu; Tyring, Stephen
       title: Clinical and Histological Spectrum of Primary Cutaneous B-Cell Lymphoma in an Ethnically-Diverse Group of Patients: A Case Series 
        date: 2021-03-06
       words: 2063
      flesch: 53
     summary: Broadly, non- Hodgkin lymphoma derived from B cells include diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, follicular lymphoma, and marginal zone lymphoma, among others.3 Here, we present the cases of three ethnically diverse patients with distinct clinical and histological forms of cutaneous B cell lymphoma. Here, we present the cases of three ethnically diverse patients with distinct clinical and histological forms of cutaneous B cell lymphoma.
    keywords: cell; diffuse; lymphoma; skin; type
       cache: skin-1123.pdf
  plain text: skin-1123.txt

        item: #113 of 1356
          id: skin-1124
      author: Cullison, Stepnaie; Ferris, Laura; Yao, Zuxu; Ibarra, Claudia; Howell, Michael; Jansen, Burkhard
       title: Combining DNA and RNA Analyses Enhances Non-Invasive Early Detection of Cutaneous Melanoma
        date: 2020-10-27
       words: 947
      flesch: 48
     summary: Studies in real-world use cohorts (n=1,415) demonstrated the presence of TERT promoter mutations in up to 24% of PLA positive and 12% of PLA negative tests. While the biologic significance of different types of TERT mutations is the subject of ongoing studies, TERT 146G>A mutations were the most frequently observed mutational change (48%) in our study cohorts.
    keywords: analyses; melanoma; tert
       cache: skin-1124.pdf
  plain text: skin-1124.txt

        item: #114 of 1356
          id: skin-1125
      author: Giesey, Rachel Lynn; Mehrmal, Sino; Uppal, Prabhdeep; Delost, Gregory
       title: The Global Burden of Skin and Subcutaneous Disease: A Longitudinal Analysis from the Global Burden of Disease Study From 1990-2017
        date: 2021-03-06
       words: 4390
      flesch: 51
     summary: Half of all skin conditions are associated with mortality, and on average, death from skin disease has been seen to occur five years younger (68.2 years) than the average age of death for all causes.2 ABSTRACT Background: The global prevalence and disability of skin and subcutaneous diseases have grown annually in recent decades. The global prevalence of all skin disease was 26.79% in 2017, up from 26.15% in 1990, while the percentage of total DALYs due to skin and subcutaneous diseases was 1.76% in 2017, up from 1.21% in 1990.9 The top three most prevalent dermatoses were fungal skin diseases (10.09%); “other skin conditions” encompassing skin diseases such as bullous diseases, connective tissue diseases, and cutaneous drug reactions DISCUSSION SKIN March 2021 Volume 5 Issue 2 Copyright 2021 The National Society for Cutaneous Medicine 130 Figure 2.
    keywords: age; burden; countries; dermatol; disease; figure; gbd; health; medicine; prevalence; rates; skin; study
       cache: skin-1125.pdf
  plain text: skin-1125.txt

        item: #115 of 1356
          id: skin-1126
      author: Hoyer, Paige; Croley, Julie ; Wagner, Jr. , Richard F. 
       title: Use of Absorbable Cutaneous Sutures Amid the COVID-19 Pandemic: Absorbable Cutaneous Sutures
        date: 2021-03-06
       words: 993
      flesch: 46
     summary: Studies have shown no significant difference in cosmetic outcomes between non-absorbing suture and absorbable suture. However, those over the age of 65 are more likely to have comorbidities.5 Patients with chronic kidney disease, type 2 diabetes, chronic obstructive pulmonary disease, obesity, compromised immune systems (e.g. solid organ transplant patients), and heart disease are at a much higher risk of significant morbidity and mortality from COVID-19.5 The American Academy of Dermatology recommends the use of absorbable sutures during the current pandemic as well.6 We requested that patients who did not return for in-person follow up, upload post- op photos via our patient portal system.
    keywords: absorbable; patients; sutures
       cache: skin-1126.pdf
  plain text: skin-1126.txt

        item: #116 of 1356
          id: skin-1127
      author: Yi, Lauren G; Tran, Benjamin A; Flowers, R Hal; Greer, Kenneth E; Guffey, Darren J
       title: Treatment of Pityriasis Rubra Pilaris with Daily Low-Dose Methotrexate: A Retrospective Cohort Study
        date: 2021-07-09
       words: 2732
      flesch: 54
     summary: 12 patients (85.7%) developed asymptomatic elevations in liver enzymes (ALT and AST) that resolved in most patients (66.7%) after dose reduction. A complete blood count and liver enzymes (ALT and AST) were checked every few months at follow-up visits while patients were on MTX.
    keywords: daily; dose; liver; mtx; patients; prp
       cache: skin-1127.pdf
  plain text: skin-1127.txt

        item: #117 of 1356
          id: skin-1128
      author: Barone, Hope; Veremis, Mary; Gildenberg, Stuart
       title: Herpes Zoster in a 2-Year-Old Child After a Single Dose of Varicella Vaccine 
        date: 2021-03-06
       words: 1546
      flesch: 44
     summary: Furthermore only 1% of pediatric HZ cases were identified in immunocompetent children.5 We report an unusual case of an immunocompetent 2-year-old child who developed herpes zoster in the same dermatomal distribution as the vaccination site received eight months prior. Although rare, at 15-93 per 100,000 person-years, the incidence of breakthrough varicella (defined as infection with wild-type varicella >42 days after vaccination) and post-vaccination HZ in children led to the implementation of a two-dose series in 2006.3 Further evaluation revealed that only 50% of breakthrough varicella or post- vaccination HZ are attributable to wild-type VZV, with the Oka vaccine-strain virus identified in the remaining cases.4
    keywords: herpes; left; vaccine; varicella; zoster
       cache: skin-1128.pdf
  plain text: skin-1128.txt

        item: #118 of 1356
          id: skin-113
      author: Callis Duffin, Kristina; Jackson, J Mark; Goncalves, Joana; Levi, Eugenia; Bagel, Jerry
       title: Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis
        date: 2017-10-27
       words: 1663
      flesch: 70
     summary: In addition, 35.4% of APR patients in UNVEIL achieved a ≥75% reduction from baseline in PGAxBSA score (PGAxBSA-75) vs. 12.3% of PBO patients (P<0.0001) (Figure 3). – Eligible patients were randomized (2:1) to receive APR or PBO, titrated over the fi rst week of treatment, through Week 16. – At Week 16, PBO patients were switched to APR, with titration.
    keywords: apremilast; baseline; pasi; patients; pgaxbsa; week
       cache: skin-113.pdf
  plain text: skin-113.txt

        item: #119 of 1356
          id: skin-1131
      author: Hattaway, Reagan; Singh, Nikhi; Rais-Bahrami, Soroush; Kole, Lauren
       title: Adaptations of Dermatology Residency Programs to Changes in Medical Education Amid the COVID-19 Pandemic: Virtual Opportunities and Social Media
        date: 2021-03-06
       words: 3063
      flesch: 43
     summary: Objective: To describe how dermatology residency programs have adapted by developing social media platforms and virtual opportunities. Conclusion: Dermatology residency programs have adapted to the COVID-19 pandemic by developing social media platforms and virtual opportunities.
    keywords: accounts; dermatology; instagram; media; opportunities; programs; residency
       cache: skin-1131.pdf
  plain text: skin-1131.txt

        item: #120 of 1356
          id: skin-1132
      author: Bangalore Kumar, Anagha; Bryce, Alan; Vishnu, Prakash; Markovic, Svetomir; McEvoy, Marian
       title: Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma
        date: 2021-03-06
       words: 4796
      flesch: 52
     summary: 7. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Curry JL, Tetzlaff MT, Nagarajan P, et al.
    keywords: dermatitis; grade; immune; iraes; melanoma; patients; response; therapy; vitiligo
       cache: skin-1132.pdf
  plain text: skin-1132.txt

        item: #121 of 1356
          id: skin-1133
      author: Altmann, Stefanie; Chahine, Adam; Casale, Jarett; Forbes, Jessica; Ferrer-Bruker, Sarah
       title: Cutaneous Type Pemphigus Vulgaris of the Scalp: A Rare Unilesional Presentation
        date: 2021-03-06
       words: 1321
      flesch: 47
     summary: Furthermore, only two previous accounts of unilesional scalp PV have been reported.6,7 Our case is a unique presentation of unilesional cutaneous PV in a young woman. The high frequency of scalp involvement in PV is likely due to the presence of high levels of desmogleins in hair follicles.8
    keywords: involvement; pemphigus; scalp; vulgaris
       cache: skin-1133.pdf
  plain text: skin-1133.txt

        item: #122 of 1356
          id: skin-1134
      author: Hobbs, Landon Kaleb; Zufall, Alina; Khalil, Shadi; Flowers, Richard
       title: Treatment of Pyodermatitis-Pyostomatitis Vegetans: A Systematic Review and Meta-analysis 
        date: 2021-07-09
       words: 6771
      flesch: 59
     summary: None PDV ABX OCS (low dose) + DAP OCS (higher dose) McCarthy 19632 5 27M, White UC PSV T-CS/CNI Mehravaran 19975 5 43F None PDV- PSV OCS+AZA OCS Merkourea 201346 5 58M CD PSV 5-ASA (“low dose”) Mesquita 201247 5 12M None PDV- PSV OCS + AZA DAP Mijandrusic-Sincic 201048 5 23F CD PSV BIO 32F UC PSV AZA Mizukami 201949 5 29F UC PSV OCS DAP Molnar 201150 5 16M CD PSV OCS, AZA+BIO Moloney 201151 5 50F UC PDV- PSV DAP DAP + AZA + 5-ASA Naish 197052 5 26M, Black UC PSV OCS Nayak 201753 5 Summary of findings in 95 reported cases Report Rating of QoE Demographic IBD PDV/ PSV Response to Treatment No Response Partial Response CR-I CR-M CR-D Abellaneda 20117 5 35M, Spanish UC PDV- PSV AZA, MTX, DAP, COL, RET, 5-ASA, MSC OCS AZA + 5-ASA Ahn 20048 5 33F, Korean UC PDV- PSV DAP, COL, OSC DAP, COL, OSC 5-ASA Al-Rimawi 19989 5 7M UC PSV OCS, 5-ASA, CHL 5F Chronic colitis PSV T-CS/CNI, OCS Atarbashi-Moghadam 201610 5 39F CD PSV 5-ASA, AZA Ayangco 200211 5 22F, White CD PSV T-CS/CNI 5-ASA Ballo 198912 5 39F UC PSV ABX, T-CS/CNI, MSC OCS 5-ASA Bens 200313 5 35F CD PSV BIO MTX Bertlich 201914 5 51F UC PDV- PSV AZA + OCS + T- CS/CNI BIO, OCS, T- CS/CNI Bianchi 20014 5 48F UC PDV ABX 5-ASA Brinkmeier 200115 5 32F, White None PDV- PSV DAP, 5-ASA OCS, T- CS/CNI, OCS + RET, OCS + OCNI Calobrisi 199516 5 65M, White UC PSV T-CS/CNI total colectomy Canpolat 201117 5 64M UC PDV OCS, ABX 5-ASA Carvalho 201618 5 79F None PDV ABX + OCS Cataldo 198119 5 48M, White CD PSV T-CS/CNI OCS Chan 199120 5 23M, White UC PSV FES, T- CS/CNI, OCS, ABX 5-ASA 17F, White UC PSV 5-ASA, T- CS/CNI, FES Chaudhry 199921 5 63M UC PSV T-CS/CNI, ABX Clark 20163 4 22F UC PSV 5-ASA, T- CS/CNI 30M UC PDV- PSV OCS, DAP, AZA, NYS, PTR 29M CD PSV OCS, DAP SKIN July 2021 Volume 5 Issue 4 Copyright 2021 The National Society for Cutaneous Medicine 336 54M CD PSV OCS, T-CS/CNI, DAP, OCNI, MM BIO 44F UC PDV- PSV OCS, T- CS/CNI, PTR 21M UC PDV- PSV DAP, T- CS/CNI 58M CD PDV- PSV OCS, T-CS/CNI, DAP, MSC Dodd 201722 5 30F CD PDV- PSV BIO, AZA OCS, T- CS/CNI BIO + DAP Dupuis 201623 5 48M Colitis PDV- PSV OCS Ficarra 199324 5 45F, Italian CD PDV- PSV Zinc OCS Forman 196525 5 45F UC PDV- PSV ACTH, ABX 44F UC PDV- PSV DAP DAP ABX, T- CS/CNI Gonzalez-Moles 200826 5 84F None PSV T-CS/CNI + NYS Hansen 198327 5 37M, White UC PSV OCS OCS
    keywords: abx; asa; cni; dap; dermatol; disease; ocs; oral; patients; pdv; pdvpsv; psv; pyostomatitis; pyostomatitis vegetans; response; treatment; vegetans
       cache: skin-1134.pdf
  plain text: skin-1134.txt

        item: #123 of 1356
          id: skin-1137
      author: Jafri, Zainab; Shedlofsky, Lydia; Newman, Andrew; Lam, Travis; Mengesha, Yebabe
       title: A Sweet Presentation of a Bitter Disease: Acute Febrile Neutrophilic Dermatosis Associated with Coccidioidomycoses
        date: 2021-03-06
       words: 1617
      flesch: 36
     summary: Coccidioidomycosis- associated AFND has rarely been reported in literature. Indurated erythematous nodules and pseudovesicles The diagnosis of classic AFND requires the presence of both major criteria and two out of the four minor criteria (Table 1).4 Symptoms and clinical manifestations typically respond rapidly to high-dose systemic corticosteroids.
    keywords: afnd; coccidioidomycosis; disease; skin; sweet; syndrome
       cache: skin-1137.pdf
  plain text: skin-1137.txt

        item: #124 of 1356
          id: skin-1138
      author: Bowers, Nathan; Porosnicu, Mercedes
       title: Increased PD-L1 Tumor Expression Correlates with High Rate of Response to PD-1 Inhibitors in Patients with Unresectable, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma
        date: 2021-01-01
       words: 1160
      flesch: 63
     summary: JAK2 0 0 P278S ASXL, CDKN2A, NOTCH1, PIK3CA, TERT Fatigue Mets to right parotid F 81 N L 9 PR On n/a NET S99F Q100 Q16 SS SNV CDKN2A BRCA2 MAP2K1 ND ND NET NET Other primary cSCC ND ND G245N R342 CASP8, MLL2, NOTCH1, RB1 Fatigue F 64 N R 4 PD On Surg, Adj RT CPS 30 8 G266R 0
    keywords: net; patients
       cache: skin-1138.pdf
  plain text: skin-1138.txt

        item: #125 of 1356
          id: skin-1139
      author: Workman, Ashleigh; Lindsley, Josh; Web, Nathaniel; Miller, Thaddeus; Stockbridge, Erica; Charles, Jean; Weis, Stephen
       title: Preventative Medicine in Dermatologic Care: Providing Immunization Education and Convenient Pneumococcal Immunizations for Patients Receiving Immunosuppressive Therapy
        date: 2021-01-01
       words: 1469
      flesch: 47
     summary: We evaluated the project’s approach of providing education with immediate onsite immunization availability relative to standard care to determine if vaccination uptake per CDC guidelines5 can be increased. We observed that many of our patients’ immunizations were incomplete and sought to increase immunization uptake through a quality improvement (QI) project beginning in Fall 2019.
    keywords: group; immunization; patients; vaccination
       cache: skin-1139.pdf
  plain text: skin-1139.txt

        item: #126 of 1356
          id: skin-114
      author: Evans, Colby; Humphrey, Louise; Pelletier, Corey; Hudgens, Stacie
       title: Group Concept Mapping to Understand the Patient Perspective and Burden of Psoriasis
        date: 2017-10-27
       words: 1488
      flesch: 38
     summary: • Clinical data and clinician-reported data will be considered against the patient reported QoL, symptom, and treatment satisfaction data to measure and characterize the unmet needs and burden of psoriasis from the GCM exercise and to identify populations of psoriasis patients who may benefit from new psoriasis treatments. Hispanics (1.6%,) and others (1.4%).3 • Topical corticosteroids are the traditional and most widely used psoriasis therapy in the US, ranging from over-the- counter 1% hydrocortisone to more potent Class 1 corticosteroids.4 – Additional treatments are phototherapy, systemic retinoids, methotrexate, cyclosporine, apremilast, and newer biological agents.5 • The symptoms and treatment of psoriasis have a significant negative impact on patient-reported quality of life (QoL). – A survey by the National Psoriasis Foundation showed that nearly 75% of patients believed psoriasis had a moderate to large negative impact on their QoL, with alterations in their daily activities.5 • There are a number of clinical outcome assessments that have been used to measure QoL in psoriasis patients ranging from psoriasis-specific measures (Psoriasis Index of Quality of Life, Psoriasis Disability Index), to skin-specific measures (Questionnaire on Experience with Skin Complaints, Dermatology Life Quality Index) to generic measures (Short Form-36, EuroQol 5D, Work Productivity Assessment Index).5 • With a high prevalence and large burden of disease, there is interest to explore and understand patient priorities and unmet needs for the treatment of psoriasis.
    keywords: exercise; gcm; patients; psoriasis; study
       cache: skin-114.pdf
  plain text: skin-114.txt

        item: #127 of 1356
          id: skin-1140
      author: Litchman, Graham; Marson, Justin; Rigel, Darrell
       title: The Ongoing Impact of COVID-19 on US Dermatology Practices
        date: 2021-01-01
       words: 1793
      flesch: 51
     summary: Comparison of US Dermatology practice during February 17-21 versus March 16-20, April 13-18, and prospective practice estimates. No significant differing telemedicine usage (39.5% hotspots vs 37.2% non-hotspots) or practice closure (21.0% hotspots vs 17.6% non-hotspots) was found in Survey 1 (March); however, a significant difference in telemedicine usage (54.5% hotspots vs 45.5% non-hotspots) and practice closure (25.4% hotspots vs 16.4% non-hotspots, when compared to a typical April week) was found in Survey 2 (April).
    keywords: april; dermatology; hotspots; practice; survey
       cache: skin-1140.pdf
  plain text: skin-1140.txt

        item: #128 of 1356
          id: skin-1141
      author: Alkul, Suzanne; Graubard, Rachel; Wasko, Carina
       title: Eccrine Poromatosis Following Lymphoma Treatment: A Case Report and Literature Review
        date: 2021-03-06
       words: 2560
      flesch: 52
     summary: Japan10 72 Female Nasolacrimal Duct Adenocarcinoma Radiation Rapid onset after radiation therapy Garshick et al., 2014; New York, NY11 46 Male AML Chemotherapy; Autologous Stem Cell Transplant Months Deckelbaum et al., 2014; Long Beach, CA12 73 Male Testicular Lymphoma Chemotherapy; Radiation 13 Years Mayo et al., 2015; Birmingham, AL13 43 Male Mantle Cell Lymphoma Chemotherapy; Autologous Stem Cell Transplant 4 Years Takahashi et al., 2015; Hokkaido, Japan14 63 Female AML Chemotherapy; Autologous Stem Cell Transplant 15 Years Aung et al., 2017; Houston, TX15 45 Male AML Chemotherapy; Allogeneic Stem Cell Transplant 3 Months Transplant complicated by CMV infection; Lesions positive for HPV and MCPyV Lim et al., 2018; London, United Kingdom16 63 Female Breast Cancer Chemotherapy; Radiation 6 Years Valdebran et Navi et al., 2008; Davis, CA,5 64 Male Non-Hodgkin Lymphoma Chemotherapy Unknown Sherman et al., 2010; Oxford, United Kingdom6 32 Male Acute Myeloid Leukemia (AML) Chemotherapy; Total Body Radiation; Allogeneic Bone Marrow Transplant (2) 6 Years Both transplants complicated by GVHD Diamantis et al., 2011; Austin, TX7 53 Male Mantle Cell Lymphoma Allogeneic Stem Cell Transplant 5 Years Transplant complicated by GVHD; Lesions positive for HPV Fujii et al., 2012; Okayama, Japan8 66 Female Chronic Lymphocytic Leukemia (CLL); B-Cell Follicular Lymphoma Chemotherapy; Radiation 16 Years Fujii et al., 2012; Okayama, Japan8 62 Male Malignant Fibrous Histiocytoma Chemotherapy; Radiation 10 Years Fujii et al., 2012; Okayama, Japan8 59 Male B-Cell Lymphoma Chemotherapy 6 Months Fujii et al., 2012; Okayama, Japan8 72 Male B-Cell Lymphoma Chemotherapy 10 Years Nguyen et al., 2012; San Diego, CA9 25 Male AML Chemotherapy; Autologous Bone Marrow Transplant 11 Years SKIN March 2021 Volume 5 Issue 2 Copyright 2021 The National Society for Cutaneous Medicine 182 Miura & Yamamoto 2013; Fukushima,
    keywords: cell; chemotherapy; eccrine; poromas; poromatosis; transplant; years
       cache: skin-1141.pdf
  plain text: skin-1141.txt

        item: #129 of 1356
          id: skin-1142
      author: Marson, Justin; Litchman, Graham; Rigel, Darrell
       title: The Differential Impact of COVID-19 on Urban Versus Rural Dermatologic Practice Logistics and Recovery: A Cross-Sectional Investigation of the First Wave
        date: 2021-03-06
       words: 2919
      flesch: 64
     summary: Rural 18.7% (0.7%-27.7%) 19.3% (21.1%-26.6%) 13.1% (5.7%-20.5%) <0.0001 Urban 26.7% (23.0%-30.5%) 19.3% (12.1%-26.6%) 10.7%B,C (8.4%-12.9%) In April 2020 urban practices reported more closed practices (21.4% vs 5.8%, p<0.0001) and predicted significantly larger patient volume decreases (-45.2% vs -31.4%, p<0.0001) and practice closures (11.9% vs. 2.5% p<0.0001) in the following 2 weeks.
    keywords: covid-19; mean; practices; survey; volume
       cache: skin-1142.pdf
  plain text: skin-1142.txt

        item: #130 of 1356
          id: skin-1143
      author: Kim, Angela; Khan, Muneeb; Lin, Ann; Wang, Hongbei; Siegel, Louis; Rozenberg, Suzanne
       title: New Bullous Eruptions in a COVID-19 Positive Patient in an Intensive Care Unit
        date: 2021-05-21
       words: 1899
      flesch: 55
     summary: The sensitivity of DIF in BP ranges 88.3-84%7,8; additionally, in a large group of BP patients, DIF detected IgG was 91.4% and 73.6% for C3. When encountering new bullous eruptions in patients with active SARS-COV-2, clinicians should take caution and consider BP in their differential diagnosis as timely diagnosis and management can improve patient outcome.
    keywords: case; dif; igg; new; patient; pemphigoid; skin
       cache: skin-1143.pdf
  plain text: skin-1143.txt

        item: #131 of 1356
          id: skin-1145
      author: Hooper, Perry; Holmes, Samantha; Que, Syril Keena T.
       title: Smoke Evacuation in Dermatology: A National Cross-Sectional Analysis Examining the Behaviors and Perceptions of Dermatologists and Dermatologic Surgeons
        date: 2021-05-21
       words: 1382
      flesch: 43
     summary: No 44 (72.1) 15 (62.5) *“Infrequent use” of smoke evacuators is defined as “use of smoke evacuator during 50% or less of cases generating surgical smoke”. **“Frequent use” of smoke evacuators is defined as “use of smoke evacuator during more than 50% of cases generating surgical smoke”.
    keywords: dermatologists; evacuation; smoke; use
       cache: skin-1145.pdf
  plain text: skin-1145.txt

        item: #132 of 1356
          id: skin-1146
      author: Brouha, Brook; Ferris, Laura; Skelsey, Maral; Peck, Gary; Rock, Jim; Nguyen, Anh; Yao, Zuxu; Howell, Michael; Jansen, Burkhard; Cockerell, Clay
       title: Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings From a Large U.S. Registry Study
        date: 2021-01-01
       words: 2215
      flesch: 41
     summary: Specifically, 18.7% of surgically excised 2-GEP-positive lesions in this registry study, compared to 4% of lesions biopsied based on visual atypia, were histopathologically confirmed as melanoma in situ or invasive melanoma.-3 Taken together with our previous reports, the 2-GEP test has the potential to transform management of pigmented lesions by non- invasively guiding biopsy decisions to detect melanoma while reducing surgical biopsies by approximately 90%.7,8 An integrated approach to optimize pigmented lesion management appears well aligned with the most recent 2019 American Academy of Dermatology (AAD) cutaneous melanoma guidelines which state “that efforts to standardize the histopathologic diagnosis and categorization of melanocytic neoplasms are underway to reduce the significant interobserver variability among pathologists. Consideration of genomic atypia may be a superior approach to guide biopsy decisions and manage pigmented lesions.
    keywords: atypia; genomic; gep; lesions; linc; melanoma; prame
       cache: skin-1146.pdf
  plain text: skin-1146.txt

        item: #133 of 1356
          id: skin-1148
      author: Surjanto, Kezia; Phan, Michael; Williams, Laura
       title: A Commentary on Colorism and Skin Bleaching in Asian and Asian American Patients
        date: 2021-03-06
       words: 446
      flesch: 38
     summary: As a result, Asians and Asian Americans use skin bleaching products, despite their ingredients’ adverse effects which include, but are not limited to: exogenous ochronosis (hydroquinone), membranous nephropathy (mercury), and superficial mycoses (steroids).1,3 With this in mind, one can understand that the practice of skin bleaching is not only an attempt to attain beauty, but also a means to evade skin tone specific discrimination.2 It is crucial for dermatologists— especially those serving a diverse patient demographic— to be aware of the origins of skin bleaching and approach patients suspected of this practice from a culturally sensitive perspective. Colorism is a bias according to a skin color hierarchy within ethnoracial groups that leads to systematic discrimination against individuals with darker skin tones.1,2 In Japan, light skin reflected nobility based on the implication that fair-skinned individuals were exempt from outdoor labor.1,2 In India, possessing darker skin implied that one was of a lower caste.2 Similar colorism trends were also present in China, Pakistan, Vietnam, Korea, the Philippines, Cambodia, Thailand, and Indonesia, ultimately associating fair skin with improved social privilege and beauty.1, 2 These biases impact individuals whose skin tone does not conform to the culturally rooted standard that is perpetuated throughout generations.
    keywords: bleaching; skin
       cache: skin-1148.pdf
  plain text: skin-1148.txt

        item: #134 of 1356
          id: skin-1149
      author: Jimenez, Antonio Roberto; Hoyer, Paige; Ross, Lindy
       title: A Rare Presentation of Concomitant Alopecia Areata and Vitiligo in a Teenager
        date: 2021-05-21
       words: 1771
      flesch: 51
     summary: The patient was diagnosed with concomitant disease and topical tofacitinib was added to her treatment regimen. The rare nature of the patient’s presentation makes concomitant disease a therapeutic challenge and can impose significant psychological distress to a pediatric patient.
    keywords: hair; patient; scalp; vitiligo
       cache: skin-1149.pdf
  plain text: skin-1149.txt

        item: #135 of 1356
          id: skin-115
      author: Knuckles, Melissa L F; Levi, Eugenia; Soung, Jennifer
       title: Defining and Treating Moderate Plaque Psoriasis in a Real-World Clinical Setting: A Dermatologist Survey and Prospective 6-Month Chart Review of Patients Treated with Apremilast
        date: 2017-10-27
       words: 1898
      flesch: 40
     summary: • US dermatologists treating patients with psoriasis were invited to complete an online survey which asked: – How they typically assess psoriasis severity – What cutoff criteria they use to defi ne moderate psoriasis – Which treatments they commonly prescribe to patients with moderate plaque psoriasis • Eligible survey participants were US dermatologists who: – Treat ≥20 adult patients with plaque psoriasis per month, ≥1% of whom must be considered to have moderate psoriasis – Spend ≥40% of practice time in medical dermatology or ≥70% in medical and surgical dermatology – Have been in practice for 2 to 30 years – Spend >75% of practice time in direct patient care Prospective 6-Month Patient Chart Review • Surveyed dermatologists were also asked to provide data from charts of 4 patients with a diagnosis of moderate plaque psoriasis whom they had seen in the last month, including ≥1 patient treated with APR; 6 months later they were invited to provide follow-up patient chart information. INTRODUCTION • Management of moderate psoriasis remains a signifi cant challenge, with some evidence suggesting patients with moderate disease are often undertreated and experience unsatisfactory clinical outcomes.1,2
    keywords: apr; month; patients; psoriasis; treatment
       cache: skin-115.pdf
  plain text: skin-115.txt

        item: #136 of 1356
          id: skin-1151
      author: Litchman DO, MS, Graham H; Thibodeaux, Quinn; Rivera-Oyola, Ryan; Koo, John; Fried, Rick; Goldenberg, Gary; Han, George; Hsu, Sylvia; Kircik, Leon; Knuckles, Melissa; Murina, Andrea; Wu, Jashin; Lebwohl, Mark
       title: Should Package Insert Warnings Deter Prescribing in Psoriasis Patients with Depression? 
        date: 2021-01-01
       words: 3229
      flesch: 46
     summary: Reports of depression for the duration of each clinical trial are also below population averages of psoriasis patients when previous data and meta-analyses are considered. IL-17A causes depression-like symptoms via NF B and p38MAPK signaling pathways in mice: implications for psoriasis associated depression.
    keywords: amgen; apremilast; brodalumab; celgene; depression; dermatology; novartis; patients; pharma; psoriasis; speaker; treatment
       cache: skin-1151.pdf
  plain text: skin-1151.txt

        item: #137 of 1356
          id: skin-1153
      author: Cockerell, Clay; Goldberg, Matthew; Estrada, Sarah; Hosler, Gregory; Martin, Howard; Russell, Brooke; Zolochevska, Olga; Depcik-Smith, Natalie; Cleaver, Nathan
       title: Performance of a 35-Gene Expression Profile Test in Suspicious Pigmented Lesions of the Head and Neck
        date: 2020-12-31
       words: 964
      flesch: 60
     summary: PowerPoint Presentation REFERENCES •Lesions on the head and neck in the ≥18 yo population were analyzed from the cohort published in Estrada et al.; samples are described in Table 1. •Clinically diagnosed melanomas tested with the 31-GEP (prognostic melanoma test available from Castle Biosciences Inc.) were included in this study. Estrada et al. SKIN J Cutan Med.
    keywords: gep; neck
       cache: skin-1153.pdf
  plain text: skin-1153.txt

        item: #138 of 1356
          id: skin-1154
      author: Kirkwood, John; Dummer, Reinhard; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Sileni, Vanna; Larkin, James; Nyakas, Marta; Haydon, Andrew; Dutriaux, Caroline; Schachter, Jacob; Robert, Caroline; Mortier, Laurent; Banerjee, Hiya; Haas, Tomas; Tan, Monique; Lau, Mike; Schadendorf, Dirk; Long, Georgina; Mandala, Mario
       title: Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma
        date: 2021-01-01
       words: 2623
      flesch: 52
     summary: Dirk Schadendorf,18 Georgina V. Long,19 Mario Mandalà20 1Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; 2Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; 3Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany; 4Melanoma and Sarcoma Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 5Division of Cancer Services, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Greenslopes, QLD, Australia; 6Melanoma Cancer Unit, Department of Experimental and Clinical Oncology, Veneto Oncology Institute-IRCCS, Padova, Italy; 7Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK; 8Department of Cancer, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; 9Melanoma Service, Department of Medical Oncology, The Alfred Hospital, Melbourne, VIC, Australia; 10Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; 11Division of Oncology, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 12Dermatology Service and Melanoma Research Unit, Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France; 13Service de Dermatologie, Université de Lille, INSERM U 1189, Lille, France; 14Clinical Development and Analytics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 15Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland; 16Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 17Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland; 18Department of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum), University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany; 19Department of Medical Oncology, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; 20Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy Background • In COMBI-AD analysis, 5-year relapse-free survival (RFS) rates were 52% in patients with stage No prior systemic anticancer therapy • ECOG PS 0-1 N = 870 Stratified by: • BRAF mutation (V600E or V600K) • Disease stage (IIIA, IIIB, or IIIC) R 1:1 n = 438 Dabrafenib 150 mg BID + Trametinib 2 mg QD n = 432 2 matched placebos Treatment (12 months)a Primary endpoint: RFS Secondary endpoints: OS, DMFS, FFR, safety Follow-upb until the end of study AJCC, American Joint Committee on Cancer; AJCC 7, AJCC Cancer Staging Manual, 7th edition; BID, twice daily; DMFS, distant metastasis–free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; FFR, freedom from relapse; OS, overall survival; QD, once daily; R, randomization; RFS, relapse-free survival.
    keywords: cure; dab; pbo; rate; stage; tram
       cache: skin-1154.pdf
  plain text: skin-1154.txt

        item: #139 of 1356
          id: skin-1155
      author: Lewis, Karl; Peris, Katty; Sekulic, Aleksandar; Stratigos, Alexander; Dunn, Lara; Eroglu, Zeynep; Chang, Anne Lynn; Migden, Michael; Li, Siyu; Yoo, Suk-Young; Mohan, Kosalai; Coates, Ebony; Okoye, Emmanuel; Baurain, Jean-Francois; Bechter, Oliver; Hauschild, Axel; Butler, Marcus; Hernandez-Aya, Leonel; Licitra, Lisa; Neves, Rogerio; Ruiz, Emily; Seebach, Frank; Lowy, Israel; Bowler, Timothy; Fury, Matthew
       title: Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)
        date: 2021-01-01
       words: 2979
      flesch: 50
     summary: Any TEAE occurring in ≥10% patients or Grade ≥3 in ≥5% patients§ Fatigue 14 (50.0) 0 Diarrhea 10 (35.7) 0 Constipation 7 (25.0) 0 Pruritus 7 Synopsis • Basal cell carcinoma (BCC) is the most common type of skin cancer1 and ultraviolet exposure is a major risk factor.2 • Surgery is a curative option for most patients, but systemic therapy is indicated for a small percentage of patients who develop advanced BCC.3 • Vismodegib is a hedgehog signalling pathway inhibitor (HHIs) that is approved for treatment of patients with metastatic BCC (mBCC) or locally advanced BCC (laBCC) who are not candidates for curative surgery or curative radiotherapy.
    keywords: cemiplimab; disease; inc; months; patients; pharmaceuticals; regeneron; reports; response; treatment
       cache: skin-1155.pdf
  plain text: skin-1155.txt

        item: #140 of 1356
          id: skin-1156
      author: Stratigos, Alexander; Sekulic, Aleksandar; Peris, Ketty; Bechter, Oliver; Kaatz, Martin; Lewis, Karl; Basset-Segiun, Nicole; Chang, Anne Lynn; Dalle, Stephanie; Orland, Almudena Fernandez; Licitra, Lisa; Robert, Caroline; Ulrich, Claas; Hauschild, Axel; Migden, Michael; Dummer, Reinhard; Li, Siyu; Mohan, Kosalai; Coates, Ebony; Jankovic, Vladimir; Flaschi, Nathalie; Okoye, Emmanuel; Bassukas, Ioannis; Loquai, Carmen; De Giorgi, Vincent; Eroglu, Zeynep; Gutzmer, Ralf; Ulrich, Jens; Puig, Susana; Seebach, Frank; Thurston, Gavin; Lowy, Israel; Bowler, Timothy; Fury, Matthew
       title: Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)
        date: 2021-01-01
       words: 3035
      flesch: 50
     summary: Any grade Grade ≥3 Any 82 (98) 43 (51) Serious 29 (35) 22 (26) Led to discontinuation 14 (17) 7 (8) Associated with an outcome of death* 3 (4) 3 (4) Occurred in ≥10% patients (any grade) or Grade 3 in ≥5% patients Fatigue 25 (30) 3 (4) Diarrhea 20 (24) 0 Pruritus 18 (21) 0 Asthenia 17 (20) 1 (1) Anemia 13 (16) 1 (1) Decreased appetite 13 (16) 1 (1) Headache 12 (14) 1 (1) Nausea 12 (14) 1 (1) Urinary tract infection 12 (14) 3 (4) Arthralgia 11 (13) 0 Caroline Robert reports grants and personal fees advisory board roles with Bristol-Myers Squibb, Pierre Fabre, Novartis, Amgen, Merck, Roche, Merck Sharp & Dhome, Sanofi, Biothera, and Ultimovacs.
    keywords: disease; fees; inc; novartis; patients; pharmaceuticals; regeneron; reports; response; roche; table; treatment
       cache: skin-1156.pdf
  plain text: skin-1156.txt

        item: #141 of 1356
          id: skin-1157
      author: Migden, Michael; Rischin, Danny; Sasane, Medha; Mastey, Vera; Pavlick, Anna; Schmults, Chrysalyne; Chen, Zhen; Guminski, Alexander; Hauschild, Axel; Bury, Denise; Hudgens, Stacie; Chang, Anne Lynn; Rabinowits, Guilherme; Ibrahim, Sherrif; Fury, Matthew; Lowy, Israel; Li, Siyu; Chen, Chieh-I
       title: Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial
        date: 2021-01-01
       words: 3010
      flesch: 55
     summary: Guilherme Rabinowits: consulting and advisory roles for EMD Serono Pfizer, Sanofi, Regeneron Pharmaceuticals Inc. and Merck and Castle and stock/other ownership interests from Syros Pharmaceuticals and Regeneron Pharmaceuticals, Inc. Funding sources Funding was provided by Regeneron Pharmaceuticals, Inc. and Sanofi.
    keywords: baseline; cycle; inc; pain; pharmaceuticals; regeneron; response; time
       cache: skin-1157.pdf
  plain text: skin-1157.txt

        item: #142 of 1356
          id: skin-1158
      author: Campbell, Garrett; Hartung, Ryan; Churko, Jared; Thorpe, David
       title: Improving Skin Barrier Function During the COVID-19 Era: Laboratory Studies of a Prescription Tri-lipid Emollient
        date: 2021-01-01
       words: 1407
      flesch: 60
     summary: For treated filter paper, cream was applied and spread uniformly using a glass slide and dried for 2 h at 30oC. Untreated filter paper was used as a control. Interpretation: No growth is proof of complete blockage of microbial passage through treated filter papers.
    keywords: barrier; filter; paper; test
       cache: skin-1158.pdf
  plain text: skin-1158.txt

        item: #143 of 1356
          id: skin-1159
      author: Roebuck, Heather
       title: COVID-19 Pandemic and Personal Protection Equipment (PPE): A Focus on Treatment of Essential Workers with Hand Dermatitis
        date: 2021-01-01
       words: 602
      flesch: 39
     summary: Subsequently, bacteria, fungi, and viruses, such as the coronavirus, can penetrate through the skin into the bloodstream causing additional comorbidities.3 Though 90% of healthcare workers experience symptoms associated with hand eczema less than 15% recognize the symptoms as onset of disease.2 Introduction 54 year old female essential worker with a history of atopic dermatitis presents with a 6 week worsening of hand dermatitis due to frequent job related hand washing and sanitizing (~20x/day). COVID-19 Training on TRAIN Trainings on Infection Prevention and Control, PPE, Self-Care/Mental Health for Professionals OpenWHO Free Covid-19 Training Courses and Exercises, Patient Handouts/Stickers/ Posters/Fun Activities Latest research, Free CME, Public Health Guidance and Patient Information with a Special JAMA Dermatology Section Available Free Evidence Based Skin Disease Booklets to Order or Download for Your Patients and Educational Grants and Funding Information Database of Clinical Studies Available Around the World New Symptom Tracker Launched to Fight COVID-19 Provides Real Time Data for Treatment Planning and Updated Recommendations Due to COVID-19, extended use of PPE introduced an increased risk of dermatological conditions among health care workers.
    keywords: daily; skin
       cache: skin-1159.pdf
  plain text: skin-1159.txt

        item: #144 of 1356
          id: skin-116
      author: Reich, Kristian; Bomas, Stefanie; Korge, Bernhard; Manasterski, Maria; Schwitchtenberg, Uwe; Mentz, Hannah; Groegel, Kathrin
       title: First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis
        date: 2017-10-27
       words: 1577
      flesch: 60
     summary: The subgroup analysis was stratifi ed based on the number of prior conventional systemic treatments (≤1 vs. >1) (Table 1). US: AbbVie Deutschland GmbH, Almirall Hermal GmbH, Astellas Pharma GmbH, Beiersdorf Derma Medical GmbH, Celgene GmbH, Janssen Cilag GmbH, Johnson & Johnson GmbH, LEO Pharma GmbH, L´Oréal GmbH, MEDA Pharma GmbH, Merz Pharmaceuticals GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfi zer GmbH, and Medical Project Design GmbH – paid speaker, advisory board member, investigator, and/or stockholder.
    keywords: dlqi; gmbh; patients; subgroup; systemic; visit
       cache: skin-116.pdf
  plain text: skin-116.txt

        item: #145 of 1356
          id: skin-1161
      author: Papp, Kim; Szepietowski, Jacek; Kircik, Leon; Toth, Darryl; Kuligowski, Michael; Venturanza, May; Sun, Kang; Simpson, Eric
       title: Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies
        date: 2021-01-01
       words: 2471
      flesch: 54
     summary: Proportion of Patients Achieving EASI-75 Pr op or tio n (S E) o f EA SI -7 5 Re sp on de rs , % † 0 10 20 30 40 50 70 60 0 2 4 8 Time, wk Vehicle (n=244) 0.75% RUX (n=483) 1.5% RUX (n=481) 4.9 12.3 19.7 28.0 47.0 53.8 33.9 54.7 62.0 **** **** EASI-75, ≥75% improvement in Eczema Area and Severity Index score from baseline; RUX, ruxolitinib cream; SE, standard error. [BID], 1.5% BID) or vehicle cream BID for 8 weeks of double-blind treatment – Patients on ruxolitinib cream could subsequently continue treatment for 44 weeks; patients initially randomized to vehicle were re-randomized 1:1 to either ruxolitinib cream regimen Figure 1.
    keywords: baseline; cream; patients; rux; ruxolitinib; vehicle; week
       cache: skin-1161.pdf
  plain text: skin-1161.txt

        item: #146 of 1356
          id: skin-1162
      author: Silverberg, Jonathan; Barbarot, Sebastien; Gooderham, Melinda; Simon, Jan; Simpson, Eric; Kurbasic, Azra; Olsen, Christina; Cork, Michael
       title: Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis
        date: 2021-01-01
       words: 2440
      flesch: 51
     summary: [95% CI –2.9, –2.3] vs –1.8 [95% CI –2.3, –1.3]; P=0.004, and ECZTRA 2, –3.0 [95% CI –3.2, –2.7] vs –1.8 [95% CI –2.3, –1.2]; P0.001) POEM sleep score ● There was a greater shift towards lower POEM sleep scores with tralokinumab compared with placebo in both ECZTRA 1 and ECZTRA 2 (Figure 4) — The majority of patients (87.5−92.8%) across treatment groups reported ≥3 nights of sleep disturbance at baseline in both trials — At week 16, 64.2% and 60.9% of tralokinumab-treated patients reported ≥3 nights of sleep disturbance compared to 81% and 78.5% of patients with placebo ● A greater proportion of tralokinumab-treated patients (35.9−39.1%) reported “No days” or “1−2 days” of sleep disturbance at week 16 versus placebo (19.1−21.5%) Winter Clinical Dermatology Conference, January 16-24, 2021 Conclusions ● Tralokinumab monotherapy 300 mg every 2 weeks demonstrated improvements compared with placebo in three sleep measures (NRS for eczema-related sleep interference, SCORAD sleep score, and POEM sleep score) during the initial 16-week treatment period ● Improvement in sleep measures was consistent across two large Phase 3 trials, ECZTRA 1 and ECZTRA 2 ● A greater proportion of tralokinumab-treated patients reported either “no days” or “1–2 days” of sleep disturbance ● Early improvement in sleep measures as early as week 1 with tralokinumab is consistent with its effects on the signs and troublesome symptoms of atopic dermatitis, including pruritus [95% CI –2.4, –1.5]; P=0.007, and ECZTRA 2, –2.9 [95% CI –3.1, –2.7] vs –1.5 [95% CI –1.9, –1.1]; P0.001) SCORAD sleep score ● There was a greater improvement in SCORAD sleep score with tralokinumab compared with placebo in both ECZTRA 1 and ECZTRA 2 (Figure 3) — Change from baseline in SCORAD sleep score was greater with tralokinumab compared with placebo, with separation observed between the treatment groups from week 2 (P0.001) and at each week onwards (P0.05) ● The LSM change from baseline at week 16 was greater with tralokinumab compared with placebo (ECZTRA 1, −2.6
    keywords: ecztra; placebo; score; sleep; tralokinumab; week
       cache: skin-1162.pdf
  plain text: skin-1162.txt

        item: #147 of 1356
          id: skin-1163
      author: Wollenberg, Andreas; Beck, Lisa; de Bruin Weller, Marjolein; Zachariae, Rebecca; Olsen, Christina; Thyssen, Jacob
       title: Conjunctivitis in Tralokinumab-Treated Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Results from Five Clinical Trials
        date: 2021-01-01
       words: 2282
      flesch: 48
     summary: ● However, the duration of the first conjunctivitis event was longer in the tralokinumab group compared to the placebo group (21.0 days vs 14 days) (Table 4) Common treatments ● The majority of patients in both treatment groups received treatment for their conjunctivitis (85.7% of tralokinumab patients vs 71.4% of placebo patients) ● Common treatments in tralokinumab-treated and placebo-treated patients included ophthalmic anti-allergics (31.0% vs 38.1%), anti-infectives (30.2% vs 19.0%), corticosteroids (23.0% vs 9.5%) and combined corticosteroids and anti-infectives (13.5% vs 14.3%) References 1. Time to onset of first conjunctivitis event (safety analysis set, AD pool, initial treatment period)
    keywords: conjunctivitis; patients; placebo; q2w; tralokinumab; treatment
       cache: skin-1163.pdf
  plain text: skin-1163.txt

        item: #148 of 1356
          id: skin-1164
      author: Simpson, Eric; Merola, Joseph; Silverberg, Jonathan; Zachariae, Rebecca; Olsen, Rebecca; Wollenberg, Andreas
       title: Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials
        date: 2021-01-01
       words: 3790
      flesch: 47
     summary: In this analysis of five clinical trials (three Phase 3 and two Phase 2), which included 2285 patients, tralokinumab 300 mg q2w was well tolerated when used as monotherapy and as combination therapy with TCS for treatment of moderate-to-severe AD in the AD pool during the initial 16-week period ● The overall frequencies of AEs were similar for tralokinumab and placebo; skin infections requiring systemic treatment, eczema herpeticum, opportunistic infections and severe or serious infections were lower with tralokinumab than with placebo ● The safety profile during prolonged tralokinumab treatment was consistent with the initial 16-week treatment period and some events decreased in frequency References 1. ● The overall frequency of AEs during the initial treatment period was similar for tralokinumab (69.0%) and placebo (71.5%) and similar to the AD pool — The majority of AEs were mild or moderate in severity ● The safety profile during prolonged tralokinumab treatment from 16–52 weeks in the monotherapy pool was consistent with the initial 16-week treatment period, based on overall frequencies of AEs, SAEs, severe AEs and AEs leading to permanent discontinuation (Figure 2)
    keywords: aes; ecztra; placebo; q2w; tralokinumab; treatment
       cache: skin-1164.pdf
  plain text: skin-1164.txt

        item: #149 of 1356
          id: skin-1165
      author: Blaiss, Michael; Cork, Michael; Lio, Peter; Kessel, Aharon; Takiya, Liza; Werth, John; O'Connell, Michael; Zang, Chuanbo; Spergel, Jonathan
       title: Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Food Allergies
        date: 2021-01-01
       words: 2020
      flesch: 50
     summary: INTRODUCTION • AD is a chronic inflammatory skin disease; patients with AD are at higher risk for other atopic comorbidities, such as food allergies1 • The prevalence of food allergy in AD ranges from 20% to 80% in this population2 – Although it is not clear whether the presence of food allergies makes AD more difficult to treat, there is an association between ingestion of food that triggers an allergic reaction and AD exacerbation3 • Crisaborole ointment, 2%, is an anti-inflammatory nonsteroidal PDE4 inhibitor for the treatment of patients aged ≥3 months (≥2 years of age outside the United States) with mild-to-moderate AD4 – Initial regulatory approval was based on the results from 2 identically designed, vehicle-controlled, phase 3 clinical studies: CORE 1 (NCT02118766) and CORE 2 (NCT02118792)5 OBJECTIVE • In the pooled study population, 1016 patients received crisaborole and 506 received vehicle – Among them, 251 reported a past medical history of food allergies and 1271 did not have a past medical history of food allergies – Baseline demographics were generally similar between treatment arms and between those who did and those who did not have food allergies – Regarding baseline disease characteristics, for those with a past medical history of food allergies, a relatively greater proportion (1) used systemic corticosteroids previously, (2) used antihistamines concurrently, (3) had moderate AD per ISGA at baseline, and (4) had greater %BSA involvement with AD lesions (Table 1) Table 1.
    keywords: allergies; crisaborole; food; history; patients; vehicle
       cache: skin-1165.pdf
  plain text: skin-1165.txt

        item: #150 of 1356
          id: skin-1166
      author: Spergel, Jonathan; Blaiss, Michael; Lio, Peter; Kessel, Aharon; Takiya, Liza; Werth, John; O'Connell, Michael; Zang, Chuanbo; Cork, Michael
       title: Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis
        date: 2021-01-01
       words: 2225
      flesch: 46
     summary: Among patients with allergic rhinitis, 53 crisaborole-treated patients (32.5%) and 22 vehicle-treated patients (27.8%) experienced at least 1 all-cause TEAE • Among crisaborole-treated patients with allergic rhinitis, 34 patients (20.9 %) experienced a mild TEAE, 16 patients (9.8%) experienced a moderate TEAE, and 3 patients (1.8%) experienced a severe TEAE • Individual TEAEs were infrequent (Table 2) • The most common treatment-related TEAE in those with allergic rhinitis and in those without allergic rhinitis (crisaborole vs vehicle) was application site pain (4.9% vs 1.3% and 4.4% vs 1.2%, respectively) • 1 crisaborole-treated patient with allergic rhinitis experienced a serious TEAE (pneumonia, 0.6%), and none treated with vehicle experienced a serious TEAE (0%); the serious TEAE was not considered treatment related • Allergic rhinitis was reported as an AE in ≤2 patients in any group; no anaphylaxis was reported in any group Table 2. In the pooled study population, 1016 patients received crisaborole and 506 received vehicle – Among them, 242 were reported to have a past medical history of allergic rhinitis and 1280 did not have a past medical history of allergic rhinitis – Baseline demographics and disease characteristics were generally balanced between treatment arms and between patients who did and those who did not have allergic rhinitis; however, for patients with a past medical history of allergic rhinitis, a relatively greater proportion used systemic corticosteroids, used antihistamines concurrently, and had greater mean %BSA involvement with AD lesions (Table 1) Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis Jonathan M. Spergel,1 Michael S. Blaiss,2 Peter Lio,3,4
    keywords: crisaborole; isga; patients; pmh; rhinitis; vehicle
       cache: skin-1166.pdf
  plain text: skin-1166.txt

        item: #151 of 1356
          id: skin-1167
      author: Bunick, Christopher; Del Rosso, James; Tyring, Stephen; Draper, Michael; Johnson, Jodi; Grada, Ayman
       title: Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models
        date: 2021-01-01
       words: 725
      flesch: 34
     summary: Anti-inflammatory effect of sarecycline and comparators in rat footpad model Antibacterial S. aureus RN450-1 E. coli PBS1478 agent MIC (mg/mL) ➢ Sarecycline showed anti-inflammatory effect comparable to doxycycline and minocycline in the rat footpad edema model.
    keywords: sarecycline
       cache: skin-1167.pdf
  plain text: skin-1167.txt

        item: #152 of 1356
          id: skin-1168
      author: Warren, RB; Blauvelt, A; Bagel, J; Papp, KA; Yamauchi, P; Armstrong, A; Langley, R; Vanvoorden, V; De Cuyper, D; Peterson, L; Cross, N; Reich, K
       title: Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
        date: 2021-01-01
       words: 2797
      flesch: 46
     summary: Author Disclosures: RBW: Research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; AB: Scientific adviser and/or clinical study investigator for AbbVie, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma and UCB Pharma; paid speaker for AbbVie; JB: Speaker, investigator and/or consultant for AbbVie, Celgene, Eli Lilly, Leo Pharma, Novartis and Ortho Dermatologics; KAP: Honoraria and/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Canfite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Gilead, GSK, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma, and Valeant/Bausch Health; consultant (no compensation) for AstraZeneca and Meiji Seika Pharma; PY: Speaker, investigator, consultant for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Sun Pharma and UCB Pharma; AA: Research investigator and/or consultant for AbbVie, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Janssen, LEO Pharma, Kyowa Kirin, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi, Sun Pharma and UCB Pharma; RL: Honoraria from AbbVie, Amgen, Boeringer Ingelheim, Centocor, Eli Lilly, Janssen, LEO Pharma, Pfizer and Valeant/Bausch Health; VV, LP, DDC, NC: Employees of UCB Pharma; KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport.
    keywords: adalimumab; bimekizumab; pharma; q4w; week
       cache: skin-1168.pdf
  plain text: skin-1168.txt

        item: #153 of 1356
          id: skin-1169
      author: Strober, B; Krueger, JG; Magnolo, N; Vender, R; Toth, DP; Thaci, D; Wang, M; Cioffi, C; Madden, C; Warren, RB
       title: Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial
        date: 2021-01-01
       words: 2179
      flesch: 31
     summary: Author Disclosures: BS: Consultant (honoraria) from AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Equillium, GSK, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma and UCB Pharma; speaker for AbbVie, Amgen, Eli Lilly, Janssen and Ortho Dermatologics; Scientific Director (consulting fee) for Corrona Psoriasis Registry; Investigator for AbbVie, Cara, Corrona Psoriasis Registry, Dermavant, Dermira and Novartis; Editor-in-Chief (honorarium) for Journal of Psoriasis and Psoriatic Arthritis; JGK: Grants paid to institution from AbbVie, Akros, Allergan, Amgen, Avillion, Biogen MA, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, Eli Lilly, Exicure, Incyte, Innovaderm, Janssen, LEO Pharma, Novan, Novartis, Paraxel, Pfizer, Regeneron, Sienna, UCB Pharma and Vitae; personal fees from AbbVie, Allergan, Almirall, Amgen, Arena, Aristea, Asana, Aurigne, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Escalier, LEO Pharma, Nimbus, Novartis, Menlo, Pfizer, Sanofi, Sienna, Sun Pharma, UCB Pharma and Valeant; NM: Honoraria, advisor, and/or paid speaker for and/or participated as principal investigator in clinical trials for AbbVie, Almirall, Asana, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Galderma, Genentech, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sun Pharma and UCB Pharma; RV: Consultant, and/or scientific advisor, and/or investigator, and/or speaker for AbbVie, Amgen, Astellas, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, Merck (MSD), Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB Pharma; DPT: Investigator and/or speaker for AbbVie, Amgen, Arcutis, Avillion, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Merck-Serono, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sun Pharma and UCB Pharma; DT: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Biogen-Idec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DS-Biopharma, Eli Lilly, Galapagos, Janssen, LEO Pharma, Morphosis, Novartis, Pfizer, Regeneron, Samsung, Sandoz-Hexal, Sanofi and UCB Pharma; Research grants received from Celgene and Novartis; MW: Employee of UCB Pharma; CC, CM: Employees and shareholders of UCB Pharma; RBW: Research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB Pharma; Consultant for AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma.
    keywords: bimekizumab; exposure; patients; pharma; ustekinumab; years
       cache: skin-1169.pdf
  plain text: skin-1169.txt

        item: #154 of 1356
          id: skin-117
      author: Reich, Kristian; Goodfield, Mark; Green, Lawrence; Nograles, Kristine; Levi, Eugenia; Langley, Richard GB
       title: Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study
        date: 2017-10-27
       words: 2217
      flesch: 65
     summary: • Improvements in nail psoriasis were achieved with APR at Week 16, and continued APR treatment over 104 weeks resulted in further improvements in nail psoriasis. At Week 16, patients in the PBO and ETN groups switched to APR, and patients in the APR group continued APR.
    keywords: apr; etn; patients; pbo; phase; psoriasis; week
       cache: skin-117.pdf
  plain text: skin-117.txt

        item: #155 of 1356
          id: skin-1170
      author: Gordon, K; Foley, P; Rich, P; Duffin, K; Pinter, A; Griffiths, CEM; Wang, M; Vanvoorden, V; Staelens, F; Ciaravino, V; Merola, JF
       title: Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial
        date: 2021-01-01
       words: 1953
      flesch: 41
     summary: Author Disclosures: KG: Honoraria and/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; PF: Grant support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; Investigator for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Eli Lilly, Galderma, Genentech, Geneseq, GSK, Hexima, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant/Bausch Health; served on the advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Mayne Pharma, Merck, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant/Bausch Health; consultant for Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, and Wintermute; received travel grants from AbbVie, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Roche, and Sanofi; speaker for or received honoraria from AbbVie, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and Roche; PR: Research grants due to being principal investigator from AbbVie, Arcutis, Bristol Myers Squibb, Centocor, Dermavant, Eli Lilly, Kadmon, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma; KD: Consultant and/or investigator for AbbVie, Arena, Avotres, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, EMD-Serono, Janssen, LEO Pharma, Merck, Novartis, Regeneron, Sanofi, Sun Pharma, Pfizer, and UCB Pharma.
    keywords: bimekizumab; dlqi; patients; pharma; ustekinumab; week
       cache: skin-1170.pdf
  plain text: skin-1170.txt

        item: #156 of 1356
          id: skin-1171
      author: Papp, KA; Lebwohl, M; Gottlieb, AB; Sebastian, M; Langley, R; Okubo, Y; Wang, M; Cioffi, C; Staelens, F; Reich, K
       title: Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial
        date: 2021-01-01
       words: 1930
      flesch: 35
     summary: Author Disclosures: KAP: Honoraria and/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Canfite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Gilead, GSK, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma and Valeant/Bausch Health; Consultant (no compensation) for AstraZeneca and Meiji Seika Pharma; ML: Employee of Mount Sinai which receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer and UCB Pharma; Consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi Pharma, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance and Verrica; ABG: Honoraria as an advisory board member and consultant for Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB Pharma and XBiotech (only stock options which she has not used); research/educational grants (paid to Mount Sinai Medical School) from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharma, UCB Pharma and XBiotech; MS: Received honoraria as an investigator, or received grants and has been an advisor/consultant for AbbVie, Affibody, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Dr. August Wolff, Dr. Reddy’s Laboratories, Eli Lilly, Galderma, Genentech, GSK, Incythe, Janssen, LEO Pharma, MedImmune, MSD, Mundipharma, Novartis, Pfizer, Regeneron and UCB Pharma; RL: Honoraria from AbbVie, Amgen, Boehringer Ingelheim, Centocor, Eli Lilly, Janssen, LEO Pharma, Pfizer and Valeant/ Bausch Health for serving as an advisory board member, principal investigator and speaker; YO: Research grants from Eisai, Maruho, Shiseido, and Torii Pharmaceutical; current consulting/advisory board agreements and/or speakers bureau and/or clinical trials from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Pharma, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, Taiho Pharma, Torii Pharmaceutical and UCB Pharma; MW, FS: Employees of UCB Pharma; CC: Employee and shareholder of UCB Pharma; KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/ Bausch Health and Xenoport.
    keywords: baseline; bimekizumab; iga; patients; pharma; psoriasis; scalp; ustekinumab
       cache: skin-1171.pdf
  plain text: skin-1171.txt

        item: #157 of 1356
          id: skin-1172
      author: Blauvelt, A; Warren, RB; Reich, K; Brock, F; Fierens, F; Ciaravino, V; Lebwohl, M
       title: Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2021-01-01
       words: 2182
      flesch: 50
     summary: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport; FB, FF, VC: Employees of UCB Pharma; ML: Employee of Mount Sinai which receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Pharma; consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi Pharma, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica. Author Disclosures: AB: Scientific adviser and/or clinical study investigator for AbbVie, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; paid speaker for AbbVie; RBW: Consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma; KR:
    keywords: czp; dlqi; mg q2w; pharma; q2w
       cache: skin-1172.pdf
  plain text: skin-1172.txt

        item: #158 of 1356
          id: skin-1173
      author: Tha?i, D; Blauvelt, A; Reich, K; Warren, RB; Piguet, V; Brock, F; Fierens, F; Ciaravino, V; Lebwohl, M
       title: Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials
        date: 2021-01-01
       words: 2022
      flesch: 44
     summary: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport. Author Disclosures: DT: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DS Biopharma, Eli Lilly, Galapagos, Janssen, LEO Pharma, Morphosis, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi Genzyme, and UCB Pharma; research grants received from Celgene, LEO Pharma, and Novartis.
    keywords: czp; patients; pharma; q2w; week
       cache: skin-1173.pdf
  plain text: skin-1173.txt

        item: #159 of 1356
          id: skin-1174
      author: Reich, K; Blauvelt, A; Lebwohl, M; Papp, KA; Rich, P; Strober, B; De Cuyper, D; Madden, C; Peterson, L; Vanvoorden, V; Warren, RB
       title: Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
        date: 2021-01-01
       words: 2655
      flesch: 38
     summary: Author Disclosures: KR: Served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medac, MSD, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health, and Xenoport; AB: Served as a scientific adviser and/or clinical study investigator for AbbVie, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; paid speaker for AbbVie; ML: Employee of Mount Sinai which receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Pharma; consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi Pharma, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica; KAP: Honoraria and/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Canfite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Gilead, GSK, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma, and Valeant/Bausch Health; consultant (no compensation) for AstraZeneca and Meiji Seika Pharma; PR: Research grants due to being principal investigator from AbbVie, Arcutis, Bristol Myers Squibb, Centocor, Dermavant, Eli Lilly, Kadmon, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma; BS: Consultant (honoraria) from AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Equillium, GSK, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Ortho Dermatologics; Scientific Director (consulting fee) for Corrona Psoriasis Registry; investigator for AbbVie, Cara Therapeutics, Corrona Psoriasis Registry, Dermavant, Dermira, and Novartis; Editor-in-Chief (honorarium) for Journal of Psoriasis and Psoriatic Arthritis; DDC, LP, VV: employees of UCB Pharma; CM: employee and shareholder of UCB Pharma; RBW: Consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma.
    keywords: bimekizumab; patients; pharma; phase; teaes; term
       cache: skin-1174.pdf
  plain text: skin-1174.txt

        item: #160 of 1356
          id: skin-1177
      author: Stein Gold, Linda; Tanghetti, Emil; Leonardi, Craig; Kwatra, Shawn; Jacobson, Abby
       title: Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Plaque Psoriasis in Patients with Mild Scaling and Mild Plaque Elevation
        date: 2021-01-01
       words: 1887
      flesch: 46
     summary: Treatment Posttreatment -40% -20% 0% 20% ** *** ** * HP/TAZ Lotion: Mild Plaque Elevation Subgroup (n=30) HP/TAZ Lotion: Mild Scaling Subgroup (n=36) Vehicle Lotion: Mild Plaque Elevation Subgroup (n=14) HP combination may provide synergistic efficacy, increase the duration of remission, and reduce side effects of both HP and TAZ when used alone1-3 � A once-daily, fixed-combination HP 0.01%/TAZ 0.045% lotion (Duobrii,® Ortho Dermatologics) was developed utilizing polymeric emulsion technology, which allows for rapid and uniform distribution of HP and TAZ, humectants, and moisturizers on the skin � HP/TAZ lotion has demonstrated efficacy and safety in patients with moderate-to-severe psoriasis,4,5 including those with lower body surface area (BSA) involvement6 OBJECTIVE � To evaluate efficacy and safety of HP 0.01%/TAZ 0.045% lotion in patients with either mild scaling or mild plaque elevation at baseline METHODS �
    keywords: elevation; lotion; plaque; scaling
       cache: skin-1177.pdf
  plain text: skin-1177.txt

        item: #161 of 1356
          id: skin-1178
      author: Stein Gold, Linda; Baldwin, Hilary; Cook-Bolden, Fran; Green, Lawrence; Ablon, Glynis; Sadick, Neil; Weiss, Jonathan; Guenin, Eric
       title: Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age
        date: 2021-01-01
       words: 1918
      flesch: 57
     summary: -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 Vehicle Lotion (n=241) -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 Vehicle Lotion (n=71)
    keywords: baseline; lotion; taz; veh; week; years
       cache: skin-1178.pdf
  plain text: skin-1178.txt

        item: #162 of 1356
          id: skin-118
      author: Strober, Bruce; Bagel, Jerry; Lebwohl, Mark; Stein Gold, Linda; Jackson, J Mark; Goncalves, Joana; Levi, Eugenia; Callis Duffin, Kristina
       title: Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)
        date: 2017-10-27
       words: 2277
      flesch: 64
     summary: • Long-term sPGA response was maintained with APR treatment in the open-label treatment phase. • Clinical responses were maintained with continued APR treatment through Week 52 and emerged in patients who switched from PBO to APR at Week 16. •
    keywords: apr; patients; pbo; phase; psoriasis; safety; treatment; week
       cache: skin-118.pdf
  plain text: skin-118.txt

        item: #163 of 1356
          id: skin-1180
      author: Weisshaar, Elke; Sciascia, Thomas; Stander, Sonja
       title: Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase
        date: 2021-01-01
       words: 1064
      flesch: 55
     summary: SST is an investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Trevi Therapeutics, Novartis, Sanofi, and Vanda Therapeutics; a consultant and/or advisory board member for Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene, Clexio, DS Biopharma, Galderma, Kiniksa, Lilly, Menlo Therapeutics, Novartis, Pfizer, Sanofi, and Trevi Therapeutics. The authors received writing/editorial support in the preparation of this poster provided by Excerpta Medica, funded by Trevi Therapeutics. CONFLICTS OF INTEREST EW is an investigator in clinical trials for Kiniksa, Menlo Therapeutics, and Trevi Therapeutics.
    keywords: patients; therapeutics
       cache: skin-1180.pdf
  plain text: skin-1180.txt

        item: #164 of 1356
          id: skin-1181
      author: Elmariah, Sarina; Chisolm, Sarah; Sciascia, Thomas; Kwatra, Shawn
       title: Modulation of the Mu and Kappa Opioid Axis for the Treatment of Chronic Pruritus
        date: 2021-01-01
       words: 1840
      flesch: 55
     summary: Tsianakas A, et al. Noble F, et al.
    keywords: itch; kor; mor; opioid; placebo
       cache: skin-1181.pdf
  plain text: skin-1181.txt

        item: #165 of 1356
          id: skin-1182
      author: Kim, Brian; Sciascia, Thomas; Yosipovitch, Gil
       title: The Role of Kappa- and Mu-Opioid Receptors in Pruritus
        date: 2021-01-01
       words: 1556
      flesch: 50
     summary: 2. Acton D, et al. Inan S, et al.
    keywords: itch; kor; kors; mor; opioid; receptors
       cache: skin-1182.pdf
  plain text: skin-1182.txt

        item: #166 of 1356
          id: skin-1183
      author: Del Rosso, J; Levy-Hacham, O; Mizrahi, O
       title: Efficacy and Safety of Microencapsulated Benzoyl Peroxide 3% and Microencapsulated Tretinoin 0.1% (E-Bpo/E-Atra) in Acne Vulgaris: Results from Two Randomized Controlled Clinical Trials
        date: 2021-01-01
       words: 1552
      flesch: 67
     summary: METHODS Design RESULTS Patients • In Study 65-04, 281 patients were randomized to E-BPO/E-ATRA and 143 to Vehicle; 249 (88.6%) and 131 (91.6%) completed the trial. E-BPO/E-ATRA was well tolerated, with results similar to Vehicle at 12 weeks.
    keywords: atra; bpo; study; vehicle
       cache: skin-1183.pdf
  plain text: skin-1183.txt

        item: #167 of 1356
          id: skin-1184
      author: Bhatia, N; Werschler, W; Baldwin, H; Sugarman, J; Stein Gold, L; Green, L; Lain, E
       title: Long-Term Efficacy and Safety of Benzoyl Peroxide Cream, 5%, Prepared with Microencapsulation in Papulopustular Rosacea: Results from an Extension of Two Phase 3, Vehicle-Controlled Trials
        date: 2021-01-01
       words: 2018
      flesch: 64
     summary: The results from this long-term extension of two phase 3 randomized controlled trials demonstrated progressive clinical improvement as reflected by percentage of patients achieving IGA success and reduction in erythema as well as good cutaneous safety and tolerability with E-BPO Cream, 5% applied for up to 52 weeks in patients with rosacea. This extends drug delivery time to improve efficacy and potently reduces the potential for skin irritation.1 • The efficacy, safety, and tolerability of E-BPO Cream, 5% were evaluated in two identical randomized, double-blind, phase 3 trials which demonstrated significant superiority of this encapsulated BPO over vehicle for percentage of patients achieving success (clear or almost clear) on the Investigators Global Assessment (IGA) and reducing the number of lesions.2 • E-BPO Cream, 5% was also well tolerated with adverse events (AEs) and cutaneous safety and tolerability was comparable to that for vehicle.
    keywords: bpo; cream; patients; phase
       cache: skin-1184.pdf
  plain text: skin-1184.txt

        item: #168 of 1356
          id: skin-1185
      author: Stein Gold, L; Del Rosso, J
       title: Microencapsulated Benzoyl Peroxide 3%, Microencapsulated Tretinoin 0.1% Cream: Efficacy for Pediatric and Adolescent Patients
        date: 2021-01-01
       words: 1070
      flesch: 61
     summary: • E-BPO/E-ATRA is an investigational, antibiotic-free, fixed-dose combination cream containing microencapsulated BPO 3% (E-BPO) and microencapsulated tretinoin 0.1% (E-ATRA). The efficacy of E-BPO/E-ATRA in pediatric and adolescent patients (9-17 years of age) was at least equivalent to that for the entire population.
    keywords: atra; bpo; vehicle
       cache: skin-1185.pdf
  plain text: skin-1185.txt

        item: #169 of 1356
          id: skin-1186
      author: Sugarman, J; Baldwin, H; Bhatia, N
       title: Efficacy of Microencapsulated Benzoyl Peroxide (E-Bpo) Cream, 5% in Elderly Rosacea Patients
        date: 2021-01-01
       words: 1123
      flesch: 62
     summary: This extends drug delivery time to improve efficacy and reduce the potential for skin irritation.1 • The efficacy, safety, and tolerability of E-BPO Cream, 5% were evaluated in two identical randomized, double-blind phase 3 trials which demonstrated significant superiority of E-BPO versus vehicle for percentage of patients achieving success (clear or almost clear) on the Investigators Global Assessment (IGA) and reducing the number of lesions.2 • E-BPO Cream, 5% was also well tolerated with adverse events (AEs) and cutaneous safety and tolerability comparable to that for vehicle.2 • The prevalence of rosacea is higher in the elderly population than the general population,3,4 but no quantitative data has been published regarding treatment efficacy on papulopustular rosacea in this subpopulation. % E-BPO (N=90) % Vehicle (N=36)
    keywords: bpo; cream; patients
       cache: skin-1186.pdf
  plain text: skin-1186.txt

        item: #170 of 1356
          id: skin-1188
      author: Eversman, Anna; Ahsanuddin, Sayeeda; Saltzman, Joel ; Silverman, Paula; Beveridge, Mara
       title: Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report
        date: 2021-05-21
       words: 1612
      flesch: 39
     summary: Imaging is often reserved for patients with additional findings concerning for malignancy.11 As the majority of dermatomyositis patients harboring internal malignancies are otherwise asymptomatic, more liberal use of imaging may be beneficial.10 In a study from Leatham et al, malignancies in patients with dermatomyositis were most frequently detected by CT scan. Current literature suggests the incidence of malignancy is lower in CADM patients compared to patients with dermatomyositis.
    keywords: amyopathic; cadm; cancer; dermatomyositis; esophageal; patients
       cache: skin-1188.pdf
  plain text: skin-1188.txt

        item: #171 of 1356
          id: skin-1189
      author: Carlos, Carmen; Brown, Christen; Elliott, Erika; Murina, Andrea
       title: Assessing Comfort in Conducting Research Among Medical Students Interested in Dermatology
        date: 2021-07-09
       words: 2041
      flesch: 41
     summary: Our analysis seeks to discover if the current method of undergraduate medical research results in a high degree of self-assessed competence with research skills. Number of research projects students participated in during medical school.
    keywords: dermatology; medical; research; residency; school; skills; students
       cache: skin-1189.pdf
  plain text: skin-1189.txt

        item: #172 of 1356
          id: skin-119
      author: Augustin, Matthias; Weglowska, Jolanta; Lebwohl, Mark; Paul, Carle; Piquet, Vincent; Sofen, Howard; Blauvelt, Andrew; Burge, Daniel; Peterson, Luke; Drew, Janice; Rollen, Robert
       title: Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)
        date: 2017-10-27
       words: 3241
      flesch: 48
     summary: At Week 16, responder rates were greater for CZP 400 mg Q2W and CZP 200 mg Q2W versus placebo for PASI 75 (74.7% and 68.2% vs 3.8%), PGA 0/1 (58.4% and 48.3% vs 3.4%), and PASI 90 (49.1% and 39.8% vs 0.3%) (p<0.0001 for all) • CZP 400 mg Q2W achieved superiority to ETN at Week 12 (p=0.0152); CZP 200 mg Q2W achieved noninferiority to ETN at Week 12 (95% confidence interval: -2.9–18.9, within the prespecified noninferiority margin of 10%) Week 16 to Week 48 • Among Week 16 PASI 75 responders, Week 48 PASI 75 (Figure 4A), PGA 0/1 (Figure 4B), and PASI 90 (Figure 4C) responder rates were greater in the patients re-randomized to CZP compared with placebo, with the highest rates seen among patients receiving CZP 400 mg Q2W in both the Initial and Maintenance Periods Figure 4. PASI 75, PGA 0/1, and PASI 90 Responder Rates From Week 16 to Week 48 in Week 16 PASI 75 Responders 100 80 60 40 20 0 R es po nd er R at e (% ) pneumonia fEscherichia coli sepsis and pyelonephritis in the same subject, endophthalmitis, pneumonia, sepsis, erysipelas, and tuberculosis gPrimary progressive multiple sclerosis; incidental finding during evaluation for low back pain and considered unrelated to treatment according to the Investigator hAnaplastic oligodendroglioma, keratoacanthoma CZP, certolizumab pegol; TEAE, treatment-emergent adverse event; Q2W, every 2 weeks CONCLUSIONS • CZP 400 mg Q2W and CZP 200 mg Q2W demonstrated statistically significant and clinically meaningful improvements in signs and symptoms of moderate-to-severe chronic plaque psoriasis versus placebo at Weeks 12 and 16 • CZP 400 mg Q2W was superior and CZP 200 mg Q2W was noninferior to ETN for PASI 75 responder rate at Week 12 • Among CZP-treated Week 16 PASI 75 responders, those who were re-randomized to CZP continued to have clinically meaningful responses in PASI 75, PGA 0/1, and PASI 90 through Week 48 that were well above the responses observed for those re-randomized to placebo – Across efficacy endpoints, treatment with CZP 400 mg Q2W in both the Initial and Maintenance Periods provided greater efficacy than either reducing the dose to CZP 200 mg Q2W after PASI 75 was achieved or treatment with CZP 200 mg Q2W in both the Initial and Maintenance Periods – The maintenance dosing regimens of CZP 200 mg Q2W and CZP 400 mg Q4W (same cumulative monthly dose) provided similar efficacy – Patients initially treated with CZP and re-randomized to placebo had a considerable loss of efficacy over time; no episodes of rebound were reported •
    keywords: czp; etn; mg q2w; pasi; placebo; psoriasis; treatment; week
       cache: skin-119.pdf
  plain text: skin-119.txt

        item: #173 of 1356
          id: skin-1190
      author: Ilyas, Muneeb; Hund, William; Vasile , Gabriella ; Weiss, Eduardo
       title: Maskne: A Potential Misnomer? 
        date: 2021-05-21
       words: 1302
      flesch: 46
     summary: Although these pathologies are certainly evident and seem to be exacerbated by prolonged mask use, the dermatologic literature lacks reports on the increasing incidence of various other cutaneous pathologies associated with wearing facial masks. Although there is an increase in acne and acneiform lesions associated with prolonged facial mask use, “maskne” may be a misnomer, causing non-dermatologic providers to misdiagnose patients with acne when they, in fact, have an alternate cutaneous pathology.
    keywords: acne; dermatitis; mask; maskne; skin
       cache: skin-1190.pdf
  plain text: skin-1190.txt

        item: #174 of 1356
          id: skin-1191
      author: Hobbs, Landon Kaleb; Guffy, Darren; Flowers, R. Hal
       title: Diffuse Dermal Angiomatosis of the Breasts: A Case Series of 8 Patients
        date: 2021-05-21
       words: 2528
      flesch: 54
     summary: In the literature one patient with DDA was reported to improve with the combination of weight loss and smoking cessation10, however another patient did not see substantial improvement despite reducing smoking and losing weight.8 Furthermore, there are reports of DDA presenting after or worsening with weight gain.1,3,4,8 In the series, we saw a trend of greater BMI among symptomatic patients compared to asymptomatic patients. Our series of DDA patients includes three patients diagnosed with FM DISCUSSION SKIN
    keywords: angiomatosis; breasts; dda; dermal; patients; series; smoking
       cache: skin-1191.pdf
  plain text: skin-1191.txt

        item: #175 of 1356
          id: skin-1193
      author: Yassky, Noa; Wei, Nancy; Lebwohl, Mark
       title: Pulmonary Manifestations in Pseudoxanthoma Elasticum: A Review of Current Literature
        date: 2021-03-06
       words: 1744
      flesch: 39
     summary: A lung biopsy in a patient with severe dyspnea revealed calcified deposits within thickened alveolar lumina and septa, widespread irregularities in elastic laminae, METHODS RESULTS SKIN March 2021 Volume 5 Issue 2 Copyright 2021 The National Society for Cutaneous Medicine 92 Table 1 Characteristics of PXE patients with pulmonary manifestations Case report Year published Age (years) Patients Country Diagnostic findings Pulmonary Symptoms Miki et al4 2007 68 1 Japan Calcification of muscular arterial walls only Exertional dyspnea* Montani D et al5 2020 39 1 France Pulmonary stenosis Exertional dyspnea Yamamoto N et al6 1996 74 1 Japan Small, calcified nodules scattered in the alveolar septa only Exertional dyspnea Jackson A et al7 1980 51 1 Malaysia Calcification and elastic fiber irregularities in pulmonary arteries, arterioles, venules and alveolar lumina and septa. Discussion: Histologic and/or radiologic investigation of PXE patients who presented with progressive exertional dyspnea revealed calcification and irregularity of the elastic laminae in the pulmonary vasculature, the alveolar septa, or both.
    keywords: calcification; elasticum; manifestations; patients; pseudoxanthoma; pulmonary; pxe
       cache: skin-1193.pdf
  plain text: skin-1193.txt

        item: #176 of 1356
          id: skin-1194
      author: Wong, Alan; Altmann, Stefanie; Krishnamurthy, Karthik
       title: Cutaneous Endometriosis: A Case Report
        date: 2021-05-21
       words: 1686
      flesch: 44
     summary: BRIEF ARTICLE Cutaneous Endometriosis: A Case Report Alan Wong, BS1; Stefanie Altmann, DO2; Karthik Krishnamurthy, DO2 1Lake Erie College of Osteopathic Medicine, Bradenton, FL 2Orange Park Medical Center, Division of Dermatology, Orange Park, FL Cutaneous endometriosis (CEM) is defined as the presence of endometrial glands and/or stroma in the dermis or subcutis.1,2 CEM primarily affects women of reproductive age and represents 0.5-1% of all ectopic endometriosis.2,3 CEM can be classified as primary or secondary, with primary CEM accounting for less than 30% of all cases.1 The cause of primary CEM is unclear and occurs spontaneously. Although risk factors for developing primary CEM are not clearly defined, age and hormone levels likely play a role since a majority of affected individuals are premenopausal.1,2 Secondary CEM, also called scar endometriosis, is believed to occur due to seeding/iatrogenic implantation of endometrial tissue into the skin during abdominopelvic surgeries.1,2 Clinically, CEM presents as a firm papule or nodule averaging 2 cm in diameter.
    keywords: cells; cem; endometriosis; patients; skin
       cache: skin-1194.pdf
  plain text: skin-1194.txt

        item: #177 of 1356
          id: skin-1195
      author: Lindsley, Joshua; Webb, Nathaniel; Workman, Ashleigh; Miller, Thaddeus; Stockbridge, Erica ; Charles, Jean; Carletti, Michael; Casperson, Stephanie ; Weis, Stephen
       title: The Effect of Offering Pneumococcal Vaccines During Specialty Care on Vaccination Rates in Patients Receiving Immunosuppressive
        date: 2021-05-21
       words: 7016
      flesch: 45
     summary: The main measure of outcome was pneumococcal immunization status after QI intervention. SKIN May 2021 Volume 5 Issue 3 Copyright 2021 The National Society for Cutaneous Medicine 250 ORIGINAL RESEARCH The Effect of Offering Pneumococcal Vaccines During Specialty Care on Vaccination Rates in Patients Receiving Immunosuppressive Therapy Joshua Lindsley1, Nathaniel Webb, MPH2, Ashleigh Workman, DO3, Thaddeus Miller, DrPH, MPH2, Erica Stockbridge, PhD1, Jean Charles, DO3, Michael Carletti, DO1,3, Stephanie Casperson RN, BSN, 4, Stephen Weis, DO1,3,4 1Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 2Department of Health Behavior & Health Systems, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX 3Department of Dermatology, Medical City Weatherford, Weatherford, TX 4John Peter Smith Hospital, JPS Health Network, Fort Worth, TX ABSTRACT Purpose: To determine whether clinician-led immunization education with immediate onsite vaccination availability will increase pneumococcal immunizations during specialty care.
    keywords: care; comparison; disease; group; health; immunization; immunosuppressive; initial; medicine; observation; patients; pneumococcal; status; table; vaccination; vaccine
       cache: skin-1195.pdf
  plain text: skin-1195.txt

        item: #178 of 1356
          id: skin-1198
      author: Sakya, Surav; Hallan, David ; Gee, Sage ; Rizk, Monica ; Brooke, Justin; Kirby, Joslyn
       title: The Top 100 Most Cited Articles on Hidradenitis Suppurativa
        date: 2021-05-21
       words: 4103
      flesch: 59
     summary: 243 158 0 20 40 60 80 100 120 140 160 180 200 220 240 260 1 9 3 6 1 9 4 0 1 9 4 4 1 9 4 8 1 9 5 2 1 9 5 6 1 9 6 0 1 9 6 4 1 9 6 8 1 9 7 2 1 9 7 6 1 9 8 0 1 9 8 4 1 9 8 8 1 9 9 2 1 9 9 6 2 0 0 0 2 0 0 4 2 0 0 8 2 0 1 2 2 0 1 6 2 0 2 0 # o f A rt ic le s Year Total number of published original HS articles by 4-year-interval from 1939 to 2020 SKIN May 2021 Volume 5 Issue 3 Copyright 2021 The National Society for Cutaneous Medicine 271 Furthermore, Jemec mentioned in his 2012 HS article that the pathogenesis of HS remains unclear; HS is a disease characterized by sebaceous gland atrophy, lymphocytic infiltration, pilosebaceous unit hyperkeratosis and formation of granulomas with hair follicle destruction.16 Bibliometric features of top articles by country Country Total Citations Average Article Citations Corresponding Authors SCP MCP MCP Ratio Denmark 2808 165 17 15 2 0.118 USA 2268 119 19 16 3 0.158 United Kingdom 1417 142 10 8 2 0.2 France 1414 157 9 6 3 0.333 Netherlands 1173 117 10 8 2 0.2 Germany 890 127 7 7 0 0 Sweden 403 101 4 4 0 0
    keywords: 100; articles; authors; citations; dermatology; hidradenitis; journal; number; research; suppurativa
       cache: skin-1198.pdf
  plain text: skin-1198.txt

        item: #179 of 1356
          id: skin-1199
      author: Chambers, Morgan; Miller, Jeffrey; Brod, Bruce; Lim, Jordan
       title: Tele-dermatology Recruitment during COVID-19: An Application of Behavioral Economic Principles
        date: 2021-07-09
       words: 1780
      flesch: 46
     summary: The application of behavioral economics, being relatively new to healthcare, has been rarely reported in dermatology. Various published examples in dermatology include the use of framing effects and status quo when discussing actinic keratosis treatment5, tanning practices in adolescents6, and sun protection practices7.
    keywords: choice; dermatology; patients; script; tele; use
       cache: skin-1199.pdf
  plain text: skin-1199.txt

        item: #180 of 1356
          id: skin-12
      author: Fosko, Scott W; Chu, Melinda B; Beal, Brandon T; Dhandha, Maulik; Armbrecht, Eric S
       title: Development of a metastatic risk model for cutaneous squamous cell carcinoma
        date: 2017-06-28
       words: 3378
      flesch: 54
     summary: The sum score for each case is calculated by adding up the total number of risk factors present. That the PC model had the highest values for SN, SP, and PPV when examined in aggregate suggests both the combination and the additive effect of risk factors contribute to cSCC metastasis.
    keywords: cancer; cscc; factors; location; metastasis; model; ppv; risk; size
       cache: skin-12.pdf
  plain text: skin-12.txt

        item: #181 of 1356
          id: skin-120
      author: Glaser, Dee Anna; Hebert, Adelaide A; Fehnel, Sheri; DiBenedetti, Dana; Nelson, Lauren; Drew, Janice; Pariser, David M
       title: Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Vaildated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity
        date: 2017-10-27
       words: 1833
      flesch: 52
     summary: Construct validity was supported by strong correlations between ASDD Item 2 and the ASDD items addressing the impact and bother of axillary sweating (Items 3 and 4, respectively) (Table 3) • Test-retest reliability was supported by ICCs of 0.93 for both age subgroups (Table 3), which is well above the 0.70 criterion, and within the confidence interval of the phase 2 estimate of 0.91 (95% CI: 0.87, 0.94)4 • The ASDD/ASDD-C Item 2 responsiveness, or ability to detect change in sweating severity, was demonstrated by large effect sizes and correlations that were within the expected range for the change in ASDD/ASDD-C Item 2 and the change in the gravimetric measures of sweat production (Table 3) [-4.0] Construct Validity, Pearson r ASDD Item 3 (impact) Week 4 —b 0.89 ASDD Item 4 (bother) —b 0.91 Sweat Productionc 0.26d 0.25d Test-retest reliability, ICC Week 4-Week 3 0.93 0.93 Responsiveness Sweat production,c r Week 4-Baseline 0.23d,e 0.22d,e Effect size of change (SD baseline units) -2.4 -2.4 Standardized response mean -1.4 -1.5 ᵃSubjects with Baseline and Week 4 scores bASDD-C (for use in patients <16 years of age) does not include items corresponding to ASDD Items 3 and 4 cMeasured gravimetrically ᵈSpearman correlation coefficient ᵉBased on the change from Baseline to Week 4 in ASDD Item 2 scores and the natural logarithm of sweat production ASDD,
    keywords: asdd; item; sweating; underarm
       cache: skin-120.pdf
  plain text: skin-120.txt

        item: #182 of 1356
          id: skin-1200
      author: Otto-meyer, Sebastian; Nahi, Skylar; Amin, Ahmad
       title: Blastomycosis Infection in the Setting of Immunosuppression with Concurrent Methotrexate and Adalimumab for Treatment of Psoriasis
        date: 2021-07-09
       words: 1547
      flesch: 40
     summary: A meta- analysis of RCTs in patients with rheumatoid arthritis found that the use of biological DMARDs did not significantly increase the risk of invasive and superficial fungal infections (OR 1.31; 95% CI 0.46–3.72) or invasive fungal infections (OR 2.85; 95% CI 0.68–11.91).3 As such, a DMARD such as methotrexate (MTX) is less likely to be the sole etiology of the susceptibility to blastomycosis infection. Although sixteen cases of blastomycosis associated with TNF- -α inhibitor use have been reported to the FDA adverse event reporting system, no systemic cases have been described with a detailed clinical course in the literature2.
    keywords: adalimumab; blastomycosis; case; inhibitor; psoriasis
       cache: skin-1200.pdf
  plain text: skin-1200.txt

        item: #183 of 1356
          id: skin-1201
      author: Wei, Angela; Hill, Sheena ; Vidmar, Dennis
       title: A Case of Hydroxyurea-Associated Cutaneous Only Polyarteritis Nodosa
        date: 2021-07-09
       words: 1611
      flesch: 43
     summary: Long-term use has been associated with several adverse cutaneous reactions, including skin ulcers, xerosis, and hyperpigmentation. While generally well-tolerated, there have been reports of adverse cutaneous reactions after prolonged use in roughly 5% of patients.4 These include skin eruptions, skin ulcers, xerosis, diffuse hyperpigmentation, alopecia, nail dystrophy, dermatomyositis-like syndrome, and an increased risk of squamous and basal cell carcinoma.4
    keywords: case; doi; hydroxyurea; nodosa; polyarteritis; skin; vasculitis
       cache: skin-1201.pdf
  plain text: skin-1201.txt

        item: #184 of 1356
          id: skin-1203
      author: Marson, Justin; Litchman, Graham; Svoboda, Ryan; Glazer, Alex; Farberg, Aaron; Winkelmann, Richard; Rigel, Darrell
       title: Assessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferences
        date: 2021-03-06
       words: 2927
      flesch: 55
     summary: Surgical excision completed before metastasis of the cancer 66.6 (62.7 – 70.4) Host immune system 71.5 (67.8 – 75.1) Early intervention 71.3 (67.7 – 75.0) Incorrect GEP result 31.2 (27.5 – 35.0) Other (please specify)† 1.9† (0.8 – 3.0) Additional benefits included using test results to determine referrals/follow-up frequency (36.3%) and informing discussion regarding potential sentinel lymph node biopsy (SLNBx) (36.0%).
    keywords: class; gep; participants; patients; risk; skin; test
       cache: skin-1203.pdf
  plain text: skin-1203.txt

        item: #185 of 1356
          id: skin-1204
      author: Heibel, Haley Danielle; Cockerell, Clay J.; Guillen, Christina; Bamgbola, Oluwatoyin ; Schmidt, John; Sharma, Poonam; White, Robert ; Youens, Susan; Heibel, Mark
       title: Finding a Sense of Gratitude and Purpose in Medicine Through Positive Role Models and a Diversity of Passions, Experiences, and Practices 
        date: 2021-05-21
       words: 6296
      flesch: 53
     summary: Dr. Oluwatoyin Bamgbola’s response on being a clinician as a teacher of life experiences: Early life experience has a strong influence not only in my decision to become a physician, but it is also a major determinant of my professional behavior. The major impediment is time, many physicians will say.
    keywords: care; community; gratitude; life; medicine; patients; physician; purpose; sense; skin
       cache: skin-1204.pdf
  plain text: skin-1204.txt

        item: #186 of 1356
          id: skin-1205
      author: Bowers, Nate; Huang, William
       title: Treatment of Refractory Pruritus with Dupilumab in a Patient with Dermatomyositis 
        date: 2021-05-21
       words: 844
      flesch: 50
     summary: In addition to inhibiting signaling of IL-4, a key driver of Th2 mediated inflammation, dupilumab also demonstrates the ability to reduce expression of IL-31.3 A recent study highlighted the role of IL-31 in DM, demonstrating increase gene expression of IL-31 and IL-31RA in lesional skin compared to non-lesional skin and healthy controls.4 Collectively, this suggest a possible mechanism of action of dupilimab through its direct effect on Th2 mediated inflammation in DM as well as an indirect effect on the expression of IL-31, a proposed driver of pruritus in DM. (B) After six weeks of treatment with dupilumab background erythema is minimal to absent with only post- inflammatory hyperpigmentation.
    keywords: dupilumab; skin
       cache: skin-1205.pdf
  plain text: skin-1205.txt

        item: #187 of 1356
          id: skin-1207
      author: Fernandez, Jennifer; Lenczowski, Joi; Hsiao, Jennifer; Shi, Vivian
       title: Nutrition Education Toolbox for Hidradenitis Suppurativa 
        date: 2021-05-21
       words: 4063
      flesch: 52
     summary: A larger follow up study evaluated 37 HS patients who followed a yeast-free diet for six years after excision of HS lesions, with 70% reporting improvement in HS symptoms without other accompanying treatment, and 87% reporting recurrence of HS symptoms within a few days after consuming a restricted food.4 symptoms.1–4 Recent survey studies indicate that up to 90% of HS patients have attempted to manage HS through dietary changes, with up to 65% of patients reporting that dietary changes were beneficial.1,5 Price et al. identified dietary modification to be the most commonly self-employed complementary alternative medicine (CAM) intervention implemented by HS patients.5
    keywords: copyright; dairy; dermatology; diet; food; hidradenitis; intake; issue; medicine; nutrition; patients; skin; suppurativa
       cache: skin-1207.pdf
  plain text: skin-1207.txt

        item: #188 of 1356
          id: skin-121
      author: Siegel, Daniel; Tanghetti, Emil; Brody, Neil; Freeman, Michael; Skov, Torsten; Petersen, Astrid; Clonier, Fabrice; Spelman, Lynda
       title: Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial
        date: 2017-11-13
       words: 5222
      flesch: 61
     summary: Methods: This randomized, double-blind, vehicle-controlled trial (NCT01998984) evaluated ingenol mebutate (IngMeb) 0.06% gel for AK treatment over extended areas. Statistical Analysis Sample size was determined based on the number of patients required to obtain 80% power when detecting a difference in AKCLEAR 100 rates between IngMeb and vehicle treatment groups, assuming a true estimate of 28% in the IngMeb groups and 7% in the vehicle group (significance level 0.05).
    keywords: actinic; baseline; count; days; group; ingmeb; patients; skin; treatment; vehicle
       cache: skin-121.pdf
  plain text: skin-121.txt

        item: #189 of 1356
          id: skin-1210
      author: Patel, Deep; Mardini, Jennifer; Chu, Christopher; Disse, Max; Flamm, Alexandra
       title: Heroin-induced Ulcer Mimicking Pyoderma Gangrenosum
        date: 2021-07-09
       words: 1404
      flesch: 48
     summary: The dermatopathology of heroin ulcers have been found to show nonspecific findings such as leukocytoclastic vasculitis, dermal pigment deposition, non-specific ulceration/scarring and necrobiosis lipoidica- like dermatitis10. We present a patient with lower extremity ulceration due to subcutaneous injection of heroin which resembled PG.
    keywords: gangrenosum; heroin; patient; skin; wound
       cache: skin-1210.pdf
  plain text: skin-1210.txt

        item: #190 of 1356
          id: skin-1213
      author: Lee, Jack; Carr, Patrick; Zlotoff, Barrett; Guffey, Darren
       title: True Serum Sickness, Pearls for Clinical Diagnosis
        date: 2021-05-21
       words: 2325
      flesch: 51
     summary: In studies detailing localization of arthralgias, 5 of 5 ATG-induced cases and 3 of 8 infliximab- induced cases reported jaw pain.4-6 In studies describing rashes in detail (all ATG), palmoplantar bands were present in 29 of 39 (74%) patients.7,8 SS remains a clinical diagnosis and biopsies are generally not indicated, however transplant patients are exposed to multiple new medications and susceptible to many infections. Further labs revealed low CH50, C3, and C4 (Table ABSTRACT Background: True serum sickness is a type 3 hypersensitivity reaction against foreign antibodies, resulting in vasculitis and an acute clinical presentation.
    keywords: atg; complement; doi; pmid; serum; sickness; skin
       cache: skin-1213.pdf
  plain text: skin-1213.txt

        item: #191 of 1356
          id: skin-1214
      author: Chadha, Simran Arinder; Shastry, Jennifer; McComb, Erin; Clarke, Christina
       title: A Case of Cutaneous Sarcoidosis with Direct Osseous Involvement
        date: 2021-07-09
       words: 1516
      flesch: 45
     summary: Sarcoidosis of the large bones can be lytic or sclerotic and may present as focal lesions or diffuse marrow infiltration.7, 9, 10 Among cutaneous manifestations, lupus pernio may be more associated with bone cysts, though uncommonly through direct extension.1 The diagnosis of cutaneous sarcoidosis requires skin biopsy and histopathological confirmation illustrating non-caseating granulomas composed of epithelioid histiocytes. However, in the absence of symptoms, there are no clear treatment guidelines for bone involvement.8 Finally, DISCUSSION CONCLUSION SKIN July 2021 Volume 5 Issue 4 Copyright 2021 The National Society for Cutaneous Medicine 421 while certain cutaneous morphologies of sarcoidosis portend a worse prognosis – for example, lupus pernio – osseous disease has a more benign natural history.2, 12 Previous studies have linked osseous sarcoidosis to favorable outcomes and the vast majority of cases remain stable or improved with treatment.12 Thus, this case demonstrates an unusual presentation of cutaneous sarcoidosis in which imaging suggested direct osseous involvement, with excellent response to intralesional steroid injection.
    keywords: bone; doi; involvement; medicine; sarcoidosis; skin
       cache: skin-1214.pdf
  plain text: skin-1214.txt

        item: #192 of 1356
          id: skin-1215
      author: Marson, Justin; Del Rosso, James; Bhatia, Neal; Rigel, Darrell
       title: Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy
        date: 2021-03-06
       words: 3664
      flesch: 51
     summary: Objective: To review the current literature reporting known known factors of AK treatment non- adherence intrinsic to patient behavior and treatment regimens and re-examine how dermatologists can navigate these challenges. At 12-month follow up, not only were there no notable adverse effects, but 42% of participants had no recurrence of originally treated AKs.34,35 Perhaps more importantly from an adherence standpoint, studies have shown that LSRs were mild- moderate, peaked within 8 days of first application and resolved entirely within 15- 29 days.33-35 Taken together these data suggest inhibition of tubulin polymerization provides an efficacious way to treat AKs that also mitigates unpleasant adverse effects of contemporary AK treatments and its shorter course may also further improve adherence to therapy.
    keywords: actinic; adherence; aks; dermatol; dermatology; doi; keratosis; patient; pmid; skin; therapies; therapy; treatment
       cache: skin-1215.pdf
  plain text: skin-1215.txt

        item: #193 of 1356
          id: skin-1216
      author: Kwong, Pearl ; Hebert, Adelaide; Utley, Collette; Olivadoti, Melissa
       title: The Hidden Impact of Molluscum Contagiosum: A Survey of Caregivers’ Experiences with Diagnosis, Treatment, and Impact on Quality of Life
        date: 2021-07-09
       words: 3711
      flesch: 54
     summary: There are few studies reporting quality of life (QoL) concerns with molluscum and most are small or use generalized methods that may not highlight the unique concerns for molluscum patients and caregivers. This online survey aimed to collect caregivers’ views on their experiences with molluscum infection in their children, including diagnosis, treatment, and the impact of the virus on the caregivers’ and their child’s life.
    keywords: caregivers; child; children; home; impact; molluscum; survey; treatment
       cache: skin-1216.pdf
  plain text: skin-1216.txt

        item: #194 of 1356
          id: skin-1219
      author: Lebwohl, Mark; Langley, Richard; Paul, Carle; Puig, Lluis; Reich, Kristian; van der Kerkhof, Peter; Tang, Lihua; Richter, Sven; Guerette, Benolt; Gisondi, Paolo
       title: Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
        date: 2021-01-01
       words: 1388
      flesch: 49
     summary: Additionally, many patients were not receiving any medication, suggesting that there remains significant unmet need Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey • More than half of patients with limited skin involvement reported their current disease as moderate or severe, had PsO involvement in special areas, and were receiving topicals or no treatment, suggesting a persistent unmet need in this patient population • In MAPP vs. UPLIFT, the proportion of patients describing their disease as moderate to severe on systematic treatment remained relatively low despite the higher number of available treatment options • Further research is needed to better understand why a significant proportion of patients with limited skin involvement and PsO in special areas perceive their current disease as moderate or severe but do not receive systemic treatment ML: Mount Sinai – employment; AbbVie, Amgen Inc., Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB – research funds; Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica – consultant.
    keywords: inc; mapp; patients; pso; uplift
       cache: skin-1219.pdf
  plain text: skin-1219.txt

        item: #195 of 1356
          id: skin-122
      author: Pariser, David M; Hebert, Adelaide A; Drew, Janice; Quiring, John; Glaser, Dee Anna
       title: Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness
        date: 2017-10-27
       words: 2583
      flesch: 47
     summary: Axillary Sweating Daily Diary; ASDD-C, ASDD-Children • At Baseline in ATMOS-1 and ATMOS-2, mean ± SD ASDD Item 3 (impact of axillary sweating) scores were 2.3 ± 0.9 and 2.4 ± 0.9, respectively – In each trial, approximately 70% of patients ≥16 years of age reported scores ≥2 on ASDD Item 3, indicating that their daily activities were at least moderately affected by axillary hyperhidrosis at Baseline (Figure 3) – 26.2% and 29.7% of patients were severely impacted by axillary sweating in ATMOS-1 and ATMOS-2, respectively, having reported scores of 3 or 4 at Baseline (Figure 3) Figure 3. Axillary Sweating Daily Diary • At Baseline in ATMOS-1 and ATMOS-2, the mean ± SD ASDD Item 4 (bother of axillary sweating) scores were 2.6 ± 0.9 and 2.6 ± 0.9, respectively – In each trial, >75% of patients ≥16 years of age reported scores ≥2 on ASDD Item 4, indicating that they were at least moderately bothered by axillary sweating at Baseline (Figure 4) – 37.5% and 40.1% of patients were severely bothered by axillary sweating in ATMOS-1 and ATMOS-2, respectively, having reported scores of 3 or 4 at Baseline (Figure 4) Figure 4.
    keywords: asdd; baseline; item; patients; sweating; underarm
       cache: skin-122.pdf
  plain text: skin-122.txt

        item: #196 of 1356
          id: skin-1221
      author: Liu, Jesse; Veenstra, Jesse
       title: COVID-19 Associated Onychomadesis
        date: 2021-05-21
       words: 719
      flesch: 57
     summary: During the initial visit, nail plate was examined histologically and demonstrated parakeratosis with bacterial colonization. At patient’s return visit three months later, the patient experienced interval loss of nail plates on all fingernails.
    keywords: covid-19; nail; onychomadesis
       cache: skin-1221.pdf
  plain text: skin-1221.txt

        item: #197 of 1356
          id: skin-1227
      author: Nam, Hannah; Lim, Jordan; Flamm, Alexandra
       title: Angiosarcoma Clinically Mimicking a Targetoid Hemosiderotic Hemangioma
        date: 2021-07-09
       words: 1397
      flesch: 50
     summary: This case report emphasizes the value of early clinical suspicion for atypical, rapidly changing vascular lesions. The National Society for Cutaneous Medicine 423 Figure 1. 2cm targetoid vascular lesion on right flank unremarkable.
    keywords: angiosarcoma; cutaneous; lesion; vascular
       cache: skin-1227.pdf
  plain text: skin-1227.txt

        item: #198 of 1356
          id: skin-1228
      author: Urso, Brittany; Lacquer, Vivian; Hillman, Joseph; Zachary, Christopher; Smith, Janellen
       title: Multifaceted Facial Tumor Posing a Therapeutic Challenge: A Multifaceted Nevus Sebaceous
        date: 2021-05-21
       words: 788
      flesch: 55
     summary: Fortunately, dermatologic surgeons routinely remove large tumors under local anesthesia and large defects can be repaired using many techniques including a combined closure as in this case. Joseph Mission Hospital, Mission Viejo, CA Nevus sebaceous (NS) are benign congenital hamartomas which primarily affect the head and neck.
    keywords: carcinoma; nevus
       cache: skin-1228.pdf
  plain text: skin-1228.txt

        item: #199 of 1356
          id: skin-1229
      author: Afrin, Antara; Kim, Lori; Ashack , Kurt ; Klis, Thomas; Bain, Michelle
       title: Medium-Sized Congenital Melanocytic Nevus with Halo Phenomenon: A Report of Two Cases
        date: 2021-07-09
       words: 1590
      flesch: 54
     summary: July 2021 Volume 5 Issue 4 Copyright 2021 The National Society for Cutaneous Medicine 428 literature has demonstrated some connection between the mainly CD8+T-cell mediated pathogenesis of halo nevi transformation with that of vitiligo’s anti-melanocyte response.5 A similar reactive oxidative species pathogenesis of both halo nevi phenomenon and vitiligo has been implicated by Yang et al through measurements of H2O2 levels in tissues.5 The similarities in pathogenesis may explain why halo nevi are up to 10 times more common in patients with vitiligo than the general population.6 This relationship between halo nevi and vitiligo is demonstrated by the patient presented in case two. Although this phenomenon is rare and likely to be benign, there are reports of melanoma development either within the halo nevus or at a distant site.1 One systematic review of adult-onset halo nevi showed that there is a 1% risk of melanoma development in the first year following halo nevi diagnosis;2 however, there is very limited research following congenital halo nevi.
    keywords: cmn; halo; medium; nevi; vitiligo
       cache: skin-1229.pdf
  plain text: skin-1229.txt

        item: #200 of 1356
          id: skin-123
      author: Pariser, David M; Hebert, Adelaide A; Drew, Janice; Quiring, John; Glaser, Dee Anna
       title: Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)
        date: 2017-10-27
       words: 3440
      flesch: 49
     summary: Axillary Sweating Daily Diary; GT, topical glycopyrronium tosylate • Improvement in scores related to the bother of axillary sweating (ASDD Item 4) was greater in GT‑treated patients than vehicle‑treated patients at every study week (Figure 4) – After 4 weeks of treatment in ATMOS‑1, Item 4 scores improved by 64% (‑1.7 point change) in GT‑treated patients and by 39% (‑0.9) in vehicle‑treated patients compared with Baseline – After 4 weeks of treatment in ATMOS‑2, Item 4 scores improved by 72% (‑1.9 point change) in GT‑treated patients and by 41% (‑1.0) in vehicle‑treated patients compared with Baseline Figure 4. The ASDD Item 2 responder rate (coprimary outcome; ≥4‑point improvement) was significantly greater for GT‑treated patients than for vehicle‑treated patients in ATMOS‑1 (53% vs 28%) and ATMOS‑2 (66% vs 27%) (p<0.001 both studies) • Improvement in axillary sweating severity (ASDD/ASDD‑C Item 2) was greater for GT‑ treated patients compared with vehicle‑treated patients at every study week (Figure 2) – After 4 weeks of treatment in ATMOS‑1, scores improved 58% (‑4.3 point change) in GT‑treated patients and 35% (‑2.5) in vehicle‑treated patients compared with Baseline – After 4 weeks of treatment in ATMOS‑2, scores improved 67% (‑4.9 point change) in GT‑treated patients and 36% (‑2.6) in vehicle‑treated patients compared with Baseline Figure 2.
    keywords: item; patients; sweating
       cache: skin-123.pdf
  plain text: skin-123.txt

        item: #201 of 1356
          id: skin-1237
      author: Ghani, Hira; Cubelli, Stefanie; Rahman, Raphia; Chervonsky, Alexandra
       title: Molecular Pathogenesis and Complications Associated with Keratosis Follicularis: A Clinical Review 
        date: 2021-07-09
       words: 3205
      flesch: 55
     summary: Moreover, in the recent cross-sectional clinical study of metabolic phenotype of DD, it has been found that DD patients have lower fasting glucose level and higher c-peptide and 33 This indicates that DD patients have a higher secretory capacity of islet cells and a higher basal insulin level.
    keywords: atp2a2; calcium; cell; darier; diabetes; disease; individuals; keratosis; patients; skin
       cache: skin-1237.pdf
  plain text: skin-1237.txt

        item: #202 of 1356
          id: skin-1239
      author: Marson, Justin; Lebwohl, Mark
       title: Apremilast as an Off-Label Therapeutic Agent: A Comprehensive Review of Safety and Efficacy Data in the Literature for Combination Therapy and Inflammatory Dermatoses
        date: 2021-05-21
       words: 11048
      flesch: 54
     summary: Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. al76 Granuloma Annulare 4 ~60 F ~43.3 (5.8); 0 30 mg BID 30 mg BID 12 6-8 Significant response within 6 weeks, almost clear by 12 weeks Significant response within 6-8 weeks Mild diarrhea, myalgia Myalgia, nausea Kieffer et al77 Hailey-Hailey disease 4 52.5 (5);25 30 mg BID 26 (4) 3/4 achieve PGA 1 after 6 months, 1/4 achieve PGA 1-2 after 5 months Diarrhea (2), Myalgia (1) requiring dose reduction to 30 mg daily Weber et
    keywords: apremilast; bid; case; combination; copyright; dermatitis; dermatology; diarrhea; improvement; issue; journal; label; medicine; mg bid; patients; psoriasis; skin; study; therapy; treatment; trial; volume; weeks
       cache: skin-1239.pdf
  plain text: skin-1239.txt

        item: #203 of 1356
          id: skin-124
      author: Piguet, Vincent; Blauvelt, Andrew; Burge, Daniel; Peterson, Luke; Drew, Janice; Rolleri, Robert; Weglowska, Jolanta
       title: Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)
        date: 2017-10-27
       words: 3367
      flesch: 54
     summary: At Week 16, CZP‑ and ETN‑treated PASI 75 responders were re‑randomized and continued for 32 weeks of maintenance treatment: – From CZP 400 mg Q2W to 400 mg Q2W, 200 mg Q2W, or placebo Q2W – From CZP 200 mg Q2W to 400 mg every 4 weeks (Q4W), 200 mg Q2W, or placebo Q2W – From ETN to CZP 200 mg Q2W (after loading dose) or placebo Q2W • At Week 16, placebo‑treated PASI 75 responders continued placebo Q2W for 32 weeks of maintenance treatment • Mean CfB -1.1 -8.1** -11.0**18 16 14 12 8 6 4 10 2 0 M ea n S co re **p<0.0001 vs placebo based on adjusted least squares mean difference from an ANCOVA model with treatment group, region, and prior biologic exposure (yes/no) as factors and Baseline DLQI score as a covariate using LOCF imputation aCZP 200 mg Q2W patients received a loading dose of CZP 400 mg at Weeks 0, 2, and 4 b1 patient did not have DLQI mean score values ANCOVA, analysis of covariance; CfB, change from Baseline; CZP, certolizumab pegol; DLQI, Dermatology Life Quality Index; LOCF, last observation carried forward; Q2W, every 2 weeks Figure 4.
    keywords: czp; dlqi; mg q2w; placebo; q2w; week
       cache: skin-124.pdf
  plain text: skin-124.txt

        item: #204 of 1356
          id: skin-1240
      author: Akhtar, Shifa; Perez, Mariana; Sharma, Jessica; Canazza, Agnese; Zaiac, Martin 
       title: Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis: A Case Series
        date: 2021-09-13
       words: 1785
      flesch: 49
     summary: Eight percent clobetasol-17- propionate in a colorless nail lacquer vehicle has produced favorable results, with one study of 15 patients demonstrating a reduction in nail alterations and in the modified Psoriasis Severity Index by 78% compared to baseline.6 There are also case reports of refractory nail psoriasis treated successfully with Cal/BD gel, with authors hypothesizing that the low viscosity of the lipophilic gel may reach the subungual gap and the gap beneath the proximal nail folds in affected nails.7 While topical therapies combining a corticosteroid and vitamin D analog are established treatments for nail psoriasis, there is scarce literature regarding the use of Cal/BD aerosol foam. A Case Series Shifa Akhtar1, BS, Mariana Perez1, BA, Jessica Sharma1, BS, Agnese Canazza2, Martin Zaiac1,2, MD 1 Florida International University, Herbert Wertheim College of Medicine, Miami, FL 2 Greater Miami Skin and Laser Center, Mount Sinai Medical Center, Miami Beach, FL An estimated 80-90% of psoriasis patients develop nail involvement, leading to decreased quality of life secondary to pain, activity restriction, and an increased risk of anxiety and depression.1 Historically, topical treatments for nail psoriasis have been considered less effective due to limited penetration through the psoriatic nail plate and prolonged duration of use leading to poor patient adherence.2 While systemic approaches with newer biologic agents have demonstrated efficacy in the treatment of moderate to severe nail psoriasis, patients with disease limited to the nail may be reluctant to use systemic biologic agents as opposed to topical agents.
    keywords: cal; foam; nail; psoriasis; treatment
       cache: skin-1240.pdf
  plain text: skin-1240.txt

        item: #205 of 1356
          id: skin-1242
      author: Snow, Tara; Harper, Chelsea D. ; Crane, Jonathan; Arida, Muammar
       title: Bilateral Nodules on the Thighs: A Case Report on Insulin Therapy-Induced Palisaded Granulomas
        date: 2021-09-13
       words: 1126
      flesch: 39
     summary: Herein, we present an unusual case of bilateral nodules on the thighs secondary to insulin injections. A 90-year-old female presented with a 14- year history of slowly enlarging pruritic nodules located on her proximal lateral thighs where insulin injections were repeatedly administered.
    keywords: complications; diabetes; injection; insulin
       cache: skin-1242.pdf
  plain text: skin-1242.txt

        item: #206 of 1356
          id: skin-1243
      author: Clark, Kayla ; Miori, Virginia ; Alvarado Jones, Virgina; Tsoukas, Maria
       title: Dermatology Residency Applicants’ Concerns Due to COVID-19
        date: 2021-07-09
       words: 1952
      flesch: 54
     summary: Concerns Due to COVID-19 Kayla A. Clark, BS1, Virginia M. Miori, PhD2, Virginia A. Jones, MD, MS1, Maria M. Tsoukas, MD, PhD1 1Department of Dermatology, University of Illinois at Chicago, Chicago, IL 2Department of Decision and System Sciences, Saint Joseph’s University, Philadelphia, PA Educational policy changes related to the Coronavirus disease 2019 (COVID-19) pandemic during the 2020-2021 residency application cycle caused challenges for dermatology residency applicants.1 As advised by the Association of American Medical Colleges (AAMC), programs conducted interviews entirely virtually.2 Due to these unique circumstances, our group created a survey to gain insight into dermatology residency applicants’ concerns attributable to the COVID-19 Despite these concerns, preliminary data released by the AAMC reveals an 8% (661 students vs. 611) increase for MD students applying to dermatology residency this cycle.3 Preliminary match results indicate a 73.9% (382/517) match rate for PGY-2 position for MD seniors in the 2020-2021 cycle compared to the 78.1% (368/471) match rate in the 2019-2020 cycle; an overall 4.2% decrease in the match rate.4,5 Consistent with MD applicant concerns, this cycle’s virtual match yielded a lower match rate.
    keywords: concerns; dermatology; home; students; uim
       cache: skin-1243.pdf
  plain text: skin-1243.txt

        item: #207 of 1356
          id: skin-1244
      author: Bowers, Nate; Haidari, Wasim; Su, Jennifer; Cardenas-de la Garza, Jesus; Feldman, Steve ; Jorizzo, Joseph
       title:  Characterization of Clinical Outcomes in Patients with Cutis Marmorata Telangiectatica Congenita
        date: 2021-07-09
       words: 1500
      flesch: 54
     summary: Cutis marmorata telangiectatica congenita: clinical features in 35 cases. Due to different reporting methodologies and inclusion of abnormalities which are prevalent in the general population, the higher rate may be secondary to incidental or SKIN July 2021 Volume 5 Issue 4 Copyright 2021 The National Society for Cutaneous Medicine 401 questionable findings.(1-3) Recent reports have characterized limb length discrepancy and other congenital vascular abnormalities as the most frequent associations.(3-5)
    keywords: cmtc; cutis; patients; skin
       cache: skin-1244.pdf
  plain text: skin-1244.txt

        item: #208 of 1356
          id: skin-1245
      author: Rodriguez, Eduardo Adrian; Visnaw, Edward; Petr, Frank; Siddiqui, Huma
       title: Atypical Targetoid Lesions as the Presenting Sign of Myeloid Sarcoma
        date: 2021-11-05
       words: 1750
      flesch: 48
     summary: No controlled trials evaluating the role of allogenic hematopoietic stem cell transplantation in patients with isolated MS have been performed but retrospective studies have demonstrated encouraging results.6 MS prognosis can be variable depending on the different backgrounds of MS formation but it is typically accepted to be poor. Clinical knowledge about a typical presentation of myeloid sarcoma is limited, given the heterogeneity in the location and size of MS lesions.
    keywords: aml; cutaneous; lesions; myeloid; patients; sarcoma
       cache: skin-1245.pdf
  plain text: skin-1245.txt

        item: #209 of 1356
          id: skin-125
      author: Reich, Kristian; Blauvelt, Andrew; Thaci, Diamant; Leonardi, Craig; Poulin, Yves; Burge, Daniel; Peterson, Luke; Arendt, Catherine; Gottlieb, Alice B
       title: Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)
        date: 2017-10-27
       words: 3654
      flesch: 58
     summary: CZP, certolizumab pegol; MCMC, Markov chain Monte Carlo; PASI 75, ≥75% reduction in psoriasis area and severity index; Q2W, every 2 weeks Figure 4. PGA 0/1 Responder Rates From Baseline to Week 48 CIMPASI-1 Week Week CIMPASI-2 80 100 60 40 20 0 R es po nd er R at e (% ) 0 2 4 8 12 16 20 24 28 32 40 48 80 100 60 40 20 0 R es po nd er R at e (% ) 0 2 4 8 12 16 20 24 28 32 40 48 Placebo (N=51) CZP 200 mg Q2Wa (N=95) CZP 400 mg Q2W (N=88) 4.2% 2.0% Placebo (N=49) CZP 200 mg Q2Wa (N=91) CZP 400 mg Q2W (N=87) 47.0% 52.7% 66.8% 72.6% 57.9% 69.5% 71.6% 66.6% *p<0.05, **p<0.0001 versus placebo aCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and Most Frequently Reported TEAEs (≥5% in Any Group): Baseline to Week 48 n (%), [incidence ratea] CIMPASI-1 CIMPASI-2 CZP 200 mg Q2W (N=100)b CZP 400 mg Q2W (N=144)b CZP 200 mg Q2W (N=95)b CZP 400 mg Q2W (N=129)b Nasopharyngitis 28 (28.0)
    keywords: czp; mg q2w; pasi; patients; placebo; q2w; week
       cache: skin-125.pdf
  plain text: skin-125.txt

        item: #210 of 1356
          id: skin-1251
      author: Abbas, Laila; Wang, Jennifer; Nijhawan, Rajiv; Srivastava, Divya
       title: The Impact of the COVID-19 Pandemic on Skin Cancers treated with Mohs Micrographic Surgery: A Retrospective Analysis at a Single United States Academic Institution
        date: 2021-07-09
       words: 1347
      flesch: 59
     summary: The aim of this single center retrospective study was to determine changes in skin cancers treated with MMS at a large, U.S. medical center in the context of evolving COVID-19 pandemic restrictions over the course of several months. MMS case logs identified patients treated with MMS for skin cancer from March– September 2020 and March–September 2019.
    keywords: cancer; covid-19; pandemic; patients; skin
       cache: skin-1251.pdf
  plain text: skin-1251.txt

        item: #211 of 1356
          id: skin-126
      author: Thaci, Diamant; Gottlieb, Alice; Reich, Kristian; Bagel, Jerry; Burge, Daniel; Peterson, Luke; Drew, Janice; Arendt, Catherine; Weglowska, Jolanta
       title: Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)
        date: 2017-10-27
       words: 3587
      flesch: 54
     summary: In both studies, at least 90% of patients in each treatment arm completed Week 16 (Figure 2) • Of those patients who entered the Maintenance Period in CIMPASI-1|CIMPASI-2, 90.9%|88.4% of CZP 400 Q2W patients and 95.9%|84.2% of CZP 200 mg Q2W patients completed Week 48 (Figure 2) • Baseline DLQI scores were comparable across treatment groups for both studies while WPAI score trends varied slightly by study (Table 1) Figure 2. CZP 200 mg Q2Wb (N=95) CZP 400 mg Q2W (N=88) 41.2% 66.3% 78.4% 68.2% 60.0% Placebo (N=49) CZP 200 mg Q2Wb (N=91) CZP 400 mg Q2W (N=87) 40.8% 74.7% 75.9% 70.1% 61.5% a≥4-point improvement in DLQI bCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and 4 Statistical comparisons not performed at Week 48 Week 16 PASI 50 nonresponders were imputed as nonresponders for all subsequent time points through Week 48; all other missing data were imputed via nonresponder imputation CZP, certolizumab pegol; DLQI, Dermatology Life Quality Index; Q2W, every 2 weeks • DLQI 0/1 responder rates were also greater at Week 16 for CZP 400 mg Q2W and 200 mg Q2W vs placebo (Figure 5) •
    keywords: czp; dlqi; mg q2w; pasi; placebo; q2w; week
       cache: skin-126.pdf
  plain text: skin-126.txt

        item: #212 of 1356
          id: skin-1262
      author: Wu, Ellen; Chadha, Simran; Krueger, Karen; Nguyen, Cuong; Guggina, Lauren
       title: Disseminated HSV-2 Infection in a Person Living with HIV (PLWH)
        date: 2021-09-13
       words: 779
      flesch: 39
     summary: We suspect immune reconstitution inflammatory syndrome (IRIS) was responsible for her exuberant HSV-2 presentation in the setting of appropriate treatment and a rapid decline in HIV VL. Viral culture confirmed HSV-2 infection, but susceptibilities could not be obtained.
    keywords: hiv; medicine; school
       cache: skin-1262.pdf
  plain text: skin-1262.txt

        item: #213 of 1356
          id: skin-1263
      author: Visconti, Michael; Buckland, Molly; Krach, Kent; Richardson, Adam; Rutt, Veronica
       title: Surgeon Experience Level and Number of Mohs Stages: A Prospective Observational Study of In-training Surgeons
        date: 2021-09-13
       words: 2955
      flesch: 42
     summary: If accurate, this would demonstrate a higher efficiency for more experienced surgeons in extirpating tumors compared to less experienced surgeons – arguing against previous findings of no significant difference in mean number of stages for different experience levels. Mean number of stages overall for all variants of BCC and SCC. above).
    keywords: attending; cohort; experience; level; mean; number; stages
       cache: skin-1263.pdf
  plain text: skin-1263.txt

        item: #214 of 1356
          id: skin-1264
      author: Whittington, Andrew ; Pearlman, Ross; Brodell, Robert 
       title: Facial Pyoderma Gangrenosum: Overcoming Anchoring Bias
        date: 2021-07-09
       words: 957
      flesch: 41
     summary: A case of recurrent PG in a 44-year-old female is presented to highlight the difficulty in making this diagnosis on the face. Abbreviations used: PG: pyoderma gangrenosum; IBD: inflammatory bowel disease Conflict of Interest Disclosures: Robert T. Brodell discloses the following: Multicenter Clinical Trials: Novartis – Principal Investigator; Corona psoriasis biologic registry.
    keywords: dermatology; journal; pyoderma
       cache: skin-1264.pdf
  plain text: skin-1264.txt

        item: #215 of 1356
          id: skin-1265
      author: Heibel, Haley Danielle; Ibad, Sidra; Dhaliwal, Parneet; Currimbhoy, Sharif; Cockerell, Clay J.
       title: A Subacute Cutaneous Lupus Erythematosus-Like Drug Eruption Related to Terbinafine in a Male
        date: 2021-07-09
       words: 1396
      flesch: 37
     summary: In addition, one case of SCLE that developed during terbinafine therapy for onychomycosis was associated with chilblain lupus.1 There have also been reports of patients with symptoms and signs of autoimmune dysfunction who developed SCLE with terbinafine therapy.2,7 Terbinafine-induced SCLE has been associated with high titers of antinuclear antibodies (ANA) and the presence of anti-Ro (SS-A) antibodies, anti-La (SS-B) antibodies, and anti-histone antibodies, although the presence of anti-histone antibodies is less common.1,3,6 DISCUSSION SKIN July 2021 Volume 5 Issue 4 Copyright 2021 The National Society for Cutaneous Medicine 439 Bonsmann et al1 observed that ANA titers and anti-histone antibodies decreased with Figure 2. Although the mechanism for terbinafine- induced SCLE has not been fully elucidated, we suggest that there may be distinctive mechanisms of terbinafine-induced SCLE of patients with and without a predisposition to or history of autoimmune or connective tissue diseases, which should be a focus for future research.
    keywords: erythematosus; lupus; patients; scle; terbinafine
       cache: skin-1265.pdf
  plain text: skin-1265.txt

        item: #216 of 1356
          id: skin-1269
      author: Weir, Sydney; Hattaway, Reagan; Singh, Nikhi ; Boyd, Carter; Hemal, Kshirpa
       title: Characterizing the Effect of the COVID-19 Pandemic on the Dermatology Literature
        date: 2021-09-13
       words: 1888
      flesch: 42
     summary: For COVID-19 related articles, we also assessed whether AAS and citations varied by the type of article (editorial, original article, or guideline) and sub- specialty of dermatology to which the article pertained. COVID-19 related articles in the dermatology literature received more widespread attention as measured by the average AAS (33 vs. 4 p<0.001) and were higher impact as measured by citation count (11 vs. 1, p<0.001) than non-COVID-19 articles.
    keywords: articles; covid-19; dermatology; literature; pandemic
       cache: skin-1269.pdf
  plain text: skin-1269.txt

        item: #217 of 1356
          id: skin-127
      author: Frias, Jennifer; Vargas, Raquel; Paez, Erika; Chopite, Marina; Reyes, Oscar; Soucre, Natalia; Swenson, Nicole; Berman, Brian
       title: Effects of Imiquimod 5% Cream in the Prevention of Excised Keloid Recurrence
        date: 2018-01-02
       words: 769
      flesch: 54
     summary: The subset of 20 treated auricular keloids were followed up to 5 years after keloid treatment, with no additional recurrences were noted. 1 Treatment of surgical keloidectomy excision sites with topical imiquimod 5% cream for 8 weeks daily has been reported to have no recurrences of the keloids at the end of the relatively short, 24 week follow up period.
    keywords: imiquimod; keloids
       cache: skin-127.pdf
  plain text: skin-127.txt

        item: #218 of 1356
          id: skin-1270
      author: Marson, Justin; Farberg, Aaron; Glazer, Alex; Litchman, Graham; Svoboda, Ryan; Winkelmann, Richard; Rigel, Darrell
       title: Expert Consensus on Sunscreen for the Primary Prevention of Skin Cancer: Results from the Skin Cancer Prevention Working Group Conference
        date: 2021-05-21
       words: 7218
      flesch: 57
     summary: Skin cancer (melanoma and NMSC) is the most common type of malignancy diagnosed annually, outnumbering all other cancer diagnoses ~3 to 1 with over 5.4 million new diagnoses per year and 1 in 5 Americans expected to be diagnosed with a type of skin cancer by the age of 70.1-4 The incidence of skin cancer has continued to rise in the past several decades and only recently began to plateau as public outreach on sun-safety has increased.3 However, timely diagnosis and adequate management and treatment of skin cancer still account for ~$6 billion in annual healthcare expenditures.7 Furthermore, despite improvements in care and diagnostic techniques, there are expected to be 7180 deaths in 2021 due to invasive melanoma alone.3,10 Table 1. As experts in the diagnosis and management of skin cancers, dermatologists are especially well-equipped to discuss with patients the risks of UVR exposure and skin cancer and benefits of multimodal sun-protective measures, including the regular and proper use of sunscreens.
    keywords: cancer; consensus; dermatol; doi; efficacy; epub; exposure; medicine; melanoma; oxybenzone; patients; pmid; prevention; protection; review; risk; safety; skin; skin cancer; society; spf; studies; sunscreen; use; uvr
       cache: skin-1270.pdf
  plain text: skin-1270.txt

        item: #219 of 1356
          id: skin-1276
      author: Brody, Gabrielle; Yale, Katerina; Nguyen, Alora; Juhasz, Margit ; Doan, Linda; Mesinkovska, Natasha Atanaskova 
       title: Laterality and site-specific distribution patterns of Lentigo Maligna and Lentigo Maligna Melanoma
        date: 2021-09-13
       words: 1395
      flesch: 57
     summary: The observed sex differences in the distribution pattern of LM and LMM support previous studies with similar findings in superficial spreading and nodular melanomas specifically, as well as studies that did not distinguish between subclassifications.7 Similar to previous studies, our study observed a significant left-sided laterality for the head/neck region (59.1% left, p=0.0178) (Table 2).3
    keywords: extremities; left; lmm; melanoma
       cache: skin-1276.pdf
  plain text: skin-1276.txt

        item: #220 of 1356
          id: skin-1278
      author: Dando, Emily; Guerrero, Angela; Collins, Mary-Katharine; James, Alaina
       title: Virtual medical student dermatologic surgery workshop increases confidence in suturing and skin biopsy skills in the era of COVID-19
        date: 2021-11-05
       words: 1283
      flesch: 45
     summary: Early and prolonged opportunities to practice suturing increases medical student comfort with suturing during clerkships: Students who participate in procedure training demonstrate increased confidence and ability when applying these skills to patients.1 In the era of COVID-19, many pre- clinical medical school curricula have transitioned to remote learning, which may reduce critical early exposure to basic procedures.
    keywords: students; suture; workshop
       cache: skin-1278.pdf
  plain text: skin-1278.txt

        item: #221 of 1356
          id: skin-128
      author: Glaser, Dee Anna; Hebert, Adelaide A; Nast, Alexander; Werschler, William P; Shideler, Stephen; Green, Lawrence; Mamelok, Richard D; Drew, Janice; Quiring, John; Pariser, David M
       title: Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis
        date: 2017-10-27
       words: 2384
      flesch: 39
     summary: This 44-week, open-label extension study (ARIDO; NCT02553798) assessed the long-term safety of GT in patients with primary axillary hyperhidrosis who completed ATMOS-1 (NCT02530281; sites in the US and Germany) or ATMOS-2 (NCT02530294, sites in US only) METHODS Study Design • ARIDO was a 44-week open-label extension of ATMOS-1/ATMOS-2, 4-week, double-blind, phase 3 clinical trials in which patients with primary axillary hyperhidrosis were randomized 2:1 to GT (3.75% topical solution) or vehicle applied once daily to each axilla for 28 days (Figure 1) – Patients who completed ATMOS-1/ATMOS-2 with ≥80% treatment compliance were eligible to continue into ARIDO and receive open-label GT for 44 weeks or to early termination (ET; Figure 1) • Eligible patients were ≥9 years of age (patients <16 years were only recruited at US sites) and had primary axillary hyperhidrosis for ≥6 months, with gravimetrically-measured sweat production of ≥50 mg/5 min in each axilla, Axillary Sweating Daily Diary (ASDD; for patients ≥16 years of age) or ASDD-Children (ASDD-C; for patients <16 years of age) axillary sweating severity item (Item 2)4 score ≥4 (0 to 10 numeric rating scale), and Hyperhidrosis Disease Severity Scale (HDSS) ≥3 Scaling (N=25) 5 (20%) 20 (80%) Mild Moderate Severe 200 160 120 80 40 0 N um be r of L S R s Patients were counted as having an LSR if any post-Baseline assessment was mild, moderate, or severe aBaseline in ATMOS-1/ATMOS-2 bPatients receiving ≥1 dose of GT and having ≥1 post-Baseline assessment in ARIDO GT, topical glycopyrronium tosylate; LSR, local skin reaction CONCLUSIONS • Safety results were consistent with anticholinergic treatment and with the safety profile observed in prior GT studies,3 with no new or unexpected findings – Most TEAEs were mild or moderate in severity and considered by the investigator to be related to study drug – A low number of subjects discontinued due to a TEAE – While approximately one-third of patients reported LSRs, most were mild or moderate in severity – Incidence of TEAEs, including prespecified anticholinergic TEAEs of interest, did not increase with long-term treatment • Efficacy measures obtained at the end of treatment in ARIDO indicated that subjects had maintained sweat production reduction and less bothersome sweating compared with Baseline in ATMOS-1/ATMOS-2 • GT was generally well tolerated and improvements in efficacy measures were maintained in patients with primary axillary hyperhidrosis when applied once daily to both axillae over a maximum of 48 weeks References 1.
    keywords: arido; atmos-2; baseline; patients; teaes; week
       cache: skin-128.pdf
  plain text: skin-128.txt

        item: #222 of 1356
          id: skin-1281
      author: Armenta, Andrew; Winsett, Frank; Wagner, Richard
       title: Pathophysiology, Risk Factors, and Prevention of Wound Dehiscence Following Dermatologic Procedures
        date: 2021-11-05
       words: 4223
      flesch: 46
     summary: Postoperative wound dehiscence: Predictors and associations. SKIN November 2021 Volume 5 Issue 6 Copyright 2021 The National Society for Cutaneous Medicine 590 IN-DEPTH REVIEW Pathophysiology, Risk Factors, and Prevention of Wound Dehiscence Following Dermatologic Procedures Andrew M. Armenta, MD1, Frank T. Winsett, MD1, Richard F. Wagner Jr. MD1 1Department of Dermatology, The University of Texas Medical Branch, Galveston, TX Skin cancer is the most common malignancy in the United States and has been increasing in incidence, affecting approximately one in five Americans.1,2 As the number of skin cancers have increased, so have the number of dermatologic procedures including biopsies, excisions and Mohs micrographic surgery.2 Behind surgical site infection, wound dehiscence is the second most common postoperative complication of dermatologic procedures and often occurs within the first postoperative week.3-6 There are many preoperative, intraoperative, and postoperative risk factors that must be considered to decrease the risk for this common complication.
    keywords: collagen; dehiscence; dermatol; factors; healing; infection; inflammation; proliferation; risk; skin; surgery; suture; tension; wound
       cache: skin-1281.pdf
  plain text: skin-1281.txt

        item: #223 of 1356
          id: skin-1287
      author: Abercrombie, McKenna; Healey, Brayden; Barone, Hope ; McNeil, Morgan; Zheng, Zijian; Sigal, Peter ; LaFond, Ann
       title: Effect of Pre-Surgical Education on Patient Satisfaction and Surgical Experience: A Quality Improvement Initiative
        date: 2022-01-17
       words: 2145
      flesch: 51
     summary: Surgical patients scheduled at our academic dermatology clinic for excision or Mohs surgery were randomly assigned to a “call”/intervention group or “non-call”/control group. Díez-Álvarez E, Arrospide A, Mar J, Alvarez U, Belaustegi A, Lizaur B, et al. Effectiveness of pre-operative education in reducing anxiety in surgical patients.
    keywords: group; intervention; patients; satisfaction; surgery
       cache: skin-1287.pdf
  plain text: skin-1287.txt

        item: #224 of 1356
          id: skin-1288
      author: Tassavor, Michael ; Hashim, Peter; Babalola, Folawiyo; Bhatt, Mehul
       title: Nonavalent Human Papillomavirus Vaccine as a Treatment for Recalcitrant Warts in an Adult with HIV
        date: 2021-07-09
       words: 1305
      flesch: 50
     summary: A recent single center retrospective cohort study (n=16, two immunocompromised patients, one lost to follow up, the second deceased due to unrelated reasons) of recalcitrant warts showed nearly 50% response to HPV vaccination, comparable to conventional treatments. After 8 injections of bleomycin, 3 months after first HPV shot While there are three FDA approved vaccines, only the nonavalent Gardasil 9 is currently available today in the United States, targeting HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.
    keywords: bleomycin; hpv; human; vaccine; warts
       cache: skin-1288.pdf
  plain text: skin-1288.txt

        item: #225 of 1356
          id: skin-1289
      author: Ghani, Hira; Rahman, Raphia; Liu, Kevin; Cubelli , Stefani 
       title: An Investigation of Makeup Ingredients and their Effects on Acne Cosmetica with Dermatologic Practice Recommendations 
        date: 2021-09-13
       words: 4073
      flesch: 45
     summary: These oils have a high comedogenic index of 3-4.19 Isopropyl Isostearate Isopropyl isostearate is an emollient found in many lotions and skin care products. Salicylic acid is less irritating than skin care products containing alpha-hydroxy acids, while providing similar improvement in skin texture and color.
    keywords: acid; acne; cosmetic; dermatol; ingredients; makeup; patients; products; sebum; skin; use; vulgaris
       cache: skin-1289.pdf
  plain text: skin-1289.txt

        item: #226 of 1356
          id: skin-129
      author: Hornberger, John; Rigel, Darrell
       title: Health Econommic Implications of a Non-Invasive Gene Expression Test for Primary Cutaneous Melanoma
        date: 2017-10-27
       words: 499
      flesch: 45
     summary: A recently described adhesive patch skin biopsy based non-invasive gene expression test (pigmented lesion assay, PLA) demonstrated utility and differentiated benign from malignant pigmented skin lesions with a test performance that exceeded visual inspection (VI) and a sensitivity that matching the gold standard of dermatopathology. A biopsy ratio reduction from 12.5 for VI to 2.4 for PLA use was observed.
    keywords: benign; melanoma
       cache: skin-129.pdf
  plain text: skin-129.txt

        item: #227 of 1356
          id: skin-1290
      author: Jiang, Angela; Kashlan, Reem; Joseph, Christine; Tang, Amy; Lim, Henry
       title: Disparities in Access to Teledermatology During the COVID-19 Pandemic in Detroit, Michigan
        date: 2021-11-05
       words: 3934
      flesch: 55
     summary: Women, however, may have a disproportionate distribution of childcare duties with children staying home, which may limit access to telehealth.21,22 Most articles posit that older patients pursue fewer dermatology virtual visits due to lower technical literacy as well more common complaints related to keratinocyte carcinomas.18,19 In this study, the pediatric patient population who completed virtual visits appeared to mirror health disparities previously reported in pediatric dermatology patients, with improved access in patients with commercial insurance, lower SDI scores, and Demographic characteristics of patients who pursued virtual visits was compared with those who did not.
    keywords: access; age; care; covid-19; insurance; pandemic; patients; teledermatology; visits
       cache: skin-1290.pdf
  plain text: skin-1290.txt

        item: #228 of 1356
          id: skin-1291
      author: Kou, Leon; Wong, Austin; Zhong, Lily; Danesh, Sid
       title: Cutaneous Metastasis of Thymic Carcinoma to the Frontal Scalp
        date: 2021-07-09
       words: 1627
      flesch: 54
     summary: TC skin metastasis is rare and could be misdiagnosed for a benign skin condition. Except for CD5 and CD117, our IHC results correlate with a previously reported TC cutaneous metastasis case.5 Positive PAX8 staining, found in approximately 77% of TCs, but rarely expressed in primary lung cancers, supported the diagnosis of TC with metastasis to the lungs and our current diagnosis of TC metastasis to the skin.10,11 TCs generally stain negative for TTF-1 and synaptophysin and our negative results further rule out the possibility of lung, thyroid, or neuroendocrine tumor metastasis.12 Positive staining for P63, found in normal thymus gland and thymic epithelial tumors, and pancytokeratin (AE1/AE3), typically positive in TCs, further support our diagnosis.3 Our patient’s skin lesion appeared 1 month after discovery of the mediastinal mass by cardiac MRI and because it was left uninvestigated, the lesion worsened over 1 year with increased size, pain, and alopecia of the surrounding area.
    keywords: cd5; metastasis; skin; staining
       cache: skin-1291.pdf
  plain text: skin-1291.txt

        item: #229 of 1356
          id: skin-1292
      author: Heibel, Haley Danielle; Bandel, Chris; Reddick, Claire; Cockerell, Clay J.
       title: A Case of Cutaneous Metastatic Tonsillar Squamous Cell Carcinoma in a Female
        date: 2022-05-06
       words: 1219
      flesch: 52
     summary: To our knowledge, only 8 cases of cutaneous metastatic tonsillar SCC previously have been reported in the English literature. Cutaneous metastatic tonsillar SCC.
    keywords: carcinoma; case; neck; patient; scc
       cache: skin-1292.pdf
  plain text: skin-1292.txt

        item: #230 of 1356
          id: skin-1293
      author: Wei, Nancy; Elbogen, Emily; Dan, Joshua; Chessky, Anna; Rivera-Oyola, Ryan; Lebwohl, Mark
       title: Telogen Effluvium in Patients recovering from COVID-19
        date: 2021-09-13
       words: 2561
      flesch: 36
     summary: Literature on dengue fever associated TE similarly found no association between severity of infection and hair loss.3,9 Additionally, coagulopathy studies of COVID-19 patients revealed coagulation functions remained fairly stable in mild COVID-19 and not significantly different from baseline (convalescent state) within the same individuals.10 Psychological and emotional stressors are a known trigger for TE, so they may contribute to the new onset TE seen in COVID-19 patients.
    keywords: covid-19; effluvium; hair; http://paperpile.com/b/oo8g4l/zeyg; infection; patients; telogen
       cache: skin-1293.pdf
  plain text: skin-1293.txt

        item: #231 of 1356
          id: skin-1294
      author: Monahan, Zachary; Cantor, Aaron; Handfield, Kent
       title: Parkinson’s Disease as a Risk Factor for Melanoma: A Review
        date: 2021-09-13
       words: 4385
      flesch: 58
     summary: Three studies offered estimated risk of development of malignant melanoma in patients with classic melanoma risk factors. Cancer risk in association with Parkinson disease: a population-based study.
    keywords: association; cancer; cohort; diagnosis; disease; factors; melanoma; parkinson; patients; risk; skin; studies
       cache: skin-1294.pdf
  plain text: skin-1294.txt

        item: #232 of 1356
          id: skin-1295
      author: Brody, Gabrielle; Nguyen, Michael O.;  Foulad, Delila Pouldar; Rojek, Nathan W. 
       title: Retiform Purpura in the Setting of COVID-19: A Harbinger of Underlying Coagulopathy and Severe Disease Course
        date: 2021-07-09
       words: 999
      flesch: 41
     summary: This case highlights the seriousness of retiform purpura in COVID-19 patients as a cutaneous finding concerning for an underlying vasculopathy that may precede further acute thromboembolic events and a worsening course of disease. Magro et al. noted that patients with pernio-like lesions secondary to COVID-19 who have mild respiratory symptoms and good outcomes have a strong inflammatory response with low viral loads, while patients with retiform purpura with severe COVID-19 disease have minimal interferon response, high viral loads and profound vasculopathy.
    keywords: case; course; covid-19; retiform
       cache: skin-1295.pdf
  plain text: skin-1295.txt

        item: #233 of 1356
          id: skin-1296
      author: Alkul, Suzanne; Liu , Yuangao ; Whipple, Scott; Verstovsek, Gordana; Kim, Soo Jung
       title: Primary Cutaneous Plasmacytoma Treated with Palliative Radiotherapy: A Case Report and Literature Review
        date: 2021-11-05
       words: 2028
      flesch: 52
     summary: He denied constitutional symptoms including ABSTRACT Introduction: Primary cutaneous plasmacytomas (PCP) are very rare plasma cell neoplasms present in the skin or subcutaneous tissue without underlying multiple myeloma (MM). Infiltrate is strongly positive for CD138 by immunohistochemistry confirming plasmacytoma P) 1B) (1A, Hematoxylin and Eosin 100x; 1B Immunoperoxidase 40x) Primary cutaneous plasmacytomas are even more rare type of EMP confined to only skin without underlying systemic disease6.
    keywords: diagnosis; lesions; nodules; pcp; plasmacytoma; skin
       cache: skin-1296.pdf
  plain text: skin-1296.txt

        item: #234 of 1356
          id: skin-1297
      author: Marson, Justin; Berto, Stefano; Mouser, Paul; Baldwin, Hilary
       title: Association between Rosacea, Environmental Factors, and Facial Cutaneous Dysbiosis: A Pilot Study from the Largest National Festival of Twins
        date: 2021-09-13
       words: 2922
      flesch: 47
     summary: Beta-diversity (differences between samples across groups) assessed with principal component analysis with Weighted UniFrac (accounting for number of different species and relative abundance) demonstrated clustering of the microbiome samples that were significantly different for facial cutaneous microbiome (E) but not for the enteric microbiome (F). Conclusion: Environmental factors may alter relative abundances of specific microbial genera and lead to microbiome diversity.
    keywords: dermatol; fdr; microbiome; participants; rosacea; skin
       cache: skin-1297.pdf
  plain text: skin-1297.txt

        item: #235 of 1356
          id: skin-1298
      author: Howard, Tara; Matin, Taraneh; Howard, John; Howard, Eduardo Weiss
       title: Rare Mucosal Lip Atypical Fibroxanthoma Treated with Mohs Micrographic Surgery
        date: 2021-11-05
       words: 943
      flesch: 46
     summary: AFX presents as a rapidly growing, solitary, red-pink, firm nodule with a mean diameter less than 2 cm and occasionally may ulcerate or bleed. ABSTRACT Atypical fibroxanthoma (AFX) is a rare dermal neoplasm of low-intermediate malignant potential found almost exclusively in the non-mucosal regions of the head and neck in light-skinned elderly males who have a history of significant sun exposure.
    keywords: afx; lip; skin
       cache: skin-1298.pdf
  plain text: skin-1298.txt

        item: #236 of 1356
          id: skin-1299
      author: Serrano, Linda; Carlberg, Valerie; Holland, Kristen
       title: Rapid Efficacy of Ixekizumab for Pediatric Acute Generalized Pustular Psoriasis 
        date: 2021-11-05
       words: 1897
      flesch: 41
     summary: 6-8 Multiple cases of adolescent males with known deficiency of the interleukin IL-36 receptor antagonist (DITRA), characterized by fevers and pustular psoriasis flares, who were refractory to a variety of treatments such as acitretin, infliximab, cyclosporine, phototherapy, adalimumab, prednisone, ustekinumab, methotrexate, apremilast, and anikinara had a notable response to secukinumab, another anti- IL-17 monoclonal antibody. Case presentation: A 17-year-old female with a history of alopecia areata and pustular psoriasis, on ustekinumab, was admitted for a severe pustular psoriasis flare with systemic symptoms including fever and tachycardia which progressed to erythroderma and required vasopressor support.
    keywords: cyclosporine; gpp; ixekizumab; patients; pediatric; psoriasis
       cache: skin-1299.pdf
  plain text: skin-1299.txt

        item: #237 of 1356
          id: skin-13
      author: Hadi, Ali; Lebwohl, Mark
       title: Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series
        date: 2017-06-28
       words: 2022
      flesch: 46
     summary: Figure 2B. Two months into apremilast treatment, note the resolution of perifollicular erythema. bSol and Clara Kest Professor and Chair of the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029 ABSTRACT ABSTRACT Importance: Lichen planopilaris and frontal fibrosing alopecia are characterized by scarring alopecia associated with pruritus, inflammation, and pain of affected areas.
    keywords: alopecia; apremilast; lichen; patients; planopilaris
       cache: skin-13.pdf
  plain text: skin-13.txt

        item: #238 of 1356
          id: skin-1300
      author: Mukovozov, Ilya; Mirali, Sara; Khaslavsky, Sofi; Kalia, Sunil
       title: Light and Laser-based Treatments for Hidradenitis Suppurativa: A Systematic Review
        date: 2021-11-05
       words: 9134
      flesch: 59
     summary: Suarez-Valladares et al. found that in a series of HS patients treated with intralesional ALA-PDT, 76.3% (n=29/38) achieved complete remission.8 In a smaller study of five Hurley stage II or III HS patients with recalcitrant disease, no significant improvement was seen, despite mild improvements in Sartorius score, VAS, and DLQI in all patients (mean change from baseline to post-treatment: Sartorius = -1.6, VAS = -0.3, DLQI = -6.4%). In a study of 24 patients, Lapins et al. showed that CO2 laser treatment with healing by secondary intention was safe, beneficial, and rapidly effective with a mean resolution period of 4 weeks.
    keywords: case; co2; co2 laser; disease; hidradenitis; improvement; ipl; laser; lesions; light; patients; pdt; recurrence; response; series; studies; study; suppurativa; therapy; treatment; yag
       cache: skin-1300.pdf
  plain text: skin-1300.txt

        item: #239 of 1356
          id: skin-1301
      author: Chopra, Shara; Sinharoy, Ankita; Flamm, Alexandra
       title: A Cross-Sectional Survey of Students and Instructors on Virtual Dermatology Teaching in a Competency-based Format
        date: 2021-11-05
       words: 2048
      flesch: 36
     summary: In a traditional in-person teaching format, student learning is assessed by whether it fulfills the ACGME (Accreditation Council for Graduate Medical Education) core competencies: patient care, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice.1 During the COVID-19 pandemic, the dermatology elective at the Penn State College of Medicine (PSCOM) was converted to a four- week virtual format in lieu of a clinical rotation. Results: Medical students (n=15, response rate=52%) were satisfied with learning objectives geared towards the ACGME core competencies in five of the six competencies.
    keywords: course; dermatology; education; instructors; learning; satisfaction; student
       cache: skin-1301.pdf
  plain text: skin-1301.txt

        item: #240 of 1356
          id: skin-1304
      author: Masterson, Wylie ; Morse, Daniel; Pacha, Omar
       title: IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris
        date: 2021-09-13
       words: 1584
      flesch: 51
     summary: PRP patients have an increase in cytokines IL-17A, IL-17F, and IL-22. Interestingly, in skin lesions of PRP patients, studies found an upregulation of helper T- cell 17 cytokines including IL-17A, IL-17F, and IL-22,5 which suggests that the IL-23- Th17 pathway plays an important role in this condition.
    keywords: case; erythrodermic; il-17a; prp; skin; treatment
       cache: skin-1304.pdf
  plain text: skin-1304.txt

        item: #241 of 1356
          id: skin-1307
      author: Glinos, George; Hooper, Madeline; Morey, G. Eli; Seminario-Vidal, Lucai
       title: Zosteriform lichen planus as a manifestation of Wolf’s isotopic response
        date: 2021-09-13
       words: 1628
      flesch: 43
     summary: Isotopic response. The temporal delay between primary VZV eruption and the subsequent presentation of zosteriform LP can range from 15 days to five years.
    keywords: herpes; lichen; response; skin; wolf
       cache: skin-1307.pdf
  plain text: skin-1307.txt

        item: #242 of 1356
          id: skin-1309
      author: Kimmel, Grace; Chima, Margot; Kim, Hee Jin; Bares, Jennifer; Yaroshinsky, Alex; Singer, Giselle; Kim, Soo Jung; Bagel, Jerry; Lebwohl, Mark
       title: Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints
        date: 2021-09-13
       words: 2034
      flesch: 56
     summary: For those patients who were non- responders at week 16, we observed a partial response (PASI-50) in 50% (AO)/30.8% (NRI). Our prior publication reported significant disease improvement with brodalumab in psoriasis patients who had previously failed treatment with an anti-IL-17A agent.
    keywords: patients; treatment; value; week
       cache: skin-1309.pdf
  plain text: skin-1309.txt

        item: #243 of 1356
          id: skin-131
      author: Sligh, James; Yao, Zuxu; Jansen, Burkhard
       title: An Adhesive Patch Biopsy Based Gene Expression Test to Non-invasively Differentiate Basal Cell and Squamous Cell Carcinomas from Actinic Keratoses and Other Skin Lesions of Similar Appearance
        date: 2017-10-27
       words: 584
      flesch: 43
     summary: The described approach of non-invasive gene expression testing differentiates primary cutaneous BCC and SCC cases from benign and precursor lesions such as AK with high sensitivity and specificity. Once fully validated in an ongoing large prospective study, such a test has the potential to reduce the number of avoidable surgical procedures while missing fewer cases of non-melanoma skin cancer.
    keywords: gene; skin
       cache: skin-131.pdf
  plain text: skin-131.txt

        item: #244 of 1356
          id: skin-1312
      author: Hubbard, Erika; Lebwohl, Mark
       title: Vascular Effects of Pseudoxanthoma Elasticum
        date: 2021-09-13
       words: 4243
      flesch: 61
     summary: Pingel S, Pausewang KS, Passon SG, et al. Increased vascular occlusion in patients with pseudoxanthoma elasticum. Utani A, Tanioka M, Yamamoto Y, et al. Relationship between the distribution of pseudoxanthoma elasticum skin and mucous membrane lesions and cardiovascular involvement.
    keywords: arterial; calcification; cardiovascular; carotid; case; crm; disease; elasticum; et al; hypertension; med; patients; pseudoxanthoma; pseudoxanthoma elasticum; pxe; vascular
       cache: skin-1312.pdf
  plain text: skin-1312.txt

        item: #245 of 1356
          id: skin-1316
      author: Wu, Jashin ; Montgomery, Paul; Long, Blake ; Dickerson , Tobin; Snyder, Margaret; Gross, Martyn ; Chaihorsky, Lena; Mamuszka, Hannah; Fried, Mike
       title: An Economic Evaluation of The Budget Impact of Precision Medicine Testing for The Treatment of Psoriasis
        date: 2021-07-09
       words: 5964
      flesch: 57
     summary: Drug costs for the future state are the same for SoC. Model Output Secondary Response Rate – average drug class response rate when a second drug is used in the same drug class after the first drug failed.
    keywords: class; costs; drug; figure; inhibitor; medicine; model; patients; precision; psoriasis; rate; response; savings; treatment; week
       cache: skin-1316.pdf
  plain text: skin-1316.txt

        item: #246 of 1356
          id: skin-1320
      author: Garraway, Caroline ; Huynh, Thy ; Brodell, Robert ; Nahar, Vinayak K.
       title: Idiopathic Aseptic Facial Granuloma
        date: 2021-09-13
       words: 1340
      flesch: 44
     summary: At 2 month follow up, he was started on a 30-day course of oral amoxicillin- clavulanate 875-125 mg twice ABSTRACT Pyodermite froide du visage, otherwise known as idiopathic facial aseptic granuloma (IFAG), is a benign lesion exclusively seen in children and presents as a cold abscess on the face.1 We report a case of a 14-year-old male with IFAG who failed initial treatment with oral doxycycline, but responded to treatment with oral 13-cis-retinoic acid, oral amoxicillin-clavulanate and intralesional triamcinolone injections over a 7 month period. Following four-months of moderate acne vulgaris on the cheeks treated with doxycycline 100 mg daily, the patient developed this erythematous, indurated, multi-lobular plaque on the left cheek typical of idiopathic facial aseptic granuloma.
    keywords: granuloma; intralesional; medicine; treatment
       cache: skin-1320.pdf
  plain text: skin-1320.txt

        item: #247 of 1356
          id: skin-1322
      author: Penny, Kayla ; Sharma, Manoj ; E. Flischel, Amy ; T. Brodell, Robert ; Nahar, Vinayak K.
       title: Atopic Dermatitis: Preventing and Managing the Itch That Rashes, and a Case for the Multi-Theory Model (MTM) for Health Behavior Change for Educational Interventions: Application of a Novel Theory to Self-Management Behaviors in Atopic Dermatitis
        date: 2021-09-13
       words: 5560
      flesch: 39
     summary: Multi-theory models (MTM) have not yet been used in AD interventions but may prove beneficial as they use behavior concepts to predict both initiation and sustenance in education health interventions. Multi-theory model (MTM) for health behavior change.
    keywords: atopic; behavior; change; children; dermatitis; health; interventions; management; model; mtm; self
       cache: skin-1322.pdf
  plain text: skin-1322.txt

        item: #248 of 1356
          id: skin-1325
      author: O'Connell, Katie; Raef, Haya; Gao, David
       title: The American Academy of Dermatology Camp Discovery Goes Virtual
        date: 2021-09-13
       words: 518
      flesch: 50
     summary: SKIN September 2021 Volume 5 Issue 5 Copyright 2021 The National Society for Cutaneous Medicine 566 COMPELLING COMMENTS The American Academy of Dermatology Camp Discovery Goes Virtual Katie A. O’Connell, MS1, Haya Raef, MS2, David X. Gao, BA3 1 Eastern Virginia Medical School, Norfolk, VA 2 Tufts University School of Medicine, Boston, MA 3 University of Illinois School of Medicine, Chicago, IL Teasing and bullying related to skin disease have been associated with depression, suicidal ideation, and social withdrawal.1 Psychological distress can further exacerbate skin conditions, initiating a vicious cycle of stress and disease. 2. Wu J, Hogeling M. Impact of summer camps for children with chronic skin conditions [published online ahead of print, 2020 Aug 3].
    keywords: camp; skin
       cache: skin-1325.pdf
  plain text: skin-1325.txt

        item: #249 of 1356
          id: skin-1327
      author: Skelsey, Maral; Brouha, Brook; Rock, Jim; Howell, Michael; Jansen, Burkhard; Clarke, Loren; Peck, Gary
       title: Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden
        date: 2021-09-13
       words: 4923
      flesch: 49
     summary: Following the extraction of RNA, samples were analyzed using quantitative PCR to assess the expression of two genes, LINC00518 and PRAME.11,12 The PLA is considered positive when one or both genes are detected; positive lesions subsequently undergo biopsy or excision for histopathologic review. A total of 3,418 lesions were assessed by PLA, and positive melanocytic lesions with corresponding histopathology were further classified by MPATH-Dx.8, 9 Many tests require a compromise with respect to NPV and PPV in which optimizing one parameter comes at the expense of the other.
    keywords: biopsy; class; lesions; melanoma; mpath; npv; pla; positive; risk; study; testing
       cache: skin-1327.pdf
  plain text: skin-1327.txt

        item: #250 of 1356
          id: skin-1328
      author: Brownstone, Nicholas; Cummins , Daniel ; Gandelman , Jocelyn ; Bhutani , Tina ; Liao , Wilson 
       title: The Goeckerman Regimen as an Effective Treatment Modality for Checkpoint Inhibitor Dermatoses 
        date: 2021-09-13
       words: 1930
      flesch: 46
     summary: Within days of starting Goeckerman therapy, he had rapid improvement in his skin lesions along with a reduction in pruritus. The decision to start Goeckerman therapy was based on the persistence of his rash and the previous failure of topical and oral steroids.
    keywords: goeckerman; pembrolizumab; psoriasis; skin; therapy; treatment
       cache: skin-1328.pdf
  plain text: skin-1328.txt

        item: #251 of 1356
          id: skin-1329
      author: Long, Tyler; Dunn, Austin; Arndt, Mary ; Parlette, Eric
       title: Melanoma Recurrence after Mohs Micrographic Surgery with MART-1: A Systematic Review and Meta-analysis
        date: 2021-11-05
       words: 5112
      flesch: 13
     summary: Mariwalla, K., Aasi, S. Z., Glusac, E. J. & Leffell, D. J. Mohs micrographic surgery histopathology concordance. Kesty, K., Sangueza, O. P., Leshin, B. & Albertini, J. G. Mohs micrographic surgery and dermatopathology concordance; An analysis of 1421 Mohs cases over 17 years.
    keywords: dermatol; mart-1; melanoma; mis; mms; mohs; recurrence; situ; studies; surgery
       cache: skin-1329.pdf
  plain text: skin-1329.txt

        item: #252 of 1356
          id: skin-133
      author: Adigun, Chris; Vlahovic, Tracey C; McClellan, Michael B; Thakker, Kailas D; Klein, Ryan R; Elstrom, Tuan A; Ward, Jr., Daniel B
       title: Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis
        date: 2017-10-27
       words: 3388
      flesch: 56
     summary: Prescribing antifungal therapy for suspected, but not confirmed nail fungus is therefore not recommended, and fungal confirmation or exclusion is an important initial step to ensure that patients are correct- ly treated. Although formulated to pen- etrate the nail unit and work with the porosity and inher- ent electrical charge of the nail plate, the newer topical an- tifungals do not address nail plate damage that has been created from years of harboring a dermatophyte infection.
    keywords: barrier; dermatol; efinaconazole; flux; nail; onychomycosis; tavaborole; treatment; ureaurethane
       cache: skin-133.pdf
  plain text: skin-133.txt

        item: #253 of 1356
          id: skin-1330
      author: Mumber, Hannah; Del Campo, Daniela; Alvarado, Manuel; Watchmaker, Jacqueline
       title: Willingness of Patients from an Urban Safety-Net Dermatology Clinic to Receive a COVID-19 Vaccine
        date: 2021-11-05
       words: 3349
      flesch: 48
     summary: When engaging with vaccine hesitant patients, dermatologists may turn to the evidence- based guidelines and scripts provided by the American Academy of Dermatology.19 Therein, dermatologists can assure patients that the vaccines have been properly tested and are recommended for the vast majority of the population including immunocompromised individuals. (0%) 1 (1.2%) Other 35 (22.6% ) 10 (14.5%) 25 (29.1%) Not disclosed 18 (11.6% ) 1 (1.5%) 17 (19.7%) COVID-19 vaccine than those who do not regularly receive the flu vaccine (p=0.0020).
    keywords: covid-19; dermatologists; dermatology; patients; safety; study; vaccination; vaccine
       cache: skin-1330.pdf
  plain text: skin-1330.txt

        item: #254 of 1356
          id: skin-1336
      author: Kou, Leon; Niu, Kevyn; Wong, Austin; Chen, Aaron; Danesh, Sid
       title: Diffuse Large B-cell Lymphoma in Bilateral Lower Extremities
        date: 2021-11-05
       words: 1275
      flesch: 54
     summary: Histologically, DLBCLLT is comprised primarily of large B cells in sheets that diffusely infiltrate the dermis. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
    keywords: cell; diffuse; lymphoma; treatment
       cache: skin-1336.pdf
  plain text: skin-1336.txt

        item: #255 of 1356
          id: skin-1337
      author: Buechler, Connor R; Veenstra, Jesse; Stein Gold, Linda
       title: Psoriasis Therapy Beyond Biologics
        date: 2021-11-05
       words: 4685
      flesch: 44
     summary: Bark C, Brown C, Svangren P. Systematic literature review of long-term efficacy data for topical psoriasis treatments. Steroidal formulations Topical corticosteroids (TCS) have been the cornerstone of psoriasis therapy since the 1950s, largely offered as creams, ointments, and lotions that act through anti- inflammatory, antimitotic, immunomodulatory, apoptotic, and vasoconstrictive functions.
    keywords: cream; dermatol; efficacy; foam; patients; phase; plaque; psoriasis; safety; therapies; therapy; topical; treatment
       cache: skin-1337.pdf
  plain text: skin-1337.txt

        item: #256 of 1356
          id: skin-1338
      author: Urban, Katelyn; Giesey, Rachel L.; Delost, Gregory R. 
       title: Pemphigus Foliaceous after COVID-19 Infection and Bamlanivimab Infusion 
        date: 2021-11-05
       words: 1327
      flesch: 44
     summary: Rachel L. Giesey, DO2, Gregory R. Delost, DO3 1 University Hospitals Regionals, Richmond Heights, OH 2 Ohio University Heritage College of Osteopathic Medicine, Athens, OH 3 Apex Dermatology and Skin Surgery Center, Mayfield Heights, OH To the authors’ knowledge, this is the first report of pemphigus foliaceous (PF) in the setting of COVID-19 infection and subsequent treatment with bamlanivimab. Given the current pandemic, the presentation of PF following COVID-19 infection and bamlanivimab infusion is of special interest and further investigation may be warranted.
    keywords: bamlanivimab; covid-19; infection; pemphigus; treatment
       cache: skin-1338.pdf
  plain text: skin-1338.txt

        item: #257 of 1356
          id: skin-134
      author: Thomson, K S; Thomson, G K; Biehle, J; Deeb, A; Crawford, J; Herrera, R; Robledo, I; Vazquez, G
       title: Bensal HP (BHP-410), a Novel Antimicrobial Agent with Activity Against MRSA, VRE, Gram-negative MDROs, Yeasts, and Dermatophytic Fungi
        date: 2017-10-27
       words: 1390
      flesch: 48
     summary: The MDROs were previously characterized for resistance mechanisms by phenotypic, biochemical and molecular methods (1) and included isolates producing the ESBLs TEM-52, SHV ESBLs, OXA-45, CTX-M-1, CTX- M-9, CTX-M-12, CTX-M-14, CTX-M-15, CTX-M-17, CTX-M-18, and CTX-M-19, chromosomal and plasmid-mediated AmpC β-lactamases that included FOX-like and CMY-2 enzymes, and carbapenemases of the IMP, VIM, KPC, and NDM families. In addition its activity against selected isolates of Mycobacterium fortuitum, Nocardia brasiliensis, yeasts and filamentous fungi was also assessed.
    keywords: activity; gram; isolates; mdro; resistance
       cache: skin-134.pdf
  plain text: skin-134.txt

        item: #258 of 1356
          id: skin-1340
      author: Taritsa, Iulianna; Walia, Shikha; Choi, Jennifer
       title: Demodicosis Mimicking Papulopustular Eruption in the Setting of Targeted Therapy
        date: 2022-01-17
       words: 1555
      flesch: 42
     summary: Demodicosis in the setting of chemotherapy and immunomodulation must remain a diagnostic consideration in cancer patients to allow for appropriate management of cutaneous findings without discontinuation of essential cancer therapy. Proteasome inhibitors like carfilzomib have also been reported to cause cutaneous eruptions, including papulonodular eruptions, urticaria, cutaneous vasculitis8, and Sweet syndrome9.
    keywords: demodex; demodicosis; inhibitor; medicine; patients; therapy
       cache: skin-1340.pdf
  plain text: skin-1340.txt

        item: #259 of 1356
          id: skin-1341
      author: Ahmed, Hana; Olivet, Meagan; Elston, Carly; Elewski, Boni 
       title: Erythema Multiforme Is Not Always Erythema Multiforme
        date: 2022-01-17
       words: 1502
      flesch: 55
     summary: Our case demonstrates that an atypical presentation of recurrent erythema multiforme, which does not respond to typical EM treatment, should raise a suspicion for RS and prompt screening for autoimmune markers and lupus erythematosus. Zeitouni et al. proposed the major criteria of LE, EM, and anti-nuclear antibodies, and the minor criteria of chilblains, anti-Ro/anti-La antibodies, and rheumatoid factor.
    keywords: case; lupus
       cache: skin-1341.pdf
  plain text: skin-1341.txt

        item: #260 of 1356
          id: skin-1343
      author: Lateef, Hanna; Kraish, Ali ; Lateef, Farooq 
       title: Successful Treatment of Confluent and Reticulated Papillomatosis with Minocycline Topical 4% Foam
        date: 2022-01-17
       words: 1991
      flesch: 50
     summary: 60 BRIEF ARTICLE Successful Treatment of Confluent and Reticulated Papillomatosis with Minocycline Topical 4% Foam Hanna Lateef, BS1, Ali Kraish, BA2; Farooq Lateef, MD, FAAD3 1 Florida State University College of Medicine 2 Ross University College of Medicine 3 Orlando Dermatology Inc. Confluent and reticulated papillomatosis was first recognized in 1927 by Henri Gougerot and Alexandre Carteaud as papillomatose pigmentée innominée, and subsequently papillomatose pigmentée confluente et reticulée.1,2 Lim JHL, Tet LH, Chong W. Confluent and reticulated papillomatosis: diagnostic and treatment challenges.
    keywords: confluent; crp; dermatol; minocycline; papillomatosis; topical; treatment
       cache: skin-1343.pdf
  plain text: skin-1343.txt

        item: #261 of 1356
          id: skin-1344
      author: Patel, Shreya; Phillips, Tania
       title: The Importance of Clinicopathological Correlation: A Case of Xanthoma Disseminatum
        date: 2022-01-17
       words: 1095
      flesch: 49
     summary: The differential diagnosis of XD includes adult-onset juvenile xanthogranuloma, eruptive xanthomas, as well as other xanthomatous diseases. There is no consensus on XD treatment; options include surgical removal, carbon dioxide laser treatment, cryotherapy, intralesional steroids, 2- chlorodeoxyadenosine, and electrocoagulation.1,3,5 Surgical removal and carbon dioxide laser have shown the best cosmetic outcomes, though 2- chlorodeoxyadenosine has recently demonstrated efficacy.1,5 Radiation therapy is effective for airway obstruction, while cyclophosphamide is used for
    keywords: case; patient; xanthoma
       cache: skin-1344.pdf
  plain text: skin-1344.txt

        item: #262 of 1356
          id: skin-1345
      author: Yang, Christopher; Quan, Victor; Amin, Ahmad
       title: Successful Use of Apremilast in Psoriasiform Dermatitis Refractory to Biologics
        date: 2021-11-05
       words: 1179
      flesch: 47
     summary: Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). The most common form of the disease is chronic plaque psoriasis (psoriasis vulgaris), which presents as sharply demarcated erythematous plaques with silvery scales.
    keywords: apremilast; dermatitis; psoriasiform; psoriasis
       cache: skin-1345.pdf
  plain text: skin-1345.txt

        item: #263 of 1356
          id: skin-1346
      author: Brownstone, Nicholas; Hakimi, Marwa; Koo, John
       title: Best Practices for Management of Delusions of Parasitosis 
        date: 2021-09-13
       words: 2102
      flesch: 48
     summary: It is well known that DOP patients who are angry at their dermatology providers will be motivated to make sure that their dissatisfaction with their provider is well known, potentially causing patient satisfaction scores to plummet. Dermatologists can, with training, diagnose DOP, build rapport and therapeutically treat DOP patients.
    keywords: dop; dose; national; patients; skin
       cache: skin-1346.pdf
  plain text: skin-1346.txt

        item: #264 of 1356
          id: skin-1347
      author: Logas, Chris; Dunn, Austin; Lazarra, Danielle; Rubin, Justin; Saleeby, Eli; Glick, Brad
       title: Dermatofibrosarcoma Protuberans Presenting as a Subcutaneous Cystic Nodule
        date: 2021-11-05
       words: 1281
      flesch: 37
     summary: Increased PDGFB expression leads to autocrine activation, tumor growth and development 4. A disadvantage of MMS is that tumor cells can be confused with normal spindle cells of the dermis.
    keywords: dfsp; http://paperpile.com/b/10uaeo/js8a; protuberans; tumor
       cache: skin-1347.pdf
  plain text: skin-1347.txt

        item: #265 of 1356
          id: skin-135
      author: Berman, Brian; Nestor, Mark
       title: Observer-Blinded, Randomized Study to Determine the Safety and Efficacy of a Silicone Gel versus a Gel Containing Onion Extract for the Appearance and Symptoms of Surgical Scars
        date: 2017-10-27
       words: 1217
      flesch: 43
     summary: The use of silicone gel sheets for treating burns has revealed that skin grafts refrain from shrinking, while the area around the burns heals by epithelialization without hypertrophy3 • Silicone gels and sheets are widely considered as first-line treatment for scars2 Objectives • To evaluate the safety and efficacy, in terms of appearance and symptoms, of a 100% silicone gel (RecedoTM) compared with an onion extract-containing gel (Mederma®) in adult subjects with postsurgical scars Methods Study Design • Randomized, evaluator-blinded, single-center, 16-week, active- comparator clinical study (Figure 1) • Baseline Characteristics 100% silicone gel BID (n=24) Onion extract- containing gel OD (n=24) Gender, n (%) Male Female 13 (54.2) 11 (45.8) 10 (41.7) 14 (58.3) Age, mean, years 61.7 60.5 Ethnicity, n (%) Hispanic or Latino Non-Hispanic or -Latino 6 (25) 18 (75) 5 (20.8) 19 (79.2) Race, n (%) White Hispanic Black/African American 20 (83.3) 4 (16.7) 0 (0) 20 (83.3) 3 (12.5) 1 (4.2) Age of scar, mean, days 45 52.4 Efficacy Evaluations VSS Score • The mean VSS score increasingly improved (decreased) from baseline for both groups during the course of the study (Figure 2) •
    keywords: gel; onion; week
       cache: skin-135.pdf
  plain text: skin-135.txt

        item: #266 of 1356
          id: skin-1350
      author: Karim , Maria; Wu, Marlyn; Ros, Adriana
       title: Multinucleate Cell Angiohistiocytoma: A Case Report and Unique Treatment Consideration
        date: 2021-11-05
       words: 1590
      flesch: 38
     summary: The multinucleate cells characteristically have angulated cytoplasms, with several hyperchromatic nuclei arranged around the periphery of the cells, comparable to the multinucleated cells seen in dermatofibroma.9 Immunohistochemical staining has been found to be positive for vimentin, CD34, CD31, and factor VIII- related antigen, with some cases reported to have CD68 expression of multinucleate cells depending on varying maturation or degenerative stages of the cells.9 The scarcity of reported cases ABSTRACT Introduction: Multinucleate cell angiohistiocytoma (MCAH) is a benign, yet exceedingly rare vascular and fibrohistiocytic proliferation.
    keywords: cell; laser; lesions; mcah; multinucleate
       cache: skin-1350.pdf
  plain text: skin-1350.txt

        item: #267 of 1356
          id: skin-1351
      author: Blake, Amy
       title: A Thousand Words for a Picture of Health
        date: 2021-11-05
       words: 749
      flesch: 46
     summary: we overestimate patients’ understanding of what we say.3 Written language poses additional challenges, as it does not permit real-time clarifications or the contextualization of body language.1 This shift now positions the medical record to serve as a real-time method of patient communication—whether or not it is well-suited for that task.
    keywords: communication; patient; words
       cache: skin-1351.pdf
  plain text: skin-1351.txt

        item: #268 of 1356
          id: skin-1353
      author: Cavanagh, Mary; Chellappan, Brinda 
       title: Social Media and Skin Cancer Prevention: A Promising Platform for Education Among Adolescents and Young Adults
        date: 2021-11-05
       words: 546
      flesch: 54
     summary: The rising incidence of skin cancer allows for the novel use of social media to encourage skin cancer education and prevention. These social media educators should consider creating content specifically for adolescents and young adults to highlight techniques for skin cancer prevention and identification.
    keywords: cancer; skin
       cache: skin-1353.pdf
  plain text: skin-1353.txt

        item: #269 of 1356
          id: skin-1355
      author: Nawaz, Nanjiba; Samaan, Christen; Flamm, Alexandra
       title: Herpes zoster in an immunocompetent young patient following mRNA-1273 vaccine for COVID-19: A case report
        date: 2022-01-17
       words: 1020
      flesch: 59
     summary: HZ has also been reported in children and immunocompetent individuals after administration of some vaccines including the live-attenuated varicella and yellow fever vaccines.1,2 Here, we present a case of HZ infection in a young, immunocompetent female following administration of the mRNA-1273 vaccine. 77 Figure 2 mRNA COVID-19 vaccines were seen in older patients.3 There are also reports of concomitant HZ in COVID-19 positive patients, both in older and younger patients.4 However, more recently there have been some reports of HZ infection in young immunocompetent individuals after receiving the COVID-19 BNT162b2 and mRNA-1273 vaccines.5,6,7
    keywords: covid-19; herpes; vaccine; zoster
       cache: skin-1355.pdf
  plain text: skin-1355.txt

        item: #270 of 1356
          id: skin-136
      author: Hoffman, Lauren; Raymond, Isabelle; Kircik, Leon
       title: The Effect of Econazole Nitrate Topical Foam, 1% on Signs and Symptoms (Pruritis) of Interdigital Tinea Pedis
        date: 2017-10-27
       words: 1427
      flesch: 53
     summary: Study Design: A single-center, investigator blinded, observational split body, pilot study was conducted to compare econazole nitrate topical foam, 1% to ketoconazole cream 2%. All subjects applied econazole nitrate topical foam, 1% (Ecoza foam) and ketoconazole cream 2% (Nizoral Cream) to either the right or left foot.
    keywords: econazole; foam; ketoconazole; nitrate; topical
       cache: skin-136.pdf
  plain text: skin-136.txt

        item: #271 of 1356
          id: skin-1365
      author: Raef, Haya; Hourihan, Maribeth; MacDonald, Jacob M;  Lewis, Janell;  Seiverling, Elizabeth V.
       title: Addressing geographic disparities in dermatology through virtual educational outreach
        date: 2022-01-17
       words: 1820
      flesch: 54
     summary: 3. Shipman SA, Wendling A, Jones KC, Kovar- Gough I, Orlowski JM, Phillips J. The decline in rural medical students: A growing gap in geographic diversity threatens the rural physician workforce. Adapting to the precautions necessitated by the COVID-19 pandemic, we developed a virtual pipeline program called the Inside Medicine Program, led by a combination of medical school students, faculty and staff.
    keywords: career; dermatology; program; school; students; workshop
       cache: skin-1365.pdf
  plain text: skin-1365.txt

        item: #272 of 1356
          id: skin-1369
      author: Stanger, Roselyn; Tan, Kathryn ; Lebwohl, Mark
       title: Diagnostic Approach to Patients with Chronic Pruritus of Unknown Origin: A Single-Site Retrospective Chart Review
        date: 2022-01-17
       words: 3339
      flesch: 54
     summary: Patients with prurigo nodularis were included if patients reported pruritus and if the lesions affected at least 5 body parts. patients had a biopsy consistent with bullous pemphigoid 1/8 (12.5%) patient with resolution of pruritus after switching lisinopril to losartan H&E: Hematoxylin and eosin; DIF: direct immunofluorescence Table 3.
    keywords: chronic; nodularis; patients; pemphigoid; prurigo; pruritus; skin; study; treatment
       cache: skin-1369.pdf
  plain text: skin-1369.txt

        item: #273 of 1356
          id: skin-137
      author: Jones, Terry M; Ellman, Herman; deVries, Tina
       title: Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies
        date: 2017-10-27
       words: 1727
      flesch: 48
     summary: In adult subjects, oral minocycline treatment had a geometric mean C max of 850 ng/mL, while topical application of 4 g FMX101 4% in adults had a geometric mean C max ranging from 1.109–1.539 ng/mL (days 1-2, days 12-13, and days 21-25) • The mean plasma concentration of oral minocycline in adult subjects reached C max by 3 hours after administration, followed by a log-linear decrease in concentration for the remaining 96-hour sample period • The mean plasma minocycline concentration of FMX101 4% increased until 8–14 hours (median T max value) on days 1, 12, and 21 • Figure 2 shows a comparison of mean plasma minocycline concentrations during the first 24 hours after a single dose of oral minocycline and after topical applications of FMX101 4% at 3 timepoints in adult subjects •
    keywords: application; fmx101; minocycline; study; subjects
       cache: skin-137.pdf
  plain text: skin-137.txt

        item: #274 of 1356
          id: skin-1373
      author: Chan, Stephanie ; Saski, Jodie; Qureshi , Abrar; Giordano , Grace; Brownstone, Nicholas; Koo, John
       title:  A Review of the Evidence for Intrinsic Ethnic Differences as Important Determinants of Skin Aging and Carcinogenesis: A Hope For All Ethnicities
        date: 2022-01-17
       words: 3131
      flesch: 53
     summary: Published by the National Society for Cutaneous Medicine. 1 IN-DEPTH REVIEW A Review of the Evidence for Intrinsic Ethnic Differences as Important Determinants of Skin Aging and Carcinogenesis: A Hope For All Ethnicities Stephanie Chan, BS1, Jodie Sasaki, MD2, Abrar Qureshi, MD, MPH1, Grace Giordano3, John Koo, MD4, Nicholas Brownstone, MD5 1 Department of Dermatology, Brown Warren Alpert Medical School, Providence, Rhode Island 2 Department of Dermatology, University of Washington Valley Medical Center, Seattle, Washington 3 Barnard College, New York, NY 4 Department of Dermatology, University of California San Francisco, San Francisco, California 5 National Society for Cutaneous Medicine, New York, NY Aging is an important and current topic in dermatology. By the year 2030, over 20% of U.S. residents are projected to be 65 years or older, compared with 13% in 2010.[1] Skin aging encompasses an entire spectrum of changes starting with fine rhytids, discolorations, and benign keratosis, progressing to deeper rhytids, pre- cancerous lesions, and eventually skin cancers.
    keywords: age; aging; differences; dna; ethnic; pmid; repair; skin; women
       cache: skin-1373.pdf
  plain text: skin-1373.txt

        item: #275 of 1356
          id: skin-1374
      author: Lebwohl, Lily; Phelps, Robert
       title: Association Between Pseudoxanthoma Elasticum and Bleeding
        date: 2022-01-17
       words: 2411
      flesch: 21
     summary: Pseudoxanthoma elasticum: a rare cause of recurrent gastrointestinal bleeding in a child. There were many sites of bleeding identified in this literature review, including the brain 9, skin 35, nose35, uterus 35 and gums, 13 but gastrointestinal bleeding was particularly common 11,15,28,30, followed by cerebral hemorrhage 12,14.
    keywords: bleeding; elasticum; figure; gastrointestinal; hemorrhage; patients; pseudoxanthoma; pxe; skin
       cache: skin-1374.pdf
  plain text: skin-1374.txt

        item: #276 of 1356
          id: skin-1375
      author: Heibel, Haley Danielle; Burger, Robin; Cockerell, Clay
       title: Desmoplastic Malignant Melanoma Clinically Presenting as a “Cyst”
        date: 2022-03-04
       words: 644
      flesch: 49
     summary: DMM often eludes clinical diagnosis as it usually does not have characteristic features of melanoma. Unusual histological variants of cutaneous malignant melanoma with some clinical and possible prognostic correlations.
    keywords: cyst; melanoma
       cache: skin-1375.pdf
  plain text: skin-1375.txt

        item: #277 of 1356
          id: skin-1376
      author: Jacob, Joanne; Brown, Alexandria; Wiggins, Claire; Alkul, Suzanne; Chan, Audrey ; Kim, Soo Jung
       title: Effectivity of E-Learning as a Resident Education and Engagement Tool
        date: 2022-01-17
       words: 898
      flesch: 52
     summary: 79 SHORT COMMUNICATION Effectivity of E-Learning as a Resident Education and Engagement Tool Joanne S Jacob, BS1, Alexandria Brown, BSA1, Claire Wiggins, MD1,2, Suzanne Alkul, MD3, Audrey Chan, MD3,4, Soo Jung Kim, MD, PhD3 1Baylor College of Medicine 2University of Texas at Austin Dell Medical School 3Department of Dermatology, Baylor College of Medicine 4Department of Pediatric Dermatology, Texas Children's Hospital The survey returned a 100% response rate of group participants.
    keywords: learning; medicine; residents; whatsapp
       cache: skin-1376.pdf
  plain text: skin-1376.txt

        item: #278 of 1356
          id: skin-1378
      author: Ahatov, Renat; Good, Allison; Ross, Lindy
       title: An Unusual Timeline of Nivolumab-induced Vitiligo in a Patient with Melanoma
        date: 2022-01-17
       words: 1546
      flesch: 54
     summary: We present a 52-year-old male patient whose initial vitiligo presentation occurred a year after starting the therapy and has continued for months after concluding Nivolumab therapy. While the sample size in that study was nine patients, previous cases in the literature report vitiligo developing 9 months or less after the initiation of Nivolumab.3,5 In our patient, the vitiligo on his right cheek began about one year after starting Nivolumab and continued to progress after the completion of Nivolumab therapy.
    keywords: melanoma; nivolumab; patient; therapy; vitiligo
       cache: skin-1378.pdf
  plain text: skin-1378.txt

        item: #279 of 1356
          id: skin-1379
      author: Appiah, Margaret; Ball, Laurel; Ikediobi, Ogechi; Daniels, Brianne
       title: A New Skin-Colored Nodule in a Patient with Cushing’s Disease: Melanocytic Schwannoma
        date: 2022-01-17
       words: 857
      flesch: 55
     summary: In Carney’s identification of seventeen patients diagnosed with melanotic schwannomas, nine patients also had a diagnosis of Cushing’s 3. Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature.
    keywords: melanocytic; melanoma; schwannoma; skin
       cache: skin-1379.pdf
  plain text: skin-1379.txt

        item: #280 of 1356
          id: skin-138
      author: Mrowietz, Ulrich; Kedem, Tal Hetzroni; Kenyan, Rita; Eini, Meir; Tamarkin, Dov; Shirvan, Mitchell
       title: Topical Minocycline Foam (FMX-103) for the Treatment of Moderate-to-Severe Rosacea: Results of a Phase 2, Randomized, Double-Blind, Multicenter Clinical Study
        date: 2017-10-27
       words: 1538
      flesch: 51
     summary: Improvement in IGA score from baseline by visit FMX-103 1.5% (n=79) FMX-103 3% (n=75) Vehicle (n=78) FMX-103 1.5% (n=79) FMX-103 3% (n=75) Vehicle (n=78) Safety • Both FMX-103 1.5% and 3% doses appeared to be generally safe and well tolerated, with no reported treatment-related systemic AEs – Overall, 47% (109/232) of subjects reported ≥1 TEAE (Table 2) – The most common AEs (≥2% of subjects) included nasopharyngitis, urinary tract infection, cystitis, and bronchitis (Table 3) – 11 (4.7%) subjects reported treatment-related TEAEs; 9 had treatment- related dermal reactions (Tables 2, 4) – Serious TEAEs were reported in 4 subjects (3 in FMX-103 groups and 1 in vehicle group) (Tables 2, 4) – 4 subjects discontinued the study due to TEAEs; only 3 subjects discontinued due to dermal-related TEAEs (skin and subcutaneous tissue disorders) (Tables 2, 4) Table 2. This was a randomized, multicenter, double-blind study evaluating the safety and efficacy of 2 different doses of the topical minocycline foam, FMX-103 1.5% and 3%, in the treatment of papulopustular rosacea, as compared with vehicle Methods • Phase 2, randomized, multicenter (18 sites in Germany), double-blind, vehicle- controlled clinical trial • Evaluated the safety and efficacy of 2 doses of a topical once-daily minocycline foam (FMX-103 1.5% and 3%) compared with vehicle foam in the treatment of moderate-to-severe papulopustular rosacea (Figure 1) – Subjects were randomized 1:1:1 to receive treatment once daily (in the evening) for 12 weeks – Safety and efficacy evaluations were performed at week 2, 4, 8, and 12, with an additional safety follow-up visit at week 16 Figure 1.
    keywords: fmx-103; rosacea; subjects; vehicle
       cache: skin-138.pdf
  plain text: skin-138.txt

        item: #281 of 1356
          id: skin-1381
      author: Bagel, Jerry; Wang, Yipeng; Montgomery, III, Paul; Abaya, Christian; Andrade, Eric; Boyce, Courtney; Tomich, Tatiana; Lee, Byung-In; Pariser, David; Menter, Alan; Dickerson, Tobin
       title: A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics
        date: 2021-11-05
       words: 6233
      flesch: 51
     summary: The Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ 2 Mindera Health, San Diego, CA 3 Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA 4 Baylor University Medical Center, Dallas, TX ABSTRACT Objective: This study was designed to develop and prospectively validate a machine learning based algorithm that could predict patient response to the most common biologic drug classes used in the management of psoriasis patients. The advent of biologic therapy as one of these systemic agents has revolutionized the management and treatment of psoriasis patients and is a direct result of the increased molecular understanding of the disease.7 Presently, there are eleven approved biologic agents approved for use in the United States for the treatment of psoriasis, with more under development.
    keywords: baseline; biologic; classifier; data; drug; il-23i; medicine; pasi; patients; predictive; psoriasis; response; skin; study; tnfi; treatment
       cache: skin-1381.pdf
  plain text: skin-1381.txt

        item: #282 of 1356
          id: skin-1383
      author: Rosenthal, MD, Amanda; Reddy, MD, Shivani; Chung, Joanie; Kim, MD, Christina; Cooper, MD, Robert; Haque, PhD, Reina
       title: Disparities in overall survival in patients with melanoma by race/ethnicity, socioeconomic status, and healthcare systems: Disparities in overall survival in patients with melanoma
        date: 2022-01-17
       words: 1721
      flesch: 64
     summary: Male 2759 (58.7%) 5850 (59%) 8609 (58.9%) Socioeconomic status (SES) Lowest SES 361 (7.7%) 510 (5.1%) 871 (6%) Lower-Middle SES 662 (14.1%) 1077 (10.9%) 1739 (11.9%) Middle SES 1033 6.65 (5.21,8.49) Race/Ethnicit y Non-Hispanic White 626 46.9 (43.3,50.7) 1 (ref) 1558 54.6 (51.9,57.3) 1 (ref) 2184 52.1 (50,54.4) 1 (ref) Hispanic 64 38.2 (29.4,48.8) 0.72 (0.54,0.95) 114 63.3 (52.2,76.1) 0.79 (0.64,0.96) 178 51.2 (44,59.3) 0.76 (0.65,0.9) Non-Hispanic Black 25 62.1 (40.2,91.7) 0.87 (0.57,1.32) 19 66.3 (39.9,103.6) 1.00 (0.63,1.60) 44 63.9 (46.4,85.7) 0.92 (0.68,1.26) Asian/Pacific Islander 13 56.1 (29.9,95.9) 0.95 (0.54,1.66) 29 71.4 (47.8,102.5) 1.24 (0.85,1.80) 42 65.8 (47.4,89) 1.12 (0.82,1.53) American Indian 1 29.5 (0.7,164.3) 0.57 (0.08,4.08) 3 68.2 (14.1,199.4) 1.73 (0.43,6.94) 4 51.4 (14,131.5) 1.06 (0.34,3.29) Other/Unkno wn 4 3.5 (0.9,8.8) 0.09 (0.03,0.25) 4 3.0 (0.8,7.7) 0.083 (0.03,0.22) Socioecono mic status (SES) Lowest SES 69 57.7 (44.9,73.1) 1.47 (1.09,2.00) 137 96.4 (80.9,113.9) 1.80 (1.47,2.22) 206 78.7 (68.3,90.2) 1.70 (1.43,2.02) Lower-Middle SES 103 47.5 (38.8,57.6) 1.40 (1.08,1.80) 264 77 (68,86.9) 1.50 (1.28,1.76) 367 65.6 (59,72.6) 1.47 (1.29,1.68) Middle SES 164 46.5 (39.7,54.2) 1.28 (1.03,1.60) 348 64 (57.4,71.1) 1.39 (1.21,1.61) 512 57.1 (52.3,62.3) 1.36 (1.21,1.53) Upper-Middle SES 210 44.3 (38.5,50.7) 1.15 (0.94,1.41) 422 50.1 (45.4,55.1) 1.19 (1.04,1.35) 632 48.0 (44.3,51.9) 1.19 (1.07,1.33)
    keywords: kpsc; melanoma; mortality; patients; ses
       cache: skin-1383.pdf
  plain text: skin-1383.txt

        item: #283 of 1356
          id: skin-1384
      author: Desai, Seemal; Draelos, Zoe; Feldman, Steve; Jackson, J. Mark
       title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Trial Investigating the Efficacy and Safety of Clobetasol Propionate Cream, 0.025% in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days
        date: 2021-11-05
       words: 1464
      flesch: 60
     summary: Clobetasol Propionate 0.025% Cream (n=176) Vehicle Cream (n=89) 0% -10% -20% -40% -30% -25.1% -7.4% *P<.001 C h an g e in B SA fr om B as el in e, % * A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Trial Investigating the Efficacy and Safety of Clobetasol Propionate Cream, 0.025% in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days All other trademarks are property of their respective owners.
    keywords: clobetasol; day; group; propionate; vehicle
       cache: skin-1384.pdf
  plain text: skin-1384.txt

        item: #284 of 1356
          id: skin-1385
      author: Kircik, Leon ; Stein Gold, Linda; Del Rosso, James; Desai, Seemal; Glick, Brad; Sofen, Howard; Tallman, Anna; Rubenstein, David; Brown, Philip 
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials
        date: 2021-11-05
       words: 1831
      flesch: 27
     summary: Endpoints and Statistical Analysis ■ The primary endpoint was PGA response at Week 12, defined as the proportion of patients with a PGA score of clear (0) or almost clear (1) and ≥2-grade improvement in PGA score from baseline to Week 12 ■ The incidence, frequency, and nature of adverse events (AEs) and serious AEs were monitored from the start of study treatment until the end-of-study visit ■ The pooled analyses used multiple imputation for the intention-to-treat (ITT) populations in PSOARING 1 and 2 ■ Tapinarof cream 1% QD and vehicle groups were compared within each subgroup for the primary endpoint using 95% confidence intervals for the relative risk calculated using Cochran-Mantel-Haenszel analyses stratified by baseline PGA score RESULTS Patient Disposition and Baseline Characteristics ■ The pooled analysis population included 1025 patients randomized to tapinarof cream 1% QD (n=683) or vehicle QD (n=342) in PSOARING 1 and 2 (ITT population) ■ Baseline disease characteristics and demographics in the pooled population were comparable across treatment groups (Table 1) ■ Overall, at baseline, 82% had a PGA score of 3 (moderate), 57% had psoriasis for >10 years, and 26% had ≥10% body surface area (BSA) affected Table 1. Although conclusions cannot be drawn due to the small number of patients in some subgroups, the frequency and type of AEs appeared to be generally comparable across subgroups and consistent with those observed in the overall population CONCLUSIONS ■ Tapinarof cream 1% QD was consistently efficacious and well tolerated irrespective of baseline PGA score, BSA affected, duration of psoriasis, sex, age, race, or country of enrollment (US or Canada) ■ Due to the small number of patients in some subgroups, limitations exist regarding the ability to draw definitive conclusions from the subgroup analysis ■ The consistent efficacy and tolerability in all subgroups support the potential use of tapinarof cream 1% QD across a broad spectrum of disease severity and patient demographics ■ A long-term extension trial (PSOARING 3) of intermittent treatment with tapinarof 1% QD based on PGA score demonstrated continued efficacy following the 12-week pivotal trials and an ~4-month remittive effect off therapy2 ■ Tapinarof cream 1% QD has potential to be the first topical psoriasis treatment with a novel mechanism of action in almost 20 years REFERENCES 1.
    keywords: baseline; inc; pga; tapinarof; vehicle
       cache: skin-1385.pdf
  plain text: skin-1385.txt

        item: #285 of 1356
          id: skin-1386
      author: Strober , Bruce; Stein Gold, Linda; Bissonnette, Robert; Armstrong , April; Blauvelt, Andrew ; Brown, Philip ; Kircik, Leon ; Tallman, Anna; Lebwohl, Mark
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
        date: 2021-11-05
       words: 2347
      flesch: 20
     summary: Anna M. Tallman,8 Mark Lebwohl7 1Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, 2Henry Ford Health System, Detroit, MI, USA, 3Innovaderm Research Inc., Montreal, QC, Canada, 4Keck School of Medicine at University of Southern California, Los Angeles, CA, USA, 5Oregon Medical Research Center, Portland, OR, USA, 6Skin Sciences PLLC, Louisville, KY, USA, 7Icahn School of Medicine at Mount Sinai, New York, NY, USA, 8Dermavant Sciences, Inc., Morrisville, NC, USA SYNOPSIS ■ In two 12-week pivotal phase 3 trials, PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), tapinarof cream 1% once daily (QD) demonstrated highly statistically and clinically significant efficacy versus vehicle and was well tolerated in adults with mild to severe plaque psoriasis1 ■ Tapinarof cream 1% QD also demonstrated maintenance of efficacy for 4 weeks after treatment discontinuation in a 12-week phase 2b trial, warranting further investigation of a potential remittive effect2 OBJECTIVE ■ To present the results of PSOARING 3 (NCT04053387), a long-term extension trial designed to assess the safety, efficacy, durability of response, tolerability, and duration of remittive effect of tapinarof during repeated intermittent treatment, based on patient Physician Global Assessment (PGA) score METHODS Study Design ■ Patients completing PSOARING 1 and PSOARING 2 were eligible to enroll in PSOARING 3 for 40 weeks of open-label treatment with tapinarof cream 1% QD, followed by four weeks of follow-up (Figure 1) B.S. has served as an honorary consultant/speaker/scientific director/investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Cara, Celgene, Corrona Psoriasis Registry, Dermavant Sciences Inc., Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, Sanofi-Genzyme.
    keywords: disease; inc; patients; pga; score; tapinarof
       cache: skin-1386.pdf
  plain text: skin-1386.txt

        item: #286 of 1356
          id: skin-1387
      author: Merola, Joe; Sofen, Howard; Thaci, Diamant; Paul, Carle; Imafuku, Shinichi; Banerjee,  Subhashis; Armstrong , April
       title: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials
        date: 2021-11-05
       words: 2576
      flesch: 54
     summary: Patients, n Placebo Deucravacitinib Apremilast 15.7 (8.1−23.2) 254 475 241 19.0 (10.2−27.7) 167 368 181 16.2 (9.7−22.7) 345 665 335 20.0 (7.6−32.4) 75 178 87 16.6 (8.4−24.8) 226 421 200 17.7 (9.7−25.7) 195 422 222 19.9 (9.1−30.7) 119 261 112 16.1 (9.3−22.9) 301 582 310 16.1 (4.8−27.4) 102 208 112 19.8 (12.0−27.7) 205 438 215 13.2 (1.0−25.3) 113 197 95 Deucravacitinib vs placebo Deucravacitinib vs apremilast Missing data were imputed with nonresponder imputation. 42.9 (28.3−57.5) Patients, n Placebo Deucravacitinib Apremilast 25 55 25 88 142 70 205 438 215 102 208 112 167 327 167 64 125 62 139 293 146 Difference (95% CI) −2.6 (−26.9 to 21.8) 20.2 (6.1−34.2) 19.8 (12.0−27.7) 16.1 (4.8−27.4) 11.6 (2.4−20.8) 18.1 (3.1−33.1) 22.9 (13.3−32.5) 19.1 (1.2−37.0) 48 94 42 Deucravacitinib vs placebo Deucravacitinib vs apremilast -35 -25
    keywords: baseline; deucravacitinib; disease; pasi; placebo
       cache: skin-1387.pdf
  plain text: skin-1387.txt

        item: #287 of 1356
          id: skin-1388
      author: Thaci, Diamant; Gordon , Kenneth ; Gooderham, Melinda; Strober , Bruce; Korman, Neil; Banerjee, Subhashis; Banerjee, Subhashis; Colston, Elizabeth; Kim, Jonghyeon; Throup, John; Morita, Akimichi
       title: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
        date: 2021-11-05
       words: 2819
      flesch: 45
     summary: Grade ≥3 laboratory abnormalities, Weeks 0−16 Placebo (n=419) n (%) Laboratory assessments over Weeks 0−52 • No clinically relevant cumulative trends were observed in any assessed laboratory parameters in PSO-1 patients who were randomized to deucravacitinib at baseline and who continued to receive treatment until Week 52 (Figure 4 and Figure 5) • Discontinuation rates due to laboratory abnormalities were not increased between Weeks 16−52 vs Weeks 0−16 Figure 4.
    keywords: deucravacitinib; laboratory; lln; uln; weeks
       cache: skin-1388.pdf
  plain text: skin-1388.txt

        item: #288 of 1356
          id: skin-1389
      author: Armstrong , April; Strober , Bruce; Gordon , Kenneth ; Zhuo, Joe; Becker, Brandon ; Kisa, Renata; Throup, John; Kim, Jonghyeon; Papp, Kim
       title: Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
        date: 2021-11-05
       words: 1928
      flesch: 45
     summary: Mean change from baseline in PSSD symptom domain scores and PSSD sign domain scores at Week 16 -5 -4 -3 -2 -1 0 M e an c h an ge f ro m b as e li n e POETYK PSO-1 PSSD symptom domain scores POETYK PSO-2 PSSD symptom domain scores Deucravacitinib 6 mg QDPlacebo Apremilast 30 mg BID -5 -4 -3 -2 -1 0 M e an c h an ge f ro m b as e li n e POETYK PSO-1 PSSD sign domain scores -5 -4 -3 -2 -1 0 POETYK PSO-2 PSSD sign domain scores -5 -4 -3 -2 -1 0 –0.6 –0.7 –0.6 –0.8 –0.5 –3.1*† –3.6*† –3.1*† –3.4*† –2.8*† –2.3 –2.7 –2.1 –2.7 –2.1 Burning Itch Pain Skin tightness Stinging –0.3 –0.5 –0.2 –0.5 –0.1 –2.9*† –3.6*† –2.9*† –3.5*† –2.7*† –2.1 –2.7 –2.3 –2.6 –1.8 Burning Itch Pain Skin tightness Stinging –0.6 –0.6 –0.7 –0.6 –0.6 –0.7 –2.2*† –3.4*† –3.9*† –3.5*† –3.9*† –4.0*† –1.6 –2.6 –2.9 –2.6 –3.0 –3.1 Bleeding Cracking Dryness Redness Scaling Shedding or flaking –0.6 –0.9 –0.8 –0.7 –0.9 –0.8 –2.3*† –3.5*† –3.8*† –3.6*† –3.6*† –3.8*† –1.8 –2.6 –2.9 –2.6 –2.7 –2.7 Bleeding Cracking Dryness Redness Scaling Shedding or flaking *P<0.0001 vs placebo.
    keywords: poetyk; psoriasis; pssd; scores; sign; symptom
       cache: skin-1389.pdf
  plain text: skin-1389.txt

        item: #289 of 1356
          id: skin-139
      author: Stein Gold, Linda; Dhawan, Sunil; Weiss, Jonathan; Draelos, Zoe D; Ellman, Herman
       title: The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies
        date: 2017-10-27
       words: 1724
      flesch: 50
     summary: Patient Satisfaction Questionnaire Results (Pooled analysis, n=534) Safety • FMX101 4% was generally safe and well tolerated in both Study 04 and Study 05 • Across the 2 studies, the percentage of subjects reporting treatment-emergent adverse events (TEAEs) ranged between 16.9% and 33% for FMX101 4%, vs 18.2% to 26.5% for vehicle (Table 2) – 1 subject receiving FMX101 4% discontinued treatment in Study 05 (ectopic pregnancy; not related to treatment), as compared with 4 subjects for vehicle across the 2 studies – 7 subjects reported 9 serious TEAEs across the 2 studies; all were considered not related to treatment – Few treatment-related TEAEs were reported in both studies • The most common TEAEs in ≥2% of subjects were nasopharyngitis and headache (Table 3) – Dermal TEAEs were reported in <1% of all subjects in the FMX101 4% treatment groups; their severity was mostly mild • The majority (>95%)a of FMX101 4% subjects reported none or mild signs and symptoms for tolerability assessment parameters at week 12 (Table 4) ªBased on observed cases. Conclusions • The results of the 2 Phase 3 studies showed that FMX101 4% was effective for the treatment of moderate-to-severe acne – There was significantly greater reduction of both inflammatory and noninflammatory lesions at week 12 from baseline with FMX101 4% vs vehicle in both Study 04 and Study 05, as well as in the pooled analysis (a co-primary end point) � A significant reduction in inflammatory lesions was observed as early as week 3 for FMX101 4% – The rate of IGA treatment success was significantly greater for FMX101 4% vs vehicle in Study 05, but not Study 04 (a co-primary end point) � Pooled analysis of IGA treatment success was statistically significant for FMX101 4% • >95% of subjects had none or mild signs and symptoms at the week 12 assessment of dermal tolerability • FMX101 4% appeared to be safe and well tolerated, with dermal AEs occurring in <1% of FMX101 4% subjects and no serious drug-related AEs reported • There was high satisfaction with FMX101 4% • The FMX101 4% open-label phase is currently ongoing to determine long-term safety The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of 2 Phase 3 Studies Linda Stein Gold, MD1; Sunil Dhawan, MD2; Jonathan Weiss, MD3; Zoe Diana Draelos, MD4; Herman Ellman, MD5 1Henry Ford Health System, Detroit, Michigan, USA; 2Center for Dermatology Clinical Research, Inc., Fremont, California, USA; 3Gwinnett Dermatology, Braselton, Georgia, USA; 4Dermatology Consulting Services, High Point, North Carolina, USA; 5Foamix Pharmaceuticals, Inc, Bridgewater, New Jersey, USA.
    keywords: fmx101; study; subjects; vehicle
       cache: skin-139.pdf
  plain text: skin-139.txt

        item: #290 of 1356
          id: skin-1390
      author: Korman, Neil; Papp, Kim; Bagel, Jerry ; Foley, Peter; Morita, Akimichi; Banerjee, Subhashis; Colston, Elizabeth; Wang, Tao; Throup, John; Thaci, Diamant
       title: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
        date: 2021-11-05
       words: 3734
      flesch: 61
     summary: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials Neil J Korman,1 Kim Papp,2 Jerry Bagel,3 Peter Foley,4 Akimichi Morita,5 POETYK PSO-2 (N=1020) Deucravacitinib 6 mg
    keywords: baseline; deucravacitinib; pasi; pharma; placebo; poetyk
       cache: skin-1390.pdf
  plain text: skin-1390.txt

        item: #291 of 1356
          id: skin-1391
      author: Nestor, Mark; Fischer, Daniel; Arnold, David; Han, Haowei; Gade, Anita; Ceci, Francesca; Dunn, Austin; Lawson, Alec
       title: A randomized, investigator-blinded study to compare the efficacy and tolerance of a 650-microsecond, 1064-nm YAG laser to a 308-nm excimer laser for the treatment of mild-to-moderate psoriasis vulgaris
        date: 2021-11-05
       words: 1246
      flesch: 63
     summary: Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd: YAG 1064-nm laser. Laser treatment of skin of color for medical and aesthetic uses with a new 650-microsecond nd:yag 1064nm laser.
    keywords: laser; microsecond; treatment
       cache: skin-1391.pdf
  plain text: skin-1391.txt

        item: #292 of 1356
          id: skin-1392
      author: Gooderham, Melinda; Alonso-Llamazares, Javier ; Bagel, Jerry ; Browning, John; Draelos, Zoe; Grande, Kimberly ; Herbert, Adelaide; Jing Loo, Wei; Hong, Chih-ho; Lebwohl, Mark; Nahm, Walter; Papp, Kim; Pariser, David; Soung, Jennifer; Stein Gold, Linda; Turchin, Irina; Feng, Amy ; Burnett, Patrick; Higham, Robert; Berk, David
       title: Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies
        date: 2021-11-05
       words: 3548
      flesch: 57
     summary: Roflumilast cream improved patient quality of life as indicated by changes in DLQI (Figure 7) CONCLUSIONS • Once-daily treatment with roflumilast cream 0.3% provided significant, consistent, and sustained improvements in the severity and burden of itch and quality of life in patients with chronic plaque psoriasis – Onset of action of patient-reported improvements were observed as early as the first timepoint measured (2 weeks) and improvement continued through Week 8 – Results were reproducible across both phase 3 studies • Roflumilast cream was associated with low rates of application-site AEs, treatment-related AEs, and discontinuations due to AEs • DERMIS-1 and DERMIS-2 support the potential use of investigational roflumilast cream as an effective and well-tolerated nonsteroidal topical therapy in patients with chronic plaque psoriasis Melinda J. Gooderham,1 Javier Alonso-Llamazares,2 Jerry Bagel,3 John C. Browning,4 The primary endpoint was analyzed using a Cochran-Mantel-Haenszel test stratified by site, baseline IGA, and baseline intertriginous involvement – Statistical significance was concluded at the 5% significance level (2-sided) – Missing IGA scores were imputed using multiple imputation • To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used – Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints RESULTS • 439 patients were enrolled in DERMIS-1 and 442 patients were enrolled in DERMIS-2 • Most patients (86.2% to 91.0%) completed the studies (Table 1) – Few patients discontinued due to adverse events (AEs) • Baseline disease characteristics were balanced across treatment groups and similar between the 2 studies (Table 2) Safety • Safety and tolerability of roflumilast cream were similar to vehicle (Table 3) • Roflumilast cream demonstrated low rates of application-site AEs, treatment-related AEs, and discontinuations due to AEs (Table 3) – Rates were comparable with vehicle • There were no treatment-related serious AEs • Application-site reactions were low • Over 96% of patients in each group had no evidence of irritation at Week 4 or 8 as assessed by the investigators Table 2.
    keywords: baseline; iga; itch; nrs; roflumilast; vehicle; week
       cache: skin-1392.pdf
  plain text: skin-1392.txt

        item: #293 of 1356
          id: skin-1393
      author: Lebwohl, Mark; Kircik, Leon ; Moore, Angela; Stein Gold, Linda; Del Rosso, James; Draelos, Zoe; Gooderham, Melinda; Green, Lawrence; Herbert, Adelaide; Papp, Kim; Bagel, Jerry ; Bhatia, Neal; Ferris, Laura; Jones, Terry ; Kempers, Steve; Pariser, David; Yamauchi, Paul; Zirwas, Matthew; Feng, Amy ; Burnett, Patrick; Higham, Robert; Berk, David
       title: Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials
        date: 2021-11-05
       words: 3542
      flesch: 55
     summary: The primary endpoint was analyzed using a Cochran-Mantel-Haenszel test stratified by site, baseline Investigator Global Assessment (IGA), and baseline intertriginous involvement – Statistical significance was concluded at the 5% significance level (2-sided) – Missing IGA scores were imputed using multiple imputation • To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used – Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints RESULTS • 439 patients were enrolled in DERMIS-1 and 442 patients were enrolled in DERMIS-2 • Most patients (86.2% to 91.0%) completed the studies (Table 1) • Baseline disease characteristics were balanced across treatment groups and similar between the 2 studies (Table 2) These were 2 identical phase 3, randomized, double-blind, vehicle-controlled studies of once-daily roflumilast cream 0.3% in patients with psoriasis (Figure 1) Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials CONCLUSIONS Once-daily roflumilast cream 0.3% demonstrated: • Clinically meaningful efficacy in psoriasis based on IGA Success at the primary endpoint of 8 weeks – Results were reproducible across both phase 3 studies • Significant improvements in difficult-to-treat areas – Significant increases in percentages of patients achieving I-IGA Success and I-IGA status of clear • Superior improvement across multiple other efficacy endpoints versus vehicle cream – Onset of efficacy occurred as early as 2 weeks •
    keywords: baseline; cream; iga; patients; psoriasis; roflumilast; usa; vehicle; week
       cache: skin-1393.pdf
  plain text: skin-1393.txt

        item: #294 of 1356
          id: skin-1394
      author: Moore, Angela; Alonso-Llamazares, Javier ; Bhatia, Neal; Devani, Alim; Bukhalo, Michael; Draelos, Zoe; Gooderham, Melinda; Kempers, Steve; Kircik, Leon ; Papp, Kim; Pariser, David; Sankeva, Marina; Sinclair, Rodney ; Zirwas, Matthew; Feng, Amy ; Burnett, Patrick; Higham, Robert; Berk, David
       title: Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study
        date: 2021-11-05
       words: 3094
      flesch: 54
     summary: -100% -80% -60% -40% -20% 0% Baseline Week 2 Week 4 Week 8 M ea n % C fB (9 5% C I) • Very few AEs led to study discontinuation – Discontinuation rates were similar between groups • ≥99% of roflumilast- and ≥98% of vehicle-treated patients had no evidence of irritation on the investigator rating of local tolerability Table 3.
    keywords: foam; iga; nrs; psoriasis; roflumilast; scalp; vehicle; week
       cache: skin-1394.pdf
  plain text: skin-1394.txt

        item: #295 of 1356
          id: skin-1395
      author: Stein Gold, Linda; Gooderham, Melinda; Papp, Kim; Ferris, Laura; Lebwohl, Mark; Adam, David; Alonso-Llamazares, Javier ; Hong, Chih-ho; Kempers, Steve; Kircik, Leon ; Jing Loo, Wei; Stewart, Daniel; Nahm, Walter; Zirwas, Matthew; Burnett, Patrick; Higham, Robert; Navale, Lynn; Berk, David
       title: Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study
        date: 2021-11-05
       words: 2222
      flesch: 52
     summary: ≥97% of patients had no evidence of irritation per physician assessment at each visit CONCLUSIONS • Patients with chronic plaque psoriasis need topical treatments that provide effective control of psoriasis with low incidence of side effects that can be used for long-term treatment • INTRODUCTION • Topical treatment options for chronic plaque psoriasis lack products that are safe with long-term usage, are well tolerated, and are used as single agents over the entire body • Roflumilast cream, a phosphodiesterase-4 (PDE-4) inhibitor that is more potent than other PDE-4 inhibitors,1 is under investigation as a once-daily, nonsteroidal, topical treatment for psoriasis • In a phase 2b randomized, double-blind, 12-week trial of 331 adults with chronic plaque psoriasis, roflumilast cream once daily was found to be superior to vehicle cream and was well tolerated2 •
    keywords: cohort; cream; iga; patients; roflumilast; study; usa; week
       cache: skin-1395.pdf
  plain text: skin-1395.txt

        item: #296 of 1356
          id: skin-1396
      author: Dickerson, Tobin; Boyd, Stephen; Andrade, Eric; Abaya, Christian; Wang, Yipeng; Lee, Byung-In
       title: A Dermal Biomarker Patch Displays Excellent Analytical Performance and Outperforms Tape Stripping in Psoriatic Skin
        date: 2021-11-05
       words: 652
      flesch: 59
     summary: Influence of time between collection and processing on quality of DBP RNA-Seq data. Statistical analysis of the data set demonstrated no statistically significant di!erence observed between body sites (ANOVA, p=0.342), in contrast to previously published data using stratum corneum tape stripping.
    keywords: mrna; samples; skin
       cache: skin-1396.pdf
  plain text: skin-1396.txt

        item: #297 of 1356
          id: skin-1398
      author: Herbert, Adelaide; Schreiber, Rhonda; Glaab, Debbie; Eichenfeld, Lawrence
       title: Phase IV Evaluation of the Adrenal Suppression Potential and PKPD of Halobetasol Propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis
        date: 2021-11-05
       words: 1350
      flesch: 57
     summary: Relationship to Treatment Seriousness Abnormal ACTH stimulation test 1 (4.2) Related mild Abnormal ACTH stimulation test 5 (20.8) Possibly Related mild Gastritis 1 (4.2) Not related moderate Hematuria 1 (4.2) Not related mild Table 3: Treatment Emergent Adverse Events (TEAEs) Figure 1: % Patients with IGA Reduction at Each Study Visit Laboratory evidence of HPA axis suppression, as evidenced by post-CST serum total cortisol level of ≤ 18μg/dL, was noted in 6 of 23 patients at Day 15 and resolved by the post-EOS study visit, ~4 weeks later. % BSA Mean (Range) Hispanic or Latino 6 (25) Affected 15.1 (11-23) Not Hispanic or Latino 18 (75) To be treated 14.5 (10-20) RACE n(%)
    keywords: day; hbp; patients; psoriasis
       cache: skin-1398.pdf
  plain text: skin-1398.txt

        item: #298 of 1356
          id: skin-1399
      author: Alexis, Andrew ; Del Rosso, James; Bhutani, Tina; Papp, Kim; Jacobson, Abby 
       title: Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis
        date: 2021-11-05
       words: 1569
      flesch: 54
     summary: Week 8 Week 12 Week 24 Week 52Screening Once-daily HP/TAZ for 8 weeks Evaluated for treatment success at week 8a Success Treatment stopped for 4 weeks No success Continued once-daily HP/TAZ for 4 weeks Evaluated for improvement at week 12b
    keywords: participants; taz; week
       cache: skin-1399.pdf
  plain text: skin-1399.txt

        item: #299 of 1356
          id: skin-14
      author: Bonomo, Lauren; Ramos-Rodriguez, Alvaro; Guttman-Yassky, Emma
       title: Systemic Manifestations of Atopic Dermatitis: A Systematic Review
        date: 2017-06-28
       words: 3249
      flesch: 53
     summary: This progression is termed the “atopic march” and is considered the classical presentation of atopic disease. If the mechanisms underlying atopic disease do indeed play a role in the development of non-atopic comorbidities, it would support the notion put forth by Brunner et al.
    keywords: allergy; atopic; dermatitis; disease; immunology; journal; patients; risk; studies; study
       cache: skin-14.pdf
  plain text: skin-14.txt

        item: #300 of 1356
          id: skin-140
      author: Bank, David; Jones, Derek H; Wong, Cindy; Mashburn, J H
       title: A Comprehensive Analysis of the Safety of a New Range of Injectable Hyaluronic Acid Products for Aesthetic Indications
        date: 2017-10-27
       words: 911
      flesch: 38
     summary: The safety dataset was compiled from post-market surveillance (PMS) reports of adverse events (AEs) received since the products were launched in 2011, including any cases reported in the literature • Among these events, 85% resolved within 28 days and 95% within 60 days - Information on the event outcome showed that 64% were resolved or resolving, but no information was available for 25% of these events • Reporting frequencies of nodules, inflammatory reactions and granulomas for OBT HA (Table 2) • Safety data from 7 sponsored interventional clinical studies and 1 observational study were reviewed - Studies; 638 subjects followed for 24 weeks to 18 months · No related serious adverse events adverse events reported ·
    keywords: emervel; events; reports; safety
       cache: skin-140.pdf
  plain text: skin-140.txt

        item: #301 of 1356
          id: skin-1400
      author: Kircik, Leon ; Green, Lawrence; Zeichner, Joshua; Alonso-Llamazares, Javier ; Jacobson, Abby 
       title: Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis
        date: 2021-11-05
       words: 1417
      flesch: 54
     summary: In this post hoc analysis of a 52-week open-label study (NCT02462083),1 we assessed the efficacy and safety of once-daily halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) in 550 participants with psoriasis stratified by baseline signs and symptoms of disease CONCLUSIONS • Long-term use of HP/TAZ was generally associated with treatment success regardless of baseline symptom severity, and no new safety signals emerged over 52 weeks • Participants with mild baseline symptoms were less likely to experience local skin reactions postbaseline compared with participants with more severe baseline symptoms • Evaluation of patients’ baseline itch, dryness, and stinging/burning may help predict outcomes of HP/TAZ treatment • Clinicians can use this information to counsel patients regarding treatment expectations when initiating HP/TAZ SYNOPSIS • Topical psoriasis treatments may be used as monotherapy for mild disease or as adjunct therapy for more severe disease2 • Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for treatment of plaque psoriasis in adults3 • Given that patients’ experiences with psoriasis differ greatly, further consideration and assessment of the utility of HP/TAZ in patients with varying symptom severity is warranted METHODS • At week 8, participants who achieved the primary endpoint of treatment success (defined as investigator’s global assessment [IGA] of clear [0] or almost clear [1]) stopped HP/TAZ and were reevaluated every 4 weeks and retreated as needed through 52 weeks.
    keywords: baseline; itch; participants
       cache: skin-1400.pdf
  plain text: skin-1400.txt

        item: #302 of 1356
          id: skin-1401
      author: Armstrong , April; Keegan, Brian; Han, George ; Jacobson, Abby
       title: Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption
        date: 2021-11-05
       words: 1153
      flesch: 49
     summary: [0.8]) improved at week 52 (prior biologic failure, 1.9 [1.1]; prior biologic nonfailure, 1.8 [0.4]), similar to DLQI scores achieved during the induction phase at week 12 (Figure 2A) – Change in DLQI from baseline to week 52 for the prior biologic failure and nonfailure subgroups were -11.5 (95% CI, -15.6 to -7.4) and -11.0 (95% CI, -12.8 to -9.2), respectively (Figure 2B) – No significant differences in DLQI were observed by prior biologic response through week 52 (P>0.05 between subgroups) These results are relevant to real-life practice given that it is relatively common for patients to stop and restart their medications because of various factors Funding: This study was sponsored by Ortho Dermatologics.
    keywords: biologic; brodalumab; pasi; week
       cache: skin-1401.pdf
  plain text: skin-1401.txt

        item: #303 of 1356
          id: skin-1402
      author: Menter, Alan; Boh, Erin ; Lewitt, George; Jacobson, Abby 
       title: Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies
        date: 2021-11-05
       words: 1107
      flesch: 30
     summary: SYNOPSIS • Brodalumab is a fully human interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe plaque psoriasis in adult patients with inadequate response or loss of response to other systemic therapies1 METHODS • In AMAGINE-2/-3 (NCT01708603 and NCT01708629), after a 12-week induction phase, patients received maintenance treatment as follows: brodalumab-treated patients were rerandomized to brodalumab 210 mg every 2 weeks (Q2W); ustekinumab-treated patients continued to receive ustekinumab; and patients receiving placebo switched to brodalumab 210 mg Q2W2 • At week 16, patients with inadequate response to ustekinumab (single static physician’s global assessment [sPGA] of ≥3 or persistent sPGA of 2 over ≥4 weeks) were eligible for rescue with brodalumab 210 mg Q2W. After week 16, patients on ustekinumab with an inadequate response remained on ustekinumab • Efficacy was assessed by psoriasis area and severity index 75%, 90%, and 100% response rates (PASI 75, 90, and 100) for patients who were rescued with 36 weeks of brodalumab 210 mg Q2W after an inadequate response to ustekinumab at week 16 (N=124) and for patients who continued on ustekinumab after an inadequate response to ustekinumab after week 16 (N=149), stratified by tumor necrosis factor α (TNFα) inhibitor treatment before entering the study (no prior TNFα inhibitor experience, prior TNFα inhibitor nonfailure, or prior TNFα inhibitor failure) RESULTS • Erin Boh,2 George Michael Lewitt,3 Abby Jacobson4 1Baylor University Medical Center, Dallas, TX; 2Tulane University School of Medicine, New Orleans, LA; 3Illinois Dermatology Institute, Chicago, IL; 4Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ OBJECTIVE • To evaluate the efficacy of brodalumab vs ustekinumab (an anti–interleukin-12/-23 monoclonal antibody) in individuals who were rescued with brodalumab or continued ustekinumab, stratified by prior treatment with tumor necrosis factor α (TNFα) inhibitors, in a post hoc analysis of two phase 3 studies (AMAGINE-2/-3) CONCLUSIONS • Patients with psoriasis who were rescued with 36 weeks of retreatment with brodalumab demonstrated higher response rates than those who continued ustekinumab, regardless of prior TNFα inhibitor treatment • Brodalumab may be a safe and effective treatment after inadequate response to previous biologics Funding: This study was sponsored by Ortho Dermatologics.
    keywords: patients; prior; ustekinumab; week
       cache: skin-1402.pdf
  plain text: skin-1402.txt

        item: #304 of 1356
          id: skin-1403
      author: Strober , Bruce; Asahina, Akihiko; Mrowietz, Ulrich; Lebwohl, Mark; Foley, Peter; Langley, Richard; Barker, Jonathan; Cioffi, Christopher; Cross, Nancy; Wang, Maggie ; Paul, Carle
       title: Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
        date: 2021-11-05
       words: 2751
      flesch: 53
     summary: All BKZ-randomized patients continued Q4W treatment at Week 16;2 BE SURE: Patients allocated to BKZ treatment were randomized 1:1 at baseline to either continue Q4W or switch to Q8W at Week 16;4 BE READY: BKZ-randomized Week 16 PASI 90 responders were re-randomized 1:1:1 to BKZ Q4W, Q8W, or placebo (PASI 90 non-responders entered an escape arm);3 bBE SURE and BE READY had a Week 56 visit that was not included in the BE BRIGHT pooled analysis. Author Disclosures: BS: Consultant (honoraria) from AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Equillium, GSK, Janssen, LEO Pharma, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Ortho Dermatologics; Scientific Director (consulting fee) for CorEvitas Psoriasis Registry; investigator for AbbVie, Cara Therapeutics, CorEvitas Psoriasis Registry, Dermavant, Dermira and Novartis; Editor-in-Chief (honorarium) for Journal of Psoriasis and Psoriatic Arthritis.
    keywords: bkz; mg q4w; pharma; q4w; q8w; week
       cache: skin-1403.pdf
  plain text: skin-1403.txt

        item: #305 of 1356
          id: skin-1404
      author: Blauvelt, Andrew ; Iversen, Lars; McBride, Sandy ; Gooderham, Melinda; Staubach, Petra; Yamauchi, Paul; Staelens, Fabienne; Vanoorden, Veerle; White, Katy ; Gisondi, Paolo
       title: Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
        date: 2021-11-05
       words: 1799
      flesch: 49
     summary: Author Disclosures: AB: Served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome. LI: Served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Regranion, Samsung, UCB Pharma, and Union Therapeutics.
    keywords: baseline; bkz; pasi; patients; pharma; sec
       cache: skin-1404.pdf
  plain text: skin-1404.txt

        item: #306 of 1356
          id: skin-1405
      author: Leonardi, C; Fahrbach, K; Neupane, B; Armstrong , A; Gordon, K; Kiri, S; Taieb, V; McClung, L
       title: Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis
        date: 2021-11-05
       words: 2191
      flesch: 49
     summary: We conducted a systematic literature review (SLR) in July 2020 to identify randomized controlled trials (RCTs) assessing the efficacy and safety of biologic and non-biologic therapies in the management of moderate to severe PSO.7 ⚫ Studies were included if they assessed the response to biologic therapies (at dosages approved by the Food and Drug Administration as well as some doses approved by the European Medicines Agency) and non-biologic therapies via the percentage improvement in PASI scores from baseline at 10 to 16 weeks (Table 1). The NNTs of biologic treatments compared to placebo to achieve one additional PASI 90 or PASI 100 response were calculated as the reciprocal of the corresponding absolute risk differences obtained from the NMA.
    keywords: bimekizumab; pasi; placebo; psoriasis
       cache: skin-1405.pdf
  plain text: skin-1405.txt

        item: #307 of 1356
          id: skin-1406
      author: Blauvelt, Andrew ; Han, George; Tyring, Steve; Soung, Jennifer; Oh, Tae; Davis, Leah; Vanoorden, Veerle; Lebwohl, Mark
       title: Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials
        date: 2021-11-05
       words: 1121
      flesch: 45
     summary: Honoraria and/or consulting fees from Amgen, Celgene, Dermavant, National Psoriasis Foundation, Ortho Dermatologics and Regeneron; grants and consulting fees from Abbvie, Actelion, Boeringher Ingelheim, Dermira, Eli Lilly, Janssen, Leo Pharma, Novartis Pharma and UCB; research grants from Cassiopeia, Galderma, and Pfizer; TO, LD: Employees of UCB Pharma; VV: Employee and shareholder of UCB Pharma; ML: Employee of Mount Sinai and receives research funds from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB Pharma; consultant for Aditum Bio, AnaptysBio, Almirall, Arcutis, Aristea, Arrive technology, Avotres Therapeutics, BioMx, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr.Reddy, Evelo, Evommune, Facilitate International Dermatologic Education, Forte, Foundation for Research and Education in Dermatology, Helsinn, LEO Pharma, Meiji, Mindera, Pfizer, Seanergy, and Verrica. Author Disclosures: AB: Scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; GH: Consultant, speaker, or research support for AbbVie, Amgen, Athenex, Boehringer Ingelheim, Bond Avillion, Bristol Myers Squibb, Castle Biosciences, Celgene, Dermavant, Dermtech, Eli Lilly, Janssen, LEO Pharma, MedX, MC2, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma; SKT:
    keywords: bimekizumab; mean; pasi; pharma
       cache: skin-1406.pdf
  plain text: skin-1406.txt

        item: #308 of 1356
          id: skin-1407
      author: Bieber, Thomas ; Beck, Lisa; Pink, Andrew; Saeki, Hidehisa; Eichenfeld, Lawrence; Werfel, Thomas; Rosholm, Anders; Ropke, Mads; Paller, Amy 
       title: Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis
        date: 2021-11-05
       words: 2115
      flesch: 43
     summary: S. cohnii (CoNS) Other species Placebo Tralokinumab Placebo Tralokinumab Baseline Week 16 Week 8 Baseline Week 16 Week 8 Baseline Week 16 Week 8 Baseline Week 16 Week 8 Figure 5. Relative abundance of the most dominant phyla and genera over time 0.0 0.2 0.4 0.6 0.8 1.0 A ve ra g e p ro p o rt io n o f m a jo r p h yl a a n d g e n u s Staphylococcus Streptococcus Lactobacillus Brochothrix Other Firmicutes Corynebacterium Micrococcus Dermacoccus Kocuria Other Actinobacteriota Moraxella Acinetobacter Paracoccus Haemophilus Photobacterium Brucella Other Proteobacteria Chryseobacterium Prevotella Porphyromonas Bacteroides Other Bacteroidota Other phyla Bacteriodota Proteobacteria Actinobacterota Firmicutes Placebo Tralokinumab Baseline Week 16 Week 8 Baseline Week 16 Week 8 Figure 1.
    keywords: baseline; tralokinumab; week
       cache: skin-1407.pdf
  plain text: skin-1407.txt

        item: #309 of 1356
          id: skin-1408
      author: Blauvelt, Andrew ; Wollenberg, Anderas; Pink, Andrew; Peris, Ketty ; Armstrong , April; Spelman, Lynda; Saeki, Hidehisa; Lynde, Charles; Herranz, Pedro; Barbarot, Sebastien; Simpson, Eric
       title: Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
        date: 2021-11-05
       words: 3309
      flesch: 34
     summary: Introduction Objectives Methods Results Patients, Demographics, and Clinical Characteristics ● 1596 adult patients were randomized to tralokinumab 300 mg q2w (1196) or placebo (400) in the initial treatment period ● Baseline demographics and clinical characteristics were well balanced between treatment groups (Table 1) - Mean duration of atopic dermatitis was 28.2 years and around one-half of patients (49.7%) had IGA 4 (severe disease) at baseline Maintenance of Week 16 Responses at Week 52 ● 412 patients achieved IGA 0/1 and/or EASI-75 at Week 16 with tralokinumab q2w and were re-randomized (2:2:1) to continue tralokinumab q2w, tralokinumab q4w, or placebo in the maintenance treatment period ● A large proportion of the patients who continued tralokinumab q2w or q4w maintained IGA 0/1 and/or EASI-75 response at Week 52 (42.4 to 57.3%), without using any rescue medication (including TCS) during the 36-week maintenance period - For patients with IGA 0/1 response at Week 16, this response was maintained by 55.9%, 42.4%, and 34.0% of patients re-randomized to tralokinumab q2w, q4w, and placebo, respectively (Figure 2A) - EASI-75 response was maintained by 57.3%, 50.4%, and 26.4%, respectively (Figure 2B) - IGA 0/1 or EASI-75 response was maintained by 56.2%, 50.0%, and 27.4% respectively, in patients who had previously achieved either or both responses (Figure 2C) Time to Relapse ● In patients who achieved IGA 0/1 with tralokinumab at Week 16 without rescue medication use, median time to relapse was not reached for patients re-randomized to tralokinumab q2w or q4w - Relapse was defined as transfer to open-label treatment, first rescue medication, or discontinuation of investigational medicinal product due to lack of efficacy, AE, or for other reasons, where lack of efficacy could not be excluded - The log-rank test P-values that resulted from the comparison of each of the tralokinumab treatment groups with placebo were P=0.004 for the tralokinumab q2w group and P=0.14 for the q4w group (Figure 3A)
    keywords: easi-75; iga; patients; q2w; q4w; tralokinumab; tralokinumab q2w; week
       cache: skin-1408.pdf
  plain text: skin-1408.txt

        item: #310 of 1356
          id: skin-1409
      author: Blauvelt, Andrew ; Pink, Andrew ; Worm, Margitta; Langley, Richard; Costanzo, Antonio; Gjerum, Le; Jorgensen, Emilie; Corriveau, Joshua; Guttman-Yassky, Emma
       title: COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial
        date: 2021-11-05
       words: 1694
      flesch: 42
     summary: Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Via Manzoni 56, 20089, Rozzano, Milano, Italy; 6LEO Pharma A/S, Ballerup, Denmark; 7LEO Pharma Inc., Madison, NJ, USA; 8Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Introduction Methods • As shown in Figure 1, ECZTEND is an ongoing, 5 year, open-label, single-arm, multicenter, long-term extension trial in patients with AD who participated in parent tralokinumab trials (ECZTRA 1-8 and TraSki)a o Approximately 1600 patients with moderate-to-severe AD across Canada, the United States, Europe, and Japan are participating in ECZTEND o Doi: 10.1016/j.jaad.2021.03.032 • Andrew Blauvelt is a scientific adviser and clinical study investigator for AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly, FLX Bio, Forte, Galderma, Janssen, LEO Pharma, Novartis, Ortho Derm, Pfizer, Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi Genzyme, Sun Pharma, UCB Pharma, and a paid speaker for AbbVie • Andrew Pink reports personal fees and nonfinancial support from LEO Pharma, Novartis, and UCB; and personal fees from AbbVie, Almirall, Janssen, La Roche Posay Lilly, and Sanofi • Margitta Worm declares that she has receipt honoraria or consultation fees by ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, LEO Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, Inc., DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co. KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG and Biotest AG • Richard Langley has served and has received compensation in the form of grant funding and/or honoraria as principal investigator for and is on the scientific advisory board or has served as a speaker for AbbVie , Amgen , Boehringer Ingelheim , Celgene , Janssen , LEO Pharma , Eli Lilly , Merck , Novartis , Pfizer , Sun Pharma , and UCB • Antonio Costanzo has served on advisory boards Celgene, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi-Genzyme and MSD • Le Gjerum, Emilie Jorgensen, and Joshua Corriveau are employees of LEO Pharma A/S • Emma Guttman-Yassky has received honoraria for consultant services from AbbVie, Almirall, Amgen, Asana Biosciences, Boerhinger Ingelhiem, Cara Therapeutics, Celgene, Concert, DBV, Dermira, DS Biopharma, Lilly, EMD Serono, Escalier, Galderma, Glenmark, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, Sienna Biopharma, and Union Therapeutics and received research grants for investigator services from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boerhinger Ingelhiem, Celgene, Concert, Dermavant, Dermira, DS Biopharma, Lilly, Glenmark, Galderma, Innovaderm, Janssen, Kiniska, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, Regeneron, Sienna Biopharma, UCB, and Union Therapeutics Acknowledgements •
    keywords: covid-19; ecztend; patients; pharma; tralokinumab; treatment; trial
       cache: skin-1409.pdf
  plain text: skin-1409.txt

        item: #311 of 1356
          id: skin-141
      author: Del Rosso, James; Stein Gold, Linda; Marchese Johnson, Sandra; Jose Rueda, Maria; Baldwin, Hilary; Lain, Edward L; Landis, Megan; Rendon, Marta; Tanghetti, Emil; Weiss, Jonathan
       title: Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin
        date: 2017-10-27
       words: 1738
      flesch: 58
     summary: At week 12 the total mean percent reduction in lesions was -62.6% compared with baseline (P < .0001) For subjects with severe AV (non-nodulocystic, non-conglobate) who are also candidates for OI - For subjects who must wait before starting oral isotretinoin - As an alternative option for those unwilling to use oral isotretinoin - For those unable to use oral isotretinoin due to contraindications SUBJECTS and METHODS • Open label, single arm, 12-week, multicenter study of A/BPO 0.3%/2.5% gel+DOX† 200 mg • Twenty-three sites enrolled males and females, 12 years of age or older, with a clinical diagnosis of severe inflammatory acne (Investigator's Global Assessment [IGA] score = 4) who had never received OI, and, in the opinion of the investigator, were candidates for OI - Subjects had ≤ 4 nodules/cysts > 1 cm in diameter on the face · Subjects were excluded if they had nodulocystic or conglobate acne, acne fulminans, or secondary acne (eg, chloracne, drug-induced acne) • Treatments: - Topical A/BPO 0.3%/2.5% gel, once daily for 12 weeks - DOX 200 mg (2x 50 mg tablets, Mayne, DORYX), twice daily (morning and evening) for 12 weeks - Cetaphil® Gentle Cleanser* (or equivalent), twice daily - Cetaphil® Daily Facial Moisturizer SPF 15* (or equivalent), at least once daily and re-apply as needed • Endpoints and Assessments: - Reduction and percent reduction in lesions at Weeks 4, 8, and 12 - IGA (IGA, 0 – 4 scale): Success (subjects rated IGA 0 or 1) at weeks 0, 4, 8, and 12 - Number and percent of subjects who, in the opinion of the investigator, are candidates for oral isotretinoin at Weeks 0, 4, 8, and 12 · Investigator evaluation of each subject’s candidacy to OI was performed independently at each visit, without consideration of previous visits - Photographs were taken of all subjects enrolled in the study at all study visits - Incidence of adverse events (AEs) and local tolerability (0
    keywords: baseline; iga; subjects; week
       cache: skin-141.pdf
  plain text: skin-141.txt

        item: #312 of 1356
          id: skin-1410
      author: Blauvelt, Andrew ; Lacour, Jean-Philippe; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Wollenberg, Andreas; Herranz, Pedro; Pink, Andrew; Peris, Ketty ; Fangel, Stine; Saeki, Hidehisa
       title: Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis
        date: 2021-11-05
       words: 3191
      flesch: 56
     summary: 282 (24.0) ECZTRA 5 (16-week monotherapy) 149 (12.7) Median (IQR) age, years 38 (27.0-50.0) Male, n (%) 675 (57.5) Region, % North America 46.2 Europe 46.5 Japan 7.3 Median (IQR) duration of AD at baseline, years 27 (18.0-40.0) Median (IQR) BSA at parent trial baseline, % 44.5 (30.0-67.0) Median (IQR) time from last dose in parent trial, days 36 (15.0-85.0) Baseline characteristics Viral upper respiratory tract infection (most commonly reported as common cold) 256 15.7 65.1 78 12.2 53.5 250 21.3 29.3 Atopic dermatitis 272 15.4 68.0 167 26.2 139.7 158 13.5 20.6 Upper respiratory tract infection 92 5.6 20.8 33 4.8 18.5 83 7.1 9.1 Safety areas of interest Conjunctivitis, including conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, and atopic conjunctivitis 126 7.5 29.0 21 3.2 12.3 65 5.9 6.9 Patients ● ECZTEND is an ongoing, up to 268-week, open-label, single-arm, multicenter, long-term extension trial in patients with atopic dermatitis who participated in parent tralokinumab trials (ECZTRA 1-8 and TraSki) (Figure 1) Key Inclusion Criteria — Completed treatment period(s) in a tralokinumab parent trial (ECZTRA 1-8 or TraSki) without any safety concerns — Complied with the clinical trial protocol in the parent trial — Able and willing to self-administer tralokinumab, or have it administered by a caregiver, at home after the initial 3 injection visits at trial site — Applied a stable dose of emollient (minimum twice daily) for at least 14 days before baseline ECZTEND Trial Design ● Patients received subcutaneous tralokinumab 300 mg every 2 weeks (q2w) plus optional topical corticosteroids (TCS) after a 300 mg or 600 mg loading dose of tralokinumab (Figure 2) ECZTEND Trial Design ● Study primary and secondary endpoints: — Number of adverse events from baseline up to Week 268 — Investigator’s Global Assessment (IGA) score of 0/1 from Week 16 to Week 248 — Eczema Area and Severity Index reduction of at least 75% (EASI-75)
    keywords: data; ecztend; ecztra; parent; patients; pharma; tralokinumab; week
       cache: skin-1410.pdf
  plain text: skin-1410.txt

        item: #313 of 1356
          id: skin-1411
      author: Gutermuth, Jan; Pink, Andrew ; Worm, Margitta; Soldbro, Lise; Mark, Thomas; Corriveau, Joshua; Bjeeregard Oland, Christian; Weidinger, Stephan
       title: Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial
        date: 2021-11-05
       words: 1690
      flesch: 48
     summary: PowerPoint Presentation Objective Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial Jan Gutermuth1, Andrew Pink2, Margitta Worm3, Lise Soldbro4, Thomas Mark4, Joshua Corriveau5, Christian Bjerregård Øland4, Stephan Weidinger6 • AD is a chronic inflammatory disease,1 characterized by eczematous skin lesions and multiple symptoms, including pruritus, sleep disturbance, and depression2-4 • Tralokinumab is a high-affinity, fully human, monoclonal antibody designed to specifically neutralize interleukin-13, a key driver of the underlying inflammation in AD5-7 • The Phase 3 ECZTRA 7 trial (NCT03761537) met its primary endpoint of EASI-75 at Week 16, confirming tralokinumab plus topical corticosteroids (TCS) is superior to placebo plus TCS in treating severe atopic dermatitis (AD) in patients not adequately controlled by, or with contraindications to, oral cyclosporine A • There can be inadequate disease control with currently available treatment options and many patients with severe AD continue to experience high disease burden To describe the efficacy and safety of tralokinumab in a subgroup of ECZTRA 7 patients with prior history of dupilumab treatment 1Department of Dermatology, Universitair Ziekenhuis Brussel and Vrije Universiteit Brussel, Brussels, Belgium; 2St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 3Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, Germany; 4LEO Pharma A/S, Ballerup, Denmark; 5LEO Pharma Inc., Madison, NJ, USA; 6Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany Introduction Methods • ECZTRA 7 was a randomized, double-blinded, multicenter, placebo-controlled Phase 3 trial (Figure 1) • Key inclusion criteria for ECZTRA 7: o Adult patients with AD for ≥1 year with inadequate response to topical or documented systemic medication in the past year o Disease not adequately controlled with, or patients with contraindications to, use of oral cyclosporine A o AD involvement of ≥10% body surface area o EASI ≥20 and IGA ≥3 at screening and at baseline o Worst daily pruritus numeric rating scale (NRS) average score of ≥4 during the week prior to baseline Table 1. One placebo patient reported 2 events of conjunctivitis, 1 mild and 1 of moderate severity; 1 tralokinumab patient reported 1 mild event of conjunctivitis Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial
    keywords: dupilumab; patients; placebo; tcs; tralokinumab
       cache: skin-1411.pdf
  plain text: skin-1411.txt

        item: #314 of 1356
          id: skin-1412
      author: Simpson, Eric; Wollenberg, Anderas; Soong, Weily; Mark, Thomas; Kuznetsova, Alexandra; Abildgaard Steffensen, Louise; Silverberg, Jonathan
       title: Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2
        date: 2021-11-05
       words: 1895
      flesch: 51
     summary: Mean EASI (SD) 32.3 (14.0), n=1590 32.2 (14.0), n=1192 32.7 (13.9), n=398 Mean total SCORAD (SD) 70.4 (13.0), n=1590 70.2 (13.2), n=1192 71.1 (12.4), n=398 Mean DLQI (SD) 17.3 (7.1), n=1572 17.2 (7.1), n=1178 17.5 (7.0), n=394 Mean weekly average worst daily pruritus NRS (SD) 7.8 (1.4), n=1577 7.8 (1.4), n=1182 7.8 (1.4), n=395 Mean weekly average eczema related sleep NRS (SD) 7.0 (2.0), n=1577 7.0 (2.0), n=1182 7.0 (2.0), n=395 • At Week 16, tralokinumab had a greater adjusted mean percentage improvement from baseline in weekly average of worst daily pruritus NRS (tralokinumab 35.5%, placebo 21.4%; p<0.001) and eczema-related sleep interference (tralokinumab 39.7%, placebo 18.4%; p<0.001) compared to placebo (Figure 2) Effect on itch and sleep over 16 weeks Figure 3. im e Tralokinumab Placebo *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** • A greater improvement from baseline was seen in worst daily pruritus NRS from Day 2 (p=0.001), and in eczema-related sleep interference from Day 1 (p<0.05) with tralokinumab compared to placebo (Figure 3)
    keywords: baseline; nrs; placebo; sleep; tralokinumab; weeks
       cache: skin-1412.pdf
  plain text: skin-1412.txt

        item: #315 of 1356
          id: skin-1413
      author: Eichenfeld, Lawrence; Silverberg, Jonathan; Bissonnette, Robert; Tallman, Anna; Rubenstein, David; Piscitelli, Stephen; Jett, John
       title: Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program 
        date: 2021-11-05
       words: 1893
      flesch: 40
     summary: [clear] or 1 [almost clear]) off therapy11,12 OBJECTIVE ■ To assess the efficacy and safety of tapinarof cream 1% QD in children and adults with moderate to severe AD in the two pivotal Phase 3 studies (ADORING 1 and 2) and a long- term extension Phase 3 trial (ADORING 3) METHODS Trial Design: ADORING 1 and 2 ■ ADORING 1 and ADORING 2 are two identically designed, Phase 3, multicenter (US and Canada), double-blind, vehicle-controlled randomized trials (Figure 2) ■ Following a 30-day screening period, patients aged ≥2 years old with an vIGA-AD score ≥3 (moderate to severe) and a percentage body surface area (%BSA) affected of ≥5–≤35% will be randomized 2:1 to tapinarof cream 1% QD or vehicle QD for 8 weeks Figure 2. Trial Design: ADORING 1 and ADORING 2 Trial Design: ADORING 3 ■ ADORING 3 is a long-term, open-label, multicenter extension trial to evaluate the long-term safety and efficacy of tapinarof 1% QD in patients with AD (Figure 3) ■ Eligible patients completing ADORING 1, ADORING 2, or the Maximal Use Pharmacokinetics trial can enroll in ADORING 3 ■ In addition, approximately 125 pediatric patients (aged 2 to <18 years) can enroll directly in ADORING 3 if they had a vIGA-AD score of ≥3 (moderate) and %BSA affected ≥40% at screening and baseline (pre-randomization), or patients with a vIGA-AD score of 2 (mild) at screening and baseline (pre- randomization) regardless of %BSA affected, and were thus not eligible for participation in the ADORING 1 and 2 pivotal trials Figure 3.
    keywords: patients; score; tapinarof; treatment; viga
       cache: skin-1413.pdf
  plain text: skin-1413.txt

        item: #316 of 1356
          id: skin-1414
      author: Papp, Kim; Szepietowski, Jacek; Kircik, Leon ; Toth, Darryl; Eichenfeld, Lawrence; Forman, Seth; Kuligowski, Michael; Venturanza, May; Sun, Kang; Simpson, Eric
       title: Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies
        date: 2021-11-05
       words: 2960
      flesch: 47
     summary: Objective ● To evaluate the long-term safety and disease control of ruxolitinib cream in patients with AD Methods Study Design and Patients ● Eligible patients were aged ≥12 years with AD for ≥2 years and had an Investigator’s Global Assessment (IGA) score of 2 or 3 and 3%–20% affected body surface area (BSA), excluding scalp ● Key exclusion criteria were unstable course of AD, other types of eczema, immunocompromised status, use of AD systemic therapies during the washout period and during the study, use of AD topical therapies (except bland emollients) during the washout period and during the study, and any serious illness or medical condition that could interfere with study conduct, interpretation of data, or patients’ well-being ● TRuE-AD1 and TRuE-AD2 had identical study designs (Figure 2) – In both studies, patients were randomized (2:2:1) to 1 of 2 ruxolitinib cream strength regimens (0.75% twice daily [BID], 1.5% BID) or vehicle cream BID for 8 weeks of double-blind continuous treatment (vehicle-controlled [VC] period); patients were instructed to continue treating lesions even if they improved – Patients on ruxolitinib cream subsequently continued treatment for 44 weeks (long-term safety
    keywords: cream; lts; patients; period; rux; ruxolitinib; vehicle
       cache: skin-1414.pdf
  plain text: skin-1414.txt

        item: #317 of 1356
          id: skin-1415
      author: Blauvelt, Andrew ; Szepietowski, Jacek; Papp, Kim ; Simpson, Eric; Silverberg, Jonathan; Kim, Brian ; Kwatra, Shawn; Kuligowski, Michael ; Venturanza, May; Sun, Kang; Kircik, Leon
       title: Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream
        date: 2021-11-05
       words: 2912
      flesch: 55
     summary: Assessments ● The effects of ruxolitinib cream on itch were assessed by the proportion of patients achieving an itch numerical rating scale score of 0 or 1 (NRS 0/1) – Patients were given an electronic diary to be completed each evening and were instructed to report their worst level of itch during the past 24-hour period from 0 (no itch) to 10 (worst imaginable itch) – The by-visit itch NRS score for post-baseline visits (Weeks 2, 4, 8) was determined by averaging the 7 daily itch NRS scores before the study visit; if ≥4 daily scores were missing, the itch NRS score for the study visit was classified as missing ● The effects on eczema-related itch were also assessed using the proportion of patients reporting no days of itch per item 1 (frequency of itch; Q1) of the Patient-Oriented Eczema Measure (POEM)8 at baseline and Weeks 2, 4, and 8 ● Itch-free state was also assessed stratified by baseline itch NRS score (<6 or ≥6) Statistical Analyses ● All analyses were conducted using the pooled data from the vehicle-controlled portion of both studies ● The proportion of patients achieving itch NRS 0/1 and the number of days with no itch per POEM Q1 were assessed using logistic regression ● Cumulative incidence plots were created for time to itch NRS 0/1 – A log-rank test was used for between-group comparisons ● The efficacy population consisted of 1208 patients (vehicle, n=244; 0.75% ruxolitinib cream, n=483; 1.5% ruxolitinib cream, n=481) Results Patients ● A total of 1249 patients (median age, 32 years) were randomized in the VC period ● The mean (SD) itch NRS score at baseline was 5.1 (2.4) ● Distribution of baseline demographics and clinical characteristics was similar across treatment groups (Table 1) Table 1. ● At Week 8, the proportion of patients achieving itch NRS 0/1 (average of daily NRS measurements over the 7 days before the Week 8 visit) was significantly higher for patients who applied ruxolitinib cream (0.75%/1.5%) compared with vehicle (45.5%/51.5% vs 23.1%; both P<0.0001; Figure 3) Figure 3.
    keywords: cream; itch; nrs; patients; rux; ruxolitinib; vehicle
       cache: skin-1415.pdf
  plain text: skin-1415.txt

        item: #318 of 1356
          id: skin-1416
      author: Blauvelt, Andrew ; Eichenfeld, Lawrence; Kuligowski, Michael; Venturanza, May; Sun, Kang; Silverberg, Jonathan
       title: Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies
        date: 2021-11-05
       words: 2306
      flesch: 36
     summary: Andrew Blauvelt, MD, MBA,1 Lawrence F. Eichenfield, MD,2 Michael E. Kuligowski, MD, PhD, MBA,3 May E. Venturanza, MD,3 Kang Sun, PhD,3 Jonathan I. Silverberg, MD, PhD, MPH4 Introduction ● Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itching, dryness, and redness1 ● Treatments for AD include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and systemic immunomodulatory agents1 ● Some topical treatments may be insufficient because of inadequate efficacy, delayed onset of efficacy, duration-of-use limitations, anatomic use restrictions, poor tolerability, and/or adverse reactions1,2 – TCS are associated with decreased skin thickness and elasticity (eg, striae); they are also not recommended for long-term application or use in sensitive areas – TCI are associated with local reactions, such as stinging and burning ● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and JAK23 ● In two phase 3 randomized studies of identical design (TRuE-AD1 [NCT03745638] and TRuE-AD2 [NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD3 Objective ● To evaluate the long-term safety and disease control of ruxolitinib cream based on types of previous medication using pooled data from two phase 3 trials in patients with AD Methods Study Design and Patients ● Eligible patients were aged ≥12 years with AD for ≥2 years and had an Investigator’s Global Assessment (IGA) score of 2 or 3 and 3%–20% affected body surface area (BSA), excluding scalp ● Key exclusion criteria were unstable course of AD, other types of eczema, immunocompromised status, use of AD systemic therapies during the washout period and during the study, use of AD topical therapies (except bland emollients) during the washout period and during the study, and any serious illness or medical condition that could interfere with study conduct, interpretation of data, or patients’ well-being – The washout period for prior therapies was 1 week for topical AD treatments, 4 weeks for systemic corticosteroids or other immunomodulating agents, and 12 weeks or 5 half-lives for biologics ● TRuE-AD1 and TRuE-AD2 had identical study designs (Figure 1) – In both studies, patients were randomized (2:2:1) to 1 of 2 ruxolitinib cream strength regimens (0.75% twice daily [BID], 1.5% BID) or vehicle cream BID for 8 weeks of double-blinded continuous treatment (vehicle-controlled [VC] period); patients were instructed to continue treating lesions even if they improved – Patients on ruxolitinib cream subsequently continued treatment for 44 weeks (long-term safety [LTS] period); patients initially randomized to vehicle were rerandomized 1:1 (blinded) to either ruxolitinib cream regimen ■ During the LTS period, patients were instructed to treat skin areas with active AD only and stop treatment 3 days after clearance of lesions; patients were to restart treatment with ruxolitinib cream at the first sign of recurrence Figure 1.
    keywords: cream; patients; period; ruxolitinib
       cache: skin-1416.pdf
  plain text: skin-1416.txt

        item: #319 of 1356
          id: skin-1417
      author: Simpson, Eric; Kircik, Leon ; Blauvelt, Andrew ; Kuligowski, Michael; Venturanza, May; Sun, Kang; Eichenfeld, Lawrence
       title: Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies
        date: 2021-11-05
       words: 2694
      flesch: 61
     summary: [NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD7 Objective ● To evaluate the long-term safety and disease control of ruxolitinib cream in a subpopulation of patients with more severe AD at baseline Methods Study Design and Patients ● Eligible patients were aged ≥12 years with AD for ≥2 years and had an IGA score of 2 or 3 and 3%–20% affected BSA, excluding scalp ● Key exclusion criteria were unstable course of AD, other types of eczema, immunocompromised status, use of AD systemic therapies during the washout period and during the study, use of AD topical therapies (except bland emollients) during the washout period and during the study, and any serious illness or medical condition that could interfere with study conduct, interpretation of data, or patients’ well-being ● TRuE-AD1 and TRuE-AD2 had identical study designs (Figure 1) – In both studies, patients were randomized (2:2:1) to 1 of 2 ruxolitinib cream strength regimens (0.75% twice daily [BID], 1.5% BID) or vehicle cream BID for 8 weeks of double-blinded continuous treatment (vehicle- controlled [VC] period); patients were instructed to continue treating lesions even if they improved – Patients on ruxolitinib cream subsequently continued treatment for 44 weeks (long-term safety
    keywords: bsa; cream; lts; patients; period; rux
       cache: skin-1417.pdf
  plain text: skin-1417.txt

        item: #320 of 1356
          id: skin-1418
      author: Simpson, Eric; Bissonnette, Robert; Kuligowski, Michael; Venturanza, May; Sun, Kang; Silverberg, Jonathan
       title: Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement
        date: 2021-11-05
       words: 2752
      flesch: 58
     summary: Assessments ● Pooled efficacy at Week 8 was assessed by achievement of the following endpoints in patients with HN involvement at baseline and the overall population: – IGA-treatment success (IGA-TS; IGA of 0/1 and ≥2-grade improvement from baseline) – ≥50%, ≥75%, and ≥90% improvement in Eczema Area and Severity Index vs baseline (EASI-50, EASI-75, and EASI-90 † Patients with missing post-baseline values were imputed as nonresponders at Weeks 2, 4, and 8.
    keywords: baseline; cream; patients; rux; vehicle; week
       cache: skin-1418.pdf
  plain text: skin-1418.txt

        item: #321 of 1356
          id: skin-1419
      author: Greywal, Tanya; Saedi, Nazanin; Ortiz, Arisa
       title: A Clinical Evaluation of the 1064nm Nd:YAG Laser with a 650-microsecond Pulse Duration for the Treatment of Acne Vulgaris
        date: 2021-11-05
       words: 433
      flesch: 53
     summary: Treatments were very well tolerated with no reported pain during or after treatment. Treatments were performed on average every 1-4 weeks for 3 to 7 treatments.
    keywords: laser; yag
       cache: skin-1419.pdf
  plain text: skin-1419.txt

        item: #322 of 1356
          id: skin-142
      author: Kaufman, Joely; Cohen, Joel; Peredo, Marina; Jonas, Brandie; Nogueira, Alessandra; Mashburn, Jay H
       title: Two On-Label Injection Volumes of AbobotulinumtoxinA (ABO) Produce Simlar Safety and Efficacy Results when Used to Treate Moderate to Sever Glabellar Lines
        date: 2017-10-27
       words: 1831
      flesch: 57
     summary: Population Group A (1.5 mL) – 0.05 mL/injection; Group B (2.5 mL) – 0.08 mL/injection; *P=.0377, Group A compared to Group B; Composite Responders = based on combined subject and blinded evaluator assessments; mITT = modified intent to treat Group A (1.5 mL) – 0.05 mL/injection; Group B (2.5 mL) – 0.08 mL/injection; Composite Responders = based on combined subject and blinded evaluator assessments; mITT ■ Responder rates for each treatment group were generally similar among all evaluations with the exception of ≥ 1-point composite responders at maximum frown at Day 2 (~ 24 hours post-treatment) where ABO 2.5 mL treatment group (Group B) had a statistically significant larger number of responders compared to ABO 1.5 mL treatment group (Group A; P = .0377).
    keywords: group; subjects
       cache: skin-142.pdf
  plain text: skin-142.txt

        item: #323 of 1356
          id: skin-1420
      author: Draelos, Zoe; Tanghetti, Emil; Stein Gold, Linda; Baldwin, Hilary ; Kircik, Leon ; Guenin, Eric
       title: Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety
        date: 2021-11-05
       words: 1457
      flesch: 48
     summary: -35.2% TAZ 0.045% � Healthy female participants aged 35–65 years (N=15) answered a questionnaire on the properties of the vehicle lotion for tazarotene 0.045% Results � Most participants (93–100%) responded favorably (strongly agree or agree) to all questions about the various attributes of the vehicle lotion after application My skin feels… The product… CORNEOMETRY AND TRANSEPIDERMAL WATER LOSS (TEWL) TANGHETTI EA, ET AL.
    keywords: cream; lotion; skin; tazarotene; vehicle
       cache: skin-1420.pdf
  plain text: skin-1420.txt

        item: #324 of 1356
          id: skin-1422
      author: Tanghetti, Emil; Gold, Michael ; Sadick, Neil; Cook-Bolden, Fran; Kircik, Leon ; Stein Gold, Linda; Tyring, Stephen; Del Rosso, James; Guenin, Eric
       title: Improvements in Acne and Skin Oiliness with Tazarotene 0.045% Lotion in Acne Patients with Oily Skin
        date: 2021-11-05
       words: 2031
      flesch: 46
     summary: In�ammatory -29.7% -40.2% -48.4% -28.9% -48.0% -57.0% -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 VEH (n=367) TAZ (n=369) *** *** ** -70% -60% -50% -40% -30% -20% -10% 0% **P<0.01; ***P<0.001 vs vehicle.
    keywords: lotion; participants; skin; taz; tazarotene; veh; week
       cache: skin-1422.pdf
  plain text: skin-1422.txt

        item: #325 of 1356
          id: skin-1423
      author: Del Rosso, James; Kircik, Leon ; Effron, Cheryl; Draelos, Zoe
       title: Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study Evaluating Efficacy and Safety
        date: 2021-11-05
       words: 913
      flesch: 34
     summary: CONCLUSIONS • In this pilot study, oral sarecycline demonstrated effectiveness for treatment of papulopustular rosacea in adults as early as 4 weeks based on IGA scores and reductions in inflammatory lesion counts • Sarecycline improved facial symptoms, including burning, erythema, and pruritis • Sarecycline was associated with a favorable safety and tolerability profile, with AEs consistent with prior studies • Additional studies are warranted to further evaluate oral sarecycline as treatment for papulopustular rosacea 1 Enrolled participants (N=102) This was a prospective, parallel-group, 12-week, randomized, investigator-blinded, pilot study of oral sarecycline treatment for adults with moderate to severe papulopustular rosacea (Figure 1) • Eligible participants were adults (aged ≥18 years) with moderate or severe rosacea based on Investigator Global Assessment (IGA) rating with ≥15 and ≤50 facial papules/ pustules and ≤2 facial nodules • Statistical analyses were conducted on an intention-to- treat basis; all tests were 2-sided and interpreted at a 5% significance level Figure 1.
    keywords: figure; rosacea; sarecycline; week
       cache: skin-1423.pdf
  plain text: skin-1423.txt

        item: #326 of 1356
          id: skin-1424
      author: Moore, Angela; Moore, Stephen; Moore, Luke; Tyring, Stephen; Tyring, Stephen
       title: Sarecycline: Rapid Improvement of Truncal Acne in Hispanic Male
        date: 2021-11-05
       words: 574
      flesch: 54
     summary: 1 • Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated. 3 • Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials.
    keywords: acne; sarecycline; trunk
       cache: skin-1424.pdf
  plain text: skin-1424.txt

        item: #327 of 1356
          id: skin-1425
      author: Bodor, Nicholas; Friedman, Adam; Smith, Stacy; Del Rosso, James; Dubois, Janet; Herbert, Adelaide; Sullivan, Tory; Rice, Zakiya; Gorlick, Joe; Kircik, Leon ; Green, Lawrence; Kirsch, Brandon ; Chadha, Deepak
       title: Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug
        date: 2021-11-05
       words: 782
      flesch: 29
     summary: Sofpironium bromide (SB) is a novel, quaternary ammonium, anticholinergic drug that is a retrometabolically designed structural analogue of glycopyrrolate. Unlike glycopyrrolate, SB includes a readily hydrolyzable ester moiety.
    keywords: dermatology; drug; glycopyrrolate
       cache: skin-1425.pdf
  plain text: skin-1425.txt

        item: #328 of 1356
          id: skin-143
      author: Meckfessel, Matthew H; Teissedre, Sandrine; Lachmann, Nadege; Santoro, Francine
       title: Tolerability and Efficacy of a Moisturizing Broad Spectrum Sunscreen Formulated for Redness-Prone Skin
        date: 2017-10-27
       words: 818
      flesch: 38
     summary: This poster  presents the results of two clinical studies that assessed the performance and tolerability  of DFM. TOLERABILITY AND EFFICACY OF A MOISTURIZING BROAD SPECTRUM SUNSCREEN FORMULATED FOR REDNESS­PRONE SKIN Matthew H Meckfessel, PhD1; Sandrine Teissedre, MSc2; Nadege Lachmann3; Francine Santoro, MD3  1Galderma Laboratories, L.P., Fort Worth, Texas; 2Galderma R&D, Sophia Antipolis, France; 3Galderma R&D, Egerkingen, Switzerland CET.P­RD105649­01 SUMMARY DFM significantly improves skin hydration and skin barrier  function and is an ideal daily broad spectrum facial moisturizer  for patients with rosacea and sensitive skin SUBJECTS and METHODS Study 1: Hydration and Skin Barrier Function  • Men and women with dry volar forearms • Inner forearms randomized to treated and control • 40 mg of product applied to 20 cm2  ­ Corneometer and transepidermal water loss (TEWL) assessed at baseline and 2, 4, 8, and 24 hours Study 2: In Use Efficacy and Tolerability • Men or women with rosacea and mild to moderate non­transient erythema • Product applied QD in the morning for 3 weeks • Assessments made on day 1 before application, day 1 30 minutes after first use and days 3, 8, and 22 before product application  ­ Objective (chromameter) and subjective (investigator and subject) assessment of redness  ­ Investigator and subject tolerability assessments · Redness and tolerability assessments made on a 5 point scale of 0 (none), 0.5 (very slight), 1 (slight), 2 (moderate) and 3 (strong)  ­ Subject satisfaction M ea n  Sc or e Baseline 30 Minutes Dryness Tightness 0 0.1 0.7 0.2 0.5 1 2 3 *P < .05 vs baseline * * Disagree Neutral Agree Percent of Subjects Overall, I like the product very much Easy to apply Suitable for sensitive skin Neutralizes the look of redness 0 100 12020 40 60 80 0 96.7 73.3 23.3 3.3 3.3 70.0 90.0 6.7 6.7 6.7 20.0 P < .05 for Agree vs Disagree for all Figure 4. Subject Assessment of Dryness and Tightness (n=30) Figure 5. Subject Satisfaction  Additionally it is also formulated with allantoin, caffeine, licorice  root extract, and vitamin E to help calm and soothe rosacea­prone skin.
    keywords: skin; subject
       cache: skin-143.pdf
  plain text: skin-143.txt

        item: #329 of 1356
          id: skin-1430
      author: Goldberg, Matthew; Siegel, Jennifer; Russell, Brooke; Rogers, Jason; Covington, Kyle ; Oelschlanger, Kristen; Poteet, Trisha; Wilkinson , Jeffrey; Berg, Michael; Falkowski, Katherine; Kurley, Sarah; Kajoian, Armineh
       title: A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions
        date: 2021-11-05
       words: 1183
      flesch: 59
     summary: The tests use proprietary algorithms to produce results of likely benign, intermediate, or malignant.5-7 › The 23-GEP has shown accuracy metrics of over 90% sensitivity in multiple clinical studies that included patient outcomes.8-10 However, the 23-GEP historically has resulted in ~23% of cases receiving either a technical failure or an intermediate result, which can be perceived as nonactionable.6,11-13 The 35-GEP test can address this shortcoming and showed both an increased sensitivity in the first validation cohort and a decreased nonactionable rate of 8.5%.7 › Clinical utility has been demonstrated with benign and malignant GEP test results;11,14 therefore, those test results are defined as actionable. is well documented and particularly prevalent among difficult-to-diagnose cases, for which histopathology may be insufficient for a definitive diagnosis.1-4 › The 23-gene expression profile (GEP; myPath Melanoma) and 35-GEP (DiffDx-Melanoma) tests are clinically available objective ancillary tools that facilitate diagnosis of melanocytic lesions with ambiguous histopathology.
    keywords: cases; gep
       cache: skin-1430.pdf
  plain text: skin-1430.txt

        item: #330 of 1356
          id: skin-1431
      author: Martin, Brian ; Taylor, Nicholas; Whitman, Eric; Quick, Ann; Bailey, Christine; Covington, Kyle ; Vetto, John
       title: Integrating the 31-gene expression profile and clinicopathologic data to determine the risk of sentinel lymph node positivity and recurrence-free survival in cutaneous melanoma
        date: 2021-11-05
       words: 851
      flesch: 70
     summary: SLN positivity risk have good outcomes based on Kaplan-Meier analysis and were not evaluated further in this study. Keller, J. et al.
    keywords: gep; i31; patients
       cache: skin-1431.pdf
  plain text: skin-1431.txt

        item: #331 of 1356
          id: skin-1432
      author: Martin, G; Berman, B; Feldman, S; Armstrong , A ; Edwards, M; Graziadio, S; McCool, R; Arber, M; Carr, E; James, D; Chapman-Rounds, M; Fumero, E; Schuchardt, M; Grada, A
       title: Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis
        date: 2021-11-05
       words: 918
      flesch: 33
     summary: Two sets of analyses were proposed; primary analyses would include only the results of studies offering participants one course or session of treatment (a trial design comparable with that of the two tirbanibulin RCTs), while the secondary analyses would include results of studies offering any number of courses or sessions of treatment, plus retreatment where offered. Based on the overlap of credible intervals shown in the statistical plots, the novel topical treatment (tirbanibulin 1% ointment) appeared to be as efficacious as existing treatments, and more so than topical placebo or diclofenac 3%.
    keywords: analysis; nma; studies; treatments
       cache: skin-1432.pdf
  plain text: skin-1432.txt

        item: #332 of 1356
          id: skin-1434
      author: Ghannoum, Mahmoud; Herrada, Janet; Gamal, Ahmed; Long, Lisa; McCormick, Thomas; Grada, Ayman
       title: Sarecycline exhibits decreased activity Against Representative Bacterial and Fungal Microflora Commonly Present in the Human Gastrointestinal Tract
        date: 2021-11-05
       words: 795
      flesch: 15
     summary: Effect of sarecycline vs. minocycline on the growth rates of Anaerobic Microorganisms Sarecycline Demonstrated Reduced Activity Against Representative Bacterial and Fungal Microflora Commonly Present in the Human Gastrointestinal Tract Phylum Genus Species Sarecycline Minocycline Fold Difference in MIC Actinobacteria Bifidobacterium Bifidobacterium adolescentis 1 1 1 Actinobacteria Collinsella Collinsella aerofaciens 1 0.5 2 Actinobacteria Eggerthella Eggerthella lenta 1 0.5 2 Actinobacteria Actinomycetales Propionibacterium freudenreichii 8 1 8 Bacteroidetes Bacteroides Bacteroides caccae 8 0.25 32 Bacteroidetes Bacteroides Bacteroides fragilis enterotoxigenic (ET) 2 4 0.5 Bacteroidetes Bacteroides Bacteroides fragilis nontoxigenic 1 0.25 4 Bacteroidetes Bacteroides Bacteroides ovatus 0.5 0.5 1 Bacteroidetes Bacteroides Bacteroides thetaiotaomicron 0.25 0.125 2 Bacteroidetes Bacteroides Bacteroides uniformis 2 0.5 4 Bacteroidetes Bacteroides Bacteroides vulgatus 0.125 0.016 7.8 Bacteroidetes Bacteroides Bacteroides xylanisolvens 1 0.25 4 Bacteroidetes Bacteroides Bifidobacterium subtile Biavati >8 8 Not Determined Bacteroidetes Odoribacter Odoribacter splanchnicus 8 4 2 Bacteroidetes Parabacteroides Parabacteroides distasonis 8 2 4 Bacteroidetes Parabacteroides Parabacteroides merdae 0.06 0.016 3.8 Firmicutes Blautia Blautia obeum 1 0.5 2 Firmicutes Clostridium Clostridium bolteae 4 0.5 8 Firmicutes Clostridium Clostridium ramosum 2 0.06 33.3 Firmicutes Clostridium Clostridium saccharolyticum 2 2 1 Firmicutes Dorea Dorea formicigenerans 0.25 0.06 4.2 Firmicutes Eubacterium Eubacterium eligens >8 4 Not Determined Firmicutes Lactobacillus Lactobacillus paracasei 1 0.25 4 Proteobacteria Escherichia Escherichia coli IAI1 16 8 2 Sac fungi Candida Candida albicans 32 16 2 Sac fungi Candida Candida glabrata 32 In vivo evaluation is ongoing • Sarecycline showed significantly less activity against E. coli compared to minocycline at all time points (P- values <0.05) • Sarecycline was significantly less active against C. tropicalis compared to minocycline at 20 and 22 hours post exposure (P-values <0.05) • Time kill study shows that with longer time exposure sarecycline has less inhibitory activity against Candida • Sarecycline showed significantly less activity against L. paracasei compared to minocycline after 24 hours of growth (P-value of 0.002)
    keywords: bacteroides; minocycline; sarecycline
       cache: skin-1434.pdf
  plain text: skin-1434.txt

        item: #333 of 1356
          id: skin-1435
      author: Wang, Jordan; Friedman, Paul; Konda, Adarsh; Parker, Catherine; Geronemus, Roy
       title: Enhanced Uptake of 2% Salicylic Acid Following 1440-nm Non-ablative Fractional Diode Laser Treatment
        date: 2021-11-05
       words: 773
      flesch: 50
     summary: salicylic acid uptake, low-power 1440-nm non-ablative fractional diode laser pretreatment with 320 MTZ/cm2 resulted in greater retention within skin tissue samples compared to untreated controls and the 80-MTZ/cm2 setting • Retention enhancement following treatment with greater MTZ density did not appear to have an additive effect on overall uptake at 24 hours, supporting the argument that salicylic acid uptake may be predominantly transfollicular • These results may guide the development of treatment protocols for clinical use of non-ablative fractional laser pretreatment to enhance uptake of salicylic acid–containing topicals Presented at the 2021 Fall Clinical Dermatology Conference • October 21-24, 2021 • Las Vegas, NV, and Virtual Funding information: This study was sponsored by Solta Medical. Experimental Parameters • Following laser pretreatment, 2% salicylic acid was applied, and uptake was determined at various time points up to 24 hours after application (Figure 1) Figure 1.
    keywords: cm2; laser; mtz; uptake
       cache: skin-1435.pdf
  plain text: skin-1435.txt

        item: #334 of 1356
          id: skin-1436
      author: Wang, Jordan; Friedman, Paul; Konda, Adarsh; Parker, Catherine; Geronemus, Roy
       title: Enhanced Uptake of 10% Ascorbic Acid After 1440-nm or 1927-nm Non-ablative Fractional Diode Laser Treatment
        date: 2021-11-05
       words: 905
      flesch: 58
     summary: Uptake Ratios of 10% Ascorbic Acid SYNOPSIS • The stratum corneum forms a vital protective barrier along the outer layer of the skin, but also prevents optimal uptake of topical formulations1 • Lasers can facilitate better penetration and absorption of topicals by disrupting the stratum corneum and tight junctions in the epidermis2 • Non-ablative lasers generally target dermal tissue and largely spare the stratum corneum, which minimizes overall thermal side effects and postprocedural recovery time, while fractionation further reduces postprocedural downtime3,4 • The relationship between topical uptake and laser device settings, such as wavelength, peak power, and spot density, must be quantified to optimize treatment benefits Enhanced Uptake of 10% Ascorbic Acid After 1440-nm or 1927-nm Non-ablative Fractional Diode Laser Treatment Jordan V. Wang, MD, MBE, MBA1; Paul M. Friedman, MD1,2; Adarsh Konda, PharmD3; Catherine Parker, NP, MSN4; Roy G. Geronemus, MD1 1Laser & Skin Surgery Center of New York, New York, NY; 2Dermatology and Laser Surgery Center, Houston, TX; 3Bausch Health US, LLC, Bridgewater, NJ; 4Solta Medical, Bothell, WA OBJECTIVE • To quantify uptake of 10% ascorbic acid following pretreatment with low-power 1440-nm or 1927-nm non-ablative fractional diode lasers (Clear + Brilliant® laser system; Solta Medical, Bothell, WA) with varying treatment densities CONCLUSIONS • Experimental Parameters • Following laser pretreatment, 10% ascorbic acid (Obagi®, Long Beach, CA; 2010 formulation) was applied, and permeation was measured up to 24 hours after application (Figure 1) •
    keywords: cm2; laser; mtz
       cache: skin-1436.pdf
  plain text: skin-1436.txt

        item: #335 of 1356
          id: skin-1437
      author: Wang, Jordan; Friedman, Paul; Konda, Adarsh; Parker, Catherine; Geronemus, Roy
       title: Quantifying Uptake of Topical 4% Hydroquinone After 1440-nm and 1927-nm Non-ablative Fractional Diode Laser Treatment
        date: 2021-11-05
       words: 785
      flesch: 45
     summary: RESULTS • Pretreatment with the 1927-nm wavelength resulted in greater cumulative uptake of 4% hydroquinone serum compared to the 1440-nm wavelength and untreated control (Figure 2) Figure 2. METHODS • Human donor skin tissue samples of 500-µm thickness were pretreated with a 1440-nm or 1927-nm laser (Clear + Brilliant® laser system; Solta Medical, Bothell, WA), or received no pretreatment (Table 1)
    keywords: uptake
       cache: skin-1437.pdf
  plain text: skin-1437.txt

        item: #336 of 1356
          id: skin-1438
      author: Wang, Jordan; Friedman, Paul; Konda, Adarsh; Parker, Catherine; Geronemus, Roy
       title: Quantifying Uptake of Eye Serum After 1440-nm or 1927-nm Non-ablative Fractional Diode Laser Treatment
        date: 2021-11-05
       words: 843
      flesch: 50
     summary: These results provide a foundation for guidance on the use of non-ablative lasers in clinical studies on topical uptake enhancement Presented at the 2021 Fall Clinical Dermatology Conference • October 21-24, 2021 • Las Vegas, NV, and Virtual Funding information: This study was sponsored by Solta Medical. Cumulative permeation of mineral eye serum after laser pretreatment.
    keywords: laser; pretreatment; uptake
       cache: skin-1438.pdf
  plain text: skin-1438.txt

        item: #337 of 1356
          id: skin-1439
      author: Desai, Seemal
       title: Cysteamine: Clinical efficacy, safety and tolerability versus best-in-class treatments for melasma 
        date: 2021-11-05
       words: 1439
      flesch: 51
     summary: At week 16, ST-CYS-5% was shown to be slightly superior in MASI score reduction compared to HQ4% when analyzed as per protocol (-39.1% versus -33%, p=0.96) 11 • Cascade reaction: increase of intracellular glutathione, amplifying natural depigmenting effects.12 • Keratolytic effect: by breaking keratin disulfide bonds, it enhances the removal of melanin contained in the superficial epidermis layers and accelerates the epidermal turnover for generation of new non-pigmented skin layers.13 5% Stabilized Cysteamine (ST-CYS-5%) versus modified Kligman’s formula (mKF)14 Material and methods Double-blinded, Investigator-driven, randomized 50 female with melasma, 20-50 years old, assigned in 2 groups: •ST-CYS-5% 15min application + moisturizer + sunscreen (daily, 16weeks)
    keywords: cys-5; cysteamine; evaluation; melasma; mmasi; weeks
       cache: skin-1439.pdf
  plain text: skin-1439.txt

        item: #338 of 1356
          id: skin-144
      author: Meckfessel, Matthew H; Teissedre, Sandrine; Lachmann, Nadege; Santoro, Francince
       title: An Effective yet Gentle Foaming Facial Cleanser Specifically Designed for Redness-Prone Skin
        date: 2017-10-27
       words: 707
      flesch: 49
     summary: ACKNOWLEDGEMENTS Study funded by Galderma R&D; poster/editorial support provided by Galderma Laboratories, L.P. INTRODUCTION Cleansing skin is an important component of maintaining healthy skin as it removes dirt, oil, make up, and helps prepare the skin for topical prescription treatments. Chromameter Assessment Disagree Neutral Agree Percent of Subjects Overall, I like the product very much Is suitable for sensitive skin Washes away face make up and skin impurities Rinses easily to leave skin soft and clean 0 50 6010 20 30 40 70 80 90 100 24.2 69.7 66.7 3.0 3.0 3.0 3.0 21.2 9.1 15.2 78.8 90.9 P < .05 for Agree vs Disagree for all Figure 5.
    keywords: day; figure; skin
       cache: skin-144.pdf
  plain text: skin-144.txt

        item: #339 of 1356
          id: skin-1440
      author: Saki, Nasrin
       title: Stabilized Cysteamine 5% Cream for the Treatment of Senile Lentigo
        date: 2021-11-05
       words: 850
      flesch: 52
     summary: doi:10.1001/archderm.1975.01630130042004 ReferencesReferences • Randomized, double-blinded; 30 subjects with dorsal hand lentigines • Cyspera® Cysteamine 5% from Scientis vs vehicle, 15-minutes daily short contact; Sunscreen daily • Colorimetry and visual analogue scale (VAS) at baseline, 4-weeks, 8-weeks and 12-weeks • Mean age 49.5; Gender 8:22 M:F distributed equally Material & MethodsMaterial & Methods Vehicle Cysteamine 0 50 100 150 200 250 300 350 400 450 500 387 294 397 481 COLORIMETRY Vehicle Cysteamine 0 1 2 3 4 5 6 7 8 9 7.46 5.09 7.33 8.27 VAS Subject 1 Baseline week-12 Subject 2 Baseline week-12 40% reduction in colorimetry (p<0.002) vs 2% reduction in non-treatment arm (p<0.405) 40% reduction In VAS (p<0.001) vs 2% reduction in non-treatment arm p<0.245) Learn more about the product: Stabilized Cysteamine 5% Cream for the Treatment of Senile Lentigo Nasrin Saki, MD, Shiraz University of Medical Sciences Stabilized Cysteamine 5% Cream for the Treatment of Senile Lentigo Nasrin Saki, MD, Shiraz University of Medical Sciences ”Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch : a randomized double blind placebo controlled study”.
    keywords: cream; cysteamine
       cache: skin-1440.pdf
  plain text: skin-1440.txt

        item: #340 of 1356
          id: skin-1441
      author: Ablon, Glynis; Berkowitz, Sheryl; Kogan, Sophia; Raymond, Isabelle
       title: Long-Term Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal and Postmenopausal Women with Self-Perceived Thinning Hair
        date: 2021-11-05
       words: 915
      flesch: 45
     summary: The results of this study showed significant and progressive improvements in hair growth during 6 and 12 months, demonstrating the ability of a nutraceutical supplement to effectively improve hair growth and quality in peri-, menopausal and postmenopausal women with thinning hair. A 13% increase was noted from Day 180 to 360 but was not statistically significant When switched over to the active treatment, subjects initially in the placebo group had: • 5.1% increase in hair growth (p<0.001) • 39% decrease in shedding (p<0.0001) from day 180 to 360.
    keywords: day; growth; hair
       cache: skin-1441.pdf
  plain text: skin-1441.txt

        item: #341 of 1356
          id: skin-1442
      author: Siegfried, Elaine; Eichenfeld, Lawrence; Kwong, Pearl ; Desai, Seemal; Cutler, Susan ; Wilson, Cynthia; Rumney, Pamela; Crosby, Christine ; Andres, Jennifer; McBride, Mark 
       title: Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)
        date: 2021-11-05
       words: 899
      flesch: 73
     summary: • Study included 180 subjects with FST I or II (n=101 VP-102; n=79 vehicle), 270 with FST III or IV (n=166 VP-102; n=104 vehicle), and 77 with FST V or VI (n=42 VP-102; n=35 vehicle). • VP-102, a single-use proprietary drug-device combination product (cantharidin 0.7%), is under investigation for treatment of molluscum contagiosum (MC).
    keywords: day; type; vehicle; vp-102
       cache: skin-1442.pdf
  plain text: skin-1442.txt

        item: #342 of 1356
          id: skin-1444
      author: Lipner, Shari; Josepth, Warren; Vlahovic, Tracy; Scher, Richard; Rich, Phoebe; Ghannoum, Mahmoud; Daniel, Ralph; Elewski, Boni
       title: Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US
        date: 2021-11-05
       words: 2026
      flesch: 43
     summary: Efinaconazole preferred for topical treatment due to higher rates of complete cure and mycologic cure versus other topical treatments. Wear �ip �ops or shower shoes.
    keywords: disease; figure; nail; onychomycosis; patients; topical; treatment
       cache: skin-1444.pdf
  plain text: skin-1444.txt

        item: #343 of 1356
          id: skin-1445
      author: Zirwas, Matthew; Draelos, Zoe; Dubois, Janet; Kircik, Leon ; Moore, Angela; Stein Gold, Linda; Alonso-Llamazares, Javier ; Bukhalo, Michael; Bruce, Suzanne; Eads, Kimmie; Green, Lawrence; Guenthner, Scott; Ferris, Laura; Forman, Seth; Kempers, Steven; Lain, Edward ; Lynde, Charles; Pariser, David; Pariser, David; Toth, Darryl; Yamauchi, paul; Burnett, Patrick; Berk, David
       title: A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis
        date: 2021-11-05
       words: 3146
      flesch: 54
     summary: Overall, 92% of patients completed the study (Table 2) – Few patients discontinued due to adverse events (AEs) • Demographics and baseline characteristics were similar in the treatment groups (Table 3) CONCLUSIONS • Roflumilast foam 0.3% demonstrated significant improvement in IGA Success, erythema, scaling, and itch – The improvements in IGA Success were statistically significant at the first post-baseline visit (Week 2) and continued through Week 8 – Roflumilast foam resulted in significant improvements in itch by Week 2 • ~80% of patients reported notable itch at baseline (WI-NRS ≥4) – Roflumilast reduced BSA affected and improved patient quality of life (DLQI) • Rates of treatment-related AEs, discontinuations due to AEs, and application-site pain were low and similar to vehicle • Vehicle (n=71) -66.6% -28.5% Significant improvements in BSA affected and DLQI at Week 8 (A) (B) 1-4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 Baseline Week 2 Week 4 Week 8 LS M ea n Cf B in D LQ I ( SE )
    keywords: baseline; derm; foam; iga; patients; roflumilast; success; usa; vehicle; week
       cache: skin-1445.pdf
  plain text: skin-1445.txt

        item: #344 of 1356
          id: skin-145
      author: Meckfessel, Matthew H; Teissedre, Sandrine; Lachmann, Nadege; Santoro, Francince
       title: Performance of a Facial Night Moisturizer for Redness-Prone Skin
        date: 2017-10-27
       words: 641
      flesch: 50
     summary: 24 hours Study 2: In Use Efficacy and Tolerability • Men or women with rosacea and mild to moderate non-transient erythema • Product applied QD in the evening for 3 weeks • Assessments made on day 1 before application, day 1 30 minutes after first use and days 8, and 22 before product application - Objective (chromameter) and subjective (investigator and subject) assessment of redness - Investigator and subject tolerability assessments · Redness and tolerability assessments made on a 5 point scale of 0 (none), 0.5 (very slight), 1 (slight), 2 (moderate) and 3 (strong) - Subject satisfaction PERFORMANCE OF A FACIAL NIGHT MOISTURIZER DESIGNED FOR REDNESS-PRONE SKIN Matthew H Meckfessel, PhD1; Sandrine Teissedre, MSc2; Nadege Lachmann3; Francine Santoro, MD3 1Galderma Laboratories, L.P., Fort Worth, Texas; 2Galderma R&D, Sophia Antipolis, France; 3Galderma R&D, Egerkingen, Switzerland CET.P-RD105328-01 SUMMARY CNM significantly improves skin hydration and skin barrier function and is an ideal nightly facial moisturizer for patients with rosacea RESULTS Skin hydration and skin barrier function significantly improved for 24 and 8 hours, respectively, compared to untreated and baseline (Figures 1 and 2). Regular use of a moisturizer by patients with rosacea can help alleviate skin dryness and restore skin barrier function.
    keywords: baseline; skin
       cache: skin-145.pdf
  plain text: skin-145.txt

        item: #345 of 1356
          id: skin-1450
      author: Enos, Clinton; O'Connell, Katie; Harrison, Ryan; McLean, Robert; Dube, Blessing ; Van Voorhees, Abby
       title: Regional Variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6-months following Biologic Initiation 
        date: 2022-01-17
       words: 1398
      flesch: 58
     summary: 41 RESEARCH LETTER Regional Variation in DLQI 0/1 Within the CorEvitas Psoriasis Registry 6-months Following Biologic Initiation Clinton W. Enos, MD, MS1, Katie A. O’Connell, MS1, Ryan W. Harrison, MS2, Robert R McLean, DSc, MPH2, Blessing Dube, MPH2, Abby S. Van Voorhees, MD1 1 Eastern Virginia Medical School Department of Dermatology, Norfolk, VA 2 CorEvitas, LLC, Waltham, MA Recently, we identified geographic variation in treatment patterns and outcomes among psoriasis patients across the United States (US) enrolled in the CorEvitas Psoriasis Registry.1 As there is a predictive correlation between reductions in psoriasis area severity index (PASI) and the Dermatology Life Quality Index (DLQI) scores among psoriasis patients treated in clinical trials with biologics,2 we assessed for geographic differences in achieving DLQI 0/1 among US patients initiating a biologic therapy in 2018 in the CorEvitas Psoriasis Registry, a multicenter registry of psoriasis patients under the care of a dermatologist.
    keywords: 0/1; corevitas; dlqi; patients; psoriasis
       cache: skin-1450.pdf
  plain text: skin-1450.txt

        item: #346 of 1356
          id: skin-1456
      author: Kim, Lori; Dodd, Erin; Chadha, Angad 
       title: Segmental Kaposi Sarcoma in an Immunocompromised Patient
        date: 2022-01-17
       words: 1496
      flesch: 49
     summary: The patient was not a candidate for local treatments alone due to the number of lesions; he was originally discharged with plans to adjust his immunosuppression and assess KS response before considering local therapies. Given the patient’s tenuous clinical status and difficulty obtaining a lung biopsy, he was treated empirically with broad-spectrum antimicrobials and soon thereafter with intravenous liposomal doxorubicin for possible KS.
    keywords: isotopic; patient; response; skin
       cache: skin-1456.pdf
  plain text: skin-1456.txt

        item: #347 of 1356
          id: skin-1457
      author: Surjanto, Kezia; Rensch, Gage; Vick, Garrett; Murina, Andrea
       title: Wells Syndrome with Sustained Response to Omalizumab
        date: 2022-03-04
       words: 1519
      flesch: 53
     summary: Autoimmunity, insect bites, drugs, contact allergens, infections, and photosensitivity are triggers that have previously been associated with this diagnosis.1 Treatment options for Wells syndrome include corticosteroids, antihistamines, antibiotics, immunosuppressants, and biologics.2 We present a case of Wells syndrome that was unresponsive to corticosteroids, antivirals, antibiotics, antihistamines, and dapsone. This case reflects one of the few reported instances of Wells syndrome that was successfully treated with omalizumab.
    keywords: omalizumab; syndrome; weeks; wells
       cache: skin-1457.pdf
  plain text: skin-1457.txt

        item: #348 of 1356
          id: skin-1458
      author: O'Connell, Katie; Svoboda, Ryan ; Anderson, Bryan; Helm, Klaus; Ken , Kimberly
       title: A Diagnostic Challenge: Desmoplastic Melanoma 
        date: 2022-03-04
       words: 1301
      flesch: 50
     summary: Due to these challenges, a delay in diagnosis of DM is not uncommon, particularly if a partial biopsy is taken or if appropriate immunohistochemistry is not performed due to low clinical suspicion.4 There are two subtypes of DM—pure DM (pDM) and mixed DM (mDM)—named by the degree of desmoplasia.3 Mixed DM arises from and thus resembles preexisting lesions of another melanoma subtype (often lentigo maligna melanoma).3 In contrast, pDM arises de novo.1,4 As with all melanoma, the mainstay of treatment is wide local excision with margins determined by Breslow depth.1,5 Compared to mDM, pDM exhibits a lower propensity for regional lymph node involvement, but a similar rate of distant metastasis, suggesting possible hematogenous spread.4 Due to the lack of robust evidence, the utility of sentinel lymph node biopsy (SLNB) for patients with pDM remains controversial.5 Histologically, DM is characterized by a paucicellular proliferation of spindled melanocytes accompanied by a densely fibrotic stroma and may closely resemble scar or other spindle cell tumors including atypical fibroxanthoma/pleomorphic dermal sarcoma, spindle cell squamous cell carcinoma (SCC), and leiomyosarcoma.1 Immunohistochemistry is essential to the diagnosis; S-100 is diffusely positive and markers of melanocytic differentiation such as Melan-A and SOX-10 are often positive but can be focally negative.1,4 The absence of staining for epithelial markers such as cytokeratins 5/6 and muscle markers such as smooth muscle actin and desmin help to differentiate DM from spindle SCC and leiomyosarcoma, respectively.
    keywords: biopsy; desmoplastic; melanoma; skin
       cache: skin-1458.pdf
  plain text: skin-1458.txt

        item: #349 of 1356
          id: skin-146
      author: Stein Gold, Linda; Lain, Edward; Harvey, Alison
       title: The Anti-Inflammatory Properties of Ivermectin and Brimonidine in the Treatment of Papulopustular Rosacea
        date: 2017-10-27
       words: 1250
      flesch: 60
     summary: Once daily IVM vehicle and BR vehicle for 12 weeks (vehicle group, n = 95) - A daily skin care regimen of gentle cleanser, moisturizing lotion and facial moisturizer SPF 15 sunscreen • Efficacy and safety endpoints - IGA success (0/1 [clear/almost clear], 5-point scale, week 12, 3 hours after BR application), IGA at each visit, CEA, 100% reduction in IL count, and subject global improvement of rosacea - AEs were monitored throughout the study RESULTS Study 1 • Anti-inflammatory synergy was observed between IVM and BR in the mouse model • IVM+BR had a similar effect on ear edema at 6 hours when compared with a potent corticosteroid or NSAID (Figure 1 and 2) Study 2 • Subjects who began IVM+BR treatment at baseline had an improved rate of IGA success when compared with both vehicle and subjects who began BR treatment at week 8 (Figure 3) • Subjects who began IVM+BR treatment at baseline had improved CEA assessments at week 12 when compared with both vehicle and subjects who began BR treatment at week 8 (Figure 4) • Subjects who began IVM+BR treatment at baseline were more likely to achieve a 100% reduction in lesions at week 12 when compared with both vehicle and subjects who began BR treatment at week 8 (Figure 5) Safety • Only 8 treatment-related AEs in 6 subjects (3.2%) were reported; none were serious or severe. The regimen of IVM+BR is a safe and effective option for the comprehensive management of this complex disease • These studies suggest that initiating rosacea therapy with IVM+BR, along with a complete daily skin care regimen, may improve and accelerate the efficacy of IVM treatment, without impairing tolerability • Treating with IVM+BR from the start was more effective than an initial period of IVM treatment alone followed by IVM+BR REFERENCES 1.
    keywords: ivm; treatment; vehicle
       cache: skin-146.pdf
  plain text: skin-146.txt

        item: #350 of 1356
          id: skin-1461
      author: Mancuso, Christopher; Reiter, Paloma; Zambrano, Regina; Saini, Ritu; Sirota-Rozenberg, Suzanne
       title: SARS-Cov-2 Infection Uncovering Latent Mycobacterium Leprae Infection
        date: 2022-03-04
       words: 1714
      flesch: 47
     summary: Will cases of leprosy reaction increase with COVID-19 infection? There are very few reports of leprosy with concurrent COVID-19.1 Limited literature suggests two theories have been postulated thus far:
    keywords: case; covid-19; infection; leprosy; patients; skin; type
       cache: skin-1461.pdf
  plain text: skin-1461.txt

        item: #351 of 1356
          id: skin-1463
      author: Kolla, Avani; Fried, Lauren; Shah, Payal; Liebman, Tracey; Stein, Jennifer; Polsky, David
       title: Impact of Electrical Impedance Spectroscopy on Clinician Confidence and Diagnostic Accuracy in Evaluating Melanocytic Skin Lesions Suspicious for Melanoma: A Pilot Study
        date: 2022-01-17
       words: 4097
      flesch: 55
     summary: Results: Addition of EIS scores increased mean biopsy sensitivity for melanoma/severely dysplastic nevi from 70% to 84% (p = .014) and mean diagnostic accuracy from 74% to 86% (p = .005). The addition of EIS scores to clinical images resulted in more accurate biopsy decision- making by clinicians in survey studies.14-16.
    keywords: confidence; eis; images; lesions; melanoma; score; students
       cache: skin-1463.pdf
  plain text: skin-1463.txt

        item: #352 of 1356
          id: skin-1464
      author: Lee, Victoria; Hoffman, Mark ; Ruiz de Luzuriaga, Arlene
       title: A Case of Amelanotic Melanoma in the Setting of Cemiplimab Therapy for Invasive Squamous Cell Carcinoma
        date: 2022-03-04
       words: 1409
      flesch: 49
     summary: Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open- label, phase 2, single-arm trial. 4. Stratigos AJ, Sekulic A, Perris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    keywords: amelanotic; cemiplimab; melanoma; therapy
       cache: skin-1464.pdf
  plain text: skin-1464.txt

        item: #353 of 1356
          id: skin-1465
      author: Sterner, Jessica; Rushing, Benjamin; Rensch, Gage; Murina, Andrea
       title: Recognizing Adnexal Tumors in Skin of Color
        date: 2022-01-17
       words: 451
      flesch: 56
     summary: This case highlights the importance of recognizing pigmented adnexal tumors in skin of color and represents a rare location for an eccrine poroma. The differential diagnosis included acrochordon, condyloma, verrucous carcinoma, basal cell carcinoma, and melanoma.
    keywords: poroma; tumor
       cache: skin-1465.pdf
  plain text: skin-1465.txt

        item: #354 of 1356
          id: skin-1467
      author: Guenin, Sophie; Elbogen , Emily; Kresch , Mindy; Lebwohl , Mark
       title: Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35): Case Series 
        date: 2022-03-04
       words: 1807
      flesch: 56
     summary: Our goal is to call for closer investigation given the anecdotal increase in HZ cases seen in our vaccinated patients. Lastly, we must also acknowledge the variety of confounding factors in reported HZ cases during the pandemic.
    keywords: cases; reactivation; vaccination; vaccine; varicella; zoster
       cache: skin-1467.pdf
  plain text: skin-1467.txt

        item: #355 of 1356
          id: skin-147
      author: Stein Gold, Linda; Papp, Kim; Lynde, Charles; Lain, Edward; Gooderham, Melinda; Johnson, Sandra; Kerrouche, Nabil; Schafer, Gregor
       title: Concurrent Administration of Ivermectin 1% Cream with Brimonidine 0.33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate-to-Severe Rosacea
        date: 2017-10-27
       words: 1488
      flesch: 64
     summary: A trend towards higher efficacy was observed in the IVM+BR/12W compared to the IVM+BR/8W subgroup for both outcomes, corroborating the additive effect of BR when taken concomitantly with IVM treatment. Vehicle group: - Once-daily IVM vehicle and once-daily BR vehicle for 12 weeks (vehicle group, n=95).
    keywords: ivm; vehicle; weeks
       cache: skin-147.pdf
  plain text: skin-147.txt

        item: #356 of 1356
          id: skin-1471
      author: Lauck, Kyle ; Nguyen, Quoc-Bao; Hebert, Adelaide
       title: Trends in Medicare Reimbursement within Dermatology: 2011-2021
        date: 2022-03-04
       words: 4793
      flesch: 54
     summary: Extrapolation to general populations is difficult when only examining Medicare reimbursement which did not include individuals with supplemental Medicare plans nor individuals with private insurance. Nominal vs. inflation adjusted changes in Medicare reimbursement 2011 to 2021 Top 20 Most Common Procedures Unadjusted Reimbursement Reimbursement Adjusted for Inflation with Medical Care CPI HCPCS Code Description 2011 2021 Percent Change P- value 2011 2021 Percent Change P-value 17003 Destruction of premalignant lesion add-on $7.14 $6.63 -7.14% 0.131 $9.35 $6.63
    keywords: lesion; minutes; office; outpatient visit; skin
       cache: skin-1471.pdf
  plain text: skin-1471.txt

        item: #357 of 1356
          id: skin-1472
      author: Brownstone, Nicholas; Dirr, McKenzie; Rigel, Darrell
       title: Ulcerations and Lymphadenopathy in a 42 year old Male 
        date: 2022-01-17
       words: 774
      flesch: 56
     summary: While still a rare disease, it is important to be aware of this presentation, as extra-pulmonary TB has increased proportionally with rising total TB cases in industrialized countries from 7.6% in 1962 to 21% in 20063. Additionally, it is useful to perform a chest X- ray and abdominal ultrasound to ensure the patient does not have pulmonary TB or TB afflicting a different anatomic region5.
    keywords: medicine; society; tuberculosis
       cache: skin-1472.pdf
  plain text: skin-1472.txt

        item: #358 of 1356
          id: skin-1475
      author: Siegel , Daniel ; Murphy , Christopher; Wangsness, Kent; Perry , Allyson ; Smith , Ian 
       title: Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced Into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma
        date: 2022-03-04
       words: 5537
      flesch: 52
     summary: 112 future years and discounted the cost by prevailing interest rates estimated from the 10-year U.S. Treasury T-Bill rate (1%) to arrive at the cost in terms of dollars today.20 Inputs for cost trend, churn rate, and cost share were based on claims dated between January 1, 2017 and December 31, 2019.19 Estimating Return-on-Investment Figure 1 includes visual representations of the ROI model calculations, including Final Savings, Genomic Assessment Savings, Procedure Avoidance Savings, PLA Costs, and Plan Net Cost Per Member Per Month. Final Savings was calculated as Genomic Assessment Savings + Procedure Avoidance Savings – PLA Costs (Figure 1A).
    keywords: benign; biopsy; claims; cost; diagnosis; lesions; melanoma; pla; procedure; savings; skin
       cache: skin-1475.pdf
  plain text: skin-1475.txt

        item: #359 of 1356
          id: skin-1476
      author: Sanín-Guana, Antonio; Lebwohl, Mark
       title: Ustekinumab in the Treatment of Erythema Nodosum with Underlying Crohn’s Disease: A Case Report
        date: 2022-03-04
       words: 1520
      flesch: 55
     summary: The presence of ANCA and HLA-B27 antigen in patients with EN and IBD also argues in favor of the important role of genetic factors.8 EN is usually treated with corticosteroids and intensification of medical therapy to control intestinal disease.5 Ustekinumab is a monoclonal antibody that targets the p-40 subunit of the interleukin-12 (IL-12) and interleukin-23 (IL-23).9 It is approved by the FDA to treat moderate to severe plaque psoriasis and psoriatic arthritis, in addition to CD and UC.11 Inflammation of the gastrointestinal tract in CD patients has been associated with a Th1-type response; ustekinumab has been suggested to inhibit differentiation of Th1 cells in patients with CD. 149 BRIEF ARTICLE Ustekinumab in the Treatment of Erythema Nodosum with Underlying Crohn’s Disease: A Case Report Antonio Sanín-Guana, BA1, Mark G. Lebwohl, MD1 1 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY Erythema nodosum (EN) is a septal panniculitis characterized by raised, tender, red or purple lesions with a diameter of 1-5 cm.
    keywords: crohn; disease; patients; ustekinumab
       cache: skin-1476.pdf
  plain text: skin-1476.txt

        item: #360 of 1356
          id: skin-1477
      author: Carrillo, Brenda
       title: The Legacy of Lucio and Latapí: A Brief History
        date: 2022-05-06
       words: 465
      flesch: 43
     summary: A Brief History Brenda Carrillo, BS1 1University of Texas Medical Branch School of Medicine, Galveston, TX Rafael Lucio Nájera and Fernando Latapí contributed greatly to the knowledge about a specific form of diffuse lepromatous leprosy, now known as Lucio-Latapí leprosy. Rafael Lucio Nájera (left) and Fernando Latapí (right)2 https://www.zotero.org/google-docs/?2qn036 https://www.zotero.org/google-docs/?2qn036 SKIN May 2022 Volume 6 Issue 3 (c) 2022 THE AUTHORS.
    keywords: https://www.zotero.org/google-docs/?iihcpu; leprosy
       cache: skin-1477.pdf
  plain text: skin-1477.txt

        item: #361 of 1356
          id: skin-148
      author: Stein Gold, Linda; York, JP; Jacovella, Jean
       title: Consistent Efficacy and Safety in Four Double-Blind, Vehicle-Controlled Studies of Ivermectin 1% Cream in the Treatment of Moderate-to-Severe Papulopustular Rosacea
        date: 2017-10-27
       words: 1488
      flesch: 62
     summary: Phase 3 studies: a statistically superior rate of success was seen, compared to vehicle - 38.4%; Week 12, Phase 3, Study 1, n = 683, P < .001 - 40.1%; Week 12, Phase 3, Study 2, n = 688, P <
    keywords: phase; week
       cache: skin-148.pdf
  plain text: skin-148.txt

        item: #362 of 1356
          id: skin-1480
      author: Krenitsky, Amanda; Ravichandran, Sairekha; Cohen, Joel; Braue, Jonathan; Correa-Selm, Lilia
       title: Successful Dupilumab Treatment of Atopic Dermatitis in a Liver Transplant Patient 
        date: 2022-03-04
       words: 1039
      flesch: 40
     summary: However, there is little literature regarding treatment of this population, and standard regimens are not well-defined.2-4 Here, we report a case of successful treatment of AD in an orthotopic LT patient with dupilumab. However, there is dearth of literature regarding treatment of this population, and standard regimens are not well-defined.2-4 Here, we report a case of successful treatment of AD in an orthotopic LT patient with dupilumab.
    keywords: dermatitis; dupilumab; liver; transplant; treatment
       cache: skin-1480.pdf
  plain text: skin-1480.txt

        item: #363 of 1356
          id: skin-1481
      author: Galambus, Justine; Vafa, Atefah
       title: Hydroxychloroquine and Acute Generalized Exanthematous Pustolosis
        date: 2022-05-06
       words: 1593
      flesch: 50
     summary: 246 BRIEF ARTICLE Hydroxychloroquine and Acute Generalized Exanthematous Pustolosis Justine Galambus, BS1, Atefah Vafa, MD2 1 Morsani College of Medicine, University of South Florida, Tampa, FL 2 Department of Rheumatology, University of South Florida, Tampa, FL Acute generalized exanthematous pustulosis (AGEP) is a rare, potentially lethal, cutaneous reaction precipitated by drugs in more than 90% of cases,1 with the most common triggers being pristinamycin, aminopenicillins, quinolones, (hydroxy)chloroquine, sulfonamides, terbinafine, and diltiazem.1 AGEP typically presents within one day of treatment after antibiotic exposure versus eleven days after other drugs, including hydroxychloroquine (HCQ, Plaquenil).1 AGEP presents with innumerable pinhead-sized pustules arising on a diffuse erythematous background and are reported to localize in intertriginous zones, the trunk, and upper extremities.2 Diagnostic criteria outside of a pustular eruption include a fever, neutrophilia with or without mild eosinophilia, subcorneal or intraepidermal pustules on skin biopsy, and spontaneous resolution in less than 15 days.1 Sidoroff et al developed a validation scale founded in these criteria to aid clinicians in the diagnosis of AGEP. HCQ-precipitated AGEP is predominantly reported in the context of HCQ’s immunosuppressive action, most commonly when used to treat Rheumatoid Arthritis,9 Sjogren’s Syndrome,5 and Systemic Lupus Erythematous.6 However, with the increased use of HCQ as an antiviral for treatment of COVID-19, several cases of AGEP have been reported.10 AGEP tends to affect women, and HCQ-precipitated AGEP ABSTRACT Acute generalized exanthematous pustulosis (AGEP) is a rare, potentially lethal, cutaneous reaction most commonly precipitated by drugs.
    keywords: agep; case; hcq; hydroxychloroquine; patient; treatment
       cache: skin-1481.pdf
  plain text: skin-1481.txt

        item: #364 of 1356
          id: skin-1485
      author: Karlin, Samantha; Ritter, Alexandra; Linkous, Courtney; Wehlage, Katherine; Wine Lee, Lara
       title: Weekly Isotretinoin Therapy (WIT) Study: A Potential Alternative for the Treatment of Moderate Acne Vulgaris
        date: 2022-03-04
       words: 1142
      flesch: 56
     summary: Conclusion: Once weekly isotretinoin may be an additional treatment option for patients with moderate acne. Despite the lower total cumulative dose achieved versus with conventional dosing, recurrence rates were similar.3 Additionally, cost of alternative dosing was lower than conventional dosing, and patient satisfaction was highest in the alternative dosing groups.2-4 ABSTRACT Background: Treatment options for moderate acne remain limited.
    keywords: acne; isotretinoin; patients
       cache: skin-1485.pdf
  plain text: skin-1485.txt

        item: #365 of 1356
          id: skin-1487
      author: MacKenzie, James; Sagher, Miriam; Sagher, Ethan; Friedman, Ben; Veenstra, Jesse
       title: An Uncommon Presentation Of Erosive Pustular Dermatosis: A Large, Crusted Plaque On The Scalp
        date: 2022-03-04
       words: 963
      flesch: 49
     summary: Rarely, large solitary crusted plaques may be the sole manifestation of EPD, but have been seldom described in the current literature.1 These diagnoses have led to months of non-productive treatment consequently prescribed to the patients, such as imiquimod and 5-fluorouracil, which may further contribute to the progression of EPD without effectively treating the underlying condition.3,4 The pathology of EPD occurs below the crust, which is why our patient returned to the office for complete debridement of the crusted plaque (Figure 1B) after a diagnosis of EPD was made.
    keywords: crusted; epd; erosive; scalp
       cache: skin-1487.pdf
  plain text: skin-1487.txt

        item: #366 of 1356
          id: skin-1489
      author: Mostafa, Niyaz; Phan, Kevin; Amin, Tajrian; Smith, Saxon
       title: Hidradenitis Suppurativa and Down Syndrome: Systematic Review and Meta-Analysis
        date: 2022-05-06
       words: 2511
      flesch: 54
     summary: The pooled proportion of HS cases in the DS group was 10.9% (95% CI, 3.8%-27.6%). The pooled proportion of HS cases in the control group was 0.4% (95% CI, 0.2%-0.8%).
    keywords: dermatol; hidradenitis; patients; review; studies; suppurativa; syndrome
       cache: skin-1489.pdf
  plain text: skin-1489.txt

        item: #367 of 1356
          id: skin-149
      author: Webster, Guy; Schaller, Martin; Tan, Jerry; Jackson, Mark; Kerrouche, Nabil; Schafer, Gregor
       title: Achieving an Endpoint of Completely Clear of Inflammatory Lesions and Erythema After Treatment of Rosacea Provides Multiple Positive Patient Outcomes: A Pooled Analysis
        date: 2017-10-27
       words: 973
      flesch: 47
     summary: 2017;28(5):469-474. METHODS Study Design • Objectives - To evaluate whether, after successful treatment, “clear” subjects had better outcomes than “almost clear” subjects • Methods - Pooled analysis of 1366 rosacea subjects from 4 randomized controlled trials with IGA assessments before and after treatment (ivermectin, metronidazole, or vehicle) Representative Photographs (10355-108-028) IGA Score: 3 2 1 0 FC17PosterGaldermaWebsterAchievingCompleteyClearLesions.pdf
    keywords: relapse; subjects
       cache: skin-149.pdf
  plain text: skin-149.txt

        item: #368 of 1356
          id: skin-1491
      author: Ngonadi, Nwanneoma; Florenzo, Brian; Flowers, Richard; Martin, Seth
       title: Granulomatous Mastitis with Erythema Nodosum: A Case Report and Systematic Review
        date: 2022-03-04
       words: 4248
      flesch: 54
     summary: Compiled Additional Findings in GM with EN Cases as Reported in Literature Finding Number of Reported Cases Additional Symptom (n) Akın M, Karabacak H, Esendağlı G, et al. Coexistence of idiopathic granulomatous mastitis and erythema nodosum: successful treatment with corticosteroids.
    keywords: breast; cases; erythema; literature; mastitis; medicine; nodosum; patients; review; symptoms; treatment
       cache: skin-1491.pdf
  plain text: skin-1491.txt

        item: #369 of 1356
          id: skin-1494
      author: Imani, Saba; Gomez-Meade, Carlos 
       title: The “Brownsville Bolster”: A Novel Bolstering Technique for Full Thickness Skin Grafts 
        date: 2022-05-06
       words: 814
      flesch: 60
     summary: 259 therefore increasing graft vascularization and viability (Figure 1D). 257 SHORT COMMUNICATION The “Brownsville Bolster”: A Novel Bolstering Technique For Full Thickness Skin Grafts Saba Imani, DO1, Carlos Gomez-Meade, DO, FAAD, FACMS2 1 University of Oklahoma, Tulsa, OK 2 Oklahoma Cancer Specialists and Research Institute, Tulsa, OK
    keywords: bolster; graft; skin
       cache: skin-1494.pdf
  plain text: skin-1494.txt

        item: #370 of 1356
          id: skin-1495
      author: Daftary, Karishma; Chovatiya, Raj
       title: Persistent Papulosquamous Dermatitis as an Early Cutaneous Manifestation of Celiac Disease
        date: 2022-05-06
       words: 825
      flesch: 45
     summary: Other dermatologic diseases associated with CD include psoriasis, palmoplantar pustulosis, urticaria, rosacea, atopic dermatitis, and aphthous stomatitis, as well as several others with less supporting evidence.3-5 The risk of developing skin disorders is highest within the first year of CD diagnosis and may persist beyond 10 years1; however, patients may experience skin symptoms in the absence of gastrointestinal symptoms. Gluten and skin disease beyond dermatitis herpetiformis: a review.
    keywords: dermatitis; disease; skin
       cache: skin-1495.pdf
  plain text: skin-1495.txt

        item: #371 of 1356
          id: skin-1497
      author: Haddadin, Rakahn; Ahadiat, Omeed 
       title: Calcinosis Cutis: Case Report Of Topical Sodium Thiosulfate (STS) Treatment In The Context Of Dermatomyositis
        date: 2022-07-07
       words: 1302
      flesch: 53
     summary: Calcinosis is an extremely painful skin condition that causes impairment in daily tasks for many patients affected. This case report discusses a patient with dermatomyositis with painful CC that was treated successfully with topical STS.
    keywords: patient; sts; topical; treatment
       cache: skin-1497.pdf
  plain text: skin-1497.txt

        item: #372 of 1356
          id: skin-1498
      author: Ramachandran, Vignesh; Loya, Asad; Phan, Kevin 
       title: Second Primary Malignancies After Initial Cutaneous Angiosarcoma: A SEER population-Based Study
        date: 2022-05-06
       words: 1583
      flesch: 55
     summary: Specifically, there was increased risk of soft tissue malignancies, and non-epithelial skin malignancies other than melanoma/basal cell/squamous cell. Specifically, there was increased risk of soft tissue malignancies, and non-epithelial skin malignancies other than melanoma/basal cell/squamous cell.
    keywords: cas; malignancies; risk; skin; spms
       cache: skin-1498.pdf
  plain text: skin-1498.txt

        item: #373 of 1356
          id: skin-15
      author: Haslam, Samuel Paul; Smith, Robert C
       title: An Interesting Case of Muir-Torre Syndrome
        date: 2017-06-28
       words: 1431
      flesch: 51
     summary: A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir- Torre variant of Lynch syndrome. The frequency of Muir-Torre syndrome among Lynch syndrome families.
    keywords: lynch; muir; sebaceous; syndrome; torre
       cache: skin-15.pdf
  plain text: skin-15.txt

        item: #374 of 1356
          id: skin-1501
      author: Bard, Jason; Kornmehl , Heather; Wentzell, Joesph
       title: Auricular Distortion Following Cryotherapy
        date: 2022-03-04
       words: 733
      flesch: 50
     summary: About half of patients reported burning or stinging pain during treatment; no serious reactions were reported.2 The ears, particularly in shorter haired individuals, are a common site of actinic damage and are therefore commonly treated with cryotherapy techniques.3,4 SKIN March 2022 Volume 6 Issue 2 (c) 2022 THE AUTHORS. In terms of efficacy, one of the largest prospective studies on cryotherapy for the treatment of actinic keratosis found an overall complete response rate of 67.2%.
    keywords: antihelix; cryotherapy; helix
       cache: skin-1501.pdf
  plain text: skin-1501.txt

        item: #375 of 1356
          id: skin-1503
      author: Liu, Yuangao; Skopicki, Natalie; Nguyen, Harrison; Blalock, Travis
       title: Surprise Medical Billing Reform: Considerations for Dermatology
        date: 2022-03-04
       words: 1254
      flesch: 50
     summary: • Providers may not know in advance who will be involved in an episode of care and other providers’ contract status. The No Surprises Act seeks to set national standards to protect patients from unexpected medical bills while establishing processes for providers and payers to resolve billing disputes.
    keywords: billing; network; patients; process; providers
       cache: skin-1503.pdf
  plain text: skin-1503.txt

        item: #376 of 1356
          id: skin-1504
      author: Hogan, Elise; Nusbaum, Kelsey; Householder, Anne
       title: Subacute Cutaneous Lupus Erythematosus Associated with Ramucirumab Therapy
        date: 2022-03-04
       words: 820
      flesch: 43
     summary: There has been increasing discussion surrounding chemotherapeutic agents inducing SCLE, with highest risk medications of docetaxel, paclitaxel, fluorouracil, capecitabine, tamoxifen citrate, and doxorubicin.3 Ramucirumab is a fully human monoclonal antibody that targets VEGFR2, indicated in patients with hepatocellular carcinoma with prior treatment of sorafenib. 174 SHORT COMMUNICATION Subacute Cutaneous Lupus Erythematosus Associated with Ramucirumab Therapy Elise Hogan, BS1, Kelsey Nusbaum, BS1, Anne Householder, MD1 1University of Cincinnati College of Medicine, Cincinnati, OH Lupus erythematosus is an autoimmune inflammatory condition with a constellation of clinical findings including fever, malaise, myalgias, and loss of appetite/weight.1 Subsets of this disease are numerous, with subacute cutaneous lupus erythematosus (SCLE) demonstrating cutaneous manifestations.
    keywords: erythematosus; lupus; ramucirumab; scle
       cache: skin-1504.pdf
  plain text: skin-1504.txt

        item: #377 of 1356
          id: skin-1505
      author: Burli, Anuk; Law, Rebecca; Maibach , Howard 
       title: Percutaneous Penetration: Reliability of Mathematical Models
        date: 2022-03-04
       words: 737
      flesch: 49
     summary: Percutaneous penetration data regarding the use of sunscreens has also been recently studied. Although we have a global understanding of factors that control percutaneous penetration, experimental human in vivo data for few compounds exist- suggesting the need for QSAR based algorithms to predict flux- based on chemical structure.
    keywords: model; penetration; vivo
       cache: skin-1505.pdf
  plain text: skin-1505.txt

        item: #378 of 1356
          id: skin-1506
      author: Yang, Jay; Kirby, Joslyn; Maczuga, Steven
       title: Exploring the Psychosocial Impact on Parents of Adolescents Diagnosed With Hidradenitis Suppurativa: A Retrospective Claims-Based Analysis
        date: 2022-03-04
       words: 4379
      flesch: 57
     summary: After adjusting for parental sex, parental age, parental HS status, parental obesity, and change in employment status, the presence of HS in the adolescent was not a significant predictor (OR: 1.06 (95% CI: 0.98, 1.16), p = 0.15) of depression in the parent(s). Regression analysis shows that after adjusting for parental sex, parental age, parental HS status, parental obesity, depression, anxiety, and adolescent sex, the presence of HS in the adolescent contributed to a higher odds (OR: 1.17 (95% CI: 1.02, 1.34), p = 0.021) of employment change in the parent(s).
    keywords: adolescent; depression; employment; families; group; parents; status
       cache: skin-1506.pdf
  plain text: skin-1506.txt

        item: #379 of 1356
          id: skin-1507
      author: Ramachandran, Vignesh
       title: Space Medicine - The Next Frontier for Dermatology 
        date: 2022-05-06
       words: 1800
      flesch: 34
     summary: This has ramifications for the dermatology community that have been briefly introduced in the past,4 but have not gone into illustrating the dearth of dermatologists involved in space medicine. On another note, the effects of radiation exposure during spaceflight have implications for skin malignancies, further highlighting the role of dermatologists in space medicine.
    keywords: astronauts; dermatology; https://doi.org/10.1038/s41526-017-0015-y https://doi.org/10.1038/s41526-017-0015-y; medicine; skin; space; spaceflight; study
       cache: skin-1507.pdf
  plain text: skin-1507.txt

        item: #380 of 1356
          id: skin-1508
      author:  Altmann , Stefanie; Jacobs, Dominique ; Brown, Thomas ; Kamath, Preetha ; Krishnamurthy, Karthik 
       title: Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination 
        date: 2022-05-06
       words: 1731
      flesch: 55
     summary: BP affects the elderly and is typically seen in patients 70 years of age and older.5 This is due to either patient loss to follow-up or negative direct immunofluorescence.3 Additionally, new-onset BP has been reported in patients with acute SARS-CoV-2 infection.7-8 Our patient was not tested for SARS-CoV-2 at the time of diagnosis, as he was asymptomatic and had just completed the mRNA vaccine series.
    keywords: cov-2; doi; patient; pemphigoid; sars; vaccine
       cache: skin-1508.pdf
  plain text: skin-1508.txt

        item: #381 of 1356
          id: skin-1509
      author: Yousefian, Faraz; Espinoza, Liliana; Berger, Sarah; Osswald, Sandra; Petr, Frank
       title: Tophaceous Gout on Ear Imitating Squamous Cell Carcinoma
        date: 2022-07-07
       words: 1252
      flesch: 44
     summary: We present a case of tophaceous gout where the tophus presented on a patient’s superior helix of the ear, clinically mimicking a squamous cell carcinoma. He reported that he was treated ABSTRACT We report a case of tophaceous gout occurring in a Hispanic 69-year-old immunocompetent man.
    keywords: antonio; gout; lesion; san
       cache: skin-1509.pdf
  plain text: skin-1509.txt

        item: #382 of 1356
          id: skin-151
      author: Berman, Brian; Nestor, Mark
       title: An Investigator Blinded Randomized Study Evaluating HOCl in the Treatment of Atopic Dermatitis-Associated Pruritus
        date: 2017-10-27
       words: 1059
      flesch: 61
     summary: At the conclusion of the study, subjects in both groups were separated into those who had less itch (difference in itch between baseline and 72 hours was positive), same itch (difference in itch between baseline and 72 hours was equal to zero), or more itch at 72 hours (difference in itch between baseline and 72 hours was negative) (Figure 3). Effect of Treatment with HOCl Gel x3 days on Itch in Atopic Dermatitis Figure 4.
    keywords: hocl; hours; itch
       cache: skin-151.pdf
  plain text: skin-151.txt

        item: #383 of 1356
          id: skin-1511
      author: Pei, Evonne; Fatima, Sakeena; Konheim, Ari; Schrom, Kory P
       title: Late Onset Junctional Epidermolysis Bullosa in Adulthood
        date: 2022-07-07
       words: 1216
      flesch: 53
     summary: The typical age of onset is at birth, and it can present with either generalized or localized mucocutaneous findings.3 A rare subtype of JEB is JEB of late onset (JEB-lo), which occurs in young adulthood or later with blisters primarily located on the hands and feet.2 The typical age of onset is at birth, and it can present with either generalized or localized mucocutaneous findings.3 A rare subtype of JEB is JEB of late onset (JEB-lo), which occurs in young adulthood or later with blisters primarily located on the hands and feet.2 Other clinical features of this rare subtype include nail dystrophy, hyperhidrosis, loss of dermatoglyphs, and skin atrophy.2,4,5 We report a case of JEB-lo diagnosed in late adulthood.
    keywords: bullosa; epidermolysis; jeb; onset; skin
       cache: skin-1511.pdf
  plain text: skin-1511.txt

        item: #384 of 1356
          id: skin-1512
      author: Adams, Derrick; Mai, Kevin
       title: A Rare Presentation of Angiolymphoid Hyperplasia with Eosinophilia Involving the Scrotum
        date: 2022-07-07
       words: 1397
      flesch: 51
     summary: Figure 2. Case reports of angiolymphoid hyperplasia with eosinophilia have been inconsistent and underreported due to cases being incorrectly diagnosed as Kimura’s disease (KD).9 While ALHE and KD have similar characteristics, they are now characterized ALHE lesions often bleed easily and present as either asymptomatic or with pain, pruritis, or pulsations.3 Renal disease and peripheral eosinophilia occur in a minority of patients.4 Involvement of the oral mucosa, bone, muscle, parapharyngeal space, tongue, colon, and salivary glands are rare.5 There are less than 30 cases reported of male urogenital involvement.
    keywords: alhe; angiolymphoid; dermatol; eosinophilia; hyperplasia
       cache: skin-1512.pdf
  plain text: skin-1512.txt

        item: #385 of 1356
          id: skin-1514
      author: Shih, Terri; Brimacombe , Allison ; Shi, Vivian; Hsiao, Jennifer Lin
       title: Online Patient Health Resources in Nonmelanoma Skin Cancer: An Assessment of Readability, Quality, and Comprehensiveness
        date: 2022-05-06
       words: 3424
      flesch: 55
     summary: 50.6% included skin cancer images, of which only 17.5% were of skin of color patients. Only 37.5% (9/24) websites included images of skin cancer, of which only 2 of the 9 (22.2%) included images of skin cancer in SOC patients.
    keywords: cancer; health; images; nmsc; online; quality; readability; search; skin; websites
       cache: skin-1514.pdf
  plain text: skin-1514.txt

        item: #386 of 1356
          id: skin-1516
      author: Langley, Richard; Thaci, Diamant; Blauvelt, Andrew ; Tsai, Tsen-Fang; Miller, Megan ; Yu, Jenny; Shen, Yaung-Kaung ; You, Yin; Yang, Ya-Wen; Papp, Kim ; Puig, Luis; Foley, Peter
       title: Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials
        date: 2022-03-04
       words: 1629
      flesch: 47
     summary: Candida infection 0.02 (0.00, 0.11) 0 (0.00, 0.16) 0.01 (0.00, 0.08) *Search criterion: MedDRA high-level term, Candida infections; preferred terms with rate >0
    keywords: gus; infections; janssen; novartis; pfizer; pharma
       cache: skin-1516.pdf
  plain text: skin-1516.txt

        item: #387 of 1356
          id: skin-1517
      author: Blauvelt, Andrew ; Thaci, Diamant; Papp, Kim; Ho, Vincent ; Ghoreschi, Kamran; Kim, Byung Soo; Miller, Megan ; Shen, Yaung-Kaung ; You, Yin; Yu, Jenny; Yang, Ya-Wen; Crowley, Jeffrey; Foley, Peter
       title: Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 
        date: 2022-03-04
       words: 1986
      flesch: 35
     summary: Right breast lump observed ~1 year prior to study entry • Lump slowly enlarged and became tender • Diagnosis on Day 202: 2.7 cm subareolar right breast mass • Gene mutation identification testing was negative • Grade 3 infiltrating ductal carcinoma with focal micropapillary features • 2 of 6 lymph nodes positive for metastasis • Recovered following right modified radical mastectomy Patient 2: SAE of Recurrent Bronchial Carcinoma Patient 3: SAE of Invasive Melanoma Demographics & Medical Hx • White; male; Germany; age 57 years; BMI 36.6 kg/m2 • Lung cancer, smoker (0.5 packs/day), family Hx of cancer, benign prostatic hypertrophy, HTN • Prior methotrexate, ultraviolet B, and topical treatment Demographics & Medical Hx • White; male; Canada; age 71 years; BMI 31.9 kg/m2 • Type I/II skin; sun exposure from recreational activities (avid golfer) • Prostate cancer, family Hx of cancer, former smoker, alcohol consumption, hyperlipidemia • Prior topical treatment VOYAGE 2 Treatment • Randomized to adalimumab • Received GUS from W28-100 VOYAGE 2 Treatment • Randomized to placebo • Received GUS at W16 and W20; rerandomized to placebo from W28-72 • Open-label GUS Q8W from W72-180 • Total GUS exposure=161 weeks Malignancy SAE • Right lower lobe lung carcinoma diagnosed on Day 753 (Stage IVB; cT4 N3 M1c) • Tumor infiltration into middle lobe; exophytic tumor growth in lower lobe • Poorly differentiated non-cornified squamous cell carcinoma, programmed death-ligand 1 negative • 3 supratentorial brain metastases • Died of bronchial carcinoma ~4 months after study discontinuation Malignancy SAE* • Right forearm invasive melanoma diagnosed on Day 1139 • Ulcerated depth=at least 0.7 mm; mitotic rate=3 cells/mm2 • Margins involved; no lymphovascular invasion • Had 2 basal cell carcinomas during study (left cheek, Day 211; left ankle, Day 1139) • Recovered after surgical removal of melanoma Age; Race; Sex; Country; Study Prior Malignancy Treatment Phase SAE (Day; Treatment Relatedness; Outcome) 57 y; Asian; F; Korea; VOY 2 Cervical cancer GUS GUS • Multiple fractures (Day 141; Not related; Resolved) • Subdural hemorrhage (Day 141; Not related; Resolved) 57 y; White; F; Germany; VOY 2 Breast cancer Withdrawal Withdrawal • Noncardiac chest pain (Day 204; Not related; Resolved) • Herniated disc (Day 231; Not related; Resolved) 64 y; White; F; Spain; VOY 2 Breast cancer GUS Withdrawal • Cardiac failure (Day 127; Not related; Resolved) • Respiratory failure (Day 238; Not related; Resolved) 68 y; White; M; USA; VOY 2 Dermatofibrosarcoma protuberans GUS GUS (open-label) GUS (open-label) • Cellulitis (Day 435; Possible; Resolved) • Presyncope (Day 1201; Not related; Not resolved) • Chest injury (Day 1378; Not related; Resolved) 59 y; White; F; USA; VOY 1 Cervical cancer GUS (open-label) • Patients with a history of malignancy are often excluded from clinical trials, which limits the availability of safety data for biologics in this population1,2 • Guselkumab (GUS), an interleukin-23 p19 subunit inhibitor, is approved for the treatment of moderate to severe psoriasis and active psoriatic arthritis • VOYAGE 1 and 2 were Phase 3 studies that demonstrated the long-term efficacy and safety of GUS in patients with moderate to severe psoriasis3,4 • These studies included a small number of patients with a history of malignancy (excluding non-melanoma skin cancer
    keywords: cancer; day; gus; history; malignancy; patients; pharma
       cache: skin-1517.pdf
  plain text: skin-1517.txt

        item: #388 of 1356
          id: skin-1519
      author: Merola, Joe; Puig, Luis; Miller, Megan ; You, Yin; Shen, Yaung-Kaung ; Yang, Ya-Wen; Blauvelt, Andrew 
       title: Mean Percentage Improvement in Psoriasis Area and Severity Index (PASI) Response and Absolute PASI Through 5 Years of Continuous Treatment With Guselkumab (GUS) in VOYAGE 1 
        date: 2022-03-04
       words: 1788
      flesch: 59
     summary: In addition to patients randomized to GUS, PBO, and ADA at baseline, treatment groups analyzed: o GUS Group: Baseline Demographics and Disease Characteristics PBO GUS ADA Total Randomized patients, n
    keywords: baseline; gus; pasi; week
       cache: skin-1519.pdf
  plain text: skin-1519.txt

        item: #389 of 1356
          id: skin-152
      author: Jacobi, Arnd; Mayer, Anke; Anastasiadou, Zografia; Augustin, Matthias
       title: Keratolytic Activity of a Novel Dimethicone Formulation (PB/LO-112) Compared to 10% Salicylic Acid Oil in Patients with Psoriasis Capitis
        date: 2017-10-27
       words: 960
      flesch: 50
     summary: EFFICACY (PSSI scaling score) Methods In this single-center, randomized, active-controlled, observer-blinded, parallel group trial, 90 patients with chronic psoriasis capitis were randomized equally into 2 groups: one receiving the dimethicone formulation LOYON® (test group) and the other receiving a topical 10% salicylic acid formulation (10-SA, standard group). Relative reduction of PSSI was in favor of PB-LO/112 after 3 treatment days (25% for PB-LO/112 vs.14% for 10-SA; and increased for PB-LO/112 to 38% after 7 days, while 10-SA remained on the initial level.
    keywords: psoriasis
       cache: skin-152.pdf
  plain text: skin-152.txt

        item: #390 of 1356
          id: skin-1520
      author: Warren , Richard; Armstrong , April; Gooderham, Melinda; Strober , Bruce; Thaci, Diamant; Imafuku, Shinichi; Sofen, Howard; Spelman, Lynda; Korman, Neil; Zheng, Min; Colston, Elizabeth; Throup , John; Kundu, Sundeep; Kisa, Renata; Banerjee, Subhashis; Blauvelt, Andrew 
       title: Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
        date: 2022-03-04
       words: 3271
      flesch: 44
     summary: Acknowledgments • These clinical trials were sponsored by Bristol Myers Squibb • Writing and editorial assistance were provided by Lisa Feder, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, funded by Bristol Myers Squibb Disclosures • RBW: Consulting fees: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, UCB, and Xenoport; Research grants: AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, and UCB; Honorarium: Biogen • AWA: Grants and personal fees: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, and Novartis; Personal fees:
    keywords: 0/1; deucravacitinib; n =; pasi; patients; placebo; week
       cache: skin-1520.pdf
  plain text: skin-1520.txt

        item: #391 of 1356
          id: skin-1521
      author: Strober , Bruce; Stein Gold, Linda; Bissonnette, Robert; Armstrong , April; Blauvelt, Andrew ; Kircik, Leon ; Brown, Philip ; Tallman, Anna; Lebwohl, Mark
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent 
        date: 2022-03-04
       words: 2507
      flesch: 25
     summary: B.S. has served as an honorary consultant/speaker/scientific director/investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Cara, Celgene, Corrona Psoriasis Registry, Dermavant Sciences Inc., Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron and Sanofi-Genzyme. R.B. has served as a consultant/advisory board member/speaker/investigator, and/or receives honoraria/grant from Almirall, Amgen, AnaptysBio, Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bausch Health, Bellus Health, Bluefin Biomedicine, Boehringer-Ingelheim, Bristol-Myers Squibb, CARA, Dermavant Sciences Inc., Eli Lilly, EMD Serono, Escalier, Evidera, Galderma, GSK, Inmagene Bio, Incyte, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Nimbus, Novan, Pfizer, Ralexar, RAPT, Regeneron, Respivant, Sanofi Genzyme, Sienna, Target RWE, and UCB.
    keywords: cream; disease; inc; patients; pga; tapinarof
       cache: skin-1521.pdf
  plain text: skin-1521.txt

        item: #392 of 1356
          id: skin-1523
      author: Kircik, Leon ; Stein Gold, Linda; Del Rosso, James; Desai, Seemal; Glick, Brad; Sofen, Howard; Tallman, Anna; Rubenstein, David; Fournier, Janine; Brown, Philip 
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials
        date: 2022-03-04
       words: 1954
      flesch: 29
     summary: Although conclusions cannot be drawn due to the small number of patients in some subgroups, the frequency and type of AEs appeared to be generally comparable across subgroups and consistent with those observed in the overall population CONCLUSIONS ■ Tapinarof cream 1% QD was consistently efficacious and well tolerated irrespective of baseline PGA score, BSA affected, duration of psoriasis, sex, age, race, or country of enrollment (US or Canada) ■ Due to the small number of patients in some subgroups, limitations exist regarding the ability to draw definitive conclusions from the subgroup analysis ■ The consistent efficacy and tolerability in all subgroups support the potential use of tapinarof cream across a broad spectrum of disease severity and patient demographics ■ A long-term extension trial (PSOARING 3) of intermittent treatment with tapinarof cream 1% QD based on PGA score demonstrated continued efficacy following the 12-week pivotal trials and an ~4-month remittive effect off therapy2 ■ Tapinarof cream 1% QD has potential to be the first topical psoriasis treatment with a novel mechanism of action in over 20 years REFERENCES 1. PGA Response by Baseline Disease Characteristics and Demographics ■ The primary endpoint (PGA of 0 or 1 and ≥2-grade improvement at Week 12) was met; PGA response rates were highly statistically significant in the tapinarof cream 1% QD group versus the vehicle group in both PSOARING 1 and 2: 35.4% vs 6.0% (P<0.0001) and 40.2% vs 6.3% (P<0.0001), respectively1 ■ The efficacy of tapinarof cream was consistent across subgroups, regardless of baseline disease characteristics such as PGA score, %BSA affected, and duration of disease, and demographics such as sex, age, race, country of enrollment (Figure 2) ■ Notably, based upon the definition of PGA response requiring achievement of PGA=0 or 1 with ≥2-grade improvement, mild patients had to achieve complete disease clearance (PGA=0) and severe patients had to improve a minimum of 3 points, to be responders Figure 2. PGA Response at Week 12 by Baseline Disease Characteristics (A) and Demographics (B) (Pooled PSOARING 1 and 2) *Lower limit of the 95% CI for the relative risk >1, indicating a significantly higher probability of PGA response with tapinarof compared with vehicle.
    keywords: baseline; inc; pga; response; tapinarof; vehicle
       cache: skin-1523.pdf
  plain text: skin-1523.txt

        item: #393 of 1356
          id: skin-1524
      author: Bagel, Jerry ; Stein Gold, Linda; Del Rosso, James; Bhatia, Neal; Johnson , Sandy ; Yamauchi, Paul; Moore, Angela; Tallman, Anna
       title: Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial
        date: 2022-03-04
       words: 2031
      flesch: 0
     summary: ■ Overall, 40.9% (312/763) of patients achieved complete disease clearance at least once during the study; this included 233 patients who entered the study with a Physician Global Assessment (PGA) score of ≥1 and 79 patients who entered with a PGA of 04 ■ The median duration of remittive effect while off therapy for patients who entered the study with a PGA of 0 was 115 days, and the mean total duration of remittive effect off therapy for patients who entered with, or achieved, a PGA of 0 was 130 days4 ■ Durability of response of up to 52 weeks was demonstrated with intermittent use of tapinarof cream 1% QD, indicating no observation of tachyphylaxis (defined as loss of response) while on therapy4 ■ Tapinarof cream 1% QD was well tolerated with long-term use and had a safety profile consistent with previous studies2,5 RESULTS Patient Satisfaction Questionnaire ■ 91.6% of eligible patients (n=763) completing PSOARING 1 and 2 elected to enroll in PSOARING 3 ■ Patient Satisfaction Questionnaires were completed by 78.5% (599/763) of patients in PSOARING 3 ■ Patients consistently reported high satisfaction rates across all parameters, including patients’ satisfaction with tapinarof efficacy, formulation elegance, application ease, impact on daily life, and preference for tapinarof cream versus prior psoriasis therapies Confidence and Satisfaction with the Efficacy of Tapinarof Cream ■ Most patients either strongly agreed or agreed with all questions on confidence and satisfaction with the efficacy of tapinarof cream (Figure 3) ■ 85.8% felt they could easily manage their psoriasis with tapinarof, and 83.6% were satisfied with how well tapinarof worked ■ In addition to the 40.9% of patients who achieved complete disease clearance and the observed remittive effect of ~4 months, 62.9% of patients either strongly agreed or agreed that tapinarof cleared their skin and kept psoriasis from coming back ■ 84.1% had confidence in tapinarof, and 84.0% would recommend tapinarof to other patients with psoriasis ■ 82.5% of patients would use tapinarof again or continue on tapinarof if it was available Figure 3. Confidence and Satisfaction with the Efficacy of Tapinarof Cream (n=599) Ease of Application and Cosmetic Elegance of Tapinarof Cream ■ Patients were consistently very satisfied with the tapinarof cream formulation and elegance (Figure 4) ■ 93.2% were satisfied with the time spent applying tapinarof, and 96.3% considered it easy to apply ■ In addition, most patients either strongly agreed or agreed that tapinarof was quickly absorbed (89.5%), felt good on their skin (79.9%), and was not greasy (89.0%) ■ 87.7% were very satisfied with the look and feel of tapinarof Figure 4.
    keywords: cream; patients; psoriasis; satisfaction; tapinarof
       cache: skin-1524.pdf
  plain text: skin-1524.txt

        item: #394 of 1356
          id: skin-1525
      author: Pinter, Andreas; Præstegaard, Morten; Selmer, Johan; Reich, Adam
       title: Calcipotriene And Betamethasone Dipropionate Cream Demonstrates High Treatment Success In Patients With Scalp Psoriasis
        date: 2022-03-04
       words: 815
      flesch: 58
     summary: • CAL/BDP cream demonstrated high PGA treatment success and satisfaction, fast onset of action and a favourable safety profile in patients with scalp psoriasis. • Efficacy analyses of scalp psoriasis, included patients with scalp involvement of at least 10% and a PGA on the scalp of at least mild severity (grade 2) at baseline (CAL/BDP cream n=112; vehicle n=38; Table 1).
    keywords: bdp; scalp
       cache: skin-1525.pdf
  plain text: skin-1525.txt

        item: #395 of 1356
          id: skin-1526
      author: Stein Gold, Linda; Selmer, John; Præstegaard, Morten; Armstrong , April
       title: Calcipotriene and betamethasone dipropionate cream demonstrates superior efficacy in moderate plaque psoriasis compared to topical suspension: a subgroup analysis of a phase 3 trial
        date: 2022-03-04
       words: 1156
      flesch: 62
     summary: Figure 2. mPASI75 (a) and DLQI Satisfaction (b) in patients with moderate psoriasis by weeks of treatment • CAL/BDP cream demonstrated significantly greater mPASI75 compared to CAL/BDP TS in moderate psoriasis patients (42.3% versus 29.7%; p=0.0027) with significant difference also at Week 4 (p=0.0008) (Figure 2a). PTCS scores for moderate psoriasis patients (CAL/BDP cream vs. TS) # Question Odds Ratio (CI 95%) P-value 1 How easy was the treatment to apply to the skin?
    keywords: bdp; cal; cream; psoriasis
       cache: skin-1526.pdf
  plain text: skin-1526.txt

        item: #396 of 1356
          id: skin-1527
      author: Le, Marilyn; Kamrani, Payvand; Hollins , L. Claire
       title: Coexistentence of Morphea and DLE in a Patient with Beta Thalassemia Leading to a Diagnosis of Systemic Lupus Erythematous
        date: 2022-05-06
       words: 1119
      flesch: 60
     summary: 243 BRIEF ARTICLE Coexistent of Morphea and DLE in a Patient With Beta Thalassemia Leading to a Diagnosis of Systemic Lupus Erythematous Marilyn Le, MS1, Payvand Kamrani, DO2, L. Claire Hollins, MD2 1 Philadelphia College of Osteopathic Medicine, Philadelphia, PA 2 Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA An 18-year-old female with beta thalassemia presented with a six-month history of rash. In this case, we describe a patient with morphea and discoid lupus erythematous in the setting of beta thalassemia leading to diagnosis of SLE.
    keywords: beta; lupus; morphea; sle; thalassemia
       cache: skin-1527.pdf
  plain text: skin-1527.txt

        item: #397 of 1356
          id: skin-1528
      author: Reich , Kristian; Armstrong , April; Zhu, Yaowei; Miller, Megan ; You, Yin; Shen, Yaung-Kaung ; Yang, Ya-Wen; Foley, Peter; Griffiths, Christopher; Strober , Bruce
       title: Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies
        date: 2022-03-04
       words: 2028
      flesch: 53
     summary: ADA positive patients in VOYAGE 1 and VOYAGE 2, respectively, were positive for NAbs to GUS • Through the end of the 5-year VOYAGE 1 and VOYAGE 2 studies of GUS in psoriasis, 15% of patients had developed ADA to GUS.
    keywords: gus; guselkumab; patients; pharma; voyage; week
       cache: skin-1528.pdf
  plain text: skin-1528.txt

        item: #398 of 1356
          id: skin-1529
      author: Keri, Jonette; Kircik, Leon ; Green, Lawrence; Ablon, Glynis; Werschler, William ; Tanghetti, Emil; Draelos, Zoe; Guenin, Eric
       title: Treating Acne in Obese and Morbidly Obese Patients With Tazarotene 0.045% Lotion: Post Hoc Analysis of Pooled Phase 3 Data
        date: 2022-03-04
       words: 1620
      flesch: 52
     summary: -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 Vehicle Lotion (n=172) TAZ 0.045% Lotion (n=160) -70% -60% -50% -40% -30% -20% -10% 0% Baseline Week 4 Week 8 Week 12 Vehicle Lotion (n=172) TAZ 0.045% Lotion (n=160)
    keywords: acne; lotion; obese; tazarotene; vehicle; week
       cache: skin-1529.pdf
  plain text: skin-1529.txt

        item: #399 of 1356
          id: skin-153
      author: Nguyen, Tien Q; Nguyen, Andrea
       title: A Case Study Series to Evaluate the Safety and Efficacy of a Novel Keratolytic in Patients Diagnosed with Plaque Psoriasis
        date: 2017-10-27
       words: 561
      flesch: 51
     summary: A Case Study Series to Evaluate the Safety and Efficacy of a Novel Keratolytic in Patients Diagnosed with Plaque Psoriasis Tien Q. Nguyen, M.D., Andrea Nguyen, MS, PA-C First O C Dermatology, Fountain Valley, CA Background Many patients with plaque psoriasis suffer from noticeable physical disease aff liction. This study evaluated the safety and effectiveness of LOYON® in treating plaque and scaling buildup in patients diagnosed with plaque psoriasis.
    keywords: psoriasis; visit
       cache: skin-153.pdf
  plain text: skin-153.txt

        item: #400 of 1356
          id: skin-1530
      author: Moore, Angela; Moore, Stephen; Moore, Luke; Grada, Ayman; Tyring, Stephen
       title: Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities
        date: 2022-03-04
       words: 600
      flesch: 50
     summary: PowerPoint Presentation INTRODUCTION RESULTS METHODS REFERENCES CONCLUSIONS CLINICAL IMPLICATIONS Baseline; IGA 4 Week 12; IGA 1 14-year-old White Male Chest Back Baseline; IGA 3 Week 12; IGA 1 13-year-old Hispanic Female Chest Back Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities Angela Yen Moore1,2, Stephen Moore1,3, Luke Moore1, Ayman Grada4, Stephen K Tyring3 1Arlington Research Center, Arlington, TX, USA; 2Baylor University Medical Center, Dallas, TX, USA 3Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA; 4Grada Dermatology Research LLC, Chesterbrook, PA, USA ▪ 60-70% of patients present with acne on the trunk.1 ▪ Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated. 3 ▪ Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials.
    keywords: acne; sarecycline
       cache: skin-1530.pdf
  plain text: skin-1530.txt

        item: #401 of 1356
          id: skin-1531
      author: Bhatia, Neal; Lain, Edward ; Baldwin, Hilary ; Brantman, Sam ; Del Rosso, James; Sivamani, Raja
       title:  Encapsulated benzoyl peroxide (E-BPO): A novel formulation of BPO for long-term management of rosacea
        date: 2022-03-04
       words: 1544
      flesch: 59
     summary: See Table 3. E-BPO Provided a Sustained Effect in Rosacea Patients for Over 1 Year (52 Weeks) Vehicle in Phase *Note: Treatment-emergent adverse events are those events with an onset after the first application of E-BPO Cream 5%.
    keywords: bpo; safety; study; subjects; week
       cache: skin-1531.pdf
  plain text: skin-1531.txt

        item: #402 of 1356
          id: skin-1532
      author: Del Rosso, James; Bhatia, Neal; Baldwin, Hilary ; Stein Gold, Linda; Desai, Seemal; Brantman, Sam 
       title: Critical Evaluation of Benzoyl Peroxide in Rosacea: Old Challenges and New Clinical Opportunities With Encapsulated Benzoyl Peroxide 
        date: 2022-03-04
       words: 1678
      flesch: 66
     summary: The disease is frequently characterized by remissions and exacerbations1 CRITICAL EVALUATION OF BENZOYL PEROXIDE IN ROSACEA: OLD CHALLENGES AND NEW CLINICAL OPPORTUNITIES WITH ENCAPSULATED BENZOYL PEROXIDE James Q. Del Rosso, DO1; Neal D. Bhatia, MD2; Hilary Baldwin, MD3; Linda Stein Gold, MD4; Seemal R. Desai, MD5,6; Sam Brantman, PharmD7 1JDR Dermatology Research, Las Vegas, NV; 2Therapeutics Clinical Research, San Diego, CA; 3The Acne Treatment & Research Center, Brooklyn, NY, and Rutgers Robert Wood Johnson Medical Center, New Brunswick, NJ; 4Henry Ford Health Systems, Detroit, MI; 5Innovative Dermatology, Plano, TX; 6Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX; 7Galderma Laboratories, L.P., Fort Worth, TX METHODS Co-primary Endpoints • Proportion of subjects with the primary measure of success, “Clear” (0) or “Almost clear” (1), in the Investigator Global Assessment (IGA) relative to baseline at Week 12 - The IGA scale ranged from “Clear” (0) to “Severe” (4) and included the number of papules/pustules and erythema severity • Absolute mean change in inflammatory lesion counts from baseline to Week 12 Secondary Endpoints • Percentage change in inflammatory lesion count from baseline to Week 12 • Absolute change in inflammatory lesion count from baseline to Week 8 Study Design of the Two Pivotal Phase 3 Trials for E-BPO Cream, 5% (Figure 1) REFERENCES 1. In both studies, E-BPO cream, 5%, demonstrated statistically significant improvement in the co-primary endpoint of the number of subjects achieving “Clear” or “Almost clear” • In Study 1, 47.4% of subjects treated with E-BPO achieved IGA success at Week 12 versus 20.7% of subjects treated with vehicle.
    keywords: baseline; bpo; study; vehicle; week
       cache: skin-1532.pdf
  plain text: skin-1532.txt

        item: #403 of 1356
          id: skin-1533
      author: Del Rosso, James; Sugarman , Jeffrey; Gold, Michael; Arekapdui, Krysten; Green, Lawrence
       title: A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin   
        date: 2022-03-04
       words: 1678
      flesch: 66
     summary: The disease is frequently characterized by remissions and exacerbations1 CRITICAL EVALUATION OF BENZOYL PEROXIDE IN ROSACEA: OLD CHALLENGES AND NEW CLINICAL OPPORTUNITIES WITH ENCAPSULATED BENZOYL PEROXIDE James Q. Del Rosso, DO1; Neal D. Bhatia, MD2; Hilary Baldwin, MD3; Linda Stein Gold, MD4; Seemal R. Desai, MD5,6; Sam Brantman, PharmD7 1JDR Dermatology Research, Las Vegas, NV; 2Therapeutics Clinical Research, San Diego, CA; 3The Acne Treatment & Research Center, Brooklyn, NY, and Rutgers Robert Wood Johnson Medical Center, New Brunswick, NJ; 4Henry Ford Health Systems, Detroit, MI; 5Innovative Dermatology, Plano, TX; 6Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX; 7Galderma Laboratories, L.P., Fort Worth, TX METHODS Co-primary Endpoints • Proportion of subjects with the primary measure of success, “Clear” (0) or “Almost clear” (1), in the Investigator Global Assessment (IGA) relative to baseline at Week 12 - The IGA scale ranged from “Clear” (0) to “Severe” (4) and included the number of papules/pustules and erythema severity • Absolute mean change in inflammatory lesion counts from baseline to Week 12 Secondary Endpoints • Percentage change in inflammatory lesion count from baseline to Week 12 • Absolute change in inflammatory lesion count from baseline to Week 8 Study Design of the Two Pivotal Phase 3 Trials for E-BPO Cream, 5% (Figure 1) REFERENCES 1. In both studies, E-BPO cream, 5%, demonstrated statistically significant improvement in the co-primary endpoint of the number of subjects achieving “Clear” or “Almost clear” • In Study 1, 47.4% of subjects treated with E-BPO achieved IGA success at Week 12 versus 20.7% of subjects treated with vehicle.
    keywords: baseline; bpo; study; vehicle; week
       cache: skin-1533.pdf
  plain text: skin-1533.txt

        item: #404 of 1356
          id: skin-1534
      author: Del Rosso, James; Kircik, Leon ; Stein Gold, Linda; Baldwin, Hilary ; Weiss, Jonathan ; Pariser, David; Callender, Valerie ; Lain, Edward ; Gold, Michael; Beer, Kenneth ; Draelos, Zoe; Sadick, Neil; Pillai, ; Radhakrishnan; Bhatt, Varsha; Tanghetti, Emil
       title: Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug
        date: 2022-03-04
       words: 2232
      flesch: 39
     summary: In�ammatory Lesions -100% -80% -60% -40% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e 0% -76.4% -69.2% -64.0% -68.1% -50.4% ** ** ** *** -20% B. Nonin�ammatory Lesions -100% -80% -60% -40% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e 0% -71.0% -60.7%-58.7%-61.1% -45.8% ** *** ** *** -20% IDP-126 Gel (n=146) , LLC is an affiliate of Bausch Health Companies Inc. � CeraVe® hydrating cleanser and CeraVe® moisturizing lotion (L’Oreal, NY) were provided as needed for optimal moisturization/cleaning of the skin � Endpoints were treatment success at week 12 (≥2-grade reduction from baseline in EGSS and clear/almost clear skin) and least-squares (LS) mean changes from baseline to week 12 in inflammatory/ noninflammatory lesions � Treatment-emergent adverse events (TEAEs) and cutaneous safety and tolerability (via 4-point scale where 0=none and 3=severe) were also assessed RESULTS Participants � A total of 741 participants were enrolled (intent-to- treat population: n=740; safety population: n=725) � Mean age was approximately 19.5 years, most participants were female and White, and most had moderate disease (EGSS 3) at baseline (Table 1) � Treatment compliance across treatment groups was ≥93% Efficacy � At week 12, over half of participants achieved treatment success with IDP-126 vs ~30% or less with vehicle and dyads (P≤0.001, all; Figure 1) � IDP-126 also demonstrated significantly greater absolute reductions in the number of inflammatory and noninflammatory lesions vs vehicle or dyads, (P<0.05, all) corresponding to >70% reductions (Figure 2) � Images depicting acne improvements in IDP-126- treated participants are shown in Figure 3 Safety � TEAE rates were higher with IDP-126 and BPO/adapalene vs clindamycin/BPO, clindamycin/adapalene, or vehicle at week 12 (Table 2) � Most TEAEs were of mild-to-moderate severity (data not shown) � With IDP-126, there was no severe scaling, erythema, hypopigmentation, or itching, and <5% of participants had severe hyperpigmentation, burning, or stinging (Table 3) FIGURE 3.
    keywords: adap; bpo; clin; clindamycin; gel; idp-126; peroxide; phosphate
       cache: skin-1534.pdf
  plain text: skin-1534.txt

        item: #405 of 1356
          id: skin-1535
      author: Sadick, Neil; Cook-Bolden, Fran; Beer, Kenneth ; Draelos, Zoe; Kircik, Leon ; Tanghetti, Emil; Guenin, Eric
       title: Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Different Adult Age Groups
        date: 2022-03-04
       words: 2143
      flesch: 51
     summary: In�ammatory Lesion Reduction -53.7% -60.6% ** ≥25 years -57.3% -60.9% Vehicle LotionTazarotene 0.045% Lotion -10% n= 374 n= 370 n= 167 n= 168 -30% -70% -50% ≥18 years 0% B. Nonin�ammatory Lesion Reduction -48.4% -59.0% *** ≥25 years -48.8% -61.1% ** -10% n= 374 n= 370 n= 167 n= 168 40% 0% 20% ≥18 years P e rc e n ta g e o f P a rt ic ip a n ts 100% C. Treatment Successa 24.8% ** 35.8% ≥25 years 26.1% 35.9% 60% n= 374 n= Safety � TEAE rates/severity/relationship to study drug and the most common TEAEs were generally similar for tazarotene-treated females in both age groups (Table 2); most TEAEs were mild to moderate in severity • Rates of treatment-related application site dryness and exfoliation were slightly higher among females ≥25 years than females ≥18 years, consistent with the association between adult female acne and dry skin � Rates of application site irritation related to tazarotene treatment were low for both female age groups (≥18 years, 1.1%; ≥25 years, 0.6%) TABLE 2.
    keywords: acne; females; lotion; tazarotene; years
       cache: skin-1535.pdf
  plain text: skin-1535.txt

        item: #406 of 1356
          id: skin-1536
      author: Berman, Brian ; Armstrong , April; Lebwohl, Mark; Grada, Ayman; Bhatia, Neal; Patel, Vishal; Rigel, Darrell; Del Rosso, James; Schlesinger, Todd; Kircik, Leon ; Salem, Raidah; Kasujee, Ismail
       title: Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol
        date: 2022-03-04
       words: 1866
      flesch: 31
     summary: TS reports receiving grant/research funding from AbbVie, Aclaris, Allergan, Anterios, AOBiome, Arcutis Premier Research, Astellas Pharma US, Inc, Athenex, Biofrontera, Biorasi, Boehringer Ingelheim, Brickell Biotech, Bristol-Myers Squibb, Cara Therapeutics, Castle BioScience, Celgene, Centocor Ortho Biotech (Now Janssen Biotech), ChemoCentryx, Coherus Biosciences, Concert Pharmaceutical, Corrona, Cutanea Life Sciences, Dermavant, Dermira, DT Pharmacy & DT Collagen (Melasma), EPI Health, Galderma (Nestle), Janssen Pharmaceuticals, Inc, Kiniksa, Leo, Lilly, Merz, Nestle Skin Health, Nimbus, Novartis, Pfizer, Processa, Pulse Biosciences, Regeneron, Sanofi Genzyme, Sisaf, and Trevi; has received honoraria from AbbVie, Allergen, Almirall, Biofrontera AG, Bristol-Myers Squibb, Castle BioScience, EPI Health, Foundation for Research and Education in Dermatology (FRED), Galderma (Nestle), Merz, Novartis, Regeneron, and Sun Pharma; and has served as a speaker, advisory board member, or consultant for AbbVie, Allergan, Almirall, Amgen, Biofrontera AG, Bristol-Meyers Squibb, Castle BioScience, Celgene, CMS Aesthetics DCME, DUSA/Sun Pharma, EPI Health, Foundation for Research and Education in Dermatology (FRED), Genentech, Greenway Therapeutix, Kintor, Merz, Nextphase, Novartis, Pharmatecture, Prolacta Biosciences, Pulse Biosciences, Regeneron, Remedly, Inc, Sanofi Genzyme, Sun Pharma, UCB, and Verrica; has received consulting fees from Lilly, Ortho Dermatologics, Pierre Fabre, Plasmed, Regeneron, and Skinceuticals/L’Oreal; has been involved in the CME Program for MED Learning Group; has been involved with OncLive SSC Insights Filming/Stacy Jaffe for MJH Associates; and owns stock in Remedly, Inc. LK has served as an investigator, speaker, advisory board member , or consultant for Abbott Laboratories; Aclaris, Inc; Allergan, Inc; Almirall; Anacor Pharmaceuticals, Inc; Assos Pharma; Astellas Pharma US, Inc; Asubio Pharma Co, Ltd; Berlex Laboratories (Bayer Healthcare Pharmaceuticals); Biogen-Idec, Inc; Biolife; Biopelle; Boehringer Ingelheim; Breckinridge Pharma; Celgene Corporation; Centocor, Inc; Colbar; CollaGenex; Combinatrix; Connetics Corporation; Coria; Dermik Laboratories; Dermira, Inc; Dow Pharmaceutical Sciences, Inc; Dusa Pharmaceuticals, Inc; Eli Lilly & Co; Embil Pharmaceutical Co, Ltd; EOS; Ferndale Laboratories, Inc; Galderma Laboratories, LP; Genentech, Inc; GlaxoSmithKline, PLC; Health Point Ltd; Idera, Inc; Innocutis Medical, LLC; Innovail; Intendis, Inc; Johnson & Johnson; Laboratory Skin Care, Inc; Leo Pharmaceuticals, Inc; L’Oreal SA; 3M; Maruho Co, Ltd; Medical International Technologies; Medicis Pharmaceutical Corp; Merck & Co, Inc; Merz; Nano Bio Corporation; Novartis Pharmaceutical Corporation; Noven Pharmaceuticals, Inc; Nucryst Pharmaceuticals Corporation; Obagi Medical Products, Inc; Onset; Ortho Dermatologics; OrthoNeutrogena; PediaPharma, Inc; Promius Pharma, LLC; PharmaDerm; Pfizer, Inc; PuraCap; QLT, Inc; Quatrix; Quinnova; Serono (Merck-Serono International SA); SkinMedica, Inc; Stiefel Laboratories, Inc; Sun Pharmaceutical Industries, Ltd; Taro; TolerRx, Inc; Triax; UCB, Inc; Valeant Pharmaceuticals North America LLC; Warner-Chilcott; XenoPort, Inc; and ZAGE. Patient inclusion criteria • Diagnosed with AK of the face and scalp • Has clinically typical, visible, and discrete AK lesions • Considered as a potential candidate for tirbanibulin treatment to manage their AK • Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin • Willing to avoid excessive sun or UV exposure and/or use relevant sunscreen protection and protective clothing during the study duration • Able to read and write English • Provide consent to participate in the study Key exclusion criteria • Patients with any dermatological condition of the face or scalp that could interfere with the clinical evaluations • Hypertrophic AK lesions, open wounds, or suspected skin cancers within close proximity of the treatment area Assessments •
    keywords: almirall; inc; patient; pharma; regeneron; research; tirbanibulin; treatment
       cache: skin-1536.pdf
  plain text: skin-1536.txt

        item: #407 of 1356
          id: skin-1537
      author: Moore, Angela; Moore, Stephen; He, Qin; Rady, Peter; Grada, Ayman; Tyring, Stephen
       title: Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma
        date: 2022-03-04
       words: 601
      flesch: 53
     summary: From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. Qin He,3 Peter Rady,3 Ayman Grada,5 Stephen Tyring3 1Arlington Research Center, Arlington, TX, USA; 2Baylor University Medical Center, Dallas, TX, USA; 3Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA; 4 Rice University, Houston, TX, USA; 5Grada Dermatology Research LLC, Chesterbrook, PA, USA INTRODUCTION • Actinic keratosis (AK) are precancerous lesions that if left untreated may lead to invasive squamous cell carcinoma (SCC) 1 (Fernandez) • Tirbanibulin (KX2-391, KX01) is a synthetic, highly selective, novel inhibitor of tubulin polymerization and Src kinase signaling developed as a first-in-class topical formulation for the treatment for AK 2 (Smolinksi) • Previous Phase I and II studies demonstrated that tirbanibulin ointment 1% was active against AK lesions on the forearm and face or scalp, respectively.
    keywords: hpv; tirbanibulin; usa
       cache: skin-1537.pdf
  plain text: skin-1537.txt

        item: #408 of 1356
          id: skin-1538
      author: Farberg, Aaron; Siegel, Jennifer; Rackely , Briana; Fitzgerald, Alison; Kurley, Sarah; Cook, Robert
       title: Appropriate utilization of the prognostic 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (cSCC) demonstrated by clinical reports and physician evaluation of real-world cases
        date: 2022-03-04
       words: 1058
      flesch: 49
     summary: The 40-GEP test has high technical reliability Figure 3D. Clinicopathologic risk group of tested patients 98.1% Successful 40-GEP 1.9% MGF Clinicopathologic Risk* % of Patients NCCN: Very High Risk 39.3% High Risk 60.5% Low Risk** 0.2% BWH T-stage: T1 38.5% T2a 39.4% T2b 21.6% T3 0.6% *Estimated based on factors reported. Risk factors included lesion located on the H or M area, ≥2cm diameter, poorly defined borders, patient immunosuppression, rapidly growing tumor, site of prior RT or chronic inflammation, History & Physical- other factor noted, high-risk subtype, Clark Level IV, >2mm invasion, poorly differentiated, LVI, PNI, invasion beyond the subcutaneous fat.
    keywords: class; figure; gep; risk; test
       cache: skin-1538.pdf
  plain text: skin-1538.txt

        item: #409 of 1356
          id: skin-1539
      author: Goldberg, Matthew; Kurley, Sarah; Siegel, Jennifer; Fitzgerald, Alison; Cook, Robert
       title: Evidence review of the prognostic 40-gene expression profile test for cutaneous squamous cell carcinoma
        date: 2022-03-04
       words: 1229
      flesch: 43
     summary: Farberg, et al. Plasseraud et al.
    keywords: class; gep; risk
       cache: skin-1539.pdf
  plain text: skin-1539.txt

        item: #410 of 1356
          id: skin-154
      author: Granger, C; Martinez-Masana, G; Garre, A
       title: An Open Label, Prospective, Clinical Study to Evaluatee the Anti-aging Effects and the Safety of a Novel Ccosmetic Facial Day Cream
        date: 2017-10-27
       words: 774
      flesch: 60
     summary: After 56 days of use, there were demonstrated improvements of skin firmness, moisturization, and elasticity. Elasticity: increase in the R2 (total recovery of the initial state/final defromation) parameter (S)=p<0.001 Fi g u re 6 R 2 va lu e (i n m m ) Figure 2. 7% decrease of ptosis volume after 56 days of use The blue zone characterizes a decrease in the cheek volume so a decrease in ptosis Te xt u re c o u n t D0 D28 D56 D0 D28 D56 -12% (S) -10% (S) 80 3 70 8 Fi g u re 4 V o lu m e (i n m m 3 ) 0. 57 9 Figure 4 and 5.
    keywords: d56; figure; skin
       cache: skin-154.pdf
  plain text: skin-154.txt

        item: #411 of 1356
          id: skin-1540
      author: Miley, Lorrie-Beth; Ahmed, Kelli ; Siegel, Jennifer; Morgan-Linnell, Sonia
       title: Attitudes of Patients with Cutaneous Melanoma Towards Prognostic Testing Using Gene Expression Profiling
        date: 2022-03-04
       words: 1188
      flesch: 60
     summary: Most respondents, whether they received 31- GEP or not, desired prognostic testing about their tumor. Acknowledgments & Disclosures References › This study was sponsored by Castle Biosciences, Inc. Did you want prognostic testing at the time of your diagnosis? Respondents were asked if they wanted prognostic information about their tumor at the time of diagnosis.
    keywords: decision; gep; regret; respondents; testing
       cache: skin-1540.pdf
  plain text: skin-1540.txt

        item: #412 of 1356
          id: skin-1542
      author: Berman, Brian ; Schlesinger, Todd; Bhatia, Neal; Grada, Ayman; Padulles, Laura; Hernandez, Francisco; Cutler, david; Lebwohl, Mark
       title: Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions
        date: 2022-03-04
       words: 1151
      flesch: 60
     summary: Composite LSR score was ≤3 in 26.5% and ≤5 in 70.2% of CC patients (Figure 2). LSR composite scores range from 0 (no reaction) to 18 (maximum reaction).
    keywords: composite; lsr; patients
       cache: skin-1542.pdf
  plain text: skin-1542.txt

        item: #413 of 1356
          id: skin-1543
      author: Schlesinger, Todd; Bhatia, Neal; Berman, Brian ; Grada, Ayman; Padulles, Laura; Hernandez, Francisco; Cutler, David; Lebwohl, Mark
       title: Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies
        date: 2022-03-04
       words: 1231
      flesch: 54
     summary: OBJECTIVE • This post-hoc analysis of the pooled Phase 3 data assessed efficacy and tolerability according to prior AK treatment in the treatment area. • Compared to pooled Phase 3 trials, in this post-hoc analysis the efficacy of tirbanibulin in pretreated areas was similar, and there were no differences in tolerability in terms of LSR.
    keywords: participants; tirbanibulin; treatment; vehicle
       cache: skin-1543.pdf
  plain text: skin-1543.txt

        item: #414 of 1356
          id: skin-1544
      author: Berman, Brian ; Gual, Adria; Grada, Ayman; Fumero, Emilio; Padulles, Laura; Hernandez, Francisco
       title: Efficacy of tirbanibulin ointment 1% across different patient populations: pooled results from two Phase 3 studies
        date: 2022-03-04
       words: 1266
      flesch: 68
     summary: The primary efficacy and key secondary endpoints were complete clearance (CC, 100% reduction from baseline) and partial clearance (PC, ≥75%) rates of AK lesions at Day 57. Logistic regression models to find independent predictors of CC and PC of AK lesions among tirbanibulin-treated patients were built.
    keywords: day; tirbanibulin; vs.
       cache: skin-1544.pdf
  plain text: skin-1544.txt

        item: #415 of 1356
          id: skin-1545
      author: Eichenfeld, Lawrence; Simpson, Eric; Papp, Kim; Szepietowski, Jacek; Kircik, Leon ; Toth, Darryl; Forman, Seth; Kuligowski, Michael; Venturanza, May; Ren, Haobo; Paller, Amy 
       title: Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies
        date: 2022-03-04
       words: 2552
      flesch: 47
     summary: [BID], 1.5% BID) or vehicle cream BID for 8 weeks of double-blind treatment (vehicle-controlled [VC] period); patients were instructed to continue treating lesions even if they improved – Patients on ruxolitinib cream subsequently continued treatment for 44 weeks (long-term safety [clear or almost clear skin]) and mean percentage of BSA affected by AD at each visit (every 4 weeks) during the LTS period ● Safety and tolerability assessments included the frequency of reported treatment-emergent adverse events (TEAEs), treatment-related adverse events, and TEAEs leading to treatment discontinuation ● Patients initially randomized to 0.75% or 1.5% ruxolitinib cream who remained on ruxolitinib cream during the LTS period were included in this analysis; patients initially on vehicle who received ruxolitinib cream during the LTS are not included in this analysis Statistical Analyses ● Data were analyzed by descriptive statistics ● The safety analysis was conducted using pooled data from both studies ● Disease control data (IGA 0/1 and BSA) are reported as observed Results Patients ● Of the 1249 patients randomized in the VC period, 245 (19.6%) were between 12–17 years old ● Distribution of baseline demographics and clinical characteristics for the pooled adolescent population was similar across treatment groups (Table 1)
    keywords: cream; lts; patients; period; ruxolitinib; ruxolitinib cream; safety
       cache: skin-1545.pdf
  plain text: skin-1545.txt

        item: #416 of 1356
          id: skin-1546
      author: Paller, Amy ; Blauvelt, Andrew ; Soong, Weily; Imafuku, Shinichi; Hong, Chih-ho; Schuttelaar, Marie ; Amoudruz, Petra; Kurbasic, Azra; Soldbro, Lise; Lophaven, Katja; Cork, Michael; Bewley, Anthony ; Simpson, Eric
       title: Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
        date: 2022-03-04
       words: 2286
      flesch: 56
     summary: Amy Paller has served as an investigator for AbbVie, Anaptysbio, Incyte, Janssen, KrystalBio, LEO Pharma, Regeneron, and UCB, received honorarium for consultancy from AbbVie, Abeona, Almirall, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Exicure, Forté, Kamari, LEO Pharma, Lilly, LifeMax, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Seanergy, and UCB, and served on a Data Safety Monitory Board for AbbVie, Bausch, Galderma, and Novan. Andrew Blauvelt is a scientific adviser and clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sun Pharma, UCB Pharma.
    keywords: leo; patients; pharma; placebo; q2w; tralokinumab; treatment; week
       cache: skin-1546.pdf
  plain text: skin-1546.txt

        item: #417 of 1356
          id: skin-1547
      author: Adjei, Susuana; Miller, Austinn; Temiz, Laurie; Tyring, Stephen
       title: A Rare Case of Empedobacter Brevis Cutaneous Infection Treated Successfully with Oral Sarecycline  
        date: 2022-03-04
       words: 836
      flesch: 54
     summary: PowerPoint Presentation Empedobacter brevis, as a part of the Flavobacteriaceae family, is a non-motile, strictly aerobic, gram negative, yellow colony-forming bacterium that typically resides in soil, plants, water sources, and hospital environments.1,2 The first reported case of a human infection was in 2002 when 11 out of 12 patients were diagnosed with endophthalmitis from an E. brevis infection post cataract surgery.3 More cases of E. brevis infections have since been reported ranging from meningitis to cellulitis.3,4,6 Treatment can be complicated by the bacteria’s beta lactamase gene, which results in resistance to extended cephalosporins and carbapenems.5 There have been a few dermatologic manifestations of E. Brevis infections reported in the literature that warrant further evaluation.6,7 We present a case of an E. brevis infection in a 61-year-old male who presented with a persistent right mid-thigh lesion. A Rare Case of Empedobacter Brevis Cutaneous Infection Treated Successfully with Oral Sarecycline Susuana Adjei, MD1; Austinn C. Miller, MD 1; Laurie A. Temiz, BA2 ; Stephen K. Tyring, MD, PhD, MBA 1,3 1Center for Clinical Studies Webster, TX; 2Meharry Medical College, Nashville, TN; 3UT Houston Department of Dermatology, Houston TX DISCUSSION Thought to be an environmental pathogen, increasing cases of human E. brevis infections are now being reported as portrayed in Table 1.
    keywords: brevis; case; empedobacter
       cache: skin-1547.pdf
  plain text: skin-1547.txt

        item: #418 of 1356
          id: skin-1548
      author: Lipner, Shari; Joseph , Warren ; Vlahovic, Tracey; Scher, Richard; Rich, Phoebe; Ghannoum, Mahmoud; Daniel, Ralph; Elewski, Boni
       title: Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US
        date: 2022-03-04
       words: 2041
      flesch: 42
     summary: Recommended Medications � The authors all agreed that treatment should be individualized for each patient based on nail involvement (number, surface area, thickness), infecting organism, patient characteristics (including comorbidities), current medications, biomechanics, cost/availability/accessibility based on insurance, and patient preference � A decision tree to provide practical guidance on therapeutic recommendations in onychomycosis treatment developed by the authors is shown in Figure 2 � Therapeutic recommendations by drug are also detailed in Figure 3 � Among oral medications, terbinafine is most commonly used as first-line treatment, followed by fluconazole � Among topical products, efinaconazole is ideal as first-line medication in pediatric patients, patients with less severe disease, and those with dermatophytomas � A topical medication was also recommended for use in combination with terbinafine or fluconazole and can be considered as maintenance therapy to prevent relapse � To improve outcomes, concurrent tinea pedis should be treated in all patients receiving topical therapy for onychomycosis Patient Education � It is important to manage patient expectations when treating onychomycosis: optimal results can take over a year and clinical cure/normal nail appearance may not be possible � Patients should also be educated on the high recurrence rates (6.5%–53%)5; as such, regular follow-up visits with patients are recommended (3–6 months after oral or 1 year after topical treatment) Efinaconazole preferred for topical treatment due to higher rates of complete cure and mycologic cure versus other topical treatments.
    keywords: disease; nail; onychomycosis; patients; topical; treatment
       cache: skin-1548.pdf
  plain text: skin-1548.txt

        item: #419 of 1356
          id: skin-1549
      author: Cockerell, Clay; Ceilley, Roger; Lebwohl, Mark; Rigel, Darrell
       title: Using Genomics to Improve Pigmented Lesion Management & Health Outcomes
        date: 2022-03-04
       words: 1195
      flesch: 51
     summary: 88 Siegel et al. also showed high rates of biopsies and excisions on benign lesions using the VAH pathway, which highlights the need for more accurate clinical assessment of pigmented lesions. [PLA] DermTech, La Jolla, CA), which studies have demonstrated has a >99% negative predictive value (NPV).3 With the ability to detect genomic atypia in pigmented lesions, this technology offers an additional tool to clinicians faced with the conundrum of determining whether a pigmented lesion should be biopsied/removed or if they can be safely monitored.4
    keywords: gep; lesions; melanoma; skin
       cache: skin-1549.pdf
  plain text: skin-1549.txt

        item: #420 of 1356
          id: skin-155
      author: Granger, C; Goni-de-Cerio, F; Martinez-Masana, G; Garre, A
       title: Ex-vivo Determination of Antifungal Activity of a New Prescription Non-Steroidal Facial Cream Against Malassezia furfur in Human Skin Explants
        date: 2017-10-27
       words: 722
      flesch: 51
     summary: Ex-vivo determination of antifungal activity of a new prescription non- steroidal facial cream against Malassezia furfur in human skin explants Fall Clinical Dermatology Conference® October 12-15, 2017. On control skin explants, inoculated in the same way, no product was applied.
    keywords: nsfc; skin
       cache: skin-155.pdf
  plain text: skin-155.txt

        item: #421 of 1356
          id: skin-1550
      author: Castro Porto Silva Lopes, Fabiana; Ahmed, Ammar
       title: Insurance Coverage for Phototherapy for Vitiligo in Comparison to Psoriasis and Atopic Dermatitis
        date: 2022-05-06
       words: 3188
      flesch: 46
     summary: Results: Vitiligo is the only disease analyzed for which multiple insurances explicitly stated they do not cover in-office phototherapy, and it is also the least covered for home phototherapy. Information about phototherapy coverage was extracted via web search.
    keywords: phototherapy; prerequisites; psoriasis; review; treatment; vitiligo
       cache: skin-1550.pdf
  plain text: skin-1550.txt

        item: #422 of 1356
          id: skin-1551
      author: Boccardi, Aleia; Trigg, Joanna ; Reiter, Paloma ; Papadopoulos, Dimitria ; Sirota Rozenberg, Suzanne
       title: Polypoid Melanoma: Diagnostic Hardships Concerning A Rare Melanoma Variant
        date: 2022-05-06
       words: 1704
      flesch: 53
     summary: Polypoid amelanotic melanoma: a diagnostic challenge. Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.
    keywords: growth; lesion; melanoma; patient; polypoid; skin
       cache: skin-1551.pdf
  plain text: skin-1551.txt

        item: #423 of 1356
          id: skin-1552
      author: Ngonadi, Nwanneoma; Hannah, Claire; Rosenbach, Misha
       title: Lichen Sclerosus et Atrophicus
        date: 2022-05-06
       words: 692
      flesch: 46
     summary: Additionally, genital LSeA increases the risk of vulvar squamous cell carcinoma by 4-5% 3, therefore, all patients with LSeA should be asked about genital symptoms and a genital examination is recommended. Extragenital LSeA is rare, with a prevalence of up to 0.3% 4.
    keywords: lichen; lsea; sclerosus
       cache: skin-1552.pdf
  plain text: skin-1552.txt

        item: #424 of 1356
          id: skin-1556
      author: Mezni, Line; Farah, Elhadadi; Nadia , Ismaili 
       title: Pustular Penile Pyoderma Gangrenosum: A Puzzling Clinical Presentation 
        date: 2022-05-06
       words: 594
      flesch: 45
     summary: Pustular pyoderma gangrenosum: an uncommon variant which is easily misdiagnosed. A Puzzling Clinical Presentation Mezni Line, MD1, Elhadadi Farah, MD1, Ismaili Nadia MD,PhD1 1Ibn Sina University Hospital Dermatology Department, Mohammed V University, Rabat, Morocco Figure 1 : Penile pyoderma gangrenosum : erosive, and sharply demarcated lesions on the glans penis Pyoderma gangrenosum (PG) is a recurrent, chronic inflammatory neutrophilic dermatosis.
    keywords: gangrenosum; pyoderma
       cache: skin-1556.pdf
  plain text: skin-1556.txt

        item: #425 of 1356
          id: skin-1558
      author: Min, Susie; Subhadarshani, Sweta ; Sharma , Pooja; Thakran, Priyesh
       title: Median Raphe Cyst
        date: 2022-07-07
       words: 694
      flesch: 51
     summary: Median raphe cyst is a rare, benign cyst of congenital origin. Median raphe cysts develop along the median raphe of the male external genitalia with the most cases having been reported in young patients.1
    keywords: cysts; median; raphe
       cache: skin-1558.pdf
  plain text: skin-1558.txt

        item: #426 of 1356
          id: skin-1559
      author: Weir, Sydney; Hattway, Reagan ; Singh, Nikhi ; King, Timothy; Kole, Lauren
       title: Interviewing Dermatology Applicants in a Virtual Setting: A Perspective after 2020-2021 Match: Perspective after Match
        date: 2022-07-07
       words: 1052
      flesch: 21
     summary: In addition to dermatology program director responses, we received a 2% response rate from medical students who successfully matched into dermatology during the 2020-2021 application cycle (N=11). Dermatology residency training programs may use this information to decide which virtual pre-interview events to offer in subsequent virtual application cycles.
    keywords: dermatology; medical; program; residency
       cache: skin-1559.pdf
  plain text: skin-1559.txt

        item: #427 of 1356
          id: skin-156
      author: Valderas-Martinez, P; Garre, A; Granger, C
       title: Efficacy and Tolerance of a New Non-Steroidal Prescription Cream in the Treatment of Mild Facial Seborrheic Dermatitis
        date: 2017-10-27
       words: 743
      flesch: 56
     summary: RESULTS Treatment proved successful in most patients (88%), and the IGA with a reduction of the IGA score at 28±2 days to 0.66 ± 0.94 compared to IGA at 2 at baseline, SD was evaluated as absent in 56% of patients. After 10±2 days, treatment proved successful in most patients (79%), and the mean score of IGA at this visit was 1.00±0.75 (Figure 1).
    keywords: patients; score
       cache: skin-156.pdf
  plain text: skin-156.txt

        item: #428 of 1356
          id: skin-1560
      author: Govea, Ramon; Hollins, Lauren
       title: Residency Program Websites as an Avenue Towards Increasing Diversity and Inclusion in Dermatology: A Cross-Sectional Analysis of Program Websites
        date: 2022-05-06
       words: 1191
      flesch: 56
     summary: Conclusions: Most dermatology residency programs do not mention D&I on their websites. Percent of dermatology websites mentioning diversity and inclusion Future studies are needed to determine how these changes correlate with URM applications and diversity in residency programs.
    keywords: d&i; dermatology; residency; websites
       cache: skin-1560.pdf
  plain text: skin-1560.txt

        item: #429 of 1356
          id: skin-1561
      author: Siddiqui, Fahad; Witkoff, Benjamin; Glick, Brad
       title: Potential Neurologic Side Effects of Oral Isotretinoin: A Case of Peripheral Neuropathy
        date: 2022-07-07
       words: 1314
      flesch: 49
     summary: Aside from its effectiveness in treating the acne itself, isotretinoin has also been noted to improve the psychosocial aspects of severe acne including depression, anxiety, and quality of life.1 Despite its effectiveness, the drug is publicly known for its association with adverse effects such as xerosis, epistaxis, cheilitis, and myalgias as well as less common side effects like depression, anxiety, insomnia, suicidal ideation, sun sensitivity, vision changes, and hair loss.2 Adverse effects of isotretinoin: A large, retrospective review.
    keywords: effects; isotretinoin; nerve; potential
       cache: skin-1561.pdf
  plain text: skin-1561.txt

        item: #430 of 1356
          id: skin-1562
      author: Garcia, Natalie; Hill, Callie; Jiminez, Victoria; Phillips, Carlton Blake
       title: Diagnostic Challenges of Hypertrophic Lupus Erythematosus
        date: 2022-07-07
       words: 873
      flesch: 49
     summary: No single criterion confidently differentiates HLE from SCC histologically, postulating the need for CD123 immunostaining in evaluating locally recurring, supposed SCCs.1 CD123 is highly expressed on the surface of plasmacytoid dendrocytes, seen in HLE lesions densely at the epidermal-dermal junction, while SCC lacks this positive band staining. 348 SKIMages Diagnostic Challenges of Hypertrophic Lupus Erythematosus Natalie Garcia BS1, Callie Hill MD2, Victoria Jiminez BS1, Leah Cardwell, MD2, Peter Pavlidakey, MD2, Carlton B Phillips, MD2 1 University of Alabama at Birmingham School of Medicine, Birmingham, AL 2 University of Alabama at Birmingham, Department of Dermatology, Birmingham, AL Hypertrophic lupus erythematosus (HLE), a variant of cutaneous LE, often occurs in the absence of systemic symptoms and can be misdiagnosed as squamous cell carcinoma (SCC) as both appear clinically as erythematous scaling plaques in sun exposed areas and histologically show significant epithelial hyperplasia.1 Distinguishing HLE from SCC can be difficult, thus a detailed clinical history and adjunct testing to rule out inflammatory conditions are necessary to direct treatment.
    keywords: cd123; hle; leg
       cache: skin-1562.pdf
  plain text: skin-1562.txt

        item: #431 of 1356
          id: skin-1563
      author: Cheng, Melissa; Pham, Diem; Kim, Gene
       title: Lobular Panniculitis in a Patient with Chronic Lymphoid Leukemia
        date: 2022-07-07
       words: 1513
      flesch: 49
     summary: Causes of lobular panniculitis include systemic lupus erythema, pancreatic disorders, α1-antitrypsin deficiency, or infection. This case discusses a 63- year-old female that presents with lobular panniculitis without vasculitis associated with chronic lymphoid leukemia.
    keywords: chronic; cll; leukemia; panniculitis; patient
       cache: skin-1563.pdf
  plain text: skin-1563.txt

        item: #432 of 1356
          id: skin-1564
      author: Wu, Albert; Cline, Abigail; Russo, Marion
       title: Step 1 as Pass/Fail: Navigating Dermatology Application Components as Holistic Review Expands
        date: 2022-05-06
       words: 978
      flesch: 50
     summary: An increasing trend in the number of publications and research projects among dermatology residency applicants. Volunteer and work experiences among dermatology residency applicants.
    keywords: application; change; dermatology; step
       cache: skin-1564.pdf
  plain text: skin-1564.txt

        item: #433 of 1356
          id: skin-1566
      author: Arriaza, Olivia; Winsett, Frank; Wilson, Janice; Kelly, Brent
       title: A Case of Dasatinib-Induced Keratosis Pilaris
        date: 2023-01-10
       words: 1716
      flesch: 40
     summary: We report a case of keratosis pilaris induced by dasatinib treatment that histologically revealed evidence of follicular destabilization, characterized by follicular epithelial thinning, leading to follicular rupture. It is well known that one of the most common non-hematologic adverse effects of TKIs cutaneous reactions, however, there is little evidence of cutaneous side effects associated with dasatinib.8 Although, keratosis pilaris-like eruptions are the most common adverse cutaneous effects reported from dasatinib treatment, they have not been well characterized as morphologies are varied.2,5,9 Bergman, et al. describes a case of neutrophilic dermatosis associated with dasatinib that presented as recurrent erythematous plaques on the face, neck, chest, arms and back.
    keywords: dasatinib; keratosis; patient; pilaris; skin
       cache: skin-1566.pdf
  plain text: skin-1566.txt

        item: #434 of 1356
          id: skin-1567
      author: Marushchak, Olga; Tan, Kathryn Jayne ; Encarnacion, Maria Rosa Noliza ; Clark, Loren; Golant, Alexandra
       title: Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion
        date: 2022-07-07
       words: 1691
      flesch: 49
     summary: Beckett N, Lawson C, Cohen G. Electrosurgical excision of acne keloidalis nuchae with secondary intention healing. The efficacy of laser-assisted hair removal in the treatment of acne keloidalis nuchae; a pilot study.
    keywords: acne; akn; dermatol; keloidalis; nuchae; topical; treatment
       cache: skin-1567.pdf
  plain text: skin-1567.txt

        item: #435 of 1356
          id: skin-1568
      author: Owji, Shayan; Han, Joseph; He, Helen; Lopera, Isabel; Tassavor, Michael; Brownstone, Nicholas; Gulati, Nicholas; Ungar, Benjamin; Ungar, Jonathan
       title: Diagnostic Efficacy of Electrical Impedance Spectroscopy Versus Dermoscopy for Pigmented Skin Lesions: A Pilot Study
        date: 2022-05-06
       words: 3049
      flesch: 51
     summary: To better understand the clinical utility of EIS, we investigated how this relatively new technology – specifically, the effect it has on clinical decisions for PSLs – compares to traditional dermoscopy. Images of twenty-four randomly selected, histologically-confirmed and EIS-evaluated PSLs, comprising 8 melanomas, 8 dysplastic nevi (6 mild-moderate dysplastic, 2 severe dysplastic), and 8 melanocytic nevi, from a previously published prospective blinded trial of 2416 lesions were included in this study.6 Twelve PSLs (half of the lesions from each diagnosis group) were randomly selected to be presented as a clinical image with associated dermoscopic image (dermoscopy group), while the other twelve lesions were presented as a clinical image with the corresponding EIS score (EIS group).
    keywords: biopsy; decisions; dermoscopy; eis; lesions; sensitivity; specificity
       cache: skin-1568.pdf
  plain text: skin-1568.txt

        item: #436 of 1356
          id: skin-1569
      author: Baah, Natasha; Skandamis, George
       title: A Novel Case of Eruptive Keratoacanthomas Associated with Apalutamide Treatment for Prostate Cancer
        date: 2022-07-07
       words: 1754
      flesch: 48
     summary: Past medical history is significant for squamous cell skin cancer on the left central forehead and prostate cancer, for which he underwent a radical prostatectomy 25 years ago. al. Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide.
    keywords: apalutamide; cancer; cell; eruptive; keratoacanthomas; patient; prostate
       cache: skin-1569.pdf
  plain text: skin-1569.txt

        item: #437 of 1356
          id: skin-157
      author: Teeple, A; Muser, E
       title: Cost Per Responder Analysis of Guselkumab versus Adalimumab using Efficacy Results fromm a Head-to-Head Clinical Trial in Patients with Moderate to Severe Plaque Psoriasis
        date: 2017-10-27
       words: 1063
      flesch: 55
     summary: Percent of Patients Reaching Each PASI Response at 48 Weeks 0 20 40 60 80 10 30 50 70 90 100 P er ce n ta g e o f P at ie n ts PASI 75 87.8% 62.6% 76.3% 47.9% 47.4% 23.4% PASI 90 Guselkumab Adalimumab PASI 100 ■ Figure 2 shows the cost per responder estimates for Guselkumab and Adalimumab for the VOYAGE 1 primary endpoint, a response of PASI 90. Figure 2. Induction Year Cost per Responder for All Three PASI Response Levels $0 $100,000 $125,000 $175,000 $225,000 $275,000 $200,000 $50,000 $25,000 $75,000 $150,000 $250,000 $300,000 C o st p er R es p o n d er PASI 75 $88,237 $99,325 $101,536 $129,807 $163,443 $265,715 PASI 90 Guselkumab Adalimumab PASI 100 Conclusions ■ This cost per responder analysis from the VOYAGE 1 trial demonstrates that guselkumab is a more cost-effective treatment with a lower cost per responder than adalimumab for achieving a PASI 90, PASI 75, and a PASI 100 response in the first year of treatment among patients with moderate to severe plaque psoriasis.
    keywords: adalimumab; cost; guselkumab; pasi
       cache: skin-157.pdf
  plain text: skin-157.txt

        item: #438 of 1356
          id: skin-1570
      author: Perez, Mariana; Witkoff, Benjamin; Lutwak, Moises ; Cohn, Michael; Weiss, Eduardo
       title: Eosinophilic Annular Erythema of Childhood: A Rare Case
        date: 2022-09-12
       words: 1741
      flesch: 41
     summary: Comparison of eosinophilic annular erythema (EAE), annular erythema of infancy (AEI), Well’s Syndrome (WS), and erythema annularis centrifugum (EAC) SKIN September 2022 Volume 6 Issue 5 (c) 2022 Eosinophilic annular erythema treated with dupilumab.
    keywords: annular; childhood; eae; eosinophilic; erythema; lesions
       cache: skin-1570.pdf
  plain text: skin-1570.txt

        item: #439 of 1356
          id: skin-1571
      author: Shamloul, Gelan; McEldrew, Emily ; Kesty, Chelsea; McClain, Richard 
       title: A Unique Presentation and Unusual Cause of Acute Generalized Exanthematous Pustulosis: Case Report 
        date: 2023-01-10
       words: 1508
      flesch: 45
     summary: A Case Report Gelan Shamloul, BS1, Emily McEldrew, DO2, Chelsea Kesty, MD2, Richard McClain, MD2 1Philadelphia College of Osteopathic Medicine, Philadelphia, PA 2Department of Dermatology, Lehigh Valley Health Network, Allentown, PA Acute generalized exanthematous pustulosis (AGEP) is a severe, acute-onset cutaneous eruption of small, sterile pustules on an erythematous base, occurring with fever and a neutrophilic leukocytosis.1,2 AGEP primarily presents as an adverse drug reaction beginning 2-14 days following drug ingestion. Nikolsky sign was negative, and there was no ABSTRACT Acute generalized exanthematous pustulosis (AGEP) is a febrile, pustular eruption that has been reported in all ages.
    keywords: acute; agep; eruption; pustules; pustulosis; weeks
       cache: skin-1571.pdf
  plain text: skin-1571.txt

        item: #440 of 1356
          id: skin-1572
      author: Brownstone, Nicholas; Rigel, Darrell
       title: Skin Cancer Screenings: Why Are the Benefits in Question? 
        date: 2022-05-06
       words: 1099
      flesch: 55
     summary: Therefore, skin cancer screening should have the potential to increase the survivability from melanoma by detecting this cancer at an earlier stage thereby positively impacting prognosis. So why do the benefits of skin cancer screening still remain controversial?
    keywords: cancer; melanoma; screening; skin
       cache: skin-1572.pdf
  plain text: skin-1572.txt

        item: #441 of 1356
          id: skin-1573
      author: Tassovar, Michael; Owji, Shayan; Han, Joseph; Dautriche, Cula; Unger, Jonathan
       title: 1st Place: Improving Dermatology Resident Billing
        date: 2022-05-06
       words: 498
      flesch: 34
     summary: The intervention consisted of four monthly billing lectures with two associated quizzes as well as a note template designed by author MT that automatically lists the correct procedural codes according to the numbers and types of procedures chosen from a dropdown list • Billing accuracy was verified by two attending dermatologists through chart review and compared between the two time periods • State population and setting CONCLUSIONS • Lectures on medical coding and a template that automatically lists the CPT codes for procedures greatly improved the billing accuracy of dermatology residents at our institution, significantly decreasing the rate of errors for procedural codes and modifiers • Residents consistently undercoded E/M rather than the opposite, perhaps due to a perception that there is no meaningful benefit to maximizing their billing • Our lectures seemed to be most impactful on procedural codes and modifiers RESULTS • Billing data from 513 patient visits, 257 from the pre-intervention period and 256 from the post-intervention period, were checked for accuracy • The accuracy of resident-billed E/M levels of service was similar between pre- and post-intervention (44.4% vs. 44.8%) • Similar rates of undercoding and overcoding were noted between the pre- and post-intervention periods (35.4% undercoded and 8.1% overcoded vs. 35.8% and 8.9%). • Substantial improvements were noted in the rate of errors with procedural codes and modifiers in the post-intervention period • 22.0% of procedural codes were incorrectly billed pre-intervention while only 3.7% were incorrectly billed post-intervention (p<0.05).
    keywords: codes; intervention
       cache: skin-1573.pdf
  plain text: skin-1573.txt

        item: #442 of 1356
          id: skin-1575
      author: Glaser, Ella; Rosemary , King ; Glaser, Dee Anna
       title: 3rd Place: Prevalence of Anxiety, Depression, and Attention Deficit Disorder in Patients with Primary Hyperhidrosis
        date: 2022-05-06
       words: 669
      flesch: 47
     summary: • There is a significant association between HH and the prevalence of anxiety, depression and ADD regardless of gender or age • Compared to the nationally reported prevalence of anxiety (5.7%)6, depression (7.8%)7 and ADD (4.4%) 8, HH patients have a statistically significant higher prevalence than the general public. • Understand the correlation between hyperhidrosis location and severity with mental health • 500 patients included • 13.8% of patients had a diagnosis of anxiety, 12.4% had depression and 6.4% had ADD • Positive correlations between the number of anatomical HH sites involved and the prevalence of psychiatric conditions • no association with overall HDSS severity or location involved with prevalence of psychiatric conditions.
    keywords: anxiety; depression; prevalence
       cache: skin-1575.pdf
  plain text: skin-1575.txt

        item: #443 of 1356
          id: skin-1576
      author: Sanghvi, Anuj; Wang, David; Lipner, Matthew; Tackett, Kelly ; Holahan, Heather; Mervak, Julie
       title: Runner Up: Accuracy and Confidence Among New First-year Dermatology Residents in the Diagnosis of Common Dermatologic Conditions in Different Fitzpatrick Skin Types
        date: 2022-05-06
       words: 602
      flesch: 31
     summary: The number of common skin conditions in the survey was limited out of consideration for the time • Survey did not fully represent the spectrum or prevalence of skin conditions seen in the practice of dermatology Limitations • New dermatology residents diagnose common dermatologic conditions in darker skin with less accuracy and confidence than in lighter skin • There is a lack of statistical significance with participants’ demographics and background characteristics • Differences identified in diagnostic accuracy and confidence may stem from a systemic deficiency in skin of color education rather than individual backgroundsnd confidence in lighter versus darker Medical students' ability to diagnose common dermatologic conditions in skin of color.
    keywords: conditions; dermatology; skin
       cache: skin-1576.pdf
  plain text: skin-1576.txt

        item: #444 of 1356
          id: skin-1577
      author: Malik, Kunal ; Ngo, Tracy; Patel, Parth; Khachemoune, Amor
       title: Runner Up: Second Intention Healing for Mohs Defects of Specific Anatomic Locations of the Lower Extremities: Identifying Indications and Mitigating Challenges
        date: 2022-05-06
       words: 1078
      flesch: 49
     summary: Furthermore, wound characteristics and outcomes of SIH for MMS defects of specific lower extremity sites is not well described in the literature.1,2 To address possible underutilization of SIH on the lower extremity, site-specific indications and challenges of SIH below-the-knee need exploration. A systematic review of the literature from inception of databases to January 2, 2021 using PubMed, EMBASE, and Cochrane Library using search terms: 1) Mohs surgery and lower extremity, leg, foot and 2) Mohs and lower extremity, leg, foot was performed.
    keywords: extremity; sih
       cache: skin-1577.pdf
  plain text: skin-1577.txt

        item: #445 of 1356
          id: skin-1578
      author: Rosenthal , Amanda; Chung, Joanie; Cooper, Robert; Haque, Reina; Kim, Christina 
       title: Runner Up: Health Disparities in Melanoma Patients: Understanding the Influence of Comorbidities on Overall Survival Among Our Poorest Patient Populations
        date: 2022-05-06
       words: 590
      flesch: 37
     summary: Specifically, we find that the survival disparity appreciated among melanoma patients of lower SES is persistent, albeit attenuated, even when adjusting for the presence of comorbidities, as defined by the ECI. Health Disparities in Melanoma Patients: Understanding the influence of comorbidities on overall survival among our poorest patient populations Amanda Rosenthal, MD1; Joanie Chung, MPH2; Robert Cooper MD3; Reina Haque, PhD2,4; Christina Kim, MD1 1 Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; 2 Department of Research & Evaluation, Kaiser Permanente Southern California; Kaiser Permanente Los Angeles Medical Center (TH), Pasadena, CA; 3 Department of Pediatric Hematology/Oncology, Southern California Permanente Medical Group, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; 4 Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA No authors have any financial relationships to disclose.
    keywords: los angeles; melanoma; ses
       cache: skin-1578.pdf
  plain text: skin-1578.txt

        item: #446 of 1356
          id: skin-1579
      author: Ramachandran, Vignesh; Ayaz, Talha; Loya, Asad
       title: Runner Up: Association of Insurance Coverage with Diagnosis of Malignant Melanoma Before and After the Affordable Care Act: A National Database Study
        date: 2022-05-06
       words: 590
      flesch: 30
     summary: Vignesh Ramachandran, MD1, Talha Ayaz, MD2, Asad Loya, MD3 1 Department of Dermatology, New York University, New York, NY 2 Department of Radiology, University of Texas Medical Branch, Galveston, TX 3 Department of Ophthalmology, Baylor College of Medicine, Houston, TX Figures 1, 2, 3: (1) national insurance trends in patients diagnosed with malignant melanoma; (2) sub-analysis of insurance trends in states which expanded Medicaid; (3) sub-analysis of insurance trends in non-expansion states 0 20 40 60 80 100 2007 2008 2009 2010 2011 2012 2013 2014 2015 In s u ra n c e R a te , % Year of Diagnosis Figure 2. However, Medicaid patients have worse all-cause and cause-specific mortality compared to non-Medicaid counterparts • We must address socioeconomic factors likely contributing these disparities through policy to ensure insurance coverage translates to quality care and survivorship REFERENCES 1.
    keywords: insurance; medicaid
       cache: skin-1579.pdf
  plain text: skin-1579.txt

        item: #447 of 1356
          id: skin-158
      author: Baldwin, H E; Bhatia, N C; Friedman, A; Prunty, T; Martin, R; Seite, S
       title: The Role of Cutaneous Microbiota Harmony in Maintaining a Functional Skin Barrier
        date: 2017-10-27
       words: 1867
      flesch: 41
     summary: Current model of relationship between skin barrier and skin microbiota 1The Acne Treatment and Research Center of Atlantic Health System, Morristown, NJ - 2Therapeutics Clinical Research Inc., San Diego, CA - 3George Washington School of Medicine and Health Sciences, Washington, DC 4AraMed Strategies, DE - 5L’Oréal Research and Innovation, Tours, France - 6La Roche-Posay Dermatological Laboratories, Asnières, France Human skin is a complex barrier organ that provides an ecological niche for a wide range of micro-organisms(1). Relationship between skin barrier and skin microbiota Moisturizers can be formulated with deionized water or thermal water.
    keywords: bacteria; barrier; growth; microbiota; skin; water
       cache: skin-158.pdf
  plain text: skin-158.txt

        item: #448 of 1356
          id: skin-1580
      author: Jfri, Abdulhadi; Meltzer, Rachel; Guggina, Lauren
       title: Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis
        date: 2022-05-06
       words: 388
      flesch: 37
     summary: Conclusion This study provides incidence of cutaneous adverse events with PI3K inhibitors, Akt inhibitors and mTOR inhibitors. It is an important target in malignancies that include PI3K inhibitors that contain three classes (Pan-class I, Isoform-selective and Dual PI3K/mTOR inhibitors), Akt inhibitors and mTOR inhibitors.
    keywords: inhibitors; mtor
       cache: skin-1580.pdf
  plain text: skin-1580.txt

        item: #449 of 1356
          id: skin-1581
      author: Hill, Callie; Ghannoum, Mahmoud; Garcia, Natalie; Elewski, Boni
       title: Runner Up: Terbinafine-Resistant Dermatophytosis in Alabama: Two Cases of Recalcitrant Dermatophytosis and the Dermatologist’s Role in Detection of Drug Resistance and Antifungal Stewardship
        date: 2022-05-06
       words: 1030
      flesch: 44
     summary: Highlight important clinical and diagnostic findings to consider when treating antifungal resistant dermatophytosis. • Speciation and susceptibility reported in Table 1 highlighting terbinafine resistance.
    keywords: dermatophytosis; resistance; terbinafine
       cache: skin-1581.pdf
  plain text: skin-1581.txt

        item: #450 of 1356
          id: skin-1583
      author: Patel, Deep; Joshi, Isha; Flamm, Alexandra
       title: Are Dermatology Electives Meeting The Learning Objectives of Rotators?
        date: 2022-09-12
       words: 1587
      flesch: 41
     summary: Medical students with an interest in dermatology expressed a greater interest in career exploration (n=8) compared to medical student not interested in dermatology (n=4). Methods: A survey was distributed to medical students and residents on a dermatology elective to assess their specific learning objectives and rotation satisfaction.
    keywords: dermatology; learning; objectives; students
       cache: skin-1583.pdf
  plain text: skin-1583.txt

        item: #451 of 1356
          id: skin-1584
      author: Burli, Anuk; Somers, Kathryn; Rotoli , Jason E. 
       title: Deaf and Hard of Hearing Patients in Dermatology: A Call to Action
        date: 2022-07-07
       words: 803
      flesch: 45
     summary: 339 SHORT COMMUNICATION Deaf and Hard of Hearing Patients in Dermatology: A Call to Action Anuk Burli, BS1, Kathryn E. Somers, MD2, Jason M. Rotoli, MD3 1 University of Rochester School of Medicine and Dentistry, Rochester, NY 2 University of Rochester Department of Dermatology, Rochester, NY 3 University of Rochester Department of Emergency Medicin, Rochester, NY Deaf and hard of hearing (DHH) patients have reported unsatisfying experiences with the healthcare system due to decreased access to care resulting from discrimination and poor experiences with communication in health care settings1. In-person dermatology visits are conducted using personal protective equipment (PPE), including a face mask, which impairs communication for DHH patients.
    keywords: dermatology; dhh; patients
       cache: skin-1584.pdf
  plain text: skin-1584.txt

        item: #452 of 1356
          id: skin-1585
      author: Brownstone, Nicholas; Zakria, Danny; Dirr, McKenzie; Lu, Yenn; Rigel, Darrell
       title: Integrating Genomic Testing for Melanoma Into Your Practice
        date: 2022-05-06
       words: 2947
      flesch: 58
     summary: doi:10.1002/hed.25473 11. Mirsky R, Prado G, Svoboda R, Glazer A, Rigel D. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. doi:10.3390/cancers13122875 8. Brouha B, Ferris L, Skelsey M, et al.
    keywords: biopsy; gep; melanoma; patient; risk; test
       cache: skin-1585.pdf
  plain text: skin-1585.txt

        item: #453 of 1356
          id: skin-1586
      author: Foy, Valerie; McEldrew, Emily ; Kesty, Chelsea; Lim, Kristina; Liu, Kevin; Asad, Haider; Bartus, Cynthia
       title: Invasive Trichosporonosis in a Child Following Chemotherapy Induction
        date: 2022-09-12
       words: 908
      flesch: 42
     summary: The tissue culture was positive for Trichosporon asahii. Fatal disseminated Trichosporon asahii fungemia in a child with acute lymphoblastic leukemia and a morbilliform eruption.
    keywords: acute; asahii; leukemia; medicine; trichosporonosis
       cache: skin-1586.pdf
  plain text: skin-1586.txt

        item: #454 of 1356
          id: skin-1588
      author: Ramesh, Malvika; Purser, Jeremy; Tarbox, Michelle
       title: The Biett Collarette as an Important Dermascopic Finding of Secondary Syphilis 
        date: 2022-09-12
       words: 773
      flesch: 48
     summary: The variety of cutaneous presentations seen in secondary syphilis can mimic other dermatologic pathologies and make diagnosis difficult. However, the individual lesions seen in secondary syphilis can be distinguished by a peripheral scale called Biett’s Collarette [Figure 1] and dermoscopy can aid physicians in clueing into the right diagnosis via visualization of this unique finding.
    keywords: diagnosis; rash; syphilis
       cache: skin-1588.pdf
  plain text: skin-1588.txt

        item: #455 of 1356
          id: skin-159
      author: Dreno, B; Martin, R; Khammari, A; Moyal, D; Henley, J B; Seite, S
       title: Skin Microbiome and Acne Vulgaris: Staphylococcus, a New Actor in Acne
        date: 2017-10-27
       words: 1020
      flesch: 52
     summary: Moreover, Proteobacteria were less abundant in areas with comedones and papulo-pustular lesions than in unaffected skin areas (29% vs 34% - p=0.001 and 31% vs 34% - p=0.05) while Firmicutes were more abundant in zones with comedones (52% vs 47% - p=0.002). The study showed that in subjects with acne, the bacterial diversity is similar on the surface of unaffected skin as well as on comedones and papulo- pustular lesions.
    keywords: comedones; papulo; skin
       cache: skin-159.pdf
  plain text: skin-159.txt

        item: #456 of 1356
          id: skin-16
      author: Bernstein, Daniel; Farberg, Aaron S.; Khorasani, Hooman; Kriegel, David
       title: Noninvasive Body Contouring: Literature Review and Summary of Objective Data
        date: 2017-06-28
       words: 4607
      flesch: 59
     summary: High Intensity Focused Ultrasound; LOFU: Low Intensity Focused Ultrasound Background: There is increasing demand for noninvasive body contouring but objective data is difficult to compare between modalities. Currently, the most accepted forms of noninvasive body contouring are cryolipolyisis (Cryo), focused ultrasound (FUS), radiofrequency (RF), and low level laser therapy (LLLT).
    keywords: body; lasers; level; med; noninvasive; patients; results; studies; surg; ultrasound
       cache: skin-16.pdf
  plain text: skin-16.txt

        item: #457 of 1356
          id: skin-160
      author: Moyal, D; Seite, S
       title: Effect of Air Pollution on Sebum Rate and Acne: How to Manage Acneic Skin in a Polluted Environment
        date: 2017-10-27
       words: 907
      flesch: 69
     summary: The objective of this study was to evaluate first the effect of pollution on sebum rate and acne lesions and then, the efficiency of a skin care product routine to reduce the effects of pollution. Sebum rate and acne lesions numbers were evaluated each week during 8 weeks in a polluted environment (Beijing, China).
    keywords: t3w
       cache: skin-160.pdf
  plain text: skin-160.txt

        item: #458 of 1356
          id: skin-161
      author: Seite, S; Moyal, D
       title: Using a Specific Cleanser for Patients with Mild Atopic Dermatitis: Relationship Between Cinical Efficacy and Skin Microbiota Modification
        date: 2017-10-27
       words: 725
      flesch: 37
     summary: We speculated that a mild cleanser (syndet) supplemented with a biomass of non-pathogenic bacteria such as Vitreoscilla filiformis, grown in a medium containing thermal spring water (LRP-VFB) could have a clinical effect on the skin symptoms and skin bacterial landscape. Swabs were taken under axenic conditions, from lesion and proximal unaffected skin to analyse microbiome.
    keywords: d14
       cache: skin-161.pdf
  plain text: skin-161.txt

        item: #459 of 1356
          id: skin-1621
      author: Yeh, Jennifer; Ward, Ashley; Reynolds, Rachel
       title: Recognizing Multiple Diagnoses: Von Zumbusch Generalized Pustular Psoriasis Flare and Adverse Drug Effect
        date: 2022-07-07
       words: 1410
      flesch: 41
     summary: Triggers include infection, medications, operations, and hypocalcemia.1, 2 We present a patient with von Zumbusch GPP who flared in the setting of a gap in etanercept dosing and hospitalization for hip fracture. Here we describe a patient with a history of von Zumbusch GPP who presented with erythroderma, neutrophilic leukocytosis, and hyperbilirubinemia in the setting of missed medication dose and hip surgery.
    keywords: drug; figure; gpp; psoriasis; skin
       cache: skin-1621.pdf
  plain text: skin-1621.txt

        item: #460 of 1356
          id: skin-1622
      author: Taylor, Mitchell; Farias-Eisner, Robin
       title: Racial and Ethnic Disparities in Malignant Melanoma: A Literature Review
        date: 2022-09-12
       words: 4119
      flesch: 50
     summary: Historically, studies with melanoma patients have directed attention to genetic mutations in BRAF, NRAS, and KIT genes, which have long been associated with melanoma and are thought to be mutually excluding.16 More recently, research has focused on further characterizing the role of BRCA1/BRCA2 mutations in the development of melanoma. al, 630 patients with a history of melanoma and 3,700 controls were genotyped for the prevalence of three common variants of BRCA2 mutations (T1915M, N991D, and N372H).20 This study found that the prevalence of the BRCA2-N991D variant was significantly greater in melanoma patients compared to the controls.
    keywords: african; americans; brca2; cancer; melanoma; minority; mutations; patients; populations; skin
       cache: skin-1622.pdf
  plain text: skin-1622.txt

        item: #461 of 1356
          id: skin-1623
      author: Shope, Chelsea; Beck, Tyler; Andrews, Laura; Friedman, Peter; Wine Lee, Lara
       title: Nonthermal Atmospheric Pressure Plasma Technology in Dermatology
        date: 2022-09-12
       words: 4610
      flesch: 54
     summary: Moreover, in vitro application of NTAP therapy to keratinocytes in culture stimulated cell growth and proliferation, as evidenced by increases in the proportion of treated cells in S and G2 phase.8 Additionally, NTAP treatment disrupted E- cadherin mediated cell-to-cell interactions, allowing for increased nuclear localization of β-catenin. Notably, 61.5% of patients were satisfied with their treatment; 76.9% of patients expressed willingness to pay for NTAP treatment, and 100% of patients felt that treatment was tolerable.
    keywords: atmospheric; cell; medicine; ntap; patients; plasma; skin; studies; study; treatment; wound
       cache: skin-1623.pdf
  plain text: skin-1623.txt

        item: #462 of 1356
          id: skin-1624
      author: Chung, Mimi; Hakimi, Marwa; Yeroushalmi, Samuel; Bartholomew, Erin; Koo, John
       title: Contrasting between Atopic Dermatitis and Psoriasis in the Quality of Life Impact and the Prevalence of Psychiatric Disorders: A Review
        date: 2022-07-07
       words: 3186
      flesch: 54
     summary: A meta-analysis on depression outcomes in PSO and AD patients found that both AD and PSO patients had increased risk of suicidal ideation compared to controls (including studies that used general population or other medical conditions as controls). AD patients also had increased odds of conduct disorder (2.74, 95%CI 1.30-5.78, p = 0.0084) compared to PSO patients (3.30, 95%CI 0.91 - 11.99, p = 0.0696).
    keywords: 95%ci; controls; patients; pso; suicidal
       cache: skin-1624.pdf
  plain text: skin-1624.txt

        item: #463 of 1356
          id: skin-1625
      author: Frantz, Robert; Herold, Mitchell; Curiel-Lewandrowski, Clara
       title: Vismodegib as a Treatment for Multiple Non-locally Advanced Basal Cell Carcinomas
        date: 2022-09-12
       words: 1052
      flesch: 46
     summary: Vismodegib was presented as an off-label option for potentially decreasing the size and number of lesions, and the patient started ABSTRACT We present the case of a 77-year-old female with seven non-locally advanced basal cell carcinomas (BCCs) of the face who achieved a clinical complete response (CR) in six lesions after completing twelve months of Vismodegib monotherapy with tolerable side effects. This case investigates the off- label practical use of Vismodegib monotherapy to treat multiple non-locally advanced BCCs and reduce the surgical burden of disease in select patients.
    keywords: lesions; patients; treatment; vismodegib
       cache: skin-1625.pdf
  plain text: skin-1625.txt

        item: #464 of 1356
          id: skin-1626
      author: Harper, Kamran; Falcone, Lauryn; Savage, Kevin; James, Alaina
       title: Clinicopathologic Correlation: Differentiating Between Localized Lichen Myxedematosus and Scleromyxedema 
        date: 2022-07-07
       words: 689
      flesch: 47
     summary: Histologically, scleromyxedema can be indistinguishable from localized lichen myxedematosus (LM).2 Unlike patients with LM, patients with scleromyxedema may develop severe complications such as dermato-neuro syndrome, which is a potentially fatal condition characterized by a flu-like prodrome followed by fever, seizures, and coma.3 It is important to differentiate scleromyxedema from LM early due to the risk of progressive systemic disease. Given that prognosis and management of LM and scleromyxedema differ, patients with histologic evidence of a cutaneous mucinosis should be screened for evidence of systemic involvement.
    keywords: lichen; scleromyxedema; skin
       cache: skin-1626.pdf
  plain text: skin-1626.txt

        item: #465 of 1356
          id: skin-1627
      author: Haquang, Joseph; Li, Rocky; Mai, Kevin; Chen, Kuang Cheng; Sisan, Fardad; YuLing, Kuo
       title: Epidemiology and Mortality Risk Factors of Sebaceous Carcinoma: A SEER – Based Population Study
        date: 2023-05-20
       words: 1668
      flesch: 58
     summary: Our article aims to build upon the limited prognostic research by ABSTRACT Background: Sebaceous carcinoma is a rare and potentially aggressive cutaneous malignancy. Hence, we sought to assess the prognostic impact of demographic and socioeconomic factors on the outcome of patients with sebaceous carcinoma.
    keywords: age; carcinoma; factors; survival
       cache: skin-1627.pdf
  plain text: skin-1627.txt

        item: #466 of 1356
          id: skin-1628
      author: Nguyen, Tue; Shah, Anaya ; Momin, Bahar ; Vu, Marie ; Browning, MD, John 
       title: An Unusual Clinical Presentation of Cutaneous Syphilis 
        date: 2022-07-07
       words: 762
      flesch: 44
     summary: 351 SKIMages An Unusual Clinical Presentation of Cutaneous Syphilis Tue Felix Nguyen, BS1, Anaya Shah, BS1, Bahar Momin, BBA1, Marie Vu, BSA1, John Browning, MD2 1UT Health San Antonio, Long School of Medicine, San Antonio, TX 2Department of Dermatology, UT Health San Antonio, San Antonio, TX Figure 1: Annular, friable violaceous plaque with surrounding erythematous raised border with solitary nodules containing pinpoint petechiae A 33-year-old Black homosexual male presented with a plaque that appeared four months after he injured his hand on a metal railing under his car seat. While intramuscular 2.4 million units benzathine penicillin G single dose remains the gold standard of treatment, minocycline has been shown to be an effective alternative therapy for early syphilis if penicillin is unavailable.5 SKIN July 2022 Volume 6 Issue 4 (c) 2022 THE AUTHORS.
    keywords: antonio; medicine; san; syphilis
       cache: skin-1628.pdf
  plain text: skin-1628.txt

        item: #467 of 1356
          id: skin-163
      author: Seite, S; Moyal, D
       title: Can the Skin Microbiota of Patients Suffering from Atopic Dermatitis be Modified after Balneotherapy?
        date: 2017-10-27
       words: 749
      flesch: 14
     summary: We assessed the evolution of skin microbiota in AD patients, before and after 3 weeks of balneotherapy including high pressure filiform showers, baths, facial and body spray treatments as well as La Roche-Posay thermal water consumption. Among the 7561 patients treated in 2016 with balneotherapy at La Roche-Posay thermal center, 27% presented with eczema or atopic dermatitis (AD).
    keywords: balneotherapy; gram; prevotella
       cache: skin-163.pdf
  plain text: skin-163.txt

        item: #468 of 1356
          id: skin-1635
      author: Motosko, Catherine; Villada, Gabriel; Bray, Fleta; Perez, Gregory
       title: A Friable, Polypoid Tumor on the Chest
        date: 2023-03-13
       words: 698
      flesch: 45
     summary: If the tumor has prominent squamous cell differentiation, CK7, Cam5.2 or CEA highlight ductal differentiation, therefore supporting the diagnosis of porocarcinoma versus squamous cell carcinoma.1 Shave biopsy demonstrated dermal islands of atypical basaloid cells with pushing borders and central areas of necrosis en masse.
    keywords: cell; miami; porocarcinoma
       cache: skin-1635.pdf
  plain text: skin-1635.txt

        item: #469 of 1356
          id: skin-1639
      author: Lamb, Jordan; Beatty, Colleen; House, Nancy; James, Alaina
       title: Digital Pigmented Squamous Cell Carcinoma In-situ: A Case Report
        date: 2022-09-12
       words: 1761
      flesch: 55
     summary: This case highlights a unique association between inflammatory disease and development of pigmented SCCIS and emphasizes the importance of surveillance for atypical presentations of skin cancer in this patient population. While skin cancer is more common in individuals with white skin, patients with brown and black skin account for 1-5% of all skin cancer cases, with SCC being the most common skin cancer in this group.4 As illustrated in our case, patients with brown and black skin are more likely to have pigmented SCCIS in sun-protected areas, particularly acral surfaces.5 Factors other than UV damage, including advanced age, immunosuppression, scars, burns, arsenic exposure, and/or HPV infection, may play a role in the pathogenesis of pigmented SCC.6 The mean age of patients with pigmented SCCIS is approximately 63 years.3 A small number of cases of pigmented SCCIS have been documented in the pediatric population related to HPV, but cases in young adults, as in this case, are rare.5 Cigarette smoking is a well-established risk factor for lung SCC and mucosal head and neck SCC, but there is inconsistent evidence on the association between smoking and development of cutaneous SCC.7 In a recent meta-analysis, people who actively smoked were found to have an increased incidence of cutaneous SCC, while people who previously smoked did not have the same increased risk.7 Given our patient’s former smoking status and lack of other known risk factors, we hypothesize that his long-term corticosteroid therapy for systemic sarcoidosis may have played a role in the development of pigmented SCCIS at a young age.
    keywords: case; patients; pigmented; risk; sccis; skin
       cache: skin-1639.pdf
  plain text: skin-1639.txt

        item: #470 of 1356
          id: skin-164
      author: Seite, S; Moyal, D
       title: Observational Study on Patients with Acne and at Risk of Post-Inflammatory Hyperpigmented Lesions
        date: 2017-10-27
       words: 859
      flesch: 54
     summary: This survey demonstrated that a dermocosmetic product containing lipohydroxy acid, salicylic acid, linoleic acid, niacinamide, piroctone olamine and procerad (anti-inflammatory and anti-melanin synthesis action) can provide good results in managing acne patients with risks of post-inflammatory hyperpigmented lesions,when associated with therapeutic treatments or alone for milder acne. The aim of this observational study was to evaluate the use of a topical formula containing ingredients (niacinamide, procerad, LHA, piroctone olamine, linoleic acid) to reduce acne lesions and PIH, alone or in adjunctive therapy, in patients with mild to moderate acne and post-inflammatory hyperpigmented lesions.
    keywords: patients; visit
       cache: skin-164.pdf
  plain text: skin-164.txt

        item: #471 of 1356
          id: skin-1640
      author: Mendis, Rajith; Morgan, Gary; Abdul-Razak, Muzib; Wong, Eva; Howle, Julie; Gebski, Val; Veness, Michael
       title: Margin Status Predicts Outcome in Patients with Cutaneous Squamous Cell Carcinoma of the Scalp: The Westmead Hospital Experience
        date: 2022-07-07
       words: 3403
      flesch: 51
     summary: Local recurrence by margin status (Low risk group (LRG): >2mm; High risk group (HRG): ≤2mm) Disease specific mortality by margin status (Low risk group (LRG): >2mm; High risk group (HRG):
    keywords: cscc; margin; patients; radiotherapy; recurrence; risk; scalp; status
       cache: skin-1640.pdf
  plain text: skin-1640.txt

        item: #472 of 1356
          id: skin-1641
      author: Han, Haowei; Berman, Brian 
       title: Clinical Management of Actinic Keratosis: Review and Update
        date: 2022-07-07
       words: 6428
      flesch: 23
     summary: It is regarded as the spectrum along the continuum to squamous cell carcinoma (SCC).9 Although the rate for individual AK to progress into SCC is low, but 82.4% of SCCs were developed from AK directly or from tissue that is adjacent to AK lesions.10 AK is principally caused by sun exposure, or ultraviolet B (UV- B) radiation (wavelength 290–320 nanometer). Conversely, other factors needs to be evaluated when judging the most suitable option for the patient.54 Another meta- analysis published in 2014 examined 10 modalities and concluded that treatments with the relatively highest efficacy were: BF- 200 ALA PDT , followed by imiquimod 5% for 16-week, ALA PDT, and 5-FU 0.5%.55 A retrospective chart review scrutinized the rate of invasive SCC incidences after more than 1 year of initial AK field treatment.
    keywords: actinic; ala; cream; dermatol; efficacy; face; field; gel; iii; imiquimod; keratosis; light; patients; pdt; phase; skin; study; treatment
       cache: skin-1641.pdf
  plain text: skin-1641.txt

        item: #473 of 1356
          id: skin-1643
      author: Lanyi, Shira; Wills, Abigail; Schenck, Olivia
       title: Numerous Spider Angiomas as the Presenting Sign of Acute Graft Versus Host Disease
        date: 2022-11-16
       words: 1468
      flesch: 61
     summary: The clinical manifestations of cutaneous GVHD are highly variable, with many morphologies mimicking another skin condition. In the dermis there were ectatic superficial blood ABSTRACT Graft versus host disease (GVHD) is a highly morbid immunologic reaction and complication commonly seen in response to allogenic hematopoietic stem cell transplant.
    keywords: acute; chronic; disease; graft; gvhd; host
       cache: skin-1643.pdf
  plain text: skin-1643.txt

        item: #474 of 1356
          id: skin-1646
      author: Armenta, Andrew Michael; Ahatov, Renat; Gleghorn, Kristyna; Winsett, Frank T; Wagner, Richard F
       title: Absorbable Sutures in the COVID-19 Era: A Post-Operative Quality Improvement Survey of Patient Satisfaction Rates Following Mohs Surgery
        date: 2022-09-12
       words: 717
      flesch: 51
     summary: The patients were asked to rate their cosmetic outcome, perception of decreased exposure to COVID-19 by eliminating suture removal appointment, comfort level on decreased post-operative visits/wound checks due to eliminating suture removal appointment, and their likelihood to opt for absorbable sutures in the future or recommend them to a friend/family (Figure 2). Absorbable sutures have been used since as early as 1860.2
    keywords: absorbable; removal; sutures
       cache: skin-1646.pdf
  plain text: skin-1646.txt

        item: #475 of 1356
          id: skin-1648
      author: Park, Meredith; Googe, Paul; Derebail, Vimal K; Saha, Manish K; Matkovic, Eduard; Cope, Jennifer; Karim , Ibne; Ziemer, Carolyn; Wu, Sam
       title: Cutaneous Acanthamoeba Infection Presenting with Granulomatous Vasculitis
        date: 2023-03-13
       words: 1838
      flesch: 42
     summary: Acanthamoeba infection is a rare cause of cutaneous lesions that may mimic granulomatous inflammatory diseases including vasculitis. 703 fungal infections and vasculitides.1,2,4 Acanthamoeba species may infect the CNS causing granulomatous amoebic encephalitis, which shows necrotizing or granulomatous response on pathologic examination.5 Granulomatous vasculitis is often associated with ANCA vasculitis, and less commonly other etiologies such as lymphomatoid granulomatosis, rheumatoid vasculitis, or herpes simplex virus.7 Given the severity of Acanthamoeba infection, cutaneous acanthamoebiasis should be considered in the differential diagnosis of granulomatous vasculitis that fails to improve on standard therapies and with clinical history suggestive of exposure.
    keywords: acanthamoeba; infection; lesions; medicine; patient; vasculitis
       cache: skin-1648.pdf
  plain text: skin-1648.txt

        item: #476 of 1356
          id: skin-1649
      author: Ahearn, Emily; Tzur, Lihi; Mahalingam, Meera; Konnikov, Nellie
       title: Successful Treatment of Cutaneous Collagenous Vasculopathy with Pulsed Dye Laser: A Case Report
        date: 2022-09-12
       words: 1832
      flesch: 52
     summary: In summary, our case reiterates previously observed improvement in CCV patients with PDL laser. Given that the clinical presentation of CCV can be indistinguishable from other vascular disorders with cutaneous telangiectasias, especially generalized essential telangiectasia (GET), diagnosis requires biopsy to confirm the histopathology.2-3 Distinctive histopathological findings of CCV include ectatic superficial blood vessels with thickened vessel walls containing type IV collagen, that stains periodic acid-Schiff (PAS) positive.1-2 Fewer than fifty cases of CCV have been reported in the literature since it was first described by Salama and Rosenthal in ABSTRACT Cutaneous collagenous vasculopathy (CCV) is clinically characterized by symmetrical, progressive telangiectasias and an absence of systemic involvement.
    keywords: biopsy; ccv; pdl; telangiectasias; vasculopathy
       cache: skin-1649.pdf
  plain text: skin-1649.txt

        item: #477 of 1356
          id: skin-165
      author: Seite, S; Moyal, D
       title: Observational Study on Patients with Atopic Dermatitis
        date: 2017-10-27
       words: 859
      flesch: 54
     summary: This survey demonstrated that a dermocosmetic product containing lipohydroxy acid, salicylic acid, linoleic acid, niacinamide, piroctone olamine and procerad (anti-inflammatory and anti-melanin synthesis action) can provide good results in managing acne patients with risks of post-inflammatory hyperpigmented lesions,when associated with therapeutic treatments or alone for milder acne. The aim of this observational study was to evaluate the use of a topical formula containing ingredients (niacinamide, procerad, LHA, piroctone olamine, linoleic acid) to reduce acne lesions and PIH, alone or in adjunctive therapy, in patients with mild to moderate acne and post-inflammatory hyperpigmented lesions.
    keywords: patients; visit
       cache: skin-165.pdf
  plain text: skin-165.txt

        item: #478 of 1356
          id: skin-1651
      author: Mai, Kevin; Pham, Quang D. ; Haquang, Joseph; Pham, Diem Q.
       title: Perioral Contact Dermatitis Caused by Limonene Hydroperoxide in Cannabis Vaping Products
        date: 2023-03-13
       words: 1591
      flesch: 51
     summary: Due to its desirable aromatic qualities, it is one of the most common chemical additives in household products including cosmetics, essential oils, and cleaning supplies.1 The non-oxidized form of limonene can cause a weak fragrance allergy.2 When exposed to air, however, limonene rapidly autoxidizes and generates limonene hydroperoxide, a more potent contact sensitizer that has been noted to cause allergic contact dermatitis (ACD).2,3 Limonene’s availability and popularity has extended its use to novel products that use aerosolization such as electronic cigarettes or vapes.4 When exposed to air, limonene autoxidizes to form limonene hydroperoxide, a potent allergen that can cause allergic contact dermatitis.
    keywords: contact; dermatitis; hydroperoxide; limonene; products; vaping
       cache: skin-1651.pdf
  plain text: skin-1651.txt

        item: #479 of 1356
          id: skin-1652
      author: Tate, Jesalyn; Wang, Jennifer; Patel, Shreya; Nijhawan, Rajiv; Srivastava, Divya
       title: Assessing Patient Reported Quality of Care and Safety in Mohs Surgery During the COVID-19 Pandemic
        date: 2022-09-12
       words: 1776
      flesch: 53
     summary: Although, prior to their visit, several patients expressed some degree of concern regarding skin cancer treatment during COVID-19, most patients reported feeling safe during their appointment and satisfied with their care. Overall, patients felt safe and satisfied, with 75.7% reporting 10/10 safety (average 9.5/10) and 84% reporting 10/10 satisfaction (average 9.7/10).
    keywords: pandemic; patients; safety; skin; study
       cache: skin-1652.pdf
  plain text: skin-1652.txt

        item: #480 of 1356
          id: skin-1656
      author: Dirr, McKenzie; Brownstone, Nicholas; Rigel, Darrell
       title: Preference Signaling in the Dermatology Residency Match
        date: 2022-07-07
       words: 766
      flesch: 31
     summary: As reported by the AAMC key findings, one- fourth of dermatology programs received up to 53% of preference signals from all applicants, indicating a skewed distribution of signals across programs.6 343 SHORT COMMUNICATION Preference Signaling in the Dermatology Residency Match McKenzie A. Dirr, BA, BS1, Nicholas Brownstone, MD2, Darrell Rigel, MD, MS3 1 Medical University of South Carolina, Charleston, SC 2 National Society for Cutaneous Medicine, New York, NY 3 Department of Dermatology, Mount Sinai Icahn School of Medicine, New York, NY The residency match, facilitated by the National Resident Matching Program (NRMP) organization, which utilizes the Association of American Medical Colleges (AAMC) Electronic Residency Application Service (ERAS), facilitates the determination of where senior medical students will continue their education as resident physicians.1 Created in 1952, the match is the culmination of a reciprocal interest between students and residency programs, whereby both entities rank prospects in order of interest.
    keywords: dermatology; match; residency
       cache: skin-1656.pdf
  plain text: skin-1656.txt

        item: #481 of 1356
          id: skin-1657
      author: Dirr, McKenzie; Brownstone, Nicholas; Rigel, Darrell
       title: Hypopigmented Patches on the Trunk of a 25-year-old Hispanic Male
        date: 2022-07-07
       words: 729
      flesch: 52
     summary: It had previously been proposed that in patients with skin of color, hypopigmentation is more common, with the potential to combine into a larger, amalgamated area of discoloration, while patients with lighter skin tones are more likely to present with hyperpigmentation. This demonstrates a case of hypopigmented TV in a patient with Fitzpatrick skin type IV, and illustrates an example of one of the many forms in which TV may present.
    keywords: patients; skin
       cache: skin-1657.pdf
  plain text: skin-1657.txt

        item: #482 of 1356
          id: skin-166
      author: Seite, S; Moyal, D
       title: Prevention of Actinic Keratosis by a Very High UVB/UVA Daily Photoprotectant
        date: 2017-10-27
       words: 461
      flesch: 55
     summary: 70 patients between 45 and 80 years old with AK lesions were included in the study. New 4 53 Female II 4 Cryo 2 62 Recurrence and new 4 4 67 Male II 5 Cryo 2 182 Recurrence 1 69 Male II 3 Cryo 0 50 Recurrence and new 1 6 In patients with relapse (recurrence or new lesions)
    keywords: lesions; new
       cache: skin-166.pdf
  plain text: skin-166.txt

        item: #483 of 1356
          id: skin-1660
      author: Sun, Haorui; Helm, Matthew; Svoboda, Ryan
       title: The Incidence of Imprecise ICD-10 Coding in Patients with Cutaneous T-cell Lymphoma: A MarketScan Database Study
        date: 2023-01-10
       words: 1720
      flesch: 52
     summary: Furthermore, the use of diagnosis codes for “CTCL” without more specific codes for individual entities can impact treatment and survival data and nullify the utility of claims- based data used for research purposes, as previously demonstrated with other disease entities.5,6 Consequently, our study aimed to determine the proportion of patients in the ABSTRACT Background: The term “Primary Cutaneous T-cell Lymphoma” (primary CTCL), although used largely interchangeably with mycosis fungoides in the past, actually represents numerous non-Hodgkin lymphomas with highly variable and distinct characteristics. Proper use of ICD-10 diagnosis codes has important implications not only for billing, but also for claims-based research, as the validity of such studies hinges on the ability to identify a complete, homogenous sample population.5
    keywords: cell; code; ctcl; diagnosis; lymphoma
       cache: skin-1660.pdf
  plain text: skin-1660.txt

        item: #484 of 1356
          id: skin-1664
      author: Patel, Jason; Hill, Callie; Hodge, Bonnie; Phillips, Carlton
       title: Multiple Sebaceous Carcinomas in an African American Patient with Muir-Torre Syndrome
        date: 2022-09-12
       words: 1070
      flesch: 55
     summary: MSH6: Expressed in tumor cells (Positive) To our knowledge, there are currently only 3 cases of sebaceous neoplasms in African American patients described in the literature.3,4,5 Of these, one case report details an African American patient with a diagnosis of MTS and a biopsy-proved sebaceous adenoma of the back.3 Moon et al. reported one patient with a pruritic, erythematous, mildly lichenified plaque on the abdomen with biopsy revealing sebaceous carcinoma; this patient did not have an associated MTS.4 Another author theorized the occurrence of sebaceous neoplasms in African Americans without MTS and a potential relationship between the immunosuppressive state in end-stage renal failure.5,6 As noted in this patient, concomitant hidradenitis suppurativa disease could delay diagnosis if sebaceous neoplasms present within typical areas of HS disease (axilla, groin, buttocks, inframammary chest) or with similar clinical features, particularly follicular occlusion lesions.7 Clinicians should obtain a careful medical and family history when cyst-like lesions present with unusual features or in patients with known MTS. It is also important to consider differences in clinical appearance of sebaceous neoplasms in skin of color.
    keywords: patient; pmid; sebaceous; syndrome
       cache: skin-1664.pdf
  plain text: skin-1664.txt

        item: #485 of 1356
          id: skin-1666
      author: Blauvelt, Andrew ; Rich, Phoebe; Sofen, Howard; Lambert, Jo; Merola, Joe; Lebwohl, Mark; Hippeli, Lauren; Kisa, Renata; Banerjee, Subhashis; Kimball, Alexa
       title: Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
        date: 2022-07-07
       words: 2573
      flesch: 55
     summary: Subhashis Banerjee,7 Alexa B Kimball8 1Oregon Medical Research Center, Portland, OR, USA; 2Oregon Dermatology and Research Center, Portland, OR, USA; 3UCLA School of Medicine, Los Angeles, CA, USA; 4Ghent University, Ghent, Belgium; 5Harvard Medical School, Boston, MA, USA; 6Icahn School of Medicine at Mount Sinai, New York, NY, USA; 7Bristol Myers Squibb, Princeton, NJ, USA; 8Beth Israel Deaconess Medical Center, Boston, MA, USA Presented at the Fall Clinical Dermatology Conference for NPs and PAs®; June 3−5, 2022; Scottsdale, AZ Acknowledgments • These clinical trials were sponsored by Bristol Myers Squibb • Writing and editorial assistance were provided by Lisa Feder, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, funded by Bristol Myers Squibb Disclosures AB: Scientific adviser and/or clinical study investigator: AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, EcoR1, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Vibliome.
    keywords: deucravacitinib; pga; placebo; week
       cache: skin-1666.pdf
  plain text: skin-1666.txt

        item: #486 of 1356
          id: skin-1667
      author: Han, George; Feldman, Steve; Bhatia, Neal; Præstegaard, Morten
       title: Dipropionate (Bdp) Cream (Cal 0.005%/Bdp 0.064% W/W) Improves Plaque Psoriasis At Week One In A Phase 3 Trial
        date: 2022-07-07
       words: 970
      flesch: 67
     summary: In this head-to-head trial, CAL/BDP cream demonstrated a faster onset of action than CAL/BDP TS. • Finally, more patients in the CAL/BDP cream group (44.8%) achieved a clinically relevant 4-point improvement in Dermatology Life Quality Index (DLQI) at week 1 than with CAL/BDP TS (40.4%; p=0.0476) or vehicle (29.7%) (Figure 3).
    keywords: bdp; cal; cream
       cache: skin-1667.pdf
  plain text: skin-1667.txt

        item: #487 of 1356
          id: skin-1668
      author: Kircik, Leon ; Draelos, Zoe; Guenin, Eric
       title: Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Safety, and Spreadability
        date: 2022-07-07
       words: 1178
      flesch: 58
     summary: Mean difference: 36.7 cm2 • On average, skin coverage with tazarotene 0.045% lotion was ~30% greater than with trifarotene 0.005% cream Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Safety, and Spreadability Leon H Kircik, MD1-3; Zoe D Draelos, MD4; Eric Guenin, PharmD, PhD, MPH5 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Indiana University Medical Center, Indianapolis, IN; 3Physicians Skin Care, PLLC, DermResearch, PLLC, and Skin Sciences, PLLC, Louisville, KY; 4Dermatology Consulting Services, PLLC, High Point, NC; 5Ortho Dermatologics, Bridgewater, NJ* *Ortho Dermatologics is a division of Bausch Health US, LLC FIG CONCLUSIONS � Tazarotene 0.045% lotion utilizes polymeric emulsion technology to enhance hydration, moisturization, and skin barrier function � Tazarotene 0.045% lotion led to significant reductions in truncal acne severity and lesion counts; ~90% of participants achieved clear or almost clear skin with 12 weeks of once-daily use and most participants had no tolerability issues � This easy-to-apply tazarotene lotion has sensory and aesthetic properties preferred by patients6 and resulted in ~30% greater skin coverage compared with trifarotene cream • Less product needed to cover the same skin area equals more applications per unit volume REFERENCES 1. STUDY 1: EFFICACY, SAFETY, AND TOLERABILITY IN TRUNCAL ACNE Tazarotene 0.045% Lotion • Most participants had no tolerability issues • There were no signi�cant changes from baseline to week 12 in any tolerability assessment Total Lesion Reductions -100% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e -80% -44.9% *** Tazarotene 0.045% Lotion (n=19)
    keywords: acne; lotion; participants; skin; tazarotene
       cache: skin-1668.pdf
  plain text: skin-1668.txt

        item: #488 of 1356
          id: skin-1669
      author: Draelos, Zoe; Blair, Amber ; Tanghetti, Emil
       title: Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream
        date: 2022-07-07
       words: 1369
      flesch: 48
     summary: After 2 weeks of use, average impression rating scores on each of the 16 questionnaire items were better (lower) for lotion versus cream (P<0.05 on 15 of 16 items; Figures 3 and 4) • Similar results were observed immediately after one use (P<0.05 on 10 of 16 items; data not shown) � More than 70% of participants agreed (rating score 1–3) that the tretinoin lotion was gentle, comfortable/soothing, spreadable, absorbent, not sticky, and left a minimal white residue versus <40% for generic cream (Figure 3) � Agreement scores on skin sensation (feels soft, smooth, comforted/soothed/calm, not dry and looks smoother, less dull, less flaky) were similarly higher for lotion versus cream (>60% vs ≤40%; Figure 4) � Overall, approximately 70% of participants preferred to take tretinoin lotion home over cream both after first use and 2 weeks of use (Figure 5) FIGURE 3. In this single-center, double-blinded, split-face study, females with acne aged ≥18 years were randomized to apply tretinoin lotion or generic cream once daily to the right or left cheek for 2 weeks • First application occurred at the research site under the supervision of a research coordinator � Assessments were conducted immediately after first use and after two weeks of split-face drug application �
    keywords: cream; lotion; tretinoin
       cache: skin-1669.pdf
  plain text: skin-1669.txt

        item: #489 of 1356
          id: skin-167
      author: Zeichner, Joshua A
       title: The Use of Lipohydroxy Acid in Skin Care and Acne Treatment
        date: 2017-10-27
       words: 655
      flesch: 64
     summary: •A 2 week study of 14 acne patients showed that twice daily LHA application resulted in a significant decrease in size and number of comedones with approximately an 85% reduction in follicular plugs(8). THE USE OF LIPOHYDROXY ACID IN SKIN CARE AND ACNE TREATMENT •Lipohydroxy acid (LHA) is a salicylic acid (SA) derivative with skin renewing, exfoliating, and acne treating properties.
    keywords: acne; dermatol; lha
       cache: skin-167.pdf
  plain text: skin-167.txt

        item: #490 of 1356
          id: skin-1676
      author: Vu, Marie; Nguyen, Tue; Lue, Melinda; Browning, John
       title: Multidisciplinary Surgical Management of Extensive Basal Cell Carcinomas
        date: 2023-01-10
       words: 1384
      flesch: 49
     summary: Mohs micrographic surgery is an option which involves precise surgical technique and complete excision of skin cancer that is checked by microscopic margin control. In addition, homeless and uninsured individuals are presumed to have a higher prevalence of skin cancer than the general population.8 As highlighted in this case, delayed detection of BCC may lead to a more invasive treatment requiring multidisciplinary teams for management.
    keywords: bcc; flap; patient; skin; treatment
       cache: skin-1676.pdf
  plain text: skin-1676.txt

        item: #491 of 1356
          id: skin-1677
      author: Mostaghimi, Arash; Meche, Aster; Ray, Markqayne; Gandhi, Kavita; Gruben, David; Sikirica, Vanja
       title: Comorbidities, Healthcare Utilization, and Costs Associated With Alopecia Totalis and Alopecia Universalis in the United States
        date: 2022-11-16
       words: 2503
      flesch: 58
     summary: 512 seldom experience spontaneous recovery.2-4 Treatment efficacy is variable and limited in this subset of AA patients, with cases often recalcitrant to treatment.5 This retrospective healthcare claims analysis used stratification of AA patients to identify a subset of AT/AU patients to compare HCRU and healthcare costs in patients diagnosed with AT/AU with non-AT/AU AA.
    keywords: alopecia; costs; index; mean; patients
       cache: skin-1677.pdf
  plain text: skin-1677.txt

        item: #492 of 1356
          id: skin-1679
      author: Shih, Terri; De, Devea; Rick, Jonathan; Shi, Vivian; Hsiao, Jennifer Lin
       title: Seasonal Trends of Ambulatory Visit Burden in Hidradenitis Suppurativa Patients
        date: 2022-09-12
       words: 1376
      flesch: 48
     summary: Survey-weighted number of HS visits per 100.000 visits by month SKIN September 2022 Volume 6 Issue 5 (c) 2022 However, there is a paucity of literature on whether there is an increased ambulatory visit burden for HS patients during the warmer months.
    keywords: ambulatory; hidradenitis; patients; suppurativa; visits
       cache: skin-1679.pdf
  plain text: skin-1679.txt

        item: #493 of 1356
          id: skin-168
      author: Bhatia, Neal D
       title: An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris
        date: 2017-10-27
       words: 1451
      flesch: 54
     summary: A recent case study showed the efficacy of ingenol mebutate against anogenital warts7 • The current study was an open-label, exploratory study using ingenol mebutate gel 0.05% for the treatment of verruca vulgaris on the hands METHODS Design • Open-label, exploratory study (Figure 1) • Conducted at a single site in the US in 2016-2017 • 16 eligible subjects were treated once daily for 2 consecutive days, on days 1 and 2 of the study, with ingenol mebutate gel 0.05% • Key inclusion criteria • Eligible subjects were >18 years of age; nonpregnant • Minimum of 2 and maximum of 5 verrucous papules diagnosed as common warts on the hands, excluding proximity to the nails Key exclusion criteria • Pregnancy • Use of any investigational drug or device that could affect common wart treatment − Use of an investigational drug or investigational device treatment within 30 days prior to visit 1 −
    keywords: day; subjects; treatment; warts
       cache: skin-168.pdf
  plain text: skin-168.txt

        item: #494 of 1356
          id: skin-1681
      author: Babadjouni, Arash; Phong, Celine H; Raffi, Jodie; Mesinkovska, Natasha A
       title: Turning Down the Fire: The Role of Botulinum Toxin Microdroplets in Refractory Rosacea Erythema
        date: 2022-09-12
       words: 1488
      flesch: 49
     summary: Anecdotal reports have linked rosacea facial erythema to diminished quality of life and self-confidence. Dilute, intradermal BTX-A (microdroplet BTX-A) can improve facial erythema and skin quality, as denoted by reduced sebum production and facial pores.
    keywords: btx; erythema; microdroplet; rosacea; treatment
       cache: skin-1681.pdf
  plain text: skin-1681.txt

        item: #495 of 1356
          id: skin-1685
      author: Taylor, Mitchell; Pham, Amelia; Clausen, Michaela; Darabi, Kamruz
       title: Eruptive Keratoacanthoma in a 59-year-old Female with Chronic Kidney Disease: A Case Report and Review of Treatment Approaches
        date: 2023-05-20
       words: 3012
      flesch: 48
     summary: A correct diagnosis of multiple KA syndrome provides medical treatment options other than surgical methods used for conventional solitary KAs and well-differentiated SCCs and provides an opportunity to avoid surgical overtreatment of lesions. The most common subtype presents as a single lesion with a central keratin-filled crater that may regress without intervention, though many are biopsied to rule out other diagnoses such as squamous cell carcinoma (SCC), amelanotic melanoma, Merkel cell carcinoma, and cutaneous infections.3, 4 Despite many shared histological features between KA and SCC, most authors regard KA as benign.5 However, due to the ambiguity and difficulty with histological differentiation between KA and invasive well- differentiated SCC, and sometimes only partial sampling techniques, current guidelines recommend surgical excision for KAs to ensure treatment of potential malignancy.1 While the most common variants of KAs manifest as sporadic and solitary lesions, a number of syndromes have been described in which individuals develop hundreds to thousands of KAs.6 Unlike solitary KAs, multiple KA syndromes affect the skin regardless of sun exposure.7
    keywords: doi; eruptive; geka; kas; keratoacanthoma; lesions; multiple; patient; treatment
       cache: skin-1685.pdf
  plain text: skin-1685.txt

        item: #496 of 1356
          id: skin-1686
      author: Ugoh, Gregory; Crain, Caroline; Goodwin, Brandon
       title: A Case of Pseudoverrucous Papules and Nodules in an Adult with Spinal Dysraphism
        date: 2022-11-16
       words: 1034
      flesch: 48
     summary: Herein we present a case of perianal PPN in a patient with Dubowitz syndrome and spina bifida. Herein, we present the case of a patient with spina bifida in association with Dubowitz syndrome who presented with perianal PPN.
    keywords: incontinence; nodules; papules; ppn
       cache: skin-1686.pdf
  plain text: skin-1686.txt

        item: #497 of 1356
          id: skin-1687
      author: Ugoh, Gregory Ugoh; Linfante, Anthony; Good, Allison; Wilson, Janice; Kroger, Kathleen
       title: Bazex Syndrome Associated with Angioimmunoblastic T-cell Lymphoma
        date: 2023-05-20
       words: 919
      flesch: 48
     summary: in 1965 in association with malignancy of the upper aerodigestive tract.1 The main features are the presence of symmetrical psoriasiform eruptions, nail dystrophy, and xerotic scaling usually accentuated on the acral surfaces, ears, and nose.2 Several mechanisms for development of Bazex syndrome have been proposed. Association with cutaneous squamous cell carcinoma, Hodgkin’s disease, peripheral T- cell lymphoma, and follicular lymphoma in- situ have been reported.3 We present a unique case of Bazex syndrome associated with AITL.
    keywords: bazex; cell; lymphoma; syndrome
       cache: skin-1687.pdf
  plain text: skin-1687.txt

        item: #498 of 1356
          id: skin-1688
      author: Taylor, Alexandra; Pile, Hannah; Altman, David
       title: A Man with Worsening Scaling Plaques and a New Onset Large Draining Ulcerated Tumor
        date: 2023-03-13
       words: 1603
      flesch: 45
     summary: 698 While LCT is very rare in early stage I of MF, it has been described in up to 50% of patients with stage IV disease.2 MF with LCT typically confers a worse prognosis with 50% survival by 1 year compared to tumor stage MF without LCT, which has an average survival of 5.5 years.2 Figure 3. Brentuximab vedotin (BV) is a monoclonal antibody targeting the CD30 antigen on cancer cells and is increasingly used in the treatment of MF patients with LCT.
    keywords: disease; fungoides; mycosis; skin
       cache: skin-1688.pdf
  plain text: skin-1688.txt

        item: #499 of 1356
          id: skin-169
      author: DiRuggiero, Douglas; Hong, Chih-Ho; Tiu, Lisa; Freeman, Scott
       title: Results of Subject's Assessment of Behavior and Attitudes (SABA) Survey Toward Psoriasis and Treatments in the PSO-INSIGHTFUL Study
        date: 2017-10-27
       words: 1300
      flesch: 56
     summary: Psoriasis impacts on my emotional well being 112 (53.1) 99 (46.9) 0 Attitudes to Psoriasis and Treatments Strongly/slightly agree, n (%) Overall, SABA responses indicate patients’ attitudes toward specific aspects of psoriasis treatment (i.e., quick treatment application, willingness to try newest treatments) are stronger than their worry of side effects or self- perception of lifestyles that limit time for treatment.
    keywords: patients; psoriasis; saba; treatment
       cache: skin-169.pdf
  plain text: skin-169.txt

        item: #500 of 1356
          id: skin-1693
      author: Shenoy, Tanya; Nahar, Vinayak; Goodwin, Melodie; Helms, Stephen E; Brodell, Robert T; Black, William
       title: Forestalling Lidomageddon: Local Solutions to the Nationwide Shortage of Lidocaine
        date: 2022-09-12
       words: 1079
      flesch: 45
     summary: ** If 50cc vials of lidocaine are not available, carefully maintain the same ratio to dilute available lidocaine with 0.9% NaCl or sodium bicarbonate SKIN September 2022 Volume 6 Issue 5 (c) 2022 THE AUTHORS. Dilute injectable lidocaine to preserve available supplies* Dermatologists generally use 1.0-2.0% lidocaine for local anesthesia.
    keywords: dermatology; epinephrine; journal; lidocaine
       cache: skin-1693.pdf
  plain text: skin-1693.txt

        item: #501 of 1356
          id: skin-17
      author: Farberg, Aaron S.; Donohue, Stephen; Farberg, Alexander; Teplitz, Rebeca W.; Rigel, Darrell S.
       title: Cutaneous Implications of Whole Body Cryotherapy
        date: 2017-06-28
       words: 1587
      flesch: 47
     summary: Recently, WBC has been advocated to help skin appear and feel healthier, fight age-related deficiencies, and increase antioxidant production. The currently available evidence appears to be insufficient to support the use of WBC for improving skin and there is some small potential for risk.
    keywords: body; cryotherapy; skin; studies; treatment; wbc
       cache: skin-17.pdf
  plain text: skin-17.txt

        item: #502 of 1356
          id: skin-1701
      author: Yeh, Jennifer; Pereira da Silva, Marcelo; Raff, Adam; Foreman, Ruth
       title: Identifying Inflammatory Gene Expression Signatures for Skin and Soft Tissue Infections
        date: 2022-11-16
       words: 1460
      flesch: 40
     summary: Comprehensive screening of inflammatory genes in SSTIs could identify biomarkers to distinguish SSTIs from mimics. SSTIs are thought to be mediated by toxin-induced inflammatory pathways3; however, published literature lacks comprehensive screening of inflammatory genes in SSTIs.
    keywords: cases; cellulitis; genes; skin; sstis; study
       cache: skin-1701.pdf
  plain text: skin-1701.txt

        item: #503 of 1356
          id: skin-1703
      author: Nguyen, Kevin; Pham, Diem Q. ; Erickson, Christof P.
       title: Psoriasiform Spongiotic Dermatitis Drug Eruption following Pfizer-BioNTech SARS-CoV-2 mRNA Vaccine Administration 
        date: 2023-03-13
       words: 2013
      flesch: 52
     summary: Furthermore, the patient’s histopathology taken from the right medial thigh revealed focal spongiosis, eosinophils at the dermis, and lymphohistiocytic infiltrate consistent with drug exanthem biopsies observed in the literature.9 Few reports of morbilliform drug eruptions have been documented after vaccination. The differential diagnosis included guttate psoriasis, drug eruption, and allergic contact dermatitis.
    keywords: covid-19; drug; patient; psoriasis; rashes; vaccine
       cache: skin-1703.pdf
  plain text: skin-1703.txt

        item: #504 of 1356
          id: skin-1706
      author: Rodrigues, Adrian E; Dolivo, David; Li, Yingxing; Hou, Chun; Sun, Lauren; Mustoe, Thomas A.; Hong, Seok Jong; Galiano, Robert D.
       title: Thermal Burn Wounds Produce Greater Scars Compared to Similarly Sized Excisional Wounds And Topical Amiloride Applied to Burn-Induced Scars Shows Scar Reduction
        date: 2022-09-12
       words: 3751
      flesch: 53
     summary: Given that skin injuries disrupt the integumentary barrier and consequently produce local dehydration by increasing transepidermal water loss (TEWL),13 and since burn scars also exhibit increased TEWL compared to normal skin,14 we hypothesized that amiloride (and celecoxib due to its COX-2 antagonistic effect) could reduce scar formation in an in vivo study by hampering collagen production in a rabbit-ear injury model. B) Bar graph illustrating a significantly reduced SEI in burn scars treated with amiloride compared to vehicle control, and C)
    keywords: amiloride; burn; celecoxib; control; ear; figure; scar; sei; skin; study; vehicle; wounds
       cache: skin-1706.pdf
  plain text: skin-1706.txt

        item: #505 of 1356
          id: skin-1707
      author: Holt, Sara; Meckley, Abigail; Harp, Taylor; Esguerra, David 
       title: Messenger RNA-1273 Moderna COVID-19 Vaccination as Potential Trigger for Case of New Onset Pemphigus Vulgaris
        date: 2022-09-12
       words: 1012
      flesch: 26
     summary: Co-managed by the Centers for Disease Control and the U.S. Food and Drug Administration, VAERS (https://vaers.hhs.gov) accepts and analyzes reports of adverse events after a person has received a vaccination.4 There are at least 20 reported cases of pemphigus claimed to be associated with the mRNA-1273 (Moderna) vaccine, however no cause-and- effect relationship has been established.4 In this case, the development of PV following COVID-19 vaccination with the mRNA-1273 (Moderna) vaccine may be coincidental, however the following factors suggest a relationship may exist: the time interval between vaccination and symptom onset, successful response to standard treatment, and lack of other risk factors such as drug intake, self or family history of autoimmune disorder, recent infection or known malignancy. Here we describe a case of new onset PV following COVID-19 vaccination with the mRNA-1273 (Moderna) vaccine.
    keywords: covid-19; vaccination; vaccine
       cache: skin-1707.pdf
  plain text: skin-1707.txt

        item: #506 of 1356
          id: skin-1709
      author: Nguyen, Christopher; Nguyen, Quoc-Bao; Lauck, Kyle; Hebert, Adelaide
       title: Five Years Later: Continuing Disparity in the Geographic Density and Distribution of U.S. Dermatologists
        date: 2023-05-20
       words: 1644
      flesch: 53
     summary: From a 2014 American Academy of Dermatology (AAD) survey, dermatologists in rural areas were more likely to report an undersupply of dermatologists, while dermatologists in urban areas were more likely to report an oversupply.1 The Glazer et al. studies analyzing the geographic distribution of practicing dermatologists in the US in 2009 and 2016 confirmed this maldistribution.2,3 Trends in dermatology: geographic density of US dermatologists.
    keywords: areas; cagr; density; dermatologists
       cache: skin-1709.pdf
  plain text: skin-1709.txt

        item: #507 of 1356
          id: skin-171
      author: Segaert, Siegfried; Shear, Neal; Chiricozzi, Andrea; Thaci, Diamant; Carrascosa, Jose M; Young, Helen; Descamps, Vincent
       title: Innovation in Topical Therapy for Psoriasis with Corticostereoid and Vitamin D Analogue Commbination
        date: 2017-10-27
       words: 2113
      flesch: 26
     summary: 80 IL-17A secretion from T-cells† Cal BD CombinationCal BD Combination Cal BD Combination Cal BD Combination 0 20 40 60 80 0 50 100 150 200 250 300 350 0 20 40 60 80 IL-10 secretion from T-cells IL-23 secretion from DCs* IL- 8 secretion from KCs‡ % o f c on tr ol % o f c on tr ol % o f c on tr ol % o f c on tr ol P≤0.01 ns P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 Figure 2. Table 2)15,22–24 � The increased efficacy of Cal/BD aerosol foam is also associated with a similar safety profile, as demonstrated in a pooled safety analysis comparing fixed-dose combination Cal/BD aerosol foam with BD foam, Cal foam, Cal/BD ointment, and vehicles (foam and ointment)25 Table 2.
    keywords: cal; combination; dermatol; foam; skin; treatment
       cache: skin-171.pdf
  plain text: skin-171.txt

        item: #508 of 1356
          id: skin-1713
      author: Mancuso, Christopher J; Danosos, Gerard; Ruppel, Tyler; Litchman, Graham H; Choudhury, Sourab
       title: Erythema Elevatum Diutinum Associated with Tuberculosis
        date: 2022-09-12
       words: 1676
      flesch: 44
     summary: The prognosis for EED patients varies based upon the underlying disorder.8 Proper and timely treatment of the underlying cause or infection should significantly improve EED lesions. These patients may experience prolonged EED as well as lung damage and associated conditions, dissemination of disease, and systemic amyloidosis, among others.11 This case demonstrates an exceedingly rare presentation of erythema elevatum diutinum caused by tuberculosis in a middle-aged woman.
    keywords: disease; diutinum; eed; erythema; tuberculosis
       cache: skin-1713.pdf
  plain text: skin-1713.txt

        item: #509 of 1356
          id: skin-1717
      author: Johnson, Jessica; Nowacki, Amy; Narang, Jatin; Young, Sarah; Fernandez, Anthony P.
       title: Severity of COVID-19 in Patients with Dermatomyositis: A Single Center, Retrospective Observational Cohort Study
        date: 2022-11-16
       words: 1269
      flesch: 49
     summary: Although dermatomyositis (DM) patients have been included in large cohorts of patients with IMIDs evaluating for COVID-19 risk and severity, there is little literature specifically evaluating DM patient cohorts. We performed a single-center, retrospective cohort study to evaluate the severity of COVID-19 in DM patients and to assess for risk factors related to severe COVID-19 disease course.
    keywords: covid-19; hospitalized; patients
       cache: skin-1717.pdf
  plain text: skin-1717.txt

        item: #510 of 1356
          id: skin-1718
      author: Bullock, Taylor; Simonds, Robert;  McBride, Jeffrey; Irfan, Mawish; Young, Sarah
       title: Neonatal Lupus Erythematosus: A Case Report and Review of the Literature
        date: 2023-03-13
       words: 3708
      flesch: 51
     summary: Additionally, skin biopsy will distinguish lesions of Langerhans cell histiocytosis from those of NLE.22,25 Autoinflammatory diseases may closely resemble cutaneous NLE manifestations, but commonly present with multisystem involvement and severe fevers. The histologic findings and laboratory abnormalities confirmed the diagnosis of neonatal lupus erythematosus.
    keywords: antibodies; block; cardiac; cutaneous; disease; erythematosus; findings; heart; lesions; lupus; manifestations; neonatal; nle
       cache: skin-1718.pdf
  plain text: skin-1718.txt

        item: #511 of 1356
          id: skin-172
      author: Soung, Jennifer; Tiu, Lisa; Veverka, Karen; Hong, Chih-Ho
       title: Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study
        date: 2017-10-27
       words: 1534
      flesch: 38
     summary: Patient Demographics and baseline characteristics (adapted from PSO-INSIGHTFUL) BMI, body mass index; BSA, body surface area; mPASI, modified psoriasis and severity index; PGA, Physician’s Global Assessment of disease severity � Full analysis set comprised all randomized patients who completed an on-study questionnaire � LTT analysis set comprised all randomized patients who had used topical treatment within 3 months before baseline Statistical Analysis Topical Product Usability Questionnaire (TPUQ) Total time spent acceptable o Quick to apply o Easily incorporated into daily routine � Significant differences observed in favor of Cal/BD foam vs topical suspension in the domains of “immediate feeling of relief” and “soothing feeling” � Significant differences observed in favor of Cal/BD topical suspension vs foam included: o Ease of application, ease of application on lesion only, and ease of spreading o Good for use on small areas o Odorless o Accurately dispensed wanted amount Cal/BD foam (n=212) Cal/BD topical suspension (n=212)
    keywords: cal; foam; topical
       cache: skin-172.pdf
  plain text: skin-172.txt

        item: #512 of 1356
          id: skin-1720
      author: Markeson, Christopher; Brownstone, Nicholas ; Parker, Jennifer; Hsu, Sylvia
       title: Allergic Contact Dermatitis to Paraphenylenediamine in Black Henna 
        date: 2022-09-12
       words: 777
      flesch: 53
     summary: Cosmetic practices, such as black henna and hair darkening, make up the majority of reported cases of PPDA allergic contact dermatitis. The prevalence of PPDA allergy is highest in hairdressers, hairdressing clients undergoing dye application, and photographic film developers due to repeated exposure.
    keywords: henna; medicine; ppda
       cache: skin-1720.pdf
  plain text: skin-1720.txt

        item: #513 of 1356
          id: skin-1727
      author: Garcia, Natalie; Mcrae, Charlotte ; Smith, Abigail; Graham, Lauren
       title: Leukemia Cutis as the Presenting Sign of Acute Myeloid Leukemia in an HIV+ patient
        date: 2023-05-20
       words: 1261
      flesch: 54
     summary: The diagnosis of leukemia cutis is important to consider, regardless of CD4 count or presence of systemic leukemia, in immunosuppressed patients. 821 BRIEF ARTICLE Leukemia Cutis as the Presenting Sign of Acute Myeloid Leukemia in an HIV+ patient Natalie Garcia, BS1, Charlotte Mcrae, BS1, Abigail Smith, MD2, Lauren Graham, MD, PhD2 1University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 2University of Alabama at Birmingham, Department of Dermatology, Birmingham, AL Leukemia Cutis (LC) is a rare extramedullary cutaneous manifestation of leukemia that varies in terms of clinical presentation, type of leukemia, and timing of presentation in relation to systemic leukemia.
    keywords: leukemia; patient; rash
       cache: skin-1727.pdf
  plain text: skin-1727.txt

        item: #514 of 1356
          id: skin-1728
      author: Batchelder, Emma; Trifoi, Mara; Hong, Julie; Maczuga, Steven; Kirby, Joslyn
       title: Biologic Treatment of Psoriasis and Tuberculosis Testing: A Retrospective Analysis 
        date: 2022-11-16
       words: 1378
      flesch: 62
     summary: TB tests were positive in 4.1% (n = 147) of patients and TNF- α inhibitors was the most frequently prescribed biologic. TB tests were positive in 4.1% (n=147/3,559).
    keywords: biologic; patients; psoriasis; testing
       cache: skin-1728.pdf
  plain text: skin-1728.txt

        item: #515 of 1356
          id: skin-1734
      author: Zakria, Danny; Brownstone, Nicholas; Dirr, McKenzie; Rigel, Darrell
       title: Erythrasma Under Wood's Lamp and the Coral Red Glow
        date: 2022-09-12
       words: 658
      flesch: 48
     summary: Topical therapy consists of clindamycin, fusidic acid, mupirocin, and Whitfield’s ointment while systemic therapy includes oral clarithromycin, erythromycin, and tetracycline.4 There is no consensus on optimal first-line agent, but topical therapy is generally preferred to limit adverse effects.1 For intertriginous disease, it is important to add a topical agent, often in conjunction with systemic therapy, in order to obtain clearance.4 While there is limited data on duration of treatment, most studies suggest a 2-week course. Published by the National Society for Cutaneous Medicine.
    keywords: erythrasma; medicine; therapy
       cache: skin-1734.pdf
  plain text: skin-1734.txt

        item: #516 of 1356
          id: skin-1735
      author: Christensen, Rachel; Powers, Colleen; Mockbee, Chelsea; Brodell, Robert
       title: Petaloid Seborrheic Dermatitis: A Variant Described Primarily in Skin of Color
        date: 2023-03-13
       words: 1730
      flesch: 50
     summary: Recognizing the symmetry and classic distribution of petaloid seborrheic dermatitis, a KOH preparation was not performed. Recognition of petaloid seborrheic dermatitis will prevent misdiagnosis and improper treatment of this common condition.
    keywords: daily; dermatitis; petaloid; seborrheic; skin
       cache: skin-1735.pdf
  plain text: skin-1735.txt

        item: #517 of 1356
          id: skin-1736
      author: Green, Jackson; Nye, Jessica; Turner, Kelly; Greives, Matthew R; Mowrey, Kate; Herbert, Adelaide A; Atkinson, Autumn
       title: Malignant Melanoma within a Giant Congenital Melanocytic Nevus in a Pediatric Patient
        date: 2023-01-10
       words: 1485
      flesch: 52
     summary: 608 BRIEF ARTICLE Malignant Melanoma within a Giant Congenital Melanocytic Nevus in a Pediatric Patient Jackson Green, BS4, Jessica Nye, BS4, Kelly Turner, PA3,4, Matthew R. Greives, MD3,4, Kate Mowrey, MS, CGC1,4, Adelaide A. Hebert, MD1,2,4, Autumn Atkinson, MD1,4 1Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, TX 2Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX 3Department of Plastic Surgery, University of Texas Health Science Center at Houston, Houston, TX 4University of Texas McGovern Medical School at Houston, Houston, TX Congenital melanocytic nevi (CMN) pose a constellation of challenges that include cosmetic and functional disfigurement, reduction in self-esteem, and the potential to develop into malignant melanoma.1, 2 Giant CMNs are defined by pigmented proliferations that are greater than 20 cm2 in diameter, and these occur in 1 in 20,000 births, most commonly on the trunk, upper extremities and head and neck regions.2, 3 CMNs can change in size and appearance with age from a flat brown plaque to a pigmented and hairy plaque with erosions, ulcerations, or a thickened verrucous surface.4 While all CMNs have the potential to transform into malignant melanoma, the highest risk of malignant transformation resides in giant congenital melanocytic nevi with reports of this transformation being as high as 14%.1-5 Regular dermatologic screenings by pediatricians are vital to assess changes in giant congenital nevi over time.4 Early biopsy and possible surgical intervention can help identify early transformation and potentially reduce the sequelae of melanoma.4 A male infant was born at 39 weeks and 6 days gestation to a 23-year-old primigravida mother who obtained appropriate prenatal care throughout the pregnancy. The patient was evaluated in the Vascular ABSTRACT While giant congenital melanocytic nevi are rare lesions in the pediatric population, malignant transformation within these lesions remains even more rare.
    keywords: houston; melanocytic; melanoma; nevi; pediatric
       cache: skin-1736.pdf
  plain text: skin-1736.txt

        item: #518 of 1356
          id: skin-1738
      author: Darnall, Ariel; Olsen, Rebecca; Hamann, Dathan; Estrada, Sarah
       title: Cutaneous Prostate Adenocarcinoma Masquerading as Cellulitis
        date: 2023-05-20
       words: 1743
      flesch: 45
     summary: To accurately distinguish cutaneous prostatic metastases from other conditions, a through history and physical exam focusing on palpation and tissue texture, combined with supportive diagnostics, can guide clinicians in differentiating malignancy from other benign skin conditions. In a study of 15 cases of cutaneous zosteriform metastases, seven of the cases were initially misdiagnosed as a herpes zoster infection and treated with antiviral medications.10 The variable presentation of cutaneous metastases of prostate cancer makes it difficult to diagnose, often resulting in delayed or improper treatment.
    keywords: cancer; cellulitis; diagnosis; lesions; metastasis; prostate; skin
       cache: skin-1738.pdf
  plain text: skin-1738.txt

        item: #519 of 1356
          id: skin-174
      author: Blauvelt, Andrew; Leonardi, Craig; Zachariae, Claus; Burge, Russel; Ridenour, Terri; McKean-Matthews, Missy; Garces, Sandra; Cameron, Gregory
       title: Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis
        date: 2017-10-27
       words: 1890
      flesch: 55
     summary: WEEK 20 20-32 Wks WEEK 0 of OLE Long-term Open-label Treatment WEEK 240 WEEK 260 Entered Part C (Week 244-260) N=73c Part A Part B Part C DLQI=Dermatology Life Quality Index; LOCF=last observation carried forward; PASI 75/90/100=Psoriasis Area and Severity Index 75%/90%/100% response; Fall Clinical Dermatology Conference (Fall CDC 2017); Las Vegas, Nevada; October 12-15, 2017; Previously presented at EADV 2017 Sponsored by Eli Lilly and Company and/or one of its subsidiaries Disclosures ♦ A. Blauvelt has served as a scientific adviser and/or clinical study investigator for: AbbVie, Aclaris, Allergan, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Genentech/Roche, GlaxoSmithKline, Janssen, Leo Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB, Valeant, and Vidac, and as a paid speaker for Eli Lilly and Company, Janssen, Regeneron, and Sanofi Genzyme; K. Gordon has served as a consultant for: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly and Company, Janssen, Novartis, and Pfizer, and has received grants from: AbbVie, Amgen, Celgene, Eli Lilly and Company and Janssen; C. Leonardi is on the speaker’s bureau of: AbbVie, Celgene, and Leo Pharma, is a consultant for: AbbVie, Amgen, Dermira, Eli Lilly and Company, Janssen, Leo Pharma, Pfizer, Sandoz, and UCB Pharma, has a conflict with: Actavis, AbbVie, Amgen, Celgene, Coherus, Cermira, Eli Lilly and Company, Galderma, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Sandoz, Stiefel, and Wyeth; C. Zachariae has received honoraria from: Eli Lilly and Company, Novartis, and Pfizer, and has consulted for and participated in advisory boards for: AbbVie, Amgen, Eli Lilly and Company, Janssen-Cilag, Novartis, and Takeda and has been a clinical study investigator for: AbbVie, Amgen, Eli Lilly and Company, Leo Pharma, MSD, Novartis, Regeneron, and Takeda; R. Burge, T. Ridenour, M. McKean-Matthews, S. Garces, and G. Cameron are shareholders and employees of Eli Lilly and Company
    keywords: company; eli; lilly; pasi; treatment; weeks
       cache: skin-174.pdf
  plain text: skin-174.txt

        item: #520 of 1356
          id: skin-1740
      author: Shope, Chelsea; Andrews, Laura; Linkous, Courtney; Sagut, Pelin; Wine Lee, Lara
       title: Predicting Skin Cancer Development after Liver Transplant
        date: 2023-01-10
       words: 1937
      flesch: 57
     summary: Sequalae includes increased risk for malignancies, most commonly skin cancer.2 Risk of skin cancer is correlated with type of organ transplanted,3 however, the majority of literature elucidating skin cancer risk is in kidney recipients.4 While liver recipients is reported as lowest risk for skin cancer, there is less data compared to kidney graft recipients, and the incidence rates reported are wide.5
    keywords: cancer; liver; recipients; risk; skin; transplant
       cache: skin-1740.pdf
  plain text: skin-1740.txt

        item: #521 of 1356
          id: skin-1741
      author: Lawson, Olivia; Langley, Collins; Davis, Michael
       title: Psoriasiform Eruption in an Immunocompromised Neurosyphilis Patient
        date: 2022-11-16
       words: 789
      flesch: 56
     summary: Diffuse papulosquamous rash on the upper back and shoulders Figure 2. Thick, scaling, psoriasiform rash on the palms (a) and soles (b).
    keywords: medicine; rash; syphilis
       cache: skin-1741.pdf
  plain text: skin-1741.txt

        item: #522 of 1356
          id: skin-1743
      author: Dirr, McKenzie A.; Bailey , Alison M. ; Marchell, Richard 
       title: Successful Treatment of Cutaneous Siderosis with Pulsed Dye Laser
        date: 2022-11-16
       words: 804
      flesch: 56
     summary: Abbreviations iron deficiency anemia (IDA) Quality-switched (Q-switched) pulsed dye laser (PDL) Conflict of Interest Disclosures: Pulsed dye laser (PDL) was the only laser available in clinic for treatment.
    keywords: iron; laser; pdl; treatment
       cache: skin-1743.pdf
  plain text: skin-1743.txt

        item: #523 of 1356
          id: skin-1746
      author: Margulies, Shae; Nagrani, Nicole; Rodriguez-Waitkus, Paul; Correa-Selm, Lilia
       title: Adult-Onset Still’s Disease with an Atypical Cutaneous Manifestation
        date: 2022-11-16
       words: 1803
      flesch: 45
     summary: Persistent pruritic papules and plaques associated with adult-onset Still’s disease: Report of six cases. Patidar, A., Parikh, P. M., Balai, M., & Mittal, A. (2020).
    keywords: adult; aosd; disease; rash; skin
       cache: skin-1746.pdf
  plain text: skin-1746.txt

        item: #524 of 1356
          id: skin-1748
      author: De, Devea;  Shih, Terri; Atluri, Swetha; Fixsen, Denise; Brooks, Brindley; Hsiao, Jennifer; Shi, Vivian
       title: Support Group Utilization and Perspectives Among Hidradenitis Suppurativa Patients
        date: 2022-11-16
       words: 1415
      flesch: 52
     summary: This study investigates the perspectives of HS patients on HS support groups and the usage of this resource among this population. Data regarding demographics, use, and perspectives of HS support groups was collected.
    keywords: groups; patients; respondents; support
       cache: skin-1748.pdf
  plain text: skin-1748.txt

        item: #525 of 1356
          id: skin-1749
      author: Levin, Adam; Guyara, Armaan; Athalye, Leela
       title: A Violaceous Mass of the Chest: An Unsuspected Diagnosis of Primary Ewing Sarcoma
        date: 2023-05-20
       words: 1073
      flesch: 55
     summary: To date, only a few cases of primary cutaneous Ewing Sarcoma have been published. We present a unique case of primary cutaneous Ewing Sarcoma, which presented as a blue to violaceous mass on a young woman’s chest.
    keywords: ewing; sarcoma; tumors
       cache: skin-1749.pdf
  plain text: skin-1749.txt

        item: #526 of 1356
          id: skin-175
      author: van der Heijde, Desiree; Okada, Masato; Lee, Chin; Shuler, Catherine L; Rathmann, Suchitrita; Lin, Chen-Yen; Mease, Philip J
       title: Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
        date: 2017-10-27
       words: 2741
      flesch: 62
     summary: IXE Q4W PBO (Washout) PBO (Washout) IXE Q2W IXE Q2W IXE Q2W IXE Q2W IXE Q4W IXE Q4W IXE Q4W IXE Q4W IXE Q2W R RPBO R PBO (Washout) + RTa IXE Q2W + RTa IXE Q4W + RTa IXE Q2W IXE Q2W + RTa IXE Q4W IXE Q4W + RTa ADAb R PBO (Washout) + RTa Screening Extension PeriodDouble-blind Treatment Period WEEK 0 80 mg IXE every 4 weeks IXE Q2W: 80 mg IXE every 2 weeks ADA: 40 mg ADA every 2 weeksb 417 patients randomized 1:1:1:1 R ADAb (N=101) IXE Q4W (N=107) IXE Q2W (N=103) PBO (N=106) METHODS Exclusion Criteria ♦ Current or prior use of biologic agents for treatment of psoriasis or psoriatic arthritis ♦ Inadequate response to ≥4 cDMARDs ♦ Current use (at study entry) of >1 cDMARD ♦ Serious infection within 3 months prior to randomization CASPAR=Classification Criteria for Psoriatic Arthritis; cDMARD=conventional disease-modifying antirheumatic drug Assessment of Structural Joint Damage ♦ Assessed using the van der Heijde modified Total Sharp Score (mTSS) • Quantifies the extent of bone erosions (20 locations per hand/wrist, 12 locations per foot) and joint space narrowing (20 locations per hand/wrist, 6 locations per foot)
    keywords: ixe; mtss
       cache: skin-175.pdf
  plain text: skin-175.txt

        item: #527 of 1356
          id: skin-1751
      author: Momin, Fareen; Reese, Vail; Wagner Jr., Richard F.
       title: Dermatological Findings in Children’s Films
        date: 2023-05-20
       words: 1548
      flesch: 39
     summary: A subsequent study analyzed animated films for the use of dermatological findings and found significantly more skin findings in antagonists compared to protagonists. Methods: To better understand how the use of dermatological findings are changing in the film industry, eighteen Disney live-action movies in relation to their earlier animated releases were compared for changes or correlation on how the industry portrays certain characters based on their roles as heroes or villains.
    keywords: antagonists; film; findings; number
       cache: skin-1751.pdf
  plain text: skin-1751.txt

        item: #528 of 1356
          id: skin-1752
      author: Broderick, John; Selby, Thomas; Trevino, Julian
       title: Aquagenic Urticaria in an Adolescent Following COVID-19 Vaccine
        date: 2022-11-16
       words: 1814
      flesch: 48
     summary: Cutaneous reactions to COVID- 19 mRNA booster vaccinations have been reported, including reactions in patients that did not have cutaneous reactions to primary vaccine doses.12 We predict similar symptoms in response to a booster vaccination because of activation of memory B cells and production of antibodies. They can accurately interpret skin reactions and provide guidance regarding further vaccination.
    keywords: covid-19; patient; reactions; urticaria; vaccination; vaccine; water
       cache: skin-1752.pdf
  plain text: skin-1752.txt

        item: #529 of 1356
          id: skin-1753
      author: Arora, Puneet; Tomac, Tracy
       title: Psoriatic Arthritis Flare in a Hospitalized Patient with Schizoaffective Disorder: A Case Report
        date: 2023-05-20
       words: 1681
      flesch: 43
     summary: In recent years, large studies have observed an increased prevalence of psoriasis in patients with schizophrenia spectrum disorders (3.3%) and broadly unspecified psychosis (35%).4 Several studies have found that the risk of psoriasis among patients with schizophrenia is significantly higher than in those without it, possibly explained by T helper 17 (Th17) activation, the main immunological trigger of psoriasis.5,6 Due to the nature of severe psychiatric illnesses, patient’s length of stay in the hospital can vary greatly from 72-hour ABSTRACT Psoriasis is a known comorbid condition in patients with schizophrenia spectrum disorders. While a recent retrospective study found both ixekizumab and the similar IL-17A antagonist secukinumab to be highly effective for the short and long-term treatment of psoriasis, further studies exploring the efficacy of these medications in treatment-resistant patients is needed.8 Both medications have the benefit of monthly IM dosing, an important consideration in patients with history of inconsistent adherence.
    keywords: arthritis; ixekizumab; patients; psoriasis; psoriatic; treatment
       cache: skin-1753.pdf
  plain text: skin-1753.txt

        item: #530 of 1356
          id: skin-1754
      author: Fischer, Daniel ; Teplitz, Rebeca; Litchman, Graham; Rozenberg, Suzanne Sirota
       title: An Atypical Case of Granulomatosis with Polyangiitis with Cutaneous Features in a 19-year-old Female
        date: 2022-11-16
       words: 892
      flesch: 43
     summary: Although the pulmonary and renal systems are most commonly impacted, GPA manifests with cutaneous findings in approximately 34% of patients. Skin lesions may be the initial presenting finding in about 13% of patients, however they do not typically manifest until 12-15 months of disease onset.2 The most common skin finding is palpable purpura involving the lower extremities (16%), followed by painful subcutaneous nodules(9.4%), maculopapular rash (6.7%), and papulonecrotic lesions that typically affect the face, scalp, and extremities(4.76%).3,4
    keywords: case; http://paperpile.com/b/nuoy1h/0adm; http://paperpile.com/b/nuoy1h/kyn1; http://paperpile.com/b/nuoy1h/vp0e
       cache: skin-1754.pdf
  plain text: skin-1754.txt

        item: #531 of 1356
          id: skin-1757
      author: Sathe, Nishad; Bershow, Andrea
       title: Cutaneous Involvement of Angioimmunoblastic T-cell Lymphoma
        date: 2023-01-10
       words: 690
      flesch: 40
     summary: The presence of skin involvement implies an advanced clinical stage, which confers a poorer prognosis.4 Due to its variable presentations in the skin, it is often misdiagnosed as a vasculitis or exanthem, particularly when its initial presentation is in the skin without prior diagnosis of internal AITL malignancy.3 The patient’s clinical stage was changed from stage II to stage IV AITL due to skin involvement, and the patient was started on CHOP treatment.
    keywords: aitl; lymphoma; skin
       cache: skin-1757.pdf
  plain text: skin-1757.txt

        item: #532 of 1356
          id: skin-1758
      author: Garcia, Natalie; Jiminez, Victoria; Smith, Abigail ; Theos, Amy
       title: Focal Hypertrichosis in an Infant as the Presenting Sign of Nevoid Basal Cell Carcinoma Syndrome
        date: 2023-01-10
       words: 745
      flesch: 57
     summary: Over the next ten years, she was followed by an outside dermatologist where she was treated for hundreds of basal cell carcinomas with multiple modalities including imiquimod cream, electrodessication and curettage, and CO2 laser under general anesthesia. She was diagnosed with localized hypertrichosis and no further workup was pursued.
    keywords: cell; hypertrichosis; syndrome
       cache: skin-1758.pdf
  plain text: skin-1758.txt

        item: #533 of 1356
          id: skin-1759
      author: Htet, Kyaw; Bui, Theresa; Srivastav, Apurv; Murina, Andrea; Kuraitis, Drew
       title: Financial Burden of Parking Fees for Phototherapy Patients: A Cross-Sectional Study
        date: 2023-01-10
       words: 1374
      flesch: 52
     summary: Full information (parking costs, city cost of living and transit score) was only available for 177 sites (Table 1). cThe n value represents the clinical sites with full information available for analysis (parking costs, city cost of living and transit score)
    keywords: cost; living; parking; phototherapy; score
       cache: skin-1759.pdf
  plain text: skin-1759.txt

        item: #534 of 1356
          id: skin-176
      author: Schreiber, Rhonda; Crane, Kaytiana; Patel, Juhin
       title: Efficacy and Tolerability of Tazarotene Foam 0.1% Across Age, Gender, and Race: An Integrated Review of Two Phase III Trials
        date: 2017-10-27
       words: 1259
      flesch: 59
     summary: % o f S u b je c ts Tazarotene Foam Vehicle Foam 32.7% 23.6% 15.9% 13.5% 0% 5% 10% 15% 20% 25% 30% 35% Females (n=756) % o f S ub je ct s Tazarotene Foam Vehicle Foam OBJECTIVES Evaluate the efficacy and tolerability of tazarotene foam 0.1%
    keywords: age; foam; tazarotene; vehicle
       cache: skin-176.pdf
  plain text: skin-176.txt

        item: #535 of 1356
          id: skin-1760
      author: Crasto, David Walton; Lutwak, Moises; Krajewski, Eduardo; Weiss, Eduardo 
       title: Anal Monkeypox Lesions
        date: 2022-11-16
       words: 732
      flesch: 47
     summary: Given the high index of suspicion for Monkeypox infection, a lesional swab was sent for polymerase chain reaction (PCR) and found positive for Orthopoxvirus DNA. Based on the history, clinical, and pathologic findings, coupled with the PCR results, a diagnosis of Monkeypox infection was made.
    keywords: infection; lesions; miami; monkeypox
       cache: skin-1760.pdf
  plain text: skin-1760.txt

        item: #536 of 1356
          id: skin-1762
      author: Ingrassia, Jenne; Maher, Jacqueline; Cline, Abigail
       title: A Review of the Risk of Cutaneous Squamous Cell Carcinoma after Vismodegib Therapy
        date: 2022-11-16
       words: 2841
      flesch: 58
     summary: The duration of vismodegib treatment until cSCC development ranged from 2 weeks to 2.7 years across all studies included. Of the 25 articles included, 14 reported patient outcome data and statistics on cSCC development after vismodegib treatment.
    keywords: carcinoma; cell; cscc; study; treatment; vismodegib
       cache: skin-1762.pdf
  plain text: skin-1762.txt

        item: #537 of 1356
          id: skin-177
      author: Albareda, Nuria; Rosenberg, Noah; Roth, Sandra; Zsolt, Ilonka; Rosen, Theodore; Hebert, Adelaide A
       title: Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results
        date: 2017-10-27
       words: 1067
      flesch: 44
     summary: Key secondary efficacy endpoints: • Clinical response at Visit 3 incorporating combined criteria of clinical success (reflecting previously accepted methodology for other topical antibiotics approved for impetigo) and Microbiological response at visits 2 and 3. Combined criteria of clinical response was defined as clinical success or improvement.
    keywords: cream; ozenoxacin; visit
       cache: skin-177.pdf
  plain text: skin-177.txt

        item: #538 of 1356
          id: skin-1772
      author: Preda-Naumescu, Ana; Sowell, Josiah; Weir, Sydney; Srikakolapu, Siddharth; Patel, Om; Aldana, Isabella; Garcia, Natalie; Kole, Lauren
       title: Community Educational Interventions: An Effective Means to Improve Photoprotection and Skin Cancer Awareness in Outdoor Occupational Workers
        date: 2023-01-10
       words: 1597
      flesch: 42
     summary: Review of the literature on outdoor workers' sun related knowledge, attitudes, and protective behaviors found that photoprotective behaviors are not widely implemented or recognized among outdoor working professionals.1,2,3,4 Safety education programs have the potential to improve ABSTRACT Introduction: Outdoor workers are at increased risk for developing skin cancer compared to the general population due to environmental conditions at work sites and riskier behavior regarding skin cancer risk factors. Two-sample paired t-test performed for each of the 10 questions was statistically significant with a p <0.05 suggesting community-based education efforts may improve awareness regarding photoprotection and skin cancer risk, and ultimately mitigate behavior.
    keywords: cancer; outdoor; risk; skin
       cache: skin-1772.pdf
  plain text: skin-1772.txt

        item: #539 of 1356
          id: skin-1776
      author: Shope, Chelsea; Andrews, Laura; DeVore, Ansley; Wine Lee, Lara; Wagner, Carol
       title: Melasma is Associated with Lower Serum Vitamin D Concentrations as Compared to Healthy Controls
        date: 2023-05-20
       words: 1434
      flesch: 50
     summary: Calcidiol (25-hydroxy- vitaminD) was utilized as a surrogate for vitamin D level. 796 basal layer of the epidermis.1,6 Activation of VDR causes inhibition of growth of both normal and malignant melanocytes.1 Epidermal proliferation and differentiation also occurs via VDR in keratinocytes.6 It has also been suggested that VDR may influence androgen and estrogen activation, which are proposed to play a role in the pathogenesis of melasma.1 Given this understanding of the VDR, one would expect vitamin D levels to be normal or even elevated in patients with melasma, a disease characterized by overactive melanocytes, and that is especially prevalent in pregnant women.
    keywords: melasma; patients; skin; vitamin
       cache: skin-1776.pdf
  plain text: skin-1776.txt

        item: #540 of 1356
          id: skin-1778
      author: Strober, Bruce; Bukhalo, Michael; Armstrong, April; Pariser, David; Kircik, Leon; Parhami, Sepideh; Montgomery, Paul; Dickerson, Tobin
       title: Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
        date: 2022-11-16
       words: 1855
      flesch: 51
     summary: MATCH-MND is the informed arm where patient test results are provided, and MATCH-TAU is a treatment as usual arm where test results are not provided to physicians. Px test results provided to physicians prior to biologic selection.
    keywords: medicine; mind.px; patients; psoriasis; results; test
       cache: skin-1778.pdf
  plain text: skin-1778.txt

        item: #541 of 1356
          id: skin-178
      author: Albareda, N; Zeichner, J; Rosenberg, N
       title: A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 412 Patients 2 Months and Older with Impetigo
        date: 2017-10-27
       words: 1027
      flesch: 42
     summary: Results After 5 days of treatment, ozenoxacin demonstrated clinical superiority to vehicle in clinical response, both for the primary endpoint as well as for the prespecified secondary endpoint of combined criteria of clinical success. The primary efficacy endpoint was clinical response (success or failure) at end of therapy (Visit 3) analyzed in the intent-to-treat clinical (ITTC) population.
    keywords: ozenoxacin; vehicle; visit
       cache: skin-178.pdf
  plain text: skin-178.txt

        item: #542 of 1356
          id: skin-1780
      author: Roster, Katie; Mulvihill, Hannah; Lakhi , Nisha 
       title:  A Missed Diagnosis of Alpha-gal Allergy in the Northern United States: A Case Report
        date: 2023-03-13
       words: 1467
      flesch: 60
     summary: This mimicking type of rash, known as Southern tick-associated rash illness (STARI), is not associated with Borrelia burgdorferi infection.9 More research is needed to determine if the population of Lone Star tick is increasing in the northern United States, or if alpha-gal syndrome is associated with additional tick species not previously reported. When sensitization occurs, patients present with gastrointestinal symptoms, urticaria, and possible anaphylaxis 3-6 hours after meat ingestion due to an immune-mediated immunoglobulin E (IgE) antibody reaction to alpha-gal, also found in non-primate mammals.1,2,3,8 Diagnosis includes an IgE antibody blood test.
    keywords: alpha; case; gal; syndrome; tick
       cache: skin-1780.pdf
  plain text: skin-1780.txt

        item: #543 of 1356
          id: skin-1782
      author: Salusti-Simpson, Michela; Porter , Hannah ; Taylor, Dustin; Piette , Evan 
       title: Blastomycosis-Like Pyoderma in a 59-year-old Male with Type 2 Diabetes Mellitus
        date: 2023-05-20
       words: 1392
      flesch: 45
     summary: Directed antibiotics have been the mainstay of treatment for BLP, although many patients do not experience full resolution. 844 BRIEF ARTICLE Blastomycosis-Like Pyoderma in a 59-year-old Male with Type 2 Diabetes Mellitus Michela Salusti-Simpson, BA1, Hannah Porter, MD, MBA, MS1, Dustin Taylor, MD2, Evan Piette, MD1 1University of Vermont Medical Center, Burlington, VT 2Brigham and Women’s Hospital, Boston, MA Blastomycosis-like pyoderma (BLP) is a rare cutaneous disorder that results from an exaggerated response to a bacterial infection, most commonly Staphylococcus aureus.
    keywords: blastomycosis; blp; case; patient; pyoderma
       cache: skin-1782.pdf
  plain text: skin-1782.txt

        item: #544 of 1356
          id: skin-1784
      author: Chokshi, Aditi; Diaz, Amaury
       title: Syphilis in HIV Positive Individuals and the Importance of a Skin Exam: A Case Report
        date: 2023-07-17
       words: 1406
      flesch: 47
     summary: If progression to tertiary syphilis occurs, patients can develop severe complications such as gummas, aortitis, tabes dorsalis, and argyll robertson pupils.2 Syphilis in HIV- infected patients often has an atypical presentation with higher rates of asymptomatic primary syphilis and accelerated disease progression. Consequently, syphilis amongst HIV patients often goes undiagnosed until it has progressed to the secondary stage of disease.3Secondary infection in HIV patients is more aggressive with increased rates of neurocognitive effects and ophthalmic involvement.4 A 68-year-old HIV-positive male presented with perianal painless erythematous lesions for a 6-week duration.
    keywords: hiv; patients; primary; skin; syphilis
       cache: skin-1784.pdf
  plain text: skin-1784.txt

        item: #545 of 1356
          id: skin-1785
      author: Ramesh, Malvika; Hope, Landon; Hope, Richard  ; Cockerell, Clay
       title: Late Onset Pseudolymphomatous Reaction to Blue Tattoo Pigment Precipitated by Covid Vaccination
        date: 2023-01-10
       words: 1583
      flesch: 50
     summary: Covid-19 infection and vaccination may induce a brisk immune response that may be a hyperimmune response in some patients and has been associated with cutaneous inflammatory reactions [ Front. Immunol., 30 September 2021 Sec. 597 phenomenon which should be added to the list of cutaneous reactions that can follow Covid-19 vaccination.
    keywords: cutaneous; papules; pseudolymphoma; reactions; tattoo; vaccination
       cache: skin-1785.pdf
  plain text: skin-1785.txt

        item: #546 of 1356
          id: skin-1787
      author: Seck, Sokhna; Bullock, Taylor; Khetarpal, Shilpi
       title: Treatment of Cutaneous Lesions in a Case of Blue Rubber Bleb Nevus Syndrome 
        date: 2023-03-13
       words: 846
      flesch: 54
     summary: Venous malformation with the morphology of a friable plaque on the left labia majora. Venous malformations typically cause pain due to thrombosis and can increase in size in response to trauma, thrombosis, or hormones.
    keywords: lesions; syndrome; venous
       cache: skin-1787.pdf
  plain text: skin-1787.txt

        item: #547 of 1356
          id: skin-1788
      author: Saleeby, Eli; Bielinski, Kenneth; Fitzgerald, Alison; Siegel, Jennifer; Ibrahim, Sherrif
       title: A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)
        date: 2022-11-16
       words: 6199
      flesch: 49
     summary: Roscher I, Falk RS, Vos L, et al: Notice of Retraction and Replacement: Roscher et al. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population- Based Data: A Nested Case-Control Study. These clinical treatment plan actions are not surprising given that GEP tests have been widely used and advocated for as risk- stratification factors that influence treatment plans in various cancer types.38–47 Specifically, the results described here and within Hooper et al.,36 mirror those of other risk-stratification gene expression profile tests (Table 4).
    keywords: cancer; carcinoma; cell; class; clinical; cscc; gep; management; patients; results; risk; study; test; treatment
       cache: skin-1788.pdf
  plain text: skin-1788.txt

        item: #548 of 1356
          id: skin-1789
      author: Ponnurangam, Rekha Gurunatham; Ramasamy, Sindhuja; Venu, Sridhar; Vijayananth, Jayakalyani
       title: A Randomized Controlled Study of Topical Benzoyl Peroxide with Oral Doxycycline Versus Topical Benzoyl Peroxide with Oral Lymecycline in Acne Vulgaris
        date: 2023-07-17
       words: 3298
      flesch: 57
     summary: Patients who were on topical or systemic anti acne medications in the last 1month, females yet to complete their family, pregnant and lactating females, patients with known hypersensitivity to any of the components of the study medication, history of regional enteritis/ulcerative colitis/antibiotic associated colitis, severe hepatic, renal or photosensitive disease were excluded from the study. 2 Tetracyclines are the most common oral antibiotic prescribed for acne vulgaris in patients above 12 years.
    keywords: acne; group; lymecycline; patients; study; weeks
       cache: skin-1789.pdf
  plain text: skin-1789.txt

        item: #549 of 1356
          id: skin-179
      author: Albareda, N; Zeichner, J
       title: A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 465 Patients 2 Years and Older with Impetigo
        date: 2017-10-27
       words: 1131
      flesch: 38
     summary: A secondary comparison (for internal validity) of retapamulin versus vehicle was done for the analysis of clinical response (clinical success or clinical failure) at the end of therapy visit (Visit 3) in the ITTC population. This broader definition of clinical success includes improvement, and reflects the same criteria for clinical success as that used in pivotal Phase 3 clinical trials of other topical antibiotics approved for impetigo.
    keywords: ozenoxacin; success; visit
       cache: skin-179.pdf
  plain text: skin-179.txt

        item: #550 of 1356
          id: skin-1790
      author: Burns, Meredith; Orlowski, Timothy; Ho-Pham, Hoang; Elston, Carly; Elewski, Boni
       title: New Onset Generalized Pustular Psoriasis Rapidly Improved with IL-36 Blockade
        date: 2023-01-10
       words: 1687
      flesch: 36
     summary: We present a case of generalized pustular psoriasis with complete response to spesolimab, an IL-36 receptor antagonist monoclonal antibody that recently became the first FDA-approved therapy for this condition. Both her cutaneous and articular disease had been well-controlled on guselkumab since February 2021 with minimal localized cutaneous disease after failing therapy with adalimumab, etanercept, ustekinumab, ABSTRACT Generalized pustular psoriasis is a relatively rare variant of psoriasis characterized by diffuse eruption of sterile pustules on an erythematous background.
    keywords: psoriasis; pustules; receptor; skin; spesolimab; treatment
       cache: skin-1790.pdf
  plain text: skin-1790.txt

        item: #551 of 1356
          id: skin-1793
      author: O'Connell, Katie; Youssef, Ronnie M; Torres, Angeli Eloise; Huggins, Richard H
       title: Perspectives of Vitiligo Patients: Voices from National Vitiligo Conferences
        date: 2023-07-17
       words: 1916
      flesch: 55
     summary: Insurance coverage for vitiligo treatments varies greatly despite robust data showing treatment efficacy in delaying disease progression.5 During the US-WVDs only a small number of those surveyed reported full insurance coverage for vitiligo treatment and, from 2020 to 2021 this number dropped even further. Additionally, dermatologists should advocate for coverage of vitiligo treatment, while also taking insurance coverage into account when discussing treatment options.
    keywords: effects; insurance; patients; treatment; vitiligo
       cache: skin-1793.pdf
  plain text: skin-1793.txt

        item: #552 of 1356
          id: skin-1794
      author: McKinley, Jayvon; Kresch-Vatch, Mindy
       title: Traction Alopecia in the Beard
        date: 2023-01-10
       words: 751
      flesch: 62
     summary: Traction alopecia in the beard. Traction alopecia: 2% topical minoxidil shows promise.
    keywords: alopecia; hair
       cache: skin-1794.pdf
  plain text: skin-1794.txt

        item: #553 of 1356
          id: skin-1795
      author: Zakria, Danny; Brownstone, Nicholas; Rigel, Darrell
       title: The Integrated 31-Gene Expression Profile (i31-GEP) Test for Cutaneous Melanoma Outperforms a Clinicopathologic-only Nomogram at Identifying Patients who can Forego Sentinel Lymph Node Biopsy
        date: 2022-11-16
       words: 4097
      flesch: 59
     summary: The i31-GEP for SLNB identified 28.5% (166/582) of patients as having a <5% risk of SLN positivity while also having an upper 95% CI ≤10% compared with 0.9% (5/582, p<0.001) using the MIA nomogram. The i31-GEP for SLNB identified 28.5% (166/582) as having both <5% risk of positivity and an upper 95% CI ≤10% compared to 0.9% (5/582, p<0.001) using the MIA nomogram (Figure 2).
    keywords: gep; i31; melanoma; mia; nomogram; patients; positivity; risk; slnb
       cache: skin-1795.pdf
  plain text: skin-1795.txt

        item: #554 of 1356
          id: skin-1796
      author: Glazer, Alex; Tassavor, Michael; Portela, Dustin; Soleymani, Teo
       title: The Integrated 31-Gene Expression Profile Test (i31-GEP) for Cutaneous Melanoma Outperforms the CP-GEP at Identifying Patients who can Forego Sentinel Lymph Node Biopsy when Applying NCCN Guidelines
        date: 2022-11-16
       words: 3719
      flesch: 57
     summary: Each of the 2 GEP tests analyzed used different genes and statistical methods during development16,28, similar to GEP tests in breast cancer, including the 21-GEP assay (Oncotype DX Breast) and the 50-gene assay (Prosigna).4,29,30 Therefore, understanding each tool’s development and validation process is important when assessing the utility of the tests. The 31-GEP has been integrated with clinical and pathological factors using a neural network algorithm to provide an individualized, precise risk of SLN positivity (i31-GEP).12 Of the variables included in the i31-GEP neural network, the 31-GEP risk score was the most significant contributor to the model.12 The CP-GEP model was developed using LASSO (logistic regression and least absolute shrinkage and selection operator), combining an 8-GEP gene signature with age and Breslow thickness, with three retrospective validation studies.14,15,19,34 However, the GEP portion of the CP-GEP model has not shown independent prognostic information from Breslow thickness and age (CP) using multivariable analysis,14,35 and Bartlett et al. called into question the utility of the CP-GEP compared to CP alone to guide SLNB.35
    keywords: gene; gep; i31; melanoma; patients; risk; slnb
       cache: skin-1796.pdf
  plain text: skin-1796.txt

        item: #555 of 1356
          id: skin-1797
      author: Dirr, McKenzie A. ; Bitterman, Avi ; Al-Dehneem, Roudha; Gottlieb, Alice B.
       title: Successful Treatment of Morphea with Topical Ruxolitinib 
        date: 2023-03-13
       words: 799
      flesch: 47
     summary: Ruxolitinib is a Janus-Kinase (JAK) 1 and 2 inhibitor with anti-inflammatory properties.4,5 Ruxolitinib works by blocking the receptor-associated protein kinases JAK1 and JAK2, inhibiting the JAK-STAT pathway.4,5 When JAK1 and JAK2 are active, this pathway produces inflammatory cytokines and hematopoiesis.4,5 Ruxolitinib blocks this mechanism, downregulating the production of pro-inflammatory cytokines, such as IL-2 and IL-6, and thus decreasing the damaging effects of inflammation.4,5 Interestingly, ruxolitinib has been found to be efficacious in other inflammatory processes, including atopic dermatitis and psoriasis.4 Right shoulder hyperpigmentation before (left) and after (right) 3 months of topical ruxolitinib 1.5% cream.
    keywords: morphea; patient; ruxolitinib; skin
       cache: skin-1797.pdf
  plain text: skin-1797.txt

        item: #556 of 1356
          id: skin-18
      author: Dong, Joanna; Bonomo, Lauren; Lebwohl, Mark
       title: Common Adverse Drug-Drug Interactions in Dermatology: Oral Therapies
        date: 2017-08-31
       words: 4130
      flesch: 44
     summary: 14 The three most commonly prescribed macrolides exhibit varying propensities to inhibit CYP3A4 and cause drug interactions: erythromycin most strongly, clarithromycin less so, and azithromycin has no effect on CYP3A4. Chan AJ, Rajakumar I. High-dose methotrexate in adult oncology patients: A case-control study assessing the risk association between drug interactions and methotrexate toxicity.
    keywords: acitretin; allopurinol; clin; cyclosporine; dermatol; drug; epinephrine; interactions; isotretinoin; mtx; patients; risk; skin; spironolactone; treatment; use
       cache: skin-18.pdf
  plain text: skin-18.txt

        item: #557 of 1356
          id: skin-180
      author: George, Rosalyn; Schlessinger, Joel; Lupin, Mark; Amato, David; McDaniel, David
       title: Evaluation of the Safety and Efficacy of Ultherapy for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea
        date: 2017-10-27
       words: 821
      flesch: 80
     summary: PSA improvement (≥1-grade improvement) was greatest in Group D at Day 90 (74%), Group D at Day 180 (75%), and Group B at Day 365 (76%). .0 % P ai n Sc or e Transducers Treatment Group 4-4.5mm 7-3.0mm 10-1.5mm 0 1 2 3 4 5 6 7 8 9 10 Group A Group B Group C Group D 6.5 6.7 6.4 3.9 4.9 5.9 5.55.6 3.9 4.6 4.4 4.4 % o f S ub je ct s Sh ow in g
    keywords: day; group; treatment
       cache: skin-180.pdf
  plain text: skin-180.txt

        item: #558 of 1356
          id: skin-1800
      author: Lambert, Jo; Paul, Carle; Gottlieb, Alice; Poulin, Yves
       title: Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials
        date: 2022-11-16
       words: 2931
      flesch: 60
     summary: Mean change from baseline responses in BSA and BSA × sPGA during POETYK PSO-1: Conclusions • In the POETYK PSO-1 and PSO-2 trials, deucravacitinib treatment was associated with greater improvements in BSA, BSA × sPGA, and BSA × sPGA 75 over time compared with placebo and apremilast in patients with moderate to severe plaque psoriasis • Deucravacitinib was associated with long-term improvements in response rates and maintenance of response in patients continuously treated over 52 weeks and in those who switched to deucravacitinib following 16 weeks of placebo Deucravacitinib (allosteric inhibitor) Unique TYK2 regulatory domain Catalytic domain (highly conserved across JAK family) ATP-binding active site (other kinase inhibitors)
    keywords: baseline; bsa; deucravacitinib; patients; placebo; poetyk; spga
       cache: skin-1800.pdf
  plain text: skin-1800.txt

        item: #559 of 1356
          id: skin-1801
      author: Korman, Neil; Passeron, Thierry; Gordon, Kenneth; Okubo, Yukari; Bagel, Jerry; Sofen, Howard; Warren, Richard; Bhatia, Neal; Spelman, Lynda; Winthrop, Kevin; Hippeli, Lauren; Kisa, Renata; Banerjee, Subhashis; Thaçi, Diamant
       title: Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
        date: 2022-11-16
       words: 3019
      flesch: 50
     summary: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, and UCB; Consulting fees: Almirall, Amgen, Dermira, Leo Pharma, Pfizer, and Sun Pharma • YO: Research grants: Eisai, Maruho, Shiseido, and Torii; Current consulting/advisory board agreements: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, and Sun Pharma; Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Jimro, Kyowa Kirin, Leo Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB; Clinical trials: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Maruho, Pfizer, Sun Pharma, and UCB • JB: Research funds payable to the Psoriasis Treatment Centre of New Jersey: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas’ (Corrona) Psoriasis Registry, Dermavant, Dermira/UCB, Eli Lilly, Glenmark, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; Consultant: AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; Speaker: AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis • HS: Clinical investigator: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and Sun Pharma • RBW: Research grants: AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, and UCB; Consulting fees: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, DiCE, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, UCB, and UNION • NB: Advisor and consultant investigator: AbbVie, Almirall, Arcutis, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, InCyte, ISDIN, Johnson & Johnson, Leo Pharma, Lilly, Ortho, Pfizer, Regeneron, Sanofi, Stemline, and Sun Pharma; Investigator: Arcutis, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Leo Pharma, Lilly, and Ortho • LS: Consultant, paid investigator, and/or speaker: AbbVie, Amgen, Anacor, Ascend, Astellas, AstraZeneca, Blaze Bioscience, Bristol Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Dermira, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Hexima, Janssen, Leo Pharma, Mayne, MedImmune, Merck, Merck-Serono, Novartis, Otsuka, Pfizer, Phosphagenics, Photon MD, Regeneron, Roche, Samumed, Sanofi Genzyme, SHR, Sun Pharma ANZ, Trius, UCB, and Zai Lab • KW: Consulting: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB; Research: Bristol Myers Squibb and Pfizer • LH, RMK, and SB: Employees and shareholders: Bristol Myers Squibb • DT: Grant/research support, consultant, scientific advisory board, and speakers bureau: AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Regeneron, Roche, Sandoz-Hexal, Sanofi, Target-Solution, and UCB Figure 1. AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Principia, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; Grant support/principal investigator: AbbVie, Amgen, Argenx, Bristol Myers Squibb, Celgene, Chemocentryx, Eli Lilly, Galderma, Kyowa Hakko Kirin, Leo Pharma, Menlo, Principia, Prothena, Rhizen, Syntimmune, Trevi, and XBiotech; Speaker: AbbVie, Eli Lilly, Janssen, Novartis, Regeneron, and Sanofi Genzyme • TP: Advisory board and consulting fees: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB • KBG:
    keywords: deucravacitinib; lte; myers; pharma; poetyk; pso-1; squibb
       cache: skin-1801.pdf
  plain text: skin-1801.txt

        item: #560 of 1356
          id: skin-1802
      author: Bagel, Jerry; Armstrong, April ; Warren, Richard; Papp, Kim; Thaçi, Diamant; Menter, Alan; Cather, Jennifer; Augustin, Matthias; Hippeli, Lauren; Daamen, Carolin; Griffiths, Christopher
       title: Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
        date: 2022-11-16
       words: 3651
      flesch: 43
     summary: Figure 7. sPGA 0/1 response rates through Week 52 in systemic treatment-naive, prior systemic treatment, and prior oral systemic treatment patients (NRI)a Deucravacitinib Placebo → deucravacitinib Patients, n 0 10 20 30 40 50 60 sP G A 0 /1 r es po n se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks Systemic treatment naive 24 28 32 36 40 44 48 52 132 132 132 132 132 132 132 132 132 132 132 127 122 127 129 132 57 Deucravacitinib Placebo – deucravacitinib 57 57 57 57 57 57 51 51 51 51 51 50 51 51 51 Patients, n 0 10 20 30 40 50 60 sP G A 0 /1 r es po n se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks Prior systemic treatment 24 28 32 36 40 44 48 52 200 200 200 200 200 200 200 200 200 200 198 199 198 197 196 200 109 Deucravacitinib Placebo – deucravacitinib 109 109 109 109 109 109 94 94 93 93 94 92 93 94 94 Patients, n 0 10 20 30 40 50 60 sP G A 0 /1 r es po n se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks The study design for POETYK PSO-1 is illustrated in Figure 2 • Eligible patients were ≥18 years of age with moderate to severe plaque psoriasis (ie, PASI ≥12, sPGA ≥3, body surface area involvement ≥10% at baseline) • Patients who previously received phototherapy, systemic treatment, and/or biologic treatment were required to complete washout periods ranging from 4 weeks to 6 months before study entry, depending on the treatment • The current analysis examined PASI 75 and sPGA 0/1 responses through 52 weeks in patients randomized to deucravacitinib and in those who crossed over from placebo to deucravacitinib at Week 16 (placebo crossovers), by prior treatment subgroups: — Systemic treatment naive (ie, neither biologic nor nonbiologic systemic treatment) — Prior systemic treatment (biologic and/or nonbiologic) — Prior oral systemic treatment (nonbiologic only) — Biologic treatment naive — Biologic treatment experienced • Nonresponder imputation was used for all reported endpoints Figure 2.
    keywords: deucravacitinib; patients; pharma; placebo; systemic; treatment
       cache: skin-1802.pdf
  plain text: skin-1802.txt

        item: #561 of 1356
          id: skin-1803
      author: Warren, Richard; Sofen, Howard; Imafuku, Shinichi; Szepietowski, Jacek; Blauvelt, Andrew; Spelman, Lynda; Toms, Jessica; Buck, Alex; Banerjee, Subhashis; Menter, Alan
       title: Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
        date: 2022-11-16
       words: 4226
      flesch: 39
     summary: Clinical efficacy responses during POETYK LTE Weeks 0—60 in patients who were receiving deucravacitinib at Week 52 in the parent study (sensitivity analysis): PASI 75a, PASI 90b, and sPGA 0/1c 77.7% 79.4% 75.7% 0 10 20 30 40 50 60 70 80 90 100 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 R e sp o n se r at e , % o f p at ie n ts Weeks PASI 75 0 10 20 30 40 50 60 70 80 90 100 R e sp o n se r at e , % o f p at ie n ts 28 Weeks 43.6% 49.6% 43.6% 70.8% 70.8% 50.7% 44.5% 71.3% TFR Deucravacitinib 6 mg QDPlacebob Deucravacitinib 6 mg QDPlacebob Primary endpoint B LI N D E D S W IT C H T O O P E N -L A B E L D E U C R A V A C IT IN IB Open-label deucravacitinib 6 mg QD (N = 1221) POETYK LTE 14856 60 68 76 88 112 124 1364 8 12 20 28 32 36 40 44 48 480 964 8 16 24 36 60 72 84Exposure relative to LTE (weeks) 1 year 2 yearsc aApremilast was titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing.
    keywords: deucravacitinib; lte; pasi; patients; pharma; poetyk; pso-1; psoriasis
       cache: skin-1803.pdf
  plain text: skin-1803.txt

        item: #562 of 1356
          id: skin-1804
      author: Blauvelt, Andrew; Rich, Phoebe; Sofen, Howard; Lambert, Jo; Merola, Joseph F; Lebwohl, Mark; Scharnitz, Thomas; Hoyt, Kim; Kisa, Renata M; Banerjee, Subhashis
       title: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
        date: 2022-11-16
       words: 2685
      flesch: 51
     summary: Acknowledgments • These clinical trials were sponsored by Bristol Myers Squibb • Writing and editorial assistance was provided by Liz Rockstein, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, funded by Bristol Myers Squibb Disclosures • AB: Speaker (received honoraria): AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Pfizer, Regeneron, Sanofi, and UCB; Scientific adviser (received honoraria): AbbVie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, AnaptysBio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly, Escient, Evelo, Evommune, Forte Bioscience, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB, Vibliome, and Xencor; Clinical study investigator (institution has received clinical study funds): AbbVie, Acelyrin, Almirall, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly, Evelo, Evommune, Galderma, Incyte, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB • PR: Research (principal investigator on pharmaceutical trials): AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Sun Pharma, and UCB • HS: Clinical investigator: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and Sun Pharma • JL: Unrestricted grants: AbbVie, Almirall, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, and UCB; Speaker: AbbVie, Almirall, Bristol Myers Squibb, Janssen-Cilag, Pfizer, and UCB; Consultant: AbbVie, BMS, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, and UCB • JFM: Consultant and/or investigator: Amgen, AbbVie, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB • ML: Research funds on behalf of Mount Sinai: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, Ortho Dermatologics, Regeneron, and UCB; Consultant: Aditum Bio, Almirall, AltruBio AnaptysBio, Arcutis, Arena, Aristea, Arrive Technologies, Avotres, BiomX, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Cara, Castle Biosciences, CorEvitas’ (Corrona) Psoriasis Registry, Dermavant, Dr Reddy’s Laboratories, Evelo Biosciences, Evommune, Forte Biosciences, Helsinn Therapeutics, Hexima, Leo Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica • TS, RMK, and SB: Employees and shareholders: Bristol Myers Squibb • KH: Contractor: Bristol Myers Squibb via Syneos Health
    keywords: deucravacitinib; patients; pga; placebo; week
       cache: skin-1804.pdf
  plain text: skin-1804.txt

        item: #563 of 1356
          id: skin-1805
      author: Del Rosso, James; Guenthner, Scott; Hong, Chih-ho; Jett, John E; Brown, Philip M; Rubenstein, David S; Piscitelli, Stephen C; Piscitelli, Stephen C
       title: Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
        date: 2022-11-16
       words: 1732
      flesch: 38
     summary: CONCLUSIONS ■ Tapinarof cream 1% QD is efficacious and well tolerated, including on intertriginous and sensitive skin areas, in patients with mild to severe plaque psoriasis ■ Topical application of tapinarof cream 1% QD in patients with psoriasis or AD resulted in minimal systemic exposure ■ The maximal-use trial in psoriasis demonstrated that tapinarof plasma exposure declined over time ■ Furthermore, tapinarof systemic exposure was also unrelated to %BSA affected for patients with psoriasis ■ This exposure–response analysis demonstrates a lack of dependence on systemic activity for the therapeutic efficacy of tapinarof cream REFERENCES 1. Pharmacokinetics of Tapinarof ■ Tapinarof plasma exposure was low overall and below quantifiable limits in the majority (62.6% [1243/1985]) of samples using a highly sensitive assay ■ Mean (SD) C min and C max were 27.6 (23.3) pg/mL and 340 (6270) pg/mL, respectively ■ There were no trends observed between tapinarof plasma concentrations and disease (AD or psoriasis), or the concentration of tapinarof cream (0.5%, 1%), or frequency (QD, BID) of application (Figure 1) ■ In a separate, post hoc analysis of the psoriasis maximal-use trial, there was also no correlation between tapinarof plasma concentration and BSA in patients with psoriasis (ranging from 21%–46%) (Figure 2) ■ In the maximal-use trial in patients with psoriasis, tapinarof plasma exposure declined over time, and was approximately 10-fold lower on Day 29 than on Day 14 Figure 1.
    keywords: exposure; patients; psoriasis; tapinarof; trial
       cache: skin-1805.pdf
  plain text: skin-1805.txt

        item: #564 of 1356
          id: skin-1806
      author: Stein Gold, Linda; Lebwohl, Mark; Bissonnette, Robert; Strober, Bruce; Tallman, Anna M; Brown, Philip M; Piscitelli, Stephen C; Rubenstein, David S
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials
        date: 2022-11-16
       words: 1952
      flesch: 42
     summary: ITT population, OC. CI, confidence interval; ITT, intention-to-treat; OC, observed cases; PASI75, ≥75% improvement in Psoriasis Area and Severity Index score; PASI90, ≥90% improvement in Psoriasis Area and Severity Index score; QD, once daily. Trial Design for PSOARING 1, 2, and 3 *Patients with PGA=2 (mild) and PGA=4 (severe) limited to ~10% each of the total randomized population; ~80% of the total randomized population with PGA=3 (moderate).
    keywords: cream; patients; pga; score; tapinarof
       cache: skin-1806.pdf
  plain text: skin-1806.txt

        item: #565 of 1356
          id: skin-1807
      author: Armstrong, April W; Bissonnette, Robert; Brown, Philip M; Tallman, Anna M; Papp, Kim A
       title: Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis
        date: 2022-11-16
       words: 2211
      flesch: 52
     summary: Absolute PASI ≤1 and %BSA of ≤0.5% Achieved by Week 4 ■ Figure 4 shows the clinical response for a patient with plaque psoriasis treated with tapinarof cream 1% QD, whose improvement by Week 4 exceeded the absolute PASI, %BSA, and PGA endpoints Figure 4. Safety ■ Treatment-emergent adverse events (TEAEs) were mostly mild to moderate ■ The most common TEAEs (in ≥5% of patients) were folliculitis, contact dermatitis, and nasopharyngitis CONCLUSIONS ■ Tapinarof cream 1% QD was well tolerated and demonstrated rapid, clinically meaningful, and durable improvements in clinical efficacy in a high proportion of patients ■ Treatment targets were achieved with tapinarof cream monotherapy, despite the challenges of meeting these goals with available systemic, biologic, topical, and combination therapies ■ The aggressive target of ≤1% BSA affected was achieved by 40% of tapinarof-treated patients within ~3 months; attainment continued to increase over time, with 50% of patients achieving this target at ~4 months ■ These findings support continuing tapinarof treatment beyond 3 months for patients who are experiencing improvement but not yet meeting the ≤1% BSA affected treatment target advocated by the National Psoriasis Foundation12 ■ An absolute PASI total score of ≤2 was achieved by 67% of tapinarof-treated patients; this is a treatment target that has been shown to correspond to a PASI90 response3 ■ These analyses may have underestimated the percentage of patients who achieved treatment targets, due to the unique forced-withdrawal design of PSOARING 3 that resulted in intermittent rather than continuous treatment REFERENCES 1.
    keywords: bsa; pasi; patients; tapinarof; treatment
       cache: skin-1807.pdf
  plain text: skin-1807.txt

        item: #566 of 1356
          id: skin-1808
      author: Stein Gold, Linda; Griffiths, Christopher E; Tallman, Anna M; Brown, Philip M; Lebwohl, Mark
       title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials
        date: 2022-11-16
       words: 1952
      flesch: 45
     summary: Endpoints and Statistical Analysis ■ The DLQI is a validated, dermatology-specific, 10-item patient questionnaire – Each item rates impact of disease on QoL on a 4-point scale from 0 (not at all) to 3 (very much) – Total scores range from 0 to 30, with lower scores indicating better health-related QoL (i.e., a lower impact of disease on QoL) – A total DLQI score of 0 or 1 indicates “no effect at all” of disease on QoL – A total DLQI score of 2–5 indicates a small effect, 6–10 a moderate effect, and >10 a very large effect on QoL8 ■ Efficacy assessments included PGA and PASI ■ Spearman rank correlations were used to evaluate relationships between changes from baseline in efficacy (assessed using PGA and PASI) and changes from baseline in DLQI score at Week 12 ■ Analyses used observed cases and were based on the intention-to-treat population ■ For the proportion of patients with DLQI of 0 or 1, P values for differences between tapinarof cream 1% QD and vehicle were calculated using Cochran- Mantel-Haenszel analyses and stratified by baseline PGA score. PSOARING 1 and PSOARING 2 Trial Design *Patients with PGA=2 (mild) and PGA= 4 (severe) were limited to ~10% each of the total randomized population; with ~80% of the total randomized population having a PGA=3 (moderate).
    keywords: cream; dlqi; tapinarof; week
       cache: skin-1808.pdf
  plain text: skin-1808.txt

        item: #567 of 1356
          id: skin-1809
      author: Draelos, Zoe D; Draelos, Matthew M; Praestegaard, Morten
       title: Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension
        date: 2022-11-16
       words: 819
      flesch: 60
     summary: The values in Figure 1 indicate the total BDP recovered from tape strips ( # 3, 5, 7…19) reflecting the total relative amount of drug deposited to SC and epidermis • Statistical significance was demonstrated in favour of enhanced drug delivery from CAL/BDP cream over CAL/BDP TS (p ≤ 0.05) at all time points. BDP deposited from CAL/BDP TS remained lower and consistent at all time points.
    keywords: bdp; cal; cream
       cache: skin-1809.pdf
  plain text: skin-1809.txt

        item: #568 of 1356
          id: skin-181
      author: Geronemus, Roy G; Brauer, Jeremy A; Kilmer, Suzanne L; Wall, Jr., Simeon H; Green, Jeremy B; Cohen, Joel L; Weiss, Robert A; Alster, Tina S; Kaminer, Michael S
       title: An Observational Study of the Safety and Efficacy of Tissue Stabilized-Guided Subcision to Improve the Appearance of Cellulite
        date: 2017-10-27
       words: 1273
      flesch: 54
     summary: Most subjects (≥93%) remained satisfied or very satisfied with the results of their treatment through 3-years. Treatment depth.
    keywords: depth; improvement; patients; treatment
       cache: skin-181.pdf
  plain text: skin-181.txt

        item: #569 of 1356
          id: skin-1810
      author: Callender, Valerie; Taylor, Susan; Cook-Bolden, Fran
       title: Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream Demonstrates High Efficacy and Convenience in Skin of Color Patients with Plaque Psoriasis
        date: 2022-11-16
       words: 1169
      flesch: 60
     summary: Psoriasis Treatment Convenience Scale (PTCS)2 was significantly higher in CAL/BDP cream than CAL/BDP TS in the total population and the Fitzpatrick type IV-VI groups. /BDP cream CAL/ BDP TS Cream vehicle Total Population: Subjects with any TEAE, n (%) 90 (26.3) 76 (22.6) 32 (27.8)
    keywords: bdp; cal; cream; treatment
       cache: skin-1810.pdf
  plain text: skin-1810.txt

        item: #570 of 1356
          id: skin-1812
      author: Ferris, Laura K;  Armstrong, April W; Del Rosso, James; Draelos, Zoe D; Gooderham, Melinda; Lebwohl, Mark; Papp, Kim A; Soung, Jennifer; Stein Gold, Linda; Krupa, David; Higham, Robert C; Burnett, Patrick; Berk, David R
       title: Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)
        date: 2022-11-16
       words: 2673
      flesch: 51
     summary: In patients with involvement in SA, local tolerability was highly favorable as reported by patient and investigator assessment of irritation, burning, and stinging (Figure 6) – ≥97.6% of patients had no evidence of irritation at Week 8 on investigator-rated assessments – The local tolerability profile as assessed by both patients and investigators was favorable • The subgroup analysis of the pooled results of the phase 3 DERMIS-1 and DERMIS-2 trials showed that once-daily roflumilast cream 0.3% demonstrated efficacy and tolerability in patients with psoriasis involvement in difficult-to-treat areas RESULTS • Baseline disease characteristics and demographics were similar across treatment groups (Table 1) • Significantly more roflumilast-treated patients achieved the primary endpoint, IGA Success at Week 8 (Figure 2) – Across the subgroups at Week 8, a greater percentage of patients in the roflumilast group achieved IGA Success compared with that of the vehicle group – More patients in the roflumilast group also had an IGA status of Clear or Almost Clear across subgroups at Week 8 (Figure 3) • More roflumilast-treated patients who had a baseline score ≥4 on the Worst Itch Numeric Rating Scale (WI-NRS) had a 4-point improvement at Week 8 across subgroups (Figure 4) •
    keywords: cream; iga; intertriginous; involvement; patients; psoriasis; roflumilast; vehicle
       cache: skin-1812.pdf
  plain text: skin-1812.txt

        item: #571 of 1356
          id: skin-1813
      author: Armstrong, April W; Young, Melodie; Seal, Melissa; Higham, Robert; Greiling, Teri
       title: Patient Perspectives on the Prevalence and Burden of Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States
        date: 2022-11-16
       words: 1694
      flesch: 40
     summary: A propensity score variable was included to adjust for respondents’ propensity to be online • Raked weights were estimated using Random Iterative Method weighting RESULTS Patient-Reported Psoriasis Symptoms • At the time of diagnosis, most participants (N=507) described their psoriasis symptoms as moderate (59%; Figure 2) Patient-Reported Burden of Psoriasis • Participants estimated that an average of 15% of their bodies was affected by psoriasis – Most patients (63%) reported ≤10% of their body was affected – The body areas most often reported to be affected by psoriasis were the scalp, elbows, legs, intertriginous areas, arms, and knees (Figure 3) • A survey was conducted by the Harris Poll in the US, on behalf of Arcutis Biotherapeutics, to understand the perspectives and burden of patients with psoriasis who use topical treatments to manage their disease •
    keywords: figure; patients; psoriasis; topical; treatment
       cache: skin-1813.pdf
  plain text: skin-1813.txt

        item: #572 of 1356
          id: skin-1814
      author: Curcio, Alyssa; Kontzias, Christina; Feldman, Steven R
       title: Improving Patient Acceptability and Adherence in Psoriasis Treatment
        date: 2022-11-16
       words: 746
      flesch: 54
     summary: The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments. If a topical medication caused a reaction, more than 40% of patients said they would call another dermatologist • If participants did not like a topical treatment's formulation, most (74.7%) said they would continue to use the medication for a week before discontinuation CONCLUSION • Topical treatments continue to be a mainstay of psoriasis treatment • Patients expect to see rapid improvement with topical treatment; otherwise, they report they will discontinue treatment • The characteristics of psoriasis treatment vehicles also affects patients’ reported willingness to use treatment and may be an important consideration in treatment planning REFRENCES 1.
    keywords: psoriasis; topical; treatment
       cache: skin-1814.pdf
  plain text: skin-1814.txt

        item: #573 of 1356
          id: skin-1815
      author: Armstrong, April W; Jayade, Sayeli; Rege, Sanika; Joshi, Namita; Patel, Vardhaman; Davidson, David; Kalirai, Samaneh; Wolin, Daniel; Boyle, Kimberly; Patel, Dipen; Seigel, Lauren
       title: Evaluating treatment choice among patients with moderate or severe psoriasis in the United States
        date: 2022-11-16
       words: 32274
      flesch: 43
     summary: [CI], 1.4–4.2) among Black respondents (P = 0.036) — Intent to start the new once-daily oral treatment increased with psoriasis severity over the past week, with 76.5% of respondents with moderate psoriasis and 82.8% of respondents with severe disease answering “yes” • Compared with patients with no psoriasis symptoms or signs over the past week, the OR of intent to start the new treatment was 3.2 (95% CI, 2.0–4.9) among patients with mild psoriasis, 5.0 (95% CI, 3.1–8.2) among patients with moderate psoriasis, and 7.6 (95% CI, 3.9–15.0) among patients with severe psoriasis; all P < 0.001 — 79.6% of patients who responded that the new once-daily oral treatment would cause them less anxiety than an injection would start the new treatment — 87.6% of respondents who believed that the new once-daily oral treatment would reduce their symptoms more than their current treatment would start the new treatment • Asked to rank characteristics of psoriasis treatment in order of importance, 58.3% of respondents ranked “extent of skin clearance” as first or second, while 43.7% ranked “route of administration” as first or second (Figure 6) • Laboratory monitoring was ranked least important by more than half (53.0%) of the patients Figure 6. [CI], 1.4–4.2) among Black respondents (P = 0.036) — Intent to start the new once-daily oral treatment increased with psoriasis severity over the past week, with 76.5% of respondents with moderate psoriasis and 82.8% of respondents with severe disease answering “yes” • Compared with patients with no psoriasis symptoms or signs over the past week, the OR of intent to start the new treatment was 3.2 (95% CI, 2.0–4.9) among patients with mild psoriasis, 5.0 (95% CI, 3.1–8.2) among patients with moderate psoriasis, and 7.6 (95% CI, 3.9–15.0) among patients with severe psoriasis; all P < 0.001 — 79.6% of patients who responded that the new once-daily oral treatment would cause them less anxiety than an injection would start the new treatment — 87.6% of respondents who believed that the new once-daily oral treatment would reduce their symptoms more than their current treatment would start the new treatment • Asked to rank characteristics of psoriasis treatment in order of importance, 58.3% of respondents ranked “extent of skin clearance” as first or second, while 43.7% ranked “route of administration” as first or second (Figure 6) • Laboratory monitoring was ranked least important by more than half (53.0%) of the patients Figure 6.
    keywords: e n; n =; n treatment; patients; psoriasis treatment; treatment characteristics; treatment group
       cache: skin-1815.pdf
  plain text: skin-1815.txt

        item: #574 of 1356
          id: skin-1816
      author: Armstrong, April W; Warren, Richard B; Zhong, Yichen; Zhuo, Joe; Cichewicz, Allie; Kadambi, Ananth; Junqueira, Daniel R; Westley, Tracy; Kisa, Renata; Daamen, Carolin; Augustin, Matthias
       title: Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis
        date: 2022-11-16
       words: 17976
      flesch: 27
     summary: The objective of this analysis was to examine the clinical effi cacy associated with deucravacitinib and other selected active biologic and nonbiologic treatments in patients with moderate to severe psoriasis Methods • Electronic databases were searched through October 2021 for RCTs of systemic treatments in adults with moderate to severe psoriasis who reported improvement in response on PASI • Phase 3 trial data were included when: — Nonresponder imputation was applied1,2 — Studies were conducted in multiple or single countries with diverse ethnic representation • NMA was performed using multinomial random effects models adjusting for baseline risk (ie, placebo response) to estimate PASI responses over short-, mid-, and long-term follow-up periods (Weeks 10−16, 24−28, and 44−60, respectively) and reported following the PRISMA Reporting Guidelines for meta-analysis3 Results • The objective of this analysis was to examine the clinical effi cacy associated with deucravacitinib and other selected active biologic and nonbiologic treatments in patients with moderate to severe psoriasis Methods • Electronic databases were searched through October 2021 for RCTs of systemic treatments in adults with moderate to severe psoriasis who reported improvement in response on PASI • Phase 3 trial data were included when: — Nonresponder imputation was applied1,2 — Studies were conducted in multiple or single countries with diverse ethnic representation • NMA was performed using multinomial random effects models adjusting for baseline risk (ie, placebo response) to estimate PASI responses over short-, mid-, and long-term follow-up periods (Weeks 10−16, 24−28, and 44−60, respectively) and reported following the PRISMA Reporting Guidelines for meta-analysis3 Results •
    keywords: mg biw; mg ixe; mg n; mg q2w; mg ris; mg sec; mg ust
       cache: skin-1816.pdf
  plain text: skin-1816.txt

        item: #575 of 1356
          id: skin-1817
      author: Armstrong, April W; Hee Park, Sang; Chirikov, Viktor; Nicolas, Pierre; Wang, Wei-Jhih; Colombo, Matthew J; Patel, Vardhaman
       title: Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
        date: 2022-11-16
       words: 10302
      flesch: 42
     summary: This post hoc analysis compared data from 2 arms in the POETYK PSO-1 trial (Figure 1) — Deucravacitinib arm: patients initiated with and continued on deucravacitinib, regardless of response status — Apremilast initiators arm: patients initiated with apremilast; at Week 24, PASI 50 responders continued with apremilast while PASI 50 nonresponders crossed over to deucravacitinib • Cumulative clinical benefit from randomization to Week 52 was determined by the total area under the curve of clinical response over 52 weeks (AUC 0–52wk ) in each arm — AUC analysis has been employed to evaluate outcomes over time in clinical trials, as the AUC refl ects the rapidity and durability, as well as the magnitude, of response3-6 • While assessments at discrete time points identify static responses, the AUC approach captures cumulative treatment effects over time — This study determined the AUC using data at a patient level (responder status at each time point over 52 weeks) • Total AUC 0–52wk was calculated separately for each efficacy endpoint, using the trapezoidal rule — Total AUC 0–52wk = 15i=0∑ (Pi+Pi+1)(Ti+1−Ti), where Ti (i = 0, 1, 2, 3, …, 15) denotes the time points of Weeks 0, 1, 2, 4, 8, 12, and 16, then every 4 weeks thereafter through Week 52, and P i denotes the response (yes = 1; This post hoc analysis compared data from 2 arms in the POETYK PSO-1 trial (Figure 1) — Deucravacitinib arm: patients initiated with and continued on deucravacitinib, regardless of response status — Apremilast initiators arm: patients initiated with apremilast; at Week 24, PASI 50 responders continued with apremilast while PASI 50 nonresponders crossed over to deucravacitinib • Cumulative clinical benefit from randomization to Week 52 was determined by the total area under the curve of clinical response over 52 weeks (AUC 0–52wk ) in each arm — AUC analysis has been employed to evaluate outcomes over time in clinical trials, as the AUC refl ects the rapidity and durability, as well as the magnitude, of response3-6 • While assessments at discrete time points identify static responses, the AUC approach captures cumulative treatment effects over time — This study determined the AUC using data at a patient level (responder status at each time point over 52 weeks) • Total AUC 0–52wk was calculated separately for each efficacy endpoint, using the trapezoidal rule — Total AUC 0–52wk = 15i=0∑ (Pi+Pi+1)(Ti+1−Ti), where Ti (i = 0, 1, 2, 3, …, 15) denotes the time points of Weeks 0, 1, 2, 4, 8, 12, and 16, then every 4 weeks thereafter through Week 52, and P i denotes the response (yes = 1;
    keywords: apremilast; auc; deucravacitinib; pasi; weeks
       cache: skin-1817.pdf
  plain text: skin-1817.txt

        item: #576 of 1356
          id: skin-1818
      author: Armstrong, April W; Papp, Kim A; Zhuo, Joe; Becker, Brandon; Zhong, Yichen; Beaumont, Jennifer L; DeRosa, Michael; Kisa, Renata M; Banerjee, Subhashis; Strober, Bruce
       title: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
        date: 2022-11-16
       words: 20335
      flesch: 48
     summary: At Week 16, change from baseline in sPGA score was correlated with changes in the PSSD total score (r s = 0.496) and DLQI total score (r s = 0.380) in the total study population • Higher PASI or sPGA response was associated with greater PSSD and DLQI responses at Weeks 16, 24, and 52 in the total study population (Figures 1–4) At Week 16, change from baseline in sPGA score was correlated with changes in the PSSD total score (r s = 0.496) and DLQI total score (r s = 0.380) in the total study population • Higher PASI or sPGA response was associated with greater PSSD and DLQI responses at Weeks 16, 24, and 52 in the total study population (Figures 1–4)
    keywords: baseline; pasi; patients; pssd; response; score; spga; spga score
       cache: skin-1818.pdf
  plain text: skin-1818.txt

        item: #577 of 1356
          id: skin-1819
      author: Lebwohl, Mark; Armstrong, April W; Merola, Joseph F; Gottlieb, Alice B; Davis, Leah; Gomez, Braulio; Wiegratz, Susanne; Cross, Nancy; Strober, Bruce
       title: Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials 
        date: 2022-11-16
       words: 2162
      flesch: 51
     summary: prior biologics (n=29) A) DLQI 0/1 response by number of prior biologics Week 48/52 74.0% 77.6%72.0% 80.3%79.6% 65.5% 82.7% 65.5% To receive a copy of this poster, scan the QR code or visit the website below. • We also report responses by type of prior biologic: anti-IL-17, anti-tumor necrosis factor (TNF), anti-IL-12/23, and anti-IL-23. •
    keywords: biologic; patients; pharma; prior; week
       cache: skin-1819.pdf
  plain text: skin-1819.txt

        item: #578 of 1356
          id: skin-182
      author: Jones, Derek H; Kerscher, Martina; Geister, Thorin; Hast, Michael A; Weissenberger, Petra
       title: Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses from Randomized. Double-Blind Pivotal Studies
        date: 2017-10-27
       words: 1572
      flesch: 42
     summary: Despite the increasing number of men seeking aesthetic procedures, they are underrepresented in the literature on aesthetic products such as botulinum toxins - A previous analysis of 17 studies on botulinum toxins in aesthetic indications showed that only ~11% of subjects in these trials were male2 • Therefore, there remains a clinical need for studies that address how men and women respond differentially to aesthetic treatments to support individualization of treatment plans • In 2016, men accounted for ~9% of all minimally cosmetic procedures.1
    keywords: incobotulinumtoxina
       cache: skin-182.pdf
  plain text: skin-182.txt

        item: #579 of 1356
          id: skin-1820
      author: Strober, Bruce; Tada, Yayoi; Mrowietz, Ulrich; Lebwohl, Mark; Foley, Peter; Langley, Richard G; Barker, Jonathan; Wang, Maggie; Vanvoorden, Veerle; Szilagyi, Balint; Ciaravino, Valerie; Paul, Carle
       title: Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
        date: 2022-11-16
       words: 2852
      flesch: 50
     summary: Author Disclosures: BSt: Consultant (honoraria): AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea Therapeutics, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, EPI Health, Evelo Biosciences, Immunic Therapeutics, Janssen, LEO Pharma, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB Pharma, Union Therapeutics, Ventyxbio, and vTv Therapeutics; Stock options: Connect Biopharma, Mindera Health; Speaker: AbbVie, Eli Lilly, Janssen, Regeneron, and Sanofi-Genzyme; Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry; Investigator: AbbVie, Cara Therapeutics, CorEvitas Psoriasis Registry, Dermavant, and Novartis; Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. YT: Honoraria and/or grants from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Pharma.
    keywords: bkz; ole; pasi; patients; pharma; q4w; responders; week
       cache: skin-1820.pdf
  plain text: skin-1820.txt

        item: #580 of 1356
          id: skin-1821
      author: Gordon, Kenneth B; Langley, Richard G; Warren, Richard B; Okubo, Yukari; Rosmarin, David; Lebwohl, Mark; Peterson, Luke; Madden, Cynthia; de Cuyper, Dirk; Gomez, Natalie Nunez; Thaçi, Diamant
       title: Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
        date: 2022-11-16
       words: 2638
      flesch: 53
     summary: • Safety data observed over three years of BKZ treatment were consistent with those observed over two years;4 EAIRs did not increase with longer BKZ exposure, and were generally lower in Q8W- vs Q4W-treated patients (Figure 1, Table 2). Over three years of BKZ treatment, 79.9% of patients experienced no oral candidiasis events.
    keywords: bkz; data; pharma; phase; treatment; years
       cache: skin-1821.pdf
  plain text: skin-1821.txt

        item: #581 of 1356
          id: skin-1822
      author: Blauvelt, Andrew; Stein Gold, Linda; Gooderham, Melinda; Strober, Bruce; Pinter, Andreas; Carrascosa, Jose-Manuel; Gisondi, Paolo; Bleier, Jonathan; Madden, Cynthia; Deherder, Delphine; Gomez, Natalie Nunez; Warren, Richard B
       title: Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
        date: 2022-11-16
       words: 2724
      flesch: 54
     summary: • Similar to the overall study population,6 EAIRs of safety topics of interest were low in moderate psoriasis patients (Table 2; Table 3). Figure 1 Study design Figure 2 Efficacy responses for moderate psoriasis patients through two years (mNRI, NRI, OC)
    keywords: 0.0; bkz; patients; pharma; psoriasis; teaes; week
       cache: skin-1822.pdf
  plain text: skin-1822.txt

        item: #582 of 1356
          id: skin-1824
      author: Thaçi, Diamant; Vender, Ron; de Rie, Menno; Conrad, Curdin; Soung, Jennifer; Strober, Bruce; Wang, Maggie; Cross, Nancy; Deherder, Delphine; Gomez, Natalie Nunez; Gottlieb, Alice B
       title: Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
        date: 2022-11-16
       words: 2692
      flesch: 60
     summary: In BE SURE, 478 patients were randomized 1:1:1 to: BKZ Q4W/Q4W (N=158), BKZ Q4W/Q8W (N=161), and ADA/BKZ Q4W (N=159) (Figure 1). BKZ Q4W/Q4W; N=158 BKZ Q4W/Q8W; N=161 ADA/BKZ Q4W; N=159 0 100 80 60 40 20 Week 56 Week 104 Week 152 P ro p o rt io n o f p a ti e n ts a c h ie v in g P A S I 9 0 ( % ) 92.6% 89.6% 94.3% 85.5% 87.3%
    keywords: bkz; ole; patients; pharma; q4w; week
       cache: skin-1824.pdf
  plain text: skin-1824.txt

        item: #583 of 1356
          id: skin-1825
      author: Blauvelt, A; Duffin, KC; Magnolo, N; Weisman, J;  Ståhle, M; Wilsmann-Theis, D; Wang, M; Wixted, K; Szilagyi, B; Puig, L
       title: Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
        date: 2022-11-16
       words: 1660
      flesch: 46
     summary: Author Disclosures: AB:Has served as a speaker (received honoraria) for AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Pfizer, Regeneron, Sanofi, and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly , Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma.
    keywords: bkz; pasi; patients; pharma; ucb; week
       cache: skin-1825.pdf
  plain text: skin-1825.txt

        item: #584 of 1356
          id: skin-1826
      author: Warren, RB; Conrad, C; Foley, P; Iversen, L; Langley, RG; Kokolakis, G; Davis, L; Vanvoorden, V; Wiegratz, S; Merola, JF
       title: Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
        date: 2022-11-16
       words: 1956
      flesch: 48
     summary: Author Disclosures: RBW: Consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma; research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis and UCB Pharma; honoraria from Astellas, DiCE, GSK and Union. CC: Consultant and/or principal investigator in clinical trials for: AbbVie, Actelion, Amgen, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi Genzyme and UCB Pharma.
    keywords: bkz; pasi; patients; pharma; week
       cache: skin-1826.pdf
  plain text: skin-1826.txt

        item: #585 of 1356
          id: skin-1827
      author: Thaçi, D; Armstrong, A; Lebwohl, M; Blauvelt, A; Paul, C; Puig, L; Wang, M; Vanvoorden, V; Madden, C; Wiegratz, S; Deherder, D; Gordon, KB
       title: Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
        date: 2022-11-16
       words: 2217
      flesch: 46
     summary: We report the proportion of patients achieving PASI ≤2 and PASI=0 through two years of treatment (OLE Week 48) among BKZ-randomized Week 16 PASI ≤2 and PASI=0 responders, who remained on the same BKZ maintenance dose upon entering the relevant OLE (Q4W/Q8W/Q8W or Q4W/Q4W/Q4W). • BKZ has demonstrated high levels of skin clearance for the treatment of moderate to severe plaque psoriasis in phase 3/3b clinical trials.1–4 Methods • Data were pooled from the BE SURE, BE VIVID and BE READY phase 3 trials, the BE BRIGHT open-label extension (OLE), and BE RADIANT (48-week double-blinded phase 3b trial and ongoing OLE).1–5 • Patients included in these analyses were randomized at baseline to BKZ 320 mg every four weeks (Q4W) to Week 16, followed by BKZ Q4W or every eight weeks (Q8W) maintenance dosing for the remainder of the double-blinded period of the trials (Figure 1).
    keywords: bkz; ole; patients; pharma; q4w; q8w; week
       cache: skin-1827.pdf
  plain text: skin-1827.txt

        item: #586 of 1356
          id: skin-1828
      author: Olivet, Meagan; Kole, Lauren
       title: Sunscreen Knowledge and Sun Protective Behaviors among Medical Students at a Southern US Institution
        date: 2023-03-13
       words: 4344
      flesch: 61
     summary: Compared to the general adult population, medical students are uniquely positioned in their level of knowledge to carry out best health practices in a multitude of areas. ABSTRACT Introduction: Literature has demonstrated that medical students have discrepancies in their knowledge and their execution of best practices concerning sun protection.
    keywords: knowledge; medical; practices; skin; students; sun; sunscreen; tan; wear; white
       cache: skin-1828.pdf
  plain text: skin-1828.txt

        item: #587 of 1356
          id: skin-1829
      author: Armstrong, A; Langley, RG; Gordon, KB; Warren, RB; Thaçi, D; Stein Gold, L; Peterson, L; Madden, C; Nunez Gomez, N; de Cuyper, D; Costanzo, A
       title: Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
        date: 2022-11-16
       words: 2420
      flesch: 53
     summary: Conclusions Over two years of BKZ treatment, EAIRs of infection TEAEs and pre-defined infections of interest, including oral candidiasis, were generally lower in patients treated with BKZ Q8W compared with Q4W. Infection rates decreased with longer duration of BKZ exposure. All patients received BKZ Q4W through Weeks 0–16.
    keywords: bkz; candidiasis; data; infections; patients; pharma
       cache: skin-1829.pdf
  plain text: skin-1829.txt

        item: #588 of 1356
          id: skin-183
      author: Sussman, Gordon; Hebert, Jacques; Gulliver, Wayne; Lynde, Charles; Yang, William H; Chambenoit, Olivier; Vieira, Antonio; De Takacsy, Frederica; Rihakova, Lenka
       title: Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study
        date: 2017-10-27
       words: 1486
      flesch: 49
     summary: If patients relapsed (UAS7 ≥16) upon withdrawal, they were retreated with their starting dose for 12 weeks Inclusion criteria • Men or women at least 18 years of age • Diagnosis of CIU/CSU and the presence of symptoms for ≥6 months prior to the screening visit • Patients must have been on an approved dose of nonsedating H 1 -antihistamine for CIU/CSU, and no other concomitant CIU/CSU treatment, for at least the 7 consecutive days immediately prior to the randomization visit and must have documented current use on the day of the randomization visit • UAS7 ≥16 (scale 0−42) and itch component of UAS7 ≥8 (scale 0−21) during 7 days prior to randomization Exclusion criteria • Patients with a clearly defined underlying etiology for chronic urticaria other than CIU/CSU • Patients with urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma or leukemia, active atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or other skin disease associated with itch that could interfere with study outcomes • Patients with a history of malignancy of any organ system • Patients should stay on same approved dose of nonsedating H 1 -antihistamine during all trial duration. et al. Design and rationale of the OPTIMA study: retreatment or step-up therapy with omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU).
    keywords: omalizumab; patients; uas7; urticaria
       cache: skin-183.pdf
  plain text: skin-183.txt

        item: #589 of 1356
          id: skin-1830
      author: Pinter, Andreas; Strober, Bruce; Rosmarin, David; Gisondi, Paolo; Vanvoorden, Veerle; Peterson, Luke; Madden, Cynthia; de Cuyper, Dirk; Warren, Richard B
       title: Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
        date: 2022-11-16
       words: 2394
      flesch: 58
     summary: Bodyweight <120 kg Bodyweight ≥120 kg BKZ Q4W (N=1,246) BKZ Q4W (N=116)
    keywords: bkz; patients; q4w; q8w
       cache: skin-1830.pdf
  plain text: skin-1830.txt

        item: #590 of 1356
          id: skin-1831
      author: Mayo, Tiffany; Armstrong, April W; Kircik, Leon; Silverberg, Jonathan; Blauvelt, Andrew; Esdalie, Ben; Schneider, Shannon; Mark, Thomas; Gooderham, Melinda; Alexis, Andrew F
       title: Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis
        date: 2022-11-16
       words: 2431
      flesch: 32
     summary: Thomas Mark owns LEO Pharma stock. Percentage of patients achieving Worst Weekly Pruritus NRS ≤3 and DLQI ≤5 by racial subgroup at Week 56 of ECZTEND Adjusting for differences in baseline characteristics and country between subgroups impacts estimated responder proportions • Adjusted for race and country as main effects, EASI-75 was achieved in 88% of Asian patients, 90% of Black patients, and 90% of White patients (Figure 4) •
    keywords: asian; black; ecztend; leo; patients; pharma; white
       cache: skin-1831.pdf
  plain text: skin-1831.txt

        item: #591 of 1356
          id: skin-1832
      author: Wollenberg, Andreas; de Bruin-Weller, Marjolein; Thyssen, Jacob P; Beck, Lisa A; Simpson, Eric L; Imafuku, Shinichi; Boguniewicz, Mark; Kurbasic, Azra; Soldbro, Lise; Strange Vest, Natacha; Arlert, Petra; Paller, Amy S
       title: Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial
        date: 2022-11-16
       words: 2364
      flesch: 43
     summary: 2017;429:208–19 Disclosures Andreas Wollenberg has received grants, personal fees, or nonfinancial support from AbbVie, Aileens, Almirall, Beiersdorf, Bioderma, Chugai, Galapagos, Galderma, GSK, Hans Karrer, LEO Pharma, Lilly, L’Oreal, Maruho, MedImmune, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron, Santen, and Sanofi-Aventis. Jacob P. Thyssen has attended advisory boards for Eli Lilly & Co., Almirall, Arena Pharmaceuticals, Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi-Genzyme, been an investigator for LEO Pharma, Sanofi-Genzyme, Eli Lilly & Co., AbbVie and Pfizer, and received speaker honorarium from LEO Pharma, Pfizer, Almirall, Abbvie, Eli Lilly & Co., Regeneron and Sanofi-Genzyme.
    keywords: conjunctivitis; patients; q2w; tralokinumab; treatment; weeks
       cache: skin-1832.pdf
  plain text: skin-1832.txt

        item: #592 of 1356
          id: skin-1833
      author: Cohen, Philip
       title: Papules on the Helical Rim: Weathering Nodules
        date: 2023-01-10
       words: 441
      flesch: 49
     summary: Weathering nodules on the helical rim of the left ear. Hence, the suspected diagnosis of weathering nodules was confirmed.
    keywords: nodules; weathering
       cache: skin-1833.pdf
  plain text: skin-1833.txt

        item: #593 of 1356
          id: skin-1834
      author: Mayo, Tiffany; Armstrong, April W; Kircik, Leon; Silverberg, Jonathan I; Blauvelt, Andrew; Esdalie, Ben; Schneider, Shannon; Mark, Thomas; Gooderham, Melinda; Alexis, Andrew F
       title: Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials
        date: 2022-11-16
       words: 2642
      flesch: 49
     summary: o ECZTRA 1 and 2 were placebo-controlled trials and ECZTRA 3 was placebo + TCS controlled The safety profile of tralokinumab treatment was consistent across racial subgroups • Tralokinumab was generally well-tolerated, with a safety profile comparable to placebo and largely consistent across racial subgroups (Table 2) • Rates of adverse events (AEs), serious AEs, and AEs leading to drug withdrawal were low in all treatment groups • Conjunctivitis rates were lower in the Asian and Black relative to White subgroup (Table 3) Figure 4. Baseline demographic and disease characteristics of patients by racial subgroup in pooled E1/2/3 Table 2.
    keywords: black; ecztra; patients; placebo; tralokinumab; white
       cache: skin-1834.pdf
  plain text: skin-1834.txt

        item: #594 of 1356
          id: skin-1835
      author: Paller, Amy S; Silverberg, Jonathan I; Hong, Chih-ho; Cork, Michael; Puig, Luis; Arlert, Petra; Kurbasic, Azra; Soldbro, Lise; Simpson, Eric L
       title: The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial
        date: 2022-11-16
       words: 1757
      flesch: 41
     summary: Patients with at least baseline data available were included in the CDLQI adjusted mean change analysis (A), and patients with CDLQI ≥6 at baseline were included in the CDLQI reduction ≥6 analysis (B). At Week 16, problem with treatment affected patients ‘not at all’ over the past 7 days in 50.0/59.4% of tralokinumab (150/300 mg) treated patients vs 39.1% receiving placebo (Figure 2H) 0 5 10 15 20 25 30 35 40 45 0 2 4 6 8 10 12 14 16 31.0 39.5 15.9Tralokinumab 150 mg Q2W (n=84)
    keywords: cdlqi; leo; patients; pharma; placebo; tralokinumab
       cache: skin-1835.pdf
  plain text: skin-1835.txt

        item: #595 of 1356
          id: skin-1836
      author: Warren, Richard B; Reich, Kristian; Simpson, Eric L; Langley, Richard; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Vacko, Emilia; Gooderham, Melinda; Deleuran, Mette; Francisco Silvestre, Juan; Weidinger, Stefan; Blauvelt, Andrew
       title: 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis
        date: 2022-11-16
       words: 2845
      flesch: 41
     summary: o A recently presented interim safety analysis of adult patients with up to 42 months of exposure confirmed the safety profile of tralokinumab4 Maintained improvements in clinically relevant outcomes at 3 years of tralokinumab treatment • Patients were controlled (mild/no disease) for the majority of the 3 years of tralokinumab treatment (Figure 3) • PowerPoint Presentation 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis Richard B Warren1, Kristian Reich2, Eric Simpson3, Richard Langley4, Antonio Costanzo5, Hidehisa Saeki6, Peter Almgren7, Emilia Vacko7, Anna Carlsson7, Melinda Gooderham8, Mette Deleuran9, Juan Francisco Silvestre10, Stefan Weidinger11, Andrew Blauvelt12 1Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK; 2Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; 4Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada; 5Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milano, Italy; Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 6Department of Dermatology, Nippon Medical School, Tokyo, Japan; 7LEO Pharma A/S, Ballerup, Denmark; 8SKiN Centre for Dermatology, Peterborough, ON, Canada; Department of Dermatology, Queen's University, Kingston, ON, Canada; Probity Medical Research, Waterloo, ON, Canada; 9Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; 10Dermatology Department, Hospital General Universitario de Alicante, Alicante, Spain; 11Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 12Oregon Medical Research Center, Portland, OR, USA ECZTEND interim efficacy analysis set n=347 Age Median years (IQR) 42.0 (30.0; 53.0)
    keywords: data; ecztend; ecztra; leo; patients; pharma; tralokinumab; treatment; years
       cache: skin-1836.pdf
  plain text: skin-1836.txt

        item: #596 of 1356
          id: skin-1837
      author: Reich, Kristian; Simpson, Eric L; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; de Bruin-Weller, Marjolein; Blauvelt, Andrew
       title: Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest
        date: 2022-11-16
       words: 2830
      flesch: 39
     summary: All patients transferred from ECZTRA 1, 2, 3, 4, 5, and 7; Up to 42 months maximum tralokinumab exposure (≤1 year in PTs and ≤2.5 years in ECZTEND) Safety analysis set (n=1442) ECZTEND interim safety analysis set n=1442 Age Median years (IQR) 38.0 (27.0; 50.0) ECZTEND interim analysis baseline demographic and disease characteristics Table 2. AESIs in ECZTEND at April 30, 2021 data cut-off Conclusions • This analysis of 1442 patients with up to 42 months of treatment supports the long-term benefit-risk profile of targeted IL-13 inhibition with tralokinumab for patients with moderate- to-severe AD, with no new safety signals identified • Exposure-adjusted incidence rates of AEs of special interest were generally similar to or lower than rates reported during the short-term, placebo-controlled period up to Week 16 and declined over time • Overall, tralokinumab demonstrated sustained long-term improvement in extent and severity of atopic dermatitis over 104 weeks of treatment in ECZTEND Figure 1.
    keywords: ecztend; ecztra; patients; pharma; safety; tralokinumab; treatment; trial; week
       cache: skin-1837.pdf
  plain text: skin-1837.txt

        item: #597 of 1356
          id: skin-1838
      author: Paller, Amy; Hebert, Adelaide A; Jett, John E; Brown, Philip M; Rubenstein, David S; Piscitelli, Stephen C
       title: Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial
        date: 2022-11-16
       words: 1851
      flesch: 54
     summary: ■ Tapinarof cream 1% QD demonstrated significant efficacy versus vehicle and was well tolerated in adults and adolescents with moderate to severe AD in a 12-week phase 2b trial (NCT02564055)13,14 – Efficacy was generally maintained through the last trial visit, 4 weeks after completing treatment13,14 ■ In a phase 1 pharmacokinetics (PK) evaluation of tapinarof cream 1% in adults (n=6) with moderate to severe AD, there were low levels of systemic absorption that decreased from baseline to Day 21 of assessment (mean 1.2 ng ≥12 years old with a baseline PP-NRS score ≥4 who achieve a ≥4-point reduction in PP-NRS score by visit – Proportion of patients 2–12 years old with a baseline PP-NRS score ≥4 who achieve a ≥4-point reduction in PP-NRS score by visit – Mean change in PP-NRS score at each visit by age group Statistical Analyses ■ Safety analyses will include all patients who received at least one application of tapinarof ■ Analyses of efficacy endpoints will be based upon the safety population RESULTS Baseline Patient Demographics and Disease Characteristics ■ Overall, 36 patients were enrolled at nine sites in the US and Canada ■ Patients’ baseline demographics and disease characteristics are shown in Table 2 – Equal proportions of patients (33.3% [12/36]) were young children (2–6 years), children (7–11 years), and adolescents (12–17 years) – Most patients (77.8%) across the three groups had a vIGA-ADTM score of 3 (moderate) – Overall mean (standard deviation [SD]) EASI score was 23.8 (9.2), with a range of 8.2–49.6 indicating moderate to severe AD – Overall mean (SD) %BSA affected was 42.8% (15.1%), with a range of 26%–90% Table 2.
    keywords: children; patients; tapinarof; trial; years
       cache: skin-1838.pdf
  plain text: skin-1838.txt

        item: #598 of 1356
          id: skin-1839
      author: Baldwin, Hilary; Graber, Emmy; Fried, Richard G; Rieder, Evan A; Harper, Julie C; Alexis, Andrew F; Stein Gold, Linda; Hebert, Adelaide A; Del Rosso, James; Kircik, Leon; Grada, Ayman; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris
        date: 2022-11-16
       words: 1355
      flesch: 63
     summary: METHODS • A 10-person consensus panel of 8 dermatologists with expertise in the treatment of acne, including pediatric and skin of color focused expertise, one dermatologist /clinical psychologist, and one dermatologist/ psychiatrist was virtually convened using a three-step modified Delphi method to establish consensus on EPQ items that relate to how acne impacts the patient’s emotional functioning, social functioning, activities of daily living. AN EXPERT PANEL QUESTIONNAIRE FOR ASSESSING PATIENT-REPORTED AND CAREGIVER-REPORTED OUTCOMES IN ACNE VULGARIS Presented at Fall Clinical Dermatology Conference, 2022 – October 19-23, 2022 – Las Vegas, NV • Acne Vulgaris, hereinafter referred to as acne, affects up to 50 million Americans and is the most common skin condition in the United States (US).
    keywords: acne; dermatology; epq; panel; time
       cache: skin-1839.pdf
  plain text: skin-1839.txt

        item: #599 of 1356
          id: skin-184
      author: Sussman, Gordon; Hebert, Jacques; Gulliver, Wayne; Lynde, Charles; Yang, William H; Chambenoit, Olivier; Deutsch, Gretty; DeTakacsy, Frederica; Rihakova, Lenka
       title: Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
        date: 2017-10-27
       words: 1590
      flesch: 47
     summary: To assess the effect of optimized retreatment after relapse (defined as weekly urticaria activity score [UAS7] ≥16) in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who were clinically well controlled (UAS7 ≤6) following their first course of treatment with omalizumab • SECONDARY: Evaluation of dose step-up therapy in those who do not respond (UAS7 >6) to an initial dose of omalizumab 150 mg; assessment of the time to relapse in patients who initially were well controlled (UAS7 ≤6); and to evaluate the benefit of extending study treatment with omalizumab 300 mg in patients who are not yet clinically well controlled (UAS7 ≤6) after 24 weeks • EXPLORATORY: Evaluation of quality of life and occurrence of angioedema episodes DESIGN AND RATIONALE OF THE OPTIMA STUDY: RETREATMENT OR STEP-UP THERAPY WITH OMALIZUMAB IN PATIENTS WITH CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA (CIU/CSU) Presented at the Fall Clinical Dermatology Conference, October 12–15, 2017, Las Vegas, NV, USA Controlled at Week 24 – UAS7 ≤6 Not controlled at Week 24 UAS7 >6 Controlled at Week 24 – UAS7 ≤6 Controlled/ Mild UAS7 ≤16 Moderate/ Severe UAS7 ≥16 Omalizumab 300 mg 0 4 8 12 16 2420 0 4 8 0 412 W e ll c o n tr o ll e d w it h o u t re la p s e Weeks W e ll c o n tr o ll e d w it h r e la p s e N o t w e ll c o n tr o ll e d Follow-up Follow-up Follow-up Omalizumab 300 mg 1st
    keywords: dosing; omalizumab; uas7
       cache: skin-184.pdf
  plain text: skin-184.txt

        item: #600 of 1356
          id: skin-1840
      author: Fried, Richard G; Rieder, Evan A; Alexis, Andrew F; Baldwin, Hilary; Graber, Emmy; Harper, Julie C; Stein Gold, Linda; Hebert, Adelaide A; Del Rosso, James; Kircik, Leon; Grada, Ayman; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title:  Impact of acne on social functioning, emotional functioning, and activities of daily living among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in real-world community practices across the U.S. (PROSES Study)
        date: 2022-11-16
       words: 1585
      flesch: 60
     summary: EPQ6: How often does acne impact your “in real life” plans? 27.3% 24.5% 48.2%48.6%* 21.0% 30.4%^ 0.0% 100.0% Never/Rarely Some of the time Most/All of the time P ro po rti on o f p at ie nt s Baseline 12 weeks EPQ7: How often are you doing something to hide your acne? 73.1% 16.2% 10.7% 88.1%* 8.7% 3.2%** 0.0% 100.0% Never/Rarely Some of the time Most/All of the time P ro po rti on o f p at ie nt s Baseline 12 weeks EPQ8: How often do you feel picked on or judged because of your acne? 72.7% 13.0% 14.2% 86.6%* 8.3% 5.1%^^ 0.0% 100.0% P ro po rti on o f p at ie nt s Baseline 12 weeks EPQ9: How concerned are you that your acne will affect your ability to reach your future goals (in school or work) and be the best you can be? 15.8% 25.7% 58.4% 16.8% 20.8% 62.4% 0.0% 100.0% Not at all/A little Somewhat Quite a bit/Very Much P ro po rti on o f p at ie nt s Baseline 12 weeks EPQ10: Do you feel that your parents understand your acne- related concerns? Sarecycline is a viable option for acne patients to reduce disease burden, due to its safety profile and efficacy demonstrated in two identical Phase-III randomized controlled trials.
    keywords: acne; baseline; time
       cache: skin-1840.pdf
  plain text: skin-1840.txt

        item: #601 of 1356
          id: skin-1841
      author: Graber, Emmy; Baldwin, Hilary; Harper, Julie C; Stein Gold, Linda; Grada, Ayman; Alexis, Andrew F; Hebert, Adelaide A; Fried, Richard G; Rieder, Evan A; Del Rosso, James; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail; Kircik, Leon
       title: Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study)
        date: 2022-11-16
       words: 1939
      flesch: 67
     summary: • Assessing the impact of sarecycline treatment on acne patient outcomes, including patient QoL, in real-world community practice settings highlights the humanistic and clinical benefits associated this narrow-spectrum antibiotic treatment option. • Majority of acne patients had significant reduction in acne severity, and majority (58.9%) had IGA success at week-12.
    keywords: acne; f p; o f; p ro
       cache: skin-1841.pdf
  plain text: skin-1841.txt

        item: #602 of 1356
          id: skin-1842
      author: Kircik, Leon; Draelos, Zoe D; Guenin, Eric
       title: Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability
        date: 2022-11-16
       words: 1321
      flesch: 57
     summary: Wk12 BL Wk12 BL Wk12 BL Wk12 BL Wk12 BL Wk12 CONCLUSIONS � Tazarotene 0.045% lotion utilizes polymeric emulsion technology to enhance hydration, moisturization, and skin barrier function � Tazarotene 0.045% lotion led to statistically significant reductions in truncal acne severity and lesion counts; ~90% of subjects achieved clear or almost clear skin with 12 weeks of once-daily use and most subjects had no tolerability issues � This easy-to-apply tazarotene lotion was associated with less irritation and ~30% greater skin coverage compared with trifarotene cream • Less product needed to cover the same skin area equals more applications per unit volume REFERENCES 1. On average, skin coverage with tazarotene 0.045% lotion was ~30% greater than with trifarotene 0.005% cream Study 3 Design Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability Leon H Kircik, MD1-3; Zoe D Draelos, MD4; Eric Guenin, PharmD, PhD, MPH5 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Indiana University Medical Center, Indianapolis, IN; 3Physicians Skin Care, PLLC, DermResearch, PLLC, and Skin Sciences, PLLC, Louisville, KY; 4Dermatology Consulting Services, PLLC, High Point, NC; 5Ortho Dermatologics*, Bridgewater, NJ *Ortho Dermatologics is a division of Bausch Health US, LLC STUDY 1: EFFICACY, SAFETY, AND TOLERABILITY IN TRUNCAL ACNE Tazarotene 0.045% Lotion8 • Subjects aged ≥12 years • Moderate truncal acne (Investigator’s Global Assessment score = 3) • Once-daily treatment with tazarotene 0.045% lotion for 12 weeks • Age (mean): 24.1 years • Sex: 52.6% female • Race: 52.6% White, 36.8% Black, 10.5% Biracial Study 1 Design Demographics Total Lesion Reductions -100% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e -80% -44.9% *** Tazarotene 0.045% Lotion (n=19) -67.7% *** -82.3% *** LS mean percent changes from baseline: IL -49.4%*** -63.8%***
    keywords: cream; day; lotion; study; tazarotene
       cache: skin-1842.pdf
  plain text: skin-1842.txt

        item: #603 of 1356
          id: skin-1844
      author: Feldman, Steven R; Han, George; Callender, Valerie; Kircik, Leon; Stein Gold, Linda; Bhatia, Neal; Tyring, Stephen K; Zeichner, Joshua
       title: Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat
        date: 2022-11-16
       words: 1287
      flesch: 41
     summary: WHAT IS NNT? � NNT is a metric for quantifying effect sizes of clinically relevant study endpoints1 � NNT represents the number of patients needed to treat to achieve an additional cure in a given timeframe1-3 • For example, NNT=3 means that 3 patients would need to be treated with active drug rather than vehicle before expecting an additional responder2 HOW IS NNT USED? IS NNT CALCULATED? � NNT is the reciprocal of the absolute risk reduction (ARR), rounded up to the nearest whole number1-3 WHAT ARE SOME LIMITATIONS OF NNT? Evaluates one binary outcome (eg, week 12 treatment success)2,4 No consideration of drug tolerability or study design/ population differences1-4 Clinical meaning subject to interpretation5 Bene�ts of a well- designed vehicle subtracted from active treatment,a leading to higher NNT values aDue to the potential of a well-designed vehicle to result in higher efficacy rates in the control group.
    keywords: acne; clin; dermatologics; nnt; ortho; treatment
       cache: skin-1844.pdf
  plain text: skin-1844.txt

        item: #604 of 1356
          id: skin-1845
      author: Zhang, Qian; Zhang, Dong; Wang, Li; Zhang, Rongli; Wei, Jingyi; Gao, Lin; Zhang, Xianghua; Kerob, Delphine; Zhang, Zhongxing
       title: Efficacy Evaluation of a Dermocosmetic with Skin Repair Properties after Fractional Laser Surgery in Acne Scars
        date: 2022-11-16
       words: 1018
      flesch: 58
     summary: 84 adults (76 women, 8 men) who underwent acne scar fractional laser were included in this open label study. Fragility of epidermis: acne and post-procedure lesional skin.
    keywords: machine; tapé; texte; texte tapé
       cache: skin-1845.pdf
  plain text: skin-1845.txt

        item: #605 of 1356
          id: skin-1848
      author: Bhatia, Neal; Armstrong, April W; Schlesinger, Todd; Kircik, Leon; Berman, Brian; Lebwohl, Mark; Rigel, Darrell; Patel, Vishal A; Del Rosso, James; Grada, Ayman; Narayanan, Siva; Kasujee, Ismail
       title: An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis
        date: 2022-11-16
       words: 1651
      flesch: 47
     summary: The panel discussed nine PROs encompassing cosmetic outcomes (‘overall appearance of the skin’, ‘ability to improve how skin looks’, ‘ability to improve skin texture’), effects of Local Skin Reactions (‘compared to previous topical treatment experience’, relative rating of ‘duration of skin reactions’, ‘severity of skin reactions’, impact on your daily activities’), relative convenience/ease of use of new treatment, overall satisfaction with new treatment, and likelihood of future use. If patient has used a topical treatment in the past: Compared to your previous experience with topical treatment X for AK, how would you rate your overall satisfaction (considering the factors such as convenience / ease of use, duration and severity of skin reactions, impact on daily life, etc.) with Treatment Y?
    keywords: patient; scale; skin; treatment
       cache: skin-1848.pdf
  plain text: skin-1848.txt

        item: #606 of 1356
          id: skin-1849
      author: Stevens, Greg; Jansen, Burkhard; Arnold, Terry; Rock, James; Wood, Jennifer; Hyde, Mark; Clarke, Loren
       title: Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis
        date: 2022-11-16
       words: 1126
      flesch: 55
     summary: In previous studies, the test was found to have a negative predictive value ≥99%. This approach improves pigmented lesion management beyond visual inspection with a negative predictive value of ≥99% and a sensitivity of 91-97%, and by enriching melanoma among biopsied lesions almost 5-fold.1-3 The real-world performance of the test and its impact on clinical practice has been addressed in a previously completed 2020 patient registry, and summarized in 2 peer reviewed publications.3,4 The objective of this study was to better understand the real-world utility of the test using a nationwide registry.
    keywords: lesions; melanoma; test
       cache: skin-1849.pdf
  plain text: skin-1849.txt

        item: #607 of 1356
          id: skin-185
      author: Hide, Michihiro; Park, Hae-Sim; Igarashi, Atsuyuki; Ye, Young-Min; Kim, Tae-Bum; Yagami, Akiko
       title: Efficacy and Safety of Omalizumab in Japanese and Korean Patients with Chronic Idopathic/Spontaneous Urticaria (CIU/CSU: Results from the Phase 3 POLARIS Study
        date: 2017-10-27
       words: 2925
      flesch: 53
     summary: UAS7 =0 • Safety was assessed through the summary of adverse events (AEs) Statistical analysis • A linear mixed model with repeated measures (country stratum, treatment group, week, and treatment-by-week interaction included as fixed effects, patient as a random effect, and baseline score as a covariate) was used to estimate treatment differences for the primary variable and selected secondary variables, including change from baseline to Week 12 in UAS7 and HSS7 • Treatment comparisons for proportions of patients at Week 12 with ISS7 MID response, UAS7 ≤6, and UAS7 =0 were performed using a logistic regression model (country stratum and treatment group as factors, and baseline value as a covariate) The difference in the proportions of responders in the active treatment and placebo groups was increased at the later assessments and were greater with omalizumab 300 mg than with omalizumab 150 mg (Figure 6) •
    keywords: baseline; omalizumab; placebo; treatment; uas7; week
       cache: skin-185.pdf
  plain text: skin-185.txt

        item: #608 of 1356
          id: skin-1850
      author: Lampley III, Nathaniel; Schlesinger, Todd; Rigo, Rachel; Rossi, Anthony M
       title: Review of Efficacy, Cost, and Adherence of Field Therapies for Actinic Keratosis
        date: 2022-11-16
       words: 593
      flesch: 47
     summary: Effective cost (EC) was calculated by dividing total cost (TC) by the clearance rate (CR), EC=TC/CR. However, total cost of 5-FU ranges from $433 (4% cream) to $1503 (0.5% cream), whereas total cost for a single round of PDT with 10% ALA gel is $540.
    keywords: cost; pdt
       cache: skin-1850.pdf
  plain text: skin-1850.txt

        item: #609 of 1356
          id: skin-1851
      author: Shim, Paul; Zeitouni, Nathalie
       title: Long-term Follow Up of ALA 10% Gel and Red-Light Photodynamic Therapy for the Treatment of Squamous Cell Carcinoma In Situ
        date: 2022-11-16
       words: 418
      flesch: 42
     summary: Synopsis • Nine out of the original twelve patients in the pilot study returned for evaluation at least one year after their last PDT treatment • Clinical assessment and possible punch biopsy were performed to evaluate clinical and histopathologic recurrence of SCCis • Cosmetic outcomes (rated 1-4) per the patient and investigator as well as patient satisfaction with PDT treatment were evaluated Methods ALA 10% gel with red-light PDT is effective to treat and induce long-term remission of SCCis of the trunk and extremities. 2021;35:102358 * one of the patients that declined biopsy had a previous negative biopsy performed 6 months after last PDT Long-term Follow Up of ALA 10% Gel and Red-Light Photodynamic Therapy for the Treatment of Squamous Cell Carcinoma In Situ Paul Shim1, Nathalie Zeitouni MD1, 2 1 University of Arizona College of Medicine, Phoenix, Arizona 2 Medical Dermatology Specialists, Phoenix, Arizona This study was investigator-initiated and funded by Biofrontera, Inc.
    keywords: gel
       cache: skin-1851.pdf
  plain text: skin-1851.txt

        item: #610 of 1356
          id: skin-1852
      author: Bierhoff, E; Cohen, JL; Szeimies, RM; Reinhold, U; Dirschka, T
       title: Efficacy of red-light photodynamic therapy with 10% ALA gel in relation to the epidermal extent of atypical keratinocytes in actinic keratosis - Retrospective exploratory analysis of three pivotal phase III trials
        date: 2022-11-16
       words: 1014
      flesch: 59
     summary: AK lesion clearance rates when using red-light PDT with 10% ALA gel or MAL does not seem to depend on KIN grades (I-III). [4]), see Figure 1A Treatment • e.g. red-light photodynamic therapy (PDT) with 10% 5-aminolevulinic acid (ALA) gel or methyl aminolevulinate (MAL) cream (not available in US) 98 19 11 3 139 30 155 3 18 1 203 4 Figure 1B: AK lesion clearance rates by treatment and KIN grade Each bar represents the percentage of AK lesions cleared/not cleared with the respective photosensitizing prodrug (10% ALA gel, MAL) or vehicle and red-light illumination, with color code indicating lamp type:
    keywords: ala; gel
       cache: skin-1852.pdf
  plain text: skin-1852.txt

        item: #611 of 1356
          id: skin-1853
      author: Schwartz, Ziv; Goldenberg, Gary
       title: Photodynamic Therapy for Facial Actinic Keratosis with Aminolevulinic Acid 10% Gel, Microneedling, and Red-Light Illumination
        date: 2022-11-16
       words: 685
      flesch: 56
     summary: The present study evaluated aesthetic improvement, AK clearance, pain during treatment, and adverse events in five subjects treated by PDT with microneedling-assisted delivery of 10% ALA gel and red-light illumination. METHODS A prospective 3-month study was conducted to evaluate aesthetic improve- ment and AK clearance relative to baseline in each of five subjects treated by PDT with microneedling-assisted delivery of 10% ALA gel and red-light illumination.
    keywords: pain
       cache: skin-1853.pdf
  plain text: skin-1853.txt

        item: #612 of 1356
          id: skin-1854
      author: Goldberg, Matthew S; Siegel, Jennifer J; Ahmed, Kelli; Kurley, Sarah J; Farberg, Aaron S
       title: A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC)
        date: 2022-11-16
       words: 1608
      flesch: 49
     summary: What is the patient’s risk of developing nodal or distant metastasis? Pre-GEP Post-GEP n % of Class 1* Pre-GEP Post-GEP n % of Class 2A 5-10% <5% 12 23.5% <5% 10-30% 3 42.9% 10-30% <5% 1 2.0% 5-10% 10-30% 2 28.6% 6 Au, et al. 2021 Case reports of patients retrospectively tested with 40-GEP 2 patients The utility of the 40-GEP test to provide additional information for guiding patient management decisions and improving outcomes is demonstrated by two cases with identical tumor staging, yet divergent outcomes.
    keywords: gep; management; patients; risk
       cache: skin-1854.pdf
  plain text: skin-1854.txt

        item: #613 of 1356
          id: skin-1855
      author: Siegel, Jennifer J; Prasai, Anesh; Farberg, Aaron S; Goldberg, Matthew S
       title: Performance and clinical decision-making using the prognostic 40-gene expression profile (40-GEP) test in 1,018 patients with high-risk cutaneous squamous cell carcinoma (SCC)
        date: 2022-11-16
       words: 1026
      flesch: 48
     summary: › When cohorts are combined, the 40-GEP continues significant performance in identifying metastatic risk, as shown with patients receiving Class 2A and Class 2B results incurring a 4- and 11-fold increase in metastasis, respectively, when compared to those with Class 1 results. Class 1 0.4x 0.4x Class 2A 1.3x 1.7x Class 2B 3.5x 3.6x Table 2. 40-GEP accurately and consistently stratifies metastatic risk Presented at Fall Clinical Dermatology Conference, October 20-23, 2022, Las Vegas NV For more information: jsiegel@castlebiosciences.com 10.
    keywords: class; gep; patients; risk
       cache: skin-1855.pdf
  plain text: skin-1855.txt

        item: #614 of 1356
          id: skin-1856
      author: Jarell, Abel; Bailey, Christine; Martin, Brian; Prieto, Peter
       title: The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can safely forego sentinel lymph node biopsy
        date: 2022-11-16
       words: 994
      flesch: 65
     summary: › All patients identified as having <5% risk by the i31-GEP had upper 95% CIs ≤10%; meaning none of these patients would have been ‘offered’ an SLNB under current guidelines. › In contrast, using the MIA nomogram, only 0.9% of the entire cohort had an SLN+ risk <5% with 95% CI ≤10%, suggesting lack of confidence in the estimate of risk and, thus, in the decision to forgo the SLNB.
    keywords: risk
       cache: skin-1856.pdf
  plain text: skin-1856.txt

        item: #615 of 1356
          id: skin-1857
      author: Jarell, Abel; Martin, Brian; Prieto, Peter
       title: The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms CP-GEP at identifying patients who can safely forego sentinel lymph node biopsy
        date: 2022-11-16
       words: 810
      flesch: 71
     summary: 2. Vickers et al. BMJ 2015. The 31-gene expression profile (GEP) was developed and validated to predict a patient’s risk of recurrence and further validated to precisely predict a patient’s individualize risk for a positive SLNB.
    keywords: gep; slnb
       cache: skin-1857.pdf
  plain text: skin-1857.txt

        item: #616 of 1356
          id: skin-1858
      author: Farberg, Aaron S; Ahmed, Kelli; Rackley, Briana B; Siegel, Jennifer J; Russell, Brooke H; Rogers, Jason H; Kurley, Sarah J; Goldberg, Matthew S
       title: A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence
        date: 2022-11-16
       words: 890
      flesch: 45
     summary: GEP results impact surgical excision planning, including margin decisions Here we present dermatologist management plans and confidence utilizing diagnostic GEP results in uncertain clinical and diagnostic scenarios. The study was supported by Castle Biosciences, Inc. Results Aaron S Farberg, MD1, Kelli L Ahmed, PhD2, Briana B Rackley, PhD2, Jennifer J Siegel, PhD2, Brooke H Russell, PhD2, Jason H Rogers, MSc2, Sarah J Kurley, PhD2, and Matthew S Goldberg, MD2,3 1Baylor Scott & White Health System, Dallas, TX 2Castle Biosciences, Inc., Friendswood, TX 3Icahn School of Medicine at Mount Sinai, New York, NY For more information: afarberg@castlebiosciences.com Methods › Clinicians were invited for study participation based on prior use of diagnostic GEP testing (minimum 3 encounters with GEP results).
    keywords: gep; results
       cache: skin-1858.pdf
  plain text: skin-1858.txt

        item: #617 of 1356
          id: skin-1859
      author: Arron, Sarah T; Fitzgerald, Alison L; Siegel, Jennifer J; Prasai, Anesh; Rackley, Briana B; Kurley, Sarah J; Moody, Brent
       title: How Mohs surgeons utilize prognostic testing for high-risk cutaneous squamous cell carcinoma (SCC): a clinical impact study
        date: 2022-11-16
       words: 1201
      flesch: 55
     summary: Following NCCN guidelines Always Often Sometimes Rarely Never Staging System used AJCC8* BWH** Both I assess patients with risk factors only Familiarity with GEP testing for SCC Not familiar Somewhat familiar Very familiar I have used a GEP test for SCC Patient Vignette › 68-year-old male › 2.6 diameter lesion on left temple › Biopsy confirmed SCC › Infiltrating subtype › Poor differentiation Figure 3. The study consisted of demographic questions, familiarity with and use of NCCN guidelines, AJCC-8 staging, BWH staging, and the 40-GEP. › Participants (n=39) were provided with background on the validation of the 40-GEP test, then evaluated the use of risk factors for the assessment of SCC patients within their practice and which were concerning enough to warrant the use of the 40-GEP.
    keywords: class; gep; risk; scc
       cache: skin-1859.pdf
  plain text: skin-1859.txt

        item: #618 of 1356
          id: skin-186
      author: Clark, Ryan; Bozkaya, Duygu; Levenberg, Mark; Faulkner, Steven; Smith, Timothy W; Gerber, Robert A
       title: Topical Treatment Utilization for Patients with Atopic Dermatitis in the United States and Budget Impact Analysis of Crisaborole Ointment, 2%
        date: 2017-10-27
       words: 2549
      flesch: 65
     summary: Patient Demographics, and Diagnosis and Treatment Rates from RWTUC Analysis* Age category (years) 2-11 12-17 18-64 65+ Total Age distribution among patients ≥2 years 11.39% 8.47% 71.27% 8.87% 100% Number of patients by age** 111,087 82,608 695,096 86,509 975,300 AD diagnosis rate by age 2.40% 1.14% 0.54% 0.69% Number of patients diagnosed with AD by age** 2,666 942 3,754 597 7,958 TCI/TCS % receiving TCI/TCS among diagnosed 50.30% 60.25% 65.14% 58.99% Number of AD patients receiving TCI/TCS treatment** 1,341 567 2,445 352 4,706 TCI Only % receiving TCI among diagnosed 4.60% 7.13% 5.61% 2.28% Number of AD patients receiving TCI treatment** 123 67 211 14 414 Key: AD – atopic dermatitis; BIM – budget impact model; RWTUC – real-world utilization and costs; TCI – topical calcineurin inhibitor; TCS – topical corticosteroid. BIM Results 285 332 4,292 4,031 3,989 414 389 385 0 1,000 2,000 3,000 4,000 5,000 Current Year 1 Year 2 Number of patients per treatment per year Crisaborole TCS TCI ± TCS A TCI Population 84 88 414 330 326 0 100 200 300 400 500 Current Year 1 Year 2 Number of patients per treatment per year Crisaborole TCI ± TCS D $0.109 $0.109 $0.123 $0.125 $0.014 $0.016 $0.000 $0.050 $0.100 $0.150 Year 1 Year 2 PMPM budget impact over 2 years: $0.015 Without crisaborole With crisaborole B $1,311,174 $1,311,174 $1,473,279 $1,500,014 $162,106 $188,841 $0 $500,000 $1,000,000 $1,500,000 $2,000,000 Year 1 Year 2 Total budget impact over 2 years: $350,946 Without crisaborole With crisaborole C $405,793 $405,793 $394,633 $394,081 -$11,160 -$11,712 $0 $100,000 $200,000 $300,000 $400,000 $500,000 Year 1 Year 2 Total budget impact over 2 years: -$22,871 Without crisaborole With crisaborole F TCS/TCI Population $0.034 $0.034 $0.033 $0.033 -$0.001 -$0.001 $0.000 $0.010 $0.020 $0.030 $0.040 Year 1 Year 2 PMPM budget impact over 2 years: -$0.001 Without crisaborole With crisaborole E Key: AD – atopic dermatitis; BIM – budget impact model; TCI – topical calcineurin inhibitor; TCS – topical corticosteroid.
    keywords: crisaborole; patients; tci; tcs; year
       cache: skin-186.pdf
  plain text: skin-186.txt

        item: #619 of 1356
          id: skin-1860
      author: King, Brett; Bergfeld, Wilma; Brzewski, Pawel; Aşkin, Özge; Passeron, Thierry; Randhawa, Simaran; Law, Ernest; Edwards, Roger A; Wolk, Robert; Zwillich, Samuel H; Lejeune, Alexandre
       title: Impact of Disease History on the Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
        date: 2022-11-16
       words: 2106
      flesch: 48
     summary: Thierry Passeron,5,6 Simran Randhawa,7 Ernest Law,7 Roger A. Edwards,8 Robert Wolk,7 Samuel H. Zwillich,7 Alexandre Lejeune9 1Yale University School of Medicine, New Haven, CT, USA; 2Cleveland Clinic, Cleveland, OH, USA; 3Department of Dermatology, Collegium Medicum, Jagiellonian University, Krakow, Poland; 4Cerrahpaşa Medical Faculty, Department of Dermatology and Venerology, Istanbul University-Cerrahpaşa, Istanbul, Turkey; 5Université Côte d’Azur, CHU Nice, Department of Dermatology, Nice, France; 6Université Côte d’Azur, INSERM, U1065, C3M, Nice, France; 7Pfizer Inc, USA; 8Health Services Consulting Corporation, Boxborough, MA, USA; 9Pfizer Inc, Paris, France BACKGROUND • Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis and is characterized by non scarring hair loss ranging from small bald patches to complete loss of scalp, face, and/or body hair1 • Ritlecitinib, an oral JAK3/TEC inhibitor, demonstrated efficacy and safety in patients aged ≥12 years with AA in the ALLEGRO phase 2b/3 study (NCT03732807)2 • Disease history, including disease duration and/or episode duration, has been associated with severity, prognosis, and treatment efficacy in AA3-5 OBJECTIVE • This post hoc analysis aimed to assess the impact of disease duration and duration of current AA episode on response to ritlecitinib • Descriptive analyses were further conducted to analyze the contribution of current episode duration on response to ritlecitinib METHODS Study design • The ALLEGRO phase 2b/3 trial was an international, randomized, double-blind, placebo-controlled, combined dose-ranging and pivotal phase 2b/3 study (Figure 1) • Patients received daily ritlecitinib (with or without a 200-mg loading dose in the first 4 weeks): 200/50, 200/30, 50, 30, or 10 mg (10 mg assessed for dose ranging only), or placebo for 24 weeks • During the 24-week extension, ritlecitinib groups continued on the 50-, 30-, or 10-mg maintenance doses, and patients initially assigned to placebo switched to ritlecitinib 200/50 or 50 mg daily Key eligibility criteria • In this post hoc analysis, multivariable logistic regression with 2 different variable selection methods was used to evaluate the effect of ritlecitinib (vs placebo), baseline disease duration, and current AA episode duration (both <1 year vs ≥1 year) on response based on Severity of Alopecia Tool (SALT) score ≤20 (≤20% scalp without hair) at Week 24, while controlling for other covariates - Covariates listed below were included in the models to evaluate the independent effect of disease and episode duration:
    keywords: duration; episode; placebo; ritlecitinib; year
       cache: skin-1860.pdf
  plain text: skin-1860.txt

        item: #620 of 1356
          id: skin-1861
      author: Zhang, Xingqi; Magnolo, Nina; Mizuashi, Masato; Mesinkovska, Natasha; Shapiro, Jerry; Zhang, Fan; Kerkmann, Urs; Law, Ernest; Wolk, Robert; Schaefer, Gregor
       title: Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
        date: 2022-11-16
       words: 1924
      flesch: 53
     summary: The ALLEGRO phase 2b/3 trial was an international, randomized, double-blind, placebo-controlled, combined dose-ranging and pivotal phase 2b/3 study (Figure 1) • Patients received once daily ritlecitinib (± a 4-week 200-mg daily loading dose): 200/50 mg, 200/30 mg, 50 mg, 30 mg, 10 mg (10 mg assessed for dose ranging only), or placebo for 24 weeks • During the 24-week extension, ritlecitinib groups continued receiving their 50, 30, or 10 mg maintenance doses, and patients initially assigned to placebo switched to 200/50 or 50 mg daily Key eligibility criteria • Patients aged ≥12 years with a diagnosis of AA and ≥50% scalp hair loss, including those with AT and AU, and a current AA episode duration of 6 months to 10 years Figure 1. At Week 48, up to 49%, 50%, and 64% of patients had a PGI-C response in the AT/AU, AT, and AU subgroups, respectively, vs up to 73% in the non-AT/non-AU subgroup Presented at the 2022 Fall Clinical Dermatology Conference; October 20 - 23, 2022; Las Vegas, Nevada REFERENCES 1.
    keywords: mg qd; qd rit; rit
       cache: skin-1861.pdf
  plain text: skin-1861.txt

        item: #621 of 1356
          id: skin-1862
      author: Ständer, Sonja; Weisshaar, Elke; Parish, Jennifer L; Szepietowski, Jacek C; Reich, Adam; Korman, Neil J; Bortey, Enoch; Sciascia, Thomas R
       title: Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study
        date: 2022-11-16
       words: 1306
      flesch: 57
     summary: Summary • The PRISM study met its primary end point and all key secondary end points – A significantly higher percentage of participants experienced an antipruritic response on week 14 with NAL ER (24.7%) versus placebo (13.9%) – Compared with placebo, NAL ER treatment also resulted in • Greater improvement in ItchyQoL at weeks 6, 10, and 14 • Greater improvement in pruriginous lesions with excoriations/crusts at weeks 10 and 14 • The safety profile of NAL ER was consistent with its known safety profile – A 36-week open-label study is ongoing to assess the long-term safety and efficacy • Use of NAL ER may provide a novel oral treatment approach References 1. The IV formulation of nalbuphine is an unscheduled opioid (ie, not controlled under the Controlled Substances Act by the Drug Enforcement Agency) in the United States and most of Europe6,7 • NAL ER may improve the balance of κ- and μ-opioid receptor activity and therefore may be an oral treatment option for patients with PN-related pruritus8 Objective • To assess the antipruritic and lesion-reducing efficacy and safety of oral NAL ER in patients with PN in the phase 2b/3 PRISM trial Methods Study Design • PRISM (NCT03497975) was a randomized, double-blind, placebo-controlled, phase 2b/3 trial of adult patients with confirmed PN, ≥10 pruriginous nodules on ≥2 distinct anatomical areas, and WI-NRS score ≥7 • Participants received oral NAL ER 162 mg or placebo twice daily •
    keywords: nal; opioid; phase; placebo
       cache: skin-1862.pdf
  plain text: skin-1862.txt

        item: #622 of 1356
          id: skin-1863
      author: Kim, Brian S; Bissonnette, Robert; Nograles, Kristine; Munera, Catherine; Shah, Nilam; Jebara, Alia; Cirulli, Joshua; Goncalves, Joana; Lebwohl, Mark
       title: A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
        date: 2022-11-16
       words: 1712
      flesch: 58
     summary: • Here we report the results of the phase 2 study (KOMFORT; NCT04706975) evaluating oral DFK for the treatment of moderate-to-severe pruritus in subjects with NP METHODS Study Design • KOMFORT was conducted in adults with a clinically confirmed diagnosis of NP • SYNOPSIS • Notalgia Paresthetica (NP) is a common sensory neuropathy of the back characterized by chronic pruritus1 • There are no approved therapies for NP • Difelikefalin (DFK) activates kappa-opioid receptors on peripheral sensory neurons and suppresses itch predominantly by a neuromodulatory effect – Intravenous (IV) DFK is approved for the treatment of moderate-to-severe pruritus in adults with chronic kidney disease undergoing hemodialysis2-5 o IV DFK is not addictive and is not a controlled substance – Oral DFK is being developed across numerous chronic pruritic conditions6 OBJECTIVE
    keywords: baseline; dfk; nrs; placebo; week
       cache: skin-1863.pdf
  plain text: skin-1863.txt

        item: #623 of 1356
          id: skin-1864
      author: Chovatiya, Raj; Aldredge, Lakshi; Heath, Candrice; Acevedo, Moises; Chu, David; Hanna, Dianne; Seal, Melissa; Zirwas, Matthew
       title: Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States
        date: 2022-11-16
       words: 2119
      flesch: 45
     summary: 1Northwestern University, Chicago, IL, USA; 2Veterans Administration Portland Health Care System, Portland, OR, USA; 3Temple University, Philadelphia, PA, USA; 4 Park Plaza Dermatology, New York, NY, USA; 5Arcutis Biotherapeutics, Westlake Village, CA, USA; 6Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States • Patients reported visiting an average of 2.3 HCPs for SD treatment and 75% have seen more than one HCP • Patients said they visit their primary HCP for SD management an average of 4.6 times per year, and 85% said they still actively work with their HCP for SD treatment – Of the 15% of patients who have stopped visiting their HCP, the reasons were improvement in symptoms (50%), ability to manage SD without prescription treatments (24%), and difficulty navigating insurance coverage for treatments (20%) (Figure 8) 90% of patients wish they had known that there are specific symptoms that can help identify SD 83% “I didn’t realize all of my symptoms (e.g., on face, body, scalp, etc.) were due to SD” agree 76% “I mistook my symptoms for a different type of skin condition” agree71% “I had not heard of SD prior to my diagnosis” agree 0 20 40 60 80 100 No one else but HCP Other Esthetician Other with SD or similar condition Nutritionist Friends Hairstylist/Barber Family member Patients (%) 45% 25% 22% 19% 19% 14% 5% 24% 0 20 40 60 80 100 None of these Worried about safety of treatments prescribed Treatment options were too expensive Lack of prescription treatment options that worked Insurance coverage for treatments was too difficult to navigate Ability to manage symptoms without prescription treatments Improvement in symptoms Patients (%) 50% 24% 20% 16% 13% 5% 13% Patient is actively meeting with HCP to manage SD REFERENCE “I didn’t think my symptoms were severe enough to warrant medical attention” “Most did not think that SD symptoms warranted medical attention” 63% Patients agree 66% HCPs agree “I was embarrassed to talk to my family or friends about my symptoms” “Most were embarrassed to talk to their family or friends about their symptoms” 59%
    keywords: figure; hcp; hcps; patients; symptoms
       cache: skin-1864.pdf
  plain text: skin-1864.txt

        item: #624 of 1356
          id: skin-1865
      author: Nestor, Mark S; Han, Haowei; Gade, Anita; Ceci, Francesca; Lawson, Alec; Dunn, Austin; Yousefian, Faraz; Smythe, Ciaran
       title: A Pilot Study, to Evaluate the Safety and Efficacy of Topically Applied Onabotulinum Toxin A Delivered through a Novel Iontophoresis Device in Subjects with Axillary Hyperhidrosis
        date: 2022-11-16
       words: 828
      flesch: 55
     summary: % -81% Subject 5 0% -69% -72% -70% Subject 6 0% -67% -60% -81% Subject 7 0% -9% -52% -60% 0% -30% 11% -7% 0% -54% -37% -81% 0% -69% -72% % -60% -100% -80% -60% -40% -20% 0% 20% Gravimetric Sweat Measurements Relative to Baseline Baseline 243.7 mg Day 28 76.3 mgGravimetric Tests: Figure 1.
    keywords: hyperhidrosis; toxin; treatment
       cache: skin-1865.pdf
  plain text: skin-1865.txt

        item: #625 of 1356
          id: skin-1866
      author: Berman, Brian; Tomondy, Paul
       title: Human Skin Absorption and Penetration Study of Four Different Topical Formulations of 5-Fluorouracil
        date: 2022-11-16
       words: 784
      flesch: 55
     summary: • We report a 20-fold reduced penetration of FU in the presence of vaseline (FU+V), and a 73% reduction in FU penetration in the presence of calcipotriol ointment (FU+C). This markedly reduced penetration of FU in the presence of vaseline (FU+V), taken with the 73% reduction in FU penetration in the presence of calcipotriol ointment (FU+C), further point to the inappropriateness of using a FU+V combination as a control for clinical studies and could lead to erroneous superiority claims.
    keywords: fu+v
       cache: skin-1866.pdf
  plain text: skin-1866.txt

        item: #626 of 1356
          id: skin-1867
      author: Passeron, T; Dreno, B; Puig, S; Goh, CL; Kang, HY; LY, F; Morita, A; Ocampo Candiani, J; Schalka, S; Wei, L; Le Floc’h, C; Kerob, D; Lim, HW; Krutmann, J
       title: Sun Exposure and Associated Risks in 17 Countries: Results from Europe Compared to Other Continents
        date: 2022-11-16
       words: 1211
      flesch: 60
     summary: % 21% 40% NOT WELL/DK 58% NOT WELL/DK 74% HOW TANNING IS PERCEIVED Non-Europeans countries in comparison were less represented in phototype 1-2 (43%).
    keywords: europe; europeans; protection; sun
       cache: skin-1867.pdf
  plain text: skin-1867.txt

        item: #627 of 1356
          id: skin-1868
      author: Schwartz, Chelsea; Lassiter , Samuel; Cleaver , David; Cleaver , Nathan
       title: A Rare Case of Cutaneous Anaplastic Large Cell Lymphoma in an Adolescent Female 
        date: 2023-01-10
       words: 1673
      flesch: 51
     summary: Histologically, this tumor typically displays cohesive sheets of large cells with a pleomorphic, anaplastic or immunoblastic CASE REPORT DISCUSSION SKIN January 2023 Volume 7 Issue 1 (c) 2022 THE AUTHORS. In comparison, PC-ALCL tends to display larger skin lesions (>1cm) and ulceration is common.
    keywords: alcl; cell; lymphoma; primary
       cache: skin-1868.pdf
  plain text: skin-1868.txt

        item: #628 of 1356
          id: skin-1869
      author: Chovatiya, Raj; Daftary, Karishma
       title: Unilateral and Localized Bullous Eruption in a 71-year-old Woman
        date: 2023-01-10
       words: 927
      flesch: 44
     summary: While widespread immunobullous eruptions like BP are well-described cutaneous adverse reactions associated with anti- CTLA-4 and -programmed cell death protein- 1 (PD-1) immunotherapy, reports of LBP following the use of these medications are extraordinarily rare.6 Diagnosis of LBP is often delayed compared to generalized BP, as the differential diagnosis of a localized bullous eruption on the leg is broad and includes trauma (e.g., burn, friction, pressure), edema, arthropod assault, contact dermatitis, leukocytoclastic vasculitis, bullous diabeticorum, acute eczema, photodermatitis, and infection (namely herpesvirus and bacterial). For new- onset bullous eruptions in patients receiving immunotherapy, it is important to consider clinical correlation alongside skin biopsy and SKIN January 2023 Volume 7 Issue 1 (c) 2022 THE AUTHORS.
    keywords: bullous; eng; lbp; pemphigoid
       cache: skin-1869.pdf
  plain text: skin-1869.txt

        item: #629 of 1356
          id: skin-187
      author: Simpson, Eric; Bushmakin, Andrew; Cappelleri, Joseph C; Luger, Thomas; Stander, Sonja; Tom, Wynnis; Ports, William C; Tallman, Anna M; Tan, Huaming; Gerber, Robert A
       title: Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis
        date: 2017-10-27
       words: 1662
      flesch: 55
     summary: Hong J et al. Eichenfield LF et al.
    keywords: dlqi; life; pruritus; pts; quality; treatment
       cache: skin-187.pdf
  plain text: skin-187.txt

        item: #630 of 1356
          id: skin-1871
      author: Elewski, Boni; Zirwas, Matthew; Kurbasic, Azra; Schneider, Shannon; Claxton, Ami; Silverberg, Jonathan
       title: Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3
        date: 2023-03-13
       words: 2836
      flesch: 54
     summary: This post-hoc analysis of US patients in the tralokinumab ECZTRA3 pivotal trial demonstrated that US patients treated with tralokinumab achieved significant symptom relief, reductions in disease severity, and improvement of health-related quality of life, with comparable safety versus placebo. In a subset analysis of US patients with moderate-to-severe AD from the pivotal trial, ECZTRA3, more patients treated with tralokinumab+TCS as needed achieved improvements in outcomes compared with placebo+TCS as needed.
    keywords: atopic; authors; baseline; dermatitis; ecztra3; patients; placebo; score; skin; tralokinumab
       cache: skin-1871.pdf
  plain text: skin-1871.txt

        item: #631 of 1356
          id: skin-1873
      author: Shope, Chelsea; Andrews, Laura; Linkous, Courtney; Girvin, Ashley; Neimy, Hannah; Wine Lee, Lara
       title: Characterizing Skin Cancers Arising for the First Time Following Solid Organ Transplant with Subsequent Recurrence
        date: 2023-03-13
       words: 1784
      flesch: 62
     summary: Risk factors for skin cancer recurrence in organ transplant recipients with skin cancer arising for the first-time post-transplant. 718 many as 70% of patients with lower Fitzpatrick phototypes (I or II) will be diagnosed with a skin cancer within 20 years following transplant.5 Among our cohort, there was a correlation between white patients, who tend to have Fitzpatrick phototypes I or II, and a higher risk for recurrence of skin cancers that arose for the first time post-transplant, in the absence of a pre-transplant history of skin cancer.
    keywords: cancer; risk; skin; transplant
       cache: skin-1873.pdf
  plain text: skin-1873.txt

        item: #632 of 1356
          id: skin-1876
      author: Trifoi, Mara; Claire Hollins, Lauren
       title: The USMLE Step 1 Transitions to Pass/Fail Scoring: Perceptions of Dermatology Residents 
        date: 2023-01-10
       words: 1312
      flesch: 59
     summary: Resident perspectives on USMLE Step 1 pass/fail score change (n=132) Statement Disagree Neutral Agree A recent survey of dermatology Program Directors (PDs) echoed many of the sentiments expressed by dermatology residents, with 61.4% of PDs disagreeing with the scoring change and 78.2% of them stating they would now require a Step 2 CK score in the Electronic Residency Application Service (ERAS).
    keywords: dermatology; residents; step; usmle
       cache: skin-1876.pdf
  plain text: skin-1876.txt

        item: #633 of 1356
          id: skin-1879
      author: Bury, Jordan; Igelman, Sean; Shamma, H Nicholas; Trevino, Julian
       title: Syringofibroadenomas of the Bilateral Lower Extremities
        date: 2023-01-10
       words: 740
      flesch: 52
     summary: Reported treatment options included excision for solitary lesions, cryotherapy, curettage, electrodessication, radiotherapy and etretinate topical therapy.2 A 52-year-old man presented to clinic with a one-year history of asymptomatic lesions located on his bilateral lower legs (Figure A).
    keywords: eccrine; lesions; syringofibroadenoma
       cache: skin-1879.pdf
  plain text: skin-1879.txt

        item: #634 of 1356
          id: skin-188
      author: Yosipovitch, Gil; Simpson, Eric; Tan, Huaming; Gerber, Robert A; Luger, Thomas; Stander, Sonja; Tom, Wynnis; Cappelleri, Joseph C; Bushmakin, Andrew G; Ports, William C; Tallman, Anna M
       title: The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis
        date: 2017-10-27
       words: 2570
      flesch: 57
     summary: [0] to severe [4]) – Patients were randomly assigned 2:1 to receive crisaborole or vehicle and instructed to apply the study drug to each lesion twice daily for 28 days – Pruritus severity was recorded twice daily using the SPS via electronic diary from baseline/day 1 through day 29 Analysis • Improvement in pruritus was indicated by an SPS score ≤1, with at least a 1-grade improvement from baseline • A minimum of 2 SPS observations were averaged for each analysis to meet the test-retest reliability threshold of acceptability (intraclass correlation coefficient ≥0.70) – Baseline for all analyses was the mean of ≥2 SPS measurements on day 1 Time to Improvement in Pruritus • Based on daily SPS values, calculated as the mean of ≥2 SPS measurements on that day Proportion of Patients Who Experienced Improvement in Pruritus • Assessed at each weekly study visit and calculated using the mean of all available postbaseline SPS scores for the patient during the corresponding preceding week (generally up to 14 measurements) Pruritus Score by Week • Weekly SPS scores were calculated as the mean of all available postbaseline SPS scores for the patient during the corresponding preceding week (up to 14 measurements) • Scores were analyzed using a repeated-measures longitudinal model with fixed effects for treatment, visit, treatment-by-visit interaction, and baseline value • The previously estimated clinically important difference (CID) of 0.20 was used as a threshold to assess the clinical meaningfulness of the treatment effect Proportion of Responders by Week • Per the pruritus score by week analysis, weekly SPS scores were calculated as the mean of all available postbaseline SPS scores for the patient during the preceding corresponding week (up to 14 measurements) • Responders were defined by a previously estimated clinically important response (CIR) of ≥0.19-point reduction in severity of pruritus from baseline The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients With Atopic Dermatitis (AD): An Extended Analysis Gil Yosipovitch,1 Eric Simpson,2
    keywords: patients; sps; week
       cache: skin-188.pdf
  plain text: skin-188.txt

        item: #635 of 1356
          id: skin-1885
      author: Griffin, Julia; Aurit, Sarah; Malouff, Timothy; Silberstein, Peter
       title: Socioeconomic Factors in the Diagnosis and Treatment of Malignant Melanoma in Hispanic vs. Non-Hispanic Patients: A National Cancer Database (NCDB) Study
        date: 2023-03-13
       words: 3540
      flesch: 46
     summary: Methods: A retrospective study utilizing the National Cancer Database (NCDB) was completed investigating Hispanic patients (n=2282) and WNH patients (n=190,469) with Stage I-IV malignant melanoma. Conclusion: In addition to various socioeconomic disparities, Hispanic patients are more likely than WNH patients to have melanoma diagnosed at higher stages and subtypes with worse prognosis.
    keywords: cancer; hispanic; melanoma; national; patients; skin; stage; wnh
       cache: skin-1885.pdf
  plain text: skin-1885.txt

        item: #636 of 1356
          id: skin-1886
      author: Beiter, Kaylin; Behnam, Christy; Shields, Bridget
       title: Recalcitrant Grover’s Disease Successfully Managed with Dupilumab and Naltrexone in a Middle-Aged Woman: A Case Study
        date: 2023-07-17
       words: 1758
      flesch: 53
     summary: doi:10.1001/jamadermatol.2020.5097 6. Barei F, Torretta S, Morini N, Ferrucci S. A case of Grover disease treated with Dupilumab: 891 BRIEF ARTICLE Recalcitrant Grover’s Disease Successfully Managed with Dupilumab and Naltrexone in a Middle-Aged Woman: A Case Study Kaylin Beiter, PhD1, Christy Behnam, MD2, Bridget E. Shields, MD2 1 Louisiana State University Health Sciences Center New Orleans School of Medicine, New Orleans, LA 2 University of Wisconsin Hospital and Clinics, Department of Dermatology, Madison, WI Grover’s disease, also known as transient acantholytic dermatosis, is an acquired dermatologic condition characterized by a pruritic, erythematous, and scaly papulovesicular eruption affecting the trunk.
    keywords: case; daily; disease; dupilumab; grover; naltrexone
       cache: skin-1886.pdf
  plain text: skin-1886.txt

        item: #637 of 1356
          id: skin-1887
      author: Beekman, Kate; DePalo, Danielle; Grichnik, James; Correa, Lilia; Zager, Jonathan
       title: At-Home Microneedling of Acral Skin to Increase Percutaneous Absorption of Imiquimod
        date: 2023-03-13
       words: 716
      flesch: 55
     summary: 743 COMPELLING COMMENTS At-Home Microneedling of Acral Skin to Increase Percutaneous Absorption of Imiquimod Kate E. Beekman, BS¹, Danielle K. DePalo, MD2, James M. Grichnik, MD, PhD2,3, Lilia M. Correa, MD2,3, Jonathan S. Zager, MD1,2 1USF Health, Morsani College of Medicine, Tampa, FL 2Moffitt Cancer Center, Department of Cutaneous Oncology, Tampa, FL 3USF Health, Department of Dermatology and Cutaneous Surgery, Tampa, FL Increased thickness of acral skin can reduce percutaneous absorption of topical imiquimod and hinder development of desired inflammatory response,1 presenting a challenge to its efficacy in treating acral skin malignancies. Insight into imiquimod skin permeation and increased delivery using microneedle pre- treatment.
    keywords: imiquimod; melanoma; microneedling; skin
       cache: skin-1887.pdf
  plain text: skin-1887.txt

        item: #638 of 1356
          id: skin-189
      author: Yosipovitch, Gil; Simpson, Eric; Bushmakin, Andrew G; Cappelleri, Joseph C; Luger, Thomas; Stander, Sonja; Tom, Wynnis; Benjamin, Katy; Ports, William C; Tallman, Anna M
       title: Validation of the Severity of Pruritus Scale for the Assessment of Pruritus in Atopic Dermatitis
        date: 2017-10-27
       words: 2628
      flesch: 45
     summary: [DFI]) Test-Retest Reliability • Assessed via an intraclass correlation coefficient (ICC) using all available SPS observations from stable subjects between baseline/day 1 and day 8 (stable group was defined as having no change on ISGA between baseline/day 1 and day 8) – ICC ≥0.70 was considered indicative of acceptable test-retest reliability; ICC ≥0.90 was considered indicative of excellent test-retest reliability11,12 Construct Validity • Convergent validity was evaluated by calculation of Pearson correlations with the ISGA, quality-of-life instruments (DLQI, CDLQI, and DFI), and signs of AD – Evidence for convergent validity was based on a Pearson correlation ≥0.40 (correlations ≥0.50 were considered indicative of a strong association) • Known-groups validity was assessed based on the difference in mean SPS scores between the “no disease group/clear” (ISGA = 0) and the “severe disease group” (ISGA = 4) – SPS scores as a function of ISGA were modeled using repeated-measures longitudinal analyses – The effect size was calculated as the difference in the mean divided by the baseline standard deviation (values of 0.20, 0.50, and 0.80 standard deviation units were considered small, medium, and large, respectively) Ability to Detect Change • Evaluated using a repeated-measures longitudinal mixed model to estimate the relationship between SPS and ISGA scores Clinically Important Difference • Estimated using a repeated-measures longitudinal model linked to a 1-cateogry difference on the ISGA Clinically Important Response • Estimated using a repeated-measures longitudinal model with the change in SPS score from baseline as the outcome and a newly created static global impression of change (SGIC) anchor as the predictor (SGIC was based on categorizing the change from baseline in ISGA scores as worse [–1], same [0], or better The safety and efficacy of crisaborole was established in 2 Phase 3 clinical trials conducted in the United States (AD-301: NCT02118766; AD-302: NCT02118792)4 • Pruritus was assessed within these trials using the SPS, a 4-point rating scale, ranging from 0 (none: no itching) to 3 (severe, bothersome itching/scratching which disturbs sleep) that was adapted from the Atopic Dermatitis Severity Index5 to quantify pruritus intensity within a 24-hour period (Table 1) Construct Validity • Convergent validity was supported by strong correlation (Pearson correlation ≥0.50) between SPS scores and ISGA, DLQI, CDLQI, and DFI instruments, and correlations of ≥0.40 with 4 of 5 of the signs of AD at day 29 (Table 4) Table 4.
    keywords: anchor; change; isga; pruritus; scale; score; sps
       cache: skin-189.pdf
  plain text: skin-189.txt

        item: #639 of 1356
          id: skin-1890
      author: Thacker, Shivani; Chakkalakal, Mincy; Goldstein, Zachary; Macknet, Kenneth Dale
       title: Beware of the “Blue Nevus”: A Case Report
        date: 2023-07-17
       words: 1278
      flesch: 48
     summary: A punch biopsy was performed with a differential diagnosis of blue nevus versus melanoma. 6. Loghavi, S., Curry, J., Torres-Cabala, C. et al. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature.
    keywords: blue; examination; melanoma; nevus
       cache: skin-1890.pdf
  plain text: skin-1890.txt

        item: #640 of 1356
          id: skin-1891
      author: Ahuja, Kripa
       title: Hypertrichosis: The Werewolf Syndrome without a Wolf Pack
        date: 2023-03-13
       words: 431
      flesch: 58
     summary: While less than 50 cases are reported in the literature, it is important to recognize the magnitude of impact this disorder creates.1 Sometimes colloquially known as “Werewolf Syndrome,” patients with hypertrichosis have been recorded since the Middle Age and the Renaissance.2 Historically, these patients were often exhibited in circuses for their peculiarity.2 Unfortunately, the stigma against excess hair continues into the modern age.3 Patients with hypertrichosis not only face social isolation and bullying but face numerous difficulties finding a job as well as finding a spouse.3 Women face a higher burden, as it is less socially acceptable for women to have excess hair.3 Patients with hypertrichosis continue to work in circuses, often before they can even walk.3 Many women with hypertrichosis are single mothers due to partner abandonment.3 With no support, they have no choice but to be exhibited as a sideshow attraction and subject their child to the same fate.3 While there is no permanent cure for hypertrichosis2, the lack of an advocacy group, patient support network, or formal organization presents even greater hardships to patients with this disease.3 In a disorder characterized by an extremely high social stigma, a social network with others facing the same difficulties may make a world of difference. As one patient with hypertrichosis commented about wolves living in a zoo: Both of our faces are covered in hair, and we both live trapped - them in the zoo and me in this body, he says.
    keywords: hypertrichosis; patients
       cache: skin-1891.pdf
  plain text: skin-1891.txt

        item: #641 of 1356
          id: skin-1893
      author: Mulholland, Alannah; Tang, Brandon; Shumak, Steven; Zhou, Linda
       title: Disseminated Varicella-zoster Virus Infection in an Immunocompetent Host
        date: 2023-05-20
       words: 525
      flesch: 42
     summary: Tissue culture of the lesions confirmed VZV infection. Disseminated VZV infection is defined by the presence of more than 20 vesicular lesions in three consecutive dermatomes and occurs in 2% of the general population.
    keywords: infection; toronto; zoster
       cache: skin-1893.pdf
  plain text: skin-1893.txt

        item: #642 of 1356
          id: skin-1894
      author: Dhandha, Maulik Manharlal; Ghosh, Debjit; Tyring, Stephen; Rady, Peter
       title: Atypical Human Papillomavirus Infection with Secondary Tinea in a Middle-Aged Caucasian Male
        date: 2023-07-17
       words: 1701
      flesch: 59
     summary: 2003; 110: 129-136. 7. Fuessel-Haws AL, He Q, Rady P, et al. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. During the physical exam, we noticed scaly and some waxy pink to tan colored papules ABSTRACT We present a case of an atypical diffuse cutaneous eruption due to HPV infection and Tinea in a 51-year-old male patient with a past medical history of mild cytopenia, vasectomy and difficult socio-economic situation.
    keywords: dna; hpv; patient; pcr; skin
       cache: skin-1894.pdf
  plain text: skin-1894.txt

        item: #643 of 1356
          id: skin-1897
      author: Yousefian, Faraz; Kowalczyk, Christopher ; Norris, Nevada;  Ricotti, Carlos; Kerdel, Francisco
       title: Acneiform Eruption of Monkeypox in a Pilot
        date: 2023-03-13
       words: 1166
      flesch: 29
     summary: In conclusion, dermatologists should have a high suspicion of monkeypox infection in individuals with acute onset of vesiculopustular rash and lymphadenopathy who have a recent travel history, prior exposure, and intimate contacts. Monkeypox was declared a global health emergency by the World Health Organization (WHO) on July 23, 2022, due to a rapid increase in reported cases.
    keywords: http://paperpile.com/b/hqcuum/3wzn; http://paperpile.com/b/hqcuum/3wzn http://paperpile.com/b/hqcuum/3wzn; http://paperpile.com/b/hqcuum/vma1; inflammatory; monkeypox
       cache: skin-1897.pdf
  plain text: skin-1897.txt

        item: #644 of 1356
          id: skin-1898
      author: dos Santos Maia, Mayara; Sérgio Lopes, Otávio; da Silva Calixto, Poliane; Satomi Takeno Herrero, Sylvia;  Monteiro de Souza, Augusto; Alberto Longui, Carlos; Rodrigues de Carvalho Filho, Ivan; Ferreira Soares, Leonardo; Delatorre, Plínio; Barbosa da Silva, Renally; Calcagno, Danielle; Rodriguez Burbano, Rommel; Moura Lima, Eleonidas
       title: Association of Single-Nucleotide Polymorphisms of Gene XPC with Susceptibility to Basal Cell Carcinoma in Brazilian Population
        date: 2023-01-10
       words: 4115
      flesch: 62
     summary: No association studies of XPC gene SNP with susceptibility to the development of Basal Cell Carcinoma were found. Docking For the docking tests using Hex 8.0.0 software [30], two anchorages were generated, the first between XPC protein with Asn residue at codon 108 and the PH domain of TFIIH p62; And a second anchorage between the mutated XPC-modeled protein at position 108, substitution of Asn with Lys and the PH domain of TFIIH p62.
    keywords: cancer; carcinoma; cell; dna; domain; gene; repair; risk; rs535425175; tfiih; xpc
       cache: skin-1898.pdf
  plain text: skin-1898.txt

        item: #645 of 1356
          id: skin-190
      author: Arnold, Scott; Hanegraaf, Sharon; Ahvenien, Tina; Alsop, Hugh; Bowles, Vernon M
       title: A Randomized Double-Blind, Vehicle-Controlled Study of the Ovicidal Efficacy of a New Head Lice Therapy, Abametapir Lotion, 0.74%, Administered for the Treatment of Head Lice Infestation
        date: 2017-10-27
       words: 679
      flesch: 66
     summary: After a single 10-minute application of abametapir lotion, 0.74% inhibited,100% of head lice eggs failed to hatch. Hatched eggs % (95% CI)
    keywords: eggs; lotion
       cache: skin-190.pdf
  plain text: skin-190.txt

        item: #646 of 1356
          id: skin-1904
      author: Jaklitsch, Erik; Mizes, Alicia; Sanchez, Francisco; Romero, Ana; Bonilla, Katherin; James, Alaina
       title: A Rare Case of Early Pregnancy-Associated Erythema Annulare Centrifugum in a Low-Resource Setting
        date: 2023-07-17
       words: 1418
      flesch: 50
     summary: Prior studies have even suggested that human chorionic gonadotropin (hCG) may contribute to this response in pregnancy associated EAC, since its production begins at implantation and peaks at week 12.5 In our case, increased levels of hCG or higher patient sensitivity immediately following implantation could have contributed to worsening symptoms in this novel early presentation. A 21-year-old woman experienced asymptomatic EAC of the trunk and extremities that resolved by week 4 of two consecutive pregnancies, abruptly reoccurred on the first day postpartum, and did not resolve for an additional three years.4 All other previously reported cases of EAC suggest that lesion onset occurs between weeks 12-33 of pregnancy in a nulliparous woman with regression in the postpartum
    keywords: annulare; eac; erythema; pregnancy; week
       cache: skin-1904.pdf
  plain text: skin-1904.txt

        item: #647 of 1356
          id: skin-1909
      author: Kim, Jessica; Neita, Onyebuchi; Dyer, Joseph M.
       title: Bullous Eruption after Off-label Use of Topical Tirbanibulin on the Chest
        date: 2023-07-17
       words: 1254
      flesch: 59
     summary: Advertised as a first-in- class topical with high efficacy and fewer adverse effects compared to alternative field therapies, its proposed molecular target is by indirect inhibition of Src.4 This decreases microtubule polymerization and Src kinase signaling, effectively downregulating the growth of human keratinocytes and inducing apoptosis.5,6 Recommended usage of tirbanibulin is once daily application to the face or scalp, to an area up to 25 cm2, for five consecutive days.7 Excipients in the commercially available formulation of tirbanibulin 1% ointment include propylene glycol and glycerol monostearate 40-55.8 A 56-year-old Caucasian female with a history of actinic keratoses and cutaneous squamous cell carcinoma presented for re- evaluation of scattered actinic keratoses on the upper chest status post application of tirbanibulin 1% ointment once daily for 5 days. Erythema and brisk vesiculation on the upper chest following tirbanibulin application.
    keywords: actinic; keratosis; ointment; tirbanibulin; topical
       cache: skin-1909.pdf
  plain text: skin-1909.txt

        item: #648 of 1356
          id: skin-191
      author: Fowler, Joseph; Allenby, Kent; Sidgiddi, Srinivas
       title: DFD-01, a Betamethasone Dipropionate 0.05% Spray, Improved Quality of Life and Treatment Satisfaction in Subjects with Moderate Psoriasis
        date: 2017-10-27
       words: 623
      flesch: 58
     summary: ¾ 14 days of twice daily DFD-01 treatment was associated with decreased mean values of IGA (-0.9), TSS (-2.7), and BSA (-1.5%). This study was funded and sponsored by the Dr. Reddy’s Laboratories group of companies DRL Publication # 786 -1.1 -0.6 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 IGA Change Baseline to Day 14 BSA 3% to 10% BSA >10% -2.6 -2.8 -2.85 -2.8 -2.75 -2.7 -2.65 -2.6 -2.55 -2.5 TSS Change Baseline to Day 14 BSA 3% to 10% BSA > 10% 44.9 48.1 43 44 45 46 47 48 49 TSQM-II Scores at Day 14 BSA 3% to 10% BSA > 10% -0.8 -2.5 -3 -2.5 -2 -1.5 -1 -0.5 0 % BSA Change Baseline to Day 14 BSA 3% to 10% BSA > 10% Change in Clinical and QoL Parameters From Baseline to Day 14 (IIT Population) 1.
    keywords: bsa
       cache: skin-191.pdf
  plain text: skin-191.txt

        item: #649 of 1356
          id: skin-1910
      author: Zakria, Danny; Brownstone, Nicholas; Berman, Brian; Ceilley, Roger; Goldenberg, Gary; Lebwohl, Mark; Litchman, Graham; Siegel, Daniel
       title: Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel Report
        date: 2023-01-10
       words: 6943
      flesch: 57
     summary: Conclusion: Based on the currently available literature, GEP tests provide valuable information beyond AJCC8 and NCCN guidelines for the prognostic assessment of CM. In addition, studies have demonstrated that genomics can identify a high-risk subset of CM patients with stage I and II disease that are at greater risk for recurrence, metastasis, and increased mortality based on their lesions’ genetic profile.3-5 Tens of thousands of CM GEP tests are currently being ordered annually in the US to aid clinicians in their prognostic assessment of patients with CM.9
    keywords: dermatol; et al; expression; expression profile; gene; gene expression; gep; melanoma; patients; profile; prognostic; risk; test
       cache: skin-1910.pdf
  plain text: skin-1910.txt

        item: #650 of 1356
          id: skin-1914
      author: Samia, Arthur; Lacy, Frank; Wu, Sam; Ziemer, Carolyn
       title: Total Skin Electron Beam Therapy-Induced Erythrodermic Subacute Radiation Dermatitis in a 54-Year-Old Man with Underlying Cutaneous T-Cell Lymphoma
        date: 2023-05-20
       words: 843
      flesch: 47
     summary: 849 subject to a patient’s cumulative radiation dose.3 Additionally, a review of the literature suggests cessation of radiation therapy, appropriate wound care, and topical corticosteroids are mainstays of treatment for SRD.4 Cetuximab therapy should be considered in extreme cases until symptomatic control.5 In patients with SRD, monitoring for secondary infection of the skin is a critical concern.6 Overall, this case is a rare presentation of radiation dermatitis presenting as erythroderma and highlights the importance of appropriate consideration of these adverse events in patients receiving TSEBT. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.
    keywords: dose; radiation; skin; tsebt
       cache: skin-1914.pdf
  plain text: skin-1914.txt

        item: #651 of 1356
          id: skin-1919
      author: Weir, Sydney; Ahmed, Hana; Broughton, Mia ; Kole, Lauren
       title: The Prevalence of Secondhand Smoke Exposure in Hidradenitis Suppurativa: A Cross-Sectional Survey Study
        date: 2023-05-20
       words: 1660
      flesch: 62
     summary: Compared to patients with AD and VV, HS patients had significantly higher rates of secondhand smoke exposure; however, there was no significant correlation between secondhand smoke and HS disease severity. While we cannot conclude if secondhand smoke is truly increased in HS patients regardless of race or other potential confounders, this raises the question if screening for secondhand smoke exposure in the HS population would have clinical value.
    keywords: exposure; secondhand; smoke
       cache: skin-1919.pdf
  plain text: skin-1919.txt

        item: #652 of 1356
          id: skin-1922
      author: Kulkarni, Maansi; Igelman, Sean ; Trevino, Julian ; Conner, Clayton
       title: Linear Depigmented Macules and Patches in an Elderly Man
        date: 2023-03-13
       words: 1359
      flesch: 46
     summary: An 82-year-old African American male with a history of small cell lung cancer presented with new onset spreading depigmented macules and patches. We report a case in which an elderly male experienced segmental vitiligo after use of durvalumab therapy for small cell lung cancer.
    keywords: cell; macules; patient; segmental; vitiligo
       cache: skin-1922.pdf
  plain text: skin-1922.txt

        item: #653 of 1356
          id: skin-1929
      author: Wescott, Raquel; Dhami, Ramneek; Wang, Lingchen; Hovenic, Whitney
       title: Hidradenitis Suppurativa: A Cross-sectional Study of Content Quality on TikTok
        date: 2023-05-20
       words: 1403
      flesch: 59
     summary: Creators can improve video quality by including treatment information, sources of their content, and current research. With its growing popularity, evaluating the educational quality of TikTok videos is important.
    keywords: discern; gqs; quality; videos
       cache: skin-1929.pdf
  plain text: skin-1929.txt

        item: #654 of 1356
          id: skin-193
      author: Hazan, Lydie; Haber, Robert S; Haber, Robert S; Husseman, Michael; Husseman, Michael; Shepherd, Katie; Shepherd, Katie; Hanegraaf, Sharon; Hanegraaf, Sharon; Ahveninen, Tina; Ahveninen, Tina; Jenkins, Lisa; Jenkins, Lisa; Alsop, Hugh; Alsop, Hugh; Bowles, Vernon M; Bowles, Vernon M
       title: Abametapir Lotion, 0.74% Demonstrates High Elimination Rates of Head Lice with a Single Application in Phase 3 Trials
        date: 2017-10-27
       words: 637
      flesch: 66
     summary: DRL Publication #783 ¾ Successful treatment of head lice infestations may be hampered by limited ovicidal efficacy of current treatments1, increasing resistance to commonly used treatments2, and poor adherence to 2-application treatment regimens. The objective of the current studies was to evaluate the efficacy of a single 10 minute application of abametapir lotion, 0.74% for the treatment of head lice infestation in subjects 6 months of age and older.
    keywords: abametapir; lotion; treatment
       cache: skin-193.pdf
  plain text: skin-193.txt

        item: #655 of 1356
          id: skin-1930
      author: Daftary, Karishma; Brieva, Joaquin; Chovatiya, Raj
       title: Malignant Angiosarcoma Masquerading as Benign Epithelioid Hemangioma
        date: 2023-07-17
       words: 1694
      flesch: 44
     summary: Per the classification system set forth by the International Society for the Study of Vascular Anomalies (ISSVA) that categorizes vascular tumors as benign, locally aggressive/borderline, or malignant, EH is designated as a benign whereas both EHE and angiosarcoma are categorized as malignant tumors.3 EHE is a rare malignant tumor with an epithelioid or histiocytoid appearance developing from vascular endothelial or pre- endothelial cells. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions.
    keywords: angiosarcoma; benign; epithelioid; features; malignant; scalp; vascular
       cache: skin-1930.pdf
  plain text: skin-1930.txt

        item: #656 of 1356
          id: skin-1932
      author: Rambhia, Pooja; D’Angelo , Sandra ; Shah, Pooja 
       title: High-grade Undifferentiated Pleomorphic Sarcoma Presenting as Acquired Lymphangioma Circumscriptum
        date: 2023-05-20
       words: 668
      flesch: 42
     summary: Prognostic factors associated with poor outcome include high histologic grade, large tumor size, presence of metastases, and unresectability1. Soft tissue sarcoma is a heterogeneous group of rare malignancies of mesenchymal origin, that represents 0.8% of all adult cancers.
    keywords: grade; lymphangioma; sarcoma
       cache: skin-1932.pdf
  plain text: skin-1932.txt

        item: #657 of 1356
          id: skin-1933
      author: Owens, Kelly; Kwock, Jeffery T.; Nicholas, Matilda W.
       title: Halo Nevi After Covid-19 Vaccination: Molecular Mimicry Attributed Cutaneous Side-Effect?
        date: 2023-07-17
       words: 1216
      flesch: 54
     summary: Although well tolerated, Covid-19 vaccination is associated with several cutaneous adverse reactions such as injection site reactions, urticaria and less commonly erythema multiforme, subacute cutaneous lupus erythematosus, pityriasis rosea, and vitiligo.1,2 To date, there has been one report of halo nevi appearing after Covid-19 vaccination. Although the etiology of halo nevi is not fully understood, it is thought that vitiligo and halo nevi share a common feature: destruction of melanocytes by cytotoxic T cells; therefore, it is possible that the occurrence of halo nevi and vitiligo after Covid-19 vaccination stems from a similar pathophysiology.5 Several theories have been proposed on the mechanism surrounding Covid-19 vaccination and autoimmune skin reactions.
    keywords: covid-19; halo; nevi; vaccination
       cache: skin-1933.pdf
  plain text: skin-1933.txt

        item: #658 of 1356
          id: skin-1935
      author: Strouphauer, Emily; Katta, Rajani
       title: Cutaneous Fungal Infections Associated with Pediatric-onset Diabetes: A Case-control Study in the All of Us Research Program
        date: 2023-07-17
       words: 1425
      flesch: 49
     summary: 876 RESEARCH LETTER Cutaneous Fungal Infections Associated with Pediatric-Onset Diabetes: A Case-Control Study in the All of Us Research Program Emily Strouphauer, BSA1, Rajani Katta, MD2 1 School of Medicine, Baylor College of Medicine, Houston, TX 2 Department of Dermatology, McGovern Medical School at University of Texas Health Science Center at Houston, Houston, TX With the rapidly increasing incidence of pediatric diabetes mellitus (DM) in the United States,1 an understanding of the risk of long- term cutaneous consequences, particularly the risk of cutaneous fungal infections, is important. This is a National Institutes of Health ABSTRACT Introduction: With the rapidly increasing incidence of pediatric diabetes mellitus (DM) in the United States, an understanding of the risk of long-term cutaneous consequences, particularly the risk of cutaneous fungal infections, is important.
    keywords: diabetes; infections; onset
       cache: skin-1935.pdf
  plain text: skin-1935.txt

        item: #659 of 1356
          id: skin-1937
      author: Masson, Rahul; Shih, Terri; De, Devea; Atluri, Swetha; Yazdani, Shahram; Sayed, Christopher; Shi, Vivian; Hsiao, Jennifer Lin
       title: Perspectives on Pediatric Hidradenitis Suppurativa Care: A Survey of Pediatric Providers
        date: 2023-03-13
       words: 1714
      flesch: 45
     summary: Among the 50 respondents, less than one-half were confident in knowing the available treatment options for HS (46%), managing mild HS (42%) or moderate-severe HS (6%), knowing pediatric HS comorbidities (30%), addressing challenges that HS patients face in school (22%), knowing when to discuss surgical treatments (20%), managing menstrual HS flares (14%), discussing the impact of HS on sexual health (14%), and managing patients with non-prescription therapies (0%). T-tests were used for comparative statistical analyses between survey responses and provider experience (number of HS patients seen monthly and number of years in practice).
    keywords: hidradenitis; patients; pediatric; providers; suppurativa; university
       cache: skin-1937.pdf
  plain text: skin-1937.txt

        item: #660 of 1356
          id: skin-1938
      author: Mathis, Alexandra; Marrone, Samantha
       title: Cryoglobulinemia Type I in Patient with History of Monoclonal Gammopathy of Unknown Significance: A Case Report
        date: 2023-07-17
       words: 1505
      flesch: 48
     summary: A French nationwide survey published by Terrier B, et al. found that out of 64 patients with cryoglobulinemia type I, 28 patients also had a diagnosis of MGUS.3 Another study published by the British Journal of Hematology also found that out of 64 patients, 40% also had a diagnosis of MGUS.6 The immunofluorescent pattern of single monoclonal antibody deposition (IgM without IgG) is suggestive of cryoglobulinemia type 1 These biopsy and laboratory findings further suggest that this presentation is more likely cryoglobulinemia type I. Type I cryoglobulinemia only accounts for 10- 15% of people with cryoglobulinemia whereas mixed constitutes the rest.8 Type I is most associated with cutaneous involvement including recurrent episodes of purpuric eruptions, livedo reticularis, acrocyanosis, Raynaud’s syndrome, and even severe infarction skin necrosis.9-11 Renal and neurologic involvement are more frequent findings in patients with mixed cryoglobulinemia, findings not seen in our patient.8 Based on presenting symptoms, physical exam findings, pathophysiology report from biopsy along with laboratory results, and current literature on cryoglobulinemia, we affirm and believe that this patient has cryoglobulinemia type I secondary to MGUS who was successfully treated with rituximab and a prednisone taper.
    keywords: cryoglobulinemia; hepatitis; medicine; monoclonal; patient; type
       cache: skin-1938.pdf
  plain text: skin-1938.txt

        item: #661 of 1356
          id: skin-194
      author: Hazan, Lydie; Cardona, David; Hanegraaf, Sharon; Ahveninen, Tina; Alsop, Hugh; Bowles, Vernon M
       title: Abametapir Lotion, 0.74%, a Novel Therapy for the Treatment of Head Lice, Pooled Safety Results from 11 Trials, in Children as Young as 6 Months
        date: 2017-10-27
       words: 886
      flesch: 69
     summary: The most frequently reported treatment-emergent AEs for pediatric subjects were in the system organ class of Skin and Subcutaneous Tissue Disorders, primarily erythema, rash, skin burning sensation, and contact dermatitis. A total of 1372 subjects were evaluated in 11 clinical studies of abametapir lotion, 0.74% including 6 studies with a total of 676 pediatric subjects (aged 6 months to 17 years).
    keywords: skin
       cache: skin-194.pdf
  plain text: skin-194.txt

        item: #662 of 1356
          id: skin-1945
      author: Haft, Michael; Knapp, Keith; Claxton, Ami; Munoz, Breda; Balu, Sanjeev; Schnieder, Shannon; Silverberg, Jonathan; Thaci, Diamant; Eichenfield, Lawrence
       title: Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry
        date: 2023-03-13
       words: 1623
      flesch: 45
     summary: In multivariate analysis controlling for sex, age, insurance, and race, only higher BSA at enrollment was associated with AST-usage • BSA of 5% OR=1.09 (1.01-1.19) • BSA of 10% OR = 1.2 (1.01-1.42) • BSA of 20% OR = 1.43 (1.02-2.01) 1 Rady Children’s Hospital, San Diego, CA 2 University of California San Diego, San Diego, CA 3 Target RWE, Durham, NC 4 LEO Pharma Inc., Madison, NJ 5 George Washington School of Medicine, Washington DC 6 University of Lübeck, Lübeck Germany Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry Haft M1,2, Knapp K3, Claxton A4, Hernandez B3, Balu S4, Schneider S4, Silverberg J5, Thaci D6, Eichenfield L1,2 on behalf of TARGET-DERM Investigators Conclusion • More than half of the patients with considerable disease severity and who experienced negative QOL from moderate-to-severe AD were not prescribed AST • Compared to AST-naïve patients, descriptive analysis showed that the AST- treated were slightly more severe as indicated by significantly higher baseline BSA, higher vIGA-ADxBSA, and higher PO-SCORAD at enrollment. Abuabara, K. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGETDERM AD study design and rational BMJ Open 2020;10:e0399282020.
    keywords: ast; enrollment; patients
       cache: skin-1945.pdf
  plain text: skin-1945.txt

        item: #663 of 1356
          id: skin-1949
      author: Del Rosso, James; Kwong, Pearl; Hussain, Iftikhar; Barbarot, Sebastien; Carrascosa, Jose; Rueda, Maria; Atwater, Amber; Elmaraghy, Hany; Sun, Luna; Chen, Sherry; Natalie, Chitra;  Weidinger, Stephan
       title: Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis
        date: 2023-03-13
       words: 1773
      flesch: 29
     summary: FLARE DEFINITIONS ■ Flare was defined 3 ways for these analyses: – Per protocol rescue flare: initiation or intensification of rescue therapy with topicals (corticosteroids, calcineurin inhibitors, crisaborole); systemics (corticosteroids, immunosuppressants, biologics, Janus Kinase inhibitors); phototherapy; or photochemotherapy – High potency TCS/systemic rescue flare: use of topical high potency corticosteroids or systemics (corticosteroids, immunosuppressants, biologics, Janus Kinase inhibitors); phototherapy; or photochemotherapy – AE flare: an exacerbation of AD, captured as a treatment-emergent adverse eventa OBJECTIVE ■ To assess the ability of lebrikizumab to reduce flares in patients with moderate-to-severe AD through the 16-week initial randomized treatment period in the advocate 1 and advocate 2 phase 3 clinical studies.4 a AD exacerbation was defined using specific Medical Dictionary for Regulatory Activities preferred terms of dermatitis atopic, rebound atopic dermatitis, or eczema. He is a research investigator, consultant, advisor, and/or speaker for AbbVie, Aclaris, Almirall, Amgen (Celgene), Anaptys Bio, Arcutis, Aslan, Asthenex, Bausch (Ortho Dermatology), Beiersdorf, Biofrontera, BioPharmX, Biorasi, Blue Creek, Boehringer Ingelheim, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermata, Dermavant, Dermira, Eli Lilly and Company, Encore, EPI Health, Evommune, Ferndale, Galderma, Genentech, Incyte, Janssen, Jem Health, La Roche Posay, LEO Pharma, MC2, Mendera, Novan, Pfizer, Ralexar, Regeneron, Sanofi-Genzyme, Sente, Solgel, Sonoma (Intraderm), Sun Pharma, UCB, Verrica, and Vyne (Foamix/Menlo).
    keywords: advocate; company; flare; lilly; rescue
       cache: skin-1949.pdf
  plain text: skin-1949.txt

        item: #664 of 1356
          id: skin-1950
      author: Ostrovskaya, Olga; Sips, Magdalena; Ulrichts, Peter; Trainor, Lance; Verheesen, Peter; Stoykov, Ivaylo
       title: Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases
        date: 2023-03-13
       words: 1773
      flesch: 41
     summary: Sesarman A, et al. 2. Ulrichts P, et al.
    keywords: efgartigimod; igg; participants; phase
       cache: skin-1950.pdf
  plain text: skin-1950.txt

        item: #665 of 1356
          id: skin-1951
      author: Perry, Allyson; Ruppenthal, Danielle; Hill, Kellie
       title: Non-Invasive Genomic Profiling in Pediatric Patients
        date: 2023-03-13
       words: 1115
      flesch: 52
     summary: Of PLA-positive samples, the proportion positive for LINC alone was higher in pediatric samples (69.5%) compared to adult samples (31.4%) While overall PLA positivity rates were similar across adult and pediatric samples, the proportion positive only for LINC was more than two times higher in pediatric samples than the adult samples.
    keywords: adult; pediatric; samples
       cache: skin-1951.pdf
  plain text: skin-1951.txt

        item: #666 of 1356
          id: skin-1953
      author: Silverberg, Jonathan I. ; Boguniewicz, Mark; Papp, Kim; Tsianakas, Athanasios; Biswas, Pinaki; Feeney, Claire; Levenberg, Mark
       title: Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
        date: 2023-03-13
       words: 1474
      flesch: 39
     summary: aFlare was defined as ≥50% loss of EASI response at randomization and IGA score ≥2. bFlare was defined as ≥50% loss of week 12 EASI response and IGA score ≥2.
    keywords: abrocitinib; patients; period; rescue
       cache: skin-1953.pdf
  plain text: skin-1953.txt

        item: #667 of 1356
          id: skin-1954
      author: Stevens, Greg; Rock, James; Jansen, Burkhard; Arnold, Terry; Wood, Jennifer; Clarke, Loren; Hyde, Mark
       title: Genomic Profiling of Lentigo Maligna within an Interim Registry Analysis​
        date: 2023-03-13
       words: 1221
      flesch: 58
     summary: This group of 53 LM, LMM, and AJMH lesions were all evaluated for correlations to the DMT markers. The gene expression test is designed to rule out melanoma by analyzing non- invasively collected skin cells from pigmented lesions for genomic atypia (LINC00518, PRAME, and/or TERT).
    keywords: ajmh; melanoma
       cache: skin-1954.pdf
  plain text: skin-1954.txt

        item: #668 of 1356
          id: skin-1955
      author: Stevens, Greg; Jansen, Burkhard; Arnold, Terry; Rock, James; Wood, Jennifer; Clarke, Loren; Hyde, Mark
       title: Concordance of Preferentially Expressed Antigen in Melanoma by Non-Invasively Collected Polymerase Chain Reaction and Immunohistochemistry on Paraffin Embedded Tissue
        date: 2023-03-13
       words: 1260
      flesch: 54
     summary: Pathologists used PRAME IHC for 102 lesions (10.2%). Pathologists used PRAME IHC for 102 lesions (10.2%).
    keywords: ihc; lesions; pcr; prame
       cache: skin-1955.pdf
  plain text: skin-1955.txt

        item: #669 of 1356
          id: skin-1956
      author: Martin, Brian; Bailey, Christine; Goldberg, Matthew; Petkov, Valentina; Cook, Robert; Covington, Kyle; Kurley, Sarah
       title: Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma
        date: 2023-03-13
       words: 860
      flesch: 58
     summary: › In the subset of patients with IIB-IIC disease (n=311), no Class 1A (0%, 0/38) patients died from melanoma compared with 6.7% (14/210; 8 IIB, 6 IIC) of Class 2B patients. A focused analysis of negative lymph node patients was performed.
    keywords: gep; patients
       cache: skin-1956.pdf
  plain text: skin-1956.txt

        item: #670 of 1356
          id: skin-1957
      author: Guenther, J. Michael; Bailey, Christine N.; Ahmed, Kelli; Johnson, Clare; Martin, Brian; Kur, Sarah; Yamamoto, Maki
       title: Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study
        date: 2023-03-13
       words: 1057
      flesch: 64
     summary: ›85% of SLNB decisions were influenced by the 31-GEP result. SLNB performed70% 92% -29% -19% 49% 3% 59% 9% 78% 10% SLNB performance reduction rate, relative to contemporary cohort SLNB positivity rate SLNB performance rate P e rc e n t, % 0 20 40 60 80 100 -20 -40 ** ** Class 1A (low risk), n=138 All Pts, n=193 Contemporary comparison cohort, n=856 Study Design Patients with CM considering SLNB Physician and patient make decision about SLNB after receiving 31-GEP results SLNB No SLNB Follow for outcomes Table 2.
    keywords: class; gep; risk; slnb
       cache: skin-1957.pdf
  plain text: skin-1957.txt

        item: #671 of 1356
          id: skin-1958
      author: Farberg, Aaron S; Ahmed, Kelli L; Rackley, Briana B ; Siegel, Jennifer J; Russell, Brooke H; Rogers, Jason H; Kurley, Sarah J; Goldberg, Matthew S
       title: A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence
        date: 2023-03-13
       words: 872
      flesch: 45
     summary: There was also an increase in management plan confidence with GEP results provided ›. › Clinicians were invited for study participation based on prior use of diagnostic GEP testing (minimum 3 encounters with GEP results). Scan or click here for more info Here we present dermatologist management plans and confidence utilizing diagnostic GEP results in uncertain clinical and diagnostic scenarios ›. Excision Follow-up Confidence GEP Result A v e ra g e % C h a n g e Benign Benign MalignantMalignant Benign Malignant -50 50 0 100 D e c re a se In c re a se Baseline Figure 1.
    keywords: clinical; gep; results
       cache: skin-1958.pdf
  plain text: skin-1958.txt

        item: #672 of 1356
          id: skin-1959
      author: Armstrong, April W.; Lebwohl, Mark; Bagel, Jerry; Schlesinger, Todd; Banerjee, Subhashis; Kisa, Renata M.; Scharnitz, Thomas; Hoyt, Kim; Strober, Bruce
       title: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)
        date: 2023-03-13
       words: 3255
      flesch: 45
     summary: Baseline demographics by baseline BSA involvement and PASI score in the pooled POETYK PSO-1 and PSO-2 population Baseline BSA involvement Baseline PASI score Parameters 10%–<15% 15%–<20% 20%–<30% ≥30% 12–<15 ≥15 Placebo (n = 105) Baseline demographics by baseline BSA involvement and PASI score in the POETYK PSO-1 population Baseline BSA involvement Baseline PASI score Parameters 10%–<15% 15%–<20% 20%–<30% ≥30% 12–<15 ≥15 Placebo- Deucravacitinib (n = 36)
    keywords: baseline; deucravacitinib; pasi; placebo; psoriasis; week
       cache: skin-1959.pdf
  plain text: skin-1959.txt

        item: #673 of 1356
          id: skin-196
      author: Jackson, J Mark; Grove, Gary L; Allenby, Kent; Houser, Tim
       title: DFD-01, a Betamethasone Dipropionate 0.05% Spray Lotion. Reduces Transepidermal Water Loss and Improves Skin Hydration and Elasticity
        date: 2017-10-27
       words: 657
      flesch: 67
     summary: ¾ Day 2 – Test sites were evaluated for 1) baseline transepidermal water loss (TEWL) using an evaporimeter, and 2) capacitance (epidermal hydration) using a corneometer. ¾ Study 2: � After subtracting changes in untreated control sites, both DFD-01 and vehicle increased R3 values, indicating greater skin elasticity.
    keywords: sites
       cache: skin-196.pdf
  plain text: skin-196.txt

        item: #674 of 1356
          id: skin-1961
      author: Peck, Gary; Reifer, Rachel; Hyde, Mark; Matthews, Sarah; Jansen, Burkhard; Skelsey, Maral
       title: Visual Assessment and Dermoscopy Enhanced by Non-invasive Genomic Testing
        date: 2023-03-13
       words: 1253
      flesch: 51
     summary: Non-invasive assessment of melanoma-associated genomic biomarkers has been shown to be effective in ruling out melanoma in uncertain pigmented skin lesions with a sensitivity of 91-97%, specificity of 53-69%, and negative predictive value >99%.7,8 RNA gene expression of Preferentially Expressed Antigen in Melanoma (PRAME) and Long Intergenic Non-Coding RNA 518 (LINC), along with somatic DNA mutations in Telomerase Reverse Transcriptase (TERT), are detected in samples of stratum corneum overlying pigmented lesions collected non-invasively using adhesive patches.7 The objective of this retrospective case series analysis was to determine whether non-invasive assessment of genomic biomarkers could enhance visual and dermoscopic detection of pigmented lesions at risk for melanoma. By non-invasive genomic assessment, 29 lesions (49.2%) expressed 2 genomic markers, 28 (47.5%) expressed PRAME and LINC and 1 lesion (1.7%) expressed PRAME and TERT.
    keywords: dermoscopic; features; invasive; melanoma; situ
       cache: skin-1961.pdf
  plain text: skin-1961.txt

        item: #675 of 1356
          id: skin-1963
      author: Stein Gold, Linda; Pinter, Andreas; Armstrong, April; Iversen, Lars; Praestegaard, Morten; Augustin, Matthias
       title: Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream
        date: 2023-03-13
       words: 1154
      flesch: 60
     summary: The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD- cream as well as treatment acceptability compared to cream vehicle and to CAL/BDP Topical Suspension (TS)/gel (sourced in the EU as Dovobet®/Daivobet® gel). The proportion of patients achieving PGA treatment success (2-step improvement to clear or almost clear) after 8 weeks was significantly greater for CAL/BDP PAD-cream (50.7%) compared to vehicle (6.1%, p<0.0001) and CAL/BDP TS/gel (42.7%, p=0.0442) (Figure 2).
    keywords: bdp; cal; cream; gel
       cache: skin-1963.pdf
  plain text: skin-1963.txt

        item: #676 of 1356
          id: skin-1965
      author: Yousefian, Faraz; Apple, Aurel; Lin, Ann
       title: Bilateral Upper Extremities Linear Eruption in a 12-year-old Boy
        date: 2023-07-17
       words: 582
      flesch: 47
     summary: The exact pathogenesis of Wells syndrome is unknown.2 Along with history, clinical picture, and dermatopathology examination could help confirm the diagnosis of Wells syndrome.
    keywords: syndrome; wells
       cache: skin-1965.pdf
  plain text: skin-1965.txt

        item: #677 of 1356
          id: skin-1966
      author: Lebwohl, Mark; Strober, Bruce; Linaberry, Misti; Hoyt, Kim; Banerjee, Subhashis; Kisa, Renata M.; Mehta, Nehal N.
       title: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials
        date: 2023-03-13
       words: 3497
      flesch: 63
     summary: mg/dL and <500 mg/dL and a calculated ASCVD risk ≥5% Objective • To report changes in lipid parameters in patients enrolled in POETYK PSO-1 and PSO-2 and treated with: — Placebo, deucravacitinib, or apremilast over 16 weeks — Deucravacitinib continuously for 52 weeks Methods Study designs • POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) were phase 3, 52-week, double-blind, randomized, placebo- and active comparator (apremilast)-controlled trials conducted globally (Figure 1) — Enrolled patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥12; static Physician’s Global Assessment [sPGA] ≥3; body surface area involvement ≥10%) were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily during Weeks 0–16 — Blinded treatment switches occurred at Week 16 and Week 24 • Patients receiving placebo crossed over to deucravacitinib at Week 16 • Patients receiving apremilast who failed to meet trial-specific efficacy thresholds in POETYK PSO-1 (≥50% reduction from baseline in PASI [PASI 50]) and in POETYK PSO-2 (≥75% reduction from baseline in PASI [PASI 75]) were switched to deucravacitinib at Week 24 • Patients receiving deucravacitinib who achieved PASI 75 at Week 24 in POETYK PSO-2 were re-randomized (1:1) to continue deucravacitinib or to switch to placebo (withdrawal); patients receiving apremilast who achieved PASI 75 were switched to placebo Figure 1. Synopsis • Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of cytokines (interleukin-23 and Type I interferons) involved in psoriasis pathogenesis1 • Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy2 based on results from the phase 3 POETYK PSO-1 and PSO-2 trials3,4 • Plaque psoriasis is associated with hypertriglyceridemia and metabolic syndrome,5,6 and the frequency of hypertriglyceridemia increases with plaque psoriasis severity7 — Triglycerides ≥150 mg/dL are among the clinical characteristics used to identify patients with metabolic syndrome8 — The American Academy of Dermatology recommends that patients with plaque psoriasis be informed about their increased risk of metabolic syndrome and have frequent lipid screenings, especially when the disease is severe5 • In clinical trials enrolling patients with moderate to severe plaque psoriasis, treatment with deucravacitinib was associated with slight increases (~10 mg/dL) in mean triglyceride levels in the absence of any changes in mean cholesterol levels2 •
    keywords: baseline; deucravacitinib; grade; patients; week
       cache: skin-1966.pdf
  plain text: skin-1966.txt

        item: #678 of 1356
          id: skin-1967
      author: Lebwohl, Mark; Egeberg, Alexander; Linaberry, Misti; Hoyt, Kim; Banerjee, Subhashis; Kisa, Renata M.; Strober, Bruce
       title: Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
        date: 2023-03-13
       words: 4369
      flesch: 48
     summary: In two phase 3 pivotal trials in patients with moderate to severe plaque psoriasis, deucravacitinib demonstrated a robust safety and efficacy profile, including superiority to placebo and apremilast4,5 • Deucravacitinib treatment did not result in clinically relevant mean changes over time across multiple laboratory parameters, including in measures of liver transaminases6 — Mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels remained unchanged and within normal limits over Weeks 0-166 — Increases in liver transaminases have been observed with Janus kinase 1/2/3 inhibitors in patients with autoimmune diseases, including plaque psoriasis7 • However, increases ≥3× the upper limit of normal (ULN) in ALT and AST were observed over 16 weeks in individual patients2 — ALT elevations ≥3× ULN were reported in 9 patients (3.6/100 person-years Prior use of infliximab, etanercept, and methotrexate ■ Patient 2 Deucravacitinib 12 ― • Patient BMI 32.7 kg/m2, no other relevant medical history or medications available ● Patient 3 Deucravacitinib Screening, 1 ― • History of coronary artery disease, myocardial infarction, hypertriglyceridemia, Type 2 diabetes, hypertension, BMI 33.4 kg/m2, and previous left nephrectomy • Previous treatment with etanercept, clobetasol, and betamethasone dipropionate; previous and continuing treatment with metformin, aspirin, losartan, lorazepam ● Patient 4 Deucravacitinib 1 ― • History of hepatic steatosis and obesity (BMI 38.6 kg/m2)
    keywords: alt; ast; baseline; deucravacitinib; patient; treatment; uln; week
       cache: skin-1967.pdf
  plain text: skin-1967.txt

        item: #679 of 1356
          id: skin-1968
      author: Lebwohl, Mark; Warren, Richard B.; Sofen, Howard; Imafuku, Shinichi; Paul, Carle; Szepietowski, Jacek C.; Spelman, Lynda; Passeron, Thierry; Colston, Elizabeth; Hippeli, Lauren; Napoli, Andrew; Kisa, Renata M.; Banerjee, Subhashis; Menter, Alan; Thaçi, Diamant; Blauvelt, Andrew
       title: Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
        date: 2023-03-13
       words: 3345
      flesch: 41
     summary: Objectives • To examine long-term efficacy responses in POETYK PSO-1 patients who: — Received continuous deucravacitinib treatment from Day 1 and entered the POETYK LTE — Achieved PASI 75 response on deucravacitinib at Week 16, continued on deucravacitinib, and entered the POETYK LTE Methods Study designs and analysis populations • In addition to the as-observed analysis, 2 methods of imputation for missing data were used to evaluate long-term efficacy: — Treatment failure rules (TFR)9: patients who discontinued treatment or the study due to worsening of psoriasis or lack of efficacy were imputed as nonresponders — Modified NRI (mNRI)10: multiple imputation analysis was used for imputation of missing values, and patients who discontinued due to worsening of psoriasis were imputed as nonresponders • Only patients who discontinued or had reached Week 112 by the cutoff date of October 1, 2021, were included Results Baseline patient demographics and disease characteristics • Baseline demographics and disease characteristics for POETYK PSO-1 patients randomized to deucravacitinib who rolled over to the POETYK LTE are presented in Table 1 • A total of 332 patients were randomized to deucravacitinib — 265 patients completed the study and entered the POETYK LTE — 173 PASI 75 responders at Week 16 entered the POETYK LTE Table 1.
    keywords: baseline; deucravacitinib; lte; pasi; patients; pharma; poetyk; treatment; week
       cache: skin-1968.pdf
  plain text: skin-1968.txt

        item: #680 of 1356
          id: skin-1969
      author: Bagel, Jerry; Armstrong, April W.; Warren, Richard B.; Papp, Kim A.; Thaçi, Diamant; Menter, Alan; Cather, Jennifer; Augustin, Matthias; Hippeli, Lauren; Daamen, Carolin; Griffiths, Christopher EM
       title: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
        date: 2023-03-13
       words: 3677
      flesch: 42
     summary: Figure 4. PASI 75 response rates through Week 52 in systemic treatment-naive, prior systemic treatment, and prior oral systemic treatment patients (NRI)a 0 10 20 30 40 50 60 P A SI 7 5 re sp on se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks Figure 7. sPGA 0/1 response rates through Week 52 in systemic treatment-naive, prior systemic treatment, and prior oral systemic treatment patients (NRI)a 0 10 20 30 40 50 60 sP G A 0 /1 r es po n se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks Systemic treatment naive 24 28 32 36 40 44 48 52 132 132 132 132 132 132 132 132 132 132 132 127 122 127 129 132 57 57 57 57 57 57 57 51 51 51 51 51 50 51 51 51 53.0% 52.3% 5.3% 51.0% 0 10 20 30 40 50 60 sP G A 0 /1 r es po n se r at e, % o f pa ti en ts 70 80 90 100 0 1 2 4 8 12 16 Primary endpoint 20 Weeks
    keywords: deucravacitinib; patients; pharma; placebo; systemic; treatment
       cache: skin-1969.pdf
  plain text: skin-1969.txt

        item: #681 of 1356
          id: skin-197
      author: Kircik, Leon; Weiss, Jonathan S; Allenby, Kent
       title: DFD-01, a VCA midpotent beteamethasone dipropionate 0.05% emollient-like spray formulation, demonstrates earlier onset of action compared with a super potent topical steroid for the treatment of moderate psoriasis
        date: 2017-10-27
       words: 495
      flesch: 50
     summary: Pooled Analysis of Early Onset of Relief of Erythema and Scaling ¾ Data from two phase 3, randomized, clinical trials enrolling adults with moderate plaque psoriasis (IGA=3; 10% to 20% BSA) were pooled. ¾ DFD-01, a VCA midpotent topical steroid, [Sernivo™ (betamethasone dipropionate)
    keywords: dfd-01
       cache: skin-197.pdf
  plain text: skin-197.txt

        item: #682 of 1356
          id: skin-1970
      author: Lebwohl, Mark; Murina, Andrea; Han, George ; Jacobson, Abby
       title: Brodalumab: 4-Year US Pharmacovigilance Report
        date: 2023-03-13
       words: 1238
      flesch: 42
     summary: One case of ulcerative colitis, which was not suspected to be related to brodalumab, was reported Malignancies • 37 malignancies were reported in 32 patients (0.81 events/ 100 PYs); none were considered related to brodalumab Depression and suicide • There were 4 new depression cases reported during year 4; no causality assessments were provided • There were no completed suicides throughout the 4-year report and no new suicide attempts reported (there was 1 previously reported suicide attempt, with no indicated causal relationship between brodalumab and the patient’s attempted self-harm) SYNOPSIS • Brodalumab is an interleukin-17 receptor A antagonist indicated for moderate-to-severe plaque psoriasis in adult patients with loss of or no response to alternative systemic therapies1 – Brodalumab has a boxed warning for suicidal ideation and behavior in the United States, even though pivotal clinical trials and recent pharmacovigilance data do not confirm a causal relationship1-3 – No completed suicides and 1 suicide attempt by a patient with a history of depression occurred during the initial 3-year pharmacovigilance reporting period3 – Arthralgia was the most common treatment-specific adverse event (AE) in the 2- and 3-year pharmacovigilance reports3,4 METHODS • Pharmacovigilance data reported to Ortho Dermatologics by US patients and healthcare providers were compiled from August 15, 2017, through August 14, 2021 • The most common AEs listed in the brodalumab package insert (incidence ≥1%; arthralgia, headache, myalgia, influenza, diarrhea, oropharyngeal pain, nausea, injection-site reactions, fatigue, neutropenia, and Tinea infections) and AEs of special interest were assessed as exposure-adjusted rates per 100 patient-years (PYs) • Brodalumab exposure was estimated as the time between the first and last prescription-dispensing authorization dates. dOne patient increased brodalumab dose.
    keywords: brodalumab; dermatologics; new; ortho; year
       cache: skin-1970.pdf
  plain text: skin-1970.txt

        item: #683 of 1356
          id: skin-1971
      author: Messier, Nancy; Couture, Frédéric; Théberge, Vanessa; Harvey, Mario; Kobayashi, Kenneth
       title: Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model
        date: 2023-03-13
       words: 1777
      flesch: 57
     summary: This results in the development of BCC tumors that are unresponsive to traditional hedgehog inhibitors targeting SMO protein activity. Twice a week intralesional treatment of mouse tumors (Fig.9) seems more effective than weekly treatment (Fig.8 and table 1) in these pre-clinical studies.
    keywords: bcc; day; mouse; treatment
       cache: skin-1971.pdf
  plain text: skin-1971.txt

        item: #684 of 1356
          id: skin-1972
      author: Del Rosso, James; Guenthner, Scott; Hong, Chih-ho; Jett, John E; Brown, Philip M.; Rubenstein, David S. ; Piscitelli, Stephen
       title: Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
        date: 2023-03-13
       words: 1780
      flesch: 31
     summary: No Correlation Between Tapinarof Exposure (C max on Days 1 and 29) and Baseline %BSA Affected in the Psoriasis Maximal-Use Trial BSA, body surface area; C max maximum plasma concentration. ≥20% 3%–20% Trial drug Tapinarof cream: 0.5% QD, 0.5% BID, 1% QD, 1% BID Vehicle cream: QD or BID Tapinarof cream: 1% QD Tapinarof cream: 1% QD Vehicle cream: QD PK sampling Weeks 1, 2, 4, 8, and 12 Days 1, 15, and 29 Weeks 4 and 12 AD, atopic dermatitis; BID, twice daily; BSA, body surface area; IGA, Investigator Global Assessment; PGA, Physician Global Assessment; PK, pharmacokinetic; QD, once daily.
    keywords: exposure; patients; psoriasis; tapinarof; trial
       cache: skin-1972.pdf
  plain text: skin-1972.txt

        item: #685 of 1356
          id: skin-1974
      author: Kircik, Leon; Draelos, Zoe ; Stein Gold, Linda; Jacobson, Abby
       title: Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action
        date: 2023-03-13
       words: 1262
      flesch: 48
     summary: Author disclosures: LK has served as an investigator, speaker, advisory board member, or consultant for Abbott Laboratories; Aclaris, Inc; Allergan, Inc; Amgen Inc; Anacor Pharmaceuticals, Inc; Assos Pharma; Astellas Pharma US, Inc; Asubio Pharma Co, Ltd; Berlex Laboratories (Bayer Healthcare Pharmaceuticals); Biogen-Idec, Inc; Biolife; Biopelle; Boehringer Ingelheim; Breckin- ridge Pharma; Celgene Corporation; Centocor, Inc; Colbar; CollaGenex; Combinatrix; Connetics Corporation; Coria; Dermik Laboratories; Dermira, Inc; Dow Pharmaceutical Sciences, Inc; Dusa Pharmaceuticals, Inc; Eli Lilly & Co; Embil Pharmaceutical Co, Ltd; EOS; Ferndale Laboratories, Inc; Galderma Laboratories, LP; Genentech, Inc; GlaxoSmithKline, PLC; Health Point Ltd; Idera, Inc; Innocutis Medical, LLC; Innovail; Intendis, Inc; Johnson & Johnson; Laboratory Skin Care, Inc; Leo Pharmaceuticals, Inc; L’Oreal SA; 3M; Maruho Co, Ltd; Medical International Technologies; Medicis Pharmaceutical Corp; Merck & Co, Inc; Merz; Nano Bio Corporation; Novartis Pharmaceutical Corporation; Noven Pharmaceuticals, Inc; Nucryst Pharmaceuticals Corporation; Obagi Medical Products, Inc; Onset; OrthoNeutrogena; PediaPharma, Inc; Promius Pharma, LLC; PharmaDerm; Pfizer, Inc; PuraCap; QLT, Inc; Quatrix; Quinnova; Serono (Merck-Serono International SA); SkinMedica, Inc; Stiefel Laboratories, Inc; Sun Pharmaceutical Industries, Ltd; Taro; TolerRx, Inc; Triax; UCB, Inc; Valeant Pharmaceuticals North America LLC; Warner-Chilcott; XenoPort, Inc; and ZAGE. At week 8 in the scalp psoriasis study6: – 10/21 patients (48%) achieved a score of IGA 0 or 1 – 15/21 patients (>70%) achieved an sIGA score of 0 or 1, and 50% maintained these scores at week 12 (Figure 3) – Nearly one-third of patients (29%) had sIGA 0, and 20% maintained sIGA 0 at week 12 • Significant improvements from baseline in PSSI 75 rates were observed at weeks 4, 8, and 12 (P≤0.0005 for all) • Rates of PSSI 75/90/100 were maintained from week 8 to 12 (Figure 4) – PSSI 75: 67% of patients achieved PSSI 75 at week 8, with 45% maintaining at week 12 – PSSI 90: 38% of patients achieved PSSI 90, with 30% maintaining at week 12 – PSSI 100: 29% of patients achieved PSSI 100, with 20% maintaining at week 12 OBJECTIVE • To review previously published results from open- label studies of HP/TAZ in palmoplantar psoriasis and scalp psoriasis in the context of reduction of proinflammatory mediators such as TNF-α CONCLUSION •
    keywords: inc; psoriasis; pssi; taz; week
       cache: skin-1974.pdf
  plain text: skin-1974.txt

        item: #686 of 1356
          id: skin-1975
      author: Kircik, Leon; Zirwas, Mathew; Kwatra, Shawn G.; Lewitt, Michael; Glover, Holly; Chao, Tomas; Brown, Philip M.; Rubenstein, David S.; Tallman, Anna 
       title: Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis
        date: 2023-03-13
       words: 2562
      flesch: 54
     summary: Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc., in accordance with Good Publication Practice (GPP) guidelines (Ann Intern Med. L.K. has served as a consultant/speaker/investigator/advisory board member for Abbott Laboratories, AbbVie, Ablynx, Aclaris, Acambis, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Assos Pharma, Astellas Pharma US, Inc., Asubio, Bausch Health, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen Idec, Biolife, Biopelle, BMS, Boehringer Ingelheim, Breckinridge Pharma, Cassiopea, Centocor, Inc., Cellceutix, Cipher, Coherus, Colbar, Combinatrix, Connetics Corporation, Coria, Dermavant Sciences, Inc., Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Inc., Dr. Reddy’s Lab, Dusa, Embil Pharmaceuticals, Eli Lilly, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Ferrer, Galderma, Genentech, Inc., GlaxoSmithKline, Glenmark, Health Point, Ltd, Idera, Incyte, Intendis, Innocutis, Innovail, Isdin, Johnson & Johnson, Kyowa Kirin, Laboratory Skin Care Inc., LEO Pharma, L’Oreal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharmaceutical Corp., Merz, Nano Bio, Novartis AG, Nven Pharmaceuticals, Nucryst Pharmaceuticals Corp., Obagi, Onset, OrthoNeutrogena, PediaPharma, Pfizer, Promius, PuraCap, PharmaDerm, QLT, Inc., Quinnova, Quatrix, Regeneron, Sanofi, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB Pharma, Valeant Pharmaceuticals Intl., Warner-Chilcott, XenoPort, and ZAGE.
    keywords: inc; itch; p<0.0001; tapinarof; vehicle; week
       cache: skin-1975.pdf
  plain text: skin-1975.txt

        item: #687 of 1356
          id: skin-1977
      author: Paller, Amy; Hebert, Adelaide A.; Jett, John E; Brown, Philip M.; Rubenstein, David S.; Piscitelli, Stephen
       title: Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial
        date: 2023-03-13
       words: 1851
      flesch: 37
     summary: BSA involvement ≥25% for adolescents (12–17 years) or ≥35% for children (2–11 years) Use of any prohibited medication or procedure within the indicated period before the baseline visit A vIGA-ADTM score of ≥3 at screening and baseline (pre-dosing) History of sensitivity to the trial medications AD present for ≥6 months for patients aged 6–17 years or 3 months for patients aged 2–5 years Previous known participation in a clinical trial with tapinarof AD, atopic dermatitis; BSA, body surface area; vIGA-ADTM, validated Investigator Global Assessment for Atopic DermatitisTM. Primary Endpoints ■ Incidence, frequency, and nature of adverse events (AEs) and serious AEs ■ Change from baseline in laboratory values and vital signs ■ Mean Investigator-assessed Local Tolerability Scale scores by visit (overall and sensitive areas) ■ Tapinarof plasma PK parameters on Day 1, including: – Area under the plasma concentration versus time curve from baseline to the last quantifiable concentration (AUC 0–last ) – Maximum plasma concentration (C max ) – Time to maximum plasma concentration (t max ) – Time of last quantifiable concentration (t last ) ■ Tapinarof plasma concentration on Day 28 Secondary Endpoints ■ Change in validated Investigator Global Assessment for Atopic DermatitisTM (vIGA-ADTM) score by visit ■ Proportion of patients with a vIGA-ADTM score of clear (0) or almost clear (1) by visit ■ Proportion of patients with ≥50%, ≥75%, and ≥90% improvement in Eczema Area and Severity Index (EASI) score by visit ■ Mean change and percent change in EASI score by visit ■ Mean change and percent change in %BSA affected by visit ■ Proportion of patients with a baseline Peak Pruritus-Numeric Rating Scale (PP-NRS) score of ≥4 who achieve a ≥4-point reduction in PP-NRS score by visit – Proportion of patients ≥12 years old with a baseline PP-NRS score ≥4 who achieve a ≥4-point reduction in PP-NRS score by visit – Proportion of patients 2–12 years old with a baseline PP-NRS score ≥4 who achieve a ≥4-point reduction in PP-NRS score by visit – Mean change in PP-NRS score at each visit by age group Statistical Analyses ■ Safety analyses will include all patients who received at least one application of tapinarof ■ Analyses of efficacy endpoints will be based upon the safety population RESULTS Baseline Patient Demographics and Disease Characteristics ■ Overall, 36 patients were enrolled at nine sites in the US and Canada ■ Patients’ baseline demographics and disease characteristics are shown in Table 2 – Equal proportions of patients (33.3% [12/36]) were young children (2–6 years), children (7–11 years), and adolescents (12–17 years) – Most patients (77.8%) across the three groups had a vIGA-ADTM score of 3 (moderate) – Overall mean (standard deviation 6. Lebwohl M, et al. N Engl J Med.
    keywords: patients; score; tapinarof; trial; years
       cache: skin-1977.pdf
  plain text: skin-1977.txt

        item: #688 of 1356
          id: skin-198
      author: Kircik, Leon; Okumu, Franklin; Kandavilli, Sateesh
       title: Permeation Analysis of Novel Steroid Vehicles to Deliver and Retain Steroid in Skin Layers Associated with Psoriasis
        date: 2017-10-27
       words: 516
      flesch: 45
     summary: The F-10 formulation had skin layer betamethasone concentrations of 33 ng, 18 ng, and 14 ng in the stratum corneum, epidermis, and dermis, respectively (Figure 1). Permeation analysis of novel steroid vehicles to deliver and retain steroid in skin layers associated with psoriasis Leon Kircik, MD1; Franklin Okumu, PhD2; Sateesh Kandavilli, PhD2 1DermResearch, PLLC, Louisville, KY; 2Promius Pharma, a subsidiary of Dr. Reddy’s Laboratories, Princeton, NJ Introduction ¾
    keywords: skin
       cache: skin-198.pdf
  plain text: skin-198.txt

        item: #689 of 1356
          id: skin-1980
      author: Rice, Zakiya; Gooderham, Melinda; Lebwohl, Mark G.; Simpson, Eric L. ; Boguniewicz, Mark; Wollenberg, Andreas; Lazariciu, Irina; Chan, Gary L.; Alderfer, Justine; Watkins, Melissa
       title: Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis
        date: 2023-03-13
       words: 1930
      flesch: 50
     summary: A greater proportion of patients achieved IGA 0/1 or EASI-75 with abrocitinib versus placebo at week 12 across all subgroups of disease severity classified by baseline IGA score, baseline EASI score, or %BSA at baseline • Efficacy responses were dose dependent across all subgroups of baseline disease severity in the pooled monotherapy population • AEs were similar in both the IGA 3 and IGA 4 baseline disease severity subgroups, with no unexpected safety signals REFERENCES 1. Eligibility Criteriaa • ≥18 years of age with AD for ≥1 year • Moderate-to-severe AD (IGA ≥3; EASI ≥16; %BSA ≥10; PP-NRS ≥4) JADE COMPARE Placebo QD (n=155) Abrocitinib 100 mg QD (n=314) Abrocitinib 200 mg QD (n=309) Eligibility Criteriaa • ≥12 years of age with AD for ≥1 year • Moderate-to-severe AD (IGA ≥3; EASI ≥16; %BSA ≥10; PP-NRS ≥4) JADE MONO-1 JADE MONO-2 0 2 4 8 Time (Weeks) 12 16 %BSA, percentage of body surface area; AD, atopic dermatitis; EASI, Eczema Area and Surface Index; EASI-75, ≥75% improvement on the EASI; IGA, Investigator’s Global Assessment; IGA 0/1, IGA score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline; IGA 3, IGA score of 3 (moderate); IGA 4, IGA score of 4 (severe); PP-NRS, Peak Pruritus Numerical Rating Scale (used with permission from Regeneron Pharmaceuticals, Inc., and Sanofi); Q2W, once every 2 weeks; QD, once daily; TEAE, treatment-emergent adverse event.
    keywords: abrocitinib; baseline; iga; inc; jade; pfizer
       cache: skin-1980.pdf
  plain text: skin-1980.txt

        item: #690 of 1356
          id: skin-1981
      author: Korman, Neil J.; Passeron, Thierry; Gordon, Kenneth B.; Okubo, Yukari; Bagel, Jerry; Sofen, Howard; Warren, Richard B.; Bhatia, Neal; Spelman, Lynda; Winthrop, Kevin; Hippeli, Lauren; Kisa, Renata M.; Banerjee, Subhashis; Thaçi, Diamant
       title: Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
        date: 2023-03-13
       words: 3215
      flesch: 51
     summary: Research grants: Eisai, Maruho, Shiseido, and Torii; Current consulting/advisory board agreements: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, and Sun Pharma; Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, Jimro, Kyowa Kirin, Leo Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB; Clinical trials: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Maruho, Pfizer, Sun Pharma, and UCB • JB: Research funds payable to the Psoriasis Treatment Center of New Jersey: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas’ (Corrona) Psoriasis Registry, Dermavant, Dermira/UCB, Eli Lilly, Glenmark, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; Consultant: AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; Speaker: AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis • HS: Clinical investigator: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and Sun Pharma • RBW: Research grants: AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, and UCB; Consulting fees: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, DICE Therapeutics, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, UCB, and UNION • The selectivity of deucravacitinib facilitates a more targeted therapeutic approach that avoids signature laboratory changes seen with the Janus kinase (JAK) 1/2/3 inhibitors — In phase 2 and phase 3 trials (POETYK PSO-1 and PSO-2) in plaque psoriasis, deucravacitinib treatment did not result in neutropenia, elevated liver enzyme and serum creatinine levels, and dyslipidemia — adverse events that have been associated with JAK 1/2/3 inhibitors3-7 • Deucravacitinib demonstrated a robust efficacy profile, including superiority to placebo and apremilast and durability and maintenance of response, in 2 multinational phase 3 trials in patients with moderate to severe plaque psoriasis5,6,8 • Patients who completed the POETYK PSO-1 and PSO-2 trials could enroll in the ongoing POETYK long-term extension (LTE) trial Objectives • To determine whether there were any clinically relevant changes in blood laboratory parameters with up to 2 years of deucravacitinib treatment in the POETYK PSO-1, PSO-2, and LTE trials • To evaluate whether deucravacitinib treatment elicits changes in the blood that are known to occur with JAK 1/2/3 inhibitors Methods Study designs • POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) were 52-week, multinational, phase 3, double-blind trials that randomized patients with moderate to severe plaque psoriasis 2:1:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily (Figure 2)
    keywords: deucravacitinib; lilly; lte; myers; pharma; poetyk; pso-1; squibb
       cache: skin-1981.pdf
  plain text: skin-1981.txt

        item: #691 of 1356
          id: skin-1982
      author: Fiorillo, Loretta; Becker, Emily; de Lucas, Raul; Belloni-Fortina, Anna; Armesto, Susana ; Maes, Peter ; Oberoi, Rajneet ; Paris, Maria ; Zhang, Wendy; Zhang, Zuoshun ; Arkin, Lisa 
       title: Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study
        date: 2023-03-13
       words: 666
      flesch: 43
     summary: This study was sponsored by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Lakshmi Narendra Bodduluru, PhD, of Cactus Life Sciences (part of Cactus Communications), and Dawn Nicewarner, PhD, CMPP, employee of and stockholder in Amgen Inc. PASI-75 response: a ≥ 75% reduction in PASI scores from baseline.
    keywords: amgen; apremilast; psoriasis; week
       cache: skin-1982.pdf
  plain text: skin-1982.txt

        item: #692 of 1356
          id: skin-1983
      author: Merola, Joseph; Parish, Lawrence; Guenther, Lyn ; Lynde, Charles ; Lacour, Jean-Philippe ; Staubach, Petra ; Cheng, Sue; Jardon, Shauna; Paris, Maria ; Chen, Mindy ; Papp, Kim 
       title: Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study
        date: 2023-03-13
       words: 937
      flesch: 37
     summary: Key takeaways Apremilast, the first oral treatment to be studied for genital psoriasis, significantly improved disease symptoms, including skin, itch, and QoL and was well-tolerated in patients who were inadequately controlled by or intolerant to medications applied to the skin For additional findings, scan the QR code 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2Parish Dermatology, Philadelphia, PA, USA; 3Guenther Research Inc., London, ON, Canada; 4Lynde Institute for Dermatology, Markham, ON, Canada; 5Probity Medical Research, Markham, ON, Canada; 6CHU de Nice - Hôpital l'Archet, Nice, France; 7Department of Dermatology, University Medical Center, Mainz, Germany; 8Amgen Inc., Thousand Oaks, CA, USA; 9Probity Medical Research, Waterloo, ON, Canada; 10K Papp Clinical Research, Waterloo, ON, Canada Up to 63% of patients with psoriasis report genital psoriasis,1,2 which can lead to: • Itching • Discomfort • Impaired QoL • Negative impact on sexual health Patient population: • Genital psoriasis severity (modified sPGA-G) score ≥ 3 • Overall psoriasis severity (sPGA) score ≥ 3 • Nongenital plaque psoriasis on ≥ 1% of BSA • Intolerant to/or not controlled by medications applied to the skin for genital psoriasis Phase 3, multicenter study Week 36 1: 1 Fo llo w -u p Week 16 Placebo Apremilast Week 32 Apremilast Apremilast Week 0 143 patients 146 patients 289 patients randomized Key secondary outcomes: • sPGA response to assess overall psoriasis severity • GPI-NRS response to assess genital itch severity • Change from baseline in DLQI score to assess the impact of psoriasis on QoL at week 16 What was our aim? To evaluate the benefit, safety, tolerability, and effect on health-related QoL of apremilast in patients with moderate to severe genital psoriasis after 16 weeks of treatment in the DISCREET study (NCT03777436) Limited treatment options are available for patients with moderate to severe genital psoriasis
    keywords: amgen; apremilast; pharma; psoriasis; spga
       cache: skin-1983.pdf
  plain text: skin-1983.txt

        item: #693 of 1356
          id: skin-1984
      author: Park, Sang Hee ; Zhong, Yichen ; Sima, Adam ; Patel, Vardhaman; Zhuo, Joe ; Roberts-Toler, Carla ; Becker, Brandon ; Hovland, Sara ; Strober, Bruce 
       title: Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy
        date: 2023-03-13
       words: 2623
      flesch: 32
     summary: (48.9) Severe (10–100), n (%) 204 (24.1) 66 (12.6) 138 (42.7) PASI score, mean (SD) 5.0 (5.9) 3.4 (5.2) 7.5 (6.1) 0.72 IGA score, mean (SD) 2.4 (1.1) 1.9 (1.1) 3.1 (0.6) 1.27 Unique nonbiologic systemics used prior to current systemic, n (%) 0 739 (87.1) 469 (89.3) 270 (83.6) 0.13 1 90 (10.6) 43 (8.2) 47 (14.6) ≥ 2 19 (2.2) 13 (2.5) 6 (1.9) Duration of current therapy (< 90 days), n (%) 386 (45.5) 241 (45.9) 145 (44.9) 0.02 IGA, Investigator’s Global Assessment; PASI, Psoriasis Area and Severity Index; SD, standard deviation. Odds of switching to biologic treatment, overall analysis • Unadjusted odds of switching were significantly higher in patients who reported greater vs lesser burden as measured by the DLQI or by VAS itch, skin pain, fatigue, or PGA; in those who reported activities impairment on the WPAI; and in those who reported moderate or extreme pain and discomfort, activities impairment, or anxiety/depression on the EQ-5D-3L (P ≤ 0.003) — Odds of switching were numerically higher among patients who reported moderate or extreme problems with walking or self-care on the EQ-5D-3L • After adjusting for disease severity and baseline characteristics, greater disease burden was an independent predictor for treatment switching to biologics (Figure 1) — Patients with DLQI scores > 5 had 55% higher odds of switching than those with DLQI scores ≤ 5 (adjusted odds ratio [aOR] = 1.55 The outcome measure was a switch to biologic treatment up to 45 days after Registry enrollment — Switching was defined as the introduction of a biologic therapy in addition to, or in place of, their current nonbiologic systemic therapy vs continuation of initial nonbiologic systemic treatment with no changes • Biologic therapies included adalimumab, certolizumab, etanercept, infliximab, ustekinumab, guselkumab, risankizumab, tildrakizumab, secukinumab, ixekizumab, brodalumab, and bimekizumab — Patients were excluded if they had switched from one nonbiologic systemic treatment to another • The study period extended from April 2015 to August 2022 — Because of the timeline, the study did not include switching from deucravacitinib, an oral, allosteric, selective tyrosine kinase 2 (TYK2) inhibitor approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy3 Independent variables • At Registry enrollment, patients completed self-reported measures of disease burden — Dermatology Life Quality Index (DLQI) • 10 items assessed dermatology-specific HRQoL • Total scores ranged from 0-30, with higher scores indicating poorer quality of life — Visual analog scale (VAS) ratings for itch, skin pain, and fatigue (each considered separate measures) •
    keywords: burden; odds; patients; psoriasis; treatment; vas
       cache: skin-1984.pdf
  plain text: skin-1984.txt

        item: #694 of 1356
          id: skin-1985
      author: Thyssen, Jacob P.; Bewley, Anthony; Ständer, Sonja; Castro, Carla; Misery, Laurent; Kim, Brian S.; Biswas, Pinaki; Chan, Gary L.; Myers, Daniela E.; Watkins, Melissa; Alderfer, Justine; Güler, Erman; Silverberg, Jonathan I. 
       title: Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis
        date: 2023-03-13
       words: 1785
      flesch: 53
     summary: PB, GC, DEM, MW, JA, and EG are employees and shareholders of Pfizer Inc. JIS served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. Abstract 639. ACKNOWLEDGMENTS Editorial/medical writing support under the guidance of authors was provided by Renata Cunha, PharmD, and Jaya Kolipaka at ApotheCom, San Francisco, CA, USA, and was funded by Pfizer Inc., New York, NY, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022; 10.7326/M22-1460).
    keywords: abrocitinib; inc; jade; patients; placebo; sanofi
       cache: skin-1985.pdf
  plain text: skin-1985.txt

        item: #695 of 1356
          id: skin-1986
      author: Armstrong, April; Lebwohl, Mark; Stein Gold, Linda; Jacobson, Abby
       title: Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis
        date: 2023-03-13
       words: 1247
      flesch: 58
     summary: Indirect Comparison of Time to Response6 Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis OBJECTIVE • To characterize the time to response of brodalumab by directly comparing brodalumab with ustekinumab or placebo in clinical studies and by indirectly comparing brodalumab with other psoriasis biologics CONCLUSIONS • Onset of response was more rapid than other psoriasis biologics in direct and indirect comparisons • Brodalumab provides a safe and effective treatment option, with rapid onset of symptom relief and improvements in quality of life, for adult patients with moderate-to-severe psoriasis SYNOPSIS • Several factors should be considered when selecting the most appropriate treatment of moderate-to-severe psoriasis, including drug effectiveness, potential adverse events, and time to response1 • The human anti–interleukin-17 receptor A monoclonal antibody brodalumab has been shown to be safe and effective for moderate-to-severe psoriasis in adults and improves clinical outcomes more rapidly than other psoriasis biologics2 METHODS • • Brodalumab treatment was associated with greater proportions of PSI total responders (defined as weekly average PSI total score ≤8, with no item scores >1) and PSI itch responders (defined as weekly average PSI itch score ≤1; P<0.0001) vs ustekinumab, indicating a rapid reduction in patient-reported symptom severity (AMAGINE-2/-3; Figure 2)8 – Additionally, a significantly greater proportion of patients treated with brodalumab vs ustekinumab achieved a PSI total score of 0 at week 12 (22.7% vs 13.4%; P<0.001)8 Figure 2. Brodalumab treatment was associated with a faster onset of symptom improvement, assessed via proportion of PSI responders, vs ustekinumab8 in AMAGINE-2/-3 for (A) PSI total score and (B) PSI itch score.
    keywords: brodalumab; pasi; psoriasis; week
       cache: skin-1986.pdf
  plain text: skin-1986.txt

        item: #696 of 1356
          id: skin-1987
      author: Brownstone, Nicholas; Farberg, Aaron; Quick, Ann; Siegel, Jennifer; Goldberg, Matthew; Lio, Peter
       title: Survey Results Identifying Clinician Strategies for Therapy Selection for Common Inflammatory Skin Diseases
        date: 2023-03-13
       words: 1035
      flesch: 41
     summary: Reason for systemic therapy discontinuation Average number systemic therapies needed for efficacy Percent all respondents that would find a molecular test for AD or psoriasis therapy guidance useful “No symptom improvement” was the top reason reported for patient discontinuation of systemic medications for AD or psoriasis. Additionally, 62.3% (165) of clinicians surveyed estimated that, on average, 2 or more systemic therapies were needed to find one that was efficacious indicating that lack of efficacy for individual patients contributes to switching systemic therapies.
    keywords: psoriasis; selection; therapy
       cache: skin-1987.pdf
  plain text: skin-1987.txt

        item: #697 of 1356
          id: skin-1988
      author: Shi, Vivian; Bhutani, Tina; Deleuran, Mette; Fonacier, Luz; Shumack, Stephen; Zhang, Fan; Cameron, Michael C. ; Chan, Gary L.; Valdez, Hernan; Yin, Natalie
       title: Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study
        date: 2023-03-13
       words: 1724
      flesch: 43
     summary: Abrocitinib is a Janus kinase 1 (JAK1) inhibitor that is under investigation for the treatment of moderate-to-severe AD2,3 OBJECTIVE • To assess the proportion of dupilumab nonresponder patients from JADE COMPARE who experienced clinically meaningful improvement in signs and symptoms of AD after switching to abrocitinib in JADE EXTEND METHODS • Phase 3 JADE COMPARE included adults with moderate-to-severe AD and inadequate response to topical medication or a need for systemic therapy to control AD • This post hoc analysis focused on patients with moderate-to-severe AD who received dupilumab and concomitant topical therapy for 16 weeks in JADE COMPARE followed by entry into JADE EXTEND (Figure 1) • 2020;156:863-873. ACKNOWLEDGMENTS Editorial/medical writing support under the guidance of authors was provided by Renee Gordon, PhD, and Richard W. Davis IV, PhD, at ApotheCom (San Francisco, CA, USA), and was funded by Pfizer Inc., New York, NY, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022; 10.7326/M22-1460).
    keywords: abrocitinib; dupilumab; group; jade
       cache: skin-1988.pdf
  plain text: skin-1988.txt

        item: #698 of 1356
          id: skin-1989
      author: Simpson, Eric L. ; Silverberg, Johnathan; Nosbaum, Audrey; Winthrop, Kevin; Guttman-Yassky, Emma; Hoffmeister, Karin M.; Egeberg, Alexander; Valdez, Hernan; Fan, Haiyun; Farooqui, Saleem A.; Chan, Gary L.; Alderfer, Justine; Romero, William; Johnson, Susan
       title: Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years
        date: 2023-03-13
       words: 2241
      flesch: 34
     summary: No risk factors were identified for serious infections in a Cox regression analysis • Potential risk factors for treatment-emergent herpes zoster included abrocitinib dose, age ≥65 years, medical history of herpes zoster, absolute lymphocyte count <1000/mm3 prior to infection, and region (Supplemental Table S2) Malignancies and Cardiovascular Events • IRs for malignancies and cardiovascular events are reported in Figure 2 for the continuous-dose cohort, and in Supplementary Figure S1 for the variable-dose cohort – IRs were higher in patients aged ≥65 years compared with younger patients Hematological Events • IRs for thrombocytopenia and lymphopenia are reported in Figure 2 for the continuous-dose cohort and in Supplementary Figure S1 for the variable-dose cohort – IRs for thrombocytopenia and lymphopenia events were higher in patients aged ≥65 years compared with younger patients Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years ◦ For JADE REGIMEN (200 mg only), only patients from the open-label run-in phase who did not subsequently enter the randomized phase were included • Patients may have received their first dose of abrocitinib in JADE EXTEND if they previously received placebo in the placebo- controlled parent studies and/or dupilumab in JADE COMPARE or JADE DARE • Patients from the phase 2b study (NCT02780167) who received abrocitinib 200 mg or 100 mg were also included – In the variable-dose cohort, patients received different doses of abrocitinib (200 mg and 100 mg) throughout exposure time in the parent study (JADE REGIMEN) and were enrolled in JADE EXTEND • Patients who completed the open-label period of JADE REGIMEN (abrocitinib 200 mg only) and entered the randomized phase (abrocitinib 200 mg, abrocitinib 100 mg, or placebo) were included • Some patients subsequently entered the JADE REGIMEN rescue phase (abrocitinib 200 mg) and/or
    keywords: abrocitinib; cohort; dose; inc; jade; patients; pfizer
       cache: skin-1989.pdf
  plain text: skin-1989.txt

        item: #699 of 1356
          id: skin-199
      author: Sidgiddi, Srinivas; Ranganathan, Usha; Gautam, Anirudh
       title: DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application
        date: 2017-10-27
       words: 719
      flesch: 63
     summary: The Cmax after multiple twice daily applications of DFD-03 was 62.99% of the Cmax of multiple once daily applications of Tazorac cream (Table 1). ¾ Blood samples were collected on days 1, 7 and 14, prior to product application and for up to 24 hours after product application.
    keywords: minute
       cache: skin-199.pdf
  plain text: skin-199.txt

        item: #700 of 1356
          id: skin-1991
      author: Kimball, Alexa B ; Alavi, Afsaneh; Jemec, Gregor BE; Gottlieb, Alice; Wei, Xiaoling; Wozniak, Magdalena B; Uhlmann, Lorenz; Martinez, Angela Llobet; Keefe, Deborah; Martin, Ruvie; Chen, Li; Muscianisi, Elisa
       title: Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials
        date: 2023-03-13
       words: 2923
      flesch: 57
     summary: LU, and ALM are employees and stockholders at Novartis Pharma AG, Basel, Switzerland. The authors thank Swati Shrivastava and Nivedita Jangale of Novartis Healthcare Pvt Ltd, Hyderabad for editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland in accordance with the Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3)
    keywords: n=180; patients; placebo; secq4w; secukinumab; sunrise; sunshine; week
       cache: skin-1991.pdf
  plain text: skin-1991.txt

        item: #701 of 1356
          id: skin-1995
      author: Armstrong, April W. ; Park, Sang Hee ; Patel, Vardhaman ; Hogan, Malcolm ; Wang, Wei-Jhih ; Davidson, David ; Chirikov, Viktor 
       title: Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years
        date: 2023-03-13
       words: 2863
      flesch: 33
     summary: Sensitivity analyses: adjusted PASI 90 response rates at Weeks 52 and 112 -0.6 (-10.0, 8.9) -0.8 (-10.2, 8.5) -4.4 (-12.4, 3.7) -3.1 (-11.1, 4.9) -0.7 (-12.0, 10.6) 7.3 (-2.0, 16.7) 7.6 (-1.8, 16.9) 6.9 (-1.3, 15.0) 6.9 (-1.1, 14.9) 2.8 (-8.0, 13.6) -20 -10 0 10 20 30 Mean difference (95% CI) Greater efficacy of deucravacitinibLower efficacy of deucravacitinib Base case Sensitivity analysis 4 Sensitivity analysis 3 Sensitivity analysis 2 Sensitivity analysis 1 Base case Sensitivity analysis 4 Sensitivity analysis 3 Sensitivity analysis 2 Sensitivity analysis 1 Week 52 Week 112 Sensitivity analysis 1: History of psoriatic arthritis and Physician Global Assessment scores plus base case variables. Study design comparison between (A) REVEAL and (B) POETYK PSO-1 and PSO-2 A. B. Screening ≤ 28 days Period A INITIAL RESPONSE 16-week DBPC Period B SUSTAINED RESPONSE 17-week open label Period C LOSS OF ADEQUATE RESPONSE 19-week DBPC Adalimumab 40 mg EOW† (n = 26) Adalimumab 40 mg EOW (n = 22) Adalimumab 40 mg EOW (n = 580) Adalimumab 40 mg EOW* (n = 812) Placebo EOW (n = 398) 1 :1 R an d o m iz at io n ≥ PASI 75 response continue to period C Patients with < PASI 75 response enter OLE Patients with PASI responses > 50 and < 75 enter OLE N = 1212 ≥ PASI 75 response continue to period B 2:1 Randomization Week 0 16 33 52 Adalimumab 40 mg EOW (n = 250) Placebo EOW (n = 240) 165100 160
    keywords: adalimumab; analysis; deucravacitinib; pasi; response; sensitivity; week
       cache: skin-1995.pdf
  plain text: skin-1995.txt

        item: #702 of 1356
          id: skin-1996
      author: Rischin, Danny; Brungs, Daniel ; Day, Fiona ; Christie, Hayden ; Patel, Vishal;  Adams, Gerard ; Estes Jackson, James; De Liz Vassen Schurmann, Maite; Kirtbaya, Dmitry ; Shin, Thuzar ; Hart, Christopher; Stankevich, Elizabeth ; Li, Siyu; Lowy, Israel ; Han, Hyunsil ; Gonçalves, Priscila ; Fury, Matthew ; Porceddu, Sandro 
       title: C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma
        date: 2023-03-13
       words: 1576
      flesch: 41
     summary: Additionally, retrospective random RT treatment plan review will be performed on approximately 20% of study patients, including the first enrolled in each site whenever possible. Some patients, however, have high risk of recurrence as assessed by immune status, primary disease stage, extent of nodal involvement, presence of extracapsular extension, and prior treatment.1,2 • Postoperative radiation therapy is recommended for patients with high-risk features, but relapse with locoregional recurrence or distant metastases may still occur.3 Cemiplimab • Cemiplimab is an anti−programmed cell death-1 (PD-1) antibody approved in the US and Europe for the treatment of patients with locally advanced or metastatic CSCC who are not candidates for curative surgery or radiotherapy and is approved or under review by other health authorities.4–8 • Results from the Phase 1 (NCT02383212) and Phase 2 (NCT02760498) trials of cemiplimab generally demonstrated a clinically meaningful activity and an acceptable safety profile in patients with advanced CSCC consistent with other anti–PD-1 agents.9,10 •
    keywords: cemiplimab; cscc; patients; radiation; risk; study; therapy
       cache: skin-1996.pdf
  plain text: skin-1996.txt

        item: #703 of 1356
          id: skin-1997
      author: Hamid, Omid; Lewis, Karl; Weise, Amy; McKean, Meredith; Papadopoulos, Kyriakos P; Crown, John; Kim, Tae Min; Lakhani, Nehal J; Kaczmar, John; Kudchadkar, Ragini; Spira, Alexander; Rabinowits, Guilherme; Kim, Kevin; Carvajal, Richard; Williamson, Stephen; Ioffe, Ella; Chen, Shuquan; Mani, Jayakumar; Jankovic, Vladimir; Brennan, Laura; Kroog, Glenn; Sims, Tasha; Lowy, Israel; Gullo, Giuseppe
       title: Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis
        date: 2023-03-13
       words: 3282
      flesch: 57
     summary: CI, confidence interval; CR, complete response; DOR, duration of response; NE, not estimable; NR, not reached; PD, progressive disease; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; PR, partial response; SD, stable disease; SOD, sum of diameters. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 100 80 60 40 20 0 -20 -40 -60 -80 -100 PD SD PR CR B e s t p e rc e n t c h a n g e fr o m b a s e lin e Patients (N=76) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 100 80 60 40 20 0 -20 -40 -60 -80 -100 P e rc e n t o f S O D c h a n g e fr o m b a s e lin e Months 0 Total (Cohorts 6 + 15) †Prior systemic therapies, including prior adjuvant therapies, excluded for Cohort 15. CI, confidence interval; DCR, disease control rate; DOR, duration of response; KM, Kaplan-Meier; LDH, lactase dehydrogenase; N1, proportion of patients with the listed LDH status; N2, proportion of patients with the listed liver metastasis status; NE, not evaluable; NR, not reached; ORR, objective response rate; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; ULN, upper limit of normal.
    keywords: anti; cohort; patients; response; treatment; weeks
       cache: skin-1997.pdf
  plain text: skin-1997.txt

        item: #704 of 1356
          id: skin-1998
      author: Rabinowits, Guilherme; Homsi, Jade ; Park, Soo; Khushalani, Nikhil ; Panella, Timothy ; Ellison, David; Gentry, Rhonda; Venna, Suraj; Strasswimmer, John; Zuniga, Richard ; Chandra, Sunandana ; Ruiz, Emily; Migden, Michael; Ibrahim, Sherrif; Mehta, Nikita ; Inocencio, Timothy ; He, Xuanyao; Zhang, Haixin; Gillis, Kathryn ; Pouliot, Jean-Francois
       title: CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
        date: 2023-03-13
       words: 2052
      flesch: 48
     summary: • Patient survival rates after early diagnosis of CSCC are good, but morbidity and mortality rates in patients with advanced CSCC not amenable to curative surgery or curative radiotherapy remain high, leaving a significant unmet need.1 • Cemiplimab is a high-affinity, highly potent, fully human, immunoglobulin G4 monoclonal antibody to the programmed cell death (PD)-1 receptor, derived using VelocImmune technology.2 • Cemiplimab (cemiplimab-rwlc in the USA) is approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of adult patients with locally advanced or metastatic CSCC who are not candidates for curative surgery or curative radiation; adult patients with locally advanced or metastatic basal cell carcinoma (BCC) previously treated with (US prescribing information [USPI])3/progressed on (Summary of Product Characteristics [SmPC])4 a hedgehog pathway inhibitor, or for whom a hedgehog pathway inhibitor is not appropriate (USPI)3/intolerant (SmPC),4 and for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer who are not candidates for surgery or definitive chemoradiation and whose tumors have a tumor proportion score of ≥50% and with no EGFR, ALK, or ROS1 aberrations.3,4 • Limited data exist on the clinical characteristics, management, disease progression, and survivorship of patients with advanced CSCC in real-world clinical practice. Here, we describe the demographics, effectiveness, and safety of an initial cohort of patients with advanced CSCC treated with cemiplimab in real-world clinical practice and enrolled in the CASE study (NCT03836105).
    keywords: cemiplimab; cscc; patients; study; table; treatment; usa
       cache: skin-1998.pdf
  plain text: skin-1998.txt

        item: #705 of 1356
          id: skin-1999
      author: Hughes, Brett; Grob, Jean-Jacques ; Bowyer, Samantha; Day, Fiona ; Ladwa, Rahul; Stein, Brian ; Muñoz-Couselo, Eva; Basset-Seguin, Nicole; Guminski, Alexander ; Mortier, Laurent ; Hauschild, Axel ; Migden, Michael ; Schmults, Chrysalyne ; Yoo, Suk-Young; Booth, Jocelyn ; Seebach, Frank ; Lowy, Israel ; Fury, Matthew;  Rischin, Danny 
       title: Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6
        date: 2023-03-13
       words: 1959
      flesch: 61
     summary: Group Advanced CSCC cemiplimab 350 mg Q3W (Group 6) CSCC, cutaneous squamous cell carcinoma; ICR, independent central review; OS, overall survival; PFS, progression-free survival; Q3W, every 3 weeks. Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC):
    keywords: cemiplimab; cscc; group; median; patients; q3w; response
       cache: skin-1999.pdf
  plain text: skin-1999.txt

        item: #706 of 1356
          id: skin-20
      author: Wong, Christina Y; Billings, Steven D; Warren, Christine B
       title: Positive Nikolsky Sign and Pinpoint “Lakes of Pus”
        date: 2017-08-31
       words: 1642
      flesch: 47
     summary: The histopathologic findings were consistent with the diagnosis of acute generalized exanthematous pustulosis (AGEP). Acute generalized exanthematous pustulosis (AGEP): A review and update.
    keywords: acute; agep; pustulosis; skin
       cache: skin-20.pdf
  plain text: skin-20.txt

        item: #707 of 1356
          id: skin-2000
      author: Stratigos, Alexander J; Sekulic, Aleksandar; Peris, Ketty; Bechter, Oliver; Prey, Sorilla; Kaatz, Martin; Lewis, Karl D; Basset-Seguin, Nicole; Chang, Anne Lynn S; Dalle, Stéphane; Orland, Almudena Fernandez; Licitra, Lisa; Robert, Caroline; Ulrich, Claas; Hauschild, Axel; Migden, Michael R; Dummer, Reinhard; Yoo, Suk-Young; Coates, Ebony; Okoye, Emmanuel; Bassukas, Ioannis; Loquai, Carmen; De Giorgi, Vincenzo; Eroglu, Zeynep; Gutzmer, Ralf; Ulrich, Jens; Puig, Susana; Seebach, Frank; Lowy, Israel; Fury, Matthew G
       title: Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up
        date: 2023-03-13
       words: 2559
      flesch: 55
     summary: Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Conclusions • This long-term follow-up analysis further confirms the safety and efficacy of cemiplimab in patients with laBCC after progression on or intolerance to HHI therapy.
    keywords: cell; dermatology; disease; hhi; labcc; months; patients; response; university
       cache: skin-2000.pdf
  plain text: skin-2000.txt

        item: #708 of 1356
          id: skin-2001
      author: Migden, Michael; Schmults, Chrysalyne; Khushalani, Nikhil; Guminski, Alexander ; Chang, Anne Lynn; Lewis, Karl ; Ansstas, George ; Bowyer, Samantha ; Hughes, Brett ; Schadendorf, Dirk ; Modi, Badri ; Dunn, Lara ; Flatz, Lukas ; Hauschild, Axel ; Yoo, Suk-Young ; Booth, Jocelyn ; Seebach, Frank ; Lowy, Israel ; Fury, Matthew ; Rischin, Danny 
       title: Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
        date: 2023-03-13
       words: 2768
      flesch: 58
     summary: 350 mg Q3W Number of subjects at risk mCSCC cemiplimab: 3 mg/kg Q2W laCSCC cemiplimab: 3 mg/kg Q2W mCSCC cemiplimab: 350 mg Q3W 30 35 26 30 33 26 29 32 26 28 31 25 24 29 23 24 27 23 23 24 23 23 23 22 23 19 22 21 19 22 20 18 21 18 16 19 18 16 17 18 15 15 18 14 14 17 11 10 13 11 9 13 11 9 12 10 7 9 6 5 0 2 5 0 1 1 0 1 1 0 1 1 0 1 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 CSCC, cutaneous squamous cell carcinoma; DOR, duration of response; ICR, independent central review; laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell carcinoma; Q2W, every 2 weeks; Q3W, every 3 weeks. CSCC, cutaneous squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group; laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell carcinoma.
    keywords: cancer; cell; cemiplimab; mcscc; patients; q2w
       cache: skin-2001.pdf
  plain text: skin-2001.txt

        item: #709 of 1356
          id: skin-2002
      author: Lewis, Karl D; Peris, Ketty; Sekulic, Aleksandar; Stratigos, Alexander J; Dunn, Lara; Eroglu, Zeynep; Chang, Anne Lynn S; Migden, Michael R; Yoo, Suk-Young; Mohan, Kosalai; Coates, Ebony; Okoye, Emmanuel; Baurain, Jean-François; Bechter, Oliver; Hauscild, Axel; Butler, Marcus O; Hernandez-Aya, Leonel; Licitra, Lisa; Neves, Rogerio I; Ruiz, Emily S; Seebach, Frank; Lowy, Israel; Goncalves, Priscila; Fury, Matthew G
       title: Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors
        date: 2023-03-13
       words: 2604
      flesch: 51
     summary: ‡Defined as the proportion of patients with complete response, partial response, stable disease or non-complete response/non-progressive disease. §Defined as the proportion of patients with complete response, partial response, stable disease, or non-complete response/non-progressive disease for ≥182 days without progressive disease.
    keywords: cell; cemiplimab; disease; hhi; icr; mbcc; oncology; patients; response; usa
       cache: skin-2002.pdf
  plain text: skin-2002.txt

        item: #710 of 1356
          id: skin-2003
      author: Piliang, Melissa; Lynde, Charles; King, Brett; Mirmirani, Paradi ; Sinclair, Rodney; Wolk, Robert ; Zwillich, Samuel ; Tran , Helen; Zhang, Fan ; Takiya, Liza 
       title: Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
        date: 2023-03-13
       words: 1784
      flesch: 46
     summary: OBJECTIVE • To evaluate the maintenance of efficacy from Week 24 to Week 48 in patients with AA and ≥50% scalp hair loss treated with ritlecitinib METHODS Study design • The ALLEGRO phase 2b/3 trial was an international, randomized, double-blind, placebo-controlled, combined dose- ranging and pivotal study (Figure 1) • Patients initially received daily ritlecitinib (± a 4-week 200-mg daily loading dose): 200/50, 200/30, 50, 30, or 10 mg (10 mg assessed for dose ranging only) or placebo for 24 weeks • During the 24-week extension period, ritlecitinib groups continued on 50-, 30-, or 10-mg maintenance doses, and patients initially assigned to placebo switched to 200/50 or 50 mg daily Figure 1. The proportions of ritlecitinib-treated patients with clinical response at Week 24, based on SALT score ≤20 or SALT score ≤10, who sustained this response through Week 48, were assessed in this post-hoc analysis • Definition of sustained response included: - Response at Week 24 and Week 48, based on SALT score ≤20 or ≤10, and - No loss of response (defined as SALT score >20 or >10) at any time point between Weeks 24 and 48 (Weeks 28, 34, or 40) • Patients with missing SALT score data at Weeks 28, 34, or 40 were included in the analysis if they had observed SALT data at Week 48; patients with missing data at Week 48 were excluded from the analysis Statistical analysis • Descriptive analyses were used to evaluate the proportion of ritlecitinib-treated patients with SALT score ≤20 or SALT score ≤10 response at Week 24, who sustained this response through Week 48 • 95% CIs were calculated based on normal approximation RESULTS Table 1.
    keywords: patients; ritlecitinib; salt; week
       cache: skin-2003.pdf
  plain text: skin-2003.txt

        item: #711 of 1356
          id: skin-2004
      author: Bhatia, Neal; Vasquez, J Gabriel; Schenkel, Brad; Heim, Jayme
       title: Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
        date: 2023-03-13
       words: 1238
      flesch: 48
     summary: Asian 1 (1.8) Ethnicity Hispanic or Latino 5 (9.1) Not Hispanic or Latino 50 (90.9) Age, years, mean ± SD 48.6 ± 15.3 Happiness with Psoriasis Control, mean ± SD 2.7 ± 2.3 ITT population. Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis Neal Bhatia1, J Gabriel Vasquez2, Brad Schenkel3, Jayme Heim2 1Therapeutics Clinical Research, San Diego, CA, USA; 2West Michigan Dermatology, Grandville, MI, USA; 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA INTRODUCTION
    keywords: satisfaction; week
       cache: skin-2004.pdf
  plain text: skin-2004.txt

        item: #712 of 1356
          id: skin-2005
      author: Blume-Peytavi, Ulrike ; Gubelin Harcha, Walter ; Yang, Qinping ; Schmieder, George ; Hordinsky, Maria; Micali, Giuseppe ; Ohyama, Manabu ; Takiya, Liza ; Zhang, Fan ; Schaefer, Gregor ; Wolk, Robert ; Kerkmann, Urs
       title: Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
        date: 2023-03-13
       words: 1968
      flesch: 50
     summary: Response based on % improvement from baseline in SALT scores over time QD, once daily; SALT, Severity of Alopecia Tool; SALT 50/75/90/100 , 50%/75%/90%/100% improvement from baseline in SALT score. Response based on % improvement from baseline in SALT score at Weeks 24 and 48 • Over 48 weeks of treatment, the most frequent adverse events (AEs), with no evident dose response, were upper respiratory tract infection, nasopharyngitis, and headache • Most AEs were mild or moderate in severity, 12 serious AEs were reported, and 26 patients permanently discontinued treatment due to AEs up to Week 48 • Overall, there were 8 cases of herpes zoster infection, 4 serious infections, 2 malignancies (both breast cancer), and 1 pulmonary embolism; no major adverse cardiovascular events, deaths, or opportunistic infections were reported Outcomes •
    keywords: mg qd; ritlecitinib; salt; week
       cache: skin-2005.pdf
  plain text: skin-2005.txt

        item: #713 of 1356
          id: skin-2006
      author: Heim, Jayme; Vasquez, J Gabriel; Schenkel, Brad; Bhatia, Neal
       title: Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
        date: 2023-03-13
       words: 1666
      flesch: 56
     summary: Asian 1 (1.8) Ethnicity Hispanic or Latino 5 (9.1) Not Hispanic or Latino 50 (90.9) Age, years, mean ± SD 48.6 ± 15.3 PGWBI score, mean ± SD Total score 78.1 ± 14.1 Positive Well-Being 12.6 ± 3.3 General Health 9.9 ± 2.5 Anxiety 16.9 ± 4.0 Depressed Mood 12.5 ± 2.1 Self-Control 12.9 ± 2.1 Vitality 13.3 ± 3.2 DLQI score, mean ± SD 9.4 ± 5.2 ITT population. DLQI score Proportion of patients with: • DLQI score of 0 or 1 • DLQI score ≤5 • ≥5-point reduction in DLQI score 64 X Time points (Weeks) shown in bold indicate when the primary efficacy endpoint was assessed (at Weeks 28 and 52) and the end of the study (at Week 64).
    keywords: dlqi
       cache: skin-2006.pdf
  plain text: skin-2006.txt

        item: #714 of 1356
          id: skin-2007
      author: Menter, Alan M; Draelos, Zoe; Heim, Jayme; Gogineni, Ranga; Griffiths, Christopher EM
       title: Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2
        date: 2023-03-13
       words: 1720
      flesch: 55
     summary: Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2 Alan M Menter1, Zoe Draelos2, Jayme Heim3, Ranga Gogineni4, Christopher EM Griffiths5 1Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA; 2Dermatology Consulting Services, High Point, NC, USA; 3West Michigan Dermatology, Grandville, MI, USA; 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 5Centre for Dermatology Research, The University of Manchester, Manchester, UK INTRODUCTION • Higher body weight is associated with reduced efficacy of some biological therapies in patients with psoriasis1 • Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy2 • To provide clarity regarding the efficacy and safety of tildrakizumab in relation to body weight, we analyzed efficacy and safety at the decile level OBJECTIVE • To evaluate the efficacy and safety of tildrakizumab across weight deciles up to Week 28 using pooled data from the two randomized, placebo-controlled, Phase 3 trials (reSURFACE 1 Proportion of patients with PASI 75/90/100 response at A) Week 12 and at B) Week 28 by body weight decile and treatment A) B) Full Analysis Set.
    keywords: decile; pasi; week; weight
       cache: skin-2007.pdf
  plain text: skin-2007.txt

        item: #715 of 1356
          id: skin-2008
      author: Nestor, Mark S; Han, Haowei; Yousefian, Faraz; Smythe, Ciaran
       title: The efficacy and safety of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light for the treatment of facial cutaneous squamous cell carcinoma in situ
        date: 2023-03-13
       words: 820
      flesch: 44
     summary: The primary efficacy endpoint was the proportion of patients achieving histological clearance of isSCC at the end of treatment/surgical excision • Tolerability was assessed from local skin reactions (LSRs) and patient-reported lesion site pain — Lesion site pain was measured using a visual analog scale ranging from 0 (no pain) to 10 (worst pain possible) within 15 minutes of each treatment session • Safety was assessed from frequency of adverse events (AEs) RESULTS Efficacy • Of 20 enrolled patients, 17 (85%) achieved histological clearance at the end of treatment • After excluding two patients with residual isSCC exhibiting skip lesions, the histological clearance rate was 17/18 patients (94%) • Images obtained during visit 1 (pretreatment; Figure 1A) and visit 10 (posttreatment; Figure 1B) show clinical clearance of isSCC with ALA-PDL-PDT Treatments and procedures • ALA 20% topical solution was applied to the lesion and adjacent skin and incubated for 18–24 hours, followed by PDL treatment (pulse duration: 0.45 milliseconds, fluence: 13 J/cm2, amount determined by the investigator) and then blue light illumination (BLU-U®; 10 J/cm2 for 16 minutes 40 seconds) • Patients underwent 2 ALA-PDL-PDT treatment sessions separated by a 30-day period •
    keywords: patient; treatment
       cache: skin-2008.pdf
  plain text: skin-2008.txt

        item: #716 of 1356
          id: skin-2009
      author: Eichenfield, Lawrence F; Hebert, Adelaide A; Stein Gold, Linda; Cartwright, Martina; Moro, Luigi; Han, Jenny; Squittieri, Nicholas; Mazzetti, Alessandro
       title: Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris
        date: 2023-03-13
       words: 2364
      flesch: 50
     summary: A multicenter, open-label, long-term extension study (CB-03-01/27) enrolled patients who completed 1 of the 12-week Phase 3 clinical trials (CB-03-01/25 and CB-03-01/26) • Male or nonpregnant female patients who completed 1 of the 12-week Phase 3 pivotal clinical trials (CB-03-01/25 and CB-03-01/26) and enrolled within 3 days of the final pivotal trial visit were eligible – Patients with any skin pathology or condition that could interfere with the study or who planned to use other topical or systemic antiacne preparations or undergo procedures on the face (or trunk, if applicable) were excluded – This analysis includes only patients aged ≥12 years old who entered the long-term extension study Treatment administered • Patients applied 1% clascoterone cream twice daily to the entire face and, if designated by the investigator and desired by the patient, to truncal acne, for 9 additional months of treatment – Total time applying clascoterone cream, including the Phase 3 studies, could be up to 12 months for patients originally randomized to clascoterone treatment – Clascoterone treatment could be discontinued if the Investigator’s Global Assessment (IGA) score was 0 or 1 (clear/almost clear) and reinstated if/when acne worsened Assessments • Safety was evaluated from frequencies of treatment-emergent adverse events (TEAEs), serious adverse events, and local skin reactions (LSRs), including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/ burning, and pruritus – Summarized in patients ≥12 years old who received at least one application of clascoterone (safety population) Safety • Overall, 108/598 (18.1%) patients in the safety population experienced a total of 187 TEAEs, with similar frequencies in patients previously treated with clascoterone compared with vehicle in the Phase 3 studies (Table 2) – The majority of TEAEs reported were mild or moderate in severity, and most were not considered related to clascoterone treatment – The most frequent TEAEs by percentage of patients affected were nasopharyngitis (2.8%) and upper respiratory tract infection (1.8%; Table 3) Table 2.
    keywords: clascoterone; patients; study; treatment
       cache: skin-2009.pdf
  plain text: skin-2009.txt

        item: #717 of 1356
          id: skin-2010
      author: Migden, Michael; Guminski, Alexander; Gutzmer, Ralf; Loquai, Carmen; Squittieri, Nicholas; Foley, Peter 
       title: Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study
        date: 2023-03-13
       words: 2038
      flesch: 39
     summary: Hedgehog inhibitors were developed to block aberrant Hedgehog signaling found in the majority of sporadic basal cell carcinomas (BCCs); inhibition of the Hedgehog pathway is among the few treatment options available for patients with advanced BCC1,2 • Sonidegib is a Hedgehog inhibitor that selectively targets Smoothened3 and is approved at a dose of 200 mg daily in the US, the EU, Switzerland, and Australia for the treatment of adult patients with locally advanced BCC (laBCC) not amenable to curative surgery or radiation therapy3–6 — Sonidegib 200 mg daily is also approved to treat metastatic BCC (mBCC) in Switzerland and Australia5,6 • Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study Michael Migden1, Alexander Guminski2,3,4, Ralf Gutzmer5, Carmen Loquai6, Nicholas Squittieri7, Peter Foley8,9,10 1University of Texas MD Anderson Cancer Center, Departments of Dermatology, Division of Internal Medicine, and Head and Neck Surgery, Division of Surgery, Houston, TX, USA; 2Department of Oncology, Royal North Shore Hospital, St Leonards, Australia; 3Melanoma Institute Australia, The University of Sydney, Sydney, Australia; 4Mater Hospital, Sydney, Australia; 5Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany; 6Department of Dermatology, University Medical Center Mainz, Mainz, Germany; 7Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 8Department of Dermatology, St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia; 9The University of Melbourne, Parkville, Victoria, Australia; 10Skin Health Institute Inc, Carlton, Victoria, Australia BACKGROUND •
    keywords: daily; grade; labcc; patients; response; sonidegib
       cache: skin-2010.pdf
  plain text: skin-2010.txt

        item: #718 of 1356
          id: skin-2011
      author: Grubbs, Hailey; Cortes, Marianne; Strasswimmer, John
       title: Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution
        date: 2023-03-13
       words: 833
      flesch: 42
     summary: SYNOPSIS • Basal cell carcinoma (BCC) is the most common cancer worldwide, with an increasing annual incidence1,2 — In patients with advanced BCC, lesions become extensively locally invasive or metastatic, and traditional first-line surgical treatment may be contraindicated3 • Tumor regrowth was noted after 5 weeks without therapy, so sonidegib was reinstated at the same dose for another 5 weeks • In total, the patient completed three 5-week sonidegib cycles with 5 weeks of medication holiday between each cycle • Following the third course of sonidegib, the patient and her family were satisfied with treatment results — More than 1 year later, she continues to deny further issues CONCLUSIONS • Combining a low dose of sonidegib with ice cream, a high-fat food, helped overcome the patient’s gastrointestinal absorption and swallowing issues • Clinical improvement of BCC was noted after 5 weeks of sonidegib treatment • Adverse effects included nausea and muscle cramping, though the patient’s bloodwork values remained within normal limits for the duration of treatment • The patient best tolerated a treatment regimen alternating 5 weeks on and 5 weeks off sonidegib REFERENCES 1) Asgari MM, et al. JAMA Dermatol.
    keywords: bcc; patient; sonidegib; treatment
       cache: skin-2011.pdf
  plain text: skin-2011.txt

        item: #719 of 1356
          id: skin-2012
      author: Vecchiolla, Michael; Bhatia, Neal
       title: Patient Perspectives on use of a water-based Calcipotriene and Betamethasone Dipropionate Cream for the treatment of Plaque Psoriasis
        date: 2023-03-13
       words: 661
      flesch: 44
     summary: A key benefit of the PAD formulation used in WYNZORA cream is a reduced surfactant requirement compared to conventional emulsion systems Presented at the 20th Anniversary Winter Clinical Dermatology Conference – Hawaii®; January 13–18, 2023; Kohala Coast, Hawaii. Synopsis • Patient satisfaction with topical medications for the treatment of plaque psoriasis is directly related to adherence and real-world efficacy1 • Poor cosmetic characteristics and the time-consuming nature of greasy topical agents cause up to 75% of patients to become nonadherent with topical psoriasis treatments2,3 • Most patients have mild psoriasis that is amenable to topical therapies4 • WYNZORA® (calcipotriene [CAL] and • To assess patient satisfaction with CAL/BDP cream applied once daily to affected areas • Patients with plaque psoriasis strongly preferred a novel, water-based CAL/BDP cream formulation to previously used prescription topical therapies •
    keywords: cream; patient; psoriasis
       cache: skin-2012.pdf
  plain text: skin-2012.txt

        item: #720 of 1356
          id: skin-2013
      author: Guminski, Alexander; Foley, Peter; Grob, Jean-Jacques; Robert, Caroline; Gutzmer, Ralf ; Squittieri, Nicholas; Kiecker, Felix
       title: Biochemistry laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study
        date: 2023-03-13
       words: 2048
      flesch: 45
     summary: Hedgehog inhibitors were developed to block aberrant Hedgehog signaling found in most sporadic basal cell carcinomas (BCCs); inhibition of the Hedgehog pathway is among the limited treatment options available for patients with advanced BCC1,2 • Sonidegib is a Hedgehog inhibitor that selectively targets Smoothened3 and is approved in the US, the EU, Switzerland, and Australia for the treatment of adult patients with locally advanced BCC (laBCC) not amenable to curative surgery or radiation therapy3–6 — Sonidegib is also approved to treat metastatic BCC (mBCC) in Switzerland and Australia5,6 • CONCLUSIONS • Through 42 months of treatment with sonidegib 200 mg daily, most patients experienced no biochemistry changes or Grade 1 biochemistry shifts • Overall safety findings at 42 months were consistent with observations at 30 months9 REFERENCES 1.
    keywords: bcc; daily; grade; patients; response; sonidegib; treatment
       cache: skin-2013.pdf
  plain text: skin-2013.txt

        item: #721 of 1356
          id: skin-2014
      author: Yousefian, Omid; Aeschliman, Lisa ; Mortillo, Susan ; Ruvolo, Eduardo
       title: Evaluation of a Novel Inorganic Tinted Sunscreen Enriched with Five Antioxidants for Protection Against UVA1 and VL Induced Hyperpigmentation and Erythema
        date: 2023-03-13
       words: 1768
      flesch: 58
     summary: Iron Oxides SPF 40; G. 9% Zinc Oxide + 7.5% Octinoxate + Iron Oxides SPF 46; H. 11% TiO2 + Erythema and Pigmentation (All Time Points, Pooled) Statistically Significant Reduction in Melanin and Oxy-Hemoglobin in novel ZnO/Fe2O3/5 AOX, Group C (All Time Points, Pooled Data) 2023 Winter Clinical Conference – Hawaii Sponsorship: Research sponsored by Beiersdorf Inc., Stamford, CT Formula Information A 24.08% Zinc Oxide Control SPF 50 C 24.08% Zinc Oxide + 5 AOX + Iron Oxides SPF 35 E 5.5% TiO2 + 10% Zinc Oxide +
    keywords: aox; iron; oxide; skin; spf; zinc
       cache: skin-2014.pdf
  plain text: skin-2014.txt

        item: #722 of 1356
          id: skin-2015
      author: Burden, David; Okubo, Yukari; Zheng, Min; Thaci, Diamant; van de Kerkhof, Peter; Hu, Na; Thoma, Christian; Choon, Siew Eng
       title: Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study
        date: 2023-03-13
       words: 1867
      flesch: 48
     summary: sex, age, race, BMI, GPPGA pustulation subscore at baseline, GPPGA total score at baseline, JDA GPP severity score at baseline, presence of plaque psoriasis at baseline, and IL36RN status • Scan the QR code at the bottom of this poster to see full details of the Effisayil 1 study design3,4 RESULTS Subgroup analysis from the Effisayil 1 study showed that the efficacy of spesolimab (pustular and skin lesion clearance) was consistent across all prespecified patient populations, including those with or without IL36RN mutations Genotyping data were available for 46 patients. The placebo arm included a higher proportion of female and Asian patients than the spesolimab arm; clinical characteristics were generally balanced between study arms Subgroup analysis of GPPGA total score of 0 or 1 at Week 1 The efficacy of spesolimab (GPPGA pustulation subscore of 0 or 1) was consistent across patient subgroups Missing values or any use of other medication for GPP within the first week of the trial were regarded as non-response for the analysis of these endpoints.
    keywords: baseline; boehringer; gppga; ingelheim; patients; spesolimab
       cache: skin-2015.pdf
  plain text: skin-2015.txt

        item: #723 of 1356
          id: skin-2016
      author: Hebert, Adelaide; Rieder, Evan; Graber, Emmy; Baldwin, Hilary; Harper, Julie; Stein Gold, Linda; Kircik, Leon; Alexis, Andrew; Del Rosso, James; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail; Fried, Richard
       title: Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among pediatric patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S: PROSES study
        date: 2023-03-13
       words: 1539
      flesch: 40
     summary: Objective: Evaluate patient self-perceived AV symptoms and impact of AV on emotional/social functioning and ADL, among pediatric patients with AV in community practices across the U.S. Methods: Single-arm, prospective cohort study (PROSES) was conducted with moderate-to- severe non-nodular AV patients >9yrs who were prescribed sarecycline in real-world U.S community practices. Conclusion: Moderate to severe AV burden and psychosocial impact was observed in this prospective cohort of pediatric patients with AV in the U.S. Emotional impact and social impact of AV were more pronounced across the pediatric age groups.
    keywords: burden; impact; yrs
       cache: skin-2016.pdf
  plain text: skin-2016.txt

        item: #724 of 1356
          id: skin-2019
      author: Farberg, Aaron; Siegel, Jennifer ; Kurley, Sarah; Fitzgerald, Alison; Prasai, Anesh; Goldberg, Matthew; Ibrahim, Sherrif; Estrada, Sarah
       title: Incorporating the 40-gene expression profile (40-GEP) test for poorly differentiated cutaneous squamous cell carcinoma (cSCC) tumors mitigates risk assessment uncertainty from histologic grading
        date: 2023-03-13
       words: 1228
      flesch: 44
     summary: Incorporating the 40-gene expression profile (40-GEP) test for poorly differentiated cutaneous squamous cell carcinoma (cSCC) tumors mitigates risk assessment uncertainty from histologic grading Aaron S. Farberg, MD1; Jennifer J. Siegel, PhD2; Sarah J. Kurley, PhD2; Alison L. Fitzgerald, PhD2; Anesh Prasai, PhD2; Matthew S. Goldberg, MD2,3; Sherrif Ibrahim, MD4; Sarah I. Estrada, MD5 1Baylor Scott & White Health System, Dallas, TX; 2Castle Biosciences Inc., Friendswood, TX; 3Icahn School of Medicine, New York City, NY 4University of Rochester, Rochester, NY; 5Affiliated Dermatology, Scottsdale, AZ Background › With 1.8 million new cases diagnosed each year, cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer in the U.S.1 While >95% of cSCC cases are cured by surgery, an estimated 5% progress to nodal or distant metastasis, where survival rates drop to 50-83% and <40%, respectively.2,3 › The degree of differentiation plays a critical role in the progression of cSCC. Independent risk assessment by the 40-GEP complements existing systems7 40-GEP Risk Class 3- year MFS (95% CI)
    keywords: class; cscc; differentiation; gep; risk
       cache: skin-2019.pdf
  plain text: skin-2019.txt

        item: #725 of 1356
          id: skin-202
      author: Blauvelt, Andrew; Fowler, Jr., Joseph F; Schuck, Ellen; Jauch, Julia; Woehling, Heike; Leonardi, Craig L
       title: A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
        date: 2017-10-27
       words: 1839
      flesch: 52
     summary: A randomized, double-blind, multicenter study to compare the efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (GP2017) with originator adalimumab in patients with moderate-to-severe chronic plaque psoriasis Andrew Blauvelt,1 Joseph F Fowler Jr,2 Ellen Schuck,3 Julia Jauch,3 Heike Woehling,3 and Craig L Leonardi4 1Oregon Medical Research Center, Portland, Oregon; 2Dermatology Specialists, Louisville, Kentucky; 3Hexal AG, Holzkirchen, Germany; 4Central Dermatology, St Louis, Missouri Introduction • GP2017 is being developed as a proposed biosimilar to originator adalimumab. – Extensive state-of-the-art analytical studies have shown that GP2017 and originator adalimumab have identical amino acid sequences, indistinguishable secondary and tertiary structures, the same level of post-translational modifications, and similar in vitro functionality.1 – Pharmacokinetic (PK) bioequivalence was demonstrated in phase I PK studies in healthy volunteers, with GP2017 and originator adalimumab having similar clinical safety and immunogenicity profiles. The purpose of this phase III confirmatory study (NCT02016105) was to show equivalent efficacy and comparable safety and immunogenicity between GP2017 and originator adalimumab up to 51 weeks in patients with moderate-to-severe chronic plaque psoriasis.
    keywords: adalimumab; gp2017; originator; pasi; week
       cache: skin-202.pdf
  plain text: skin-202.txt

        item: #726 of 1356
          id: skin-2020
      author: Singh, Gaurav; Tolkachjov, Stan; Farberg, Aaron
       title: Integration of the 40-Gene Expression Profile (40-GEP) for Management and Treatment of High-risk Cutaneous Squamous Cell Carcinoma (cSCC): A Real-world Algorithm 
        date: 2023-03-13
       words: 1057
      flesch: 34
     summary: T2a AJCC v8: T3 BWH: T2b Rationale for 40-GEP 2.2 cm diameter, multiple stages of Mohs surgery, larger defect size (4.2 x 4.2cm) multiple stages of Mohs surgery, larger defect size (4.4 x 4.1cm) Multiple stages of Mohs surgery, poor clinical margins, patient with a history of multiple cSCCs Treatment approach pre-40-GEP CT scan, RT, and follow-up every 1-month SLNB, RT, and follow-up every 6 months Imaging to evaluate for distant metastasis was considered 40-GEP Result Class 1 (Low Risk) A Real-world Algorithm Gaurav Singh, MD, MPH, FAAD1, Stanislav N. Tolkachjov, MD2,3, Aaron S. Farberg, MD4 1Gaurav Singh MD, Milwaukee, WI; 2Epiphany Dermatology, Dallas, TX; 3University of Texas at Southwestern, Dallas, TX; 4Baylor Scott & White Health System, Dallas, TX Background › The prognostic 40-gene expression profile (40-GEP) test has established both analytical and improved clinical validity for risk stratification when compared to current staging systems.
    keywords: class; gep; risk; treatment
       cache: skin-2020.pdf
  plain text: skin-2020.txt

        item: #727 of 1356
          id: skin-2021
      author: Long, Georgina V. ; Del Vecchio, Michele ; Weber, Jeffrey ; Hoeller, Christoph ; Grob, Jean-Jacques ; Mohr, Peter ; Grabbe, Stephan ; Dutriaux, Caroline ; Chiarion-Sileni, Vanna ; Mackiewicz, Jacek ; Rutkowski, Piotr ; Arenberger, Petr ; Quéreux, Gaëlle ; Meniawy, Tarek; Ascierto, Paolo A. ; Durani, Piyush ; Lobo, Maurice ; Campigotto, Federico; Gastman, Brian; Kirkwood, John M. 
       title: Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)
        date: 2023-03-13
       words: 3333
      flesch: 58
     summary: The purpose of this report was to present the primary results of CheckMate 76K evaluating nivolumab (NIVO) vs PBO as adjuvant treatment in patients with resected stage IIB or IIC melanoma 87% 93%82% 83% 0 20 40 60 80 100 C 5-year risk of disease recurrencea (CMMR)1 Stage IIB Stage IIC 35% 43% 86% 80%77% 74% 0 20 40 60 80 100 IIB IIC IIIA IIIB IIB IIC IIIA IIIB M SS ( % ) M SS ( % ) 5-year MSS ratea (CMMR)1,2 5-year MSS rate (AJCCv8)3 Methods • In CheckMate 76K (NCT04099251), treatment-naive patients ≥ 12 years with completely resected stage IIB or IIC melanoma were randomized 2:1 to receive NIVO or PBO as shown in Figure 2 • The primary endpoint was investigator-assessed RFS (time between randomization and first recurrence) – Recurrence events included the following: local, regional, or distant recurrence; new primary melanoma and melanoma in situ; death (due to any cause) – Imaging assessments occurred every 26 weeks during years 1–3 and every 52 weeks in years 4 and 5 • Key secondary endpoints were distant metastasis-free survival (DMFS; time between randomization and first distant recurrence or death) and safety • Recurrence was investigator-assessed with imaging assessments approximately every 6 months in the first 3 years and annually in years 4 and 5 – Tumor assessments were performed per contrast-enhanced computed tomography (CT) of the chest, abdomen, pelvis, and all other known and suspected sites of disease, unless known contraindications for CT intravenous contrast • The design of CheckMate 76K includes an optional on-protocol NIVO open-label portion following recurrence on either NIVO (at ≥ 6 months from treatment) or PBO (at any time after recurrence) – The results presented here are from the initial blinded phase portion of the study • TRAEs in ≥ 5% patients in the NIVO group 6.
    keywords: melanoma; nivo; patients; pbo; rfs; stage
       cache: skin-2021.pdf
  plain text: skin-2021.txt

        item: #728 of 1356
          id: skin-2023
      author: King, Andrew ; Wong, Nikita; Potts, Geoffrey
       title: Successful Treatment of Refractory Hailey-Hailey Disease with Dupilumab: A Case Report
        date: 2023-03-13
       words: 1494
      flesch: 51
     summary: Although used for an off-label purpose, in this case, further studies should assess the clinical response and safety of patients with recalcitrant HHD treated with dupilumab. Although used for an off-label purpose, in this case, further studies should assess the clinical response and safety of patients with recalcitrant HHD treated with dupilumab.
    keywords: case; disease; dupilumab; hailey; hhd; treatment
       cache: skin-2023.pdf
  plain text: skin-2023.txt

        item: #729 of 1356
          id: skin-2024
      author: Mayo, Tiffany; Armstrong, April;  Kircik, Leon; Silverberg, Jonathan;  Blauvelt, Andrew;  Esdaile, Ben; Schneider, Shannon; Mark, Thomas; Gooderham, Melinda; Alexis, Andrew
       title: Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials
        date: 2023-03-13
       words: 2668
      flesch: 49
     summary: Scan to download a copy of this poster Copies of this poster and its content, obtained through this QR code, are for personal use only and may not be reproduced without written permission from the authors The safety profile of tralokinumab treatment was consistent across racial subgroups • Tralokinumab was generally well-tolerated, with a safety profile comparable to placebo and largely consistent across racial subgroups (Table 2) • Rates of adverse events (AEs), serious AEs, and AEs leading to drug withdrawal were low in all treatment groups • Conjunctivitis rates were lower in the Asian and Black relative to White subgroup (Table 3) Figure 4. In this post hoc analysis, tralokinumab was well-tolerated and improved the signs and symptoms of moderate-to-severe AD, regardless of race, with further improvements up to 52 weeks of treatment • Limitations of this analysis include disparate sample sizes across racial subgroups Tralokinumab improved signs and symptoms of AD across racial subgroups at Week 16 • Across three pooled trials at Week 16, tralokinumab significantly improved efficacy outcomes in the Asian and White subgroups relative to placebo.
    keywords: ecztra; patients; pharma; placebo; tralokinumab; white
       cache: skin-2024.pdf
  plain text: skin-2024.txt

        item: #730 of 1356
          id: skin-2025
      author: Mayo, Tiffany; Armstrong, April; Kircik, Leon; Silverberg, Jonathan; Blauvelt, Andrew; Esdaile, Ben; Schneider, Shannon; Mark, Thomas; Gooderham, Melinda; Alexis, Andrew
       title: Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis
        date: 2023-03-13
       words: 2475
      flesch: 33
     summary: Thomas Mark owns LEO Pharma stock. Percentage of patients achieving Worst Weekly Pruritus NRS ≤3 and DLQI ≤5 by racial subgroup at Week 56 of ECZTEND Adjusting for differences in baseline characteristics and country between subgroups impacts estimated responder proportions • Adjusted for race and country as main effects, EASI-75 was achieved in 88% of Asian patients, 90% of Black patients, and 90% of White patients (Figure 4) •
    keywords: asian; black; ecztend; leo; patients; pharma; tralokinumab
       cache: skin-2025.pdf
  plain text: skin-2025.txt

        item: #731 of 1356
          id: skin-2026
      author: Paller, Amy; Silverberg, Jonathan; Hong, H. Chih ho; Cork, Michael; Puig, Luis; Arlert, Petra; Kurbasic, Azra; Soldbro, Lise; Simpson, Eric
       title: The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial
        date: 2023-03-13
       words: 1784
      flesch: 41
     summary: Patients with at least baseline data available were included in the CDLQI adjusted mean change analysis (A), and patients with CDLQI ≥6 at baseline were included in the CDLQI reduction ≥6 analysis (B). At Week 16, problem with treatment affected patients ‘not at all’ over the past 7 days in 50.0/59.4% of tralokinumab (150/300 mg) treated patients vs 39.1% receiving placebo (Figure 2H) 0 5 10 15 20 25 30 35 40 45 0 2 4 6 8 10 12 14 16 31.0 39.5 15.9Tralokinumab 150 mg Q2W (n=84)
    keywords: cdlqi; leo; patients; pharma; placebo; tralokinumab
       cache: skin-2026.pdf
  plain text: skin-2026.txt

        item: #732 of 1356
          id: skin-2027
      author: Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard; Costanzo, Antonio ; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew
       title: Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest
        date: 2023-03-13
       words: 2857
      flesch: 39
     summary: All patients transferred from ECZTRA 1, 2, 3, 4, 5, and 7; Up to 42 months maximum tralokinumab exposure (≤1 year in PTs and ≤2.5 years in ECZTEND) Safety analysis set (n=1442) ECZTEND interim safety analysis set n=1442 Age Median years (IQR) 38.0 (27.0; 50.0) ECZTEND interim analysis baseline demographic and disease characteristics Table 2. AESIs in ECZTEND at April 30, 2021 data cut-off Conclusions • This analysis of 1442 patients with up to 42 months of treatment supports the long-term benefit-risk profile of targeted IL-13 inhibition with tralokinumab for patients with moderate- to-severe AD, with no new safety signals identified • Exposure-adjusted incidence rates of AEs of special interest were generally similar to or lower than rates reported during the short-term, placebo-controlled period up to Week 16 and declined over time • Overall, tralokinumab demonstrated sustained long-term improvement in extent and severity of atopic dermatitis over 104 weeks of treatment in ECZTEND Figure 1.
    keywords: ecztend; ecztra; patients; pharma; safety; tralokinumab; treatment; trial; week
       cache: skin-2027.pdf
  plain text: skin-2027.txt

        item: #733 of 1356
          id: skin-2028
      author: Warren, Richard; Reich, Kristian; Simpson, Eric; Langley, Richard; Costanzo, Antonio ; Saeki, Hidehisa; Almgren, Peter; Vacko, Emilia; Carlsson, Anna; Gooderham, Melinda; Deleuran, Mette; Silvestre, Juan Francisco; Weidinger, Stefan; Blauvelt, Andrew
       title: 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis
        date: 2023-03-13
       words: 2869
      flesch: 41
     summary: o A recently presented interim safety analysis of adult patients with up to 42 months of exposure confirmed the safety profile of tralokinumab4 Maintained improvements in clinically relevant outcomes at 3 years of tralokinumab treatment • Patients were controlled (mild/no disease) for the majority of the 3 years of tralokinumab treatment (Figure 3) • PowerPoint Presentation 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis Richard B Warren1, Kristian Reich2, Eric Simpson3, Richard Langley4, Antonio Costanzo5, Hidehisa Saeki6, Peter Almgren7, Emilia Vacko7, Anna Carlsson7, Melinda Gooderham8, Mette Deleuran9, Juan Francisco Silvestre10, Stefan Weidinger11, Andrew Blauvelt12 1Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK; 2Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; 4Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada; 5Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milano, Italy; Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 6Department of Dermatology, Nippon Medical School, Tokyo, Japan; 7LEO Pharma A/S, Ballerup, Denmark; 8SKiN Centre for Dermatology, Peterborough, ON, Canada; Department of Dermatology, Queen's University, Kingston, ON, Canada; Probity Medical Research, Waterloo, ON, Canada; 9Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark; 10Dermatology Department, Hospital General Universitario de Alicante, Alicante, Spain; 11Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 12Oregon Medical Research Center, Portland, OR, USA ECZTEND interim efficacy analysis set n=347 Age Median years (IQR) 42.0 (30.0; 53.0)
    keywords: data; ecztend; leo; patients; pharma; tralokinumab; treatment; years
       cache: skin-2028.pdf
  plain text: skin-2028.txt

        item: #734 of 1356
          id: skin-2029
      author: Wollenberg, Andreas; Cork, Michael; Flohr, Carsten; Bewley, Anthony; Blauvelt, Andrew; Hong, Chih-ho; Imafuku, Shinichi; Schuttelaar, Marie L.A.; Simpson, Eric; Soong, Weily; Amoudruz, Petra; Wendicke Lophaven, Katja ; Kurbasic, Azra; Soldbro, Lise; Strange Vest, Natacha ; Paller, Amy
       title: Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial
        date: 2023-03-13
       words: 2777
      flesch: 48
     summary: ≥75% improvement from baseline in Eczema Area and Severity Index (EASI-75) at Week 16 • Patients achieving primary endpoints without rescue treatment were re-randomized to tralokinumab Q2W or every 4 weeks (Q4W), at their same initial tralokinumab dosage for 36 weeks of maintenance treatment as shown in Figure 1, while Placebo responders continue in the Placebo Q2W • Patients not achieving primary endpoints at Week 16, those receiving rescue treatment from Week 2 to Week 16, and those meeting other specific criteria† were transferred to open-label treatment of tralokinumab 300 mg Q2W plus optional mild-to-moderate strength topical corticosteroids (TCS) Disclosures Andreas Wollenberg has received grants, personal fees, or nonfinancial support from AbbVie, Aileens, Almirall, Beiersdorf, Bioderma, Chugai, Galapagos, Galderma, GSK, Hans Karrer, LEO Pharma, Lilly, L’Oreal, Maruho, MedImmune, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron, Santen, and Sanofi-Aventis.
    keywords: leo; patients; pharma; placebo; q2w; tralokinumab; treatment; weeks
       cache: skin-2029.pdf
  plain text: skin-2029.txt

        item: #735 of 1356
          id: skin-203
      author: Berman, Brian; Nestor, Mark S; Fox, Joshua; Jones, Michael; Schmieder, George; Weiss, Eduardo T
       title: Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biological Effective Dose 30 of Superficial Radiation
        date: 2017-10-27
       words: 413
      flesch: 50
     summary: One of the 3 following superficial radiation BED 30 fractionation protocols was employed post keloidectomy: one fraction of 13 Gy on postoperative day 1; or 2 fractions of 8 Gy on postoperative days 1 and 2; or 3 fractions of 6 Gy on postoperative days 1, 2 and 3. Superficial radiation therapy (SRT) reduces wound fibroblast proliferation and enhances apoptosis.
    keywords: m.d; radiation
       cache: skin-203.pdf
  plain text: skin-203.txt

        item: #736 of 1356
          id: skin-2030
      author: Lio, Peter; Kim, Yestle; Balu, Sanjeev; Guana, Adriana; Bates, Dawn; Mackie, deMauri; Costantino, Halley ; Lopez, Amanda; Soung, Jennifer
       title: Real World Baseline Characteristics and Early Patient Reported Outcomes in Adult Patients with Moderate to Severe Atopic Dermatitis Treated with Tralokinumab
        date: 2023-03-13
       words: 2278
      flesch: 52
     summary: This study will provide insights into the impact of tralokinumab on adult patients in the real world (non- clinical trial) setting • Goal of this study is to have at least 250 patients complete the study from baseline to 52 weeks Summary of PO-SCORAD and TSQM-9 • After 4 weeks of tralokinumab use, patients saw improvements in their PO-SCORAD (13.6%, SD=62.6%) and average weekly itch (22.3%, SD=48.8%) scores (Table 2) • Patients also saw improvements in their mean TSQM-9 global satisfaction (6.0 points, SD=23.3), TSQM-9 convenience (9.8 points, SD=20.7), and TSQM-9 effectiveness (5.1 points, SD=18.3) scores (Table 2) • Improvements were seen in both ‘ever taken dupilumab’ and ‘never taken dupilumab’ groups in PO- SCORD and TSQM-9 outcomes (Table 2) Abbreviations %, percentage; AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; Max, maximum; Min, minimum; n, number of patients; NRS, Numeric Rating Scale; PO- SCORAD, Patient-Oriented SCORing Atopic Dermatitis; PRO, patient-reported outcomes; TSQM-9, Treatment Satisfaction Questionnaire for Medication. Mean % improvement at week 4 (SD) 13.56 (62.56) 2.37 (74.64) 26.79 (41.33)
    keywords: baseline; dupilumab; improvement; mean; patients; week
       cache: skin-2030.pdf
  plain text: skin-2030.txt

        item: #737 of 1356
          id: skin-2031
      author: Eichenfield, Lawrence; Shi, Vivian; Yu, JiaDe; Pierce, Evangeline; Atwater, Amber; Austin, Jenny; Salmon, Phoebe; Piercy, James; Anderson, Peter ; Paller, Amy
       title: Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe
        date: 2023-03-13
       words: 1094
      flesch: 45
     summary: 803 currently mild patients were excluded ■ 427 moderate and 304 severe patients or their parent/guardian completed a PSC ■ For 60.1% of moderate patients and 62.4% of severe patients, the physician reported the patient had suffered acute episodes (flares) as part of their disease pattern; 53.7% of moderate and 57.1% of severe patients experienced 1 or more flares during the last 12 months (Fig 1) ■ Of those with flares in the last 12 months, moderate patients suffered a median [interquartile range] of 2[2-3] flares and severe patients suffered a median of 3[2-4] (Fig 2) ■ Moderate patients were more likely to have mild or moderate flares (determined by physicians) while severe patients had more moderate and severe flares (Fig 2) ■ The median duration of a typical flare for both moderate and severe patients was 14 days (Fig 3) ■ 64.5% of severe patients self-reported the degree of bother of flares as high, 21.1% reported moderate bother and 14.5% reported low bother. For moderate patients, 38.6% reported a high degree of bother, 29.7% moderate bother and 31.6% low bother (Fig 4) Figure 4.
    keywords: flares; patients
       cache: skin-2031.pdf
  plain text: skin-2031.txt

        item: #738 of 1356
          id: skin-2032
      author: King, Brett ; Shapiro, Jerry ; Ohyama, Manabu ; Egeberg, Alexander ; Dutronc, Yves ; Chen, Yun-Fei ; Wu, Wen-Shuo ; Ding, Yuxin ; Somani, Najwa ; Sinclair, Rodney 
       title: Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib
        date: 2023-03-13
       words: 2020
      flesch: 48
     summary: ≤60 years for males and ≤70 years for females ■ Hair loss involving ≥50% of the scalp, as measured by the SALT score ■ Current episode of AA >6 months to <8 yearsc ■ No spontaneous improvement in the 6 months prior to screening ■ No concomitant treatments for AAd Statistical Analyses ■ The full analysis set for patients randomized to 2mg or 4mg baricitinib was considered in these analyses. ■ For each response pattern, the following outcomes were analyzed: – Proportion of patients achieving the BRAVE-AA1/2 primary endpoint of SALT score ≤20 (≤20% scalp hair loss), and – Proportion of patients achieving ≥50% improvement from baseline in SALT score (SALT50).
    keywords: baseline; data; patients; response; salt; score
       cache: skin-2032.pdf
  plain text: skin-2032.txt

        item: #739 of 1356
          id: skin-2033
      author: Piraccini, Bianca Maria ; Ohyama, Manabu ; Craiglow, Brittany ; Bewley, Anthony ; Ding, Yuxin; Chen, Yun-Fei; Dutronc, Yves; Pierce, Evangeline ; Durand, Frederick ; Mostaghimi, Arash 
       title: Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
        date: 2023-03-13
       words: 1504
      flesch: 29
     summary: Yves Dutronc,5 Evangeline Pierce,5 Frederick Durand,5 Arash Mostaghimi6 1University of Bologna, Bologna, Italy; 2Kyorin University Faculty of Medicine, Tokyo, Japan; 3Yale School of Medicine, New Haven, USA; 4The Royal London Hospital, London, UK; 5Eli Lilly and Company, Indianapolis, USA; 6Brigham and Women’s Hospital, Harvard Medical School, Boston, USA BACKGROUND ■ Alopecia areata (AA) is a common autoimmune disorder that results in hair loss1 – Hair loss can range in severity, from loss of hair in small localized patches on the scalp, to complete loss of hair on the scalp (alopecia totalis) and/or body (alopecia universalis)1 ■ Severe AA is frequently associated with health-related quality of life (HRQoL) impairment and psychological burden2 ■ However, the impact of hair regrowth on HRQoL and psychosocial burden has not been sufficiently investigated OBJECTIVE ■ To evaluate the association between scalp hair regrowth and improvement of HRQoL and psychological burden in patients with severe AA using pooled data from the Phase 3, randomized, placebo-controlled trials, BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) CONCLUSIONS ■ Patients with severe AA who achieved scalp hair regrowth at Week 36 experienced improvements in HRQoL and symptoms of anxiety and depression when compared with those who had no or minimal regrowth – Higher benefit was observed in patients achieving a SALT ≤20 response – Improvements were also observed in the intermediate response group, but generally to a lesser extent than those in the SALT ≤20 response group ■ These results support the clinical relevance of SALT ≤20, the primary endpoint for the baricitinib clinical program in severe AA ■ Longer treatment duration may be needed to assess the full impact on scalp hair regrowth, HRQoL, and symptoms of anxiety and depression ABBREVIATIONS AA=alopecia areata; B/AB=borderline/abnormal; BARI=baricitinib; HADS-A=Hospital Anxiety and Depression Scale– Anxiety; HADS-D=Hospital Anxiety and Depression Scale–Depression; HRQoL=health-related quality of life; LSM=least squares mean; mLOCF=modified last observation carried forward; NRI=non-responder imputation; PBO=placebo; QD=once daily; SALT=Severity of Alopecia Tool; W=Week KEY RESULTS Scan or click the QR code or use this URL (https://lillyscience.lilly.com/congress/wcdc2023) for a list of all Lilly content presented at the congress.
    keywords: hads; hair; lilly; salt
       cache: skin-2033.pdf
  plain text: skin-2033.txt

        item: #740 of 1356
          id: skin-2034
      author: Pierce, Evangeline; Kleyn, C. Elise; Grond, Susanne; Austin, Jenny; Reed, Catherine; Ständer, Sonja
       title: Impact Of Day-to-Day Sleep Disruption on The Burden of Disease In Moderate-severe Adult Atopic Dermatitis Patients
        date: 2023-03-13
       words: 1217
      flesch: 56
     summary: KEY RESULTS Winter Clinical Dermatology Conference; Hawaii, USA; January 13-18, 2023 Figure 2. WPAI due to AD in moderate-to-severe adult AD patients according to the frequency of S-D. Figure 3. J Austin is an employee of Adelphi Real World C Reed, S Grond and E Pierce are employees of Eli Lilly and Company
    keywords: day; patients
       cache: skin-2034.pdf
  plain text: skin-2034.txt

        item: #741 of 1356
          id: skin-2035
      author: Senna, Maryanne; Kwon, Ohsang; Piraccini, Bianca; Sinclair, Rodney;  Ball, Susan; Ding, Yuxin; Chen, Yun-Fei; Dutronc, Yves; King, Brett
       title: Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
        date: 2023-03-13
       words: 2204
      flesch: 19
     summary: [SALT] score ≥50) was demonstrated in the Phase 2/3 trial, BRAVE-AA1, and the Phase 3 trial, BRAVE-AA2, 2 randomized, double-blinded, placebo-controlled trials2,3 – The primary endpoint was the proportion of patients who achieved SALT score ≤20 at Week 36 – Key secondary endpoints included the proportion of patients with no or minimal gaps on eyebrows and eyelashes at Week 36 ■ However, the clinical response for the scalp, eyebrows, and eyelashes may vary between patients and over time OBJECTIVE ■ To evaluate whether patients with AA treated with baricitinib who had not achieved SALT score ≤20 at Week 52 achieved clinically meaningful improvements in eyebrow or eyelash loss CONCLUSIONS ■ The data show an impact of baseline severity and duration of hair loss (disease and current episode) on SALT score response rates for scalp, eyebrow, and eyelash hair loss ■ Not surprisingly, the highest response rates for eyebrow and eyelash regrowth were observed in patients who had also experienced scalp hair regrowth ■ However, about half of the patients with partial scalp response and 15-20% of those with no scalp response experienced meaningful improvement in eyebrow and eyelash regrowth with baricitinib 4-mg, which has been identified as a highly important treatment goal for patients ■ Further analyses may be required to clarify if these observations represent different patterns of clinical responses or are linked to different kinetics of hair regrowth between the scalp, eyebrows, and eyelashes ■ Longer studies may be required to observe complete benefit ABBREVIATIONS AA=alopecia areata; BARI=baricitinib; BMI=body mass index; CI=confidence interval; ClinRO=clinician-reported outcome; ClinRO EB=ClinRO Measure for Eyebrow Hair Loss; ClinRO EL=ClinRO Measure for Eyelash Hair Loss; COVID-19=coronavirus disease 2019; PBO=placebo; QD=once daily; SALT=Severity of Alopecia Tool; SALT30=≥30% improvement from baseline in total SALT score; W=Week Study Design,a BRAVE-AA1 and BRAVE-AA2 KEY RESULTS Scan or click the QR code or use this URL (https://lillyscience.lilly.com/congress/wcdc2023) for a list of all Lilly content presented at the congress. % or less scalp hair loss (80% scalp coverage) ■ SALT scores with subscripts refer to percent improvement from baseline (eg, SALT30=≥30% improvement from baseline in total SALT score) Response Subgroups ■ Baricitinib 4-mg and 2-mg subgroups were defined by the degree of scalp hair regrowth (SALT score) at Week 52 – SALT score ≤20 Response:
    keywords: hair; patients; response; salt; score
       cache: skin-2035.pdf
  plain text: skin-2035.txt

        item: #742 of 1356
          id: skin-2037
      author: Blauvelt, Andrew; Alonso-Llamazares, Javier; Bhatia, Neal; Draelos, Zoe; DuBois, Janet; Forman, Seth; Gooderham, Melinda; Guenthner, Scott; Hebert, Adelaide; Lain, Edward; Moore, Angela; Papp, Kim; Stein Gold, Linda; Zirwas, Matthew; Kato, Saori; Snyder, Scott; Krupa, David; Burnett, Patrick; Berk, David; Chu, David
       title: Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial
        date: 2023-03-13
       words: 1940
      flesch: 50
     summary: Vehicle Foam (N=153) n=296 n=151 n=277 n=140 n=264 n=136 ~80% of Patients Achieved IGA Success at Week 8 >50% of Patients Achieved IGA of Clear Week 2 Week 4 Week 8 P e rc e n ta g e o f P a ti e n ts Roflumilast Foam 0.3% (n=206) • Writing support was provided by Christina McManus, PhD, Alligent Biopharm Consulting LLC, and funded by Arcutis Biotherapeutics, Inc. 100% 98.9% 100%100% 100% 100% Baseline Week 4 Week 8 P a ti e n ts ( % ) 92.4% 96.1% 97.8%92.8% 92.7% 94.8% Baseline Week 4 Week 8 P a ti e n ts ( % )
    keywords: foam; iga; patients; roflumilast; week
       cache: skin-2037.pdf
  plain text: skin-2037.txt

        item: #743 of 1356
          id: skin-2038
      author: Green, Lawrence; Bagel, Jerry; Han, George; Jacobson, Abby; Sikes, Martha
       title: Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety
        date: 2023-03-13
       words: 1217
      flesch: 45
     summary: In the phase 3 studies, 430 adults were randomized to HP lotion (n=285) or vehicle lotion (n=145) • HP 0.01% lotion was statistically superior to vehicle at week 8 in percent reduction from baseline in affected BSA and percentage of participants achieving treatment success (Figure 3) Adverse Events • Rates of TEAEs through week 8 were similar for participants treated with HP 0.01% lotion and those treated with vehicle, as were TEAE severity and incidence of treatment-related TEAEs (Figure 4) OBJECTIVE • To summarize the in vitro epidermal permeation of halobetasol propionate (HP) 0.01% lotion and its clinical efficacy and safety in participants with plaque psoriasis CONCLUSION • 6.17 1.72 0 2 4 6 8 10 HP 0.01% Lotion HP 0.05% Cream Pe rc en t o f a pp lie d do se , m ea n TEAE Rate HP 0.01% Lotion n=284 n=142 of participants with TEAEs: 11.7 9.8 35.2 40.9 52.9 49.1 Vehicle Lotion HP 0.01% 0% 20% 40% 60% 80% 100% Severe Moderate Mild 21.5% Vehicle Lotion23.9% Maximum TEAE Severity vs n=34 n=61 Yes Yes No No Vehicle Lotion HP 0.01% 0% 20% 40% 60% 80% 100% n=61 n=34 Related to Treatment -35.2 -5.9 -50 -40 -30 -20 -10 0 HP Lotion (n=265) Vehicle Lotion (n=131)
    keywords: figure; lotion; treatment; vehicle
       cache: skin-2038.pdf
  plain text: skin-2038.txt

        item: #744 of 1356
          id: skin-204
      author: Du, Ana; Raab, Susana; Yatskayer, Margarita; Lynch, Stephen
       title: A Split-Face Design Clinical Trial to Evaluate the Efficacy of a Masque when Used Post-Full Face Fraxel® Laser Treatment
        date: 2017-10-27
       words: 533
      flesch: 45
     summary: * * * *statistically significant at P>0.05 when compared to baseline and untreated site Post masque rinse-off Ba se lin e/ Po st F ra xe l® Post m asque rinse-off TreatedUntreated The tested masque was effective in improving the appearance of redness following masque application and after rinse-off, reduced skin temperature and soothed signs of discomfort such as pain, burning, heat sensation, and tightness immediately upon masque application, following a Fraxel® procedure. The results indicated that the tested masque was effective in improving the appearance of redness (Figure 2) and reducing pain/discomfort, burning, heat sensation, and tightness on the treated side post-product application and/or post-product rinse off when compared to baseline and between the treated and untreated sides.
    keywords: masque; post
       cache: skin-204.pdf
  plain text: skin-204.txt

        item: #745 of 1356
          id: skin-2040
      author: Lebwohl, Mark; Stein Gold, Linda; Gooderham, Melinda; Papp, Kim; Ferris, Laura; Adam, David; Hong, H. Chih-ho; Kircik, Leon; Zirwas, Matthew; Burnett, Patrick; Higham, Robert; Krupa, David; Berk, David
       title: Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial
        date: 2023-03-13
       words: 2313
      flesch: 56
     summary: 1.0% • Safety was consistent with the parent trial (Tables 2 and 3) • 94% of adverse events (AEs) were rated mild or moderate in severity • 97% of AEs were unrelated or unlikely to be related to treatment as determined by the investigator • ≥97% of patients had no evidence of irritation per investigator local tolerability assessment at each visit (Figure 8) Figure 8. ~57.1% (n=185) of patients achieved IGA 0/1 during the trial; patients have a 50% probability of a duration of IGA of Clear or Almost Clear of more than 10 months (40.1 weeks) Duration of IGA Clear or Almost Clear (Weeks) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 P ro b a b il it y I G A C le a r o r A lm o st C le a r 4 12 20 28 360 8 16 24 32 44 56 6440 48 6052 Censored 170 138 114 93 69185 166 123 101 82 41 5 063 37 28At risk Roflumilast Cream Phase 2b (Trial #201; NCT03638258)2 Roflumilast Cream Phase 2 Long-term Safety (Trial #202; NCT03764475) Eligibility • Diagnosis of at least mild plaque psoriasis • Age ≥18 years • 2-20% BSAa Roflumilast cream 0.3% QD Roflumilast cream 0.15% QD Vehicle QD Endpoints Primary: Safety • Occurrence of TEAEs • Occurrence of SAEs Secondary: Efficacy • IGA clear or almost clear • Intertriginous-IGA clear or almost clear • PASI • BSA 12 weeks R a n d o m iz a ti o n 1:1:1 N=331 Eligibility • Diagnosis of at least mild plaque psoriasis for at least 6 months •
    keywords: cohort; iga; patients; roflumilast; trial; week
       cache: skin-2040.pdf
  plain text: skin-2040.txt

        item: #746 of 1356
          id: skin-2041
      author: Draelos, Zoe; Farris, Patricia; Baldwin, Hilary; Tanghetti, Emil
       title: Comparison of Cutaneous Irritation With Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005% Cream
        date: 2023-03-13
       words: 1351
      flesch: 36
     summary: • Assessments were analyzed using a Wilcoxon signed-rank test; group differences were considered significant at a P-value of ≤0.05 Comparison of Cutaneous Irritation With Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005% Cream Zoe D Draelos, MD1; Patricia Farris, MD2; Hilary Baldwin, MD3,4; Emil A Tanghetti, MD5 1Dermatology Consulting Services, High Point, NC; 2 Tulane University School of Medicine Department of Dermatology, New Orleans, LA; 3 The Acne Treatment and Research Center, Brooklyn, NY; 4Robert Wood Johnson University Hospital, New Brunswick, NJ; 5 Center for Dermatology and Laser Surgery, Sacramento, CA RESULTS Study 1: Adapalene 0.3% Gel vs Tazarotene 0.045% Lotion � 20 White adults (22–69 years; 95% female) were enrolled and completed this study � Tazarotene 0.045% lotion and adapalene 0.3% gel were both assessed as mildly irritating, with Dermal Effects mean scores <1 (Figure 2) • Differences in Dermal Effects mean scores between drugs were not statistically significant at any assessment, though there was slightly less irritation overall with tazarotene lotion than adapalene gel (highest mean scores: 0.50 and 0.80, respectively) � Other Effects mean scores were negligible (≤0.05) with both drugs � No irritation was observed at the control patch site at any study visit FIGURE 2. Study 2: Trifarotene 0.005% Cream vs Tazarotene 0.045% Lotion � 20 adults (22–74 years; 90% female; 90% White, 10% African American) were enrolled and completed this study � Dermal Effects mean scores with trifarotene cream were significantly greater than with tazarotene lotion at the first assessment (2 days after first patch application; P<0.05) and increased over the remaining visits (highest mean scores: 2.20 vs 0.70, respectively; P<0.001, all; Figure 3) � Other Effects mean scores were significantly greater with trifarotene cream than with tazarotene lotion, beginning at the second assessment (4 days after first patch application) and continuing through remaining visits (highest mean scores: 0.70 vs 0.20, respectively; P<0.01, all)
    keywords: lotion; study; tazarotene
       cache: skin-2041.pdf
  plain text: skin-2041.txt

        item: #747 of 1356
          id: skin-2043
      author: Gamal, Ahmed; Elshaer, Mohammed ; Long, Lisa; McCormick, Thomas ; Elewski, Boni; Ghannoum, Mahmoud
       title: Efinaconazole in the Age of Antifungal Resistance
        date: 2023-03-13
       words: 1124
      flesch: 42
     summary: [n=15 each]) RESULTS � Efinaconazole showed superior potent activity against a broad panel of susceptible and resistant dermatophyte, Candida, and mold isolates (Figures 1–3) � E�naconazole (0.016 – 2) More potent antifungal activity All Mold Isolatesa (n=45) E�naconazole was the most active compound against different types of molds, including those with high itraconazole and terbina�ne MICs aScedosporium, Fusarium spp., Scopulariopsis.
    keywords: antifungal; isolates; mic
       cache: skin-2043.pdf
  plain text: skin-2043.txt

        item: #748 of 1356
          id: skin-2045
      author: Graber, Emmy; Baldwin, Hilary; Harper, Julie; Stein Gold, Linda; Alexis, Andrew; Fried, Richard; Rieder, Evan; Del Rosso, James; Kircik, Leon; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail; Hebert, Adelaide
       title: Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age
        date: 2023-03-13
       words: 944
      flesch: 46
     summary: Results: A total of 253 AV patients completed the study (female: 66.40%; 9-17yrs: 39.92%; >=18yrs: 60.08%; Facial IGA success at week-12 was 56.47% for male and 60.12% for female; 57.43% for patients 9-17yrs old and 59.87% for patients >=18yrs old. Ismail Kasujee,11 Adelaide Hebert12 1The Dermatology Institute of Boston and Northeastern University, Boston, MA; 2Acne Treatment and Research Center, Brooklyn, NY; 3The Dermatology and Skin Care Center of Birmingham, Birmingham, AL; 4Henry Ford Health System, Bloomfield, MI; 5Weill Cornell Medical College, New York, NY; 6Yardley Dermatology Associates, Yardley, PA; 7New York University Grossman School of Medicine, New York, NY; 8JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV; 9Icahn School of Medicine, Mount Sinai, New York, NY, 10Avant Health LLC, Bethesda, MD; 11Almirall SA, Barcelona, Spain; 12UTHealth McGovern Medical School, Houston, TX. INVESTIGATOR GLOBAL ASSESSMENT (IGA) OF ACNE VULGARIS AND IGA SUCCESS AMONG PATIENTS WITH MODERATE TO SEVERE NON-NODULAR ACNE VULGARIS (AV) ADMINISTERED SARECYCLINE IN COMMUNITY PRACTICES ACROSS THE U.S: PROSES STUDY ANALYSIS BY GENDER AND AGE Introduction: The objective of this analysis was to evaluate facial IGA and the associated IGA success, stratified by age and gender, among AV patients administered sarecycline in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non- nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US.
    keywords: iga; patients; success
       cache: skin-2045.pdf
  plain text: skin-2045.txt

        item: #749 of 1356
          id: skin-2046
      author: Baldwin, Hilary; Del Rosso, James; Kircik, Leon; Stein Gold, Linda; Hebert, Adelaide; Rieder, Evan; Alexis, Andrew; Harper, Julie; Fried, Richard; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail; Graber, Emmy
       title: Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication 
        date: 2023-03-13
       words: 1012
      flesch: 44
     summary: INVESTIGATOR GLOBAL ASSESSMENT (IGA) OF ACNE VULGARIS AND IGA SUCCESS AMONG PATIENTS WITH MODERATE TO SEVERE NON-NODULAR ACNE VULGARIS (AV) ADMINISTERED SARECYCLINE IN COMMUNITY PRACTICES ACROSS THE U.S IN PROSES STUDY: ANALYSIS BY CONCOMITANT MEDICATION USE Introduction: IGA success at week-12 was defined as >2-grade improvement and score 0-clear or 1- almost clear at week-12.
    keywords: iga; patients; success
       cache: skin-2046.pdf
  plain text: skin-2046.txt

        item: #750 of 1356
          id: skin-2047
      author: Kircik, Leon; Schlesinger, Todd; Armstrong, April; Berman, Brian; Bhatia, Neal; Del Rosso, James; Lebwohl, Mark; Patel, Vishal; Rigel, Darrell; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)
        date: 2023-03-13
       words: 1107
      flesch: 56
     summary: The primary objective of the study was to evaluate patient-reported outcomes in terms of AK symptoms, and impact of AKs on emotions and functioning, among AK patients treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AK of the face or scalp who were newly initiated with tirbanibulin treatment in real-world practices in the U.S, as part of usual care. OBJECTIVE • The primary objective of the study was to evaluate patient-reported outcomes in terms of AK symptoms, and impact of AKs on emotions and functioning, among AK patients treated with tirbanibulin in community practices across the U.S. RESULTS • PROAK study (NCT05260073) was initiated in 2022, with more than 75% of the study patients treated with tirbanibulin between April and August of 2022.
    keywords: baseline; patients; usa; week-8
       cache: skin-2047.pdf
  plain text: skin-2047.txt

        item: #751 of 1356
          id: skin-2048
      author: Schlesinger, Todd; Kircik, Leon; Armstrong, April; Berman, Brian; Bhatia, Neal; Del Rosso, James; Lebwohl, Mark; Patel, Vishal; Rigel, Darrell; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)
        date: 2023-03-13
       words: 1225
      flesch: 51
     summary: • Overall, in 77.93% and 33.79% of study patients (not mutually exclusive), AK lesions on their face and scalp respectively were treated with tirbanibulin. [30.00, 90.00] Gender, % FemaleMale 31.38 68.62 Primary health insurance, % Private Insurance Medicaid Medicare Uninsured 41.72 3.10 53.79 1.38 History of skin cancer, % 61.72 Fitzpatrick skin type, % Type I Type II Type III Type IV Type V 7.59 71.38 18.62 1.38 1.03 Baseline patient self- reported skin-texture, % Dry Smooth Rough Bumpy Scaly Blistering Peeling 39.66 47.59 19.66 18.62 35.17 0.34 6.21 Baseline severity of skin photodamage in AK affected area, % Absent Mild Moderate Severe 1.03 21.38 56.55 20.34 73.79% 17.24% 8.97% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Completely / Partially Cleared Moderately Cleared Minimally / Not Cleared P ro po rti on o f P at ie nt s at w ee k- 8 Figure 1: Majority of patients who were administered tirbanibulin at baseline achieved IGA success at week-8 7.24% 7.59% 85.17% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Very / Somewhat Unlikely Neutral Somewhat / Very Likely P ro po rti on o f P at ie nt s at w ee k- 8 Figure 2: For majority of patients, clinicians reported their desire to consider tirbanibulin again Table 2: Site Characteristics (N=32) Current workplace: Private, office-based practice, % 100 Total number of board-certified dermatologists in the clinic/practice, Mean 3.53 Number of patients with AKs managed by the clinic in a given month, Mean 136.34 Number of years practicing dermatology, Mean 15.66 IGA Success N = 290 N = 290
    keywords: iga; patients; tirbanibulin; week-8
       cache: skin-2048.pdf
  plain text: skin-2048.txt

        item: #752 of 1356
          id: skin-205
      author: Gallo, Richard L; Raab, Susana; Yatskayer, Margarita; Lynch, Stephen
       title: Evaluation of the Efficacy and Tolerability of a Topical Facial Serum in Improving Signs of Aging
        date: 2017-10-27
       words: 708
      flesch: 38
     summary: Bioinstrumental measurement analysis showed statistically significant improvement in hydration (p<0.001), barrier properties of the stratum corneum (p=0.017) and skin density (p=0.012) at week 12 when compared to baseline. In addition to the improvements observed in the clinical skin attributes, the study panel also showed improvements in skin hydration and barrier properties of the stratum corneum, skin density, increased HA content, and an increase in histochemical markers expression associated with HA such as HAS2 and Col1a1. 4804 A 12-week, single center, clinical study was conducted on 59 females, ages 42-60, presenting with mild to moderate facial sagging, loss of firmness, rough skin texture, nasolabial fold wrinkles, marionette wrinkles and presence of fine lines/wrinkles in the crow’s feet area, including those with self-perceived sensitive skin.
    keywords: skin; week
       cache: skin-205.pdf
  plain text: skin-205.txt

        item: #753 of 1356
          id: skin-2052
      author: Li, Vivian; Guenin, Sophie; Lebwohl, Mark 
       title: Treatment of Severe Recalcitrant Atopic Dermatitis with Dupilumab in a Kidney Transplant Patient
        date: 2023-05-20
       words: 1609
      flesch: 51
     summary: Dupilumab treatment resulted in significant improvement of symptoms, including reduced pruritus, and ultimately achieved disease control. A 30-year-old male first presented to us with severe atopic dermatitis in the context of an atopic triad.
    keywords: atopic; dermatitis; dupilumab; patient; skin; treatment
       cache: skin-2052.pdf
  plain text: skin-2052.txt

        item: #754 of 1356
          id: skin-2054
      author: Nesvik, Jazmine; Marshall, Leslie; Cleaver, David; Cleaver, Jonathan; Cleaver, Lloyd
       title: Apremilast in the Management of Generalized Granuloma Annulare: A Case Series
        date: 2023-07-17
       words: 2326
      flesch: 48
     summary: Needing to explore other off-label options for this patient, it was decided to trial apremilast given its known anti-inflammatory effects and well- studied safety profile with minimal adverse effects. Objective: 1) To discuss whether treatment with apremilast could lead to improvement or resolution of generalized granuloma annulare.
    keywords: annulare; apremilast; granuloma; patients; steroids; treatment
       cache: skin-2054.pdf
  plain text: skin-2054.txt

        item: #755 of 1356
          id: skin-2056
      author: Gottlieb, Alice; Burge, Russel ; Malatestinic, William ; Zhu, Baojin; Zhao, Yunyang ; McCormack, Julie ; Kimel, Miriam; Feely, Meghan; Merola, Joseph
       title: Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective
        date: 2023-05-20
       words: 1119
      flesch: 40
     summary: Percentage of patients with 0/1 scoresBSA: Mean % Involvement Skin Pain NRS: Percentage of patients with 0/1 scores P < 0.001 for all within-group comparisons of responses at baseline and at Week 24 DISCLOSURES  A. B. Gottlieb has received honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai  PowerPoint Presentation Assessments ■ Web-based questionnaires administered at baseline, Weeks 2, 4, 8, 12, and 24 ■ Patients were divided into mild (BSA <3%), moderate (BSA 3-10%), or severe (BSA>10%)3 Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective Key Eligibility Criteria ■ Patients with psoriasis enrolled in the US Ixekizumab CSP ■ ≥18 years of age ■ Commercial insurance ■ Initiated ixekizumab within 7 days of screening ■ Device with access to the internet Alice B. Gottlieb1, Russel Burge2, William N. Malatestinic2, Baojin Zhu2, Yunyang Zhao2, Julie McCormack3, Miriam Kimel3, Meghan Feely2, Joseph F. Merola4 1Icahn School of Medicine at Mount Sinai, New York, USA; 2Eli Lilly and Company, Indianapolis, USA; 3Evidera, Bethesda, USA; and 4Harvard Medical School, Brigham and Women’s Hospital, Boston, USA METHODS US Ixekizumab CSP Design Patient Demographics and Baseline Characteristics REFERENCES 1.
    keywords: baseline; psoriasis; week
       cache: skin-2056.pdf
  plain text: skin-2056.txt

        item: #756 of 1356
          id: skin-2057
      author: Jeanfreau, Alissa; Beiter, Kaylin; Hilton , Deborah
       title: Understanding the Factors Associated with US Dermatology Resident Trainees' Diagnostic Confidence and Skill for Skin of Color Pathology 
        date: 2023-07-17
       words: 2901
      flesch: 43
     summary: We first assessed overall performance on the assessment tool and found no significant difference between performance across skin types (84.7% correctly diagnosed overall; 85.4% for conditions in light skin types; 84.3% in darker skin types; p>0.05). We then analysed respondent score performance on diagnosis of cancerous conditions for images of patients with lighter versus darker skin types and found a significant difference (100% for conditions in lighter skin types; 75% in darker skin types; p<0.0001).
    keywords: color; conditions; dermatology; health; images; lesions; patients; skin; types
       cache: skin-2057.pdf
  plain text: skin-2057.txt

        item: #757 of 1356
          id: skin-2061
      author: Stashower, Julian; Wills, Abigail; Zlotoff, Barrett
       title: Vesiculobullous Erythema Migrans with Central Necrosis
        date: 2023-07-17
       words: 668
      flesch: 50
     summary: Lyme disease typically presents with erythema migrans at the site of inoculation and a flu-like illness. Diagnosis of Lyme disease is primarily clinical, as histopathologic findings are non- specific and serologic tests, culture, and polymerase chain reaction have poor sensitivities, especially in the acute phase of the disease.
    keywords: disease; erythema; lyme
       cache: skin-2061.pdf
  plain text: skin-2061.txt

        item: #758 of 1356
          id: skin-2063
      author: Gladys, Taylor; Kim, Taehan; Beatty, Colleen J; Choudhary, Sonal
       title: Case of Generalized Granuloma Annulare Treated with Low Dose Naltrexone + PUVA
        date: 2023-07-17
       words: 1475
      flesch: 47
     summary: Once on the dose of LDN at 4.5 mg, she began PUVA treatments, twice weekly. Generalized granuloma annulare presenting as erythematous papules coalescing on medial aspect of left arm (A) and left abdomen (B).
    keywords: annulare; granuloma; puva; treatment
       cache: skin-2063.pdf
  plain text: skin-2063.txt

        item: #759 of 1356
          id: skin-2071
      author: Paller, Amy; Knapp, Keith; Munoz, Breda; Claxton, Ami; Balu, Sanjeev; Schnieder, Shannon; Eichenfield, Lawrence
       title: Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET DERM Registry
        date: 2023-05-20
       words: 1501
      flesch: 38
     summary: vIGA-AD (scores 0-4) • Body Surface Area (BSA) (score %) • vIGA-AD x BSA (score 0-400) Table 1. EG is an employee of Mount Sinai and has received research grants research Grants paid to her institution: Boehringer Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen and has been a consultant with: Abbvie, Almirall, Amgen, Aslan Pharmaceuticals, AstraZeneca, Biolojic Design, Boerhinger-Ingelhiem, Bristol Meyers Squibb, Cara Therapeutics, Connect, Pharma, DBV Technologies, Eli Lilly, EMD Serono, Evidera, Galderma, Gate Bio, Genentech, Incyte, Inmagene, Janssen Biotech, Kyowa Kirin, Leo Pharma, Merck, Pfizer, Q32 Bio, RAPT, Regeneron, Sanofi, SATO, Siolta, Target, UCB, Ventyx TARGET-DERM AD All patients N=2930 Age 12-17 (N=364) Study population N=128 • AST-naïve (n=40) • AST-treated (N=88)) AST-treated N=88 • Moderate N=57 • Severe N=31 ___________________________ • Prospective N=50 • Retrospective N=34 • Failed N=4 AST-naïve N=40 • Moderate N=28 • Severe N=12 Had 1+ follow-up visits (N=128) Moderate or severe AD: vIGA-AD of 3 or 4 (N=196) Figure 1.
    keywords: ast; target
       cache: skin-2071.pdf
  plain text: skin-2071.txt

        item: #760 of 1356
          id: skin-2072
      author: Haft, Michael; Knapp, Keith; Claxton, Ami; Munoz, Breda; Balu, Sanjeev; Schnieder, Shannon; Silverberg, Jonathan; Thaci, Diamant; Eichenfield, Lawrence
       title: Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry
        date: 2023-05-20
       words: 1623
      flesch: 46
     summary: In multivariate analysis controlling for sex, age, insurance, and race, only higher BSA at enrollment was associated with AST-usage • BSA of 5% OR=1.09 (1.01-1.19) • BSA of 10% OR = 1.2 (1.01-1.42) • BSA of 20% OR = 1.43 (1.02-2.01) 1 Rady Children’s Hospital, San Diego, CA 2 University of California San Diego, San Diego, CA 3 Target RWE, Durham, NC 4 LEO Pharma Inc., Madison, NJ 5 George Washington School of Medicine, Washington DC 6 University of Lübeck, Lübeck Germany Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry Haft M1,2, Knapp K3, Claxton A4, Hernandez B3, Balu S4, Schneider S4, Silverberg J5, Thaci D6, Eichenfield L1,2 on behalf of TARGET-DERM Investigators Conclusion • More than half of the patients with considerable disease severity and who experienced negative QOL from moderate-to-severe AD were not prescribed AST • Compared to AST-naïve patients, descriptive analysis showed that the AST- treated were slightly more severe as indicated by significantly higher baseline BSA, higher vIGA-ADxBSA, and higher PO-SCORAD at enrollment. Abuabara, K. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGETDERM AD study design and rational BMJ Open 2020;10:e0399282020.
    keywords: ast; enrollment; patients
       cache: skin-2072.pdf
  plain text: skin-2072.txt

        item: #761 of 1356
          id: skin-2077
      author: Plaza, Jose A; Estrada, Sarah I; Russell, Brooke H; Siegel, Jennifer J; Rogers, Jason; Wilkinson, Jeffrey K; Kurley, Sarah J; Goldberg, Matthew S; Motaparthi, Kiran
       title: Subtype performance of the ancillary diagnostic 23- and 35-gene expression profile (GEP) tests for difficult-to-diagnose melanocytic lesions
        date: 2023-05-20
       words: 911
      flesch: 50
     summary: GEP workflow overall performance accuracy metrics Figure 1. Current clinical GEP workflow Presented at the Inaugeral Winter Clinical – Miami™ 2023 Meeting , February 17-20, 2023.
    keywords: gep; workflow
       cache: skin-2077.pdf
  plain text: skin-2077.txt

        item: #762 of 1356
          id: skin-208
      author: Migden, Michael R; Dummer, Reinhard
       title: Sonidegib Efficacy and Safety in Patients with Locally Advanced Basal Cell Carcinoma Based on Tumor Aaggressiveness
        date: 2017-10-27
       words: 1753
      flesch: 43
     summary: He has served as a consultant or participated on advisory boards for Novartis Pharmaceuticals Corporation, Merck Sharp & Dohme, Bristol- Myers Squibb, Roche, GlaxoSmithKline, Amgen, and Takeda. Figure 3: Best Overall Response by laBCC Subtype at 30 Months Figure 4: Adverse Events Regardless of Cause in ≥20% of Patients with laBCC DCR, disease control rate; laBCC, locally advanced BCC; ORR, objective response rate. 0% 20% 40% 60% 80% 100% P at ie nt s, % Aggressive n = 37 Nonaggressive n = 29 5% 3% 32% 54% 5% 10% 38% 48% 3% DCR: 90% ORR: 52% DCR: 92% ORR: 59% Complete Response Partial Response Stable Disease Progressive Disease Unknown Sonidegib 200 mg 45 8 3 38 14 36 12 24 12 2 18 8 6 15 9 3 2 17 11 2 23 3 2 8 9 2 15 3 11 2 Muscle spasms Alopecia Dysgeusia Nausea Weight decrease CK increase Fatigue Diarrhea Appetite decrease Myalgia Vomiting 0 10 20 30 40 50 60 70 80 Patients, % A E s in ≥ 2 0% o f p at ie nt s w ith la B C C tr ea te d w ith s on id eg ib 2 00 m g Figure 4: Adverse Events Regardless of Cause in ≥20% of Patients with laBCC 56% 52% 47% 38% 32% 29% 29% 27% 18% 18% 12%
    keywords: labcc; patients; response; sonidegib; subtypes
       cache: skin-208.pdf
  plain text: skin-208.txt

        item: #763 of 1356
          id: skin-2080
      author: Solelymani, Teo; Martin, Brian; Tassavor, Michael
       title: The i31-gene expression profile test for cutaneous melanoma identifies patients with head and neck tumors who could forego sentinel lymph node biopsy
        date: 2023-05-20
       words: 672
      flesch: 48
     summary: SLNB reduction rates in each T-category when using the i31-GEP for SLNB to guide decisions No patient (0/59) with an i31-GEP predicted SLN positivity risk of <5% had a positive SLNB. Sensitivity: true positive/(true positive + false negative); specificity: true negative/(true negative + false positive); negative predictive value: true negative/(true negative + false negative) H&N tumor, Received SLNB (T1a HR-T2a) Perform SLNB SLN – 95.0% (151/159) SLN+ 5% (8/159) i31-GEP for SLNB Low risk of SLN+ (<5%) High risk of SLN+ (>10%) Perform SLNB SLN+ 8% (8/100) Could have avoided SLNB SLN- 100% (59/59)
    keywords: gep; i31; slnb
       cache: skin-2080.pdf
  plain text: skin-2080.txt

        item: #764 of 1356
          id: skin-2081
      author: Zakria, Danny; Morgan-Linnell, Sonia K.; Brownstone, Nicholas
       title: The i31-GEP for sentinel lymph node (SLN) biopsy outperforms the MSKCC nomogram in predicting the risk of having a positive SLN in patients with cutaneous melanoma
        date: 2023-05-20
       words: 968
      flesch: 53
     summary: PowerPoint Presentation Patients with T1–T2 tumors from previously published multicenter cohort studies who had undergone the SLNB procedure were analyzed by both the i31-GEP and the MSKCC nomogram (n=465).6 Accuracy metrics were compared using <5% predicted risk as a negative result and ≥5% as a positive result. › The i31-GEP for SLNB has demonstrated clinical utility to guide SLNB decisions in patients with T1-T2 tumors as well as guiding subsequent treatment plans with risk-of-recurrence.
    keywords: gep; i31; risk; slnb
       cache: skin-2081.pdf
  plain text: skin-2081.txt

        item: #765 of 1356
          id: skin-2086
      author: Stein Gold, Linda; Pinter, Andreas; Augustin, Matthias
       title: Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Cream for the Treatment of Plaque Psoriasis Evaluated from Pooled Phase 3 Data
        date: 2023-05-20
       words: 1140
      flesch: 64
     summary: Mean DLQI improvement 2023 Winter Clinical - Miami *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001; CAL/BDP PAD-cream vs. CAL/BDP gel/TS CAL/BDP PAD-cream (n=551) CAL/BDP gel/TS (n=542) PAD-cream vehicle (n=178) Overall, 1271 patients were included in this analysis, 551 patients were in the CAL/BDP PAD-cream group, 542 patients were in the CAL/BDP gel/TS group, and 178 patients were in the PAD-cream vehicle group.
    keywords: bdp; cal; cream; pad
       cache: skin-2086.pdf
  plain text: skin-2086.txt

        item: #766 of 1356
          id: skin-209
      author: Siu, Sarah Y; Ferzli, Georgina M; Brody, Neil
       title: Reduction of Facial Redness with Resveratrol Added to Topical Product Containing Green Tea Polyphenols and Caffeine
        date: 2017-10-27
       words: 1970
      flesch: 64
     summary: Since the molecular targets of each component are not iden�cal, the components may act independently and synergis�cally to reduce cutaneous inflamma�on. The most common causes of facial redness and rashes include inflammatory dermatoses, infec�ons, and connec�ve �ssue disorders.
    keywords: data; redness; resveratrol; treatment
       cache: skin-209.pdf
  plain text: skin-209.txt

        item: #767 of 1356
          id: skin-2091
      author: Feldman, Steven; Han, George; Callender, Valerie; Kircik, Leon; Stein Gold, Linda; Bhatia, Neal; Tyring, Stephen; Zeichner, Joshua
       title: Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat
        date: 2023-05-20
       words: 1284
      flesch: 41
     summary: WHAT IS NNT? � NNT is a metric for quantifying effect sizes of clinically relevant study endpoints1 � NNT represents the number of patients needed to treat to achieve an additional cure in a given timeframe1-3 • For example, NNT=3 means that 3 patients would need to be treated with active drug rather than vehicle before expecting an additional responder2 HOW IS NNT USED? IS NNT CALCULATED? � NNT is the reciprocal of the absolute risk reduction (ARR), rounded up to the nearest whole number1-3 WHAT ARE SOME LIMITATIONS OF NNT? Evaluates one binary outcome (eg, week 12 treatment success)2,4 No consideration of drug tolerability or study design/ population differences1-4 Clinical meaning subject to interpretation5 Bene�ts of a well- designed vehicle subtracted from active treatment,a leading to higher NNT values aDue to the potential of a well-designed vehicle to result in higher efficacy rates in the control group.
    keywords: acne; clin; dermatologics; nnt; ortho; treatment
       cache: skin-2091.pdf
  plain text: skin-2091.txt

        item: #768 of 1356
          id: skin-2092
      author: Harper, Julie; Kircik, Leon; Gold, Michael Gold; Hebert, Adelaide ; Sugarman, Jeffrey; Green, Lawrence; Stein Gold, Linda; Baldwin, Hilary; Del Rosso, James; Guenin , Eric
       title: Early and Sustained Reductions in Moderate-to-Severe Acne With Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel
        date: 2023-05-20
       words: 1406
      flesch: 50
     summary: The first triple-combination, fixed-dose acne topical in development, clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel, was efficacious and safe in 3 clinical studies3,4 OBJECTIVE � To determine threshold lesion reductions for IDP-126 gel and compare to its dyads and vehicle gel METHODS � A phase 2 (N=741; NCT03170388) and two phase 3 (N=183; N=180; NCT04214639; NCT04214652), double-blind, 12-week studies enrolled participants aged ≥9 years with moderate-to-severe acne � Participants were randomized to receive once-daily IDP-126 or vehicle gel; the phase 2 study included three additional dyad gel randomization arms: BPO/adapalene; clindamycin phosphate/BPO; and clindamycin phosphate/adapalene � Endpoints included least-squares mean percent change from baseline in inflammatory and noninflammatory lesion counts � The percentage of participants achieving ≥33%, ≥50%, and ≥75% thresholds in lesion reduction was evaluated RESULTS FIGURE 1. ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC • Presented at Winter Clinical Miami 2023 • February 17-20, 2023 • Miami, FL SYNOPSIS � Adherence to acne treatment is highest when the outcome is rapid and substantial1 �
    keywords: gel; idp-126; vehicle; week
       cache: skin-2092.pdf
  plain text: skin-2092.txt

        item: #769 of 1356
          id: skin-2095
      author: Gottlieb, Alice; Burge, Russel; Malatestinic, William; Zhu, Baojin; Zhao, Yunyang; McCormack, Julie; Kimel, Miriam; Feely, Meghan; Merola, Joseph
       title: Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program
        date: 2023-05-20
       words: 1047
      flesch: 31
     summary:  A. B. Gottlieb has received honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai; R. Burge, W. N. Malatestinic, B. Zhu, Y. Zhao, M. Feely are shareholders and employees of: Eli Lilly and Company; M. Feely is a clinical instructor at: Mount Sinai Hospital and has received consulting, travel, or speaker fees from: Aerolase, Castle Biosciences, Galderma Aesthetics, Glow Recipe, La Roche-Posay - L'Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical; J. McCormack and M. Kimel declare no conflicts of interest; J. F. Merola is a consultant and/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma  This study was sponsored by Eli Lilly and Company.
    keywords: bsa; pharma; response; target
       cache: skin-2095.pdf
  plain text: skin-2095.txt

        item: #770 of 1356
          id: skin-2097
      author: Guenin, Sophie; Shah, Syed; Lebwohl, Mark
       title: Oral Jak Inhibitor Upadacitinib Use in Treatment of Pemphigus Foliaceus : Case Report 
        date: 2023-07-17
       words: 1608
      flesch: 50
     summary: Our patient’s rapid response to upadacitinib, a selective JAK1 inhibitor, suggests a novel, steroid-sparing agent for PF treatment. Dsg1 antibodies result in autoantibody-triggered signaling events that further promote keratinocyte dissociation.7 Pemphigus has been largely considered a T helper (Th) 2-dominant disease with predominance of Th2 cytokines such as IL-4 in PF patients. IL-4
    keywords: foliaceus; patient; pemphigus; treatment; upadacitinib
       cache: skin-2097.pdf
  plain text: skin-2097.txt

        item: #771 of 1356
          id: skin-21
      author: Arnold, Morgan; Vu, Mai-anh; Grimshaw, Emily
       title: Hailey-Hailey Disease Complicated by Herpes Simplex Viral Infection
        date: 2017-08-31
       words: 1118
      flesch: 55
     summary: Although cases of Hailey - Hailey herpeticum are much less common than the better-studied eczema herpeticum, it is important for physicians to be aware that any disease that disrupts the stratum corneum increases the risk of superimposed HSV infection, which constitutes a medical emergency. A 51-year-old man with a history of Hailey- Hailey disease and recurrent MRSA cutaneous infections presented with a rash in his groin persisting for two weeks.
    keywords: disease; hailey; infection; skin
       cache: skin-21.pdf
  plain text: skin-21.txt

        item: #772 of 1356
          id: skin-210
      author: Siu, Sarah Y; Ferzli, Georgina M; Brody, Neil
       title: Topical Green Tea Polyphenols and Caffeine as a Treatment for Acne Vulgaris
        date: 2017-10-27
       words: 1797
      flesch: -1704
     summary: dŽƉŝĐĂů�'ƌĞĞŶ�dĞĂ�WŽůLJƉŚĞŶŽůƐ�ĂŶĚ��ĂīĞŝŶĞ�ĂƐ�Ă�dƌĞĂƚŵĞŶƚ�ĨŽƌ��ĐŶĞ�sƵůŐĂƌŝƐ ^ĂƌĂŚ�z͘ �^ŝƵ͕�'ĞŽƌŐŝŶĂ�D͘�&Ğƌnjůŝ�ĂŶĚ�EĞŝů��ƌŽĚLJ The Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY, 11203University Hospital of Brooklyn /ŶƚƌŽĚƵĐƟŽŶ Acne vulgaris is the most prevalent skin disorder in the US with 40-50 million individuals ĂīĞĐƚĞĚ͘�/ƚ�ĂīĞĐƚƐ�ϴϱй�ŽĨ�ĂĚŽůĞƐĐĞŶƚƐ͕�ĨƌŽŵ�ĂŐĞƐ�ϭϮͲϮϰ͕�ĂŶĚ�ĐĂŶ�ĐŽŶƟŶƵĞ�ŽŶ�ŝŶƚŽ�ĂĚƵůƚŚŽŽĚ͕� ǁŝƚŚ�ϮϬй�ŽĨ�ŵĞŶ�ĂŶĚ�ϯϱй�ŽĨ�ǁŽŵĞŶ�ƐƟůů�ĂīĞĐƚĞĚ�ŝŶƚŽ�ƚŚĞŝƌ�ϯϬƐ͘΀ϭ΁��ůƚŚŽƵŐŚ�ĂĐŶĞ�ŝƐ�ŶŽƚ�ůŝĨĞ� ƚŚƌĞĂƚĞŶŝŶŐ�ŝƚ�ĐĂƵƐĞƐ�ƐŝŐŶŝĮĐĂŶƚ�ƉƐLJĐŚŽƐŽĐŝĂů�ŵŽƌďŝĚŝƚLJ�ĂŶĚ�ŚĂƐ�ƉŚLJƐŝĐĂů�ƐĞƋƵĞůĂĞ�ŝŶĐůƵĚŝŶŐ� ůŝĨĞůŽŶŐ�ƐĐĂƌƌŝŶŐ͘΀Ϯ΁�ĐŶĞ�ŝƐ�Ă�ĐŽŵƉůĞdž�ŝŶƚĞƌĂĐƟŽŶ�ŽĨ�ƚŚĞ�ŝŵŵƵŶĞ�ƐLJƐƚĞŵ�ƌĞĐŽŐŶŝƟŽŶ�ŽĨ� Propionibacterium acnes�ďĂƐĞĚ�ŽŶ�ĂŶ�ŝŶĚŝǀŝĚƵĂůƐ�ŐĞŶĞƟĐƐ�ƉůĂLJĞĚ�ŽƵƚ�ŝŶ�ƚŚĞ�ĨŽůůŝĐƵůĂƌ� ĂƉƉĂƌĂƚƵƐ͘�P. acnes�ŝƐ�Ă�ŬĞLJ�ƉůĂLJĞƌ�ŝŶ�ƚŚĞ�ƉĂƚŚŽŐĞŶĞƐŝƐ�ŽĨ�ĂĐŶĞ͘�dŚĞƐĞ�'ƌĂŵͲƉŽƐŝƟǀĞ͕� ĂŶĂĞƌŽďŝĐͬŵŝĐƌŽĂĞƌŽƉŚŝůŝĐ�ƌŽĚƐ�ĂƌĞ�ĨŽƵŶĚ�ǁŝƚŚŝŶ�ƐĞďĂĐĞŽƵƐ�ĨŽůůŝĐůĞƐ͘�dŚĞLJ�ƉƌŽĚƵĐĞ�ƉŽƌƉŚLJƌŝŶƐ� ƚŚĂƚ�ŇƵŽƌĞƐĐĞ�ƵŶĚĞƌ�tŽŽĚ Ɛ͛�ůĂŵƉƐ�ŝůůƵŵŝŶĂƟŽŶ͘΀ϭ΁ �ĂĐŚ�ŽĨ�ƚŚĞ�ƉŽƉƵůĂƌ�ĂĐŶĞ�ƚƌĞĂƚŵĞŶƚƐ�ŝƐ�Ă�ƚĂƌŐĞƚ�ŽĨ�ĂƩĂĐŬ�ŝŶ�ƚŚĞ�ůŝƚĞƌĂƚƵƌĞ�ĂŶĚ�ůĂLJ�ƉƌĞƐƐ�ĨŽƌ� ĂƐƐŽƌƚĞĚ�ƌĞĂƐŽŶƐ͘�/ƐŽƚƌĞŝŶŽŝŶ͕�ŽŶĞ�ŽĨ�ƚŚĞ�ŵŽƐƚ�ĞīĞĐƟǀĞ�ƚƌĞĂƚŵĞŶƚƐ�ŚĂƐ�ďĞĞŶ�ĂƩĂĐŬĞĚ�ďĞĐĂƵƐĞ� ŽĨ�ƐŝĚĞƐ�ĞīĞĐƚƐ͕�ŝŶĐůƵĚŝŶŐ�ůŝǀĞƌ�ĞŶnjLJŵĞ�ĂďŶŽƌŵĂůŝƟĞƐ͕�ĚLJƐůŝƉŝĚĞŵŝĂ�ĂŶĚ�ƚĞƌĂƚŽŐĞŶŝĐŝƚLJ͕ �ĂŶĚ�ŝƚƐ� ƵƐĞ�ŝƐ�ůŝŵŝƚĞĚ�ŝŶ�ŵĂŶLJ�ĐŽƵŶƚƌŝĞƐ͘΀ϯ΁�KƌĂů�ĂŶĚ�ƚŽƉŝĐĂů�ĂŶƟďŝŽƟĐƐ͕�ǁŚŝůĞ�ĞīĞĐƟǀĞ�ĨŽƌ� ŝŶŇĂŵŵĂƚŽƌLJ�ůĞƐŝŽŶƐ�ĂƌĞ�ĂĐĐƵƐĞĚ�ŽĨ�ůĞĂĚŝŶŐ�ƚŽ�ďĂĐƚĞƌŝĂů�ƌĞƐŝƐƚĂŶĐĞ͘΀ϰ΁�dŽƉŝĐĂů�ƌĞƟŶŽŝĚƐ͕�ƚŚĞ� ĐƵƌƌĞŶƚ�ĮƌƐƚͲůŝŶĞ�ƚƌĞĂƚŵĞŶƚ�ĨŽƌ�ĂĐŶĞ͕�ĐĂƵƐĞ�ŝƌƌŝƚĂƟŽŶ�ĂŶĚ�ďƵƌŶŝŶŐ�ŽŶ�ŝŶŝƟĂƟŽŶ͘΀ϱ΁��Ɛ�Ă�ƌĞƐƵůƚ͕� ƚŚĞƌĞ�ĞdžŝƐƚƐ�Ă�ŶĞĞĚ�ĨŽƌ�ŶĞǁ�ĚƌƵŐƐ�ǁŝƚŚ�ĨĞǁĞƌ�ƐŝĚĞ�ĞīĞĐƚƐ�ǁŝƚŚŽƵƚ�ĚŝŵŝŶŝƐŚŝŶŐ�ĞĸĐĂĐLJ͘ �'ƌĞĞŶ� ƚĞĂ�ƉŽůLJƉŚĞŶŽů�;'dWͿ�ŚĂƐ�ŐĂŝŶĞĚ�ŝŶƚĞƌĞƐƚ�ŝŶ�ƌĞĐĞŶƚ�LJĞĂƌƐ�ďĞĐĂƵƐĞ�ŽĨ�ŝƚƐ�ƉŽƚĞŶƚ�ĂŶƟŵŝĐƌŽďŝĂů� ĂŶĚ�ĂŶƟͲŝŶŇĂŵŵĂƚŽƌLJ�ĂĐƟǀŝƟĞƐ͘΀ϲ΁��ǀŝĚĞŶĐĞ�ŚĂƐ�ƐŚŽǁŶ�ƚŚĂƚ�'dW�ŚĂƐ�ĂŶƟďĂĐƚĞƌŝĂů�ĞīĞĐƚƐ�ŽŶ�W͘� ĂĐŶĞƐ͕�ĂƐ�ǁĞůů�ĂƐ�ƐĞďŽƐƵƉƌĞƐƐŝǀĞ͕�ĂƉŽƉƚŽƟĐ͕�ĂŶĚ�ĂŶƟͲŝŶŇĂŵŵĂƚŽƌLJ�ĞīĞĐƚƐ�ŽŶ�ƐĞďŽĐLJƚĞƐ͘΀ϳ΁� �ĂīĞŝŶĞ�ŝƐ�ĂŶŽƚŚĞƌ�ǁĞůůͲŬŶŽǁŶ�ĂŶƟͲŝŶŇĂŵŵĂƚŽƌLJ�ŝŶŐƌĞĚŝĞŶƚ͘�dŽŐĞƚŚĞƌ͕ �'dW�ĂŶĚ�ĐĂīĞŝŶĞ� ƐLJŶĞƌŐŝƐƟĐĂůůLJ�ƉƌŽƚĞĐƚ�ĐĞůůƐ�ĨƌŽŵ�ŽdžŝĚĂƟǀĞ�ĐŚĂůůĞŶŐĞ͘ Methods tĞ�ŝĚĞŶƟĮĞĚ�Ă�ŐƌŽƵƉ�ŽĨ�ϭϯ�ƉĂƟĞŶƚƐ�ĨƌŽŵ�ŽƵƌ�ƉƌŝǀĂƚĞ�ƉƌĂĐƟĐĞ�ĚĂƚĂďĂƐĞ�ĨƌŽŵ�ϮϬϬϴ�ƚŽ�ϮϬϭϲ� ǁŚŽ�ŚĂĚ�ƚŚĞ�ƌĞƋƵŝƐŝƚĞ�ŝŵĂŐĞƐ�ĚƵƌŝŶŐ�ϲ�ŵŽŶƚŚƐ�ŽĨ�ƚƌĞĂƚŵĞŶƚ͘�tĞ�ĂŶĂůLJnjĞĚ�ƚŚĞ�ŝŵĂŐĞƐ�ŽĨ�ƚŚĞ� ƉĂƟĞŶƚƐ�;ĂŐĞƐ�ϭϴ�ƚŽ�ϰϬͿ�ǁŝƚŚ�ŵŝůĚ�ƚŽ�ŵŽĚĞƌĂƚĞ�ĂĐŶĞ�ǀƵůŐĂƌŝƐ�ƚŽ�ĞǀĂůƵĂƚĞ�ƚŚĞ�ĞĸĐĂĐLJ�ŽĨ�Ă� ĐŽŵŵĞƌĐŝĂůůLJ�ĂǀĂŝůĂďůĞ�ƚŽƉŝĐĂů�ƉƌŽĚƵĐƚ�ĐŽŶƚĂŝŶŝŶŐ�ϵϬй�'dW�ĂŶĚ�ĐĂīĞŝŶĞ�h^W͘�^ƵďũĞĐƚƐ�ǁĞƌĞ� ƉŚŽƚŽŐƌĂƉŚĞĚ�ƵŶĚĞƌ�ŇƵŽƌĞƐĐŝŶŐ�ĐŽŶĚŝƟŽŶƐ�ƵƐŝŶŐ��ĂŶĮĞůĚ�ŝŵĂŐŝŶŐ�ĞƋƵŝƉŵĞŶƚ�ďĞĨŽƌĞ� ƚƌĞĂƚŵĞŶƚ�ĂŶĚ�Ăƚ�ŵŽŶƚŚůLJ�ĨŽůůŽǁͲƵƉƐ͘�ϭϯ�ďůŝŶĚĞĚ�ƉĂŝƌƐ�ŽĨ�ƉƌĞ�ĂŶĚ�ƉŽƐƚͲƚƌĞĂƚŵĞŶƚ�ƉŚŽƚŽŐƌĂƉŚƐ� ǁĞƌĞ�ƐŚŽǁŶ�ƚŽ�Ϯϴ�ĚĞƌŵĂƚŽůŽŐLJ�ƌĞƐŝĚĞŶƚƐ�ǁŚŽ�ƐĞƌǀĞĚ�ĂƐ�ĞǀĂůƵĂƚŽƌƐ͘��ǀĂůƵĂƚŽƌƐ�ǁĞƌĞ�ĂƐŬĞĚ�ƚŽ� ƐĞůĞĐƚ�ǁŚŝĐŚ�ƉŚŽƚŽ�ŝŶ�Ă�ƉĂŝƌ�ŚĂĚ�ƚŚĞ�ĨĞǁĞƐƚ�ŶƵŵďĞƌ�ŽĨ�ŽƌĂŶŐĞ�ƐƉŽƚƐ͘�dŚĞ�ĞǀĂůƵĂƚŽƌƐ�ǁĞƌĞ�ŶŽƚ� ƚŽůĚ�ƚŚĞ�ŽƌĂŶŐĞ�ƐƉŽƚƐ�ǁĞƌĞ�ŽĨ�ƉŽƌƉŚLJƌŝŶ�ŇƵŽƌĞƐĐĞŶĐĞ͘�/ŶƚƌĂĐůĂƐƐ�ĐŽƌƌĞůĂƟŽŶ�ĐŽĞĸĐŝĞŶƚ�;/��Ϳ� ǁĂƐ�ƵƐĞĚ�ƚŽ�ŵĞĂƐƵƌĞ�ƚŚĞ�ŝŶƚĞƌͲƌĂƚĞƌ�ƌĞůŝĂďŝůŝƚLJ�ŽĨ�ĞǀĂůƵĂƚŽƌƐ�ŽĨ�ƚŚĞ�ƉŚŽƚŽŐƌĂƉŚ�ƉĂŝƌƐ͘ Results dŚĞ�ĞǀĂůƵĂƚŽƌƐ�ĨŽƵŶĚ�Ă�ĚĞĐƌĞĂƐĞ�ŝŶ�ŽƌĂŶŐĞ�ƐƉŽƚƐ�ĐŽƌƌĞƐƉŽŶĚŝŶŐ�ƚŽ�P. acnes�ŇƵŽƌĞƐĐĞŶĐĞ�ŝŶ�ϭϮ� ŽƵƚ�ŽĨ�ϭϯ�ƉĂŝƌƐ�ŽĨ�ŝŵĂŐĞƐ͘ dŚĞƌĞ�ǁĂƐ�Ă�ƐŝŶŐůĞ�ƐĞƚ�ŽĨ�ƉŚŽƚŽƐ�ŝŶ�ǁŚŝĐŚ�ƚŚĞ�ŵĂũŽƌŝƚLJ�ŽĨ�ĞǀĂůƵĂƚŽƌƐ�ǁĞƌĞ�ŶŽƚ�ĂďůĞ�ƚŽ� ĚŝƐƟŶŐƵŝƐŚ�ƚŚĞ�ƉŽƐƚͲƚƌĞĂƚŵĞŶƚ�ŝŵĂŐĞ͘ dŚĞ�ĂǀĞƌĂŐĞ�ŵĞĂƐƵƌĞƐ�/���ĂŵŽŶŐƐƚ�ĞǀĂůƵĂƚŽƌƐ�ǁĂƐ�Ϭ͘ϵϯϰ�;ϵϱй��/�Ϭ͘ϴϲϴ�ƚŽ�Ϭ͘ϵϳϲͿ dŚĞ�ĚĞĐƌĞĂƐĞ�ŝŶ�ŇƵŽƌĞƐĐĞŶĐĞ�ŝŶ�P. acnes�ǁĂƐ�ƐĞĞŶ�ĂƐ�ĞĂƌůLJ�ĂƐ�ϭ�ŵŽŶƚŚ�ĂŶĚ�ĐŽŶƟŶƵĞĚ�ĨŽƌ�ƚŚĞ�ϲ� ŵŽŶƚŚƐ�ƚŚĂƚ�ƚŚĞ�ƉĂƟĞŶƚƐ�ǁĞƌĞ�ĨŽůůŽǁĞĚ͘ dŚĞƌĞ�ǁĂƐ�ƐƵďũĞĐƟǀĞ�ŝŵƉƌŽǀĞŵĞŶƚ�ŝŶ�ƚŚĞ�ĂƉƉĞĂƌĂŶĐĞ�ŽĨ�ĂĐŶĞ�ĂŶĚ�ƚƌĞĂƚŵĞŶƚ�ǁĂƐ�ǁĞůů� ƚŽůĞƌĂƚĞĚ�ǁŝƚŚ�ŶŽ�ĂĚǀĞƌƐĞ�ŽƵƚĐŽŵĞƐ͘�;�ĂƚĂ�ƉƌĞƐĞŶƚĞĚ�ĞůƐĞǁŚĞƌĞͿ Discussion dŚĞ�'dW�ĂŶĚ�ĐĂīĞŝŶĞ�ƚŽƉŝĐĂů�ƚƌĞĂƚŵĞŶƚ�ĚĞĐƌĞĂƐĞĚ�ƚŚĞ�ƉŽƌƉŚLJƌŝŶ�ůĞǀĞůƐ͕�ǁŚŝĐŚ�ŝŶĚŝĐĂƚĞĚ�Ă� ĚĞĐƌĞĂƐĞ�Žƌ�ĐŚĂŶŐĞ�ŝŶ�ŵĞƚĂďŽůŝĐ�ĨƵŶĐƟŽŶ�ŽĨ�P. acnes͘�tĞ�ĚŝĚ�ŶŽƚ�ĞǀĂůƵĂƚĞ�ďLJ�ĐŽůŽŶLJ�ĐŽƵŶƚƐ� that the P. acnes�ǁĂƐ�ƌĞĚƵĐĞĚ�ďƵƚ�ƚŚĞƌĞ�ǁĂƐ�ĐŽƌƌĞƐƉŽŶĚĞŶĐĞ�ďĞƚǁĞĞŶ�ƚŚĞ�ĚĞĐƌĞĂƐĞ�ŝŶ� ƉŽƌƉŚLJƌŝŶ�ůĞǀĞůƐ�ĂŶĚ�ƚŚĞ�ĐůŝŶŝĐĂů�ŝŵƉƌŽǀĞŵĞŶƚ�ŝŶ�ĂĐŶĞ͘ KƵƌ�ŝŶŝƟĂů�ƵƐĞ�ŽĨ�ƚŚŝƐ�ĐŽŵŵĞƌĐŝĂůůLJ�ĂǀĂŝůĂďůĞ�ĂŶƟŽdžŝĚĂŶƚ�ŝŶ�ŽƵƌ�ĂĐŶĞ�ƉĂƟĞŶƚƐ�ǁĂƐ�ƚŽ�ƚŚĞ� ŵŝƟŐĂƚĞ�ƚŚĞ�ŝƌƌŝƚĂŶƚ�ĞīĞĐƚƐ�ŽĨ�ƚƌĞƟŶŽŝŶ͘�dŚŝƐ�ƉƌŽĚƵĐƚ�ĐŽŶƚĂŝŶƐ�Ăůů�ŽĨ�ƚŚĞ�ŶĂƚƵƌĂůůLJ�ŽĐĐƵƌƌŝŶŐ� ƉŽƌƟŽŶƐ�ŽĨ�ŐƌĞĞŶ�ƚĞĂ�ǁŚŝĐŚ�ŝŶĐůƵĚĞƐ�ŵŽůĞĐƵůĞƐ�ƚŚĂƚ�ŚŝƐƚŽƌŝĐĂůůLJ�ǁĞƌĞ�ŬŶŽǁŶ�ƚŽ�ŚĂǀĞ� ĂŶƟďĂĐƚĞƌŝĂů�ƉƌŽƉĞƌƟĞƐ�ƚŚĂƚ�ŝŶĐůƵĚĞ�P. acnes͘ >ŝŵŝƚĂƟŽŶƐ ^ŵĂůů�ƐĂŵƉůĞ�ƐŝnjĞ tĞ�ĚŝĚ�ŶŽƚ�ƋƵĂŶƟƚĂƚĞ�ďĂĐƚĞƌŝŽůŽŐŝĐĂůůLJ�Ă�ƌĞĚƵĐƟŽŶ�ŝŶ�P. acnes͘ Conclusion 'dW�ĂŶĚ�ĐĂīĞŝŶĞ�ĂƌĞ�Ă�ŶŽǀĞů�ƚƌĞĂƚŵĞŶƚ�ƚŚĂƚ�ŽďǀŝĂƚĞƐ�ŵŽƐƚ�ŽĨ�ƚŚĞ�ƌĞĂƐŽŶƐ�ƚŚĂƚ�ŽƚŚĞƌ�ƐƚĂŶĚĂƌĚ� ĂĐŶĞ�ŵĞĚŝĐĂƟŽŶƐ�ĂƌĞ�ĂƩĂĐŬĞĚ�ŝŶ�ůŝƚĞƌĂƚƵƌĞ͘�dŚĞ�ĨŽƌŵƵůĂƟŽŶƐ�ĞŝƚŚĞƌ�ĐƌĞĂŵ�Žƌ�ƐĞƌƵŵ�ĚŽĞƐ�ŶŽƚ� ŝƌƌŝƚĂƚĞ�ƚŚĞ�ƐŬŝŶ�ĂŶĚ�ŵĂLJ�ĚĞĐƌĞĂƐĞ�ƚŚĞ�ŝƌƌŝƚĂƟŽŶ�ŽĨ�ƌĞƟŶŽŝĚƐ͘ dŽƉŝĐĂů�'dW�ĂŶĚ�ĐĂīĞŝŶĞ�ǁĞƌĞ�ĨŽƵŶĚ�ƚŽ�ďĞ�Ă�ǀŝĂďůĞ�ŶŽŶͲĂŶƟďŝŽƟĐ�ĂŶĚ�ŶŽŶͲŝƌƌŝƚĂƟŶŐ�ĂĚĚŝƟŽŶ�ƚŽ� ŽƵƌ�ĂƌŵĂŵĞŶƚĂƌŝƵŵ�ŽĨ�ĂĐŶĞ�ƚƌĞĂƚŵĞŶƚƐ͘ Disclosures dŚĞ�ĐŽŵŵĞƌĐŝĂůůLJ�ĂǀĂŝůĂďůĞ�ƉƌŽĚƵĐƚ�ǁĂƐ�ŐĞŶĞƌŽƵƐůLJ�ĚŽŶĂƚĞĚ�ďLJ�dŽƉŝdž�WŚĂƌŵĂĐĞƵƟĐĂůƐ͕�/ŶĐ͘�/ƚ�ŝƐ� ŵĂƌŬĞƚĞĚ�ĂƐ�ZĞƉůĞŶŝdž��&�ĂŶĚ�ĂǀĂŝůĂďůĞ�ŝŶ�ĐƌĞĂŵ�ĂŶĚ�ƐĞƌƵŵ�ĨŽƌŵƵůĂƟŽŶƐ͘��ƌ͘ ��ƌŽĚLJ�ǁĂƐ� ŝŶǀŽůǀĞĚ�ŝŶ�ƚŚĞ�ĐŽŶĐĞƉƚƵĂůŝnjĂƟŽŶ�ĂŶĚ�ĚĞƐŝŐŶ�ŽĨ�ƚŚĞ�ƉƌŽĚƵĐƚ͘ References ϭ͘��ŽůŽŐŶŝĂ͕�:͕͘�:ŽƌŝnjnjŽ͕�:͘�>͕͘�Θ�^ĐŚĂīĞƌ͕ �:͘�s͘ �͕��ĞƌŵĂƚŽůŽŐLJ͘ �ϮϬϭϮ͕�WŚŝůĂĚĞůƉŚŝĂ͗��ůƐĞǀŝĞƌ�^ĂƵŶĚĞƌƐ͘ Ϯ͘�>ĂLJƚŽŶ͕��͘D͕͘�KƉƟŵĂů�ŵĂŶĂŐĞŵĞŶƚ�ŽĨ�ĂĐŶĞ�ƚŽ�ƉƌĞǀĞŶƚ�ƐĐĂƌƌŝŶŐ�ĂŶĚ�ƉƐLJĐŚŽůŽŐŝĐĂů�ƐĞƋƵĞůĂĞ͘��ŵ�:��ůŝŶ��ĞƌŵĂƚŽů͕�ϮϬϬϭ͘�Ϯ;ϯͿ͗�Ɖ͘�ϭϯϱͲϰϭ͘ ϯ͘�dŚŝďŽƵƚŽƚ͕��͘D͕͘�KǀĞƌǀŝĞǁ�ŽĨ�ĂĐŶĞ�ĂŶĚ�ŝƚƐ�ƚƌĞĂƚŵĞŶƚ͘��ƵƟƐ͕�ϮϬϬϴ͘�ϴϭ;ϭ�^ƵƉƉůͿ͗�Ɖ͘�ϯͲϳ͘ ϰ͘�ZŽƐƐ͕�:͘/͕͘�Ğƚ�Ăů͕͘�WŚĞŶŽƚLJƉŝĐ�ĂŶĚ�ŐĞŶŽƚLJƉŝĐ�ĐŚĂƌĂĐƚĞƌŝnjĂƟŽŶ�ŽĨ�ĂŶƟďŝŽƟĐͲƌĞƐŝƐƚĂŶƚ�WƌŽƉŝŽŶŝďĂĐƚĞƌŝƵŵ�ĂĐŶĞƐ�ŝƐŽůĂƚĞĚ�ĨƌŽŵ�ĂĐŶĞ�ƉĂƟĞŶƚƐ ����ĂƩĞŶĚŝŶŐ�ĚĞƌŵĂƚŽůŽŐLJ�ĐůŝŶŝĐƐ�ŝŶ��ƵƌŽƉĞ͕�ƚŚĞ�h͘^͘�͕͘�:ĂƉĂŶ�ĂŶĚ��ƵƐƚƌĂůŝĂ͘��ƌ�:��ĞƌŵĂƚŽů͕�ϮϬϬϭ͘�ϭϰϰ;ϮͿ͗�Ɖ͘�ϯϯϵͲϰϲ͘ ϱ͘�^ƚƌĂƵƐƐ͕�:͘^͕͘�Ğƚ�Ăů͕͘�'ƵŝĚĞůŝŶĞƐ�ŽĨ�ĐĂƌĞ�ĨŽƌ�ĂĐŶĞ�ǀƵůŐĂƌŝƐ�ŵĂŶĂŐĞŵĞŶƚ͘�:��ŵ��ĐĂĚ��ĞƌŵĂƚŽů͕�ϮϬϬϳ͘�ϱϲ;ϰͿ͗�Ɖ͘�ϲϱϭͲϲϯ͘ ϲ͘��ĂďƌĞƌĂ͕��͕͘�Z͘��ƌƚĂĐŚŽ͕�ĂŶĚ�Z͘�'ŝŵĞŶĞnj͕��ĞŶĞĮĐŝĂů�ĞīĞĐƚƐ�ŽĨ�ŐƌĞĞŶ�ƚĞĂͲͲĂ�ƌĞǀŝĞǁ͘�:��ŵ��Žůů�EƵƚƌ͕ �ϮϬϬϲ͘�Ϯϱ;ϮͿ͗�Ɖ͘�ϳϵͲϵϵ͘ ϳ͘�zŽŽŶ͕�: z͘͘ ͕�Ğƚ�Ăů͕͘��ƉŝŐĂůůŽĐĂƚĞĐŚŝŶͲϯͲŐĂůůĂƚĞ�ŝŵƉƌŽǀĞƐ�ĂĐŶĞ�ŝŶ�ŚƵŵĂŶƐ�ďLJ�ŵŽĚƵůĂƟŶŐ�ŝŶƚƌĂĐĞůůƵůĂƌ�ŵŽůĞĐƵůĂƌ�ƚĂƌŐĞƚƐ�ĂŶĚ�ŝŶŚŝďŝƟŶŐ�W͘�ĂĐŶĞƐ͘�: ����/ŶǀĞƐƚ��ĞƌŵĂƚŽů͕�ϮϬϭϯ͘�ϭϯϯ;ϮͿ͗�Ɖ͘�ϰϮϵͲϰϬ͘ FC17PosterTopixSiuTopicalGTPCaffeine.pdf
    keywords: ă �; ăŷě �; ŝŷ �; ƚž �; � đăīğŝŷğ; � žĩ; � ƚśğ; � �
       cache: skin-210.pdf
  plain text: skin-210.txt

        item: #773 of 1356
          id: skin-211
      author: Kimball, Alexa B; Mariette, Xavier; Abraham, Bincy; Flynn, Ann; Forger, Frauke; Molto, Anna; Flipo, Rene Marc; van Tubergen, Astrid; Shaughnessy, Laura; Simpson, Jeff; Teil, Marie; Helmer, Eric; Wang, Maggie; Chakravarty, Eliza
       title: Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
        date: 2017-10-27
       words: 2047
      flesch: 56
     summary: • Key inclusion criteria: – Patients were ≥30 weeks pregnant with a singleton or twins at the time of informed consent. – Patients were being treated with CZP as per the locally approved label and prescriber’s discretion. – Patients started or decided to continue CZP treatment independently from and prior to participating in this study and in accordance with the treating physician. – Patients received a CZP dose within 35 days prior to delivery. Median (min, max), unless stated otherwise Mothers (n=16)a Age, years 31 (18, 40) Mother’s indication for CZP treatment, n Rheumatoid arthritis 11 Crohn’s disease 3
    keywords: birth; czp; data; infants; mothers; pharma; weeks
       cache: skin-211.pdf
  plain text: skin-211.txt

        item: #774 of 1356
          id: skin-2113
      author: Chovatiya, Raj; Balu, Sanjeev; Kim, Yestle; Althoff, Amanda G.; Rasouliyan, Lawrence
       title: Early Insights into the Characteristics of Tralokinumab Patients in a Real-World Setting in the United States
        date: 2023-05-20
       words: 1713
      flesch: 48
     summary: *Other biologics include the following: certolizumab pegol, secukinumab, etanercept, adalimumab, tildrakizumab-asmn, infliximab, brodalumab, golimumab, risankizumab-rzaa, ustekinumab, ixekizumab, and/or guselkumab 16.7% 14.4% 10.0% 3.3% 5.6% 2.2% 29.5% 20.0% 13.3% 14.3% 4.8% 6.7% 0% 5% 10% 15% 20% 25% 30% 35% Any systemic infection Any skin infection Any cardiovascular disease Asthma Any oncologic disease Allergic rhinitis Percent of Patients with History of Medical Condition Biologic Naïve (n=90) Biologic Experienced (n=105) This study provides early insights into the baseline characteristics of tralokinumab patients in a real-world setting in the US • While many characteristics were similar between biologic-naïve and biologic- experienced patients, a higher proportion of biologic-experienced patients had a greater degree of documented disease severity • Understanding the types of patients who were being prescribed tralokinumab may help identify other patients who may benefit from tralokinumab to manage their moderate- to-severe AD • Additional real-world studies are required to observe the changes in clinical outcomes after the initiation of tralokinumab over a longer period of time Objective The objective of this study was to understand the demographic, medical history, and clinical baseline characteristics of adult patients who were prescribed tralokinumab for the treatment of AD in a real- world setting.
    keywords: biologic; patients; tralokinumab
       cache: skin-2113.pdf
  plain text: skin-2113.txt

        item: #775 of 1356
          id: skin-2115
      author: Stein Gold MD, Linda; Weiss MD, Jonathan S.; Fowler MD, Joseph F.; Hebert MD, Adelaide A.; Hebert MD, Adelaide A.; Sugarman MD, Jeffrey
       title: Efficacy of a Novel Formulation of Betamethasone Dipropionate 0.05% Spray Versus Augmented Betamethasone Dipropionate 0.05% Lotion In Patients >= 18 Years of Age with Moderate Plaque Psoriasis: A Pooled Analysis
        date: 2023-05-20
       words: 1231
      flesch: 66
     summary: P�zer, Arcutis, Abbvie, Leo, Xencor Honoraria (advisory boards and lectures): P�zer, Arcutis, Leo, Ortho Dermatologics, Incyte, Almirall DSMB: Ortho Dermatologics, GSK, Regeneron, Sano� JS Consulting: Galderma, Incyte, Sol-Gel Advisory Boards: Incyte, P�zer, Sol-Gel Speaker: Galderma, Incyte, P�zer Honoraria: Galderma, Incyte, Sol-Gel Pooled e�cacy analysis included patients with stable disease (present for ≥ 3 months), an Investigator Global Assessment (IGA) = 3, and a Body Surface Area (BSA) of 10-20% who received either BDS (N = 356) or BDL (N = 90).
    keywords: bds; day; success
       cache: skin-2115.pdf
  plain text: skin-2115.txt

        item: #776 of 1356
          id: skin-212
      author: Eichenfield, Lawrence F; Armstrong, April; Green, Lawrence; Rastogi, Shipra; Pillai, Radhakrishnan; Israel, Robert
       title: Improvements in Lesional Pain and Itch Symptoms with Brodalumab in Psoriasis Studies
        date: 2017-10-27
       words: 1936
      flesch: 63
     summary: The interleukin-17 receptor A (IL-17RA) antagonist brodalumab has demonstrated efficacy and safety for the treatment of moderate-to-severe plaque psoriasis in phase 3 clinical studies1,2 – AMAGINE-1: adult patients were randomized to receive placebo, brodalumab 140 mg, or brodalumab 210 mg every 2 weeks (Q2W)1 – AMAGINE-2/-3: patients were randomized to receive placebo, brodalumab (140 or 210 mg Q2W), or ustekinumab (45 or 90 mg depending on body weight)2 – Brodalumab demonstrated superior efficacy at week 12 vs placebo and ustekinumab - AMAGINE-1: brodalumab 140 The effect of brodalumab on lesional pain and itch, as measured within the PSI, was assessed in patients with moderate-to-severe psoriasis from three phase 3, multicenter, randomized, double-blind, placebo- and active-comparator– controlled studies (AMAGINE-1/-2/-3) METHODS Procedures • Patients in the AMAGINE-1/-2/-3 studies were randomized to receive treatment during the 12-week induction phase as follows: AMAGINE-1: brodalumab (140 or 210 mg Q2W) or placebo; AMAGINE-2: brodalumab (140 or 210 mg Q2W), placebo, or ustekinumab; AMAGINE-3: brodalumab (140 or 210 mg Q2W), placebo, or ustekinumab • Patients used a daily electronic diary to rate the severity of symptoms during the previous 24 hours on a PSI scale of 0 (not at all severe) to 4 (very severe) –
    keywords: brodalumab; itch; mg q2w; placebo; q2w
       cache: skin-212.pdf
  plain text: skin-212.txt

        item: #777 of 1356
          id: skin-213
      author: Lebwohl, Mark G; Green, Lawrence; Hsu, Sylvia; Rastogi, Shipra; Lin, Tina; Pillai, Radhakrishnan; Israel, Robert J
       title: Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials
        date: 2017-10-27
       words: 909
      flesch: 63
     summary: N A PS I s co re , m ea n (S D ) 6 0 4 2 10 12 14 8 BL BL * BLWeek 12 Week 12 Week 12 Brodalumab 140 mg Q2W Placebo Brodalumab 210 mg Q2W 261n 466 472 1.1 (3.2)Improvement over baseline(as observed), mean (SD) 3.6 (3.9) 4.4 (3.8) 5.16.08.4 9.59.69.5 * BL, baseline; NAPSI, nail psoriasis severity index; Q2W, every 2 weeks; SD, standard deviation. N A PS I s co re im pr ov em en t ov er b as el in e, % 30 0 20 10 50 60 40 Placebo 11.6% 37.5% 46.3% Brodalumab 140 mg Q2W Brodalumab 210 mg Q2W 261 n466 472 NAPSI, nail psoriasis severity index; Q2W, every 2 weeks.
    keywords: brodalumab; napsi; q2w
       cache: skin-213.pdf
  plain text: skin-213.txt

        item: #778 of 1356
          id: skin-214
      author: Lebwohl, Mark; Papp, Kim A; Wu, Jashin J; Blauvelt, Andrew; Menter, Alan; Rastogi, Shipra; Pillai, Radhakrishnan; Israel, Robert
       title: Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies
        date: 2017-10-27
       words: 1638
      flesch: 62
     summary: No pattern emerged between timing of the events and the initiation or withdrawal of brodalumab • Controlled data do not suggest a causal relationship between brodalumab treatment and SIB © 2017. The dermatology life quality index (DLQI) assesses the socio-psychological impact of the skin disease8 on patients’ lives and was measured in AMAGINE-1/-2/-3 • Data on psychiatric AEs were pooled for all trials and were summarized as follow-up time–adjusted event rates – The follow-up time–adjusted event rate is the total number of events reported during the follow-up observation time divided by total patient-years of observation; this includes gaps and interruptions in exposure and time beyond the exposure period RESULTS • Mean HADS anxiety and depression scores significantly improved with brodalumab compared with placebo by 12 weeks (Figure 1) •
    keywords: brodalumab; depression; patients; time; week
       cache: skin-214.pdf
  plain text: skin-214.txt

        item: #779 of 1356
          id: skin-2140
      author: Schlesinger, Todd; Kircik, Leon; Del Rosso, James; Rigel, Darrell; Lebwohl, Mark; Berman, Brian; Armstrong, April; Bhatia, Neal; Patel, Vishal A.; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)
        date: 2023-05-20
       words: 5769
      flesch: 54
     summary: Clinician-reported satisfaction with tirbanibulin treatment compared with previous AK topical medications was higher than patient-reported satisfaction, most likely due to clinicians comparing the results based on their daily experience with AK patients. By contrast, this study has some strengths as to be able to assess QoL, treatment satisfaction and short-term effectiveness in daily practice tirbanibulin use in AK patients.
    keywords: authors; clinicians; inc; issue; keratosis; medicine; outcomes; patients; satisfaction; skin; society; study; tirbanibulin; treatment; week
       cache: skin-2140.pdf
  plain text: skin-2140.txt

        item: #780 of 1356
          id: skin-2142
      author: Fischer, Daniel ; Litchman, Graham
       title: A Case of a Large, Painful Dermatofibrosarcoma Protuberans Arising from a Traumatic Scar
        date: 2023-05-20
       words: 1593
      flesch: 36
     summary: John’s Episcopal Hospital, Far, Rockaway, NY Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive and seldom metastatic soft tissue tumor usually confined to the dermis and subcutaneous tissues.1 The first case of DFSP was described in 1924 and termed by Hoffman in 1925.2 It accounts for less than 0.1% of all malignant neoplasms and 1% of soft tissue sarcomas.3 Diagnosis requires skin biopsy with histochemical analysis and mainstay of treatment is surgery. Dermatofibrosarcoma protuberans typically presents as a slow growing, nontender plaque that with time develops an asymmetric and multinodular, red, yellow, or brown appearance.1 DFSP most commonly appears on the trunk or extremities and less often on the head and neck but can appear almost anywhere.3 Local recurrence following excision is fairly common.4
    keywords: case; chest; dermatofibrosarcoma; dfsp; mass; protuberans
       cache: skin-2142.pdf
  plain text: skin-2142.txt

        item: #781 of 1356
          id: skin-2146
      author: Zakria, Danny; Armstrong, April; Berman, Brian; Del Rosso, James; Lebwohl, Mark; Schlesinger, Todd; Rigel, Darrell
       title: The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel
        date: 2023-05-20
       words: 5586
      flesch: 61
     summary: 7 voted 9 Higher complexity, longer duration, and adverse effects negatively impact adherence to AK treatments. 7 voted 9 Lower adherence to AK treatments can lead to lower efficacy.
    keywords: adherence; aks; carcinoma; dermatol; keratosis; medicine; patients; review; skin; study; tirbanibulin; topical; treatment
       cache: skin-2146.pdf
  plain text: skin-2146.txt

        item: #782 of 1356
          id: skin-2149
      author: Rigel, Darrell; Lebwohl, Mark; Schlesinger, Todd; Armstrong, April; Berman, Brian; Bhatia, Neal; Del Rosso, James; Kircik, Leon; Patel, Vishal A.; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Impact of Actinic Keratosis on patient-reported AK symptoms, emotions and functioning measured using Skindex-16, among patients with Actinic Keratosis administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)
        date: 2023-05-20
       words: 1843
      flesch: 60
     summary: [min, max] 66.30 [30.00, 90.00] Gender, % FemaleMale 31.38 68.62 Primary health insurance, % Private Insurance Medicaid Medicare Uninsured 41.72 3.10 53.79 1.38 History of skin cancer, % 61.72 Fitzpatrick skin type, % Type I Type II Type III Type IV Type V 7.59 71.38 18.62 1.38 1.03 Baseline patient self- reported skin-texture, % Dry Smooth Rough Bumpy Scaly Blistering Peeling 39.66 47.59 19.66 18.62 35.17 0.34 6.21 Baseline severity of skin photodamage in AK affected area, % Absent Mild Moderate Severe 1.03 21.38 56.55 20.34 Table 2: Site Characteristics N=32 Current workplace: Private, office-based practice, % 100 Total number of board-certified dermatologists in the clinic/practice, Mean 3.53 Number of patients with AKs managed by the clinic in a given month, Mean 136.34 Number of years practicing dermatology, Mean 15.66 77.51% 91.35% 0.00% 100.00% Baseline Week - 8 P ro po rti on o f p at ie nt s (N =2 88 ) Reporting ‘never or least bothered’ SK2: CFB: 19.23%* 87.19% 98.22% 0.00% 100.00% Baseline Week - 8 P ro po rti on o f p at ie nt s (N =2 81 ) Reporting ‘never or least bothered’ SK14: Over the past week, how often has skin condition made it hard to show affection?
    keywords: f p; p ro; week
       cache: skin-2149.pdf
  plain text: skin-2149.txt

        item: #783 of 1356
          id: skin-215
      author: Patel, Rakesh; Strimling, Robert; Doggett, Stephen; Willoughby, Mark; Mafong, Erick; Miller, Kenneth; Dardick, Lawrence
       title: Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery for the Treatment of Early-Stage Non-Melanoma Skin Cancer: A Matched Pair Cohort Study
        date: 2017-10-27
       words: 1594
      flesch: 74
     summary: EBX=electronic brachytherapy; MMS=Mohs micrographic surgery; BCC=basal cell carcinoma; SCC=squamous cell carcinoma; BSC=basosquamous carcinoma Table 2. Scalp 14 (6.7%) 14 (6.7%) Nose 33 (15.9%) 33 (15.9%) Torso 12 (5.8%) 12 (5.8%) Lower Extremity 23 (11.1%) 23 (11.1%) Upper Extremity 30 (14.4%) 30 (14.4%) EBX=electronic brachytherapy; MMS=Mohs micrographic surgery; BC- C=basal cell carcinoma; SCC=squamous cell carcinoma; T=tumor; N=nodes (lymph); M=metastases; G=grade 1.
    keywords: ebx; mms
       cache: skin-215.pdf
  plain text: skin-215.txt

        item: #784 of 1356
          id: skin-2150
      author: Lebwohl, Mark; Rigel, Darrell; Schlesinger, Todd; Armstrong, April; Berman, Brian; Bhatia, Neal; Del Rosso, James; Kircik, Leon; Patel, Vishal A.; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Comparison of patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across U.S.: PROAK Study
        date: 2023-05-20
       words: 1166
      flesch: 44
     summary: [min, max] 66.30 [30.00, 90.00] Gender, % FemaleMale 31.38 68.62 Primary health insurance, % Private Insurance Medicaid Medicare Uninsured 41.72 3.10 53.79 1.38 History of skin cancer, % 61.72 Fitzpatrick skin type, % Type I Type II Type III Type IV Type V 7.59 71.38 18.62 1.38 1.03 Baseline patient self- reported skin-texture, % Dry Smooth Rough Bumpy Scaly Blistering Peeling 39.66 47.59 19.66 18.62 35.17 0.34 6.21 Baseline severity of skin photodamage in AK affected area, % Absent Mild Moderate Severe 1.03 21.38 56.55 20.34 6.55% 14.14% 78.97% 10.00% 14.14% 75.86% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Extremely/Very/Dissatisfied Somewhat Satisfied Extremely/Very/Satisfied P ro po rti on o f P at ie nt s at W ee k- 8 Satisfaction Ratings Figure 1: Majority of patients and clinicians were ‘extremely/very /satisfied’ with how skin looks, after the 8-week treatment course Clinician Patient Table 2: Site Characteristics (N=32) Current workplace: Private, office-based practice, % 100 Total number of board-certified dermatologists in the clinic/practice, Mean 3.53 Number of patients with AKs managed by the clinic in a given month, Mean 136.34 Number of years practicing dermatology, Mean 15.66 N = 290 6.55% 12.41% 80.69% 9.65% 15.5… 74.83% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Extremely/Very/Dissatisfied Somewhat Satisfied Extremely/Very/Satisfied P ro po rti on o f P at ie nt s at W ee k- 8 Satisfaction Ratings Figure 2: Majority of patients and clinicians were ‘extremely/very /satisfied’ with skin texture, after the 8-week treatment course Clinician PatientN = 290 Patient’s self-reported satisfaction and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area at individual patient-level were assessed among study patients at Week-8 on a seven- point adjectival response scale of 1 (extremely dissatisfied) – 7 (extremely satisfied).
    keywords: patients; skin; tirbanibulin; treatment
       cache: skin-2150.pdf
  plain text: skin-2150.txt

        item: #785 of 1356
          id: skin-2154
      author: Graber, Emmy; Baldwin, Hilary; Alexis, Andrew F.; Del Rosso, James; Fried, Richard G.; Harper, Julie C.; Hebert, Adelaide; Kircik, Leon; Rieder, Evan A.; Stein Gold, Linda; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S: An analysis of PROSES study cohort
        date: 2023-05-20
       words: 1171
      flesch: 33
     summary: Objective: Evaluate patient self-perceived AV symptoms and impact of AV on emotional/social functioning and ADL, among AV patients in community practices across the U.S. Methods: Single-arm, prospective cohort study (PROSES: NCT04820673) was conducted with moderate-to-severe non-nodular AV patients >9yrs who were prescribed sarecycline in real-world U.S community practices. SYNOPSIS CONCLUSIONS • Moderate to severe AV burden/impact was observed at study entry, in this prospective cohort of AV patients in the U.S. Emotional impact and social impact of AV were especially more pronounced among the AV population.
    keywords: impact; items; patients
       cache: skin-2154.pdf
  plain text: skin-2154.txt

        item: #786 of 1356
          id: skin-2155
      author: Graber, Emmy; Baldwin, Hilary; Alexis, Andrew F.; Del Rosso, James; Fried, Richard G.; Harper, Julie C.; Hebert, Adelaide; Kircik, Leon; Rieder, Evan A.; Stein Gold, Linda; Narayanan, Siva; Koscielny, Volker; Kasujee, Ismail
       title: Clinician satisfaction with treatment outcomes among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication use
        date: 2023-05-20
       words: 946
      flesch: 43
     summary: OBJECTIVE The objective of this analysis was to evaluate clinician satisfaction with treatment outcomes, stratified by the use or non-use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. RESULTS Table 1: Patient Baseline Characteristics N=253 Age Group, % Pediatric (<18 yrs) 39.92 Adult (≥18 yrs) 60.08 Age Group, Mean yrs Pediatric (<18 yrs) 14.81 Adult (≥18 yrs) 26.63 Gender, % 0.00% 5.14% 6.72% 37.55% 50.59% 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% Very Dissastified Dissatisfied Neutral Sastisfied Very Satisfied P ro po rti on o f P at ie nt s Figure 1: For Majority of Patients, Clinicians Were “Very Satisfied / Satisfied” with Sarecycline Outcomes at Week-12 88.14% N=253 Table 2: Concomitant Medication Use N=253 Has not used any acne medication, % 49.80 Topical medication, % Topical retinoids 24.51 Salicylic acid 1.19 Benzoyl peroxide 5.93 Topical antibiotics 13.44 Topical Dapsone 5.14 Azelaic acid 2.77 Topical Clascoterone 0.79 Other* 17.00 Oral Medication^, % 4.74 *11.07% were on adapalene/benzoyl peroxide; ^4.35% were on spironolactone.
    keywords: patients; sarecycline; treatment
       cache: skin-2155.pdf
  plain text: skin-2155.txt

        item: #787 of 1356
          id: skin-2167
      author: Dirr, McKenzie A. ; Dick, Mary; Boyd, Alan S. ; Milam, Philip B. 
       title: Actinomycetoma Following Traumatic Inoculation of Nocardia Brasiliensis
        date: 2023-07-17
       words: 684
      flesch: 39
     summary: Mycetomas ensue from implantation of a pathogen into skin resulting in edema, nodules, abscesses, fistulas, sinuses, and purulent drainage with variably colored granules.1,2,3 There are several subtypes of mycetomas, including eumycotic (fungal pathogens), botryomycosis (bacterial pathogens), and actinomycotic (filamentous branching organisms, including Nocardia species).1 Most mycetomas occur following trauma with exposure to contaminated soil.1 Actinomycetomas can be caused by various species of aerobic filamentous organisms, including Nocardia brasiliensis, a gram- positive, filamentous, aerobe found in soil.1,2,3 Chronic infections may result from this microbe’s capacity to adapt and survive the host’s immune response. Tissue culture was positive for Nocardia brasiliensis approximately 20 days later, confirming diagnosis of actinomycetoma.
    keywords: actinomycetoma; medical; nocardia; nodules
       cache: skin-2167.pdf
  plain text: skin-2167.txt

        item: #788 of 1356
          id: skin-2169
      author: Cohen, Philip
       title: Generalized Eruptive Keratoacanthomas of Grzybowski and the Sign of Zorro
        date: 2023-07-17
       words: 947
      flesch: 46
     summary: He who wore a black mask that covered the areas around his eyes and the bridge of his nose to conceal his identity.2 The sign of Zorro, in association with generalized eruptive keratoacanthomas of Grzybowski, was initially described in 2014.2 It represents the prominent appearance of multiple individual and confluent keratoacanthomas predominantly restricted to the periorbital region--including the eyebrows, eyelids, and even extending to include the cutaneous and mucosal conjunctiva (Figure 1A).2,5 Since the distribution of keratoacanthomas presents like a mask covering these affected areas, this unique feature has more recently also been referred to as the mask of Zorro.5 SKIN July 2023 Volume 7 Issue 4 (c) 2023 THE AUTHORS. Generalized eruptive keratoacanthomas of Grzybowski is a non-hereditary onset of hundreds to thousands of small keratoacanthomas that can appear not only on the skin but also the mucous membranes of the eyes and mouth.
    keywords: eruptive; grzybowski; keratoacanthomas; zorro
       cache: skin-2169.pdf
  plain text: skin-2169.txt

        item: #789 of 1356
          id: skin-217
      author: Team, Editorial
       title: Why Publish this Special Issue? A New Paradigm in the Use of Technology to Aid in the Widespread Dissemination of Dermatologic Knowledge
        date: 2017-10-27
       words: 317
      flesch: 35
     summary: While publication expenses and space limitations have limited the ability to distribute scientific posters through traditional print venues, we at SKIN see the great potential in using an online platform to make free open access to poster presentations beyond those who attend a conference a possibility. Poster Supplement Section Editors Mark Lebwohl MD Professor and Chairman, Dermatology, Icahn School of Medicine at Mount Sinai, New York James Del Rosso DO Adjunct Clinical Professor, Touro University College of Osteopathic Medicine, Henderson, NV Darrell S Rigel MD, MS Clinical Professor of Dermatology, New York University School of Medicine, New York, NY
    keywords: skin
       cache: skin-217.pdf
  plain text: skin-217.txt

        item: #790 of 1356
          id: skin-2179
      author: Moloney, Mairead; Teplitz, Rebeca; How, Brian; Sirota-Rozenberg, Suzanne
       title: A Suspected Case of Imported Yaws in New York
        date: 2023-07-17
       words: 1820
      flesch: 55
     summary: Secondary Yaws, “Daughter Yaws,” are smaller and more widespread than primary Yaws.1 They occur close to body orifices and heal spontaneously over three to six months.1,3 Both primary and secondary lesions are highly contagious.4 About 10% of individuals will progress to non- contagious tertiary Yaws, in which, abscesses form, become necrotic, and ulcerate.1 The diagnosis of Yaws is typically made clinically.1,3 906 BRIEF ARTICLE A Suspected Case of Imported Yaws in New York Mairead Moloney, BS1, Rebeca Teplitz, DO2, Brian How, DO2, Suzanne Sirota-Rozenberg, DO, FAAD, FAOCD2 1 New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY 2 St. John’s Episcopal Hospital, Far Rockaway, NY Yaws is a non-venereal endemic treponematosis, which is morphologically and antigenically identical to venereal syphilis, caused by Treponema pallidum, subspecies pallidum.1,2 Yaws is caused by subspecies pertenue, and is characterized by chronic skin infections.3 Yaws occurs in warm, humid, tropical climates, with an annual temperature of >27°C, and an annual rainfall of >1,300 mm/year.1,4 Transmission occurs through direct skin-to- skin contact with an infected lesion.3,4 Risk factors include broken skin and injuries, such as bites and wounds.5-7 Lesions are most commonly found on the lower extremities.2,3 A majority of cases (70-85%) occur in children under 15 years old.2
    keywords: azithromycin; endemic; jamaica; patient; skin; yaws
       cache: skin-2179.pdf
  plain text: skin-2179.txt

        item: #791 of 1356
          id: skin-218
      author: Tessiatore, Kristen; Sadhwani, Divya; Mancl, Kimberly; Rodriguez-Waitkus, Paul; Seminario-Vidal, Lucia
       title: Disseminated Cutaneous Mycobacterium Haemophilum Infection and Concomitant Crusted Scabies in an Iatrogenically Immunocompromised Patient - A Case Report
        date: 2018-03-09
       words: 1552
      flesch: 38
     summary: M. haemophilum may take up to eight weeks to grow in culture, requires iron supplemented media, and grows optimally at 30-32C. There is no standardized antibiotic regimen for M. haemophilum infection. Whereas scabies infestation is readily diagnosed, M. haemophilum infection poses a diagnostic challenge due to its rarity as well as varied clinical and histologic presentations.
    keywords: haemophilum; infection; infestation; mycobacterium; scabies; skin
       cache: skin-218.pdf
  plain text: skin-218.txt

        item: #792 of 1356
          id: skin-2186
      author: Senna, Maryanna; Forman, Seth ; Bordone, Lindsey ; De La Cueva Dobao, Pablo ; Wolk, Robert ; Zwillich, Samuel ; Zhang, Fan ; Mohamed Ahmed, Haytham ; Takiya, Liza 
       title: Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
        date: 2023-07-17
       words: 1892
      flesch: 61
     summary: Safety • Ritlecitinib was well tolerated through Week 48 in patients with AA • Among patients who did not meet clinical response at Week 24, the most common AEs (≥5% of patients in any treatment group) were nasopharyngitis, nausea, headache, and folliculitis CONCLUSIONS • Target hair regrowth responses may be achieved at later time points with continued ritlecitinib treatment in patients with AA who do not initially achieve target response at Week 24 Study population • Inclusion criteria: - Age ≥12 years - AA with ≥50% scalp hair loss, including patients with alopecia totalis (AT) and alopecia universalis (AU) - Current AA episode duration of 6 months to 10 years • Patients with other causes of alopecia or previous use of any JAK inhibitor were excluded • Hospital Universitario Infanta Leonor, Madrid, Spain; 5Pfizer Inc, Groton, CT, USA; 6Pfizer Inc, New York, NY, USA; 7Pfizer Inc, Dubai, United Arab Emirates; 8Pfizer Inc, Collegeville, PA, USA Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study BACKGROUND • Alopecia areata (AA) is an autoimmune disease that has an underlying immuno-inflammatory pathogenesis and is characterized by nonscarring hair loss ranging from small patches to complete scalp, face, and/or body hair loss1 • Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety in patients aged ≥12 years with AA and ≥50% scalp hair loss in the ALLEGRO phase 2b/3 trial (NCT03732807)2 - Significant improvements in the proportion of patients with Severity of Alopecia Tool (SALT) score ≤20 (≤20% of scalp without hair) and SALT score ≤10 (≤10% of scalp without hair) at Week 24 were observed in the 50 mg and 30 mg ritlecitinib treatment groups (± 200 mg loading dose) vs placebo OBJECTIVE • To assess response to ritlecitinib between Weeks 28–48 among subpopulations of patients with AA who did not achieve target efficacy response criteria at Week 24 METHODS Study design • The ALLEGRO phase 2b/3 trial was a randomized, double-blind, placebo-controlled, combined dose-ranging and pivotal study (Figure 1) Figure 1.
    keywords: patients; response; rit; week
       cache: skin-2186.pdf
  plain text: skin-2186.txt

        item: #793 of 1356
          id: skin-219
      author: Parker, Jennifer J; Rademaker, Alfred; Donnelly, Eric; Choi, Jennifer
       title: Risk Factors for the Development of Acute Radiation Dermatitis in Breast Cancer Patients
        date: 2018-01-02
       words: 4194
      flesch: 63
     summary: In our study, BMI, total radiation dose, and radiation fractionation schedule appear to be the most important factors for development of breast radiation dermatitis. Previous studies have sought to examine which patient and treatment factors play a role in acute skin reaction from breast radiation therapy.
    keywords: breast; cancer; dermatitis; dose; grade; increase; odds ratio; radiation; risk; skin
       cache: skin-219.pdf
  plain text: skin-219.txt

        item: #794 of 1356
          id: skin-2192
      author: Chovatiya, Raj; Aldredge, Lakshi; Heath, Candrice; Acevedo, Moises; Chu, David H.; Hanna, Diane; Seal, Melissa; Zirwas, Matthew
       title: Patient and Healthcare Provider Perspectives on the Disease Burden of Seborrheic Dermatitis in the United States: Results From a National Survey
        date: 2023-07-17
       words: 2146
      flesch: 43
     summary: The average age of patients in the survey was 40 years and 55% were male (Figure 1) • 67% of the HCPs were physicians, 24% were PAs, and 10% were NPs (Figure 2) – The mean number of years in practice was 3.1 and the mean number of patients seen per week, for all skin conditions, was 158 • The majority of patients (71%) reported their symptoms as being moderate in severity – HCPs may be underestimating the percentage of patients experiencing moderate symptoms • Patients reported living with SD for an average of 3.6 years, with 20% waiting ≥6 years before seeking SD treatment (Figure 3) • Almost half of patients reported that SD negatively impacts their emotional (49%) and physical (42%) well-being “a lot/a great deal” – However, among the 85% of HCPs who assessed quality of life (n=511), only 32% said living with SD has “a lot/a great deal” of negative impact on patients’ lives • Patients with SD reported significant mental health impacts (Figure 4) – 77% reported anxiety, 72% reported depression, and 69% reported anxiety about interacting with other people – HCPs agreed that SD symptoms make patients feel anxiety (79%), depression (70%), and anxiety about interacting with other people (84%) The majority of patients reported SD impairs their ability to do their job, with almost half of patients having ever missed work due to SD symptoms •
    keywords: dermatitis; impact; patients; symptoms
       cache: skin-2192.pdf
  plain text: skin-2192.txt

        item: #795 of 1356
          id: skin-2194
      author: Lebwohl, Mark; Stein Gold, Linda; Gooderham, Melinda J.; Papp, Kim A.; Ferris, Laura K.; Adam, David N.; Hong, H. Chih-ho; Kircik, Leon H.; Zirwas, Matthew; Burnett, Patrick; Higham, Robert
       title: Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial
        date: 2023-07-17
       words: 2825
      flesch: 55
     summary: ≥97% of patients had no evidence of irritation per investigator local tolerability assessment at each visit (Figure 8) CONCLUSIONS • In this phase 2 long-term safety study, roflumilast cream 0.3%, a once-daily, nonsteroidal topical PDE4 inhibitor, was well-tolerated with a safety profile consistent with the parent phase 2b trial (Trial 201) – Rates of discontinuations due to AEs and lack of efficacy were low – No tachyphylaxis occurred and efficacy was consistent over time (IGA Success, IGA 0/1, and percentage change from baseline in BSA and PASI) – Of the 185 patients who achieved IGA Clear/Almost Clear during the open-label trial, the median durability of IGA of Clear/Almost Clear was 10 months (40.1 weeks) Figure 4. = no evidence of irritation 1 = minimal erythema, barely perceptible 2 = definite erythema, readily visible; minimal edema or minimal papular response 3 = erythema and papules 4 = definite edema 5 = erythema, edema and papules 6 = vesicular eruption 7 = strong reaction spreading beyond application site ~57.1% (n=185) of patients achieved IGA 0/1 during the trial; patients have a 50% probability of a duration of IGA of Clear or Almost Clear of more than 10 months (40.1 weeks) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Pr ob ab ili ty IG A C le ar or A lm os t C le ar 4 12 20 28 360 8 16 24 32 44 56 6440 48 6052 Censored Duration of IGA Clear or Almost Clear (Weeks)
    keywords: cohort; cream; iga; patients; roflumilast; trial; vehicle; week
       cache: skin-2194.pdf
  plain text: skin-2194.txt

        item: #796 of 1356
          id: skin-2197
      author: Ahuja, Kripa; DeSena, Grace
       title: Xylazine: An Ulcerating Addiction
        date: 2023-07-17
       words: 627
      flesch: 51
     summary: Regular use of xylazine has been associated with the formation of skin ulcers.1- 3 Though the mechanism of action is incompletely understood, a possible pathophysiology may be rooted in xylazine’s role as an alpha-2-agonist.1–3 Cutaneously, xylazine functions as a vasoconstrictor, which can drastically reduce skin perfusion and impair wound healing.3 958 COMPELLING COMMENTS Xylazine:
    keywords: skin; ulcers; xylazine
       cache: skin-2197.pdf
  plain text: skin-2197.txt

        item: #797 of 1356
          id: skin-2198
      author: Hyams, David; Byun, Jung; Martin, Brian; Bailey, Christine; Stumpf, Timothy; Petkov, Valentina
       title: Combining the 31-gene expression profile test for cutaneous melanoma with the American Joint Committee on Cancer staging identifies the highest-risk patients with stage I-II disease
        date: 2023-07-17
       words: 839
      flesch: 54
     summary: 4. O’Connell, E. et al. Hsueh, E. C. et al. JCO Precision Oncology 5, 589–601 (2021).
    keywords: class; patients
       cache: skin-2198.pdf
  plain text: skin-2198.txt

        item: #798 of 1356
          id: skin-22
      author: Haslam, Samuel P; Ross, Lindy S; Lowe, Alison C; Kelly, Brent C
       title: Hypertrophic Lichen Planus versus Well-Differentiated Squamous Cell Carcinoma: A Histological Challenge 
        date: 2017-08-31
       words: 1551
      flesch: 51
     summary: In regards to immunohistochemistry, P53 expression is seen in all cases of PEH and 75% of SCC cases, although the staining pattern is less intense and extensive in PEH as compared to SCC 4 . To address the problem that there have not been immunohistochemical or molecular tests to date to differentiate SCC from PEH, multiplex PCR was tested and shown to differentiate cutaneous SCC from PEH in 53 of 58 cases (93%) 6 .
    keywords: hypertrophic; peh; scc
       cache: skin-22.pdf
  plain text: skin-22.txt

        item: #799 of 1356
          id: skin-220
      author: Del Rosso, James
       title: What's New in the Medicine Chest? Part 1
        date: 2017-11-13
       words: 57
      flesch: 45
     summary: Part 1 James Del Rosso, DO Video Length: 25:03 Video Description: In a CME podium lecture presented at the 2017 Fall Clinical Dermatology Conference® in Las Vegas, Nevada, James Del Ross, DO, reviews recent advances in dermatopharmacology. Topics highlighted include advances in photoprotection, atopic dermatitis, oral antibiotics, and rosacea.
    keywords: advances
       cache: skin-220.pdf
  plain text: skin-220.txt

        item: #800 of 1356
          id: skin-2201
      author: Stein Gold, Linda; Kircik, Leon; Werschler , William; Baldwin, Hilary; Callender, Valerie; Green , Lawrence; Sadick, Neil; Sugarman, Jeffrey; Draelos, Zoe; Tanghetti , Emil; Bhatia, Neal
       title: Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne
        date: 2023-07-17
       words: 1907
      flesch: 50
     summary: By Sex -100% -60% -77.7% 144n= -57.9% 68 Males -77.5% 98 -57.1% 53 0% NIL: 8 (-80%) Baseline EGSS: 3 IL: 43 NIL: 47 25-Year-Old Female – Black, Hispanic Week 12 EGSS: 2 IL: 2 (-95%) NIL: 14 (-70%)
    keywords: dermatologics; egss; gel; idp-126; lesions; treatment
       cache: skin-2201.pdf
  plain text: skin-2201.txt

        item: #801 of 1356
          id: skin-2202
      author: Draelos, Zoe; Tanghetti , Emil; Stein Gold, Linda; Kircik, Leon; Bhatia, Neal; Zeichner, Joshua; Sugarman, Jeffrey
       title: Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants
        date: 2023-07-17
       words: 1661
      flesch: 38
     summary: CIPT: 77.8%), Black (RIPT/CIPT: ~68%), and non-Hispanic (89.3%; 91.1%), with a Fitzpatrick skin type of IV-VI (65.4%; 80.0%) Dermal Sensitization and Irritation � Overall, irritation with IDP-126 was moderate and not clinically significant � RIPT: The highest normalized total irritation score was observed for BPO 2.5%/ adapalene 0.3% gel, which was significantly greater than IDP-126 (401 vs 264; P<0.001; Figure 3) Adverse Events � In both studies, most TEAEs were of mild-moderate severity, and <3% of participants discontinued due to AEs/TEAEs (Table 1) �
    keywords: bpo; cipt; gel; idp-126; irritation; participants
       cache: skin-2202.pdf
  plain text: skin-2202.txt

        item: #802 of 1356
          id: skin-2203
      author: Feldman, Steven; Vlahovic, Tracey; Joseph, Warren; Daniel, C Ralph; Elewski, Boni; Rich, Phoebe; Lipner, Shari
       title: Monthly Usage of Efinaconazole 10% Solution in Two Phase 3 Randomized Trials: Is One 4-mL Bottle Enough for Proper Treatment?
        date: 2023-07-17
       words: 1224
      flesch: 43
     summary: Steven R Feldman, MD, PhD1; Shari R Lipner, MD, PhD2; Tracey C Vlahovic, DPM3; Warren S Joseph, DPM4; C Ralph Daniel, MD5; Boni Elewski, MD6, Phebe Rich, MD7 1Wake Forest School of Medicine, Winston-Salem, NC; 2Weill Cornell Medicine, New York, NY; 3Temple University School of Podiatric Medicine, Philadelphia, PA; 4Arizona College of Podiatric Medicine, Midwestern University, Glendale, AZ; 5University of Mississippi Medical Center, Jackson, MS; 6University of Alabama at Birmingham School of Medicine, Birmingham, AL; 7Oregon Health and Science University, Portland, OR SYNOPSIS � Topical therapies for onychomycosis require extended treatment durations, and incomplete or intermittent treatment can contribute to high rates of reinfection or relapse1 � Excellent adherence to treatment is necessary to maximize efficacy,2 and prescribing an adequate quantity of medication is essential for good adherence � Efinaconazole 10% topical solution—an azole antifungal used to treat onychomycosis in patients aged 6 years and older—is available in 4- or 8-mL bottles � In the absence of data on patient characteristics influencing the amount of efinaconazole needed, 87% of efinaconazole prescriptions in 2022 were written for one 4-mL bottle per month3 OBJECTIVES � To determine monthly efinaconazole usage by baseline patient demographics and clinical characteristics METHODS � Two identical, double-blind, phase 3 studies (NCT01008033; NCT01007708) enrolled adult participants (18–70 years; N=1655) with mild-to-moderate distal lateral subungual onychomycosis affecting 20–50% of ≥1 great (target) toenail4 � Participants were randomized (3:1) to treatment with efinaconazole 10% solution or vehicle, self-applied once daily for 48 weeks � Bottles of study product (10 mL) were weighed upon dispensation at each study visit (every 4 weeks) and upon return at the following visit � Monthly efinaconazole use was analyzed post hoc based on the total number of affected toenails and percent involvement of the target toenail at baseline as well as body mass index (BMI) and sex RESULTS � At baseline, efinaconazole-treated participants in both studies (N=656 and 580) had on average over one-third involvement of their target toenails (36.2% and 36.7%) and 3.7–3.8 affected toenails4 � Among efinaconazole-treated participants with usage data for this analysis (n=1067), 85% had target toenail involvement of ≥25%, and over 55% had ≥4 affected toenails � As expected, percent involvement of the target toenail, BMI, or sex did not significantly impact average monthly efinaconazole usage (Figure 1) �
    keywords: efinaconazole; ortho; usage
       cache: skin-2203.pdf
  plain text: skin-2203.txt

        item: #803 of 1356
          id: skin-2205
      author: Hashemi, David; Bhatia, Neal
       title: The JAK-Cytokine Interface – A Review and Update on Prospective Clinical Considerations
        date: 2023-07-17
       words: 1553
      flesch: 55
     summary: Atopic dermatitis represents one of the most studied, and consequently most targeted, conditions for JAK inhibition to date, with three FDA approvals of JAK inhibitors, two ABSTRACT Janus kinases (JAKs) are non-receptor tyrosine kinases that work together with signal transducers and activators of transcription (STAT) proteins to form the JAK/STAT pathway. In addition to these 4 initial dermatologic conditions for which JAK inhibitors have been approved to date, there have been a broad range of additional conditions reported for which JAK inhibition may hold promise12.
    keywords: alopecia; downstream; factors; inhibition; inhibitors; jak
       cache: skin-2205.pdf
  plain text: skin-2205.txt

        item: #804 of 1356
          id: skin-221
      author: Team, Editorial
       title: SKIN Fall Clinical Dermatology Conference® Poster Supplement Copyright Statement
        date: 2017-10-31
       words: 15
      flesch: 44
     summary: Copyright 2017 The National Society for Cutaneous Medicine Reprint requests should be sent to jofskin@gmail.org.
    keywords: copyright
       cache: skin-221.pdf
  plain text: skin-221.txt

        item: #805 of 1356
          id: skin-2216
      author: Sparling, Kennedy
       title: History in The Making: The Transformative Impact of TikTok on Dermatology
        date: 2023-07-17
       words: 662
      flesch: 54
     summary: 960 COMPELLING COMMENTS History in The Making: The Transformative Impact of TikTokTM on Dermatology Kennedy Sparling, BS1 1 University of Arizona, College of Medicine - Pheonix, Phoenix, AZ Have you heard the terms ‘jello skin’, ‘retinol sandwiching’, or ‘skin cycling’? By learning from the past, healthcare professionals have the opportunity to use TikTokTM to correct misinformation and promote evidence-based practices to the public.
    keywords: dermatology; skin; tiktoktm
       cache: skin-2216.pdf
  plain text: skin-2216.txt

        item: #806 of 1356
          id: skin-222
      author: Paniagua, Lizy; Subrt, Adrian; Gibson, Bernard
       title: Microsporum Canis Infection Presenting As Cutaneous Pseudolymphoma. Case Report And Review Of The Literature
        date: 2018-11-09
       words: 1758
      flesch: 51
     summary: This case illustrates that differentiating between cutaneous pseudolymphoma and Microsporum canis cutaneous infection mimicking histopathologically a cutaneous T cell lymphoma is discussed. cutaneous lymphoma can be challenging.
    keywords: canis; cell; lymphoma; microsporum; patient; pseudolymphoma
       cache: skin-222.pdf
  plain text: skin-222.txt

        item: #807 of 1356
          id: skin-2222
      author: Reeves, Carlie; Falcone, Lauryn ; Beatty, Collen J; Kazlouskaya, Viktoryia; English III, Joseph
       title: Patch-Type Granuloma Annulare with Clinical and Histological Features of Morphea: A True Overlap?
        date: 2023-07-17
       words: 2327
      flesch: 58
     summary: The patient was diagnosed with interstitial GA and possible morphea overlap and started on methotrexate 15 mg per week. Histologically, GA is characterized by mucin deposition, lymphohistiocytic infiltrate, and degeneration of collagen2.
    keywords: cd34; doi; granuloma; morphea; patient; pmid; type
       cache: skin-2222.pdf
  plain text: skin-2222.txt

        item: #808 of 1356
          id: skin-2225
      author: Gooderham, Melinda; Spelman, Lynda; Imafuku, Shinichi; Romanelli, Marco; Merola, Joseph F.; Armstrong, April W.; Colston, Elizabeth; Banerjee, Subhashis; Scharnitz, Thomas; Blauvelt, Andrew
       title: Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
        date: 2023-07-17
       words: 3790
      flesch: 64
     summary: This study was sponsored by Bristol Myers Squibb • Writing and editorial assistance was provided by Jieming Fang, MD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, funded by Bristol Myers Squibb Disclosures • MG: Advisory board, principal investigator, and lecture fees: AbbVie, Galderma, Leo Pharma, Pfizer, and Regeneron; Advisory board and lecture fees: Actelion; Principal investigator and consulting fees: Akros Pharma; Advisory board, principal investigator, lecture fees, and consulting fees: Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, and Valeant; Principal investigator: Arcutis, Bristol Myers Squibb, Dermira, GlaxoSmithKline, MedImmune, Merck, Roche Laboratories, and UCB; Principal investigator and lecture fees: Glenmark • LS: Consultant, paid investigator, and/or speaker: AbbVie, Amgen, Anacor, Ascend, Astellas, AstraZeneca, Blaze Bioscience, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Hexima, Janssen, Leo Pharma, Mayne Pharma, MedImmune, Merck, Merck-Serono, Novartis, Otsuka, Pfizer, Phosphagenics, Photon MD, Regeneron, Roche, Samumed, Sanofi Genzyme, SHR Pharmacy, Sun Pharma ANZ, Trius, UCB, and Zai Lab •
    keywords: apremilast; baseline; body; decile; deucravacitinib; pasi; weight
       cache: skin-2225.pdf
  plain text: skin-2225.txt

        item: #809 of 1356
          id: skin-223
      author: Shin, Grace; Smith, Michael; Toro, Butros; Ehrlich, Adam; Luther, Sanjana; Midani, Deena; Hong, Inki; Stierstorfer, Michael
       title: Utility of Food Patch Testing in the Evaluation and Management of Irritable Bowel Syndrome
        date: 2018-03-09
       words: 6519
      flesch: 64
     summary: Questionnaires assessing abdominal pain/discomfort and global improvement in IBS symptoms were used to assess one month and three or more month outcomes. In that study, 27% of the 51 individuals with IBS symptoms benefited from limited type 4 food allergen patch testing and subsequent dietary avoidance of the foods identified by the testing.
    keywords: avoidance; food; ibs; improvement; month; p p; patch
       cache: skin-223.pdf
  plain text: skin-223.txt

        item: #810 of 1356
          id: skin-224
      author: Team, Editorial
       title: Interview with Bill Humphries, Executive Vice President (Dermatology) of Ortho Dermatologics
        date: 2017-11-13
       words: 847
      flesch: 57
     summary: Patients are more educated and engaged in their treatment, creating a robust dialogue in the office. Last but not least is the payer environment; dermatological medications are on the radar screen of the payers and the challenge of patients getting the brand that is prescribed for them a significant hurdle.
    keywords: humphries; patients
       cache: skin-224.pdf
  plain text: skin-224.txt

        item: #811 of 1356
          id: skin-225
      author: Accetta, Julia; Obayomi, Aderonke; Evers-Meltzer, Rachel; Alldredge, Virginia; Murina, Andrea
       title: Scarring Alopecia: The Attitudes, Knowledge and Referral Patterns of Hair Stylists and Barbers
        date: 2018-07-06
       words: 1571
      flesch: 51
     summary: 33 28.0 Confidence in ability to identify permanent vs nonpermanent hair loss Not at all confident 41 34.7 Somewhat confident 59 50 Very confident 18 15.3 Believe scalp exam by a hairdresser is effective in hair loss detection Not at all helpful 21 17.8 Somewhat helpful 67 56.8 Very helpful 30 25.4 Interest in learning more about hair loss Interventions targeting the education, detection and physician referral ABSTRACT Disorders of hair loss are commonly encountered by hair stylists, who are in a unique position to identify early signs and symptoms.
    keywords: alopecia; hair; hairdressers; loss; stylists
       cache: skin-225.pdf
  plain text: skin-225.txt

        item: #812 of 1356
          id: skin-226
      author: Jones, Megan A; Winkelmann, Richard R; Del Rosso, James Q
       title: Status Report on the Safety of Topical Dapsone Therapy for Dermatologic Disease
        date: 2018-01-02
       words: 5265
      flesch: 53
     summary: In 20 human studies and 7 case reports, 39 of 6,384 total patients (<1%) experienced adverse effects that were considered more than mild or resulted in discontinuation of topical dapsone. The literature supports topical dapsone 5% and 7.5% gels as safe and effective medications for the treatment of dermatologic disease.
    keywords: acne; application; dapsone; efficacy; gel; patients; safety; site; site ae; study; topical; treatment; vulgaris
       cache: skin-226.pdf
  plain text: skin-226.txt

        item: #813 of 1356
          id: skin-227
      author: Team, Editorial
       title: Three Exciting New Features Aimed at Improving the Experience of the Readers of SKIN
        date: 2017-11-13
       words: 355
      flesch: 53
     summary: As such, we are excited to announce several new features of that are debuting with the publication of Volume 1, Issue 3. As a journal made by dermatologists for dermatologists, we are constantly looking for ways to implement new features aimed at serving the needs of the dermatology community.
    keywords: skin
       cache: skin-227.pdf
  plain text: skin-227.txt

        item: #814 of 1356
          id: skin-228
      author: Goldenberg, Gary
       title: Therapeutic Update
        date: 2017-11-13
       words: 45
      flesch: 16
     summary: Therapeutic Update Gary Goldenberg, MD Video Length: 21:00 Video Description: In a CME podium lecture presented at the 2017 Fall Clinical Dermatology Conference® in Las Vegas, Nevada, Gary Goldenberg, MD, reviews late-breaking research covering the treatment of a broad selection of dermatologic disorders.
    keywords: goldenberg
       cache: skin-228.pdf
  plain text: skin-228.txt

        item: #815 of 1356
          id: skin-23
      author: Editors, The
       title: Time for a New Concept in the Dermatology Literature
        date: 2017-06-28
       words: 581
      flesch: 11
     summary: Editors-in-Chief Mark Lebwohl MD Professor and Chairman, Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY Roger Ceilley MD Clinical Professor of Dermatology, University of Iowa School of Medicine, Des Moines, IA James Del Rosso DO Adjunct Clinical Professor, Touro University College of Osteopathic Medicine, Henderson, NV Editors Brian Berman MD, PhD Professor Emeritus, Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL Robert Thomas Brodell MD Professor and Chair of Department of Dermatology, University of Mississippi, Jackson, MS M. Shane Chapman MD Chair of Dermatology, Dartmouth-Hitchcock Medical Center, Hanover, NH Clay Cockerell MD Clinical Professor of Dermatology and Pathology, Director of Dermatopathology, University of Texas Southwestern, Dallas, TX Seemal Desai MD Clinical Assistant Professor, Department of Dermatology, University of Texas Southwestern Medical, Dallas, TX Scott Dinehart MD Director, Arkansas Skin Cancer Center, Little Rock, AR Boni Elewski MD James E. Elder, MD, Endowed Professor for Graduate Education and Chair, University of Alabama at Birmingham, AL David Pariser MD Professor of Dermatology, Eastern Virginia Medical School, Norfolk, VA Darrell S Rigel MD, MS Clinical Professor of Dermatology, New York University School of Medicine, New York, NY Theodore Rosen MD Professor of Dermatology, Baylor College of Medicine, Chief of VA Dermatology Service, VA Medical Center, Houston, TX Kenneth Tomecki MD Vice Chairman, Dermatology, Cleveland Clinic, Cleveland, OH Resident/Fellow Editorial Board Aaron S. Farberg MD, Icahn School of Medicine at Mount Sinai, New York, NY Alex M. Glazer MD, University of Arizona, Tucson, AZ Richard R. Winkelmann DO, Ohio University, Columbus, OH Resident/Medical Student Associate Editors Michael Cameron MD, University of Colorado, Department of Dermatology, Denver, CO Rebeca Teplitz, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY Microsoft Word - Skin Introduction 061416.docx Time for a New Concept in the Dermatology Literature Introducing SKIN:
    keywords: dermatology; professor; skin
       cache: skin-23.pdf
  plain text: skin-23.txt

        item: #816 of 1356
          id: skin-231
      author: Alashqar, Mais Bassam
       title: Caffeine in the Treatment of Atopic Dermatitis and Psoriasis: A Review
        date: 2019-03-11
       words: 6172
      flesch: 55
     summary: Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., ... & Hammond, E. M. (2012). Hanifin, J. M., Chan, S. C., Cheng, J. B., Tofte, S. J., Henderson, W. R., Kirby, D. S., & Weiner, E. S. (1996).
    keywords: atopic; caffeine; dermatitis; dermatology; journal; psoriasis; skin
       cache: skin-231.pdf
  plain text: skin-231.txt

        item: #817 of 1356
          id: skin-232
      author: none
       title: Distinguishing Features: Staphylococcal Scalded Skin Syndrome vs Toxic Epidermal Necrolysis
        date: 2018-03-09
       words: 1543
      flesch: 45
     summary: Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. The National Society for Cutaneous Medicine 135 BRIEF ARTICLES Distinguishing Features: Staphylococcal Scalded Skin Syndrome vs. Toxic Epidermal Necrolysis Hannah Badon BS a , Joy King MD b , Robert T. Brodell MD b,c , Adam Byrd MD d a University of Mississippi Medical Center, Jackson, MS b Department of Pathology, University of Mississippi Medical Center, Jackson, MS c Department of Dermatology, University of Mississippi Medical Center, Jackson, MS Staphylococcal scalded skin syndrome (SSSS) and toxic epidermal necrolysis (TEN) share many clinical features.
    keywords: epidermal; skin; ssss; staphylococcal; syndrome
       cache: skin-232.pdf
  plain text: skin-232.txt

        item: #818 of 1356
          id: skin-233
      author: Borda, Luis J; Oberlin, Kate E; Nichols, Anna J
       title: Cutaneous Manifestations of Disseminated Histoplasmosis in a Patient with AIDS
        date: 2018-07-06
       words: 1625
      flesch: 42
     summary: 1 The clinical manifestations of disseminated histoplasmosis depend on the severity of immunodeficiency of the host and the degree of exposure to the pathogen. 1,2 Patients often present with hepatosplenomegaly, pancytopenia, gastrointestinal and oropharyngeal lesions. Disseminated histoplasmosis is often seen in immunocompromised individuals, such those with acquired immunodeficiency syndrome (AIDS).
    keywords: aids; histoplasmosis; medicine; patients; skin; therapy
       cache: skin-233.pdf
  plain text: skin-233.txt

        item: #819 of 1356
          id: skin-234
      author: Desrosiers, Andrew S; Bernieh, Anas; Byrd, Adam C; Brodell, Robert T
       title: An Eruption of Follicular Keratotic Spicules with Alopecia
        date: 2018-07-06
       words: 782
      flesch: 46
     summary: A physical examination revealed follicular keratotic papules and associated hair loss distributed throughout the scalp, post- auricular area, and posterior neck (Figure 1). 4 There is no single reliable criterion for differentiating between primary and mycosis fungoides-associated FM.
    keywords: follicular; hair; primary
       cache: skin-234.pdf
  plain text: skin-234.txt

        item: #820 of 1356
          id: skin-235
      author: Limmer, Allison L; Krejci-Manwaring, Jennifer; Limmer, Bobby L
       title: Case Report of a Successful Hair Transplantation in a Patient with Lichen Planopilaris / Frontal Fibrosing Alopecia Due to Incidental Chemotherapy for Breast Carcinoma
        date: 2018-03-09
       words: 1195
      flesch: 55
     summary: One case report indicates hair transplantation in LPP patients can be successful if scalp and beard hair are combined and platelet rich plasma (PRP) is injected intradermally prior to graft placement. Lowered, fuller frontal hairline (A) and improvement of hair growth at the crown and mid-scalp (B).
    keywords: hair; scalp; transplantation
       cache: skin-235.pdf
  plain text: skin-235.txt

        item: #821 of 1356
          id: skin-236
      author: Cao, Kevin; Marion, Tyler; Roman, Jorge
       title: Rorschach Nevus
        date: 2018-03-09
       words: 372
      flesch: 62
     summary: The National Society for Cutaneous Medicine 155 COMPELLING COMMENTS Rorschach Nevus Kevin Cao BS a , Tyler Marion BS MBA a , Jorge Roman MD b a The University of Texas Medical Branch School of Medicine, Galveston, TX b Department of Internal Medicine, Texas Health Presbyterian Hospital, Dallas, TX In the novel Sula by Toni Morrison, a powerful use of symbolism was expressed in the main antagonist’s skin. 1 The most interesting facet of Sula’s birthmark is how it is perceived differently by different characters.
    keywords: birthmark; sula
       cache: skin-236.pdf
  plain text: skin-236.txt

        item: #822 of 1356
          id: skin-237
      author: Hobbs, Mitchell; King, Joy; El Feghaly, Rana; Brodell, Robert
       title: Primary Cutaneous Cryptococcosis in an Immunocompetent 6-Year-Old Female
        date: 2018-07-06
       words: 1137
      flesch: 46
     summary: The National Society for Cutaneous Medicine 240 BRIEF ARTICLE Primary Cutaneous Cryptococcosis in an Immunocompetent 6-Year-Old Female Mitchell Hobbs MD a , Joy King MD PhD b , Rana El Feghaly MD MSCI c , Robert Brodell MD d a University of Mississippi School of Medicine, Department of Pediatrics b University of Mississippi School of Medicine, Department of Pathology c University of Missouri-Kansas City School of Medicine, Department of Pediatrics d University of Mississippi School of Medicine, Department of Dermatology Primary cutaneous cryptococcosis (PCC) refers to an infectious process seen in immunocompetent patients wherein cryptococcal organisms directly inoculate the skin by exposure, typically in unclothed areas. Primary cutaneous cryptococcosis (PCC) is defined as direct inoculation and infection of the skin, and it is a rare condition in immunocompetent patients.
    keywords: cases; cryptococcosis; medicine; patients; primary
       cache: skin-237.pdf
  plain text: skin-237.txt

        item: #823 of 1356
          id: skin-238
      author: Shihab, Nahla; Talbott, Whitney; Kahn, Nathalie O; Alia, Erisa; Weinberg, Jeffrey M
       title: Cutaneous Rosai-Dorfman Disease: A Case Report
        date: 2018-07-06
       words: 1573
      flesch: 49
     summary: The National Society for Cutaneous Medicine 243 BRIEF ARTICLE Cutaneous Rosai-Dorfman Disease: A Case Report Nahla Shihab MD a , Whitney Talbott MD b , Parth Desai BS c , Nathalie O Kahn d , Erisa Alia MD e , Jeffrey M. Weinberg MD f a Resident Physician, Department of Dermatology and Venereology, Universitas Indonesia/Cipto Mangunkusumo National Hospital, Jakarta, Indonesia b Resident Physician, Department of Dermatology, Mount Sinai Medical Center, New York, NY c Medical Center, Mercer University School of Medicine, Macon, GA d Undergraduate Student, Barnard College, Columbia University, New York, NY e Research Fellow, Department of Dermatology, Mount Sinai Medical Center, New York, NY f Associate Clinical Professor of Dermatology, Mount Sinai St. Luke’s, Mount Sinai Beth Israel, New York, NY Rosai-Dorfman Disease (RDD) or sinus histiocytosis with massive lymphadenopathy (SHML) is a benign, self-limited proliferation of histiocytosis, first described by Rosai and Dorfman in 1969. Clusters of pink and brown, hyperpigmented papules and nodules in patients with cutaneous Rosai- Dorfman disease Figure 2.
    keywords: crdd; cutaneous; dermatol; disease; dorfman; rosai
       cache: skin-238.pdf
  plain text: skin-238.txt

        item: #824 of 1356
          id: skin-239
      author: Svoboda, Ryan M; Zuckerman, Joshua D; Rigel, Darrell S
       title: Clinical Experience with a Novel Topical Adhesive for Dermatologic Excisional Wound Closure: A Case-Series
        date: 2018-01-02
       words: 1455
      flesch: 47
     summary: To describe our experience using a novel formulation of 2-octyl cyanoacrylate for skin closure after surgical excision of cutaneous lesions. We describe the results of 9 office-based dermatologic excisions in 8 patients utilizing a novel formulation of 2-octyl cyanoacrylate for skin closure.
    keywords: adhesive; closure; cyanoacrylate; skin
       cache: skin-239.pdf
  plain text: skin-239.txt

        item: #825 of 1356
          id: skin-24
      author: Kailas, Ajay; Solomon, James A; Rigel, Darrell S; Mostow, Eliot; McMichael, Amy J; Pritchett, Ellen N; Jackson-Richards, Diane; Desai, Seemal R; Taylor, Susan C
       title: The Importance of Recognition of the Skin Cancer Risk of Native Americans: A Call to Action
        date: 2017-08-31
       words: 940
      flesch: 54
     summary: Yet despite this, skin of color articles that utilize direct interventions (such as focus groups or classes) in order to educate ethnic populations of skin cancer risk have also often excluded Native Americans 5 . Better data needs to be collected from this group to assess the knowledge gaps related to skin cancer both in patients and providers.
    keywords: americans; cancer; m.d; skin
       cache: skin-24.pdf
  plain text: skin-24.txt

        item: #826 of 1356
          id: skin-240
      author: Del Rosso, James Q
       title: What's New in the Medicine Chest? Part 2
        date: 2018-01-02
       words: 66
      flesch: 42
     summary: Part 2 James Del Rosso, DO Video Length: 17:26 Video Description: In a CME podium lecture presented at the 2017 Fall Clinical Dermatology Conference® in Las Vegas, Nevada, James Del Ross, DO, reviews recent advances in dermatopharmacology. Topics highlighted include new and emerging therapies for atopic dermatitis, acne vulgaris, rosacea, actinic keratosis, seborrheic keratosis, and axillary hyperhidrosis.
    keywords: james
       cache: skin-240.pdf
  plain text: skin-240.txt

        item: #827 of 1356
          id: skin-241
      author: Team, Editorial
       title: A Letter from the Editors
        date: 2018-01-02
       words: 304
      flesch: 52
     summary: 1 The Official Journal of the Fall Clinical and Winter Clinical Dermatology Conferences Welcome to Volume 2, Issue 1 of SKIN: Editors-in-Chief Mark Lebwohl MD Professor and Chairman, Dermatology, Icahn School of Medicine at Mount Sinai, New York Roger Ceilley MD Clinical Professor of Dermatology, University of Iowa School of Medicine, Des Moines, IA James Del Rosso DO Adjunct Clinical Professor, Touro University College of Osteopathic Medicine, Henderson, NV
    keywords: dermatology
       cache: skin-241.pdf
  plain text: skin-241.txt

        item: #828 of 1356
          id: skin-242
      author: Zeichner, Joshua
       title: The Newest in Dermatology-Acne, Atopic Dermatitis, Actinic Keratoses, Psoriasis, Skin Cancer, and More
        date: 2018-01-02
       words: 61
      flesch: 3
     summary: 48 The Newest in Dermatology-Acne, Atopic Dermatitis, Actinic Keratoses, Psoriasis, Skin Cancer, and More Joshua Zeichner, MD Video Length: 34:43 Video Description: In a CME podium lecture presented at the 2017 Fall Clinical Dermatology Conference® in Las Vegas, Nevada, Joshua Zeichner, MD, reviews cutting edge research presented at this year’s academic poster session, covering all aspects of dermatology.
    keywords: dermatology
       cache: skin-242.pdf
  plain text: skin-242.txt

        item: #829 of 1356
          id: skin-243
      author: Rajaii, Roxanne; Moon, Summer; Nyckowski, Timothy; Pui, John; Mahon, Michael
       title: Reticular Erythematous Mucinosis (REM): Case Report and Review of Literature
        date: 2018-11-09
       words: 2017
      flesch: 43
     summary: Reticular erythematous mucinosis (REM) is a rare disorder that requires both a clinical and a pathological diagnosis. Reticular erythematous mucinosis was initially classified in 1974, though similar clinical and histological descriptions of plaque-like cutaneous mucinosis date back to 1960.2,3,4,5 REM typically affects middle- aged females with a female: male ratio of 2:1.5,6 Its hallmark features of are erythematous macules and papules that coalesce into a reticulated pattern, favoring the midline chest and mid-back.5, 6,7 The macules and papules may be indurated but lack scale or other surface changes, and may also be less commonly found on the neck, face, upper abdomen, and limbs.1,5,7Most patients show no associated clinical symptoms, though 20-30% of patients report pruritus or a slight burning sensation.1,5,6 REM is a subtype of cutaneous mucinoses that often requires histologic assessment for diagnosis, demonstrating an accumulation of dermal-type mucin in the upper and mid dermis, which is predominantly composed of hyaluronic acid and other glycasimoglycans.
    keywords: dermatol; erythematous; mucinosis; patients; pmid; pubmed; rem; reticular
       cache: skin-243.pdf
  plain text: skin-243.txt

        item: #830 of 1356
          id: skin-245
      author: Sipprell III, William H; Maan, Harjot S; Ibrahim, Sherrif F
       title: Treatment of Telangiectasia Macularis Eruptiva Perstans with an Intense Pulsed Light Device
        date: 2018-07-06
       words: 1491
      flesch: 55
     summary: Post-treatment of bilateral arms showing complete resolution of telangiectasias 14 months after treatment. He is without recurrence 14 months after treatment.
    keywords: macularis; patient; telangiectasia; tmep; treatment
       cache: skin-245.pdf
  plain text: skin-245.txt

        item: #831 of 1356
          id: skin-246
      author: Nahmias, Zachary P; Hsu, Tina; Bledsoe, C Brad; Skinner, Robert; Todd-Bell, Rebecca
       title: Mycobacterium marinum Infection in a Post-Katrina Carpenter: The Importance of Exposures
        date: 2018-04-30
       words: 988
      flesch: 44
     summary: Among Hurricane Katrina evacuees and rescue workers, there were at least 30 cases of methicillin-resistant Staphylococcus aureus infection and 24 cases of hurricane- associated Vibrio vulnificus and V. parahaemolyticus wound infections reported. We report a unique case of M. marinum that developed on the right knee following participation in a Hurricane Katrina reconstruction project.
    keywords: hurricane; infection; katrina; marinum
       cache: skin-246.pdf
  plain text: skin-246.txt

        item: #832 of 1356
          id: skin-247
      author: Wagner, Keith; Juarez, Daniel; Gibson, Bernard
       title: Incorporating Discussion of Seborrheic Keratoses During Primary Care Visits
        date: 2018-04-30
       words: 1611
      flesch: 49
     summary: The tool used in our QIP appears to be an easily- implementable provider instrument that could help to ensure streamlined attention to primary care patients with SK lesions. Of the six patients reporting symptomatic SK (itching or bleeding), 3 patients had more than 20 SK, 2 had between 11 and 20 SK, and 1 had between 1 and 10.
    keywords: care; patients; primary; skin
       cache: skin-247.pdf
  plain text: skin-247.txt

        item: #833 of 1356
          id: skin-249
      author: Kaminetsky, Joshua R; Feit, Eric J; Ungar, Jonathan P
       title: Treatment of Pityriasis Rubra Pilaris with Adalimumab: A Case Report
        date: 2018-09-07
       words: 1381
      flesch: 46
     summary: Indeed, over the last ten years there have been a growing number of reports of TNF inhibitors demonstrating success in treating refractory patients or those intolerant of retinoids or antimetabolites. Similarly, it has been demonstrated that TNF-alpha levels are upregulated in areas of skin affected by PRP.3 It follows, therefore, that TNF inhibitors could produce a beneficial effect in treating the disease.
    keywords: adalimumab; pilaris; pityriasis; rubra; tnf; treatment
       cache: skin-249.pdf
  plain text: skin-249.txt

        item: #834 of 1356
          id: skin-25
      author: Mansouri, Yasaman; Amir, Yasmin; Min, Michelle; Khanna, Raveena; Huang, Ruiqi; Suarez-Farinas, Mayte; Lebwohl, Mark
       title: Impact of Temperature on Injection-Related Pain Caused by Subcutaneous Administration of Ustekinumab: A Three-arm Crossover Open-label Randomized Controlled Trial
        date: 2017-11-13
       words: 4551
      flesch: 58
     summary: The National Society for Cutaneous Medicine 117 ORIGINAL RESEARCH Impact of Temperature on Injection-Related Pain Caused by Subcutaneous Administration of Ustekinumab: A Three-Arm Open-Label Randomized Controlled Trial Yasaman Mansouri MD a,c , Yasmin Amir BA a , Michelle Min MD MSci a , Raveena Khanna BA a,d , Ruiqi Huang MSci b , Mayte Suarez-Farinas PhD a,b , Mark Lebwohl MD a Departments of Dermatology a , Population Health Science and Policy b , Icahn School of Medicine at Mount Sinai, New York NY c Metropolitan Hospital Center, New York, NY d Creighton University School of Medicine, Omaha NE ABSTRACT Background: Adherence to subcutaneous biologic agents for the treatment of psoriasis can be negatively influenced by injection pain. Systematic review and meta- analysis of the effect of warming local anaesthetics on injection pain.
    keywords: effect; gender; heat; ice; injection; intervention; pain; patients; skin; study; vas
       cache: skin-25.pdf
  plain text: skin-25.txt

        item: #835 of 1356
          id: skin-250
      author: Moy, Stephanie; Moy, Lawrence S; Lesser, Timothy
       title: Striae Cream with Regenetrol Complex(TM) Demonstrates Efficacy on Stretch Marks: A Double-Blind Controlled Study
        date: 2018-07-06
       words: 2508
      flesch: 59
     summary: Clinically, stretchmarks are characterized by a thinning of the skin in streaks usually located around the hips, thighs, buttocks, abdomen, and shoulders. The most common developments of stretchmarks occur during third trimester pregnancy (~40%), pubertal growth spurts or rapid weight gain (~30%), active weight training (~30%), and excessive use of topical cortisones.
    keywords: cream; improvement; patients; skin; stretchmarks; striae
       cache: skin-250.pdf
  plain text: skin-250.txt

        item: #836 of 1356
          id: skin-252
      author: Papp, Kim; Reich, Kristian; Blauvelt, Andrew; Thaci, Diamant; Sinclair, Rodney; Tyring, Stephen K; Cichanowitz, Nicole; Green, Stuart; Li, Qing; La Rosa, Carmen
       title: Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies
        date: 2018-02-23
       words: 2392
      flesch: 38
     summary: Baseline Characteristics for Patients Entering Extension Period reSURFACE 1 reSURFACE 2 TIL 100 mg TIL 200 mg Total TIL 100 mg TIL 200 mg Total Subjects in population, n 239 267 506 382 349 731 Male 159 (66.5) 183 (68.5) 342 (67.6) 291 (76.2) 242 (69.3) 533 Two-Year Cumulative Number (Rate) of Patients With AEs of Interest reSURFACE 1 reSURFACE 2 TIL 100 mg n (Exposure- Adjusted Rate per 100 PY) TIL 200 mg n (Exposure- Adjusted Rate per 100 PY) TIL 100 mg n (Exposure- Adjusted Rate per 100 PY) TIL 200 mg n (Exposure- Adjusted Rate per 100 PY) Severe infections 5 (0.8) 6 (0.8) 7 (0.8) 9 (1.1) Malignancies 6 (0.9) 2 (0.3) 4 (0.5) 7 (0.9)
    keywords: extension; patients; resurface; til; tildrakizumab
       cache: skin-252.pdf
  plain text: skin-252.txt

        item: #837 of 1356
          id: skin-253
      author: Menter, Alan; Sobell, Jeff; Silverberg, Jonathan I; Lebwohl, Mark; Rastogi, Shipra; Pillai, Radhakrishnan; Israel, Robert J
       title: Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial
        date: 2018-02-23
       words: 1442
      flesch: 41
     summary: 2016;175:273-286. CONCLUSIONS • Treatment with brodalumab resulted in substantial psoriatic lesion clearing for >2 years in most patients with moderate-to-severe psoriasis • Skin clearance response rates, as determined by sPGA 0/1, PASI 75, PASI 90, and PASI 100, were maintained from weeks 52 to 120 in patients who received brodalumab 210 mg Q2W • Patients receiving continuous treatment with brodalumab had higher rates of PASI 100 compared with patients who received placebo or ustekinumab during the induction phase PASI 75 90.6 88.4 PASI 90 77.6 76.8 PASI 100 53.3 56.2 R es po nd er s, % 60 0 40 20 80 100 sPGA 0/1 79.2 1015 597 1162 689 995 598 683 438 n 76.6 Week 52 (n=1282) Week 120 (n=779) Most patients were male, with a mean (standard deviation) age of 44.6 (12.8) years (Table 1) • A total of 1392 patients entered the long-term extension phase on brodalumab 210 mg Q2W, and 1282 patients had a valid measurement at week 52 Efficacy • Skin clearance response rates at weeks 52 and 120 were similar in patients who received brodalumab 210 mg Q2W during the long-term extension (Figure 2) •
    keywords: brodalumab; mg q2w; pasi; patients; phase
       cache: skin-253.pdf
  plain text: skin-253.txt

        item: #838 of 1356
          id: skin-254
      author: Reich, Kristian; Lebwohl, Mark; Paul, Carle; Ropke, Mads; Rosen, Monika; Hansen, Klaus
       title: Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis
        date: 2018-02-23
       words: 1608
      flesch: 54
     summary: No patients had neutralizing ADAs, including those who received brodalumab 210 mg after ustekinumab (Table 1) Effect of anti-drug antibodies Pharmacokinetics • Because anti-brodalumab antibody incidence was <3% of the patient population, anti-brodalumab antibody status was not evaluated in a population pharmacokinetic model; however, based on tabulated pharmacokinetic data (data not shown), no trends were observed to suggest reduction in pharmacokinetics due to the presence of binding ADAs Efficacy • There was no clear initial indication that patients with ADAs developed tolerance to brodalumab with loss of therapeutic effect, based on Static Physician’s Global Assessment (sPGA) responses. Carle Paul,3 Mads Røpke,4 Monika Rosen,4 Klaus Hansen4 1Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany; 2Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Paul Sabatier University, Toulouse, France; 4LEO Pharma, Ballerup, Denmark Winter Clinical Dermatology Conference - Hawaii® • January 12-17, 2018 • Lahaina, HI INTRODUCTION • Brodalumab is a human anti–interleukin (IL)-17 receptor A monoclonal antibody, which is delivered via subcutaneous injection, that demon- strated high efficacy in the treatment of moderate-to-severe psoriasis1–4 • Biologic therapies, such as brodalumab, have the potential to elicit an immune response in humans, which may result in the production of anti-drug antibodies (ADAs)5 • ADAs may change the pharmacokinetic and/or pharmacodynamic profile of a drug and thereby compromise its efficacy and/or safety profile6 – ADAs have been associated with hypersensitivity and immune reactions,7,8 which may be preceded by localized inflammation at an injection site9,10 – Neutralizing antibodies can prevent the drug from binding to the target receptor11 •
    keywords: adas; brodalumab; injection; patients; site
       cache: skin-254.pdf
  plain text: skin-254.txt

        item: #839 of 1356
          id: skin-255
      author: Van Voorhees, Abby S; Hsu, Sylvia; Elewski, Boni; Rastogi, Shipra; Israel, Robert J
       title: Efficacy and Safety of Brodalumab in Obese Patients with Moderate-to-Severe Plaque Psoriasis
        date: 2018-02-23
       words: 1198
      flesch: 55
     summary: Most patients were male, with an approximate mean (standard deviation) age of 45.8 (13.3) years for nonobese patients and 47.0 (12.4) years for obese patients (Table 1) • In a post hoc comparison of patients receiving continuous brodalumab 210 mg Q2W, rates of achieving sPGA score of 0 or 1 (sPGA 0/1), 75% improvement in PASI (PASI 75), PASI 90, and PASI 100 were higher among nonobese patients than obese patients at weeks 12 and 52 (Figure) •
    keywords: nonobese; obese; pasi; patients
       cache: skin-255.pdf
  plain text: skin-255.txt

        item: #840 of 1356
          id: skin-256
      author: Draelos, Zoe D; Kempers, Steven E; Smith, Stacy R; Wilson, David C; Powala, Christopher V; Bradshaw, Mark; Estes, Esther; Shanler, Stuart D
       title: Safety and Efficacy of A-101 Hydrogen Peroxide Topical Solution 40% in Adults with Seborrheic Keratosis: Results from the Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study
        date: 2018-02-23
       words: 1298
      flesch: 64
     summary: 0.002 P < 0.0001 Vehicle A-101 40% 0 20 10 30 40 50 60 70 Se b or rh e ic K e ra to se s, % 0 30 20 10 40 50 60 70 Se b or rh e ic K e ra to se s, % 48% 64% 10% 15% A B Day 106 Day 106 Vehicle A-101 40% Figure 2: Mean Per-Patient Percent of SKs (A) or Facial SKs (B) Judged to be Clear/Near Clear (PLA ≤ 1) Safety • Patients were randomized 1:1 to receive A-101 or matching vehicle.
    keywords: a-101; clear; pla; sks
       cache: skin-256.pdf
  plain text: skin-256.txt

        item: #841 of 1356
          id: skin-258
      author: Feldman, Steven R; Harris, Susan; Rastogi, Shipra; Israel, Robert J
       title: Distribution of Depression and Suicidality in a Psoriasis Clinical Trial Population
        date: 2018-02-23
       words: 927
      flesch: 54
     summary: Author disclosures: The authors disclose past or current financial relationships with the following companies: Feldman – AbbVie, Advance Medical, Almirall, Anacor, Astellas, Baxter, Boehringer Ingelheim, Caremark, Celgene, Cosmederm Bioscience, Galderma, GlaxoSmithKline/Stiefel, Informa, Janssen, LEO Pharma, Eli Lilly & Co, Merck, Merz, Mylan, National Biological Corporation, National Psoriasis Foundation, Novan, Novartis, Parion, Pfizer, Qurient, Regeneron, Suncare Research, Taro, UpToDate, Valeant Pharmaceuticals North America LLC, Gerson Lehrman, Guidepoint Global, www.DrScore.com, and Causa Research; Harris – Valeant Pharmaceuticals North America LLC; Israel – Valeant Pharmaceuticals North America LLC; and Rastogi – Ortho Dermatologics and Valeant Pharmaceuticals North America LLC. Incidence of baseline SIB across geographic regions in patients who received any dose of brodalumab in any of the 4 trials.
    keywords: brodalumab; patients; sib; trials
       cache: skin-258.pdf
  plain text: skin-258.txt

        item: #842 of 1356
          id: skin-259
      author: Williamson, T; Cameron, J; McLeod, K; Turner, B; Quillen, A; LaRose, A
       title: Patient Concerns and Treatment Satisfaction in Patients Treated with Azelaic Acid Foam for Rosacea
        date: 2018-02-23
       words: 5676
      flesch: 49
     summary: Assesses patient self-reported rosacea subtype and severity and evaluates drug characteristics that contribute to patient satisfaction/dissatisfaction and treatment decisions with rosacea topical treatments. Assesses patient self-reported rosacea subtype and severity and evaluates drug characteristics that contribute to patient satisfaction/dissatisfaction and treatment decisions with rosacea topical treatments.
    keywords: patients; rosacea; satisfaction; study; treatment
       cache: skin-259.pdf
  plain text: skin-259.txt

        item: #843 of 1356
          id: skin-26
      author: Dando, Emily E; Anvekar, Rina A
       title: Psoriasis Therapies and the Risk of Cutaneous Malignancy
        date: 2017-08-31
       words: 4461
      flesch: 55
     summary: Paul, C.F., et al., Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. Chiesa Fuxench, Z.C., et al., The Risk of Cancer in Patients With Psoriasis: A Population- Based Cohort Study in the Health Improvement Network.
    keywords: dermatol; nmsc; patients; psoriasis; risk; skin
       cache: skin-26.pdf
  plain text: skin-26.txt

        item: #844 of 1356
          id: skin-260
      author: Weber, TM; Arrowitz, CE; Jiang, LI; Qian, K; Filbry, A
       title: Efficacy of an Ointment Body Spray to Improve the Appearance of Dry, Ashy Skin and Alleviate Moderate to Severe Dryness on the Heel
        date: 2018-02-23
       words: 603
      flesch: 50
     summary: Wk 2 Treated Untreated N=31 C o rn eo m et er U n it s Skin Hydration a,c b,c OBS=Ointment Body Spray ap<0.05 vs Baseline bp<0.001 vs Baseline cp<0.05 vs Control 5.7 4.3 3.4 5.8 5.8 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Baseline Week 1 Week 2 Ashen Appearance M ea n C lin ic al G ra d in g S co re s a,b a,b a,b a,b 5.7 4.8 4.1 5.7 5.9 5.9 a,b a,b Dryness 5.5 4.1 3.1 5.5 5.6 5.6 Flaking N=31 ap<0.001 vs Baseline bp<0.001 vs Control Treated Untreated 0 1 2 3 4 5 6 7 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 Baseline Day 5 Day 10 Day 15 M ea n C lin ic al G ra d in g S co re 0 1 2 3 4 5 6 7 Scaling Dryness Cracking 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 OBS AHO a a a a a a a a a a a a a a a a a a a a a a a a Roughness N=18ap=0.001 OBS Significantly Improved Skin Hydration of Dry Skin Compared with Baseline and Untreated Skin 19.6 23.5 24.9 20.4 20.1
    keywords: baseline; day
       cache: skin-260.pdf
  plain text: skin-260.txt

        item: #845 of 1356
          id: skin-261
      author: Bagel, Jerry; Nia, John; Hashim, Peter; Patekar, Manmath; de Vera, Ana; Hugot, Sophie; Sheng, Kuan; Xia, Summer; Muscianisi, Elsa; Blauvelt, Andrew; Lebwohl, Mark
       title: Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis: CLARITY, a Randomized, Controlled, Phase 3b Trial
        date: 2018-02-23
       words: 2056
      flesch: 57
     summary: S Xia: Employee of Novartis Beijing Novartis Pharma Co. Ltd. M Patekar, A de Vera, S Hugot: Employees of Novartis Pharma AG.
    keywords: 2011; pasi; secukinumab; ustekinumab; week
       cache: skin-261.pdf
  plain text: skin-261.txt

        item: #846 of 1356
          id: skin-262
      author: Weber, TM; Arrowitz, CE; Scherdin, U; Schoelermann, AM; Filbry, A
       title: A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis
        date: 2018-02-23
       words: 311
      flesch: -14
     summary: Figure 4. Figure 5. 55% 6% 35% 2% Atopic Eczema Xerosis Psoriasis Ichthyosis N=80 2.29 1.61 0.34 0.86 0.51 0.13 0 0.5 1.0 1.5 2.0 2.5 Dryness Scaling Cracks M ea n C lin ic al G ra d in g S co re * * * OBS=Aquaphor Ointment Body Spray *p<0.0001 vs Baseline N=80 Baseline End of Study 0 20 40 60 Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None 0 20 40 60 0 25 50 75 Reduction in Dryness Reduction in Scaling Reduction in Cracks N=70 N=20 End of Study 0.59 1.39 1.39 1.1 0.15 0.81 0.41 0.39 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Burning Erythema Itching Tightness M ea n C lin ic al G ra d in g S co re * * * * OBS=Aquaphor Ointment Body Spray *p<0.0001 vs Baseline N=80 Baseline End of Study Reduction in Itching Reduction in Erythema 0 20 40 60 0 20 40 60 % o f Su b je ct s % o f Su b je ct s N=62 N=57 Reduction in Burning Reduction in Tightness OBS=Aquaphor Ointment Body Spray Mean Duration of Treatment=16.2 days % o f Su b je ct s % o f Su b je ct s 0 20 40 60 0 20 40 60 80 N=35 N=52 Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Severe/ Very Severe Moderate Slight None Progression to Reduced Symptom Severity Baseline End of Study p p FC17PosterBeiersdorfWeberMoisturizingSpray.pdf INTRODUCTION RESULTS CONCLUSIONS METHODS OBJECTIVE Subjects Study design Assessments TM Weber,1 CE Arrowitz,1 U Scherdin,2 AM Schoelermann,2 A Filbry2 1Beiersdorf Inc, Wilton, CT, USA; 2Beiersdorf AG, Hamburg, Germany A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis Figure 1.
    keywords: reduction; severe/
       cache: skin-262.pdf
  plain text: skin-262.txt

        item: #847 of 1356
          id: skin-263
      author: Bhatia, N; Ahmadyar, M; Hansra, H; Del Rosso, J; Baldwin, H; Daniels, AM
       title: Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study
        date: 2018-02-23
       words: 1193
      flesch: 55
     summary: Change in lesion count from baseline to 12 weeks E F F IC A C Y E N D P O IN T S S T U D Y D E S IG N » Cutaneous tolerability (4-point severity scales, investigator- and subject-reported) » Hematology & chemistry lab tests » No clinically significant laboratory test findings were noted -100% -80% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 Series1 Series2 -100% -80% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 Series1 Series2 1%; n=10 2%; n=9 P e rc e n ta g e r e d u c ti o n i n a v e ra g e n u m b e r o f le s io n s P e rc e n ta g e r e d u c ti o n i n a v e ra g e s e v e ri ty o f le s io n s (0 -4 I G A s c a le ) 1%; n=10 2%;
    keywords: minocycline; rosacea; treatment; week
       cache: skin-263.pdf
  plain text: skin-263.txt

        item: #848 of 1356
          id: skin-264
      author: Cook, Robert W; Monzon, Federico A; Hyams, David
       title: A Retrospective Case Series to Evaluate the Clinical Utility of a 31-Gene Expression Profile Test in Cutaneous Melanoma Patients
        date: 2018-02-23
       words: 812
      flesch: 58
     summary: • Documented management changes were categorized as increased intensity, decreased intensity, or no change, based on comparison of management plans before and after receipt of GEP test result. Prospective, single center 90 patients 52% of management decision based on GEP result using decision tree model Current study Retrospective, single center 70 patients 100% changed management after inclusion of GEP result Slide Number 1
    keywords: class; gep; management; test
       cache: skin-264.pdf
  plain text: skin-264.txt

        item: #849 of 1356
          id: skin-265
      author: Fleming, Martin; Johnson, Clare; Covington, Kyle; Gadzia, Joseph; Dillon, Larry; Monzon, Federico A
       title: Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort
        date: 2018-02-23
       words: 885
      flesch: 56
     summary: • Post-test management recommendations were collected at the subsequent visit following receipt of GEP test result. Cohort demographics Conclusions • Overall, 49% of tested patients had a change in clinical management.
    keywords: class; gep; management; test
       cache: skin-265.pdf
  plain text: skin-265.txt

        item: #850 of 1356
          id: skin-266
      author: Bauer, Johann W; Paller, Amy; Mellerio, Jemima E; Hovnanian, Alain; Pan, John J; Zografaos, Panagiotis; Licholai, Greg P; Murrell, Dedee F
       title: Use of an Investigator's Global Assessment Scale to Evaluate Disease Severity in Patients swith Epidermolysis Bullosa Simplex
        date: 2018-02-23
       words: 2085
      flesch: 25
     summary: Similarly, at 16 weeks, the proportion of lesions treated with diacerein 1% ointment showing a 2-point reduction in IGA score trended higher, as compared with vehicle-treated lesions (70% vs 47%; P=.067) (Figure 5) Figure 4. Percentage of lesions with a 2-point reduction in IGA score 58% 40% Diacerein (n=76) Placebo (n=58) -18 P er ce nt 100 80 60 40 20 0 70% 47% Diacerein (n=76) Placebo (n=58) -23 P er ce nt 100 80 60 40 20 0 P=.036 P=.067 aThe correlation was between the total blister count and the mean (over lesions)
    keywords: blisters; diacerein; iga; lesions; placebo; weeks
       cache: skin-266.pdf
  plain text: skin-266.txt

        item: #851 of 1356
          id: skin-267
      author: Chapman, M Shane; Cirulli, Joshua; McBride, Sandy
       title: Sustained Improvement in Patient-Reported Outcomes with Continued Apremilast Treatment over 104 Weeks in Patients with Moderate to Severe Psoriasis
        date: 2018-02-23
       words: 2460
      flesch: 67
     summary: MCID de� ned as a ≥5-point decrease from baseline in patients with baseline DLQI score >57 – Pruritus visual analog scale (VAS; 0–100 mm); MCID de� ned as a decrease from baseline ≥20%8 – 36-Item Short Form Health Survey version 2 (SF-36v2) Mental and Physical Component Summary scores (MCS and PCS); both MCIDs de� ned as an increase of ≥2.5 points from baseline9 – Patient Health Questionnaire-8 (PHQ-8); MCID de� ned as achievement of score ≤4 (no signi� cant depressive symptoms)10 Safety Assessments • Safety was assessed based on adverse events (AEs), vital signs, clinical laboratory assessments, and physical examinations. CONCLUSIONS • In biologic-naive patients with moderate to severe psoriasis, improvements in patient-reported outcomes, including QOL and pruritus, were generally maintained with continued APR treatment up to 104 weeks.
    keywords: apr; etn; mcid; patients; pbo; week
       cache: skin-267.pdf
  plain text: skin-267.txt

        item: #852 of 1356
          id: skin-268
      author: Glaser, Dee Anna; Hebert, Adelaide A; Nast, Alexander; Werschler, William P; Shideler, Stephen; Green, Lawrence; Mamelok, Richard D; Drew, Janice; Quiring, John; Pariser, David M
       title: Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis
        date: 2018-02-23
       words: 2450
      flesch: 37
     summary: In ATMOS-1/ATMOS-2 patients with primary axillary hyperhidrosis were randomized 2:1 to GT (3.75% topical solution) or vehicle applied once daily to each axilla for 28 days (Figure 1) • Patients who completed ATMOS-1/ATMOS-2 with ≥80% treatment compliance were eligible to continue into ARIDO and receive open-label GT for up to 44 weeks or until early termination, including patients terminated once the study objective of 100 patients receiving treatment for ≥12 months was achieved (Figure 1) • Key inclusion criteria for ATMOS-1/ATMOS-2 were: – ≥9 years of age (patients <16 years were recruited only at US sites) – Primary axillary hyperhidrosis for ≥6 months – Gravimetrically-measured sweat production of ≥50 mg/5 min in each axilla – Axillary Sweating Daily Diary (ASDD; for patients ≥16 years of age) or ASDD-Children (ASDD-C; for patients <16 years of age) axillary sweating severity item (Item 2) 4 score ≥4 (0 to 10 numeric rating scale) – Hyperhidrosis Disease Severity Scale (HDSS) ≥3 • Key exclusion criteria for ATMOS-1/ATMOS-2 were: – History of a condition that could cause secondary hyperhidrosis – Prior surgical procedure or treatment with a medical device for axillary hyperhidrosis – Treatment with iontophoresis within 4 weeks or treatment with botulinum toxin within 1 year for axillary hyperhidrosis – Axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks – New or modified psychotherapeutic medication regimen within 2 weeks – Treatment with medications having systemic anticholinergic activity, centrally acting alpha-2 adrenergic agonists, or beta-blockers within 4 weeks unless dose had been stable ≥4 months and was not expected to change – Conditions that could be exacerbated by study medication Figure 1. The majority of patients (86.6%; N=564) completing ATMOS-1/ATMOS-2 (369 patients [65.4%] had received GT, and 195 [34.6%] had received vehicle) continued into ARIDO (Figure 2) • Of the patients enrolled in ARIDO, most patients were female (55.3%) and white (83.3%) with a mean age of 33.0 years and mean BMI of 27.3 kg/m2 (Table 1) •
    keywords: arido; atmos-1; patients; safety; study; teaes; week
       cache: skin-268.pdf
  plain text: skin-268.txt

        item: #853 of 1356
          id: skin-269
      author: Pariser, David M; Hebert, Adelaide A; Drew, Janice; Quiring, John; Glaser, Dee Anna
       title: Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)
        date: 2018-02-23
       words: 3373
      flesch: 50
     summary: Axillary Sweating Daily Diary; ASDD-C, ASDD-Children; GT, topical glycopyrronium tosylate • Improvement in scores related to the impact of axillary sweating (ASDD Item 3) scores was greater for GT-treated patients than vehicle-treated patients at every study week (Figure 3) – After 4 weeks of treatment in ATMOS-1, scores improved by 63% (-1.5 point change) in GT-treated patients and 39% (-0.8) in vehicle-treated patients compared with Baseline – After 4 weeks of treatment in ATMOS-2, scores improved by 72% (-1.7 point change) in GT-treated patients and 41% (-1.0) in vehicle-treated patients compared with Baseline Figure 3. Percent Improvement From Baseline in Scores Related to the Impact of Axillary Sweating (ASDD Item 3) by Week VehicleGT VehicleGT 80 60 40 20 0 P er ce nt Im pr ov em en t i n S co re s R el at ed to th e Im pa ct of A xi lla ry S w ea tin g (A S D D It em 3 ) ATMOS-1 Week ATMOS-2 0 1 2 3 4 80 60 40 20 0 Week 0 1 2 3 4 72% 41% 63% 39% Data are representative of the intent-to-treat (ITT) population of patients 3 (a great deal), 4 (an extreme amount) ASDD, Axillary Sweating Daily Diary; GT, topical glycopyrronium tosylate • Improvement in scores related to the bother of axillary sweating (ASDD Item 4) was greater in GT-treated patients than vehicle-treated patients at every study week (Figure 4) – After 4 weeks of treatment in ATMOS-1, Item 4 scores improved by 64% (-1.7 point change) in GT-treated patients and by 39% (-0.9) in vehicle-treated patients compared with Baseline – After 4 weeks of treatment in ATMOS-2, Item 4 scores improved by 72% (-1.9 point change) in GT-treated patients and by 41% (-1.0) in vehicle-treated patients compared with Baseline Figure 4.
    keywords: asdd; item; patients; sweating
       cache: skin-269.pdf
  plain text: skin-269.txt

        item: #854 of 1356
          id: skin-27
      author: Weiss, Amy R; Drossner, Robbie B; Jacobson, Mark
       title: Sixteen Years of a Pruritic Unilateral Axillary Eruption: A Rare Presentation of Extramammary Paget’s Disease
        date: 2017-11-13
       words: 1233
      flesch: 50
     summary: 1,2 Accordingly, Ohno, et al. has even recommended skin biopsy from the contralateral axilla and anogenital region, even if they appear clinically normal. 4 Treatment options for axillary EMPD are the same as those used for non-axillary EMPD, and they include Mohs micrographic surgery, wide local excision, radiotherapy, photodynamic therapy, CO2 laser ablation as well as the use of topical therapies such as imiquimod 5% cream, topical 5- fluorouracil, and retinoic acid. Fewer than fifteen cases of axillary EMPD have been reported in the literature in the past ten years.
    keywords: axilla; disease; empd; paget
       cache: skin-27.pdf
  plain text: skin-27.txt

        item: #855 of 1356
          id: skin-270
      author: Pariser, David M; Hebert, Adelaide A; Drew, Janice; Quiring, John; Glaser, Dee Anna
       title: Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness
        date: 2018-02-23
       words: 2624
      flesch: 47
     summary: Axillary Sweating Daily Diary; ASDD-C, ASDD-Children • At Baseline in ATMOS-1 and ATMOS-2, mean ± SD ASDD Item 3 (impact of axillary sweating) scores were 2.3 ± 0.9 and 2.4 ± 0.9, respectively – In each trial, approximately 70% of patients ≥16 years of age reported scores ≥2 on ASDD Item 3, indicating that their daily activities were at least moderately affected by axillary hyperhidrosis at Baseline (Figure 3) – 26.2% and 29.7% of patients were severely impacted by axillary sweating in ATMOS-1 and ATMOS-2, respectively, having reported scores of 3 or 4 at Baseline (Figure 3) Figure 3. Axillary Sweating Daily Diary • At Baseline in ATMOS-1 and ATMOS-2, the mean ± SD ASDD Item 4 (bother of axillary sweating) scores were 2.6 ± 0.9 and 2.6 ± 0.9, respectively – In each trial, >75% of patients ≥16 years of age reported scores ≥2 on ASDD Item 4, indicating that they were at least moderately bothered by axillary sweating at Baseline (Figure 4) – 37.5% and 40.1% of patients were severely bothered by axillary sweating in ATMOS-1 and ATMOS-2, respectively, having reported scores of 3 or 4 at Baseline (Figure 4) Figure 4.
    keywords: asdd; baseline; item; patients; sweating; underarm
       cache: skin-270.pdf
  plain text: skin-270.txt

        item: #856 of 1356
          id: skin-271
      author: Jones, Terry M; Ellman, Herman; deVries, Tina
       title: Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies
        date: 2018-02-23
       words: 1759
      flesch: 46
     summary: In adult subjects, oral minocycline treatment had a geometric mean C max of 850 ng/mL, while topical application of 4 g FMX101 4% in adults had a geometric mean C max ranging from 1.109–1.539 ng/mL (days 1-2, days 12-13, and days 21-25) • The mean plasma concentration of oral minocycline in adult subjects reached C max by 3 hours after administration, followed by a log-linear decrease in concentration for the remaining 96-hour sample period • The mean plasma minocycline concentration of FMX101 4% increased until 8–14 hours (median T max value) on days 1, 12, and 21 • Figure 2 shows a comparison of mean plasma minocycline concentrations during the first 24 hours after a single dose of oral minocycline and after topical applications of FMX101 4% at 3 timepoints in adult subjects •
    keywords: application; auc; fmx101; minocycline; subjects
       cache: skin-271.pdf
  plain text: skin-271.txt

        item: #857 of 1356
          id: skin-272
      author: Stein Gold, Linda; Dhawan, Sunil; Weiss, Jonathan; Draelos, Zoe D; Ellman, Herman
       title: The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies
        date: 2018-02-23
       words: 1734
      flesch: 53
     summary: Conclusions • The results of the 2 Phase 3 studies showed that FMX101 4% was effective for the treatment of moderate-to-severe acne – There was significantly greater reduction of both inflammatory and noninflammatory lesions at week 12 from baseline with FMX101 4% vs vehicle in both Study 04 and Study 05, as well as in the pooled analysis (a co-primary end point) � A significant reduction in inflammatory lesions was observed as early as week 3 for FMX101 4% – The rate of IGA treatment success was significantly greater for FMX101 4% vs vehicle in Study 05, but not Study 04 (a co-primary end point) � Pooled analysis of IGA treatment success was statistically significant for FMX101 4% • >95% of subjects had none or mild signs and symptoms at the week 12 assessment of dermal tolerability • FMX101 4% appeared to be safe and well tolerated, with dermal AEs occurring in <1% of FMX101 4% subjects and no serious drug-related AEs reported • There was high satisfaction with FMX101 4% • The FMX101 4% open-label phase is currently ongoing to determine long-term safety The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of 2 Phase 3 Studies Linda Stein Gold, MD1; Sunil Dhawan, MD2; Jonathan Weiss, MD3; Zoe Diana Draelos, MD4; Herman Ellman, MD5 1Henry Ford Health System, Detroit, Michigan, USA; 2Center for Dermatology Clinical Research, Inc., Fremont, California, USA; 3Gwinnett Dermatology, Braselton, Georgia, USA; 4Dermatology Consulting Services, High Point, North Carolina, USA; 5Foamix Pharmaceuticals, Inc, Bridgewater, New Jersey, USA. Safety • FMX101 4% was generally safe and well tolerated in both Study 04 and Study 05 • Across the 2 studies, the percentage of subjects reporting treatment-emergent adverse events (TEAEs) ranged between 16.9% and 33% for FMX101 4%, vs 18.2% to 26.5% for vehicle (Table 2) – 1 subject receiving FMX101 4% discontinued treatment in Study 05 (ectopic pregnancy; not related to treatment), as compared with 4 subjects for vehicle across the 2 studies – 7 subjects reported 9 serious TEAEs across the 2 studies; all were considered not related to treatment – Few treatment-related TEAEs were reported in both studies • The most common TEAEs in ≥2% of subjects were nasopharyngitis and headache (Table 3) – Dermal TEAEs were reported in <1% of all subjects in the FMX101 4% treatment groups; their severity was mostly mild • The majority (>95%)a of FMX101 4% subjects reported none or mild signs and symptoms for tolerability assessment parameters at week 12 (Table 4) ªBased on observed cases.
    keywords: fmx101; study; subjects; vehicle
       cache: skin-272.pdf
  plain text: skin-272.txt

        item: #858 of 1356
          id: skin-274
      author: Bagel, Jerry; Zapata, James; Nelson, Elise; Keegan, Brian
       title: Psoriasis Patients on Chronic Biologic Therapy May Benefit from Additional Treatment-Study Design and Baseline Characteristics
        date: 2018-02-23
       words: 1040
      flesch: 57
     summary: Patients with psoriasis desire disease clearance. More than 50% of patients with psoriasis are dissatisfied with their treatment, including biologic
    keywords: biologic; patients; psoriasis
       cache: skin-274.pdf
  plain text: skin-274.txt

        item: #859 of 1356
          id: skin-275
      author: Hanke, C William; Albrecht, Lorne; Kyhl, Laerke K; Larrson, Thomas; Oesterdal, Marie L; Spelman, Lynda
       title: Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial
        date: 2018-02-23
       words: 1403
      flesch: 50
     summary: Primary • Complete clearance (AKCLEAR 100), defined as a 100% reduction from baseline in the number of clinically visible AK lesions, at Week 8 Secondary • Partial clearance (AKCLEAR 75), defined as ≥75% reduction from baseline in the number of clinically visible AK lesions, at Weeks 4 and 8 • Percent reduction in AK lesion count from baseline at Week 8 Safety • Local skin responses (LSRs) and adverse events (AEs), assessed by investigators on Days 1 and 4, and Weeks 1, 2, 4, and 8, respectively Physician- and patient-reported outcomes • Global photo-damage outcome assessment by investigator at Week 8 • Patient Treatment Satisfaction Questionnaire for Medication (TSQM) v.1.4, and cosmetic outcome at Week 8 • Ingenol mebutate (IngMeb; Picato®) is indicated for the topical treatment of actinic keratosis (AK) in areas of skin up to 25 cm21 • Two or three consecutive days of treatment with IngMeb provides clinically relevant clearance of AK lesions on the face/scalp (0.015% gel) and trunk/extremities (0.05% gel) when compared with vehicle gel;2 in addition, treatment effects of IngMeb gel are maintained long term3 • However, some patients may require treatment of AK over areas of skin larger than 25 cm2 Background Methods • Phase III, randomized, parallel-group, double-blind, vehicle-controlled, eight-week trial in patients with AK (Figure 1) • Patients were eligible if they had 5–20 clinically typical, visible and discrete AK lesions within a selected treatment area of sun-damaged skin on either the full face, full balding scalp (>25 cm2–250 cm2) or a contiguous area of (~250 cm2) on the chest Table 1. Serious AEs occurred in 1.5% vs 1.1% of patients receiving IngMeb or vehicle, respectively; none were treatment related • The most frequently reported AEs (occurring in ≥2% patients receiving IngMeb 0.027% gel) included application-site pain and application-site pruritus (Table 2) Figure 4.
    keywords: gel; ingmeb; vehicle
       cache: skin-275.pdf
  plain text: skin-275.txt

        item: #860 of 1356
          id: skin-276
      author: Hong, Chih-Ho; Patel, Dharm S; Lophaven, Katja W
       title: Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study
        date: 2018-02-23
       words: 1543
      flesch: 66
     summary:  Subjects’ Preference Assessment (SPA) and Vehicle Preference Measure (VPM) were completed by patients to assess preference differences based on vehicle and overall preference of Cal/BD foam and gel. Overall patient preferences, by age, for Cal/BD foam or gel.
    keywords: foam; gel; preference
       cache: skin-276.pdf
  plain text: skin-276.txt

        item: #861 of 1356
          id: skin-277
      author: Paul, Carle; Leonardi, Craig; Menter, Alan; Reich, Kristian; Stein Gold, Linda; Warren, Richard B; Moller, Anders; Lebwohl, Mark
       title: Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study
        date: 2018-02-23
       words: 1994
      flesch: 50
     summary: An observed case approach was used for other variables ● This subgroup analysis demonstrates that Cal/BD foam is effective in patients with moderate-to-severe psoriasis; it should be noted however, that it is difficult to treat psoriasis patients who have large BSA involvement purely with topical therapy. A foam formulation has been developed with the aim of enhancing adherence and increasing the therapeutic options available ● Studies with Cal/BD foam have demonstrated greater in vitro drug penetration and a greater antipsoriatic effect over 4 weeks of treatment than Cal/BD ointment and vehicle, with a comparable tolerability profile4–7 ● The Phase III PSO-ABLE study (NCT02132936) in patients with mild-to-severe psoriasis demonstrated that Cal/BD foam had superior efficacy at week 4 compared with Cal/BD gel at week 8 (based on the recommended treatment periods in the approved labels)8 ● This analysis from PSO-ABLE assesses the efficacy of Cal/BD foam and gel in the subgroup of patients with moderate-to-severe psoriasis Materials and methods PSO-ABLE STUDY DESIGN ● Prospective, multicentre, investigator-blinded ● Patients were randomized 4:4:1:1 to once-daily Cal/BD foam, Cal/BD gel, foam vehicle or gel vehicle for up to 12 weeks8 PATIENTS ● Aged ≥18 years with mild-to-severe psoriasis according to the physician’s global assessment of disease severity (PGA), involving 2–30% body surface area (BSA), and a modified (excluding the head, which was not treated) Psoriasis Area and Severity Index (mPASI) of ≥2 ● For inclusion in this subgroup analysis, a patient was required to have ‘moderate-to-severe’ psoriasis based on the ‘Rule of Tens’9: – BSA affected ≥10% or mPASI score >10 or Dermatology Life Quality Index (DLQI) score >10 ASSESSMENTS AND ENDPOINTS ● Efficacy was assessed at weeks 4, 8 and 12 by calculating: – Proportion of patients achieving a ≥75% or ≥90% reduction in mPASI – Change from baseline in BSA affected – Proportion of patients who were clear/almost clear of psoriasis, with a ≥2 grade improvement according to PGA (defined as ‘treatment success’)
    keywords: cal; note; pcg; set; workstation-2
       cache: skin-277.pdf
  plain text: skin-277.txt

        item: #862 of 1356
          id: skin-278
      author: Queille-Roussel, Catherine; Nielsen, Jakob
       title: Vasoconstrictor Potencey of Fixed Combination Calcipotriol Plus Betamethasone Dipropionate Foam Versus Other Corticosteroid Psoriasis Treatments
        date: 2018-02-23
       words: 1133
      flesch: 40
     summary: Kruskal-Wallis test for the overall effect, and Wilcoxon Signed Rank test for the pairwise comparisons (Cal/BD foam vs other treatments) Results PATIENTS � A total of 36 healthy volunteers were randomized and analysed (Table 1) ASSESSMENT OF SKIN BLANCHING � All active treatments resulted in greater skin blanching compared with foam vehicle (Figure 1; Table 2) � Skin blanching with Cal/BD foam was significantly lower than with CP cream (P<0.001), similar to BD ointment and MF cream, and significantly higher than HB ointment and foam vehicle (P<0.001 for both) Introduction � Many topical corticosteroids (CS) of differing potencies and formulations are available for treating psoriasis vulgaris � Topical CS potency can be assessed by the vasoconstriction assay (McKenzie-Stoughton), which is based on the blanching response of skin induced by topical CS application on healthy skin1 – This assay is recommended for topical CS potency ranking based on a correlation with clinical efficacy in psoriasis � A foam formulation of fixed-dose combination calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed as a treatment option for patients with psoriasis – Clinical studies have demonstrated greater efficacy with Cal/BD foam versus the gel and ointment formulations 2-6 � The objective of this study was to compare the CS potency of BD in Cal/BD foam with existing CS-containing topical products Methods PATIENTS � The study enrolled healthy, non-smoking volunteers aged 18–50 years – All subjects were required to demonstrate adequate vasoconstriction prior to the study, defined as a visual skin blanching score of at least one unit following non-occlusive BD 0.05% ointment application for 4–6 hours � Subjects were excluded if they received systemic treatments or any medications that could interfere with the blanching reaction within 2 weeks, or had used topical CS on the test sites within 4 weeks prior to enrolment STUDY DESIGN �
    keywords: note; pcg; workstation-2
       cache: skin-278.pdf
  plain text: skin-278.txt

        item: #863 of 1356
          id: skin-279
      author: Soung, Jennifer; Tiu, Lisa; Veverka, Karen; Hong, Chih-Ho
       title: Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study
        date: 2018-02-23
       words: 1586
      flesch: 52
     summary: Mean TPUQ domain scores were often significantly in favor of both Cal/BD foam and topical suspension compared with LTT  LTT analysis set comprised all randomized patients who had used topical treatment within 3 months before baseline Statistical Analysis Topical Product Usability Questionnaire (TPUQ) 
    keywords: cal; foam; topical
       cache: skin-279.pdf
  plain text: skin-279.txt

        item: #864 of 1356
          id: skin-28
      author: Del Rosso, James
       title: Antibiotic Resistance Considerations of Importance to Clinical Dermatologists
        date: 2017-08-31
       words: 4228
      flesch: 43
     summary: Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society Part 1: antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use. In addition, reducing antibiotic use in a given community can reduce the prevalence of bacteria resistant to that antibiotic over time, supporting the importance of judicious prescribing of antibiotic therapy.
    keywords: acne; antibiotic; dermatol; resistance; rosacea; skin; topical; treatment; use
       cache: skin-28.pdf
  plain text: skin-28.txt

        item: #865 of 1356
          id: skin-280
      author: Stein Gold, Linda; Yamauchi, Paul; Pariser, David; Xu, Zhenyi; Osterdal, Marie L; Bagel, Jerry
       title: Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis
        date: 2018-02-23
       words: 1375
      flesch: 54
     summary: In total, 323 patients were randomized to Cal/BD foam, and 103 to vehicle – Of these, 225/323 (70%) patients in the Cal/BD foam treatment group, and 75/103 (73%) patients in the vehicle group had a baseline itch VAS score of >30 � Among patients with baseline itch VAS score of >30, mean (±SD) baseline score was 66.1 ± 19.9 in the Cal/BD foam group and 69.9 ± 18.1 in the vehicle group � Treatment groups were generally well balanced in terms of demographic and baseline factors, although the gender balance was different between Cal/BD foam and vehicle (Table 1) ASSESSMENT OF ITCH � Patients receiving Cal/BD foam reported significant and rapid reduction in itch relief compared with patients receiving vehicle – Itch relief was observed by day 3 and continued to improve during the 4-week study (Figure 1; Table 2) � Significant treatment differences were noted at the first assessment on day 3 (P=0.019) and were maintained at all subsequent time points throughout treatment (Figure 1; Table 2) � Baseline demographic and clinical characteristics of patients with baseline itch score >30 Cal/BD foam (n=225) Vehicle (n=75) Age, years 50.6 (14.0) 45.6 (12.9)
    keywords: itch; note; patients; pcg; workstation-2
       cache: skin-280.pdf
  plain text: skin-280.txt

        item: #866 of 1356
          id: skin-281
      author: Wollenberg, Andreas; Howell, Michael D; Guttman-Yassky, Emma; Silverberg, Jonathan I; Birrell, Claire; Kell, Christopher; Ranade, Koustubh; Dawson, Michelle; van der Merwe, Rene
       title: A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis
        date: 2018-02-23
       words: 2695
      flesch: 54
     summary: Furthermore, tralokinumab demonstrated significant improvements in quality of life (as shown by reduction in DLQI) and pruritus, compared with placebo • Patients treated with tralokinumab 300 mg in the DPP-4-high subgroup demonstrated significant efficacy in both primary endpoints compared with placebo; the observed effect sizes were greater than in the ITT population, suggesting that DPP-4 may serve as a predictive biomarker for patients who may benefit from tralokinumab treatment • However, treatment with Class 3 TCS may have impacted on efficacy effect sizes observed, providing a limitation to the study design • These data suggest that targeting IL-13 is a promising approach for AD treatment. We report the findings from a Phase 2b study of tralokinumab in patients with moderate to severe AD ▪ Serum dipeptidyl peptidase 4 (DPP-4) has been reported as a predictive biomarker for tralokinumab efficacy in patients with severe asthma7 Introduction Figure 1.
    keywords: baseline; patients; placebo; tcs; tralokinumab
       cache: skin-281.pdf
  plain text: skin-281.txt

        item: #867 of 1356
          id: skin-282
      author: Wu, Jashin; Veverka, Karen; Lu, Minyi; Armstrong, April W
       title: Real World Experience with Calicpotriene and Betamethasone Dipropionate Foam 0.005%/0.064% (Cal/BD Foam) in the Treatment of Adult Psoriasis Itch from Retrospective Chart Review
        date: 2018-02-23
       words: 1224
      flesch: 69
     summary: Plaque areas (N = 177) # plaque areas evaluated with response to Cal/BD foam 126 # plaque areas at mild-mod-sev 113/126 # plaque areas at mild-mod-sev that were ‘clear’ or ‘almost clear’ at time of best response 80 # plaque areas at mild-mod-sev that were ‘clear’ or ‘almost clear’ at time of best response with 2 grade improvement 63 Table 4. Response of Plaques to Cal/BD Foam Plaque areas (N=177) Response to Cal/BD foam (n) 128 Itch (n), prior to Cal/BD foam treatment 64/128 126/177 plaque areas were evaluated for which response could be attributed to Cal/BD foam, and of those, 113 were mild-moderate-severe before treatment initiation.
    keywords: cal; foam; itch
       cache: skin-282.pdf
  plain text: skin-282.txt

        item: #868 of 1356
          id: skin-283
      author: Wu, Jashin J; Lu, Minyi; Veverka, Karen A; Smulders, Maartje; Papademetriou, Eros; Junhua, Yunjua; Feldman, Steven R
       title: The Psoriasis Patient Journey: Progression from Topical to Biologic Treatment for Psoriasis Patients in the United States
        date: 2018-02-23
       words: 1740
      flesch: 57
     summary: (1.9%) Region East, n (%) 925 (13.7%) 848 (14.2%) 77 (10.4%) Midwest, n (%) 3669 (54.5%) 3304 (55.2%) 365 (49.3%) South, n (%) 1342 (19.9%) 1099 (18.4%) 243 (32.8%) West, n (%) 550 (8.2%) 502 (8.4%) 48 (6.5%) Missing, n (%) 243 (3.6%) 235 (3.9%) 8 (1.1%) Index Topical Agent for Patients who continued topical treatment in the 36-month follow-up period (N=5017) Estimated median cumulative duration during 36-month follow-up period days (IQR) Steroid Class 1-2 392.5 (247-572.5) Steroid Class 3-7 368 (246-571) Vitamin D 437.5 (301-633.5) A gap of 45 days or longer was assumed to be a stop or pause in topical treatment 
    keywords: biologic; patients; topical; treatment
       cache: skin-283.pdf
  plain text: skin-283.txt

        item: #869 of 1356
          id: skin-284
      author: van der Heijde, Desiree; Okada, Masato; Lee, Chin; Shuler, Catherine L; Rathmann, Suchitrita; Lin, Chen-Yen; Amato, David; Mease, Philip J
       title: Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
        date: 2018-02-23
       words: 1487
      flesch: 102
     summary: #$%&'()*+ >*,-,(?$:&5:-35-?7*6$+5-&2-*6.&$9&2/-67&2&6*7-:$,?52,$,- *28-&2.&+&3&2/-?:5/:$,,&52-51-,3:(63(:*7-@5&23-8*)*/$-&2-?*3&$23,->&3.- ?,5:&*3&6-*:3.:&3&,-3:$*3$8-15:-AB->$$%,A C D.$-$11&6*64-51-&#$%&'()*+ &2-?:59&8&2/-?$:,&,3$26$-51-67&2&6*7- :$,?52,$,-3.:5(/.-EA->$$%,-51-3:$*3)$23-.*,-+$$2-,.5>2-&2- FGHD0G;IJB ! 8VVY+BC ,ZA\+G7*6$+5<_V+`P8\+a^-)/-gS $9$:4-B->$$%, <_V+`C8\
    keywords: v+`c8; v+`p8
       cache: skin-284.pdf
  plain text: skin-284.txt

        item: #870 of 1356
          id: skin-288
      author: Thiboutot, Diane; Zaenglein, Andrea; Hebert, Adelaide; Eichenfield, Lawrence
       title: Efficacy, Tolerability, and Safety of SB204 Gel in Adolescents (9 to 17 Years of Age) with Acne Vulgaris
        date: 2018-02-23
       words: 853
      flesch: 47
     summary: In a subset of only adolescent subjects (9 to 17 years of age) treated with topical SB204 4% once-daily, there was a statistically significant reduction (p<0.05) in inflammatory, non-inflammatory and total lesion reductions with SB204 4% compared to vehicle • The percent change from baseline in the number of non-inflammatory lesions was -33.4% for SB204 and -24.2% for vehicle (p=0.0013) • The percent change from baseline in the number of total lesions was -37.4% for SB204 and -29.1% for vehicle (p<0.001)
    keywords: lesions; sb204; vehicle
       cache: skin-288.pdf
  plain text: skin-288.txt

        item: #871 of 1356
          id: skin-289
      author: Sussman, Gordon; Hebert, Jacques; Gulliver, Wayne; Lynde, Charles; Yang, William H; Chambenoit, Olivier; Vieira, Antonio; DeTakaosy, Frederica; Rihakova, Lenka
       title: Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study
        date: 2018-02-23
       words: 1498
      flesch: 48
     summary: The OPTIMA (efficacy of optimized retreatment and step-up therapy with omalizumab in patients with chronic idiopathic/ spontaneous urticaria [CIU/CSU]; NCT02161562) study was designed to address some of the key gaps in the knowledge of optimal CIU/CSU treatment with omalizumab • Owing to the intermittent nature of CIU/CSU, physicians may want to consider stopping omalizumab treatment in patients who are symptom free for a period of time • Symptoms may re-emerge after a period of treatment withdrawal; the primary objective of the study was therefore to determine the efficacy and safety of retreatment in patients who respond to an initial course of omalizumab OMALIZUMAB RETREATMENT OF PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA/SPONTANEOUS URTICARIA (CIU/CSU) FOLLOWING RETURN OF SYMPTOMS: PRIMARY RESULTS OF THE OPTIMA STUDY Gordon Sussman,1 • Based on weekly Urticaria Activity Score (UAS7), patients entered one of the following phases: treatment withdrawal (if UAS7 ≤6), step-up to 300 mg (if 150 mg initially and UAS7 >6 at Weeks ≥8 to 24), or continued treatment for 12 more weeks (if 300 mg initially and UAS7 >6 at Week 24) • Patients with a history of malignancy of any organ system • Patients should stay on same approved dose of nonsedating H1-antihistamine during all trial duration.
    keywords: omalizumab; patients; uas7; urticaria
       cache: skin-289.pdf
  plain text: skin-289.txt

        item: #872 of 1356
          id: skin-29
      author: Nolan, Katherine; Ishteiwy, Reema; Alexis, John; Zaiac, Martin; Nichols, Anna
       title: Minocycline-Induced Agranulocytosis Presenting as Ecthyma Gangrenosum
        date: 2017-11-13
       words: 1638
      flesch: 43
     summary: Pertinent laboratory analyses included decreased white blood cell count of 0.74 10 3 /ul, hemoglobin 11.2 g/dL, hematocrit 33.5% (mean cell volume 87.5 fL) and absolute neutrophil count of 0.16 10 3 /ul but increased platelet count 514 10 3 /ul, ESR 72 mm/hr, CRP 153 Ahmed F, Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy - a case report.
    keywords: blood; medicine; miami; minocycline; patient; usa
       cache: skin-29.pdf
  plain text: skin-29.txt

        item: #873 of 1356
          id: skin-290
      author: von Stebut, E; Reich, K; Thaci, D; Koenig, W; Pinter, A; Korber, A; Rassaf, T; Waisman, A; Mani, V; Yates, D; Frueh, J; Sieder, C; Melzer, N; Gori, T
       title: Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study
        date: 2018-02-23
       words: 1851
      flesch: 54
     summary: % 2.2% 0.1% 1.2% -3.0% -2.0% -1.0% 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% SEC 300 mg Week 12 n = 39 SEC 300 mg Week 52 n = 38 SEC 150 ABSTRACT • Introduction: An increased incidence of cardiovascular (CV) events has been reported in psoriasis subjects.
    keywords: fmd; mg secukinumab; secukinumab; subjects; week
       cache: skin-290.pdf
  plain text: skin-290.txt

        item: #874 of 1356
          id: skin-291
      author: Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandala, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Drummer, Reinhard; Kirkwood, John M
       title: Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma
        date: 2018-02-23
       words: 3348
      flesch: 60
     summary: Study Rationale3, 5–8 Time From Randomisation, months O S , p ro p o rt io n a liv e 0 6 12 18 24 30 36 42 1.0 0.0 0.8 0.6 0.4 0.2 48 54 60 66 Dabrafenib Dacarbazine Dabrafenib plus trametinib Dabrafenib plus placebo pERK Proliferation, survival, invasion, metastasis RAS MEK mut BRAF Dabrafenib MAPK pathway Trametinib Overall Survival Benefit in BRAF V600–Mutant Stage IV Melanoma Can we prevent stage IV? MAPK, mitogen-activated protein kinase; mut, mutated; pERK, phosphorylated extracellular signal- regulated kinase. Overall Survival Months From Randomisation Group Events, n (%) Median (95% CI), months HR (95% CI) Dabrafenib plus trametinib 166 (38)
    keywords: dabrafenib; trametinib
       cache: skin-291.pdf
  plain text: skin-291.txt

        item: #875 of 1356
          id: skin-292
      author: Coates, LC; Gladman, DD; Nash, P; FitzGerald, O; Kavanaugh, A; Rasouliyan, L; Pricop, L; Ding, K; Gaillez, C
       title: Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 2-Year Results from a Phase 3 Study
        date: 2018-02-23
       words: 2727
      flesch: 61
     summary: 104 104 0.0 8 6 4 2 0 0.2 0.4 0.6 0.8 1.0 M ed ia n (Q 1, Q 3) c ou nt M ed ia n (Q 1, Q 3) s co re M ed ia n (Q 1, Q 3) s co re M ed ia n (Q 1, Q 3) le ve l Leeds Enthesitis Tender Dactylitis SF-36 PCSC-Reactive Protein (mg/L) n = 22 n = 22n = 19 n = 19n = 3 0 n = 30n = 2 7 n = 27 n = 15 n = 1 5 n = 15 n = 15 n = 2 n = 2 n = 19 n = 1 9 n = 11 n = 1 1 n = 12 n = 22 n = 19 n = 30 n = 27 n = 15 n = 15 n = 2 n = 19 n = 11 n = 12 n = 12 n = 22 n = 19 n = 30 n = 27 n = 15 n = 15 n = 2 n = 19 n = 11 n = 12 The median value is denoted by symbol in the figure while the upper and lower error bars represent third (Q3) and first (Q1) quartiles, respectively n, number of patients in respective disease states at assessment LDA, low disease activity; PASDAS, psoriatic arthritis disease activity score; Q, quartile; SF-36 PCS, Short Form-36 physical component summary; SJC, swollen joint count; TJC, total joint count; VAS, visual analog scale • TNF-naïve patients receiving secukinumab were more likely than TNF-IR patients to achieve PASDAS remission and LDA (Figure 5A) • Median Core Components of PASDAS Remission and LDA Patient Global VASPhysician Global VAS SJC 66 16 16 16 16 M ed ia n (Q 1, Q 3) s co re WeeksWeeks LDA LDARemission LDA Remission Remission LDA Remission WeeksWeeks M ed ia n (Q 1, Q 3) s co re M ed ia n (Q 1, Q 3) s co re M ed ia n (Q 1, Q 3) s co re 40 30 20 10 0 0 2 4 6 8 0 2 4 6 8 0 5 10 15 20 16 16104 104 1616 104104 104 104 104 104 TJC 68 n = 22 n = 22 n = 30 n = 30 n = 27 n = 27 n = 15 n = 15 n = 15 n = 15 n = 2 n = 2 n = 19 n = 19 n = 11 n = 11 n = 22 n = 22 n = 19 n = 19 n = 12 n = 12 n = 30 n = 30 n = 27 n = 27 n = 15 n = 15 n = 15 n = 15 n = 2 n = 2 n = 19 n = 19 n = 11 n = 11 n = 19 n = 19 n = 12 n = 12 Secukinumab 300 mg s.c.
    keywords: lda; pasdas; remission; week
       cache: skin-292.pdf
  plain text: skin-292.txt

        item: #876 of 1356
          id: skin-293
      author: Emery, P; McInnes, IB; Mease, PJ; Schiff, M; Pricop, L; Shen, S; Wang, Z; Gaillez, C
       title: Secukinumab Sustains Individual Clinical Responses Over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
        date: 2018-02-23
       words: 2095
      flesch: 63
     summary: Placebo-treated patients were re-randomized (1:1) to receive s.c. secukinumab (300 or 150 mg) at Week 16 (non-responders) or Week 24 (responders) based on clinical response • The key inclusion and exclusion criteria have been reported elsewhere4 Endpoints and Assessments • Post-hoc analysis of data from patients with PsA who were originally randomized to receive secukinumab 300 and 150 mg and completed the 16-week double-blind treatment period followed by long-term uncontrolled treatment • Shift analyses were performed on ACR responses between Week 24 (primary endpoint) and Week 104 (sustained effect). N = number of patients who completed Week 104 and had ACR response available at both Weeks 24 and 104; n1 = number of patients with no ACR response at Week 24 who completed Week 104 and had ACR response available; n2–n4 = number of patients with ACR response at Week 24 who completed Week 104 and had ACR response available •
    keywords: patients; secukinumab; week
       cache: skin-293.pdf
  plain text: skin-293.txt

        item: #877 of 1356
          id: skin-294
      author: Blauvelt, A; Armstrong, A; Rich, P; Kisa, R; Guana, A; Meng, X; Callis Duffin, K
       title: Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials
        date: 2018-02-23
       words: 2819
      flesch: 57
     summary: In patients receiving secukinumab, response rates were similar between IGA mod 2011 0 and PASI 100 and between IGA mod 2011 0/1 and PASI 90 groups – At Week 52, with secukinumab 300 mg, IGA mod 2011 0 was achieved by 37.8% of patients and PASI 100 was achieved by 40.8% of patients; similarly, IGA 0/1 was achieved by 64.9% of patients and PASI 90 was achieved by 68.1% of patients8 RESULTS Secukinumab Provides Complete or Almost-complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials A Blauvelt1, A Armstrong2, P Rich3, R Kisa4, A Guana4, X Meng4, K Callis Duffin5 1Oregon Medical Research Center, Portland, OR, USA; 2University of Southern California Keck School of Medicine, Los Angeles, CA, USA; 3Oregon Dermatology and Research Center, Portland, OR, USA; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5University of Utah, Salt Lake City, UT, USA Download document at the following URL: http://novartis.medicalcongressposters.com/Default.aspx?doc=a90dd And via Text Message (SMS) ABSTRACT • Introduction: Investigator’s Global Assessment modified 2011 (IGA mod 2011) is a more robust measure of psoriasis clearance than traditional IGA and Physician’s Global Assessment scales.
    keywords: iga; mod; secukinumab; week
       cache: skin-294.pdf
  plain text: skin-294.txt

        item: #878 of 1356
          id: skin-295
      author: Gulliver, Wayne; Sussman, Gordon; Hebert, Jacques; Lynde, Charles W; Papp, Kim A; Yang, William H; Chambenoit, Olivier; Viera, Antonio; DeTakaosy, Frederica; Rihakova, Lenka
       title: Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study
        date: 2018-02-23
       words: 1930
      flesch: 49
     summary: Mean UAS7 during the second dosing period with omalizumab 300 mg Baseline n=141 Week 4 n=136 Week 8 n=133 Week 12b n=130 Mean UAS7 Change from baseline 22.4 14.6 12.4 12.7 −7.8 −10.0 −9.7 −20 −10 0 10 20 30 40 M e a n (+ 9 5 % C I) U A S 7 M e a n c h a n g e fr o m b a s e li n e in U A S 7 M e a n (+ 9 5 % C I) U A S 7 M e a n c h a n g e (− 9 5 % C I) f ro m b a s e li n e in U A S 7 30.4 21.9 20.3 5.2 7.7 7.9 −8.5 −10.1 −22.3 −19.1 −16.8 −40 −30 −20 −10 0 10 20 30 40 Baseline n=141 Week 4 n=141 Week 8a n=141 Week 12 n=26 Week 16 n=18 Week 20 n=9 b) Mean UAS7 during the first dosing period with omalizumab 150 mg Mean UAS7 Change from baseline Figure 4. ≤1 year >1–≤2 years >2–10 years >10 years 28 (15.7) 25 (14.0) 84 (47.2) 41 (23.0) 22 (16.2) 25 (18.4) 54 (39.7) 35 (25.7) 50 (15.9) 50 (15.9) 138 (43.9) 76 (24.2) Baseline UAS7, mean (range) 29.7 (16.0–42.0) 30.0 (16.0–42.0) 29.8 (16.0–42.0) #
    keywords: ciu; csu; omalizumab; patients; uas7
       cache: skin-295.pdf
  plain text: skin-295.txt

        item: #879 of 1356
          id: skin-296
      author: Sussman, Gordon; Hebert, Jacques; Gulliver, Wayne; Lynde, Charles; Lang, William H; Chambenoit, Olivier; Deutsch, Gretty; DeTakaosy, Frederica; Rihakova, Lenka
       title: Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
        date: 2018-02-23
       words: 1609
      flesch: 47
     summary: dosing Controlled at Week 24 – UAS7 ≤6 Not controlled at Week 24 – UAS7 >6 Study treatment withdrawal Follow- up Figure 2. Primary endpoint • Proportion of patients that achieved UAS7 ≤6 at the end of the second dosing period, after being clinically well controlled (UAS7 ≤6) in the initial dosing period followed by relapse (UAS7 ≥16) when treatment was discontinued Secondary endpoints • Difference in UAS7 between start and end of the second dosing period in patients who stepped up treatment from omalizumab 150 mg to 300 mg • The proportion of patients that were clinically well controlled (UAS7 ≤6) at the end of the second dosing period in patients who stepped up treatment from omalizumab 150 mg to 300 mg • The time to relapse (UAS7 ≥16) after withdrawal of omalizumab in patients who were clinically well controlled following their first course of omalizumab treatment • Difference in the UAS7 between the end of the initial dosing period and the end of the second dosing period in patients who extended treatment with omalizumab 300 mg Secondary endpoints (continued) • The UAS7 change from baseline measured at the end of the initial dosing period in patients who received omalizumab 300 mg • The UAS7 change from baseline measured at the end of the second dosing period in all patients •
    keywords: dosing; omalizumab; uas7
       cache: skin-296.pdf
  plain text: skin-296.txt

        item: #880 of 1356
          id: skin-297
      author: van de Kerkhof, PCM; Reich, K; Leonardi, CL; Blauvelt, A; Mehta, NN; Tsai, TF; You, R; Papanastasiou, P; Milutinovic, M; Griffiths, CEM
       title: Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment
        date: 2018-02-23
       words: 2404
      flesch: 51
     summary: Here, we report exposure-adjusted incidence rates (IRs) for treatment-emergent adverse events per year from a pooled analysis of all secukinumab psoriasis trials to date (19 studies, 4674 patients, 10,061 patient-years exposure). Secukinumab has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations, including nails, scalp, palms and soles involvement and psoriatic arthritis1–5 • Here we report exposure-adjusted incidence rates (IRs) for treatment-emergent adverse events per year from a pooled analysis of all secukinumab psoriasis trials to date (19 studies, 4,674 secukinumab patients, ~10,000 patient-years exposure) METHODOLOGY • Adverse event (AE) IRs (per 100 patient years) were examined per year for subjects who received either secukinumab 300 mg (every 4 weeks) or any dose of secukinumab (including subcutaneous 300 mg, 150 mg, 75 mg, 25 mg or intravenous infusion
    keywords: psoriasis; safety; secukinumab; year
       cache: skin-297.pdf
  plain text: skin-297.txt

        item: #881 of 1356
          id: skin-298
      author: Magrey, Marina; Wolin, Daniel; Mordin, Margaret; McLeod, Lori; Davenport, Eric; Hur, Peter
       title: US Patient Satisfaction with Secukinumab Treatment Among Patients with Both Psoriatic Arthritis and Psoriasis: Data from a Web-Based Survey
        date: 2018-02-23
       words: 1692
      flesch: 51
     summary: These results provide early insight into secukinumab treatment satisfaction among US patients with PsO in conjunction with PsA REFERENCES 1. BACKGROUND • Psoriasis (PsO) is a chronic, inflammatory disease that affects the skin, with an estimated prevalence of 2.6% to 3.7% in the United States1 • PsO is associated with many comorbidities, including psoriatic arthritis (PsA)2; up to 30% of patients with PsO may have a concurrent diagnosis of PsA3,4 • Secukinumab is a fully human, interleukin-17A inhibitor approved for treatment of both PsA and PsO; it has demonstrated significant efficacy in moderate to severe plaque PsO, improvement of physical functioning and quality of life, resolution of enthesitis and dactylitis, and inhibits progression of joint structural damage5-9 • Little is known about treatment satisfaction and symptom control with secukinumab among patients with PsA and PsO in a real-world setting OBJECTIVE • To evaluate patient-reported secukinumab treatment satisfaction and PsA symptom control in US patients with PsO in conjunction with PsA in a real-world setting METHODS Study Design and Patient Population • Data were collected from a cross-sectional, panel-based web survey of patients with PsA in the United States – A random sample of patients were invited to participate in the survey by Survey Sampling International through their patient panels – Of 2755 patients screened for PsA or ankylosing spondylitis (AS), 269 patients with PsA were eligible for the analysis • Eligible patients were ≥ 18 years of age with a self-reported diagnosis of PsA, initiated secukinumab ≥ 3 months before survey participation, and had received secukinumab continuously since initiation – Of the 269 eligible patients with PsA, 266 completed the survey; 66 patients had concurrent AS and were not included in this analysis, and 3 did not consent to participate – Patients included in this analysis also had a self-reported diagnosis of PsO in conjunction with active PsA Study Variables and Data Analysis • Patient characteristics, including demographics, clinical characteristics, and medication history, were assessed at the time of survey participation •
    keywords: patients; psa; secukinumab; symptom; treatment
       cache: skin-298.pdf
  plain text: skin-298.txt

        item: #882 of 1356
          id: skin-299
      author: Weller, Karsten; Staubach, Petra; Metz, Martin; Chapman-Rothe, Nadine; Sieder, Christian; Brautigam, Matthias; Maurer, Marcus
       title: Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study
        date: 2018-02-23
       words: 2017
      flesch: 54
     summary: OBJECTIVE • To examine the effect of omalizumab treatment on angioedema-related QoL, including patient fear of a life-threatening angioedema (swelling) episode, in the X-ACT study (NCT01723072) METHODS Study design • The X-ACT (Xolair Effects on Angioedema in Chronic Spontaneous Urticaria Treatment) study was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study conducted in Germany7 • Patients were randomized 1:1 to receive subcutaneous omalizumab 300 mg or placebo every 4 weeks for 28 weeks, with an 8-week follow-up period (Figure 1) Angioedema-related QoL and disease activity • Improvement in angioedema-related QoL correlated with reduced angioedema activity (Week 12: 0.526, P<0.001; Week 28: 0.501, P<0.001; Pearson correlation coefficient) • Poster presented at the Winter Clinical Dermatology Conference, January 12–17, 2018, Lahaina, HI, USA INTRODUCTION • Chronic idiopathic/spontaneous urticaria (CIU/CSU) is defined as the repeated occurrence of spontaneous wheals (hives) and/or angioedema for at least 6 weeks without a specific external trigger1,2 • Between 33% and 67% of patients with CIU/CSU are reported to experience hives and angioedema; 1%–13% experience only angioedema3 • Angioedema is a major driver of quality of life (QoL) impairment in patients with CIU/CSU;4 owing to the unpredictable development of disfigurement and/or functional impairment, angioedema episodes can have a significant impact on daily activities and social interactions5 • Omalizumab is approved as an add-on therapy in patients with CIU/CSU refractory to H1-antihistamines.6 Subcutaneous omalizumab (300 mg) has been shown to reduce the frequency and severity of angioedema in H1-antihistamine-refractory CIU/CSU, as well as reducing QoL impairment7 OMALIZUMAB IMPROVES ANGIOEDEMA-RELATED QUALITY OF LIFE (QOL) IMPAIRMENT IN PATIENTS WITH CHRONIC IDIOPATHIC/CHRONIC SPONTANEOUS URTICARIA (CIU/CSU): RESULTS FROM THE X-ACT STUDY Karsten Weller,1 Petra Staubach,2 Martin Metz,1 Nadine Chapman-Rothe,3 Christian Sieder,4 Matthias Bräutigam,4 Marcus Maurer1 1Charité – Universitätsmedizin Berlin, Berlin, Germany; 2University Medical Center Mainz, Mainz, Germany; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Pharma GmbH, Nuremberg, Germany Patient-reported outcomes: QoL, disease activity, and psychological well-being •
    keywords: angioedema; life; omalizumab; placebo; qol; week
       cache: skin-299.pdf
  plain text: skin-299.txt

        item: #883 of 1356
          id: skin-30
      author: Del Rosso, James
       title: Clinically Important Considerations with the Use of Oral Doxycycline
        date: 2017-11-13
       words: 2379
      flesch: 43
     summary: 2,14,17,18 Although the potential for photoxicity associated with oral doxycycline use is well- recognized, a recent systematic review of phototoxicity of doxycycline identified mostly Tip #1: Consider the Formulation When Prescribing Oral Doxycycline Tip #2: Reduce the Potential for “Pill Esophagitis” by Optimizing Patient Education on Proper Administration of Oral Doxycycline Tip #3: Consider Potential Dose- Related Phototoxicity and Employ Preventative Measures to Reduce Risk SKIN November 2017 23 For treatment of chronic inflammatory disorders such as AV, it is reasonable to suggest to patients to temporarily discontinue oral doxycycline use over the short duration of a vacation to be spent outdoors in a sunny climate or location of high UV exposure.
    keywords: antibiotic; del; dermatol; doxycycline; rosso; use
       cache: skin-30.pdf
  plain text: skin-30.txt

        item: #884 of 1356
          id: skin-300
      author: Wei, Wenhui; Ghorayeb, Eric; Andria, Michael; Walker, Valery; Chao, Jingdong; Schnitzer, James; Kennedy, Martha; Chen, Zhen; Belland, Angela; White, John; Silverberg, Jonathan I
       title: A Real-World Study Evaluating AdeQUacy of Existing Systematic Treatments for Patients with Moderate-to-Severe Atopic Dermatitis (AD-QUEST): Baseline Treatment Patterns and Unmet Needs Assessment
        date: 2018-02-23
       words: 4903
      flesch: 36
     summary: Acknowledgements The�study�was�funded�by�Sanofi�and�Regeneron�Pharmaceuticals�Inc.�Medical�writing�support�was�provided�by�Abby�Armitt,�Prime,� Knutsford,�UK�and�funded�by�Sanofi�and�Regeneron�Pharmaceuticals,�Inc. Disclosures Wenhui�Wei�is�a�former�employee�and�current�stockholder�of�Sanofi�and�an�employee�of�Regeneron�Pharmaceuticals,�Inc.�Eric�Ghorayeb� and�James�Schnitzer�are�employees�of�and�stockholders�in�Sanofi.�Michael�Andria,�Jingdong�Chao,�Martha�Kennedy�and�Zhen�Chen�are� employees�of�and�stockholders�in�Regeneron�Pharmaceuticals,�Inc.�Valery�Walker,�Angela�Belland�and�John�White�are�employees�of� Optum,�a�company�that�received�research�funding�for�the�current�study.�Jonathan�Silverberg�is�a�member�of�an�institution�that�received� research�funding�for�the�current�study. Percent�impairment�in�regular�daily�activities�in� the�past�7�days�due�to�AD 792 18.88�(24.76) n % Work�time�missed�due�to�AD 564 2.11 *DLQI�scores�range�from�0�(no�effect�on�QoL)�to�30�(extremely�large�effect�on�QoL).�†TSQM�scores�range�from�0–100�where�higher� scores�represent�better�satisfaction.
    keywords: et �; itch �; rajka �; � ad; � al.; � langeland; � patients; � regeneron
       cache: skin-300.pdf
  plain text: skin-300.txt

        item: #885 of 1356
          id: skin-301
      author: Papadopoulos, Kyriakos P; Owonikoko, Taofeek K; Johnson, Melissa L; Brana, Irene; Gil-Martin, Marta; Perez, Raymond P; Moreno, Victor; Salama, April K; Calvo, Emiliano; Yee, Nelson S; Safran, Howard; Gonzalez-Martin, Antonio; Aljumaily, Raid; Mahadevan, Daruka; Mohan, Kosalai K; Li, Jingjin; Stankevich, Elizabeth; Lowy, Israel; Fury, Matthew G; Homsi, Jade
       title: Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study
        date: 2018-02-23
       words: 2533
      flesch: 49
     summary: • Cutaneous squamous cell carcinoma (CSCC) is the 2nd most common skin cancer in US.2 • Risk factors for CSCC include ultraviolet exposure, advanced age, immunosuppression.3 – There is a predominance of males and a median age of 71 years at diagnosis.4 • CSCC has a surgical cure rate of >95% in early stage disease; however, a small percentage of patients develop unresectable locally advanced or metastatic CSCC4 – US mortality: 3,900–8,800/year.4 • There is no widely accepted standard of care systemic therapy for locally advanced or metastatic CSCC (mCSCC).5 – Conventional cytotoxic chemotherapy can induce tumor responses, but often is poorly tolerated among older patients with CSCC. – In a single arm trial with cetuximab (n=36), median overall survival was 8.1 months.6 • In Phase 1 dose escalation study of cemiplimab, a durable radiologic complete response to cemiplimab was achieved in a CSCC patient.1,7 • There is a higher mutation burden in CSCC than any tumor type in The Cancer Genome Atlas (TCGA).8 • Immunosuppression is a well-described risk factor for CSCC (especially in solid organ transplant patients).9 • Programmed death-ligand 1 (PD-L1) expression has been associated with high-risk disease10; CSCC tumors may therefore be responsive to PD-1 checkpoint blockade.
    keywords: cemiplimab; cscc; patients; pharmaceuticals; regeneron; research; response; study; treatment; usa
       cache: skin-301.pdf
  plain text: skin-301.txt

        item: #886 of 1356
          id: skin-303
      author: Kudchadkar, Ragini; Chang, Anne Lynn S
       title: Long-Term Safety of Sonidegib in Basal Cell Carcinoma: 30-Month Results from the BOLT Trial
        date: 2018-02-23
       words: 2890
      flesch: 52
     summary: Anne Lynn S. Chang, MD2 1Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA; 2Associate Professor, Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. Presented at 2018 Winter Clinical Dermatology Conference – Hawaii, Lahaina, Hawaii, USA BACKGROUND Basal cell carcinoma (BCC) is the most common form of skin cancer1 – More than 4 million cases are diagnosed in the United States (US) each year2 The incidence and prevalence of BCC is expected to increase as the population ages3 ~95% of patients with BCC have mutations in the hedgehog (HH) signaling pathway Patient Demographics and Disease History Sonidegib Dose (QD) 200 mg (n=79) 800 mg (n=151) Median age (range), years 67 (25-92) 65 (24-93) Male, % 61 64 Eastern Cooperative Oncology Group performance status, % 0 63 63 1 24 29 2 10 7 Unknown 3 1 Aggressive histological/cytological subtype for patients with laBCC based on randomization/stratification, % n=66 n=128 Aggressive subtypea 56 59 Nonaggressive subtypeb 44 41 Metastasis, % 18 15 Metastatic sites, % of total patients with metastasis Lung 71 52 Lymph nodesc 7 30 Bone 14 22 Otherd 21 30
    keywords: decrease; grade; labcc; mbcc; patients; sonidegib
       cache: skin-303.pdf
  plain text: skin-303.txt

        item: #887 of 1356
          id: skin-304
      author: Zaenglein, Andrea; Del Rosso, James
       title: An Open-Label Study Evaluating the Long-Term Efficacy, Quality of Life, and Safety of Lidose-Isotretinoin (ABSORICA) Capsules Administered Without Food in Patients with Severe Recalcitrant Nodular Acne: Interim Analysis of 20-Week Active Treatment Period
        date: 2018-02-23
       words: 1656
      flesch: 52
     summary: Study Design Screening Within ≤30 days of baseline Visit: Weeks: Baseline EOT EOS 2 3 4 5 6 7 8 9 10 11 12 13 141 0 2 4 8 12 16 20 24 32 46 72 98 124 Screening period (0–45 days) Active treatment period (20 weeks) Post-treatment period (104 weeks) EOT values reflect the last visit for which a subject had data in the ATP.
    keywords: acne; baseline; eot; treatment
       cache: skin-304.pdf
  plain text: skin-304.txt

        item: #888 of 1356
          id: skin-305
      author: Elewski, Boni; Menter, Alan; Crowley, Jeffrey; Tyring, Stephen; Zhao, Yang; Lowry, Simon; Rozzo, Stephen; Mendelsohn, Alan; Parno, Jeffrey; Gordon, Kenneth
       title: Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
        date: 2018-02-23
       words: 1781
      flesch: 71
     summary: ( 7.1) 29.5 ( 6.9) Body Surface Area: % (SD) 28.9 (16.1) 33.5 (18.6) 32.0 (16.6) 35.7 (19.9) 32.2 (17.7) Disease Duration: years (SD) 14.3 (10.9) 16.8 (11.1) 17.8 (12.8) 14.3 (10.4) 16.2 (11.5) PASI: mean (SD) 18.5 ( 5.8) 20.9 ( 7.9) 19.6 ( 6.6) 20.6 ( 8.5) 19.9 ( 7.2) Previous medical conditions (%) ( 7.6) Body Surface Area: % (SD) 30.8 (17.5) 29.6 (15.3) 31.7 (17.5) 33.2 (19.6)
    keywords: pasi; patients; week
       cache: skin-305.pdf
  plain text: skin-305.txt

        item: #889 of 1356
          id: skin-306
      author: Blauvelt, Andrew; Reich, Kristian; Lebwohl, Mark; Burge, Daniel; Arendt, Catherine; Peterson, Luke; Rolleri, Robert; Gottlieb, Alice
       title: Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials
        date: 2018-02-23
       words: 3039
      flesch: 37
     summary: The safety profile for both CZP doses was consistent with the anti-TNF class in psoriasis; based on the known safety profile of CZP,6 no new safety signals were observed (Table 2) – The incidence of TEAEs was generally similar between CZP 400 mg Q2W and placebo groups, and was lower in the CZP 200 mg Q2W group versus placebo; TEAEs infrequently led to discontinuation • Serious TEAEs and serious infections and infestations were infrequent across treatment groups (CZP 400 mg Q2W: 4.7% and 0.6%, respectively; CZP 200 mg Q2W: 1.4% and 0%; placebo: 4.5% and 0%) (Table 2) – Two serious infections were reported in the CZP 400 mg Q2W group – hematoma infection and abdominal abscess in 1 patient following a bicycle accident, and pneumonia in 1 patient • aCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and 4 bVulvovaginal candidiasis cReported as fungal infection preferred term in the database dHematoma infection and abdominal abscess in 1 patient (bicycle accident), and pneumonia in 1 patient eBasal cell carcinoma Safety Set includes all randomized patients who received ≥1 dose of study medication CZP, certolizumab pegol; TEAE, treatment-emergent adverse event; Q2W, every 2 weeks Conclusions • In the phase 3 program, certolizumab pegol (CZP) 400 mg Q2W and CZP 200 mg Q2W were each associated with statistically significant, clinically meaningful improvements in moderate-to-severe chronic plaque psoriasis – Clinically meaningful differences in PASI 75 and PGA 0/1 responder rates versus placebo were observed as early as Week 4 – Greater improvement in quality of life as measured by CfB in DLQI and
    keywords: czp; mg q2w; pasi; placebo; q2w; weeks
       cache: skin-306.pdf
  plain text: skin-306.txt

        item: #890 of 1356
          id: skin-307
      author: Blauvelt, A; Strober, B; Langley, R; Burge, D; Pisenti, L; Yassine, M; Kavanagh, S; Arendt, C; Rolleri, R; Reich, K
       title: Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
        date: 2018-02-23
       words: 2367
      flesch: 65
     summary: (5.0) 10.1 (7.3, 13.8) 41 (6.5) AEs leading to death 0.1 (0.0, 0.8) 1 (0.1) 0 0 0.2 (0.0, 1.3) 1 (0.2) Patients who received both CZP 200 mg Q2W and CZP 400 mg Q2W are included in the population count for the ‘All CZP’ group. (0.2) Anti-TNF 119 (12.4) 57 (12.4) 71 (11.3) Anti-IL-17 142 (14.8) 78 (17.0) 89 (14.2) Anti-IL-12/IL-23 47 (4.9) 15 (3.3) 39 (6.2) Patients who received both CZP 200 mg Q2W and CZP 400 mg Q2W are included in the population count for the All CZP group.
    keywords: czp; mg q2w; patients; pharma; q2w; weeks
       cache: skin-307.pdf
  plain text: skin-307.txt

        item: #891 of 1356
          id: skin-308
      author: Hansen, Jes B; Faurby, Mads D; Corliss, Meg; Feldman, Steven R
       title: Real-World Treatment and Patient-Specific Characteristics of Actinic Keratosis in the USA
        date: 2018-02-23
       words: 2040
      flesch: 58
     summary: No patients with >5 baseline AK lesions (n=29) receiving a procedure achieved AKCLEAR 100; 9.7% of patients receiving topical treatment (n=31) achieved AKCLEAR 100. As number of baseline lesions increased, procedure treatment became less effective (Figure 5A); the opposite trend was seen with topical treatment (Figure 5B).
    keywords: patients; procedure; topical; treatment
       cache: skin-308.pdf
  plain text: skin-308.txt

        item: #892 of 1356
          id: skin-309
      author: Rosen, Jordan; Nolan, Katherine; Shaikh, Noah; Rosen, Les; Zaiac, Martin
       title: Coexisting Basal Cell Carcinoma and Squamous Cell Carcinoma in Congenital Nevus Sebaceous
        date: 2018-04-30
       words: 1589
      flesch: 61
     summary: SKIN May 2018 Volume 2 Issue 3 Copyright 2018 The National Society for Cutaneous Medicine 181 BRIEF ARTICLES Coexisting Basal Cell Carcinoma and Squamous Cell Carcinoma in Congenital Nevus Sebaceous Jordan Rosen BS a , Katherine Nolan MD a , Noah Shaikh BS a , Les Rosen MD a , Martin Zaiac MD a a Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL Nevus sebaceous (NS) is a congenital epidermal hamartoma that is present in less than 1% of newborns. 1 NS appears classically on the face or scalp as a waxy, yellow- or orange-colored linear or round plaque. NS frequently increases in size during puberty.
    keywords: cell; nevus; sebaceous
       cache: skin-309.pdf
  plain text: skin-309.txt

        item: #893 of 1356
          id: skin-31
      author: Lee, Jonathan J; Dando, Emily; Bibee, Kristin; Jedrych, Jaroslaw; Ho, Jonhan; Patton, Timothy
       title: Early-Onset Basal Cell Carcinoma in Young Female Endurance Athletes: A Report of Three Cases
        date: 2017-08-31
       words: 1100
      flesch: 48
     summary: In addition to sun exposure acquired during frequent training, dosimetric studies of full distance Ironman triathletes have documented substantial amounts of UV exposure during a single 8-10 hour event (mean minimal erythema dose of 8.3). C) Case 3: 34-year-old Caucasian female triathlete with nodular BCC on right cheek.
    keywords: bcc; cell; exposure; onset; use
       cache: skin-31.pdf
  plain text: skin-31.txt

        item: #894 of 1356
          id: skin-310
      author: Briscoe, Cristopher C; Nahmias, Zachary P; Rosman, Ilana S; Anadkat, Milan J
       title: Nail Biopsy in the Diagnosis of Systemic Amyloidosis
        date: 2018-07-06
       words: 1364
      flesch: 54
     summary: In light of the growing literature regarding nail changes as a presenting sign of systemic amyloidosis and the promising utility of nail biopsy, we suggest a low threshold for biopsy in appropriate patients when nail changes characteristic of amyloidosis are refractory to conventional treatment. While nail changes are a relatively rare finding of systemic amyloidosis, they have been noted in at least 32 cases to date (Table 1).
    keywords: amyloidosis; biopsy; changes; nail
       cache: skin-310.pdf
  plain text: skin-310.txt

        item: #895 of 1356
          id: skin-311
      author: McMurray, Stacy L; Reynolds, Matthew; Dinehart, Matthew S; Dinehart, Scott M
       title: Do Second-Time Users of Topical Imiquimod have a More Rapid Onset of Clinical Response?
        date: 2018-04-30
       words: 1802
      flesch: 59
     summary: In this report, we present observations that arose from a quality improvement (QI) project initially designed to improve documentation of treatment response time in patients with actinic keratoses. However, the potential for immune recall demonstrated by time-to-onset of clinical response has not been formally investigated.
    keywords: days; imiquimod; onset; time; users
       cache: skin-311.pdf
  plain text: skin-311.txt

        item: #896 of 1356
          id: skin-312
      author: Chow, Peter; Angulo, Pablo; Adkins, Kasie K
       title: Current Therapy for Advanced Melanoma and a Look at Future Signaling Pathways to Target
        date: 2018-07-06
       words: 4796
      flesch: 57
     summary: 40 Combined these findings suggest that Wnt/beta-catenin signaling is important for melanoma cell homeostasis, and if dysregulated, can lead to transformation of melanoma cells. In order to further improve survival rates in melanoma patients harboring a BRAFV600 mutation, combination therapy targeting other aspects of the RAS-RAF-MAPK pathways have been believed to be a potential method to overcome escape pathways of melanoma cells to BRAF inhibitor monotherapy.
    keywords: braf; cancer; cell; drug; inhibitor; kit; medicine; melanoma; mutation; notch; pathway; patients; resistance; signaling; skin; survival; therapy; tumor
       cache: skin-312.pdf
  plain text: skin-312.txt

        item: #897 of 1356
          id: skin-313
      author: Dinehart, Matthew S; McMurray, Stacy; Dinehart, Scott M; Lebwohl, Mark
       title: L-Carnitine Reduces Muscle Cramps in Patients taking Vismodegib
        date: 2018-03-09
       words: 2576
      flesch: 62
     summary: The most common side effect of HHIs is muscle cramps, reported in about 60-70% of patients. 2,3 Muscle cramps are a frequent source of patient dissatisfaction and often result in a significant negative impact on patient quality of life. We report 3 patients taking vismodegib who experienced a reduction in muscle cramps after starting L-carnitine, a dietary supplement.
    keywords: carnitine; cell; cramps; muscle; patient; treatment; vismodegib
       cache: skin-313.pdf
  plain text: skin-313.txt

        item: #898 of 1356
          id: skin-314
      author: Cockerell, Clay
       title: Clinical Photographs Should Accompany Skin Biopsies in Many Instances to Improve Patient Care
        date: 2018-03-09
       words: 1370
      flesch: 45
     summary: This classic “CPC” was the tradition of clinical diagnosis for many years where clinical features of a disease were correlated with anatomic features at autopsy. Finally, if it is not convenient to submit clinical images digitally, a print photograph can be provided.
    keywords: dermatology; diagnosis; skin
       cache: skin-314.pdf
  plain text: skin-314.txt

        item: #899 of 1356
          id: skin-316
      author: Nestor, Mark; Berman, Brian
       title: Efficacy of a Silicone-Based Gel Containing Pracaxi Oil (Pentaclethra macroloba) for Treating Post-Surgical Scars
        date: 2018-11-09
       words: 4076
      flesch: 54
     summary: Baseline average scores were compared against end of study average scores. The objective of this 16-week, randomized, double-blind comparison study was to determine the safety and efficacy of a unique silicone-based gel containing Pracaxi oil versus a silicone-based gel containing Cepalin onion extract for improving the appearance of hypertrophic surgical scars.
    keywords: efficacy; extract; gel; oil; onion; pracaxi; product; scar; scores; silicone; study; subjects; treatment; week
       cache: skin-316.pdf
  plain text: skin-316.txt

        item: #900 of 1356
          id: skin-320
      author: Dillon, Larry D; Gadzia, Joseph E; Davidson, Robert S; McPhee, Michael; Covington, Kyle R; Cook, Robert W; Johnson, Clare; Monzon, Federico A; Milanese, Eric D; Vetto, John; Jarell, Abel D; Fleming, Martin D
       title: Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients
        date: 2018-03-09
       words: 3915
      flesch: 57
     summary: The National Society for Cutaneous Medicine 112 Current guidelines for cutaneous melanoma indicate that patient management and intensity of surveillance should ultimately be tailored to an individual patient’s probability of recurrence, as this is the most important factor to consider in determining follow-up and management plans. 13,14 Aside from analytical and clinical validity, a critical evaluation of a prognostic test is to determine its clinical utility, which can be demonstrated by the impact of the test on changes in patient management.
    keywords: cases; class; gep; management; melanoma; patients; risk; study; test
       cache: skin-320.pdf
  plain text: skin-320.txt

        item: #901 of 1356
          id: skin-321
      author: Glazer, Alex M; Farberg, Aaron S; Svoboda, Ryan M; Rigel, Darrell S
       title: Comparison of Survey Modality and Response Rate in Dermatologists’ Perceptions and Opinions of Sunscreens
        date: 2018-03-09
       words: 1749
      flesch: 51
     summary: Despite some experts espousing survey response rates ≥60% as valid, there is no consensus as to what an adequate response rate is for a scientific survey. Response rates varied widely by survey modality (30% mail, 9% email 95% live).
    keywords: dermatologists; response; sunscreen; survey
       cache: skin-321.pdf
  plain text: skin-321.txt

        item: #902 of 1356
          id: skin-322
      author: Nahmias, Zachary P; Merrill, Eric D; Briscoe, Cristopher C; Mount, Charles E; Abner, Sabra; Schaffer, Andras; Anadkat, Milan J
       title: Development of Bullous Pemphigoid While Receiving PD-1 Checkpoint Inhibitor Nivolumab
        date: 2018-04-30
       words: 1846
      flesch: 50
     summary: 4 Future studies are needed to better define the efficacy of using targeted immunotherapy alongside anti-PD-1 treatment. 1 More than 40% of melanoma patients treated with anti-PD-1 therapy develop dermatologic complications.
    keywords: melanoma; nivolumab; patient; pemphigoid; skin; therapy; treatment
       cache: skin-322.pdf
  plain text: skin-322.txt

        item: #903 of 1356
          id: skin-324
      author: Prado, Giselle; Nichols, Anna; Zaiac, Martin
       title: Resolution of Post-Surgical Hypergranulation Tissue with Topical Aluminum Chloride
        date: 2018-09-07
       words: 1426
      flesch: 51
     summary: We report our experience using aluminum chloride to treat a series of two patients with hypergranulation tissue. Both patients had lengthy treatment courses after Mohs surgery with growth of hypergranulation tissue that resolved once aluminum chloride was placed on the wound.
    keywords: aluminum; hypergranulation; tissue; wound
       cache: skin-324.pdf
  plain text: skin-324.txt

        item: #904 of 1356
          id: skin-325
      author: Marion, Tyler; Gibbons, Jake A
       title: Cocaine and the Local Anesthetic
        date: 2018-04-30
       words: 446
      flesch: 55
     summary: Although cocaine is no longer used for numbing effects, it paved the way for the development of local anesthetics still used today. SKIN May 2018 Volume 2 Issue 3 Copyright 2018 The National Society for Cutaneous Medicine 205 Compelling Comments Cocaine and the Local Anesthetic Tyler Marion BS MBA a , Jake Alan Gibbons BSA a a The University of Texas Medical Branch, Galveston, TX The first use of local anesthetics dates back to the 16th century when Bernabe Cobo, a Spanish missionary, noted that toothaches could be alleviated by chewing coca leaves.
    keywords: anesthetic; cocaine
       cache: skin-325.pdf
  plain text: skin-325.txt

        item: #905 of 1356
          id: skin-329
      author: Castillo, David Ernesto; Nagrani, Nicole; Castillo, David; Reyes Mu?oz, Rocio; C?rdenas Guevara, Mayerlis; Morales, Samuel D.; Nichols, Anna
       title: A Case of Familial Focal Dermal Hypoplasia: A Report of 3 Cases in Consecutive Generations
        date: 2018-09-07
       words: 1771
      flesch: 49
     summary: Focal dermal hypoplasia (FDH), or Goltz syndrome, is a rare multisystem disorder affecting mesodermal and ectodermal structures, with the skin, eyes, teeth, and musculoskeletal systems most commonly affected. Focal dermal hypoplasia (FDH), or Goltz syndrome, is a rare genetic disorder resulting from mutations in the PORCN gene.
    keywords: dermal; fdh; patient; plaques; skin
       cache: skin-329.pdf
  plain text: skin-329.txt

        item: #906 of 1356
          id: skin-332
      author: Nagrani, Nicole; Gonzalez, Adrianna; Nichols, MD PhD, Anna
       title: The Cutaneous Horn: Fascinating Since 1588
        date: 2018-09-07
       words: 497
      flesch: 56
     summary: Ultimately, Bartholin concluded that cutaneous horns were not supernatural phenomenon as originally believed, but rather were produced by skin tumors. In 1642 Thomas Bartholin encountered this report, which stimulated his interest in cutaneous horns and propelled Figure 1.
    keywords: horn; skin
       cache: skin-332.pdf
  plain text: skin-332.txt

        item: #907 of 1356
          id: skin-333
      author: Marion, Tyler; Gibbons, Jake Alan
       title: Diaries of James Clarke White
        date: 2018-11-09
       words: 437
      flesch: 54
     summary: Post A. James Clarke White, M.D. Additionally, White contributed to medical literature by publishing his own book entitled Dermatitis Venenata.2 In 1914, White privately published Sketches of My Life, a diary of personal reflections from his times at Harvard.1 Dr. White was a figurehead of dermatology and served a critical role in its development as a unique medical specialty.
    keywords: medical; white
       cache: skin-333.pdf
  plain text: skin-333.txt

        item: #908 of 1356
          id: skin-334
      author: Armenta, Andrew M; Steele, Alex; Massey, Paul R
       title: Dermoscopy: Past and Future
        date: 2019-01-09
       words: 562
      flesch: 48
     summary: Dermoscopy was first applied in the United States by dermatologist Jeffrey Michael of Houston, Texas in 1922.1 American surgeon Leon Goldman described dermoscopy’s effectiveness in pigmented skin lesions1 and in 1971, Scottish dermatologist Rona MacKie argued that dermoscopy could be used to distinguish benign and malignant lesions. 2. Murzaku, E.C., S. Hayan, and B.K. Rao, Methods and rates of dermoscopy usage: a cross-sectional survey of US dermatologists stratified by years in practice.
    keywords: dermoscopy; medicine; texas
       cache: skin-334.pdf
  plain text: skin-334.txt

        item: #909 of 1356
          id: skin-336
      author: Hamann, Dathan; Ulman, Catherine
       title: Bilateral acquired blaschkoid dermatitis
        date: 2019-01-09
       words: 572
      flesch: 56
     summary: Bilateral lichen striatus. The National Society for Cutaneous Medicine 42 SHORT COMMUNICATIONS Bilateral Acquired Blashkoid Dermatitis Dathan Hamann, MD1, Catherine Ulman, MD1 1Contact Dermatitis Institute, Phoenix, AZ 2Division of Dermatology, Ohio State University, Columbus, OH Acquired blaschkoid dermatitis (ABD) is a rare self-limited inflammatory skin disease characterized by eczematous papules and plaques that follow the embryonic migration lines of Blaschko.
    keywords: bilateral; blaschkoid; dermatitis
       cache: skin-336.pdf
  plain text: skin-336.txt

        item: #910 of 1356
          id: skin-337
      author: Lopez, Adriana T; Shugar, Joel; Lebwohl, Mark
       title: Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis
        date: 2018-09-07
       words: 1599
      flesch: 40
     summary: Of 74 hospitalized patients evaluated for mucocutaneous complications of chemotherapy, AI was reported in patients treated with doxorubicin (n=11), cytarabine DISCUSSION SKIN September 2018 Volume 2 Issue 5 Copyright 2018 While physical exam findings of AI can be virtually identical to that of IV, AI develops in adulthood and is frequently associated with underlying systemic disease.2 AI has been correlated with several conditions including hyperparathyroidism3, malnutrition4 and LyP5; however, it is most commonly observed as a paraneoplastic syndrome in Hodgkin’s disease.6 Chemotherapy associated AI has rarely been described with the majority of documented cases confined to one study.
    keywords: gemcitabine; ichthyosis; paclitaxel; patient; skin
       cache: skin-337.pdf
  plain text: skin-337.txt

        item: #911 of 1356
          id: skin-338
      author: Svoboda, Ryan M; Cockerell, Clay J; Ceilley, Roger I; Rigel, Darrell S
       title: Evaluating the Utility of Self and Clinical Skin Examinations to Screen for Skin Cancer: The Importance of Considering Publications of All Levels of Evidence
        date: 2018-04-30
       words: 1242
      flesch: 45
     summary: 3 Although these studies are important because they can eliminate confounding and demonstrate causality, other study designs have merit as well and should not be completely discounted. While there is value in recognizing the hierarchy of evidence, sole reliance on study design is a flawed tactic.
    keywords: evidence; medicine; skin; studies
       cache: skin-338.pdf
  plain text: skin-338.txt

        item: #912 of 1356
          id: skin-339
      author: Zambito, Jeanette R
       title: The History of Cosmetic Nail Treatments, From Babylon to Beyoncé
        date: 2018-09-07
       words: 450
      flesch: 60
     summary: Around 3000 BC, China elevated nail art by using a crude form of nail lacquer composed of beeswax and egg whites. From there, it was only a matter of time before we were left with the sculpted, studded, pierced, and stenciled nails of today.
    keywords: nails; rochester
       cache: skin-339.pdf
  plain text: skin-339.txt

        item: #913 of 1356
          id: skin-34
      author: Nyckowski, Timothy; Ceilley, Roger; Bean, Andrew
       title: Atypical Fibroxanthoma of the External Ear: Case Report and Review of Literature
        date: 2017-11-13
       words: 1519
      flesch: 55
     summary: Pesapane F, Nazzaro G, Lunardon L, Coggi A, Gianotti R. Two friends with eroded nodules on the ears: atypical fibroxanthoma case report. The National Society for Cutaneous Medicine 169 BRIEF ARTICLES Atypical Fibroxanthoma of the External Ear: Case Report and Review of the Literature Timothy Nyckowski BS a , Roger Ceilley MD a,b , Andrew Bean MD a a Dermatology P.C., West Des Moines, IA b University of Iowa Carver College of Medicine, Department of Dermatology, Iowa City, IA Atypical fibroxanthoma (AFX) is a tumor first reported in 1961 to describe a dermal tumor of atypical spindle cells.
    keywords: afx; atypical; fibroxanthoma; skin; tumor
       cache: skin-34.pdf
  plain text: skin-34.txt

        item: #914 of 1356
          id: skin-340
      author: Ly, Priscilla; Hoyer, Paige; Subrt, Adrian; Goodwin, Brandon; Kelly, Brent
       title: A Rare Case of Multicentric Reticulohistiocytosis
        date: 2018-09-07
       words: 2501
      flesch: 46
     summary: The arthritis may persist for several years before skin nodules erupt, making this disease difficult to differentiate from rheumatoid arthritis.10 The papulonodular lesions in MRH appear reddish-brown and can vary in size, involving the upper trunk, Multicentric reticulohistiocytosis (MRH) is a rare, histiocytic disorder that primarily affects the skin and joints. Multicentric reticulohistiocytosis.
    keywords: case; disease; lesions; medicine; mrh; multicentric; patient; reticulohistiocytosis; skin
       cache: skin-340.pdf
  plain text: skin-340.txt

        item: #915 of 1356
          id: skin-343
      author: Gibbons, Jake; Marion, Tyler
       title: Fast Absorbing Cat-Gut Sutures
        date: 2019-01-09
       words: 430
      flesch: 54
     summary: Lister applied his own antiseptic techniques during his experimentation with the suture, as he understood the risk of infection when exposing patients to raw intestine.3 Further advancements in the development of absorbable sutures were made, leading to the development of sutures such as polyglycan 910 and polyglycolic acid. These sutures provide additional tensile strength and knot security, while eliciting less tissue inflammation.1 Though absorbable gut sutures are not used superficially for skin closure, they are used by dermatologists in sewing split thickness skin grafts in sensitive areas of the face and in the mouth to promote rapid healing and obviate the need for suture removal.
    keywords: catgut; sutures
       cache: skin-343.pdf
  plain text: skin-343.txt

        item: #916 of 1356
          id: skin-344
      author: Shi, Vivian Y; Foolad, Negar; Ornelas, Jennifer; Burney, Waqas; Maarouf, Melody; Hassoun, Lauren; Monico, Gabriela; Takeda, Nicole; Bosanac, Suzana; Eichenfield, Lawrence F; Sivamani, Raja K
       title: The Comparative Effects of Various Moisturizers on Epidermal Barrier Function Recovery After Bathing in Atopic Dermatitis.
        date: 2018-07-06
       words: 1811
      flesch: 58
     summary: AD subjects had higher hydration following CER (442.9% 394.4%  413.2%) than healthy subjects (334.7%  282.7%  296.7%) throughout the entire study. AD subjects had higher hydration following CER than healthy subjects throughout the entire study.
    keywords: bathing; hydration; minutes; moisturizers; tewl
       cache: skin-344.pdf
  plain text: skin-344.txt

        item: #917 of 1356
          id: skin-345
      author: Esaa, Fatema S; Travis, Skylar N; Scott, Glynis A; Richardson, Christopher T
       title: Unilateral Pemetrexed-induced Pseudocellulitis Mimicking Bacterial Cellulitis
        date: 2018-11-09
       words: 1373
      flesch: 22
     summary: It is used as either a single agent or in combination with cisplatin or carboplatin.2 A variety of cutaneous adverse reactions (CARs) have been reported with usage of pemetrexed and combinations of pemetrexed and cisplatin/carboplatin. Pemetrexed- induced pseudocellulitis is important to recognize as it may be dose-limiting or necessitate treatment modification.
    keywords: antibiotics; erythema; patient; pemetrexed; pseudocellulitis
       cache: skin-345.pdf
  plain text: skin-345.txt

        item: #918 of 1356
          id: skin-346
      author: none
       title: Widespread Erythematous Plaques in a Multigravid Female
        date: 2019-01-09
       words: 1510
      flesch: 42
     summary: The National Society for Cutaneous Medicine 31 BRIEF ARTICLES Widespread Erythematous Plaques in a Multigravid Female Alex Harrison, BS,1 George Gibbons, MD,2 Joseph Dyer, DO,3 1Edward Via College of Osteopathic Medicine, Auburn, AL 2Dermpath Diagnostics, Tampa, FL 3Avail Dermatology, Fayetteville, GA Dermatologic conditions in pregnancy can be attributed to physiological adaptations, changes in pre-existing skin diseases, or development of new dermatologic conditions specific to pregnancy.1,2 Although controversy exists, there is an ill-defined group of pruritic conditions that are considered pregnancy-specific skin dermatoses, which include pemphigoid gestationis, polymorphic eruption of pregnancy (PEP), intrahepatic cholestasis of pregnancy, atopic eruption of pregnancy, and generalized pustular psoriasis of pregnancy (GPPP).3 Excluding intrahepatic cholestasis of pregnancy, which presents with secondary skin lesions like excoriations, prurigo nodularis, and occasionally jaundice, these conditions can often manifest as widespread erythematous plaques and papules. We present a case of generalized pustular psoriasis of pregnancy that manifested in an atypical fashion and could have been overlooked without the utilization of biopsy and histopathological analysis.
    keywords: conditions; gppp; pregnancy; psoriasis; skin
       cache: skin-346.pdf
  plain text: skin-346.txt

        item: #919 of 1356
          id: skin-347
      author: none
       title: Serum Sickness Secondary to Fluoxetine
        date: 2018-09-07
       words: 772
      flesch: 47
     summary: A number of drug classes including antibiotics, beta-blockers, and anti- depressants have been implicated in SSLRs, with only 3 reported cases associated with fluoxetine.3-5 Given the benign clinical course, absence of organ dysfunction, and onset of rash within few days of drug onset, our patient was initially diagnosed with a serum sickness-like reaction secondary to fluoxetine. Serum sickness with fluoxetine, although rare, has been reported.5,6 Although our patient was young and relatively healthy, such a reaction has the potential for severe consequences especially in patients with immunosuppression, autoimmune disease, or other significant comorbidities.
    keywords: fluoxetine; serum; sickness
       cache: skin-347.pdf
  plain text: skin-347.txt

        item: #920 of 1356
          id: skin-349
      author: none
       title: Was It Auspitz's Sign?
        date: 2019-01-09
       words: 490
      flesch: 57
     summary: Bernhard, J.D., Auspitz sign is not sensitive or specific for psoriasis. Although first described in psoriasis, this clinical feature can be demonstrated in other skin conditions like Darier’s disease and actinic keratosis.1 Today, most associate this psoriatic pinpoint bleeding with Carl Heinrich Auspitz, an Austrian dermatologist.
    keywords: auspitz; texas
       cache: skin-349.pdf
  plain text: skin-349.txt

        item: #921 of 1356
          id: skin-351
      author: Vaughn, Alexandra; Nguyen, Mimi; Maarouf, Melody; Van Skiver, Melisa; Tran, Khiem; Rybak, Iryna; Sivamani, Raja; Shi, Vivian Yan
       title: Multi-Center Randomized Clinical Study of The Effects of Natural Oils on Xerosis and Skin Barrier Properties
        date: 2018-09-07
       words: 1365
      flesch: 49
     summary: INTRODUCTION Objective: To compare the effect of natural oils and white petrolatum on skin barrier function in patients with xerosis. The participants preferred natural oils to white petrolatum, implying that these moisturizer options may improve patient compliance.
    keywords: hydration; moisturizers; oil; skin; study; week
       cache: skin-351.pdf
  plain text: skin-351.txt

        item: #922 of 1356
          id: skin-353
      author: Rodriguez, Eduardo Adrian; Arnold, Morgan Leigh; Wilkerson, Michael G
       title: A Review of Auto-Injector Pen Safety and Preventative Strategies
        date: 2018-09-07
       words: 2652
      flesch: 49
     summary: EpiPen (epinephrine injection, USP) Auto-Injector and its Authorized Generic. Additionally, 45.2% of the participants in the unmodified group had presumptive unintentional injection injuries while only 5% of participants in the modified group did.13 Therefore, further efforts should be made by manufacturers to provide both clinicians and patients with safer and more intuitive designs.
    keywords: auto; epinephrine; injection; injector; injuries; safety; use
       cache: skin-353.pdf
  plain text: skin-353.txt

        item: #923 of 1356
          id: skin-355
      author: Dallo, Christopher; Falck, Benjamin
       title: Adrenal Insufficiency and its Presidential Touch
        date: 2019-03-11
       words: 557
      flesch: 51
     summary: Kennedy’s glowing skin may have been attributed to primary adrenal insufficiency – an autoimmune destruction of the adrenal gland that results in decreased cortisol levels. The series of candidate debates held during that election cycle, dubbed the “Great Debates”, were similarly historic as they represent the first televised presidential debates in the nation’s history and played a critical role in Kennedy’s success.
    keywords: kennedy; skin
       cache: skin-355.pdf
  plain text: skin-355.txt

        item: #924 of 1356
          id: skin-356
      author: Beal, Brandon T; Dhandha, Maulik M; Chu, Melinda B; Varra, Vamsi; Armbrecht, Eric S; Slutsky, Jordan B; Fosko, Scott W
       title: Tumor Characteristics Predicting Perineural Invasion in Cutaneous Squamous Cell Carcinoma Identified by Stepwise Logistic Regression Analysis
        date: 2018-11-09
       words: 2000
      flesch: 54
     summary: Aims: To determine risk factors associated with the presence of PNInv using the high-risk cSCC criteria developed by the National Comprehensive Cancer Network (NCCN). As independent risk factors for cSCC, tumor size, location on the face, and moderately or poorly differentiated histology have been associated with metastasis and death,1-6 while acantholytic, adenosquamous, or desmoplastic subtypes DISCUSSION SKIN November 2018 Volume 2 Issue 6 Copyright 2018 The National Society for Cutaneous Medicine 362 of cSCC have received considerably less attention in the literature.
    keywords: cscc; factors; pninv; risk
       cache: skin-356.pdf
  plain text: skin-356.txt

        item: #925 of 1356
          id: skin-357
      author: Beal, Brandon T; Cundall, Hannah L; Fernandez, Anthony P
       title: A female with thick intertriginous vegetative plaques
        date: 2019-03-11
       words: 595
      flesch: 24
     summary: Pyostomatitis vegetans is characterized by pustular and vegetative plaques of the oral mucosa, and is considered to be the oral equivalent of PDV. Direct immunofluorescence (DIF) to evaluate for pemphigus vegetans revealed weak granular deposition of complement C3 at the basement membrane zone.
    keywords: cleveland; pyostomatitis; vegetans
       cache: skin-357.pdf
  plain text: skin-357.txt

        item: #926 of 1356
          id: skin-359
      author: Marion, Tyler; Gibbons, Jake Alan
       title: The Rose of Dermatology
        date: 2019-05-03
       words: 438
      flesch: 53
     summary: Unfortunately, her tenure as chair was cut short as she fell victim to lymphocytic leukemia and passed away in 1940.3 To honor Dr. Hirschler, an award of her namesake, the Rose Hirschler Award, is given annually to female dermatologists who have made significant contributions to medicine and dermatology. Dr. Hirschler was a true pioneer for women in dermatology, paving the way for future females entering the field.
    keywords: dermatology; hirschler
       cache: skin-359.pdf
  plain text: skin-359.txt

        item: #927 of 1356
          id: skin-36
      author: Nyckowski, Timothy; Ceilley, Roger; Wilson, Joshua
       title: Sarcoidosis Developing During Secukinumab Therapy: Case Report
        date: 2017-08-31
       words: 1775
      flesch: 44
     summary: 2 Evidence for the involvement of IL-17A in the pathogenesis of sarcoidosis includes: (1) increased circulating IL-17A+ memory T cells, (2) increased IL-17A producing cells (IL-17A/IFN-γ and IL-17A/IL- 4 cells) in BAL samples, (3) increased T cells producing IL-17A in the lungs of sarcoidosis patients, and (4) differential distribution of IL-17A producing T cells in local granulomas. Ostadkarampour M, Eklund A, Moller D, Glader P, Olgart Höglund C, Lindén A, Grunewald J, Wahlström J. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome.
    keywords: cells; disease; il-17; report; sarcoidosis; secukinumab; skin
       cache: skin-36.pdf
  plain text: skin-36.txt

        item: #928 of 1356
          id: skin-360
      author: Kaminetsky, Joshua; Aziz, Mina; Kaushik, Shivani
       title: A Review of Biologics and Other Treatment Modalities in HIV-Associated Psoriasis
        date: 2018-11-09
       words: 5036
      flesch: 43
     summary: Their use can be particularly challenging in patients who are immunosuppressed at baseline, such as transplant recipients or HIV patients. Data regarding the use of biologic agents in treating psoriasis in HIV patients is limited, as these patients are often not included in clinical trials.
    keywords: agents; art; cd4; hiv; patients; psoriasis; skin; therapy; treatment
       cache: skin-360.pdf
  plain text: skin-360.txt

        item: #929 of 1356
          id: skin-361
      author: Hobson, Julia Graham; Scott, Glynis A; Mercurio, Mary Gail
       title: Langerhan's Cell Histiocytosis Masquerading as Intertrigo
        date: 2019-01-09
       words: 1185
      flesch: 40
     summary: Girschikofsky M, Arico M, Castillo D et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Recurrent BRAF mutations in Langerhans cell histiocytosis.
    keywords: cell; histiocytosis; langerhan; lch; patient
       cache: skin-361.pdf
  plain text: skin-361.txt

        item: #930 of 1356
          id: skin-364
      author: Zambito, Jeanette R; Shah, Pooja R; Scott, Glynis A; Evans, Andrew; Beck, Lisa A
       title: CVID-associated Granulomatous Dermatosis Resembling Sarcoidosis
        date: 2019-07-08
       words: 1756
      flesch: 47
     summary: Approximately 10% of CVID patients are reported to have noncaseating granulomatous disease that is indistinguishable from sarcoidosis on pathology; it most commonly affects the lungs, lymph nodes, and liver. The National Society for Cutaneous Medicine 256 involvement of the skin or bone marrow is less common, seen in approximately 20% and 5% of CVID patients, respectively2,3,4.
    keywords: bone; cvid; disease; immunodeficiency; patients; sarcoidosis; skin
       cache: skin-364.pdf
  plain text: skin-364.txt

        item: #931 of 1356
          id: skin-365
      author: Ikpeama, Chinelo; Gleghorn, Krystina; Akunna, Tara; Ryan, Michael; Wilkerson, Michael
       title: Why Dermatology? A Survey of Factors Influencing Resident Physician Selection of A Career in Dermatology
        date: 2018-11-09
       words: 862
      flesch: 48
     summary: % of Respondents (n = 242) Age of respondents % of Respondents (n = 242)
    keywords: career; dermatology; respondents
       cache: skin-365.pdf
  plain text: skin-365.txt

        item: #932 of 1356
          id: skin-366
      author: Benavidez, Jacob E
       title: Nobel Niels
        date: 2019-03-11
       words: 463
      flesch: 47
     summary: Grzybowski A, Pietrzak K. From patient to discoverer—Niels Ryberg Finsen (1860–1904)—the founder of phototherapy in dermatology. Presently, phototherapy is a treatment staple for various cutaneous disorders, but its inspiration and elucidation are resultant of the Faroese physician's struggle with Niemann-Pick disease.1 Bathing in the sun, Finsen experienced reduced fatigue from his disease, inspiring his life's work.1 Finsen developed a lamp with a quartz lens and an artificial light source generated by electric carbon arcs.
    keywords: finsen; light
       cache: skin-366.pdf
  plain text: skin-366.txt

        item: #933 of 1356
          id: skin-367
      author: Linsley, Catherine; Aziz, Mina
       title: A Case of Azacitidine-Induced Toxic Erythema of Chemotherapy
        date: 2019-01-09
       words: 802
      flesch: 40
     summary: However, TEC following azacitidine therapy has not been reported. Her past medical history was significant for MDS for 3 years, controlled on monthly azacitidine, until transformation to AML due to missing 2 cycles of treatment.
    keywords: azacitidine; mds; tec; treatment
       cache: skin-367.pdf
  plain text: skin-367.txt

        item: #934 of 1356
          id: skin-369
      author: Brown, Ashley E.; Starling, Caroline T.
       title: Vitiligo and Beauty
        date: 2018-11-09
       words: 552
      flesch: 45
     summary: Giles, K, Davison, R. 'I think I'm beautiful': Model Winnie Harlow, who suffers from rare Vitiligo skin condition, gives empowering talk at Women in the World event. Saunders, J. ‘You gotta have tough skin’!
    keywords: skin; vitiligo
       cache: skin-369.pdf
  plain text: skin-369.txt

        item: #935 of 1356
          id: skin-37
      author: Glazer, Alex M.; Farberg, Aaron S.; Donohue, Stephen; Rigel, Darrell S.
       title: Analysis of Dermatologic Disorders Occurring in Major League Baseball Players
        date: 2017-08-31
       words: 1103
      flesch: 48
     summary: 3 However, MLB players experienced a different mix with a greater proportion of mechanical, infectious, and contact related skin conditions likely due to the baseball- related activities that impact on these athletes’ skin on a day-to-day basis. In contrast, the 3 most common dermatoses seen among the non-player personnel control group were rash, tinea, and concerning skin lesion which more closely resembled the distribution of skin diseases among the general population.
    keywords: baseball; mlb; players; skin
       cache: skin-37.pdf
  plain text: skin-37.txt

        item: #936 of 1356
          id: skin-370
      author: Berman MD, PhD, Brian; Nestor, MD, PhD, Mark S.; Gold, MD, Michael H.; Goldberg, JD, MD, David J.; Fox, Joshua; Schmieder, DO, George
       title: Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biologically Effective Dose 30 of Superficial Radiation
        date: 2018-11-09
       words: 589
      flesch: 50
     summary: One of the following superficial radiation BED 30 fractionation protocols was employed post keloidectomy: one fraction of 13 Gy on post-operative day 1; or 2 fractions of 8 Gy on post-operative days 1 and 2; or, in the majority of cases, 3 fractions of 6 Gy on post-operative days 1, 2 and 3. Radiation dermatitis was not reported. The observed 3.0% rate of keloid recurrence following surgical keloidectomy and treatment of the excision site with superficial radiation therapy (BED 30) is markedly lower than that reported in the literature following keloid excision alone.
    keywords: keloidectomy; post; radiation
       cache: skin-370.pdf
  plain text: skin-370.txt

        item: #937 of 1356
          id: skin-371
      author: Beal, Brandon T; Varra, Vamsi; Chu, Melinda B; Armbrecht, Eric S; Walker, Ronald J; Varvares, Mark A; Fosko, Scott W
       title: Surgical Continuity of Care: A Multidisciplinary Approach to Managing the Mohs Micrographic Surgery Positive Deep Margin at the Parotid in Cutaneous Squamous Cell Carcinoma
        date: 2019-07-08
       words: 2431
      flesch: 53
     summary: This study demonstrates that resection with negative surgical margins results in excellent long-term local and regional disease control, and overall survival for cSCC patients with positive deep MMS margin at the parotid fascia. Positive deep margin.
    keywords: fascia; hns; louis; margin; mms; parotid; patients
       cache: skin-371.pdf
  plain text: skin-371.txt

        item: #938 of 1356
          id: skin-373
      author: Hill, Callie Roberts; Wang, Apphia; Elewski, Boni E.; Pavlidakey, Peter G
       title: Subcutaneous panniculitis-like T-Cell lymphoma: A mixed diagnostic approach to diagnosing a vague clinical picture
        date: 2019-03-11
       words: 3484
      flesch: 48
     summary: 8. Gorodetskiy, V.R., et al., Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response. Immunohistochemical staining of CD8+ was notable for neoplastic cells rimming numerous adipocytes.
    keywords: cell; cell lymphoma; lymphoma; panniculitis; patient; sptcl
       cache: skin-373.pdf
  plain text: skin-373.txt

        item: #939 of 1356
          id: skin-374
      author: Glaser, Ella; Kurta, Anastasia; Glaser, Dee Anna
       title: Eccrine Nevus of the Forearm Controlled With Topical Glycopyrrolate
        date: 2018-11-09
       words: 722
      flesch: 50
     summary: Figure 2: Minor starch iodine test after two-year long maintenance therapy with topical glycopyrrolate - this figure shows significant improvement in hyperhidrosis severity. The National Society for Cutaneous Medicine 436 Figure 1: Left forearm after a Minor starch iodine test highlighting localized hyperhidrosis.
    keywords: eccrine; hyperhidrosis; nevus
       cache: skin-374.pdf
  plain text: skin-374.txt

        item: #940 of 1356
          id: skin-376
      author: Hosseinipour, Mojgan; Baigrie, Dana Marie; Crane, Jonathan
       title: Subcorneal Pustular Dermatosis Successfully Treated with Acitretin in a Patient with Glucose-6-Phoshate Dehydrogenase Deficiency
        date: 2020-01-28
       words: 1723
      flesch: 43
     summary: We report a case of subcorneal pustular dermatosis in a G6PD deficient patient successfully treated with acitretin. Based on clinical and histopathological examination, findings were most consistent with subcorneal pustular dermatosis.
    keywords: acitretin; dapsone; dermatosis; patient; treatment
       cache: skin-376.pdf
  plain text: skin-376.txt

        item: #941 of 1356
          id: skin-377
      author: Orloff, Jeremy N; Kaminetsky, Joshua R; Aziz, Mina
       title: Psoriasis and Obesity: A Review of the Current Literature
        date: 2018-11-09
       words: 7710
      flesch: 53
     summary: One study found that psoriasis patients consume more fat, saturated fat, and alcohol.13 Psoriasis Patients with Diabetes Type 2 are at High Tisk of Developing Liver Fibrosis During Methotrexate Treatment.
    keywords: acad; dermatol; disease; et al; levels; obese; obesity; patients; psoriasis; skin; study; tnf; treatment; weight
       cache: skin-377.pdf
  plain text: skin-377.txt

        item: #942 of 1356
          id: skin-378
      author: Varra, Vamsi; Rodriguez, Marla; Beal, Brandon; Fernandez, Anthony
       title: Myeloid sarcoma - a case report
        date: 2019-05-03
       words: 869
      flesch: 44
     summary: Common positive immunohistochemical markers are CD43, CD68, lysozyme, myeloperoxidase, and CD117.2,4,5 Peripheral smear, flow cytometry, and bone marrow biopsy (BMB) are needed to categorize the disease and determine the extent of involvement. The diagnosis of myeloid sarcoma is challenging due to its rarity and heterogeneity of presentation.
    keywords: myeloid; sarcoma; skin
       cache: skin-378.pdf
  plain text: skin-378.txt

        item: #943 of 1356
          id: skin-379
      author: Cornacchia, Matthew Alexander; Munger, David; Andikyan, Vaagn; Halasz, Charles L
       title: Sweet Syndrome Following Gynecologic Surgery: Pelvic Abscess as a Cause
        date: 2019-01-09
       words: 1345
      flesch: 43
     summary: The National Society for Cutaneous Medicine 36 Figure 1: Erythematous papulovesicular lesions of Sweet syndrome on the patient’s lower extremities. We describe a case of Sweet syndrome in a 54-year-old woman provoked by a post-surgical pelvic infection.
    keywords: neutrophilic; patient; sweet; syndrome
       cache: skin-379.pdf
  plain text: skin-379.txt

        item: #944 of 1356
          id: skin-380
      author: Prado, Giselle; Nichols, Anna J; Florez-White, Mercedes; Kerdel, Francisco
       title: Reporting of Quality of Life in Clinical Trials of Biologics for Plaque Psoriasis: A Systematic Review
        date: 2018-09-07
       words: 8291
      flesch: 66
     summary: Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    keywords: baseline; change; dermatol; dlqi; endpoint; life; mean; patients; psoriasis; quality
       cache: skin-380.pdf
  plain text: skin-380.txt

        item: #945 of 1356
          id: skin-381
      author: Tausend, William; Hoyer, Paige; Arnold, Morgan; Wagner, Keith; Ross, Lindy; Goodwin, Brandon P; Wilson, Janice M
       title: Successful Treatment of Vitiligo with Crisaborole 2% Ointment
        date: 2019-03-11
       words: 981
      flesch: 51
     summary: Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo. More research is needed to demonstrate the efficacy and safety of topical crisaborole in the treatment of vitiligo and the potential role of PDE-4 inhibitors in vitiligo.
    keywords: crisaborole; ointment; treatment; vitiligo
       cache: skin-381.pdf
  plain text: skin-381.txt

        item: #946 of 1356
          id: skin-382
      author: Graham, Lauren Van Duyn
       title: Rapid access clinic expedites patient connection with dermatologic services and improves productivity
        date: 2019-01-09
       words: 1045
      flesch: 55
     summary: The average RAC encounter generated approximately 55% more wRVUs on average than non-RAC clinic visits due to a high proportion of new patients and procedures performed in RAC vs non-RAC clinic. RAC implementation reduced appointment wait times considerably.
    keywords: patients; rac; table; times
       cache: skin-382.pdf
  plain text: skin-382.txt

        item: #947 of 1356
          id: skin-383
      author: Svoboda, Ryan M; Del Rosso, James Q; Zeichner, Joshua A; Draelos, Zoe D
       title: Revisiting the Beneficial Effects of Estrogen on the Skin: A Comprehensive Review of the Literature and a Look to the Future
        date: 2018-09-07
       words: 4270
      flesch: 42
     summary: These findings led Dunaif and Finnerty to hypothesize that estrogens act locally at the HISTORICAL PERSPECTIVE SKIN September 2018 Volume 2 Issue 5 Copyright 2018 The National Society for Cutaneous Medicine 310 skin to promote epidermal thickening, but that this effect is antagonized when higher systemic concentrations are achieved, possibly due to a secondary mechanism of action at a remote site.10 These early experiments laid the scientific foundation for the treatment of aging skin with estrogens. The effect of topical oestradiol on skin collagen of postmenopausal women.
    keywords: aging; changes; collagen; effects; estrogen; journal; medicine; potential; skin; treatment; use; women
       cache: skin-383.pdf
  plain text: skin-383.txt

        item: #948 of 1356
          id: skin-385
      author: Mirsky, Rachel S; Prado, Giselle; Svoboda, Ryan M; Rigel, Darrell S
       title: Oxybenzone and Sunscreens: A Critical Review of the Evidence and a Plan for Discussion with Patients
        date: 2018-09-07
       words: 1971
      flesch: 50
     summary: Additionally, they raised oxybenzone concentrations to levels much greater than those found in the ocean. However, a meta-analysis of 64 studies measuring oxybenzone rates of sensitization and irritation found only 0.07% of 19,570 patients had true contact dermatitis to oxybenzone when undergoing patch testing.12
    keywords: bleaching; effects; hawaii; medicine; oxybenzone; patients; skin; sunscreen
       cache: skin-385.pdf
  plain text: skin-385.txt

        item: #949 of 1356
          id: skin-386
      author: Soh, Jonathan Matthew; Pentland, Alice P
       title: Current Curriculum on Reflectance Confocal Microscopy: a national survey of dermatology faculty and residents
        date: 2019-01-09
       words: 1387
      flesch: 54
     summary: Similar to traditional biopsy and pathology; RCM payment best approximates the time and effort that goes into acquiring and interpreting each lesion and is similar to that of traditional biopsy and pathology payments. We surveyed dermatology residency programs to explore the exposure trainees have to RCM.
    keywords: faculty; rcm; times; week
       cache: skin-386.pdf
  plain text: skin-386.txt

        item: #950 of 1356
          id: skin-387
      author: Dunn, Carly; Applebaum, Danielle S.
       title: Lues maligna in an immunocompetent male
        date: 2019-03-11
       words: 1186
      flesch: 44
     summary: Lues maligna (malignant syphilis) is an aggressive, rapidly developing, rare variant of secondary syphilis and is characterized by flu-like prodromal symptoms followed by an eruption of irregularly scattered erythematous papules and pustules that quickly progresses into well-defined necrotic ulcers. The patient was diagnosed with lues maligna given his Lues maligna (malignant syphilis) is an aggressive, rapidly developing, rare variant of secondary syphilis and is characterized by flu-like prodromal symptoms followed by an eruption of irregularly scattered erythematous papules and pustules that quickly progress into well-defined necrotic ulcers.
    keywords: bookmark; lues; maligna; medicine; syphilis
       cache: skin-387.pdf
  plain text: skin-387.txt

        item: #951 of 1356
          id: skin-388
      author: LaCour, Matthew
       title: Geometric Facial Erosions on a Newborn
        date: 2019-03-11
       words: 1509
      flesch: 47
     summary: MiDAS syndrome or MLS (microphthalmia with linear skin defect) is an X-linked dominant genodematosis characterized by cutaneous, ocular, central nervous system, and cardiac defects. MiDAS syndrome (microphthalmia, dermal aplasia, and sclerocornea) or MLS (microphthalmia with linear skin defect) is an X-linked dominant condition first described in the early 1990s.
    keywords: defects; linear; microphthalmia; midas; skin; syndrome
       cache: skin-388.pdf
  plain text: skin-388.txt

        item: #952 of 1356
          id: skin-389
      author: Hosking, Anna-Marie; Chapman, Lance; Smith, Janellen
       title: Crohn's Disease Presenting as Isolated Lower Lip Swelling
        date: 2019-05-03
       words: 873
      flesch: 45
     summary: Clinical examination revealed lower lip edema, cheilitis, and two oral aphthous ulcerations without evidence of facial palsy (Figure 1). History was significant for asthma, bipolar disorder, headaches, and a history of gastrointestinal disease (records were requested to verify a diagnosis).
    keywords: crohn; disease; oral
       cache: skin-389.pdf
  plain text: skin-389.txt

        item: #953 of 1356
          id: skin-391
      author: Samaan, Christen Botros
       title: Survey of Sun Protection Policies in Juvenile Detention Centers in Pennsylvania: Are we also Protecting Vulnerable Communities?
        date: 2019-03-11
       words: 1257
      flesch: 51
     summary: The objective of this study was to determine the prevalence of sun protection policies, environmental features, and attitudes in institutions responsible for school-aged populations in juvenile detention centers. The relationship between sun protection policies and practices in schools with primary-age students: the role of school demographics, policy comprehensiveness and SunSmart membership.
    keywords: cancer; centers; protection; skin; sun
       cache: skin-391.pdf
  plain text: skin-391.txt

        item: #954 of 1356
          id: skin-392
      author: Fraser, Lindsey Wold; Castillo, Stephanie A; Momtahen, Shabnam; Chapman, Michael Shane
       title: Frequently debrided and misdiagnosed: Post-surgical pyoderma gangrenosum
        date: 2019-03-11
       words: 1705
      flesch: 42
     summary: She was treated for a presumed post-operative wound infection with multiple courses of IV vancomycin, piperacillin/tazobactam, Post-surgical pyoderma gangrenosum is rare. Consequently, post-surgical pyoderma gangrenosum is frequently misdiagnosed as an infection, leading to detrimental surgical debridement, unnecessary antibiotic use, and delay of proper treatment.
    keywords: gangrenosum; pspg; pyoderma; wound
       cache: skin-392.pdf
  plain text: skin-392.txt

        item: #955 of 1356
          id: skin-393
      author: Dunn, Carly; McMurray, Stacy L.; Jones, Allison; Pattanaik, Debendra
       title: New-Onset Vitiligo Following Etanercept for Ankylosing Spondylitis
        date: 2019-09-13
       words: 1269
      flesch: 49
     summary: Although the exact mechanism is unknown, it is postulated that TNF-α inhibition modifies the cytokine balance and affects downstream pathways, resulting in activation of autoreactive T cells and immunologic imbalance.4,7 A retrospective study by Exarchou et al showed that 10 out of 183 (5.5%) patients with AS who had been treated with TNF-α inhibitors had immune-mediated skin lesions (with one case of vitiligo).1 A 10-year population-based study demonstrated an increased risk of vitiligo in patients receiving TNF-α inhibitors, with an incidence rate of 5.9 vs 2.5 per 10,000 person-years in those on TNF-α inhibitors versus control, respectively. Other therapy options include an alternative TNF-α inhibitor or another biological agent in patients whose underlying inflammatory condition had not improved or whose skin lesions progress.8 With growing literature describing immune- mediated skin diseases following TNF-α inhibitors, dermatologists, rheumatologists, and gastroenterologists need to be aware of these potential side-effects.
    keywords: patient; tnf; vitiligo
       cache: skin-393.pdf
  plain text: skin-393.txt

        item: #956 of 1356
          id: skin-394
      author: Pearlman, Dale Lawrence
       title: A novel hydrocortisone-ethanol gel ointment for treating atopic dermatitis (eczema) in children: A double blind, randomized, controlled clinical trial
        date: 2019-01-09
       words: 2512
      flesch: 53
     summary: Evidence of systemic ethanol effect via percutaneous absorption on eczematous skin: None of the treated patients in the study Figure 1: A patient with atopic dermatitis behind the knee randomized to treatment with HC ointment. Average score was 68% improved in the HC-EG ointment treated patients vs 37% in the HC ointment treated patients.
    keywords: atopic; ethanol; hydrocortisone; ointment; patients; treatment
       cache: skin-394.pdf
  plain text: skin-394.txt

        item: #957 of 1356
          id: skin-396
      author: Abdalla, Jennifer Elise; Cruse, Allison; Patel, Neelam; Brodell, Robert
       title: Terra Firma-Forme Dermatosis, Keratotic Form
        date: 2019-05-03
       words: 977
      flesch: 56
     summary: Fernández-Crehuet P, Ruiz-Villaverde R. Terra firma–forme dermatosis. In this case, however, the failure to clear the lesion with alcohol swabs led to the serendipitous finding that the brown, confluent, keratotic papules could be flicked off with a fingernail under a glove or by rubbing the area with a glass slide.
    keywords: case; dermatology; dermatosis; tffd
       cache: skin-396.pdf
  plain text: skin-396.txt

        item: #958 of 1356
          id: skin-399
      author: Barrick, Carl; Chin, An Guo Michael; Rutt, Veronica; Lountzis, Nektarios; Bartus, Cynthia
       title: Fibroelastolytic Papulosis in a Middle-Age Female: Presentation and Review of Treatment
        date: 2019-05-03
       words: 1707
      flesch: 53
     summary: Fibroelastolytic papulosis (FEP) is a rare benign skin disorder that can be distressing to patients, and has no established treatment guidelines to date. FEP can be distressing to patients, and it is important to explore additional treatment options.
    keywords: case; fep; fibroelastolytic; papulosis; treatment
       cache: skin-399.pdf
  plain text: skin-399.txt

        item: #959 of 1356
          id: skin-40
      author: Hoyer, Paige; Ly, Priscilla; Ross, Lindy; Wilkerson, Michael
       title: Timolol for Treatment of Recalcitrant Pyogenic Granulomas: a Case Report and Review of the Literature
        date: 2017-11-13
       words: 2192
      flesch: 52
     summary: No response of other lesions 15 M Abdomen 4mm 0.5% Timolol maleate (ii gtt QID) 12 days Partial response Chiriac A, et al. 2016 (9) 2 M Palpebral area N/A 0.1% Timolol in occlusive dressing (BID) + 2 applications of 70% Trichloroacetic Acid (1 every 7 days) 2 weeks Complete resolution 13 mos F Face N/A 0.1% Timolol in occlusive dressing (BID) + 1 application of 70% Trichloroacetic Acid 2 weeks Complete resolution Knöpfel M, et al. 2016 (12) 2 M Scalp N/A 0.5% Timolol GFS (BID) 1 month Almost complete resolution Hoyer P, et al. 2017 40 F Finger N/A Electrodessication → Electrodessication + Kenalog 5mg/ml → 0.5% Timolol GFS (BID) → Electrodessication + 0.5% timolol GFS (BID) 1 month 1 month 2 weeks 1 month Regrowth of lesion Regrowth of lesion Bleeding and pain Complete resolution Topical Timolol was an effective treatment for our case of Pyogenic Granuloma. Sex Location Diameter (mm) Treatment Treatment Duration Treatment response Wine L, et a.l 2013 (6) 32 mos F Cheek N/A Curettage + 0.5% Timolol GFS (BID) 6 months Complete Resolution 4 F Cheek N/A 2% Timolol GFS (BID) 2 months Partial response at 2 months, Resolution at 3 months 6 M Lower eyelid N
    keywords: gfs; granuloma; pyogenic; resolution; timolol; topical; treatment
       cache: skin-40.pdf
  plain text: skin-40.txt

        item: #960 of 1356
          id: skin-403
      author: Limmer, Allison L; Holland, Levi C; Garcia, Annabelle L
       title: Unusual presentation and successful treatment of necrobiosis lipoidica in a 15-year-old girl
        date: 2019-05-03
       words: 1397
      flesch: 40
     summary: This case demonstrates the appropriateness of keeping necrobiosis lipoidica in the differential diagnosis for patients presenting with plaques or ulcerating lesions, especially of the pretibial area, even with no associated comorbidities and/or uncommon histopathology. When NL is suspected in patients without glucose intolerance, affirmative diagnosis can be difficult, and other comorbidities may be probed, as NL has been associated with conditions such as hypertension, dyslipidemia, and thyroid disorders.
    keywords: cells; lipoidica; necrobiosis; patient
       cache: skin-403.pdf
  plain text: skin-403.txt

        item: #961 of 1356
          id: skin-404
      author: Tran, Andrew; Sarac, Rebecca; Prussick, Lisa; Radosta, Stella; Murina, Andrea
       title: A Review of Treatments for Dissecting Cellulitis of the Scalp
        date: 2019-05-03
       words: 3629
      flesch: 54
     summary: Histologically, there are abscesses, inflammatory infiltrates of neutrophils, dermal fibrosis, and decreased INTRODUCTION Dissecting cellulitis of the scalp (DCS) is a rare and chronic skin disorder that presents with suppurative nodules on the scalp with associated scarring alopecia. Mundi, J. P.; Marmon, S.; Fischer, M.; Kamino, H.; Patel, R.; Shapiro, J., Dissecting cellulitis of the scalp.
    keywords: case; cellulitis; dcs; disease; months; treatment; yes
       cache: skin-404.pdf
  plain text: skin-404.txt

        item: #962 of 1356
          id: skin-405
      author: Kirby, Joslyn; Burbach, Laura; Butt, Melissa; Butts, Jessica; Felix, Todd; Schlegel, Daniel; Shumaker, Kassidy
       title: Topical Corticosteroid Clinical Decision Support for Primary Care Providers: There’s an App for That!
        date: 2018-11-09
       words: 872
      flesch: 52
     summary: Laura Burbach1, Melissa Butt, MPH 2, Jessica Butts, MD3, Todd Felix, MD3, Daniel Schlegel, MD3, Kassidy Shumaker2, Joslyn S Kirby, MD, MS, Med2 1Penn State College of Medicine, Hershey PA 2Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey PA, 3Department of Family and Community Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA Literature has indicated that 20-36% of patients in PCP offices have dermatologic conditions1. A study of the app was performed with PCPs to determine changes in potency, vehicles and amount of corticosteroid prescriptions before and after app use (CorticoCream Calculator, https://www.padermatology.org/corticream- calculator.html).
    keywords: app; hershey; potency; use
       cache: skin-405.pdf
  plain text: skin-405.txt

        item: #963 of 1356
          id: skin-407
      author: Crain, Caroline; Gibbons, Jake Alan; Marion, Tyler
       title: The Father of Modern Cryotherapy
        date: 2019-07-08
       words: 422
      flesch: 54
     summary: Its use dates back to the mid nineteenth century by Dr. James Arnott of England. This technique was useful in reducing tumor size, decreasing bleeding, and ameliorating pain.1 In his own words, Dr. Arnott described the significance of his work: “congelation arresting the accompanying inflammation, and destroying the vitality of the cancer cell, is not only calculated to prolong life for a great period, but may, not improbably, in the early stage of the disease, exert a curative action.”2
    keywords: arnott; cryotherapy
       cache: skin-407.pdf
  plain text: skin-407.txt

        item: #964 of 1356
          id: skin-408
      author: Fasciano, Danielle; Innes, Matthew; Dorn, David; Ullman, David; Reddy, Vishnu; Ergen, Elizabeth; Pavlidakey, Peter
       title: Lepromatous leprosy: an elusive mimicker mistaken for polyarteritis nodosa and disseminated tuberculosis
        date: 2019-07-08
       words: 1796
      flesch: 44
     summary: The pancytopenia observed in this case may have been due to lepromatous infiltration of bone marrow, azathioprine toxicity or sepsis. Comparative cytomorphology of skin, lymph node, liver and bone marrow in patients with lepromatous leprosy.
    keywords: bone; case; disease; leprosy; marrow; skin
       cache: skin-408.pdf
  plain text: skin-408.txt

        item: #965 of 1356
          id: skin-410
      author: Draelos, Zoe Diana; Fowler, Joseph F; Cornelison, Raymond
       title: A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz™), 0.025% versus Clobetasol Propionate (Temovate®)
        date: 2018-11-09
       words: 4389
      flesch: 51
     summary: No statistical justification was made for the sample size of 50 subjects and the study was not powered to detect a statistically significant difference between treatment groups when measuring HPA axis suppression or efficacy. Additionally, in this sample, topical therapy with IMP was associated with a trend towards a lower incidence of HPA axis suppression than TMV without comprising efficacy.
    keywords: axis; cream; day; group; imp; study; subjects; tmv; treatment
       cache: skin-410.pdf
  plain text: skin-410.txt

        item: #966 of 1356
          id: skin-412
      author: Lebowitz, Emily; Lebwohl, Mark
       title: Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs
        date: 2019-03-11
       words: 4411
      flesch: 53
     summary: Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.
    keywords: apremilast; brodalumab; depression; dermatol; patients; phase; placebo; psoriasis; suicide; symptoms; treatment
       cache: skin-412.pdf
  plain text: skin-412.txt

        item: #967 of 1356
          id: skin-413
      author: Prado, Giselle; Teplitz, Rebeca; Winkelmann, Richard; Del Rosso, James; Rigel, Darrell
       title: Clinical Efficacy & Safety of Oral Polypodium Leucotomos Extract for Photoprotection: A Systematic Review
        date: 2018-11-09
       words: 2974
      flesch: 55
     summary: Middelkamp -Hup 200314 Open label, Pre and post exposure Oral PLE* 7.5mg/kg vs. On the other hand, polypodium leucotomos extract (PLE) has been shown to have photoprotective properties.
    keywords: cells; extract; leucotomos; med; oral; patients; ple; polypodium; skin
       cache: skin-413.pdf
  plain text: skin-413.txt

        item: #968 of 1356
          id: skin-414
      author: Cockerell, Clay
       title: How to Discuss Equivocal Melanocytic Neoplasms with Patients
        date: 2018-11-09
       words: 788
      flesch: 53
     summary: The fact that many patients with these lesions do well even if there is evidence of lymph node involvement provides encouragement that things may not be as bad as they might seem. Using this framework, dermatologists will be more prepared to answer patient questions, dispel fears, and optimize patient outcomes.
    keywords: diagnosis; patients
       cache: skin-414.pdf
  plain text: skin-414.txt

        item: #969 of 1356
          id: skin-417
      author: Ahluwalia, Jusleen
       title: The microbiome in preadolescent acne: assessment and prospective analysis on the influence of benzoyl peroxide
        date: 2018-12-17
       words: 521
      flesch: 51
     summary: The National Society for Cutaneous Medicine 95 RISING DERM STARS The microbiome in preadolescent acne: assessment and prospective analysis on the influence of benzoyl peroxide Jusleen Ahluwalia MD1, Lawrence F Eichenfield MD1 1Department of Dermatology, UC San Diego, San Diego, CA Background/Objectives: The pathogenesis of preadolescent acne has not been well studied, and it is uncertain if Propionibacterium acnes is a predominant organism in the microbiome in this age group.1-4 The aim of this study was to analyze the microbiome of preadolescent females, and to assess if benzoyl peroxide (BP) impacts the microbiome. Results show that preadolescent acne can vary in its microbial profile, reflecting surrounding changes associated with the onset of puberty.
    keywords: acne; microbiome; skin
       cache: skin-417.pdf
  plain text: skin-417.txt

        item: #970 of 1356
          id: skin-418
      author: Novice, Taylor Shea; Oberlin, David; McHargue, Chauncey
       title: A case of cutaneous metastatic adenosquamous carcinoma of the cervix
        date: 2019-07-08
       words: 1599
      flesch: 49
     summary: 4. Fumerton R, Afifi T, Martinka M, de Gannes G. Cutaneous metastases of cervical adenosquamous carcinoma. The National Society for Cutaneous Medicine 271 BRIEF ARTICLES A case of cutaneous metastatic adenosquamous carcinoma of the cervix Taylor Novice, BS,1 David Oberlin, MD,2 and Chauncey McHargue, MD2 1University of Michigan School of Medicine, Ann Arbor, MI 2Department of Dermatology, Henry Ford Hospital, Detroit, MI Cervical cancer is the most common gynecologic cancer among women worldwide, and the third most common in the United States.1 Histologically, cervical cancer is divided into 4 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, undifferentiated and adenosquamous carcinoma.1,2 Cutaneous metastasis is very rare among all subtypes with a reported incidence of 0.1% to 2%; of note, the adenosquamous carcinoma subtype has been reported the least.3-5 We present a case report of ulceronodular cutaneous metastasis of adenosquamous carcinoma of the cervix.
    keywords: cancer; carcinoma; cervix; metastases; skin
       cache: skin-418.pdf
  plain text: skin-418.txt

        item: #971 of 1356
          id: skin-421
      author: Dhandha, Maulik M
       title: Passion to Heal – Dermatology volunteering in the Maasai Mara, Kenya
        date: 2019-05-03
       words: 1211
      flesch: 53
     summary: This “gap” of ideal versus available treatment was even more pronounced in Kenya. The key challenges to our work there were limited resources and time available, socio-economic difficulties of the local population, lack of an established dermato-pathology center, etc. Management of dermatology patients involved making clinical diagnoses without histopathology and empiric treatment from an available medication formulary.
    keywords: kenya; patients; skin; treatment
       cache: skin-421.pdf
  plain text: skin-421.txt

        item: #972 of 1356
          id: skin-43
      author: Paniagua Gonzalez, Lizy M; Lowe, Alison; Wilkerson, Michael
       title: Ulcerative Tinea Corporis in an Immunosuppressed patient
        date: 2017-11-13
       words: 1482
      flesch: 39
     summary: The National Society for Cutaneous Medicine 168 Clinicians should have a strong suspicion for atypical presentations of common infections in transplant patients. Lillis, J.S., Dawson, E.S., Chang, R., White, C.R. Disseminated dermal Trichophyton rubrum infection- an expression of dermpatophyte dimorphism?
    keywords: dermatophytosis; infection; patient; tinea; transplant
       cache: skin-43.pdf
  plain text: skin-43.txt

        item: #973 of 1356
          id: skin-44
      author: Maarouf, Melody; Wickenheiser, Marilyn; Sligh, James; Culpepper, Keliegh; Shi, Vivian
       title: Disordered Presentation of Paraneoplastic Pancreatitis, Polyarthritis and Panniculitis (PPP) Syndrome in a Patient with End-Stage Pancreatic Cancer
        date: 2018-01-02
       words: 1465
      flesch: 39
     summary: Zhang G, Cao Z, Yang G, Wu W, Zhang T, Zhao Y. Pancreatic panniculitis associated with pancreatic carcinoma: A case report. We report a case of PPP due to stage IV pancreatic cancer presenting with polyarthritis following chemotherapy induction, whose diagnosis was delayed due to late manifestation of pancreatic panniculitis.
    keywords: carcinoma; pancreatic; panniculitis; polyarthritis; ppp; syndrome
       cache: skin-44.pdf
  plain text: skin-44.txt

        item: #974 of 1356
          id: skin-444
      author: Chovatiya, Raj
       title: Association of Pemphigus and Pemphigoid with Osteoporosis and Pathological Fractures
        date: 2018-12-17
       words: 581
      flesch: 34
     summary: A pooled analysis across all 7 years showed that patients with pemphigus had significantly higher odds (multivariate logistic regression including age, sex, primary payer, income quartile, history of long-term steroids; OR, 95% CI) of diagnosis with osteopenia (2.200, 1.590- 3.045), osteoporosis (2.536, 2.159-2.978), osteomalacia (29.699, 4.049-217.834), and pathologic fracture (2.035, 1.422-2.912) Similarly, patients with pemphigoid had significantly higher odds of diagnosis with osteoporosis (1.550, 1.392-1.727) and pathologic fracture (1.517, 1.222-1.884).
    keywords: pemphigoid; pemphigus
       cache: skin-444.pdf
  plain text: skin-444.txt

        item: #975 of 1356
          id: skin-445
      author: Dubin, Danielle
       title: Prophylactic botulinum toxin in post-excisional scars: a randomized, doubleblinded, controlled clinical trial
        date: 2018-12-17
       words: 592
      flesch: 55
     summary: Figure 2: Box plot comparing VAS and mMSS for the placebo versus botulinum toxin study arms. Botulinum toxin is utilized as a treatment for facial rhytids due to its ability to induce a chemical paralysis of the musculature2.
    keywords: botulinum; toxin
       cache: skin-445.pdf
  plain text: skin-445.txt

        item: #976 of 1356
          id: skin-446
      author: Ekelem, Chloe
       title: Optical Coherence Tomography for the Scalp
        date: 2018-12-17
       words: 538
      flesch: 39
     summary: We successfully devised an imaging cap to precisely relocate scalp areas, captured images that minimize data loss to light absorption, and described parameters of follicular disease, such as number of follicles, hair thickness, presence and absence of doublets and triplets, as well as epidermal thickness. Control subjects were expected to have larger average follicular diameter and higher average hair-bearing follicle density compared to alopecia subjects in all scalp regions.
    keywords: scalp; subjects
       cache: skin-446.pdf
  plain text: skin-446.txt

        item: #977 of 1356
          id: skin-447
      author: Guzman, Anthony
       title: Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially-Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum
        date: 2018-12-17
       words: 602
      flesch: 52
     summary: Conclusions: VP-102 was well-tolerated with either a 6 or 24-hour exposure and was associated with a significantly reduced lesion count, improved quality of life and complete clearance of MC lesions in nearly half of the patients. Eleven subjects (44.0%) achieved total lesion clearance by EOS.
    keywords: cantharidin; subjects; treatment
       cache: skin-447.pdf
  plain text: skin-447.txt

        item: #978 of 1356
          id: skin-448
      author: Landriscina, Angelo
       title: Silver Sulfadiazine retards wound healing in mice via alterations in cytokine expression
        date: 2018-12-17
       words: 720
      flesch: 41
     summary: This study aimed to elucidate SSD’s impact on wound healing and suggest mechanisms by which it occurs. The inflammatory reaction in wound healing is regulated by a delicate balance between pro- and anti-inflammatory cytokines, with the IL-1 family regulating chemokine production by keratinocytes, fibroblasts and macrophages.3,4 While expression of the IL-1 family is dependent on the complex interplay between members of the family, given our results, we hypothesize that SSD alters gene expression of IL-1 family genes resulting in impaired downstream cytokine production and ultimately delayed wound healing.
    keywords: healing; ssd; wound
       cache: skin-448.pdf
  plain text: skin-448.txt

        item: #979 of 1356
          id: skin-449
      author: Mollanazar, Nicholas
       title: Off-Label Treatment of Prurigo Nodularis with Dupilumab: A Case Series Study
        date: 2018-12-17
       words: 633
      flesch: 54
     summary: To quantify the effectiveness of dupilumab in treating the itch of PN, average patient reported numeric rating scale itch intensity (NRSi) were calculated on a scale of 0-10 before and during therapy with dupilumab. 2018;54(3):527-531. doi:10.1016/j.jaad.2005.12.010 5. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study.
    keywords: nrsi; patients; treatment
       cache: skin-449.pdf
  plain text: skin-449.txt

        item: #980 of 1356
          id: skin-45
      author: Kesterson, Katrina; Subrt, Adrian; Wilkerson, Michael
       title: Evolution of a Doxycycline-Induced Phototoxic Rash With an Unusual Distribution
        date: 2018-07-06
       words: 1308
      flesch: 48
     summary: 6 Based on studies in current literature, the incidence of doxycycline phototoxicity follows a dose-dependent trend. 4. Lim D, Murphy G. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor.
    keywords: day; doxycycline; phototoxic; rash; sunscreen
       cache: skin-45.pdf
  plain text: skin-45.txt

        item: #981 of 1356
          id: skin-450
      author: Moy, Lauren
       title: Non-Invasive Buccal Swab Gene Testing for Skin Cancer Risk
        date: 2018-12-17
       words: 403
      flesch: 36
     summary: The National Society for Cutaneous Medicine 109 RISING DERM STARS Non-Invasive Buccal Swab Gene Testing for Skin Cancer Risk Lauren Moy, MD1 1Department of Dermatology, Loyola University, Chicago, IL Background: The awareness of skin cancer is increasing, and there are new commercial kits on the market which advertise the ability to provide a patient with a skin cancer risk profile. In this pilot study, we aimed to examine whether previously identified melanoma and non-melanoma associated SNPs which were found to be present in a relatively heterogeneous population with a history of skin cancer versus an age and environmental matched controls.
    keywords: cancer; skin
       cache: skin-450.pdf
  plain text: skin-450.txt

        item: #982 of 1356
          id: skin-451
      author: Rothstein, Brooke
       title: Topical JAK inhibitor Ruxolitinib for Vitiligo Treatment
        date: 2018-12-17
       words: 674
      flesch: 52
     summary: Conclusion: Twice daily application of topical ruxolitinib 1.5% cream provided significant facial vitiligo re-pigmentation and may offer a valuable new treatment for vitiligo. Three of 6 patients experienced re- pigmentation of non-acral upper extremity vitiligo (12.6% ± 19.5%), two of whom underwent simultaneous nbUVB phototherapy and had previously failed phototherapy and topical ruxolitinib 1.5% cream as single agent treatment regimens.
    keywords: patients; vitiligo
       cache: skin-451.pdf
  plain text: skin-451.txt

        item: #983 of 1356
          id: skin-452
      author: Rzepecki, Alexandra
       title: Staphylococcus Aureus Nasal Colonization is Associated with Severity of Radiation Dermatitis in Patients Receiving Radiotherapy
        date: 2018-12-17
       words: 786
      flesch: 51
     summary: Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Objective: The goals of our prospective study were to 1) characterize the incidence of baseline bacterial colonization in patients undergoing RT, and 2) examine the association between radiation dermatitis severity and baseline bacterial colonization.
    keywords: baseline; colonization; skin
       cache: skin-452.pdf
  plain text: skin-452.txt

        item: #984 of 1356
          id: skin-453
      author: Theodosakis, Nicholas
       title: Inhibition of isoprenoid synthesis synergizes with MAPK blockade to prevent growth in targeted therapy-resistant melanoma
        date: 2018-12-17
       words: 611
      flesch: 50
     summary: Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., Mcarthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012). Mouse studies of dual therapy with statins and BRAF inhibitors in the setting of vemurafenib-resistant BRAF-mutant melanoma provide additional in vivo evidence of efficacy, supporting a possible role for trials of statin and MAPK inhibitor combination therapy in human cancer patients.
    keywords: braf
       cache: skin-453.pdf
  plain text: skin-453.txt

        item: #985 of 1356
          id: skin-454
      author: Raoof, Joseph; Hooper, Deirdre; Moore, Angela; Zaiac, Martin; Sullivan, Tory; Kircik, Leon; Lain, Edward; Jankivevic, Jasmina; Stuart, Iain
       title: FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study
        date: 2018-12-17
       words: 1851
      flesch: 57
     summary: The study met both co-primary end points of absolute change from baseline in inflammatory lesion count and proportion with IGA treatment success at week 12 – Significant reduction in number of both inflammatory and noninflammatory lesions at week 12 from baseline in FMX101 4% treatment group vs vehicle treatment group – Significant improvement in IGA treatment success at week 12 in FMX101 4% treatment group vs vehicle treatment group • IGA treatment success at week 12 •
    keywords: figure; fmx101; treatment; vehicle; week
       cache: skin-454.pdf
  plain text: skin-454.txt

        item: #986 of 1356
          id: skin-455
      author: Schreiber, Rhonda; Lewis, Caitlin; Crane, Kaytiana
       title: Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance
        date: 2018-12-17
       words: 1845
      flesch: 74
     summary: It has been previously well established that topical vehicle impacts not only safety, efficacy, and tolerability, but also pa�ent preference and therefore adherence to treatment protocols.3,4 This data clearly shows that the foam formula�on rated strongly in a range of proper�es which other studies have found to be important to pa�ents when choosing a topical vehicle.2 Recent research also shows that pa�ent vehicle preference is an important, but o�en overlooked, factor in maintaining compliance.3-6 A worldwide study found that poor adherence occurs in 40% of pa�ents receiving topical treatment for acne.2 Topical treatments for acne include formula�ons such as creams, lo�ons, ointments, gels, solu�ons and foams.
    keywords: ent; foam; ons
       cache: skin-455.pdf
  plain text: skin-455.txt

        item: #987 of 1356
          id: skin-456
      author: Paller, Amy S; Stein Gold, Linda; Lee, James; Tallman, Anna M; Rubenstein, David
       title: Patient-reported outcomes in subjects with atopic dermatitis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study
        date: 2018-12-17
       words: 2152
      flesch: 37
     summary: ■ Of those randomized, 191 subjects (77%) completed the study including the Week 16 follow-up visit ■ Overall, mean demographic and baseline characteristics were comparable across treatment groups (Table 1) ■ Most subjects (91%) had a baseline IGA score of 3 (moderate) and a baseline mean Eczema Area and Severity Index (EASI) score of 11.3 (standard deviation 6.0) ■ Primary endpoint: IGA response rates (defined as IGA score 0 or 1 and ≥2-grade improvement) at Week 12 were higher in the tapinarof cream groups than the vehicle groups (53% [1% BID], 46% [1% QD], 37% [0.5% BID], 34% [0.5% QD] vs 24% [vehicle BID] and 28% [vehicle QD]) and were maintained for 4 weeks after the end of study treatment (non-responder imputation method)2 Table 1. Safety Overview and Most Common TEAEs (Occurring in ≥5% of Subjects in Any Group) Preferred term, n (%)
    keywords: bid; groups; tapinarof
       cache: skin-456.pdf
  plain text: skin-456.txt

        item: #988 of 1356
          id: skin-457
      author: Guttman-yassky, Emma; Pavel, Ana B; Estrada, Yeriel; Zhou, Lisa; Salhi, Yacine; Gudi, Girish; Ca, Vinu; Macoin, Julie; Back, Jonathan; Wolff, Gerhard
       title: GBR 830 Induced Progressive and Sustained Improvements in Atopic Dermatitis Skin Biomarkers and Clinical Parameters
        date: 2018-12-17
       words: 2101
      flesch: 66
     summary: Prior treatment with systemic corticosteroids, topical steroids, phototherapy, and/or biologics Study Endpoints ◾◾ Co-primary: treatment-emergent adverse events (TEAEs; frequency, severity); change from baseline in epidermal hyperplasia and active AD mRNA expression biomarker signatures measured from lesional skin biopsies ◾◾ Key secondary: P R E S E NTE D AT TH E FA LL C
    keywords: baseline; day; gbr; placebo
       cache: skin-457.pdf
  plain text: skin-457.txt

        item: #989 of 1356
          id: skin-458
      author: Macoin, Julie; Lissilaa, Rami; Sancheti, Pavankumar; Reddy, Venkateshwar; Back, Jonathan; Wolff, Gerhard
       title: Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses
        date: 2018-12-17
       words: 1920
      flesch: 61
     summary: ◾◾ GBR 830 significantly reduced memory antibody response to keyhole limpet hemocyanin (KLH) in cynomolgus monkeys from Day 84 onward, with no effect on primary antibody response to KLH (Figure 3) Figure 3. ◾◾ GBR 830 was equally effective as clobetasol propionate (Temovate®) compared with isotype control in ameliorating the psoriasis phenotype in a human psoriatic skin transplant model (Figure 6) ◾◾ A reduction in CD3+ T cell number was observed in the GBR 830 treatment group but was not statistically significant from the isotype control group Figure 6.
    keywords: gbr; group
       cache: skin-458.pdf
  plain text: skin-458.txt

        item: #990 of 1356
          id: skin-459
      author: Wollenberg, Andreas; Guttman-Yassky, Emma; Torpet, Mathias; Silverberg, Jonathan I
       title: Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis
        date: 2018-12-17
       words: 2354
      flesch: 48
     summary: Frequency of patients with one or more eye disorders in the placebo and pooled tralokinumab treatment groups 4 3 Conjunctivitis 1 Keratitis 6 7 All eye disorders F re q u en cy ( % ) 14 12 10 8 6 4 2 0 Eye disorder Placebo (n=51) Pooled tralokinumab (n=153) LEO1825A_Wollenberg4x4-V2 Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis Andreas Wollenberg,1 Emma Guttman-Yassky,2 Mathias Torpet,3 Jonathan I Silverberg4 1Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany; 2Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3LEO Pharma A /S, Ballerup, Denmark; 4Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Objectives • To evaluate the risk of developing ADAs with tralokinumab treatment in the Phase 2b study.
    keywords: eye; patients; placebo; tralokinumab
       cache: skin-459.pdf
  plain text: skin-459.txt

        item: #991 of 1356
          id: skin-460
      author: Silverberg, Jonathan I; Kragh, Nana; Guttman-Yassky, Emma; Wollenberg, Andreas
       title: Treatment with tralokinumab improves health-related quality of life in adult patients with moderate to severe atopic dermatitis: results from a Phase 2b, randomised, double-blind, placebo-controlled study
        date: 2018-12-17
       words: 2317
      flesch: 49
     summary: Tralokinumab 150 mg SC Q2W + TCS (n=51) Tralokinumab 45 mg SC Q2W + TCS (n=50) Patients with moderate to severe AD TCS TCS Placebo SC Q2W + TCS (n=51) AD, atopic dermatitis; Q2W, every 2 weeks; SC, subcutaneous; TCS, topical corticosteroids. Tralokinumab 150 mg SC Q2W + TCS (n=51) Tralokinumab 45 mg SC Q2W + TCS (n=50) Patients with moderate to severe AD TCS TCS Placebo SC Q2W + TCS (n=51) AD, atopic dermatitis; Q2W, every 2 weeks; SC, subcutaneous; TCS, topical corticosteroids.
    keywords: health; patients; placebo; tcs; tralokinumab
       cache: skin-460.pdf
  plain text: skin-460.txt

        item: #992 of 1356
          id: skin-462
      author: Pariser, D; Gopalan, R; Drew, J; Green, L
       title: Clinical Management of Anticholinergic Adverse Events with Glycopyrronium Cloth, a Treatment for Primary Axillary Hyperhidrosis
        date: 2018-12-17
       words: 2087
      flesch: 25
     summary: Moderate dehydration, considered not related to study drug b Serious TEAEs are those that: resulted in death, were immediately life threatening, required inpatient hospitalization, resulted in persistent or significant disability, or judged to require medical/surgical attention in order to avoid any of the previously mentioned outcomes c Mydriasis and dry mouth appear twice in the table since they meet criteria for common TEAEs and are associated with anticholinergic use GT, topical glycopyrronium tosylate; TEAE, treatment-emergent adverse event TEAEs of Special Interest • TEAEs of special interest (blurred vision, mydriasis, and symptoms associated with urinary retention/hesitation) occurred in 13.3% (61/459) of GT-treated patients and no vehicle-treated patients (Table 2) – Most were considered related to study drug, of mild to moderate severity, and transient – Severe TEAEs of special interest occurred in only one subject who had both severe mydriasis and severe urinary retention; these events, along with mild blurred vision and TEAEs of dry mouth (severe) and anhidrosis (severe), led to discontinuation, and all resolved after study drug withdrawal – One subject had a serious TEAE of unilateral mydriasis of moderate severity; given a head injury the prior week, the subject was hospitalized to rule out a central nervous system disorder, and the event resolved after study drug withdrawal • Among the 6.8% of pooled GT-treated patients experiencing mydriasis, most events were unilateral (74.2% [23/31]), while most blurred vision events were bilateral (68.8% [11/16]); treatment was not discontinued in most cases (Table 2) • Hyperhidrosis affects an estimated 4.8% of the US population, or approximately 15.3 million people, and negative psychological consequences (eg, anxiety, depression) are associated with the disorder1 • The impact of hyperhidrosis on quality of life is comparable to, or greater than, the impact of psoriasis or eczema2 • Glycopyrronium tosylate (GT) is a topical anticholinergic approved in the US for primary axillary hyperhidrosis in patients 9 years and older (glycopyrronium cloth, 2.4%, for topical use) • GT safety and efficacy were evaluated in two, replicate, randomized, phase 3 clinical trials (ATMOS-1 and ATMOS-2); the primary efficacy and safety results of these studies have been previously reported, and in these trials, GT reduced sweating severity and sweat production compared to vehicle and was generally well tolerated3 OBJECTIVE • To examine the safety and tolerability profile of GT in the ATMOS-1 and ATMOS-2 trials and how treatment-emergent adverse events (TEAEs) associated with anticholinergic compounds were managed/resolved during those trials METHODS ATMOS-1 and ATMOS-2 Study Design and Patients • ATMOS-1 (NCT02530281; sites in the US and Germany) and ATMOS-2 (NCT02530294; US sites only) were replicate, randomized, parallel-group, 4-week, double-blind, phase 3 clinical trials3 (Figure 1) • Patients with primary axillary hyperhidrosis were randomized (2:1) to GT 3.75% topical solution (equivalent to 2.4% glycopyrronium) or vehicle applied once daily to each axilla • Eligible patients were ≥9 years of age (patients <16 years were only recruited at US sites), had primary axillary hyperhidrosis for ≥6 months, gravimetrically-measured sweat production of ≥50 mg/5 min in each axilla, Axillary Sweating Daily Diary (ASDD) sweating severity (Item 2)4 score ≥4, and Hyperhidrosis Disease Severity Scale (HDSS) grade ≥3 • Patients were excluded for history of a condition that could cause secondary hyperhidrosis; prior surgical procedure or treatment with a medical device for axillary hyperhidrosis; treatment with iontophoresis within 4 weeks or treatment with botulinum toxin within 1 year for axillary hyperhidrosis; axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks; new or modified psychotherapeutic medication regimen within 2 weeks; and/or treatment with medications having systemic anticholinergic activity, centrally acting alpha-2 adrenergic agonists, or beta-blockers within 4 weeks unless dose had been stable ≥4 months and was not expected to change Figure 1. Study Design Week 0
    keywords: drug; patients; teaes; vehicle
       cache: skin-462.pdf
  plain text: skin-462.txt

        item: #993 of 1356
          id: skin-463
      author: Pariser, D; Green, L; Drew, J; Gopalan, R; Yan, V; Glaser, D
       title: Onset of Action With Glycopyrronium Cloth in the Treatment of Primary Axillary Hyperhidrosis
        date: 2018-12-17
       words: 3191
      flesch: 39
     summary: For the analyses evaluating daily ASDD/ASDD-C Item 2 responder rate over the first 7 days: – A markedly greater proportion of GT patients achieved ≥4-point ASDD/ASDD-C Item 2 improvement from Baseline starting on Day 2 vs VEH patients: Daily (Days 0-7) and Weekly Change From Baseline in ASDD Item 3 (Impact) and Item 4 (Bothersomeness) -0.2 0 -1.2 -1.0 -0.6 -0.8 -0.4 -1.4 -1.6 M ea n C ha ng e fr om B as el in e A S D D It em 3 Days Weeks 0 1 2 3 4 5 6 7 2 3 4 GT (n=447)
    keywords: asdd; baseline; item; vehicle; week
       cache: skin-463.pdf
  plain text: skin-463.txt

        item: #994 of 1356
          id: skin-464
      author: Hebert, Adelaide A; Glaser, Dee Anna; Green, Lawrence; Werschler, William P; Forsha, Douglass W; Drew, Janice; Gopalan, Ramanan; Pariser, David M
       title: Short- and Long-Term Efficacy and Safety of Glycopyrronium Cloth for the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analyses from the Phase 3 Studies
        date: 2018-12-17
       words: 3573
      flesch: 37
     summary: Through Week 44/ET in ARIDO (up to 48 weeks of GT from the start of the double-blind ATMOS-1/ATMOS-2 trials), improvements in efficacy measures, including sweat production, HDSS responder rate, and DLQI/CDLQI, were maintained, with similar results between the pediatric and older subgroups (Figure 4) – From Baseline in ATMOS-1/ATMOS-2 to Week 44/ET in ARIDO: • Median sweat production decreased by -50.3 and -75.1 mg/5 minutes in the pediatric and older subgroups, respectively, reflecting a maintenance of sweat reduction benefit (median decreases were 61.3 and 58.7 mg/5 minutes in GT-treated patients after 4 weeks of GT treatment in the double-blind trials) The proportion of HDSS responders was consistent over the study course and similar to that observed after 4 weeks of GT treatment in the double-blind trials (59.9% and 60.2%, pediatric and older subgroups, respectively) • Mean DLQI and CDLQI scores improved by 8.7 ± 6.2 and 6.2 ± 4.9, which were maintained from a mean decrease of 8.4 ± 6.0 and 8.1 ± 5.4, respectively, in GT-treated patients after 4 weeks of treatment in ATMOS 1/ATMOS-2 Figure 4. ARIDO Outcomes at Week 44/End of Treatment ≥9 to ≤16 Years N=30 -50.3 >16 Years N=400 -75.1 ≥9 to ≤16 Years N=26 -6.2 >16 Years N=406 -8.7 ≥9 to ≤16 Years N=30 56.7 >16 Years N=407 63.6 Sweat Productiona HDSS Responder Rate CDLQ/DLQI 0 -80 -60 -40 -20 -100 M ed ia n A bs ol ut e C ha ng e fr om B as el in eb (m g/ 5 m in ) 0 -8 -6 -4 -2 -10 100 20 40 60 80 0P ro po rt io n of P at ie nt s (% ) M ea n C ha ng e fr om B as el in e aGravimetrically-measured average from the left and right axillae; bBaseline in ATMOS-1/ATMOS-2 for vehicle-treated and GT-treated patients who continued into ARIDO and received GT-treatment thereafter Pooled ATMOS-1/ATMOS-2 data; intent-to-treat (ITT) population P-values were not calculated for this post hoc analysis; multiple imputation (MCMC) was used to impute missing values for sweat production and HDSS responder rate CDLQI, children’s DLQI; DLQI, Dermatology Life Quality Index; ET, end of treatment/early termination; GT, topical glycopyrronium tosylate; HDSS, Hyperhidrosis Disease Severity Scale; MCMC, Markov chain Monte Carlo; SD, standard deviation Safety • Overall, GT was well tolerated across short and long-term treatment, and most adverse events were mild to moderate in severity, and infrequently led to discontinuation, regardless of age (Table 3) – Of two serious TEAEs reported in the double-blind trials, both occurred in the GT arm of the older subgroup and only one lead to discontinuation (moderate unilateral mydriasis; related to treatment)
    keywords: asdd; baseline; dlqi; patients; week; years
       cache: skin-464.pdf
  plain text: skin-464.txt

        item: #995 of 1356
          id: skin-465
      author: Ferris, Laura; Jansen, Burkhard; Yao, Zuxu; Rock, Jim; Skelsey, Maral; Peck, Gary; Cockerell, Clay J
       title: Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter
        date: 2018-12-17
       words: 1641
      flesch: 51
     summary: Ten percent of PLA negative cases harbored mutations in the TERT promoter region. Mutation analyses were performed by Sanger sequencing of adhesive patch and FFPE tissue block samples.
    keywords: cases; melanoma; mutations; pla
       cache: skin-465.pdf
  plain text: skin-465.txt

        item: #996 of 1356
          id: skin-466
      author: Prado, Giselle; Cook, Robert W; Covington, Kyle R; Monzon, Federico A; Rigel, Darrell S
       title: Improvement of risk assessment in cutaneous melanoma (CM) by a prognostic 31-gene expression profile (31-GEP) test over AJCC-based staging alone
        date: 2018-12-17
       words: 1429
      flesch: 69
     summary: % S u rv iv a l MSS p<0.0001 Class (n) 5-year RFS (95% CI) 5-year DMFS (95% CI) 5-year MSS (95% CI) 1A (312) 90% (87-93%) 94% (91-97%) 99% (98-100%) 1B (80) 81% (73-90%) 85% (77-93%) 95% (90-100%) 2A (84) 68% (58-79%) 75% (66-85%) 91% (85-98%) Cox multivariate regression analysis for MSS was performed comparing AJCC binary risk and 31-GEP test results.
    keywords: ajcc; class; gep; risk; stage
       cache: skin-466.pdf
  plain text: skin-466.txt

        item: #997 of 1356
          id: skin-467
      author: Cook, Robert W; Plasseraud, Kristen M; Kurley, Sarah J; Covington, Kyle R; Monzon, Federico A
       title: Literature review of a prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM) risk prediction
        date: 2018-12-17
       words: 1624
      flesch: 52
     summary: Melanoma Staging (per NCCN) Low Risk Class 1 High Risk Stage IIB-III High Risk Class 2 Low Risk Class 1 Continue high intensity management Appropriate treatment or clinical trial AJCC Staging 31-GEP Test Management Decision Recommendation changes with GEP result in patient vignettes Technical reliability Sufficient tumor content Insufficient content (<40%) Conference 2018 Design (n) GEP Impact Prospectively tested patients, Retrospective chart review; (156 patients)10 53% Prospective documentation of pre and post test plans; (247 patients)11 49% Prospectively tested patients, Retrospective chart review; (90 patients)12 52% Physician survey of clinical decisions with or without test results; (169 physicians)13 47- 50% Physician survey of clinical factors that affect use of 31-GEP test; (181 physicians)14 * *overall GEP impact not assessed with study design Table 1.
    keywords: class; gep; risk; test; validity
       cache: skin-467.pdf
  plain text: skin-467.txt

        item: #998 of 1356
          id: skin-468
      author: Moore, Angela Y; Nguyen, Madalyn
       title: Combination Therapy with Short Contact Topical Calcipotriene Foam and Fluorouracil Following Cryotherapy for Actinic Keratosis
        date: 2018-12-17
       words: 1271
      flesch: 58
     summary: • Cryotherapy followed by short contact topical calcipotriene foam in combination with 5-fluorouracil cream may offer increased efficacy and safety in the treatment of actinic keratoses. A decrease in total AK lesion count was noted at months1, 3, and 6 using measures of central tendency, but a statistically significant decrease in total lesion count was only observed at month 6 compared to baseline count (p=0.03383).
    keywords: ln2; treatment
       cache: skin-468.pdf
  plain text: skin-468.txt

        item: #999 of 1356
          id: skin-469
      author: Xu, Shuai; Wang, Stacy
       title: Assessing Patient Concerns Regarding Seborrheic Keratoses on the Face: Comparison Against Other Cosmetic Concerns
        date: 2018-12-17
       words: 1565
      flesch: 50
     summary: Interest in Aesthetic Procedures z Many survey participants were extremely interested or very interested in skin rejuvenation procedures (48%) or dental aesthetics (43%; Figure 4) z A total of 597/702 survey participants (85%) found the blinded product X consisting of high- concentration hydrogen peroxide (HP40) for the in-office treatment of SKs by a dermatologist to be extremely appealing or very appealing Figure 4. z Among survey participants who had visited a dermatologist in the past 2 years, the most common reasons for doing so were routine skin cancer check (66%), removal of noncancerous skin growths, marks, or spots (52%), or to have a suspicious mole or spot checked (47%)
    keywords: face; participants; sks; survey
       cache: skin-469.pdf
  plain text: skin-469.txt

        item: #1000 of 1356
          id: skin-47
      author: none
       title: Capecitabine-Induced Subacute Cutaneous Lupus Erythematosus in a Patient with Systemic Lupus Erythematosus
        date: 2018-01-02
       words: 1866
      flesch: 56
     summary: Floristan U, Feltes RA, Sendagorta E, et al. Subacute cutaneous lupus erythematosus induced by capecitabine. Novak GV, Marques M, Balbi V, et al. Anti- RO/SSA and anti-La/SSB antibodies:
    keywords: capecitabine; lupus; scle; sle
       cache: skin-47.pdf
  plain text: skin-47.txt

        item: #1001 of 1356
          id: skin-470
      author: Xu, Shuai; Wang, Stacy; Estes, Esther
       title: The Hidden Impact of Seborrheic Keratoses: Analysis of a Psychometric Survey of an Ethnically Diverse Cohort of U.S. Adults
        date: 2018-12-17
       words: 1874
      flesch: 55
     summary: Among survey participants who had visited a dermatologist, the most common reasons for doing so were routine skin cancer check (66%); removal of noncancerous skin growths, marks, or spots (52%); and to have a suspicious mole or spot checked (47%) Coping Strategies for SKs z A majority of survey participants (n=591; 84%) reported attempts to mask or modify their SKs — Makeup application was the most common strategy (53%; 65% of females and 8% of males), followed by use of over-the-counter products, such as wart removers or anti- aging products (44%), and avoidance of sun exposure (27%) (Figure 3) Figure 3.
    keywords: face; participants; sks; survey; treatment
       cache: skin-470.pdf
  plain text: skin-470.txt

        item: #1002 of 1356
          id: skin-471
      author: Callender, Valerie; Frankel, Ellen; Weiss, Jonathan; Werschler, William; Powala, Christopher; Beger, Brian; Estes, Esther; Shanler, Stuart
       title: Open-Label Study of A-101, a 40% Hydrogen Peroxide Topical Solution, in Patients With Seborrheic Keratosis
        date: 2018-12-17
       words: 1072
      flesch: 51
     summary: The main objective of the current study was to evaluate the safety of A-101 40 after completion of up to 4 treatments per lesion of 4 target SKs on the trunk, extremities, and face MATERIALS AND METHODS Patients and Study Design z Multicenter, open-label study (NCT02667288) z Eligible patients: aged ≥ 18 years with 4 eligible SKs on the trunk, extremities, and face, identified by the study investigator z Eligible lesions were stable, typical SKs, measuring 5-15 mm in length and width, > 0-2 mm in thickness, with a Physician Lesion Assessment (PLA)™ grade of ≥ 2 (Table 1)2 — Target SKs could not be located on the eyelid, within 5 mm of the orbital rim, inside the orbital rim, in an intertriginous area, or pedunculated z All SKs were treated on Day 1; on Days 22, 43, and 64, any previously treated SKs with a PLA score > 0 were retreated z Patients were followed for 84 days after the fourth treatment visit (total 148 days) Stinging 0% 0% 0% 100% Erosion 0% 0% 0% 100% Ulceration 0% 0% 0% 100% Vesicles/bullae 0% 0% 0% 100% Figure 1.
    keywords: patients; sks; treatment
       cache: skin-471.pdf
  plain text: skin-471.txt

        item: #1003 of 1356
          id: skin-472
      author: Brickman, Chaim M; Behar, Vered; Zelinger, Galit; Becker, Oren M
       title: VDA-1102 : A Novel Well-Tolerated Treatment For Actinic Keratosis
        date: 2018-12-17
       words: 609
      flesch: 53
     summary: High HK2 levels in human AK and SCC cells High HK2 levels in skin SCC vs. Low HK2 levels in normal skin Efficacy on UVB-damaged Skin of Hairless SKH-1 Mice Day 50 HK1 & HK2 Levels in UBV-damaged Mouse Skin 4-8 AK lesions (Grades 1-2) in a 25cm2 area on face or scalp Local Skin Reactions Pharmacokinetic analysis for the parent compound (VDA-1102) and for its major metabolite demonstrated no systemic exposure of either. Immunohistochemistry of SK208 and SK805 human tissue microarrays from US Biomax; Right panel: Western blot; HT 297.T human AK cells; A431 human skin SCC cells.
    keywords: blq; hk2; vda-1102
       cache: skin-472.pdf
  plain text: skin-472.txt

        item: #1004 of 1356
          id: skin-473
      author: Migden, Michael R; Berkin, Carola; Chang, Anne Lynn; al., Et
       title: Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma
        date: 2018-12-17
       words: 2171
      flesch: 46
     summary: Group 3 – Adult patients with metastatic (nodal and/or distant) CSCC Cemiplimab 3 mg/kg Q2W IV, for up to 96 weeks (retreatment optional for patients with disease progression during follow-up) Cemiplimab 350 mg Q3W IV, for up to 54 weeks Tumor imaging every 8 weeks for the assessment of efficacy (confirmatory scans performed no sooner than 4 weeks following initial documentation of tumor response) Conclusions • The results of the prespecified interim analysis of patients with locally advanced CSCC from this Phase 2 prospective study show that treatment with cemiplimab 3 mg/kg Q2W is associated with substantial activity and durable responses.
    keywords: cemiplimab; cscc; disease; patients; response; study; treatment
       cache: skin-473.pdf
  plain text: skin-473.txt

        item: #1005 of 1356
          id: skin-474
      author: Owonikoko, Taofeek K; Papadopoulos, Kyriakos P; Johnson, Melissa L; al., Et
       title: Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data
        date: 2018-12-17
       words: 2152
      flesch: 55
     summary: • Primary analysis of the Phase 2 study (NCT02760498) provides further evidence of substantial antitumor activity and durable response with cemiplimab treatment in advanced CSCC. Furthermore, these results showed that CSCC tumors, whether distantly metastatic or locally and/or regionally advanced, are responsive to cemiplimab.
    keywords: cemiplimab; cscc; disease; patients; response; treatment; usa
       cache: skin-474.pdf
  plain text: skin-474.txt

        item: #1006 of 1356
          id: skin-475
      author: Rischin, Danny; Migden, Michael R; Chang, Anne Lynn S; al., Et
       title: Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma
        date: 2018-12-17
       words: 2428
      flesch: 54
     summary: Background • Cutaneous squamous cell carcinoma (CSCC) is rivalled in incidence only by basal cell carcinoma as the most common cancer in the US.1 • Risk factors for CSCC include chronic sun exposure, advanced age, ultraviolet radiation-sensitive skin, and immunosuppression.2 • More than 95% of CSCC patients are cured with surgery; however, due to the very high incidence of the disease, an estimated 3,932–8,791 patients died from CSCC in 2012 in the US.3,4 • There is no approved systemic therapy for patients with advanced CSCC (locally advanced CSCC that is no longer amenable to surgery or radiation therapy, and metastatic CSCC). Methods • Patients with metastatic CSCC from Group 1 of the Phase 2, non-randomized, global, pivotal trial of cemiplimab in patients with advanced CSCC are included in this analysis (Figure 1).
    keywords: cemiplimab; cscc; disease; lesion; patients; response; target; teaes; treatment
       cache: skin-475.pdf
  plain text: skin-475.txt

        item: #1007 of 1356
          id: skin-476
      author: Lateef, Farooq; Lateef, Hanna
       title: Treatment of Palmo-plantar Keratoderma of Unna-Thost with Tazarotene Foam 0.1%
        date: 2018-12-17
       words: 990
      flesch: 55
     summary: A diagnosis of Palmoplantar Keratoderma of Unna Thost was made. Tazarotene foam, with its decreased absorption into the bloodstream8, proved to be a good choice.
    keywords: foam; keratoderma; palmoplantar; patient; tazarotene
       cache: skin-476.pdf
  plain text: skin-476.txt

        item: #1008 of 1356
          id: skin-477
      author: Teeple, A; Muser, E
       title: Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis
        date: 2018-12-17
       words: 1819
      flesch: 52
     summary: Response rates were assumed to be unchanged from week 16 and extrapolated to week 52; however, this may under represent guselkumab PASI 90 results, given that response rates increased past week 16 in VOYAGE 1. ■ A sensitivity analysis was conducted for patients achieving a PASI 75 response at 48 weeks. ■ Certolizumab pegol is Monoclonal antibody to TNF-Alpha admistered by subcutaneous injection that is indicated for the treatment of moderate to severe plaque psoriasis ■ Efficacy data through week 16 from clinical trials for both products are available (VOYAGE 1 and VOYAGE 2 for guselkumab
    keywords: pasi; response; weeks
       cache: skin-477.pdf
  plain text: skin-477.txt

        item: #1009 of 1356
          id: skin-478
      author: Lucas, J; Teeple, A; Hetherington, J; Muser, E
       title: Assessing the Relationship Between Disease Severity and Patient-Reported Outcomes in Psoriasis Patients in the US
        date: 2018-12-17
       words: 851
      flesch: 58
     summary: ■ Of the mild patients 47% were prescribed a biologic at the time of completing the survey vs. 42.9% of moderate patients, and 67.7% of severe patients. Kruskal-Wallis, Fisher’s Exact and Student’s T-Test where used where appropriate. Results ■ Of the 261 patients included; 132 had mild disease, 98 had moderate disease and 31 had severe disease activity at the time of completing the survey.
    keywords: disease; patients
       cache: skin-478.pdf
  plain text: skin-478.txt

        item: #1010 of 1356
          id: skin-479
      author: Cai, Q; Teeple, A; Wu, B; al., Et
       title: Economic Burden of Comorbid Anxiety and Depression among Patients with Moderate to Severe Psoriasis
        date: 2018-12-17
       words: 1768
      flesch: 40
     summary: Three Most Frequently Occurring Comorbid Conditions and Concomitant Medications used Among Study Patients 39.2% 45.1% 44.4% 54.9% 46.5% 35.9% 33.8% 32.7% 30.3% 30.0% 31.0% 17.7% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% Psoriatic Arthritis Hypertension Hyperlipidemia Opioids Respiratory Medication Anticholinergics Matched PsO with Treated Anxiety/Depression Matched PsO without Treated Anxiety/Depression §All p<0.01 Clinical Characteristics ■ Compared with controls, PsO patients with treated anxiety/depression had significantly higher overall burden of comorbidity, as measured by the Quan-Charlson Comorbidity index (all p<0.01). ■ Compared with matched PsO controls, PsO patients with both treated anxiety and depression had $14,539 higher mean costs, PsO patients with treated depression only had $10,262 higher mean costs and PsO patients with treated anxiety only had $7,052 higher mean costs (all p<.01; Figure 3).
    keywords: anxiety; costs; depression; patients; pso
       cache: skin-479.pdf
  plain text: skin-479.txt

        item: #1011 of 1356
          id: skin-481
      author: Cai, Q; Teeple, A; Wu, B; Shrivastava, S; Muser, E
       title: Trends in Prevalence of Psychiatric Comorbidities among Patients with Moderate to Severe Psoriasis
        date: 2018-12-17
       words: 1748
      flesch: 46
     summary: ■ Similarly, the prevalence of treated anxiety and/or depression among moderate to severe PsO patients increased from 14.5% in 2014 to 15.9% in 2016, as compared with 9.0% (p<0.001) in 2014 and 9.7% (p<0.001) in 2016 for matched controls. — The prevalence of treated MDD among moderate to severe PsO patients increased from 3.4% in 2014 to 8.6% in 2016, as compared with 2.0% (p<0.001) in 2014 and 2.9% (p<0.001) in 2016 for matched controls. ■ Non-PsO (control) cohort: Members with no diagnosis of PsO, or disorders similar to PsO, were randomly selected from 2014-2016 and matched to PsO patients in a 1:1 ratio on age, gender, health plan type and region.
    keywords: patients; pso
       cache: skin-481.pdf
  plain text: skin-481.txt

        item: #1012 of 1356
          id: skin-482
      author: Bhatia, Neal; Rubenstein, David; Tallman, Anna M; Lee, James
       title: Patient-reported outcomes in subjects with plaque psoriasis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study
        date: 2018-12-17
       words: 2201
      flesch: 50
     summary: [vehicle BID] and 5% [vehicle QD]) and were maintained for 4 weeks after the end of study treatment3 Subject Impressions ■ At baseline, 88% of subjects rated their psoriasis symptoms as moderate or severe across all treatment groups: 43–61% rated as moderate and 28–44% rated as severe ■ At Week 12, a greater proportion of subjects in the tapinarof cream groups (82–88% in the 1% groups and 77–80% in the 0.5% groups) rated the overall severity of their psoriasis symptoms as ‘very/moderately improved’ compared with 35–48% in the vehicle groups (Figure 2a) Figure 2a. Safety Overview and Most Common TEAEs (Occurring in ≥5% of Subjects in Any Group) Preferred term, n (%)
    keywords: bid; psoriasis; subjects; tapinarof
       cache: skin-482.pdf
  plain text: skin-482.txt

        item: #1013 of 1356
          id: skin-483
      author: Augustin, M; Wegtowska, J; Lebwohl, M; Paul, C; Piguet, V; Sofen, H; Blauvelt, A; Peterson, L; Arendt, C; Rolleri, R
       title: Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study
        date: 2018-12-17
       words: 2407
      flesch: 62
     summary: Clinical response in ETN PASI 50 non-responders following switch to CZP A) PASI 75 SUMMARY These data show that CZP may be an e�ective treatment option in patients who require treatment switch from etanercept. Author Disclosures: MA: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GlaxoSmithKline, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB Pharma, Xenoport; JW: Amgen, Celgene, Coherus, Dermira Inc., Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Pfizer, Regeneron, Sandoz, UCB Pharma; ML: Allergan, Aqua LEO Pharma, Promius.
    keywords: czp; pasi; week
       cache: skin-483.pdf
  plain text: skin-483.txt

        item: #1014 of 1356
          id: skin-484
      author: Augustin, M; Wegtowska, J; Lebwohl, M; Paul, C; Piguet, V; Sofen, H; Blauvelt, A; Peterson, L; al., Et
       title: Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
        date: 2018-12-17
       words: 1922
      flesch: 53
     summary: Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Biopepis, Sanofi, Takeda, UCB Pharma, Valeant, Xenoport; DT: AbbVie, Almiral, Amgen, Boehringer-Ingelheim, Celgene, Dignity, Dr. Reddy, Galapagos, GlaxoSmithKline, Janssen, LEO Pharma, Morphosis, MSD, Eli Lilly, Novartis, Pfizer, Sandoz-Hexal, Regeneron/ Sanofi, UCB Pharma; CL: AbbVie, Actavis, Amgen, Boehringer Ingelheim Pharma, Celgene, Coherus, Corrona, Dermira Inc., Eli Lilly, Galderma, Glenmark, Janssen, LEO Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Stiefel, Wyeth, UCB Pharma, Vitae. Author Disclosures: MA: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GlaxoSmithKline, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB Pharma, Xenoport; JW: Amgen, Celgene, Coherus, Dermira Inc., Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Pfizer, Regeneron, Sandoz, UCB Pharma; ML: Allergan, Aqua LEO Pharma, Promius.
    keywords: czp; pasi; patients; pharma; q2w; week
       cache: skin-484.pdf
  plain text: skin-484.txt

        item: #1015 of 1356
          id: skin-485
      author: Sheahan, A; Lee, E; Pisenti, L; Yassine, M; Suruki, R
       title: Frequency of Inadequate Response to Treatment Among Psoriasis Patients on First-Line Biologics
        date: 2018-12-17
       words: 1277
      flesch: 50
     summary: CONCLUSIONS • Inadequate response in first line PSO biologic treatment is common, with non-switch discontinuation being the most frequent type. Ustekinumab (n=1719) Golimumab (n=102) Apremilast (n=2013) Secukinumab (n=117) Infliximab (n=330) Adalimumab (n=5942) 42.4 6.7 23.6 27.3 37.6 19.7 29.1 5.1 33.3 44.1 12.7 24.2 10.8 18.0 41.2 23.8 10.7 35.6 24.3 30.5 62.1 29.7 46.9 10.9 35.4 49.8 Non-IR Above-label dosing Switch to another biologicNon-switch discontinuation Add-on treatment 5.5 3.9 5.9 5.6 8.5 9.0 6.9 2.9 3.5 12.50.2 Not persistent 30% Persistent 70% Not persistent 47% Persistent 53% 3 months after switch 6 months after switch 90 80 70 60 50 40 30 20 10 100 0 % P at ie n ts Overall 15.4 63.9 BL Biologic monotherapy BL Concomitant systemic corticosteroid BL Concomitant immunosuppressive Biologic Immunosuppressive Systemic corticosteroid 20.7 15.6 19.0 65.4 3.9 11.8 84.3 0.9 47.4 51.8 Treatment at baseline • Demographics and characteristics, including the distribution of index biologics, were similar in patients who did and did not experience IR (Table 1).
    keywords: biologic; patients; switch
       cache: skin-485.pdf
  plain text: skin-485.txt

        item: #1016 of 1356
          id: skin-486
      author: Lebwohl, M; Siegel, M; Shankle, L; Pisenti, L; Yassine, M; Van Vorhees, S
       title: A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis
        date: 2018-12-17
       words: 1702
      flesch: 56
     summary: Do you currently have..., % respondents No or very little PSO 14.8 25.0 2.2 Only a few patches (1–2% BSA) 21.3 25.0 11.0 Scattered patches (3–4% BSA) 29.5 37.5 64.8 Scattered patches (5–10% BSA) 21.3 0 While preparing for pregnancy, where do you/did you get your information about family planning as it relates to your psoriasis and/or psoriatic arthritis?, % respondents Online source (i.e. WebMD) 45.9 12.5 80.2 National Psoriasis Foundation 42.6 50.0 78.0 Internet forums/ chat rooms 34.4 50.0 49.5 OB/GYN or Midwife 36.1 25.0 52.7 HCP for psoriatic disease 55.7 25.0 28.6 Family and/or friends 6.6 25.0 37.4 What type(s) of additional information do you/did you want related to family planning and psoriasis and/or psoriatic arthritis?, % respondents How to manage a flare during pregnancy 60.7 62.5 62.6 Safety of medications during pregnancy 77.0 50.0 38.5 How the disease could affect the developing fetus 41.0 62.5 64.8 How disease is genetically passed/relative risk 57.4 25.0 51.6 What other resources would be most helpful to you related to psoriatic disease and family planning?, % respondents Internet resources that specifically address pregnancy and psoriatic disease 71.7 62.5 47.2 Lactation resources 43.3 50.0 65.2 Mental health resources 38.3 37.5 39.3 Patient support groups 35.0 37.5 53.9 The 3 most selected answers for each question by each subgroup are highlighted in bold.
    keywords: family; hcp; patients; pso; treatment
       cache: skin-486.pdf
  plain text: skin-486.txt

        item: #1017 of 1356
          id: skin-487
      author: Griffiths, CEM; Papp, KA; Song, M; Randazzo, B; Li, S; Shen, YK; Han, C; Blauvelt, A
       title: Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis
        date: 2018-12-17
       words: 1761
      flesch: 59
     summary: Proportion of Patients Who Achieved IGA Score of 0 Through Week 156, Primary Analysis† Guselkumab PBO→Guselkumab Guselkumab* Adalimumab→Guselkumab 0 4 8 12 16 20 24 28 32 36 40 44 48 52 60 68 76 84 92 100 108 116 124 132 140 148 156 Weeks P e rc e n ta g e o f P a ti e n ts Guselkumab n= PBO→Gus n= Guselkumab* n= Ada→Gus n= 0 20 40 60 80 100 55.6 55.6 53.1 53.553.6 334 269 448 429468 174 329 165 329 278 275 56.4 27.3 50.5 †NRI through Week 48, then TFR beyond Week 48. Proportion of Patients Who Achieved PASI 75 Response Through Week 156, Primary Analysis† Guselkumab PBO→Guselkumab Guselkumab* Adalimumab→Guselkumab 0 4 8 12 16 20 24 28 32 36 40 44 48 52 60 68 76 84 92 100 108 116 124 132 140 148 156 Weeks P e rc e n ta g e o f P a ti e n ts Guselkumab n= PBO→Gus n= Guselkumab* n= Ada→Gus n= 0 20 40 60 80 100 94.9 95.8 95.8 93.7 72.4 96.4 87.8 93.8 334 269 448 431468 174 329 165 329 279 275 †NRI through Week 48, then TFR beyond Week 48.
    keywords: guselkumab; week
       cache: skin-487.pdf
  plain text: skin-487.txt

        item: #1018 of 1356
          id: skin-488
      author: Nyeland, Martin E; Becia, Lidia; Patel, Dharm S; Veverka, Karen A; Swensen, Andrine R
       title: Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses
        date: 2018-12-17
       words: 1464
      flesch: 59
     summary: topical treatment, yes 637 (85.1%) 122 (82.4%) Treatment period[weeks] Consumption per treatment period Pack cost # Units per Pack Unit Unit per pack Price per Unit Cal/BD foam 51.1% 4 117.1 g* $987.09 $1974.18 1 2 60 g 60 g x 2 60-120 g $16.45 per g Apremilast 21.6% 16 6570 mg** $1012.5 - 3939.71 27-60 10-30 mg 690- 1800 mg $2.19 per mg Data Source MAIC (Table 2) Approved FDA indication *4 pooled Cal/BD studies **FDA indication Analysource®, accessed April 2018 (third party provider of WAC pricing data) 
    keywords: cal; foam; treatment
       cache: skin-488.pdf
  plain text: skin-488.txt

        item: #1019 of 1356
          id: skin-489
      author: Papp, Kim A; Merola, Joseph F; Gottlieb, Alice B; al., Et
       title: Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response
        date: 2018-12-17
       words: 1886
      flesch: 7
     summary: By Week 12, in the three highest bimekizumab dose groups almost all patients had an absolute PASI <2 with the majority of patients at or near zero (Figure 3); PASI improvements were correlated with reductions in DLQI, with the majority of patients achieving a DLQI of 0 or 1 (no impact of psoriasis on disease-specific HRQoL) at Week 12 (Figure 3) All or nearly all patients with baseline DLQI ≥4 achieved MCID in DLQI at Week 12 in the top three bimekizumab dose groups; 3x MCID and 4x MCID were also achieved by a substantially greater percentage of bimekizumab patients with baseline DLQI ≥12 and ≥16, respectively, compared with placebo (Figure 4A). MCID in DLQI was achieved rapidly and differentiated from placebo after first dose across all bimekizumab groups (Figure 4B) BKZ 64 mg; n=33 BKZ 160 mg; n=37 BKZ 320 mg; n=37 BKZ 160 mg (320 mg LD); n=34 BKZ 480 mg; n=31 A) B) 79.6 53.6 64.3 52.5 0 20 40 60 80 100 ≤1 >1 – ≤3 >3 – ≤5 >5 DLQI of 0 or 1, % patients* B S A a ff ec te d by p so ri as is B) n=40 n=14 n=28 n=108 77.7 73.9 51.7 29.4 0 20 40 60 80 100 ≤1 >1 – ≤2 >2 – ≤5 >5 DLQI of 0 or 1, % patients* A bs ol ut e PA S I Absolute PASI in bimekizumab-treated patients BSA affected by psoriasis in bimekizumab-treated patients A) n=17 n=29 n=23 n=121 0 20 40 60 80 100 0 2 4 6 8 10 12 PA S I1 00 r es po ns e, % ( S E ) of p at ie nt s 28.2%** 27.9%*** 48.8%*** 60.0%*** 55.8%*** 0% Weeks BE ABLE 1: summary of key results • In this Phase 2b, double-blind, placebo-controlled study (NCT02905006), patients with moderate-to-severe plaque psoriasis were randomized (1:1:1:1:1:1) to receive bimekizumab 64 mg, 160 mg, 160 mg with 320 mg loading dose, 320 mg, 480 mg, or placebo every 4 weeks for 12 weeks; the primary objective was to evaluate the dose response of bimekizumab7 • There was a significant dose response for Psoriasis Area Severity Index (PASI)90 (P<0.0001) at Week 12.
    keywords: bkz; dlqi; mcid; patients; pharma; week
       cache: skin-489.pdf
  plain text: skin-489.txt

        item: #1020 of 1356
          id: skin-49
      author: Paniagua Gonzalez, Lizy M; Shimizu, Ikue
       title: Basal Cell Carcinoma with Adnexal Differentiation, a Rare Entity and Challenging Histopathology Presentation. Case Report
        date: 2017-11-13
       words: 1844
      flesch: 45
     summary: This histopathological presentation of basal cell carcinoma is uncommon and we sought to report the clinical and pathological features of this case. Basal cell carcinoma with adnexal differentiation is an uncommon histopathological presentation.
    keywords: adnexal; bcc; carcinoma; cells; differentiation
       cache: skin-49.pdf
  plain text: skin-49.txt

        item: #1021 of 1356
          id: skin-490
      author: Feldman, Steven R; Schreiber, Rhonda; Crane, Kaytiana; Comito, Madelyn
       title: Patient Perception of Vehicle and How This Influences Adherence to Topical Treatment Regimens
        date: 2018-12-17
       words: 1286
      flesch: 60
     summary: EASIER TO USE CALCIPOTRIENE 0.005% FOAM 167 (25) 108 (16) 80 (12) 39 (6) 7 (1) VEHICLE FOAM 70 (11) 59 (9) 51 (8) 19 (3) 5 (1) CONTINUE ADLs IMMEDIATELY AFTER APPLYING CALCIPOTRIENE 0.005% FOAM 178 (27) 87 This presentation was sponsored by Mayne Pharma • Two identically designed, 8-week, blinded, multicenter, parallel group clinical trials were conducted with 659 subjects with mild to moderate plaque-type psoriasis randomized in a 2:1 ratio to topical calcipotriene foam, 0.005%, (n=437) or vehicle foam (n=222) • Subjects ≥ 12 years with mild to moderate plaque psoriasis involving 2-20% of body surface areas (BSA)
    keywords: calcipotriene; foam; vehicle
       cache: skin-490.pdf
  plain text: skin-490.txt

        item: #1022 of 1356
          id: skin-491
      author: Travis, Skylar N; Zambito, Jeanette R
       title: Dermatoethics in the Selfie Era
        date: 2019-07-08
       words: 615
      flesch: 63
     summary: The National Society for Cutaneous Medicine 284 COMPELLING COMMENTS Dermatoethics in the “Selfie” Era Jeanette R Zambito, M.S. Ed1, Skylar N Travis, MD1 1University of Rochester School of Medicine and Dentistry “Please”, her mother implored. Corresponding Author: Skylar N Travis, MD Dermatology Resident, PGY4 University of Rochester Medical Center Skylar_travis@urmc.rochester.edu References: 1.
    keywords: jenner; kylie
       cache: skin-491.pdf
  plain text: skin-491.txt

        item: #1023 of 1356
          id: skin-492
      author: Dickman, Jeffrey; Noparstak, Michael; Nathoo, Rajiv
       title: Dermoscopy of Inflammatory Linear Verrucous Epidermal Nevus: Brown and Red Glomerular Structures Over a White Background as an Identifying Feature
        date: 2019-09-13
       words: 1008
      flesch: 53
     summary: Inflammatory linear verrucous epidermal nevus: a case report and short review of the literature. Cutis. Carbotti M, Coppola R, Graziano A, Verona Rinati M, Paolilli FL, Zanframundo S, Panasiti V. Dermoscopy of verrucous epidermal nevus: large brown circles as a novel feature for diagnosis.
    keywords: epidermal; ilven; linear; structures
       cache: skin-492.pdf
  plain text: skin-492.txt

        item: #1024 of 1356
          id: skin-494
      author: Bellew, Jonathan; Taylor, Chad; Daulat, Jaldeep; Mackey, Vernon
       title: Isotretinoin induced nail fold pyogenic granuloma resolution with combination therapy: A case report and review of the literature
        date: 2019-07-08
       words: 1412
      flesch: 40
     summary: Pyogenic granulomas improving two weeks following discontinuation of isotretinoin therapy. Other associations include fluctuating hormonal states such as during pregnancy or with oral contraceptive treatment.[1] We present a case of eruptive pyogenic granulomas of the peri-ungal fingers in an adolescent male undergoing systemic retinoid therapy for severe recalcitrant nodulocystic acne, highlighting this important but rarely reported adverse effect of systemic isotretinoin therapy.
    keywords: granulomas; isotretinoin; pyogenic; therapy; treatment
       cache: skin-494.pdf
  plain text: skin-494.txt

        item: #1025 of 1356
          id: skin-495
      author: Cook-Bolden, Fran E; Weinkle, Susan H; Guenin, Eric; Blatt, Varsha
       title: Novel Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a Hispanic population
        date: 2018-12-17
       words: 899
      flesch: 52
     summary: -70% -60% -50% -40% -30% -20% -10% 0% Tretinoin 0.05% lotion (N=371) Vehicle (N=395) P e rc e n t ch an g e f ro m b as e lin e in m e an in fl am m at o ry le si o n s Baseline Week 4 Week 8 Week 12 *P=0.006 versus vehicle **P=0.001 versus vehicle * Treatment Related AEs reported by ≥1% patients Application site pain 7 (2.0%) 0
    keywords: vehicle; week
       cache: skin-495.pdf
  plain text: skin-495.txt

        item: #1026 of 1356
          id: skin-497
      author: Maarouf, Melody; Kromenacker, Bryan; Brucks, Eric; Shi, Vivian
       title: Expedited Resolution of 5-Fluorouracil-Induced Erythema and Barrier Dysfunction with White Petrolatum
        date: 2019-07-08
       words: 1257
      flesch: 45
     summary: Following finalization of AK treatment, twice-daily application of topical Clobetasol proprionate 0.05% for 4 days did not show significant reduction of local skin responses, pain, or pruritus. The National Society for Cutaneous Medicine 282 White petrolatum is an effective therapeutic agent in reducing erythema and expediting skin barrier recovery following topical 5-FU.
    keywords: erythema; petrolatum; skin; treatment
       cache: skin-497.pdf
  plain text: skin-497.txt

        item: #1027 of 1356
          id: skin-498
      author: Armstrong, April; Agada, Noah; Xu, Wen; Gallo, Gaia
       title: An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab
        date: 2018-12-17
       words: 2462
      flesch: 74
     summary: N = 7 9 1 2 3 2 8 4 2 1 3 5 6 8 9 5 8 7 1 P Y = 1 8 0 5 3 5 7 8 4 3 1 2 ,0 6 2 1 5 ,2 1 3 2 0 6 2 5 6 4 6 4 0 3 3 Abbreviations AC=active comparator; CI=confidence interval; DB=double-blind; EP=optional extension period after Week 24 endpoint where patients received 80 mg IXE Q4W up to Wk 60; ETN=50 mg etanercept twice weekly; FAE=fumaric acid esters 105-mg starting dose followed by 215 mg given orally 1 to 3 times per day; IR=incidence rate; IXE=ixekizumab; IXE Q2W=80 mg ixekizumab every 2 weeks; IXE Q4W=80 mg ixekizumab every 4 weeks; IXE Q12W=80 mg ixekizumab every 12 weeks; LTE=long-term extension; MACE=major adverse cerebro-cardiovascular events; MTX=methotrexate 7.5-mg starting dose up to 30 mg given orally once a week; =number of patients; n=number of patients who received ixekizumab and included in the September 2017 lock for integrated safety analyses; OL=open-label; PAC=placebo-controlled and active comparator; PBO=placebo; PsO=psoriasis; Pts=patients; PY=patient-years; R=randomized;
    keywords: e p
       cache: skin-498.pdf
  plain text: skin-498.txt

        item: #1028 of 1356
          id: skin-499
      author: Wasel, Norman; Dutronc, Yves; Schinzel, Birgit; Lacour, Jean-Philippe
       title: Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients With Moderate-to-Severe Plaque Psoriasis: 52-Week Data From the IXORA-S Trial
        date: 2018-12-17
       words: 1850
      flesch: 47
     summary: Improvement of nail psoriasis was observed in both treatment groups Adjusted Change From Baseline in NAPSI Total Score Was Significantly Greater as Early as Week 8 for Ixekizumab Versus Ustekinumab and Was Sustained Through Week 52, ITT Population With Baseline Fingernail Psoriasis, mBOCF * p<.05; ‡ p<.0001 IXE versus UST based on ANOVA with treatment, weight, geographic region, and baseline NAPSI score as factors ANOVA=analysis of covariance; ITT=Intent-to-Treat; IXE Q2W/Q4W=ixekizumab 80 mg every 2 weeks to Week 12 followed by ixekizumab 80 mg every 4 weeks; LSM=least squares mean; mBOCF; modified baseline observation carried forward; NAPSI=Nail Psoriasis Severity Index; UST=45 mg ustekinumab for patients ≤100 kg and 90 mg ustekinumab for patients >100 kg at Weeks 0 and 4 and every 12 weeks thereafter per label  Progressively more patients achieved complete resolution (NAPSI = 0) of nail psoriasis in both treatment groups * p<.05; † p≤.001; ‡ p<.0001 IXE versus UST based on Fisher's exact test for treatment comparison ITT=Intent-to-Treat; IXE Q2W/Q4W=ixekizumab 80 mg every 2 weeks to Week 12 followed by ixekizumab 80 mg every 4 weeks; NAPSI=Nail Psoriasis Severity Index; NRI=non-responder imputation; UST=45 mg ustekinumab for patients ≤100 kg and 90 mg ustekinumab for patients >100 kg at Weeks 0 and 4 and every 12 weeks thereafter per label Patients Who Achieve Low PASI Scores at Week 52 May Still Experience Significant Nail Involvement at Week 52, ITT Population With Baseline Fingernail Psoriasis
    keywords: psoriasis; weeks
       cache: skin-499.pdf
  plain text: skin-499.txt

        item: #1029 of 1356
          id: skin-50
      author: none
       title: Linear Psoriasis: A Case Report of a 71-Year-Old Female
        date: 2018-01-02
       words: 1403
      flesch: 53
     summary: Linear psoriasis is a rare variant of psoriasis of unknown etiology. Together with the clinical presentation, a diagnosis of linear psoriasis was favored.
    keywords: case; ilven; linear; psoriasis; skin
       cache: skin-50.pdf
  plain text: skin-50.txt

        item: #1030 of 1356
          id: skin-500
      author: Papp, Kim A; Blauvelt, Andrew; Sullivan, John; al., Et
       title: Efficacy of Ixekizumab in Patients Previously Treated with IL-17 Inhibitors
        date: 2018-12-17
       words: 1202
      flesch: 41
     summary: CI=confidence interval; IL-17=interleukin-17; ITT=Intent-to-Treat; IXE Q2W=80 mg ixekizumab every 2 weeks; IXE Q4W=80 mg ixekizumab every 4 weeks; NRI=non-responder imputation; PASI=Psoriasis Area and Severity Index n (%) IXE Q4W IXE Q2W Naïve (n=243) Experienced (n=67) Naïve (n=233) Experienced (n=73) Naïve (n=461) Cerebrocardiovascular events 2 (0.8) 1 (1.5) 2 (0.9) 0 9 (0.2) 0 Inflammatory bowel disease 1 (0.4) 0 1 (0.4) 0 3 (0.7) 1 (0.7) Malignancies 2 (0.8) 0 5 (2.1) 1 (1.4) 0 2 (1.4) IXE Q4W/ IXE Q2W Slide Number 1
    keywords: ixe; ixekizumab; weeks
       cache: skin-500.pdf
  plain text: skin-500.txt

        item: #1031 of 1356
          id: skin-502
      author: Glazer, Alex; Cockerell, Clay
       title: Histopathologic discordance in melanoma can have substantial impacts on patient care
        date: 2019-03-11
       words: 2034
      flesch: 44
     summary: In effect, the accuracy of melanoma staging to estimate metastatic risk is critical to subsequent care, neither under- treating or over-treating the patient based on their tumor. As recognized by AJCC, melanoma staging, just as it has in the past, will continue to change as contemporary data supports additional prognostic features.
    keywords: cases; melanoma; patients; stage; staging
       cache: skin-502.pdf
  plain text: skin-502.txt

        item: #1032 of 1356
          id: skin-503
      author: Smith, Abigail; Elewski, Boni
       title: How to Manage Onychomycosis
        date: 2019-01-09
       words: 2462
      flesch: 56
     summary: Topical treatment also has a role in improving efficacy and maintaining response to systemic treatment. Topical treatment may also reduce the total amount of antifungal agent required.
    keywords: antifungals; efinaconazole; onychomycosis; patients; terbinafine; treatment
       cache: skin-503.pdf
  plain text: skin-503.txt

        item: #1033 of 1356
          id: skin-504
      author: Yale, Katerina Lynn; Juhasz, Margit; Atanaskova Mesinkovska, Natasha
       title: Treatment of Brachioradial Pruritus: A Systematic Review
        date: 2019-05-03
       words: 6788
      flesch: 54
     summary: Further high-quality studies on BRP treatments would help elucidate clear management for this disorder. After removing duplicate data (Pinto et al./Waccholz et al. and Pereira et al./Stienke et al.), 399 patients with BRP were included.4,9–11 Given that most data on BRP treatment comes from case series and reports, the overall quality of the evidence reviewed is low (Table 1-4).
    keywords: arm; brachioradial; brp; capsaicin; case; dermatol; gabapentin; patients; pruritus; report; study; treatment
       cache: skin-504.pdf
  plain text: skin-504.txt

        item: #1034 of 1356
          id: skin-506
      author: Lowther, Christopher; Fiddler, Troy; Whitcroft, Ian A; Sapp, Juanita; Marks, Etan; Cockerell, Clay
       title: 61-Year-Old White Female with a Non-Healing Ulcerated Ankle Mass
        date: 2019-09-13
       words: 1230
      flesch: 59
     summary: The majority of patients with Merkel cell carcinoma are 70 years or older with an increased incidence in renal transplant patients, chronic lymphocytic leukemia and HIV.1 Polyomavirus is associated with up to 80% of tumors.4 The primary lesion of Merkel cell carcinoma is often absent of distinctive clinical characteristics and is rarely suspected at the time of biopsy. Pathologic nodal evaluation approves prognostic accuracy and Merkel cell carcinoma; J Amer Acad Derm. 2010; 63(5): 751 – 761.
    keywords: carcinoma; cell; merkel; patients; skin
       cache: skin-506.pdf
  plain text: skin-506.txt

        item: #1035 of 1356
          id: skin-508
      author: Marks, Etan; Persad, Leah; Cockerell, Clay
       title: Review of Instructive Cases from the Zola Cooper and Lee T. Nesbitt Seminar
        date: 2019-01-09
       words: 4018
      flesch: 47
     summary: In this setting, there is a wide range of differential diagnoses when occurring in an adult including Merkel cell carcinoma, metastatic small cell carcinoma of the lung, lymphoma and small cell melanoma. Involving the superficial dermis, there were a few scattered interstitial eosinophils, neutrophils, and extravasated red blood cells (Figure 14).
    keywords: case; cd8; cell; copyright; cutaneous; diagnosis; figure; history; issue; lymphoma; skin; volume
       cache: skin-508.pdf
  plain text: skin-508.txt

        item: #1036 of 1356
          id: skin-509
      author: Bice, Kristen; Hood, Channing; Almukhtar, Rawaa; Gerdes, Michelle; Martin, Pamela; Lee, Brian
       title: Pemphigus Vulgaris Following Influenza: A Case Report
        date: 2019-12-02
       words: 1659
      flesch: 48
     summary: There have been reports in the literature of pemphigus being induced by the influenza vaccine10,11 and a report of mucocutaneous pemphigus occurring after life-threatening H1N1 infection.12 Taken together with the present case, we propose that influenza virus may be another potential viral trigger for pemphigus vulgaris. The association between viruses may be causal, may be due to molecular mimicry of viral and host proteins, or may be due to exposure of previously hidden host proteins after virus-induced tissue damage.3 We report a 17-year-old male who presented with a case of mucosal-predominant pemphigus vulgaris temporally associated with influenza virus infection.
    keywords: case; influenza; md1; negative; pemphigus; skin; vulgaris
       cache: skin-509.pdf
  plain text: skin-509.txt

        item: #1037 of 1356
          id: skin-51
      author: Amin, Mina; Hashim, Peter
       title: Steatocystoma Multiplex: Case Report and Review of Treatment
        date: 2018-01-02
       words: 1566
      flesch: 54
     summary: Cyst removal by incision and drainage was followed by (A) no further treatment, (B) electrodessication, or (C) tricholoroacetic acid treatment, respectively. Multiple soft cysts on the neck and chest.
    keywords: cysts; lesions; multiplex; steatocystoma; treatment
       cache: skin-51.pdf
  plain text: skin-51.txt

        item: #1038 of 1356
          id: skin-510
      author: Simmons, Brian James; Hoyt, Brian S; Linos, Konstantinos; Yan, Shaofeng; Zug, Kathryn A
       title: Crospovidone Induced Vasculopathy of the Skin
        date: 2019-09-13
       words: 777
      flesch: 51
     summary: Given the critical role that dermatologists play in the workup of skin signs of drug abuse, it is important that providers recognize this uncommon and likely underreported complication of drug abuse. A 46-year-old man with a past medical history of intravenous drug use (IVDU), alcohol abuse and chronic hepatitis C presented with new onset left hand swelling, redness and tenderness for 4 days.
    keywords: crospovidone; drug; red; skin
       cache: skin-510.pdf
  plain text: skin-510.txt

        item: #1039 of 1356
          id: skin-511
      author: Sequeira, Andrew Jose; SEQUEIRA, MARIO Jose
       title: Long Term Follow Up of Cutaneous Sinus Histiocytosis (Rosai-Dorfman Disease)
        date: 2019-09-13
       words: 1068
      flesch: 45
     summary: Various treatments with varying success have been attempted for cutaneous lesions including: cryotherapy, carbon dioxide laser, cortico-steroids (topically, orally and intralesionally), surgical excision, radiotherapy, dapsone, acitretin, imatinib and thalidomide.8 A conservative treatment approach is often appropriate.9 In the current case new lesions were treated with localized excisional biopsies successfully. Sinus histiocytosis with massive lymphadenopathy also known as Rosai- Dorfman disease was originally described in 1969.1
    keywords: cutaneous; disease; dorfman; rosai
       cache: skin-511.pdf
  plain text: skin-511.txt

        item: #1040 of 1356
          id: skin-512
      author: Shenoy, Adele; Kim, Carey; Gottlieb, Alice
       title: Pediatric Alopecia Areata in Three Siblings
        date: 2019-09-13
       words: 1534
      flesch: 57
     summary: Our case demonstrates the complex interplay between genetic and environmental factors in the development of alopecia areata within families. Given the patients’ concurrent presentation of erythema and scaling which resolved with griseofulvin, our patients likely had tinea capitis superimposed on alopecia areata.
    keywords: alopecia; areata; hair; loss
       cache: skin-512.pdf
  plain text: skin-512.txt

        item: #1041 of 1356
          id: skin-513
      author: Lerman, Irina; Sipprell, William H.; Scott, Glynis A.; Richardson, Christopher T.
       title: Iohexol-Induced Acute Generalized Exanthematous Pustulosis (AGEP): Case Report
        date: 2019-09-13
       words: 1625
      flesch: 37
     summary: The majority of AGEP cases are associated with antimicrobial medications, although other agents and etiologies have also been implicated. Findings were consistent with a pustular drug eruption / hypersensitivity reaction, also known as acute generalized exanthematous pustulosis (AGEP).2 Although less likely, pustular psoriasis was included in the histologic differential diagnosis.
    keywords: acute; agep; case; contrast; pustules; pustulosis
       cache: skin-513.pdf
  plain text: skin-513.txt

        item: #1042 of 1356
          id: skin-515
      author: Barrick, Carl; Chea, Emily; Gupta, Naeha; McClain, Richard; Purcell, Steven
       title: Sterile Neutrophilic Folliculitis with Vasculopathy in a Young Male Patient with Infective Endocarditis
        date: 2019-09-13
       words: 1095
      flesch: 24
     summary: Herein, we present a case of sterile neutrophilic folliculitis with vasculopathy in a 34-year-old male hospitalized for infective endocarditis. The histopathologic findings and negative cultures led to the final diagnosis of sterile neutrophilic folliculitis with perifollicular vasculopathy.
    keywords: extremities; folliculitis; neutrophilic; vasculopathy
       cache: skin-515.pdf
  plain text: skin-515.txt

        item: #1043 of 1356
          id: skin-516
      author: Brodell MD, Robert Thomas; Ferringer, Tammie
       title: Dermatopathology: An Exciting, Innovative, and Compelling Dermatology Subspecialty Worthy of Continued Consideration among Dermatology Residents
        date: 2019-07-08
       words: 1037
      flesch: 52
     summary: Though the number of fellowships has declined, pathology residents have continued to apply for dermatopathology fellowships at a strong rate. Jobs dried up for new graduates of dermatopathology programs as laboratories froze hiring to help maintain salaries of their physicians and staff.
    keywords: dermatology; dermatopathologists; dermatopathology
       cache: skin-516.pdf
  plain text: skin-516.txt

        item: #1044 of 1356
          id: skin-518
      author: Jones, Terry; Stuart, Iain
       title: Pharmacokinetics of Minocycline Foam FMX103 in Subjects With Moderate-to-Severe Facial Papulopustular Rosacea Under Maximum-Use Conditions: Results of a Phase 1 Study
        date: 2019-03-11
       words: 1619
      flesch: 60
     summary: Number of serious TEAEs 0 0 Subjects with any severe TEAE, n (%) Number of severe TEAEs 0 0 Subjects with any TEAE leading to discontinuation of study, n (%) Number of TEAEs leading to discontinuation 0 0 aArthralgia, headache. Study drug concentrations by time points in PK population, day 1 to day 14 Visit Time Point FMX103 1.5% (N=20) Mean (SD)
    keywords: day; dose; fmx103; hours; study
       cache: skin-518.pdf
  plain text: skin-518.txt

        item: #1045 of 1356
          id: skin-52
      author: Del Rosso, James
       title: Capsule Commentaries: Selected Oral Antifungal Drug-Drug Interactions with Itraconazole and Terbinafine
        date: 2018-04-30
       words: 900
      flesch: 48
     summary: 11 Commentary: When oral antifungal therapy is needed in a patient on an antidepressant that is metabolized by CYP 2D6, an alternative approach to antifungal therapy that is also expected to be effective and devoid of drug- drug interactions appears to be a prudent approach. 1-4 Commentary: If antifungal therapy is needed in a patient using a statin metabolized by CYP3A4, potential options are (1) topical antifungal therapy if appropriate for the infection being treated (2) use of a non-CYP3A4-inhibiting antifungal agent such as terbinafine or (3) temporary discontinuation of the statin therapy with the approval of the prescribing clinician.
    keywords: drug; interactions; itraconazole; terbinafine
       cache: skin-52.pdf
  plain text: skin-52.txt

        item: #1046 of 1356
          id: skin-520
      author: Draelos, Zoe D
       title: The Effect of an Anti-Inflammatory Botanical Cleanser/Night Mask Combination on Facial Redness Reduction
        date: 2019-03-11
       words: 1145
      flesch: 48
     summary: CONCLUSION The anti-inflammatory botanically based night time mask and cleanser provided excellent moisturization, minimized barrier damage and facial redness. OBJECTIVE The objective of this research was to examine the moisturizing and redness reducing effect of an anti-inflammatory botan- ical calm and repair night mask plus sulfate free foaming oil cleanser in subjects with mild to moderate facial redness.
    keywords: cleanser; mask
       cache: skin-520.pdf
  plain text: skin-520.txt

        item: #1047 of 1356
          id: skin-521
      author: Caserta, Franceso; Lenn, Jon; Hofland, Hans
       title: Variables Affecting Delivery of Glycopyrronium Tosylate Through Human Skin In Vitro
        date: 2019-03-11
       words: 1418
      flesch: 39
     summary: In vitro permeation models can be a powerful tool to gain insight into drug absorption (flux) profiles under varying conditions and to optimize clinical trial design3 Objective • To determine using in vitro skin penetration studies how GT delivery through human skin is impacted by varying conditions including occlusion, wash-off, and skin thickness Methods • Across all experiments: – Human skin was dermatomed to a thickness of approximately 0.5 mm and mounted into flow-through diffusion cells (MedFlux-HT®) – GT solution was applied at 10mg/cm2 and allowed to dry Occlusion • Human abdominal skin was obtained from 3 donors after abdominoplasty • Two methods of occlusion were used: 1) parafilm was pressed on the surface for the donor compartment, which leaves a small closed-off column of air above the skin; 2) saran wrap was pressed down on top of the surface of the skin • Non-occluded skin was used as control • These data underscore the importance of characterizing skin flux under clinical conditions and will inform future hyperhidrosis clinical trial designs with topical agents REFERENCES 1.
    keywords: donor; occlusion; skin
       cache: skin-521.pdf
  plain text: skin-521.txt

        item: #1048 of 1356
          id: skin-523
      author: Hren, Catherine; Tschen, Eduardo; Jones, Terry; al., et
       title: Safety of Hydrogen Peroxide Topical Solution, 40% (w/w) in Patients With Skin of Color and Seborrheic Keratoses: Pooled Analysis of Two Phase 3, Randomized, Double- Blind, Vehicle-Controlled, Parallel-Group Studies
        date: 2019-03-11
       words: 1480
      flesch: 38
     summary: We conducted a post hoc, pooled analysis of data from the two Phase 3 pivotal clinical trials to evaluate the safety and tolerability of HP40 treatment in patients with skin of color, defined as having Fitzpatrick Skin Types ≥IV MATERIALS AND METHODS Patients z This was a pooled, post hoc analysis of data from two Phase 3, multicenter, randomized, double-blind, vehicle-controlled studies (NCT02667236, NCT02667275) z Eligible patients were required to be ≥18 years of age and have 4 target
    keywords: hp40vehicle hp40vehicle; posttreatment; pretreatment visit; visit
       cache: skin-523.pdf
  plain text: skin-523.txt

        item: #1049 of 1356
          id: skin-524
      author: Dubois, Janet; Grande, Kimberly; Schnyder, Judith; al., et
       title: Assessing Patient Satisfaction With Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment of Seborrheic Keratoses on the Face, Neck, and Décolletage: Objectives and Design of the Phase 4, Open-Label SK-FAN Study
        date: 2019-03-11
       words: 2419
      flesch: 47
     summary: The Phase 4, open-label Seborrheic Keratoses of the Face, Neck and Décolletage (SK-FAN) study was designed to assess participants’ satisfaction following HP40 treatment of SKs located on these body regions OBJECTIVE z z A schematic of the study design is presented in Figure 1 and the detailed timing of key study procedures is summarized in Table 1 z During the study, HP40 is applied to all target lesions at visit 2, then again at visits 5 (day 15) and 7 (day 29) if target lesions meet the retreatment criterion (see “Investigational Product and Treatments” section) z Assessments of participant satisfaction with HP40 treatment take place during visits 2, 3, 6, 8, 10, and 11 (see “Subject Satisfaction Assessment”
    keywords: hp40; study; treatment; visit
       cache: skin-524.pdf
  plain text: skin-524.txt

        item: #1050 of 1356
          id: skin-525
      author: Kim, Hee; Hansen, Jes; Faurby, Mads; al., et
       title: Efficacy and Safety of Ingenol Mebutate in Patients With Actinic Keratosis on Face and Scalp: Subgroup Analysis of Two Vehicle-Controlled Trials According to Age (
        date: 2019-03-11
       words: 1733
      flesch: 67
     summary: (0.0) 0 Conclusions � There were no significant differences in rates of AK clearance between younger and older patients treated with ingenol mebutate gel 0.015% based on this post hoc analysis of Phase 3 studies of the face and scalp − Complete clearance rate: 45.1% (<65 y) vs 39.1% (≥65 y) − Partial clearance rate: 66.7% (<65 y) vs 60.9% (≥65 y) � Reduction from baseline in AK count was also similar for the 2 subgroups − Mean reduction: 76.0% (<65 y) vs 69.1% ( ≥65 y) − Median reduction: 85.7% (<65 y) vs 80.0% (≥65 y) � No differences between younger and older patients were observed in the severity and time course of resolution of LSRs � The frequency of AEs was numerically lower in those <65 y (31.8%) than in those ≥65 y (42.3%) � Ingenol mebutate gel 0.015% is an effective and safe treatment option for patients with AKs on the face and scalp, regardless of age References 1.
    keywords: gel; ingenol; patients; ≥65
       cache: skin-525.pdf
  plain text: skin-525.txt

        item: #1051 of 1356
          id: skin-526
      author: Owonikoko, Taofeek; Papadopoulos, Kyriakos; Johnson, Melissa; al., et
       title: Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data
        date: 2019-03-11
       words: 2361
      flesch: 52
     summary: Although CSCC has a surgical cure rate of >95%, an estimated 3,932–8,791 patients died from CSCC in 2012 in the United States (US).2,3 • Cemiplimab (REGN2810) is a high-affinity, highly potent human monoclonal antibody directed against programmed death-1 (PD-1).4,5 • Cemiplimab is the only Food and Drug Administration (FDA)-approved treatment for patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation in the US.6 • In the primary analysis (data cut-off October 2, 2017), by independent central review, of Phase 1 CSCC expansion cohorts, cemiplimab demonstrated encouraging efficacy results with acceptable safety profile in patients with advanced CSCC.5 • Here, we report longer follow-up data, per investigator assessment, from the CSCC expansion cohorts of the Phase 1 study (NCT02383212).
    keywords: cemiplimab; cscc; disease; lesion; metastatic; patients; response; treatment; usa
       cache: skin-526.pdf
  plain text: skin-526.txt

        item: #1052 of 1356
          id: skin-527
      author: Van Voorhees, Abby; Stein Gold, Linda; Lebwohl, Mark; al., et
       title: Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
        date: 2019-03-11
       words: 2314
      flesch: 64
     summary: Analyses were based on patients in the ITT population with baseline Scalp Itch NRS score • Demographic and baseline clinical characteristics were generally comparable between the PBO and APR treatment groups (Table 1).
    keywords: apr; itch; patients; pbo; psoriasis; scalp; week
       cache: skin-527.pdf
  plain text: skin-527.txt

        item: #1053 of 1356
          id: skin-528
      author: Hebert, Adelaide; Glaab, Debbie; Schreiber, Rhonda
       title: A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis
        date: 2019-03-11
       words: 1532
      flesch: 52
     summary: SYNOPSIS To evaluate the safety and tolerability of calcipotriene foam, 0.005%, in subjects 12 to 16 years of age with plaque psoriasis via analysis of calcium metabolism and to evaluate whether these changes were related to the average dose administered, age, body surface area (BSA), BSA treated, and/or %BSA treated. No relationship was seen between PD markers for calcium metabolism and the covariates average dose, age, BSA, BSA treated and/or %BSA treated.
    keywords: bsa; calcium; day; psoriasis; ratio
       cache: skin-528.pdf
  plain text: skin-528.txt

        item: #1054 of 1356
          id: skin-529
      author: Yamauchi, Paul; Chen, Chi-Chang; Ding, Yao; al., et
       title: Demographic and Clinical Characteristics of Patients With Plaque Psoriasis Initiating Secukinumab in Clinical Practice: Data From US Dermatology Electronic Medical Records
        date: 2019-03-11
       words: 1437
      flesch: 51
     summary: SYNOPSIS • Psoriasis is a chronic, systemic, immune-mediated disease of the skin that affects > 7.4 million people in the United States, with an estimated prevalence of 2% to 4%1 • Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, a cornerstone cytokine involved in the development of psoriasis2 • Secukinumab has demonstrated efficacy in clinical trails and effectiveness in real-world settings in the treatment of patients with psoriasis3-9 • However, there remain limited real-world data characterizing US patients with psoriasis who initiate secukinumab in routine clinical practice OBJECTIVE • To describe demographic and clinical characteristics of US patients with plaque psoriasis who initiated secukinumab in clinical practice, using clinical data obtained from the Modernizing Medicine Data Services (MMDS) electronic medical records (EMRs) dermatology panel METHODS Study Design and Patient Population • Blauvelt A, et al.
    keywords: baseline; patients; period; psoriasis; secukinumab
       cache: skin-529.pdf
  plain text: skin-529.txt

        item: #1055 of 1356
          id: skin-530
      author: Yamauchi, Paul; Chen, Chi-Chang; Ding, Yao; al., et
       title: Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records
        date: 2019-03-11
       words: 1946
      flesch: 53
     summary: SYNOPSIS • Psoriasis is a chronic, systemic, immune-mediated disease of the skin that affects > 7.4 million people in the United States, with an estimated prevalence of 2% to 4%1 • Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown long-lasting efficacy and safety in the treatment of the complete spectrum of psoriasis manifestations, including nail, scalp, and palmoplantar psoriasis and psoriatic arthritis2-8 • There remains limited information on the effectiveness of secukinumab treatment in patients with plaque psoriasis in US real-world settings OBJECTIVE • To describe real-world effectiveness outcomes in US patients with plaque psoriasis who initiated secukinumab in clinical practice, using clinical data obtained from the Modernizing Medicine Data Services (MMDS) electronic medical records (EMRs) dermatology panel METHODS Study Design and Patient Population • All data were collected from Modernizing Medicine’s Electronic Medical Assistant (EMA) system – EMA delivers structured, real-world data captured from > 500,000 unique patients with psoriasis – Data from EMRs for patients in the United States with a clinical diagnosis of psoriasis were deidentified in accordance with HIPAA (Health Insurance Portability and Accountability Act) for research use • Eligible patients in the MMDS database had a diagnosis of plaque psoriasis during the study period of July 1, 2014, to March 31, 2018, had ≥ 1 prescription order for secukinumab within the index period (January 1, 2015, to September 30, 2017), and were aged ≥ 18 years at the time of secukinumab initiation (index date) • Patients had ≥ 1 clinical visit for any reason during the 6-month pre-index (baseline) period and ≥ 1 clinical visit for any reason within each of the first and second 6 months following secukinumab initiation Study Variables and Data Analysis • Outcomes were assessed in two cohorts: patients who had ≥ 6 months of follow-up and those who had ≥ 12 months of follow-up • Demographic characteristics (age, sex, race, body weight, US region), treatment history (during 6-month pre-index period only), and clinical characteristics (comorbidities, psoriasis subtype, body surface area [BSA], and Physician Global Assessment [PGA]) were assessed by dermatology providers during the 6-month baseline period • Mean (SD) and categorical BSA and Physician Global Assessment (PGA) scores were evaluated during the 6-month baseline period and at 6-month (window, 5-7 months) and 12-month (window, 11-13 months) follow-up visits among patients with scores reported at baseline and follow-up • Categorical changes from baseline to 6- and 12-month follow-up visits were calculated among patients with both baseline and follow-up BSA and PGA measurements available Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis:
    keywords: baseline; follow; month; patients
       cache: skin-530.pdf
  plain text: skin-530.txt

        item: #1056 of 1356
          id: skin-531
      author: Lebwohl, M; Piguet, V; Sofen, H; al., et
       title: The Efficacy of Certolizumab Pegol Re-Treatment on Plaque Psoriasis Following a Blinded Treatment Break: Results from the CIMPACT Trial
        date: 2019-03-11
       words: 1676
      flesch: 52
     summary: OBJECTIVE • To assess the efficacy of certolizumab pegol in patients with moderate to severe plaque psoriasis who responded to initial treatment, relapsed during a treatment break, and were subsequently re-treated. • Certolizumab pegol (CZP) is a unique, Fc-free, PEGylated, anti-tumor necrosis factor (TNF) biologic, approved by both the FDA and EMA for the treatment of moderate to severe PSO.1,2 • Here, we assess efficacy of CZP in patients with PSO who responded to initial treatment, underwent a blinded treatment break, relapsed, and were subsequently re-treated.
    keywords: czp; pasi; q2w; treatment
       cache: skin-531.pdf
  plain text: skin-531.txt

        item: #1057 of 1356
          id: skin-532
      author: Blauvelt, A; Warren, RB; Reich, K; al., et
       title: Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2019-03-11
       words: 2263
      flesch: 63
     summary: aCZP 200 mg Q2W patients received CZP 400 mg Q2W at Weeks 0, 2 and 4. • Patients receiving CZP 400 mg Q2W consistently reported greater quality of life improvements across all subdomains.
    keywords: czp; dlqi; patients; q2w; weeks
       cache: skin-532.pdf
  plain text: skin-532.txt

        item: #1058 of 1356
          id: skin-533
      author: Alkeswani, Amena; Graham, Lauren V
       title: Meeting the Challenges of the Dermatomyositis Workup: A Management Paradigm
        date: 2019-03-11
       words: 2164
      flesch: 50
     summary: This finding is present in two third of DM patients and may mimic the appearance of some papulosquamous diseases, such as psoriasis Patients may have at least one elevated muscle enzyme, though cases of amyopathic DM or significant loss of muscle mass are exceptions [8].
    keywords: dermatomyositis; disease; findings; muscle; patients; skin
       cache: skin-533.pdf
  plain text: skin-533.txt

        item: #1059 of 1356
          id: skin-54
      author: Del Rosso, James Q
       title: Capsule Commentaries: Drug Reaction Considerations with Oral Minocycline
        date: 2018-03-09
       words: 1963
      flesch: 45
     summary: 1-4 Minocycline is also a viable oral therapy option for the short-term treatment of papulopustular rosacea (PPR) in cases where oral doxycycline cannot be used, however, subantibiotic dosing with oral minocycline is not available; oral minocycline may also be used for the treatment of many cutaneous infections where doxycycline is used, such as staphylococcal infections, some mycobacterial infections, Lyme disease, and selected rickettsial diseases. , oral minocycline was shown to be effective after failure with a 4-week course of oral doxycycline.
    keywords: acne; antibiotic; cases; dermatol; drug; minocycline; therapy
       cache: skin-54.pdf
  plain text: skin-54.txt

        item: #1060 of 1356
          id: skin-569
      author: Brodell MD, Robert Thomas; Brodell, David William
       title: Storytelling in Dermatology
        date: 2019-09-13
       words: 1025
      flesch: 60
     summary: Fourthly, good stories are relatable. Good story emotional leads to motive for action.
    keywords: patient; stories; story; university
       cache: skin-569.pdf
  plain text: skin-569.txt

        item: #1061 of 1356
          id: skin-57
      author: White, Skyler M; Kesterson, Katrina N; Wilkerson, Michael G
       title: Persistent Cutaneous Infection Due to Mycobacterium Immunogenum, a Relatively Novel Species
        date: 2018-01-02
       words: 1716
      flesch: 42
     summary: The National Society for Cutaneous Medicine 69 BRIEF ARTICLES Persistent Cutaneous Infection Due to Mycobacterium immunogenum, a Relatively Novel Species Skylelr Michelle White MD a , Katrina N Kesterson MS b , Michael George Wilkerson a a Department of Dermatology, The University of Texas Medical Branch, Galveston, Texas b College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee A 30-year-old female presented to the dermatology clinic for an evaluation of a tender lesion on her right leg that was increasing in size. Mycobacterium immunogenum (formerly M. immunogen) was first characterized in 2001 as belonging to the Mycobacterium chelonae-Mycobacterium abscessus group of nontuberculous mycobacteria.
    keywords: immunogenum; infection; mycobacterium; patient; treatment
       cache: skin-57.pdf
  plain text: skin-57.txt

        item: #1062 of 1356
          id: skin-570
      author: Hille, David M
       title: Identifying changes in trends in the age standardized incidence of melanoma in Australia
        date: 2019-07-08
       words: 1154
      flesch: 65
     summary: For age standardized incidence for all persons, the model maximized adjusted R- squared (adj-R2 = 0.95) at a breakpoint at 1998. Cancer is a notifiable disease in Australia.5 Age standardized incidence for males, females, and all persons, between 1982 to 2015, was retrieved from the AIHW.
    keywords: breakpoint; incidence; melanoma
       cache: skin-570.pdf
  plain text: skin-570.txt

        item: #1063 of 1356
          id: skin-571
      author: Afanasiev, Olga
       title: SkinSpecs: A solution that addresses an unmet need for tracking chronic skin diseases in the office and at home
        date: 2019-03-11
       words: 652
      flesch: 46
     summary: Dermatologists want a better workflow for documenting chronic skin diseases in the office and in between visits: Sixty percent of providers stated they need a better way of documenting chronic skin conditions in the office, and 60% stated they would like their patients to document their skin condition at home. The National Society for Cutaneous Medicine 118 RISING DERM STARS® SkinSpecs: A solution that addresses an unmet need for tracking chronic skin diseases in the office and at home Olga Afanasiev, MD, PhD1, Mika Tabata, BS, Akhila Narla, BA, Justin Ko, MD, MBA 1Department of Dermatology, Stanford University, Stanford, CA Background/Objectives: Chronic skin diseases are challenging and frustrating for both patients and physicians.
    keywords: patients; skin
       cache: skin-571.pdf
  plain text: skin-571.txt

        item: #1064 of 1356
          id: skin-572
      author: Aronson, Adam
       title: Pilot study of use of neural network for quantitative before-and-after analysis of dermatologic cosmetic procedures
        date: 2019-03-11
       words: 643
      flesch: 46
     summary: The National Society for Cutaneous Medicine 120 RISING DERM STARS® Pilot study of use of neural network for quantitative before-and-after analysis of dermatologic cosmetic procedures Adam Aronson, MD1, Anastasia Georgievskaya, Hillary Jahangir-Johnson, MD, Ksenia Guseva 1Department of Dermatology, University of Iowa, Iowa City, IA Background/Objectives: In dermatologic cosmetic procedures, quantitative measures of efficacy have historically been lacking. Following collection of all before and after photographs, four blinded dermatology residents will also score each photograph for the same parameters for comparison of reliability between trained scorers and neural network.
    keywords: networks; procedure; skin
       cache: skin-572.pdf
  plain text: skin-572.txt

        item: #1065 of 1356
          id: skin-573
      author: Cohen, Jeffrey
       title: Access to Injectable Biologic Medications by Medicare Beneficiaries: Geographic Distribution of U.S. Dermatologist Prescribers
        date: 2019-03-11
       words: 757
      flesch: 48
     summary: The densities of IB- prescribing dermatologists were 4.55 and 6.51 for urban populations of greater than 20,000 people adjacent and non-adjacent to metropolitan areas, respectively. Each county was assigned a nine-point Rural-Urban Continuum Code (RUCC) based on size, degree of urbanization, and proximity to metropolitan areas.
    keywords: counties; urban
       cache: skin-573.pdf
  plain text: skin-573.txt

        item: #1066 of 1356
          id: skin-574
      author: Cymerman, Rachel
       title: De novo versus nevus-associated melanomas: differences in associations with prognostic indicators and survival
        date: 2019-03-11
       words: 326
      flesch: 30
     summary: In NYU2, de novo melanoma was again significantly associated with tumor thickness > 1.0mm (p<0.0001), ulceration (p<0.0001), nodular subtype (p<0.0001), stage > 1 (p<0.0001), older age (p<0.0001), and shorter overall survival (p<0.0001). In NYU1, de novo melanomas were associated with tumor thickness > 1.0mm (p<0.0001), ulceration (p=.024), nodular subtype (p=.009), stage > 1 (p<0.0001), older age (p<0.0001), and shorter overall survival (p=.0007).
    keywords: novo; p<0.0001
       cache: skin-574.pdf
  plain text: skin-574.txt

        item: #1067 of 1356
          id: skin-575
      author: Dagrosa, Alicia
       title: Photodynamic therapy with δ-aminolevulinic acid and blue light for the treatment of actinic cheilitis
        date: 2019-03-11
       words: 519
      flesch: 46
     summary: The National Society for Cutaneous Medicine 127 RISING DERM STARS® Photodynamic therapy with δ-aminolevulinic acid and blue light for the treatment of actinic cheilitis Dagrosa AT, MD1, Paul J, Chen Y, Gangar P, Ressler D, Chapman MS 1Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH Background/Objectives: Actinic cheilitis is a common precancerous malformation of the lower lip caused by ultraviolet radiation. Photodynamic therapy (PDT) is a potential treatment option for actinic cheilitis.
    keywords: cheilitis; treatment
       cache: skin-575.pdf
  plain text: skin-575.txt

        item: #1068 of 1356
          id: skin-576
      author: Eikenberg, Joshua
       title: Post-operative pain after Mohs micrographic surgery: analyzing physician perceptions of postoperative pain and how those perceptions affect opioid prescribing practices
        date: 2019-03-11
       words: 778
      flesch: 61
     summary: Flap 40 (15.4) Secondary intention 17 (6.5) Graft with Cartilage 4 (1.5) Conclusion: Physician predictions of perceived patient pain were within two points of patient reported pain in most cases. It is also unclear if physician perceptions of patient pain affect opioid prescribing practices or if receiving prescription opioids affects patient reported satisfaction with pain control.
    keywords: pain; patient
       cache: skin-576.pdf
  plain text: skin-576.txt

        item: #1069 of 1356
          id: skin-577
      author: Eshagh, Karin
       title: Effect of Suture Spacing on Wound Cosmesis
        date: 2019-03-11
       words: 376
      flesch: 51
     summary: Thus, it is important to understand if an increased number of subdermal sutures is actually beneficial in terms of wound cosmesis. To our knowledge, there are no studies published on the effect of subdermal suture spacing on wound cosmesis.
    keywords: sutures
       cache: skin-577.pdf
  plain text: skin-577.txt

        item: #1070 of 1356
          id: skin-579
      author: Feldstein, Stephanie
       title: Development and validation of the tape-to-trace method: An objective outcome measure for linear postoperative scars
        date: 2019-03-11
       words: 1051
      flesch: 57
     summary: Figure 1: Relationship between scar width as determined with the trace-to-tape method and POSAS surface area score and POSAS overall opinion score. We have devised a simple and inexpensive method of assessing scar surface area called the trace-to-tape method.
    keywords: method; posas; scar; tape
       cache: skin-579.pdf
  plain text: skin-579.txt

        item: #1071 of 1356
          id: skin-58
      author: Glazer, Alex M; Svoboda, Ryan M; Teplitz, Rebeca W; Rigel, Darrell S
       title: Editorial: Overcoming Consumer Challenges in Sunscreen Selection
        date: 2018-04-30
       words: 1593
      flesch: 56
     summary: For example, consumer comprehension of newly FDA-mandated sunscreen labeling information is subpar, with only around 10% understanding the concepts of SPF, broad- spectrum, and water-resistance.1 These knowledge gaps provide an impetus for consumers to turn to external advice when choosing between sunscreen products that at first glance appear comparable. In an attempt to improve this, research targeted at developing efficacy measures more directly related to the cancer-protective mechanisms of sunscreen is underway.10-13 Multiple studies have demonstrated that the regular use of sunscreen decreases skin cancer risk.14-16 Even with a minor improvement in sunscreen use, it has been estimated that 230,000 cases of invasive melanoma could be prevented in the US over the next 15 years.17 Despite an apparently easy opportunity for primary prevention, an abundance of Internet information may be discouraging people from appropriate sunscreen usage, thereby exposing them to undue risk.
    keywords: consumer; dermatol; medicine; spf; sunscreen; use
       cache: skin-58.pdf
  plain text: skin-58.txt

        item: #1072 of 1356
          id: skin-580
      author: Glaser, Katherine
       title: Hairy Legs Revisited: Peroneal Alopecia
        date: 2019-03-11
       words: 577
      flesch: 56
     summary: Suggested associations include friction from tight fitting clothing, androgenetic alopecia, thyroid disease, diabetes, and peripheral vascular disease. Routine skin examination was performed including evaluation for androgenetic alopecia using the Norwood- Hamilton scale.
    keywords: alopecia
       cache: skin-580.pdf
  plain text: skin-580.txt

        item: #1073 of 1356
          id: skin-581
      author: Habashy, Jacquiline
       title: The Ram Relaxation Technique: A Painless Biopsy Method. A Needle-free, Anesthesia-free Shave Biopsy Approach
        date: 2019-03-11
       words: 740
      flesch: 60
     summary: This particular phobia is a subset of acute procedure anxiety and is diagnosed only when the patient’s fears are targeted to the procedure and its immediate effects, such as pain and bleeding, rather than fears not particular to the procedure itself, for example the illness that is being screened or diagnosed. Such procedures require the use of local anesthesia due to increased depth of incision.
    keywords: biopsy; pain; skin
       cache: skin-581.pdf
  plain text: skin-581.txt

        item: #1074 of 1356
          id: skin-582
      author: Juhasz, Margit
       title: Characterizing The Alopecia Areata Microbiome
        date: 2019-03-11
       words: 592
      flesch: 49
     summary: The National Society for Cutaneous Medicine 143 Figure 1: Comparison of the scalp bacterial microbiome from alopecia patients to healthy controls reveals significantly decreased Firmicutes (p=0.00063) in alopecia samples. Microbiome samples were collected from 25 subjects with AA and 25 healthy controls living in Southern California at a single, academic medical center; controls were age, gender and race- matched to alopecia patients.
    keywords: alopecia; microbiome; patients
       cache: skin-582.pdf
  plain text: skin-582.txt

        item: #1075 of 1356
          id: skin-583
      author: Min, Michelle
       title: Cell Cycle Activators and Tumor Suppressors that Correlate with Melanoma Progression
        date: 2019-03-11
       words: 573
      flesch: 49
     summary: Results: HELLS expression levels were remarkably higher in metastatic melanoma compared to benign nevi (p=0.02) and primary melanoma (p=0.05) (Figure 1A). Meanwhile, SPINT2 expression levels were almost nonexistent in metastatic skin samples; this was evident when comparing metastatic melanoma to nevi (p=0.03) and primary melanoma (p=0.03) (Figure 1B).
    keywords: expression; melanoma; tumor
       cache: skin-583.pdf
  plain text: skin-583.txt

        item: #1076 of 1356
          id: skin-584
      author: Nathan, Neera
       title: Tackling lower extremity surgical site infection in dermatologic surgery
        date: 2019-03-11
       words: 730
      flesch: 48
     summary: The National Society for Cutaneous Medicine 146 RISING DERM STARS® Tackling lower extremity surgical site infection in dermatologic surgery Neera R. Nathan, MD, MSHS1, Su Luo, MD and Suzanne M. Olbricht, MD 1Department of Dermatology, Harvard Medical School, Boston, MA Background/Objectives: Surgical site infection (SSI) leads to excess healthcare costs and may contribute to increasing bacterial resistance rates due to use of antibiotics. Site-specific infection rate following lower extremity dermatologic surgery.
    keywords: cases; infection; surgery
       cache: skin-584.pdf
  plain text: skin-584.txt

        item: #1077 of 1356
          id: skin-585
      author: Prado, Giselle
       title: Impact of Consumer Preferences, Product Characteristics, and Unregulated Marketing Claims on Online Sunscreen Purchases
        date: 2019-03-11
       words: 366
      flesch: 52
     summary: Variables collected included cost, formulation, product claims, ingredients, consumer ratings, and number of reviews. Consumers who purchase online prefer sunscreens with a higher number of reviews and more marketing claims.
    keywords: claims; sunscreen
       cache: skin-585.pdf
  plain text: skin-585.txt

        item: #1078 of 1356
          id: skin-586
      author: Rohr, Bethany
       title: Understanding of abbreviations in dermatology: A survey of primary care providers.Understanding of abbreviations in dermatology: A survey of primary care providers
        date: 2019-03-11
       words: 368
      flesch: 47
     summary: The National Society for Cutaneous Medicine 149 RISING DERM STARS® Understanding of abbreviations in dermatology: A survey of primary care providers Bethany Rohr MD1, Andrea Berger MAS, Jill Henley DO, Nichole Hossler MD, Eric Hossler MD 1Department of Dermatology, Geisinger Health System, Danville, PA Background/Objectives: Abbreviations in medical documentation limit effective communication between health care providers. Conclusion: Niche dermatologic abbreviations are often unrecognized by primary care providers and should be avoided in medical documentation.
    keywords: medicine; providers
       cache: skin-586.pdf
  plain text: skin-586.txt

        item: #1079 of 1356
          id: skin-587
      author: Routt, Ethan
       title: Long Term Outcomes for Basal Cell Carcinoma Treated with Vismodegib Extended Alternate Day Dosing
        date: 2019-03-11
       words: 524
      flesch: 42
     summary: The National Society for Cutaneous Medicine 151 Conclusion: EAD dosing provided a titratable, well tolerated regimen for vismodegib therapy that maintained efficacy over eight months or more. Further study will help determine whether EAD dosing might extend vismodegib’s utility, providing an option of lower dose, long-term suppressive therapy for BCC patients unable to tolerate surgery or radiation.
    keywords: dosing; vismodegib
       cache: skin-587.pdf
  plain text: skin-587.txt

        item: #1080 of 1356
          id: skin-589
      author: Tiao, Janice
       title: The use of doxycycline in lichen planopilaris and frontal fibrosing alopecia: a retrospective study of 138 patients at a tertiary referral clinic
        date: 2019-03-11
       words: 489
      flesch: 53
     summary: The National Society for Cutaneous Medicine 155 RISING DERM STARS® The use of doxycycline in lichen planopilaris and frontal fibrosing alopecia: a retrospective study of 138 patients at a tertiary referral clinic Janice Tiao, MD1, Lynne J. Goldberg, MD 1Department of Dermatology, Boston University Medical Center, Boston, MA, USA Background/Objectives: Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are lymphocyte-mediated primary cicatricial alopecias (1). The best data supports hydroxychloroquine as the first-line systemic therapeutic agent (1,3), although expert opinion cites doxycycline as an acceptable first-line alternative and small series support its potential efficacy (4-5).
    keywords: lpp; subjects
       cache: skin-589.pdf
  plain text: skin-589.txt

        item: #1081 of 1356
          id: skin-59
      author: Svoboda, Ryan M; Franco, Abigail I; Rigel, Darrell S
       title: Electrical Impedance Spectroscopy Versus Clinical Inspection Approaches: Melanoma Efficacy Detection Comparison
        date: 2018-04-30
       words: 1876
      flesch: 52
     summary: Additionally, we determined the correlation between EIS score and pathologic staging in biopsy- proven melanoma lesions. The clinical ABCD rule was the only method that detected melanoma lesions that were missed by EIS (6 lesions).
    keywords: detection; eis; lesions; melanoma; score
       cache: skin-59.pdf
  plain text: skin-59.txt

        item: #1082 of 1356
          id: skin-590
      author: Wieder, Shira
       title: Atypical Intraepidermal Melanocytic Proliferation – But now what?
        date: 2019-03-11
       words: 601
      flesch: 52
     summary: Methods: In this retrospective study, a cohort of AIMP cases was selected. 2/312 (0.64%) of cases had the same location identified as the site of the previous AIMP’s suggestive of progression to melanoma.
    keywords: aimp; cases
       cache: skin-590.pdf
  plain text: skin-590.txt

        item: #1083 of 1356
          id: skin-591
      author: Winkelmann, Richard
       title: Wedding Dermatology: a proposed timeline to optimize skin clearance and the avoidance of a true dermatologic emergency
        date: 2019-03-11
       words: 327
      flesch: 61
     summary: Balancing acne treatment efficacy while mitigating potential side effects with the goal of clear skin on one specific day has never been studied in dermatology. The National Society for Cutaneous Medicine 160 Table 1. 2016 AAD Acne Treatment Guidelines and proposed timeline for ideal wedding acne treatment.
    keywords: acne; treatment
       cache: skin-591.pdf
  plain text: skin-591.txt

        item: #1084 of 1356
          id: skin-592
      author: Crain, Caroline Brooke; Nguyen, Adam; Wilson, Janice; Wilkerson, Michael
       title: A Case of Widespread Cutaneous Metastases from Esophageal Adenocarcinoma
        date: 2019-12-02
       words: 1376
      flesch: 45
     summary: The incidence of cutaneous metastases from esophageal adenocarcinoma is about 1% and typically involves the overlying skin of the primary tumor or the scalp.6 CK20 is typically expressed in tumors of the lower gastrointestinal tract, while CK7 is expressed in Barrett’s esophagus and esophageal adenocarcinoma.12 Ormsby et al. found that Barrett’s-related adenocarcinomas consistently revealed a CK7+/CK20- pattern, whereas gastric adenocarcinomas demonstrated much more variation in the CK7/20 immunophenotype.13 The CK7+/CK20- pattern was present in both the cutaneous and esophageal specimens from our patient, supporting the diagnosis of cutaneous metastasis from esophageal adenocarcinoma.
    keywords: adenocarcinoma; esophageal; metastases; patient; skin
       cache: skin-592.pdf
  plain text: skin-592.txt

        item: #1085 of 1356
          id: skin-593
      author: Nazarian, Roya S.; Vyas, Nikki; Scheinfeld, Noah; Phelps, Robert G.
       title: Bilateral Porokeratosis Ptychotropica on the Gluteal Cleft: A Case Report and Review of the Literature
        date: 2019-12-02
       words: 1524
      flesch: 45
     summary: Verrucous porokeratosis of the gluteal cleft (porokeratosis ptychotropica): a rare disorder easily misdiagnosed. However, newly described histologic subsets are emerging.2,3 Porokeratosis ptychotropica (PP) is a rare variant of porokeratosis, that is distinctive based on its clinical presentation of pruritic, verrucous papules and plaques located most commonly in the perinatal cleft with extension to the buttocks.
    keywords: case; lesions; porokeratosis; ptychotropica; treatment
       cache: skin-593.pdf
  plain text: skin-593.txt

        item: #1086 of 1356
          id: skin-594
      author: Regan, Paul
       title: Dermatologic Etymology: What's in a Name?
        date: 2020-01-28
       words: 368
      flesch: 62
     summary: In medical terminology, the meaning of many anatomic descriptions and disease names can be derived from their Greek and Latin roots. Why does intertrigo refer to skin folds?
    keywords: etymology
       cache: skin-594.pdf
  plain text: skin-594.txt

        item: #1087 of 1356
          id: skin-596
      author: Dhandha, Maulik Manharlal; Cooper, Markiza; Hurley, M Yadira; Chaudhry, Sofia B
       title: Drug Induced Autoimmunity Related Neutrophilic Dermatosis by Calcium Channel Blockers
        date: 2019-12-02
       words: 1356
      flesch: 49
     summary: Neutrophilic dermatosis revisited: an initial presentation of lupus? Histology is characterized by an interstitial neutrophilic infiltrate with leukocytoclasia along with a variable degree of vacuolar interface dermatitis.1 The nomenclature of ARND encompasses multiple prior case reports and series that describe a similar condition by different terminology, including nonbullous neutrophilic dermatosis (NBND), nonbullous Sweet-like neutrophilic dermatosis, and nonbullous neutrophilic lupus erythematosus (NBNLE).
    keywords: dermatosis; eruption; lupus; neutrophilic
       cache: skin-596.pdf
  plain text: skin-596.txt

        item: #1088 of 1356
          id: skin-597
      author: Fagan, Kiley K; Zelickson, Blake R; Skinner Jr, Robert B; Fisher, Kristopher R
       title: Herbicide Induced Sclerodermoid Reaction Mimicking a Photodistributed Pattern
        date: 2019-12-02
       words: 818
      flesch: 50
     summary: Providers should be aware that sclerodermoid reactions induced by topical agents, such as herbicide sprays, can present in unusual patterns such as the pseudo-photodistribution in this case. Sclerodermoid reactions are a subtype of morphea and have been documented in the literature occurring after exposures including silica, solvents, hair dyes, epoxy resins, welding fumes, pesticides, herbicides, and plant solvents.1 Herbicidal compounds known for causing sclerodermoid reactions include malathion, diniconazole, bromicil, diuron, and aminotriazole.2,3 The active ingredient in the herbicide Pasture Pro, 2,4- Dichlorophenoxyacetic acid (2,4 D), has not been reported to our knowledge as a cause of scleroderma.
    keywords: case; patient; scleroderma; skin
       cache: skin-597.pdf
  plain text: skin-597.txt

        item: #1089 of 1356
          id: skin-599
      author: Prado, Giselle; Svoboda, Ryan M; Glazer, Alex; Farberg, Aaron S; Rigel, Darrell S
       title: Factors Influencing Dermatology Rank List Preferences Among Successful Applicants
        date: 2019-05-03
       words: 1146
      flesch: 39
     summary: SKIN May 2019 Volume 3 Issue 3 Copyright 2018 The National Society for Cutaneous Medicine 208 RESEARCH LETTER Factors Influencing Dermatology Rank List Preferences Among Successful Applicants Giselle Prado MD1, Ryan M Svoboda MD, MS2, Alex Glazer, MD3, Aaron S Farberg, MD4, Darrell S Rigel, MD, MS5 1National Society for Cutaneous Medicine, New York, NY 2Department of Dermatology, Duke University School of Medicine, Durham, NC 3Department of Dermatology, University of Arizona, Tucson, AZ 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 5Ronald O. Perelman Department of Dermatology, NYU School of Medicine, New York, NY A recent study has suggested that increasing the number of residency positions would help alleviate the shortage of dermatologists.1 Filling these positions would be straightforward using the demand from the existing applicant pool, however choosing the applicants that best “fit” with a program remains a challenge.2 Several studies have looked at applicant factors that predict success of matching, but no recent studies have determined the factors that influence how applicants order their rank list. Current Dermatology residents throughout the U.S. were invited to participate in an anonymous validated 10 question survey.
    keywords: dermatology; medicine; program; residents
       cache: skin-599.pdf
  plain text: skin-599.txt

        item: #1090 of 1356
          id: skin-60
      author: Nevo, Ofir Noah; La Grenade, Lois; Diak, Ida-Lina; Levin, Robert
       title: Acute Generalized Exanthematous Pustulosis in Association with Hydroxyzine and Cetirizine
        date: 2017-11-13
       words: 1496
      flesch: 36
     summary: Selected characteristics of acute generalized exanthematous pustulosis cases reported in association with hydroxyzine, cetirizine, and levocetirizine received by the FDA through March 30, 2016 (n=26) Age, years Mean = 52.1 Median = 57.5 Range = 11 to 93 Sex Female = 14 Male = 12 Time to onset of AGEP from initiation of drug product of interest, days (n = 25) Mean = 3.2 Median = 1 Range = 0 to 13 No. (%) Drug product reported* As a result, FDA has required labeling changes for hydroxyzine products to inform clinicians to avoid using hydroxyzine, cetirizine, and levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions to any one of the above agents due to the risk of cross-reactivity.
    keywords: agep; cases; cetirizine; drug; hydroxyzine
       cache: skin-60.pdf
  plain text: skin-60.txt

        item: #1091 of 1356
          id: skin-600
      author: Ezekor, Maureen; Desai, Seemal R
       title: How to Manage Melasma
        date: 2019-05-03
       words: 1716
      flesch: 43
     summary: Broad spectrum sunscreens that combine UVA and UVB filters with visible light blockers, such as iron oxide, are preferable to broad-spectrum UV filters alone, with the former group showing greater improvement and reduced relapses.2,4, Oral therapies have emerged as effective treatment options for melasma, and often as an adjunctive to topical therapies. � Oral therapies and procedural treatments can be used as adjunctive therapies to topical treatments after topical treatments have failed.
    keywords: dermatology; melasma; skin; therapies; treatment
       cache: skin-600.pdf
  plain text: skin-600.txt

        item: #1092 of 1356
          id: skin-601
      author: Desrosiers, Andrew; Huynh, Thy; Helms, Stephen; Brodell, Robert
       title: The role of dupilumab in managing allergic contact dermatitis
        date: 2019-07-08
       words: 2121
      flesch: 55
     summary: The distinction between dupilumab’s use in ACD patients with and without underlying AD is important, as ACD responses are polarized toward a TH2 response in the skin of AD patients.17 Four studies demonstrated significant improvement in recalcitrant ACD with dupilumab in a series of predominantly AD patients. For ACD patients who are responsive to dupilumab and are unable to avoid relevant allergens, the cost of long- term dupilumab treatment can be prohibitive.
    keywords: acd; atopic; contact; dermatitis; dupilumab; patients; skin
       cache: skin-601.pdf
  plain text: skin-601.txt

        item: #1093 of 1356
          id: skin-602
      author: Nanda, Sonali; Miteva, Mariya; Nichols, Anna
       title: Black Dot Tinea Capitis: Magnified
        date: 2019-12-02
       words: 785
      flesch: 54
     summary: Circle hairs are thin, long, regularly twisted hairs with tapered ends compared to comma hairs which are dark, short hairs of uniform color, thickness, and sharp diagonal ends.2 Trichotillomania displays black dots, broken hairs of variable lengths, coiled hairs, flame hairs, v-sign, and tulip hairs with surrounding normal hair. These hairs become brittle and break at the level of the scalp, leaving microscopic ‘dots’ that represent the remaining hair in the follicle.1 Under magnification, tinea capitis can present with many microscopic findings including broken hairs, corkscrew hairs, comma hairs, barcode hairs, zigzag hairs, and black dots.3 Comma hairs, seen on the scalps of all skin types, are specific for tinea capitis, whereas corkscrew hairs have been described only in African-American children.2 Identifying comma hairs spares the need for biopsy in children by excluding the most common differential diagnoses of patchy alopecia in this age.
    keywords: capitis; hairs; tinea
       cache: skin-602.pdf
  plain text: skin-602.txt

        item: #1094 of 1356
          id: skin-603
      author: Orlowski, Timothy Jay; Reynolds, Hoyt Harris; Elewski, Boni Elizabeth
       title: Lichen Planopilaris Associated with Spray-on Sunscreen
        date: 2020-01-28
       words: 826
      flesch: 55
     summary: Microsoft Word - 8. 603 Proof done.docx SKIN January 2020 Volume 4 Issue 1 Copyright 2020 The National Society for Cutaneous Medicine 62 BRIEF ARTICLES Lichen Planopilaris Associated with Spray-on Sunscreen Timothy J. Orlowski, MD,1 H. Harris Reynolds, MD,2 Boni E. Elewski, MD2 1479th Flying Training Group, Aviation Medicine Department, Naval Hospital Pensacola, Pensacola, FL USA 2University of Alabama at Birmingham, Department of Dermatology, Birmingham, AL USA A 49 year old female was referred to our university-based dermatology outpatient clinic for a three year history of scarring hair loss affecting her anterior hairline and extending centrally in her part area (Figure 1). This sunscreen was applied directly to the areas of hair loss visible on physical exam.
    keywords: hair; lichen; sunscreen
       cache: skin-603.pdf
  plain text: skin-603.txt

        item: #1095 of 1356
          id: skin-604
      author: Bhattacharya, Kaustuv; Joshi, Namita; Shah, Ruchit; Nahar, Vinayak K.
       title: Impact of Depression on Health-Related Quality of Life among Skin Cancer Survivors
        date: 2019-12-02
       words: 5755
      flesch: 55
     summary: Comorbid depression was identified in 20% of skin cancer survivors. After adjusting for covariates, skin cancer survivors with depression had higher odds of having poor general health status (Odds Ratio [OR] = 1.67, 95% Confidence Interval
    keywords: cancer; depression; health; hrqol; melanoma; mental; patients; physical; reference; skin; skin cancer; study; survivors
       cache: skin-604.pdf
  plain text: skin-604.txt

        item: #1096 of 1356
          id: skin-605
      author: Afanasiev, Olga K; Tabata, Mika; Ko, Justin M
       title: The Need for Objective and Remote Tracking of Chronic Skin Diseases
        date: 2019-12-02
       words: 2000
      flesch: 49
     summary: While neoplasms can be tracked via measurements or photographs, chronic inflammatory skin diseases can have a prolonged and dynamic course that fluctuates in presentation, severity, and ABSTRACT Importance: Managing chronic skin disease is often frustrating for both providers and patients, sometimes resulting in delayed diagnosis, inadequate therapy, and inconsistent care. Conclusions and Relevance: This study identifies that dermatologists and patients need a solution that objectively and remotely monitors chronic skin diseases to guide treatments, empower patients, and provide more cohesive care in a complex healthcare system.
    keywords: assessment; dermatologists; disease; office; patients; skin; visits
       cache: skin-605.pdf
  plain text: skin-605.txt

        item: #1097 of 1356
          id: skin-606
      author: Yanovsky, Rebecca L; Smith, Gideon P
       title: Analysis of Self-Reported Data Accuracy Among Board-Certified and Trainee Dermatologists in the CMS National Provider Identifier Registry
        date: 2019-09-13
       words: 1094
      flesch: 43
     summary: These inaccuracies have implications for dermatologists anywhere NPI numbers are used, including validation of healthcare transactions, adverse actions from licensing authorities, and identification of providers in patient’s electronic medical records. While studies exist on the accuracy of self- reported data in other specialties,4 the accuracy of the NPI registry among dermatologists is unknown.
    keywords: dermatologists; national; provider; specialty
       cache: skin-606.pdf
  plain text: skin-606.txt

        item: #1098 of 1356
          id: skin-61
      author: Watchmaker, Jacqueline; Legler, Sean; de Leon, Dianne; Pascoe, Vanessa; Stavert, Robert
       title: Clinical Characteristics of Patients Diagnosed with Strongyloidiasis in a United States Urban Outpatient Dermatology Department: A Case Series
        date: 2017-11-13
       words: 1880
      flesch: 49
     summary: The National Society for Cutaneous Medicine 156 BRIEF ARTICLES Clinical Characteristics of Patients Diagnosed with Strongyloidiasis in an Urban Outpatient Dermatology Department: A Case Series Jacqueline Watchmaker MD a , Sean Legler BS b , Dianne de Leon MD c , Vanessa Pascoe MD d , Robert Stavert MD MBA c a Boston University Department of Dermatology, 609 Albany Street, Boston, MA 02118 b Harvard Medical School, 25 Shattuck St, Boston, MA 02115 Dermatologists should consider serologic testing for strongyloidiasis in patients with a history of exposure and unexplained pruritus ABSTRACT Background: Although considered a tropical disease, strongyloidiasis may be encountered in non-endemic regions, primarily amongst immigrants and travelers from endemic areas.
    keywords: brazil; endemic; patients; pruritus; strongyloides; strongyloidiasis
       cache: skin-61.pdf
  plain text: skin-61.txt

        item: #1099 of 1356
          id: skin-610
      author: Foshee, James; Griffin, Thomas; Cam, Kristin; Rivlin, Michael; Keller, Matthew
       title: Adjunct Treatment of Recalcitrant Hand Plaques in Nephrogenic Systemic Fibrosis After Imatinib Therapy
        date: 2019-12-02
       words: 1679
      flesch: 39
     summary: 6. Elmholdt, T. R., Pedersen, M., Jørgensen, B., Ramsing, M. & Olesen, A. B. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    keywords: fibrosis; gadolinium; imatinib; intralesional; nsf; skin
       cache: skin-610.pdf
  plain text: skin-610.txt

        item: #1100 of 1356
          id: skin-612
      author: Regan, Paul A; Sciacca Kirby, Joslyn
       title: Optimizing Medical Student Dermatology Education with the American Academy of Dermatology’s Basic Dermatology Curriculum
        date: 2019-12-02
       words: 1650
      flesch: 47
     summary: Adult learners, however, desire the ability to set the pace of their self-directed learning, and each newer generation of medical students is becoming more reliant on technology as an educational resource.3 Medical schools and dermatology programs can accommodate these preferences by incorporating the American Academy of Dermatology’s Basic Dermatology Curriculum into medical student education. Medical school dermatology curriculum: are we adequately preparing primary care physicians?
    keywords: curriculum; dermatology; medical; modules; skin; students
       cache: skin-612.pdf
  plain text: skin-612.txt

        item: #1101 of 1356
          id: skin-613
      author: Edelman, Alexandra; Jackson, Mark; Knable, Alfred
       title: Erythema Multiforme Major caused by topical Imiquimod
        date: 2019-12-02
       words: 942
      flesch: 56
     summary: Squamous cell carcinoma in situ on right upper arm of patient (A) before biopsy and (B) two weeks after imiquimod treatment, coinciding with onset of erythema multiforme. Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Erythema Multiforme.
    keywords: cream; erythema; imiquimod; topical
       cache: skin-613.pdf
  plain text: skin-613.txt

        item: #1102 of 1356
          id: skin-614
      author: Kosche, Cory; Zheng, Lida; Guggina, Lauren
       title: Adult-Onset Still’s Disease Presenting as an Atypical Cutaneous Eruption
        date: 2019-12-02
       words: 1319
      flesch: 46
     summary: However, in atypical cutaneous eruptions of AOSD, often described as persistent pruritic eruptions, histopathology may also show dyskeratotic keratinocytes in the upper epidermis.6 Clinically, this patient had a persistent scaling linear eczematous eruption, accentuated in photo distributed areas, as well as an urticarial “evanescent” eruption. Histopathological diagnosis of persistent pruritic eruptions associated with adult-onset Still's disease.
    keywords: adult; disease; eruption; onset
       cache: skin-614.pdf
  plain text: skin-614.txt

        item: #1103 of 1356
          id: skin-615
      author: Owen, Joshua L; Kosche, Cory; Choi, Jennifer N
       title: Verrucous Keratoses Associated with Checkpoint Inhibitor Immunotherapy
        date: 2020-01-28
       words: 1673
      flesch: 42
     summary: This report adds to the spectrum of cutaneous squamoproliferative lesions induced by checkpoint inhibitor immunotherapy. Eruptive squamous cell carcinomas associated with programmed cell death protein-1 inhibitor therapy.
    keywords: anti; cell; immune; immunotherapy; lesions; vks
       cache: skin-615.pdf
  plain text: skin-615.txt

        item: #1104 of 1356
          id: skin-616
      author: Barber, Cara; Ashack, Kurt; Boulter, Joshua; Ashack, Richard
       title: Ampicillin use in Acne
        date: 2019-09-13
       words: 1557
      flesch: 50
     summary: Lastly, average severity was decreased from 1.67 to 1.12 (p < 0.001) in patients with nodulocystic acne, from 1.45 to 0.77 (p < 0.001) with inflammatory acne patients, and from 1.00 to 0.38 (p < 0.001) in patients with comedonal acne. Lastly, average severity was decreased from 1.67 to 1.12 (p < 0.001) in patients with nodulocystic acne, from 1.45 to 0.77 (p < 0.001) with inflammatory acne patients, and from 1.00 to 0.38 (p < 0.015) in patients with comedonal acne.
    keywords: acne; ampicillin; medicine; patients; severity
       cache: skin-616.pdf
  plain text: skin-616.txt

        item: #1105 of 1356
          id: skin-617
      author: Chu, Justin; Genece, Jordan; Amir, Yasmin; Lebwohl, Mark
       title: Asymmetric Prurigo Nodularis after Paralysis: A Case Report
        date: 2020-01-28
       words: 918
      flesch: 55
     summary: Prurigo nodules on the patient’s arms (a) and legs (b). New drugs like the neurokinin receptor antagonists and antibodies to IL-31 are promising as neurokinin receptors contribute to itch transmission and IL-31 is known as the itch cytokine.6 Our patient presented with an asymmetric distribution of prurigo nodules due to her underlying right-sided paralysis, highlighting the role of the itch-scratch cycle in the pathogenesis of prurigo nodularis and the importance of managing underlying pruritus in the treatment of this complex disease.
    keywords: nodularis; prurigo; scratch
       cache: skin-617.pdf
  plain text: skin-617.txt

        item: #1106 of 1356
          id: skin-619
      author: Nazarian, Roya S.; Pan, Michael; Utz, Sarah; Geller, Lauren
       title: Adolescent Sun Protection Behaviors and Beliefs
        date: 2019-12-02
       words: 2288
      flesch: 56
     summary: With regards to skin cancer prevention knowledge, the vast majority of study participants had accurate information about proper photo protection and skin cancer prevention, despite poor practices. The National Society for Cutaneous Medicine 410 RESEARCH LETTERS Adolescent Sun Protection Behaviors and Beliefs Roya S. Nazarian, BA,1 Michael Pan, MD,1 Sarah Utz, MD,2 Lauren Geller, MD1 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 2Department of Dermatology, Wayne State School of Medicine, Detroit, MI Skin cancer is the most common malignancy in the United States, with a rising incidence, including in children and adolescents at a rate of 2% per year.1 Exposure to ultraviolet (UV) radiation, either from natural sunlight or indoor tanning, is a known risk factor for the development of skin cancer.
    keywords: cancer; protection; skin; sun; sunscreen; use
       cache: skin-619.pdf
  plain text: skin-619.txt

        item: #1107 of 1356
          id: skin-62
      author: Maderal, Andrea D; Federman, Daniel G; Kirsner, Robert S
       title: Granulomatous Mastitis as a Presentation of Sarcoidosis
        date: 2018-01-02
       words: 1535
      flesch: 52
     summary: Breast involvement in sarcoidosis is classified into three categories: sarcoidosis patients with breast cancer, breast cancer patients showing sarcoidosis-like breast reactions, and sarcoidosis patients with breast granulomas, which is referred to as breast sarcoidosis. Involvement of the breast in sarcoidosis is rare, and can be defined into three subsets, including granulomas localized to the breast, referred to as breast sarcoidosis.
    keywords: breast; granulomas; involvement; patients; sarcoidosis; skin
       cache: skin-62.pdf
  plain text: skin-62.txt

        item: #1108 of 1356
          id: skin-620
      author: Callaghan, Daniel; Arndt, Kenneth
       title: Reply: Terra Firma-Forme Dermatosis, Keratotic Form
        date: 2019-12-02
       words: 609
      flesch: 66
     summary: Dermatol Online J. 2015 Dermatol Online J. 2005 Aug 1;11(2):15.
    keywords: dermatosis; terra
       cache: skin-620.pdf
  plain text: skin-620.txt

        item: #1109 of 1356
          id: skin-621
      author: Weiss, Amy; Nawrocki, Shiri; Laureano, Ana Cristina; Scherl, Sharon; Shulman, Kenneth; Kwon, Eun Ji
       title: A Rare Case of Dermatitis Herpetiformis Presenting as Fingertip Petechiae
        date: 2020-01-28
       words: 1754
      flesch: 46
     summary: Only six cases of acral petechial lesions as the sole initial presenting sign of DH in adult patients have been described in the literature.1-6 Because DH is often the first presenting sign of CD, dermatologists should be aware of this unusual clinical presentation. In most patients with DH, the enteropathy is asymptomatic.
    keywords: dermatitis; herpetiformis; patient; petechiae
       cache: skin-621.pdf
  plain text: skin-621.txt

        item: #1110 of 1356
          id: skin-622
      author: Galimberti, Fabrizio Vittorio; Perez, Gregory
       title: Cutaneous Metastasis from Gastric Carcinoma, an Uncommon Clinical Presentation
        date: 2019-12-02
       words: 1120
      flesch: 54
     summary: Here we report a case of gastric carcinoma associated cutaneous metastasis in a patient who reported a history of an unspecified malignancy under remission. Cutaneous metastases occur in 0.6 to 10.4% of cancer patients.1
    keywords: cancer; gastric; metastases; skin
       cache: skin-622.pdf
  plain text: skin-622.txt

        item: #1111 of 1356
          id: skin-623
      author: Loesch, Mathew; Ganocy, Stephen J; Jaworsky, Christine
       title: Clear Cell Squamous Cell Carcinoma: Clinical and Histologic Parameters and a Review of the Literature
        date: 2020-03-08
       words: 3651
      flesch: 55
     summary: Such lesions have been described clinically as nodules or ulcerated masses that can INTRODUCTION Background: Clear cell squamous cell carcinoma (ccSCC) is an uncommon subtype of squamous cell carcinoma. A: squamous cell carcinoma in situ without clear cell change (200X) contrasted with B: clear cell squamous cell carcinoma in situ (200X);
    keywords: age; carcinoma; cases; ccscc; cell; change; clear; skin; study
       cache: skin-623.pdf
  plain text: skin-623.txt

        item: #1112 of 1356
          id: skin-624
      author: Hope, Landon; Ibad, Sidra; Marks, Etan; Hope, Richard; Cockerell, Clay
       title: Dysmorphic Trichophyton rubrum Mimicking Blastomycosis
        date: 2020-03-08
       words: 1138
      flesch: 46
     summary: T. rubrum has been reported to be an invasive organism in immunocompromised hosts.1 Blastomycosis is a deep fungal infection that is more prevalent in immunocompromised hosts than T. rubrum. Specifically, Blastomycosis spp. did not grow, but T. rubrum was identified.
    keywords: figure; rubrum
       cache: skin-624.pdf
  plain text: skin-624.txt

        item: #1113 of 1356
          id: skin-625
      author: Schneider, Samantha L; Jahnke, Marla; Leiferman, Kristin M; Chaffins, Marsha; Krakowski, Andrew C; Ozog, David
       title: Improvement with Fractional Ablative Laser and Topical Poly-L-Lactic Acid in an RDEB Patient
        date: 2019-12-02
       words: 1665
      flesch: 43
     summary: Type VII collagen was detected in TAS and resembled type VII collagen immunostaining in a normal human control, whereas type VII collagen immunostaining was not detected in UAS or NS (Figure 3). No type VII collagen is detected in the untreated affected skin (Figure 3A) or in the clinically normal-appearing skin (Figure 3C); however, type VII collagen is detected in treated affected skin (Figure 3B) along the basement membrane zone (BMZ), white arrowhead, suggesting that FABL and topical PLLA treatments may induce collagen VII expression.
    keywords: collagen; figure; laser; skin; type; vii
       cache: skin-625.pdf
  plain text: skin-625.txt

        item: #1114 of 1356
          id: skin-628
      author: Marks, Etan; Caruso, Hillary G.; Kurley, Sarah J; Ibad, Sidra; Plasseraud, Kristen M; Monzon, Federico A; Cockerell, Clay J
       title: Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma
        date: 2019-07-08
       words: 4084
      flesch: 57
     summary: Clinical GEP testing data De-identified consecutive 31-GEP clinical test results and associated tumor clinicopathologic data (n=579) between 2014 and 2019 from a large dermatopathology practice were used to determine proportions of 31-GEP classes in T1 melanoma tumors by 0.1 mm increments in Breslow thickness. We then evaluated 31-GEP class distribution in thin melanoma tumors from a large dermatopathology practice and in all cases clinically tested during the last year.
    keywords: breslow; class; gep; melanoma; patients; test; thickness; tumors
       cache: skin-628.pdf
  plain text: skin-628.txt

        item: #1115 of 1356
          id: skin-629
      author: Hashim, Peter; Liu, Stephanie; Desman, Garrett T; Giordano, Cerrene N
       title: Schwannoma of the Scalp Mimicking a Pilar Cyst
        date: 2019-12-02
       words: 672
      flesch: 57
     summary: Schwannomas are generally considered benign neoplasms, although malignant lesions have been reported, including on the scalp. Midline occipital scalp with the outlined border of the schwannoma.
    keywords: cyst; scalp; schwannomas
       cache: skin-629.pdf
  plain text: skin-629.txt

        item: #1116 of 1356
          id: skin-630
      author: Nazarian, Roya S.; Nia, John; Vyas, Nikki; Desman, Garrett; Geller, Lauren
       title: Generalized Pustular Psoriasis in an Adolescent Treated with Cyclosporine: A Diagnostic and Therapeutic Challenge
        date: 2019-12-02
       words: 1790
      flesch: 46
     summary: On examination he was noted to have conjunctival erythema, palatal petechiae, and pinpoint pustules on an erythematous INTRODUCTION CASE REPORT Generalized pustular psoriasis (GPP) is rare in the pediatric population, accounting for only 0.5-0.6% of psoriasis cases in children. 5. Elston GE, Charles-Holmes R, Carr RA. Precipitation of generalized pustular psoriasis by prednisolone.
    keywords: acute; agep; case; dermatology; gpp; psoriasis; pustules
       cache: skin-630.pdf
  plain text: skin-630.txt

        item: #1117 of 1356
          id: skin-633
      author: Shah, Pooja R; Esaa, Fatema; Beck, Lisa A
       title: Herpes Simplex Masquerading as Cat-Scratch Disease
        date: 2020-05-08
       words: 635
      flesch: 43
     summary: The patient was treated empirically with oral clindamycin and azithromycin for possible bacterial infection, resulting in only partial clinical response. However, superficial lymphangitis may also occur secondary to nonbacterial etiologies including viral or fungal infections, arthropod bites, or iatrogenic interventions.1 Although the natural history of herpes simplex lymphangitis is self-resolution, antiviral therapy may shorten the duration of symptoms and help prevent recurrence.2 Our patient demonstrates a unique case of cutaneous herpes simplex infection with centrifugal spread complicated by lymphangitis and regional lymphadenopathy.
    keywords: finger; lymphangitis
       cache: skin-633.pdf
  plain text: skin-633.txt

        item: #1118 of 1356
          id: skin-639
      author: Michael, Mary; Newman, Andrew; Barr, Jason; Lam, Travis
       title: Dermatitis Artefacta Resembling Pyoderma Gangrenosum
        date: 2020-03-08
       words: 1249
      flesch: 42
     summary: Skin lesions that do not fit a particular clinical-pathological diagnosis and resist conventional treatments should prompt clinicians to consider a diagnosis of DA. Less common causes include physical injury, infection, vasculopathy, panniculitis, malignancy, medications, brown-recluse spider envenomation, and pyoderma gangrenosum (PG).1 PG is a poorly understood, noninfectious, neutrophilic dermatosis that presents as recurrent skin ulcers, most commonly on the lower extremity.2 The initial lesion starts as a tender pustule, progressing to a necrotic bulla that ulcerates with purulent drainage.2 Approximately half of patients that develop PG present with a chronic underlying systemic inflammatory or malignant disease such as ulcerative colitis, rheumatoid arthritis, chronic active hepatitis, Crohn’s disease, IgA monoclonal gammopathy, and hematologic malignancies.2-4 Ulcers can also be due to self-mutilation from an underlying psychological condition known as dermatitis artefacta (DA).
    keywords: diagnosis; skin; ulcers
       cache: skin-639.pdf
  plain text: skin-639.txt

        item: #1119 of 1356
          id: skin-641
      author: Morris, Caroline Rose; Hurst, Eva A
       title: Electrosurgery and Implantable Electronic Devices: A Survey of Current Practices among Cutaneous Surgeons
        date: 2019-09-13
       words: 3618
      flesch: 44
     summary: Routinely (>90%) implemented precautions ICD; % respondent s (n) Pacemaker; % respondent s (n) Deep brain stimulator/Cochle ar implant; % respondents (n) Spinal cord/nerve stimulator; % respondent s (n) Utilize only short bursts of current (<5 sec) 63% (101) 70% (98) 60% (72) 62% (62) Avoid use around device 63% (100) 67% (95) 56% (67) 58% (59) Use of minimal power/lowest effective settings 54% (86) 67% (94) 57% (68) 54% (55) Code/crash cart available 47% (75) 50% (70) 45% (54) 42% (41) Have staff available trained in ACLS 44% (69) 42% (60) 42% (50) 36% (36) Pre- and postoperative monitoring (BP, HR) 42% (68) 42% (59) 32% (39) 32% (33) The National Society for Cutaneous Medicine 327 There is an ever-increasing number of patients with implantable electronic devices (IEDs) as indications for a multitude of cardiac and neurologic diseases continues to expand.
    keywords: brain; device; electrosurgery; emi; patients; precautions; rate; stimulator; use
       cache: skin-641.pdf
  plain text: skin-641.txt

        item: #1120 of 1356
          id: skin-644
      author: Xiong, David Dayi; Beal, Brandon Tyler; Manmohan, Manisha; Uberti, Maria Georgina; Riley, Kathryn; Fernandez, Anthony
       title: Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Case Report
        date: 2020-01-28
       words: 921
      flesch: 40
     summary: The National Society for Cutaneous Medicine 79 BRIEF ARTICLES Subcutaneous Panniculitis-Like T-cell Lymphoma: A Case Report David D. Xiong, BA,1 Brandon T. Beal, MD,2 Manisha Manmohan, MD,2 M. Georgina Uberti, MD,3 Kathryn Riley, MD,2 Anthony P. Fernandez, MD, PhD2 1Cleveland Clinic Lerner College of Medicine, Cleveland OH 2Cleveland Clinic Foundation, Department of Dermatology, Cleveland OH 3Cleveland Clinic Foundation, Departments of Anatomic Pathology and Dermatology, Cleveland OH Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an unusual cutaneous T-cell lymphoma (TCL) accounting for <1% of non-Hodgkin lymphomas which typically presents with subcutaneous nodules or deep plaques. SPTCL is an uncommon TCL characterized by subcutaneous nodules that may be scattered across the body.
    keywords: cell; like; lymphoma
       cache: skin-644.pdf
  plain text: skin-644.txt

        item: #1121 of 1356
          id: skin-645
      author: Mackey, Brandon; Mackey, Vernon T
       title: Successful Deoxycholate Acid Use in a Male Patient for Resistant Lower Abdominal Wall Fat
        date: 2020-07-12
       words: 1381
      flesch: 47
     summary: The number of treatment options available for healthcare providers is continuing to increase and strive to fulfill the growing demand and need for these types of procedures.1 In the past the only treatment options for patients included invasive and expensive surgical procedures with serious potential side effects.2 In the more recent history several less invasive treatments have become available but still carry post- operative recovery time and pain. Treatment options where discussed in detail including expectations, complications, side effects, and cost.
    keywords: fat; injection; label; patient; treatment
       cache: skin-645.pdf
  plain text: skin-645.txt

        item: #1122 of 1356
          id: skin-646
      author: Afanasiev, Olga K; Tabata, Mika; Narla, Akhila; Scott, Gregory; Ko, Justin M
       title: SkinSpecs: A Mobile Solution that Addresses an Unmet Need for Tracking Chronic Skin Diseases in the Office and at Home
        date: 2019-09-13
       words: 3298
      flesch: 43
     summary: Dermatologist preferred SkinSpecs 3D reconstruction over written description, standard photographs or video capture for documentation, but photographs were the capture of choice for longitudinal monitoring of chronic skin disease and for educational purposes (Figure 5). This study set out to engineer and test a mobile-based 3D imaging solution for chronic skin diseases to enhance clinical workflow and patient care.
    keywords: capture; dermatologists; disease; figure; patients; skin; skinspecs; video
       cache: skin-646.pdf
  plain text: skin-646.txt

        item: #1123 of 1356
          id: skin-647
      author: Juhasz, Margit; Fortman, Jamie; Lin, Jessica; Landaverde, Yessica; Levy, Joshua; Pham, Christine; Myers, Nicole; Ekelem, Chloe; Parajuli, Ritesh; Wenzel, Lari; Mesinkovska, Natasha Atanaskova
       title: The Perception of Chemotherapy-Induced Alopecia in Cancer Patients Currently Undergoing Treatment
        date: 2020-01-28
       words: 7039
      flesch: 62
     summary: Objective: To determine whether cancer patients who are actively receiving chemotherapy are interested in preventing or treating CIA. Materials and Methods: This is a survey-based, cross-sectional study of cancer patients undergoing chemotherapy infusion at a tertiary medical center.
    keywords: alopecia; bit; cancer; chemotherapy; cia; copyright; hair; hair loss; issue; loss; patients; treatment
       cache: skin-647.pdf
  plain text: skin-647.txt

        item: #1124 of 1356
          id: skin-65
      author: Beal, Brandon T; Blaha, Taryn; Xiong, David D; Schneider, Sarah H; Billings, Steven D; Fernandez, Anthony P; Khetarpal, Shilpi
       title: A Rare Presentation of Toxic Epidermal Necrolysis – Like Acute Systemic Lupus Erythematosus
        date: 2018-03-09
       words: 1284
      flesch: 41
     summary: Histopathologically, vacuolar interface change, limited keratinocyte apoptosis, ABSTRACT A 25-year-old woman with a history of systemic lupus erythematosus (SLE) was transferred from an outside hospital with a worsening painful generalized rash and oral ulcerations for the prior three weeks due to concern for Stevens-Johnson Syndrome / toxic epidermal necrolysis. 1-5 A 25-year-old woman with a history significant for systemic lupus erythematosus (SLE) was transferred from an outside hospital with a worsening painful generalized rash and oral ulcerations for the prior 3 weeks due to concern for Stevens- Johnson Syndrome / toxic epidermal necrolysis.
    keywords: asle; epidermal; erythematosus; lupus; skin
       cache: skin-65.pdf
  plain text: skin-65.txt

        item: #1125 of 1356
          id: skin-650
      author: Wheless, Margaret C; Zelickson, Blake Reid; Patel, Tejesh S; Jones, Allison V
       title: Oral Contraception Inducing Bullous Pemphigoid in an Adolescent
        date: 2020-03-08
       words: 918
      flesch: 52
     summary: The National Society for Cutaneous Medicine 177 SHORT COMMUNICATIONS Oral Contraceptive Pills Inducing Bullous Pemphigoid in an Adolescent Margaret C. Wheless BS,1 Blake R. Zelickson MD PhD,1 Tejesh S. Patel MD,1 Rituximab Therapy in Patients with Bullous Pemphigoid: A Retrospective Study of 20 Patients.
    keywords: bullous; pemphigoid; rituximab
       cache: skin-650.pdf
  plain text: skin-650.txt

        item: #1126 of 1356
          id: skin-651
      author: Sansone, Stephen; Amir, Yasmin; Lebwohl, Mark
       title: Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease
        date: 2020-05-08
       words: 1762
      flesch: 50
     summary: Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. However, these medications are associated with side effects and concerns for long-term risks, specifically that of an increased risk of malignancies like lymphoma.1-4 Recent discovery of key components in the pathogenesis of psoriasis has led to the development of novel therapies targeting interleukins (ILs) 12, 23, and 17.
    keywords: arthritis; malignancy; patients; psoriasis; psoriatic; risk
       cache: skin-651.pdf
  plain text: skin-651.txt

        item: #1127 of 1356
          id: skin-653
      author: Zarei, Mina; Forouzandeh, MAHTAB; Ledon, Jennifer; Elgart, George W; Cho-Vega, Jeong Hee
       title: Dural-Based Metastatic Malignant Melanoma Masquerading as Meningiomata: A Diagnostic Challenge
        date: 2020-01-28
       words: 1194
      flesch: 33
     summary: On immunohistochemistry, tumor cells were focally positive for Ki-67 and EMA, diffusely positive for Melan-A, HMB45, S100, and E- cadherin, weakly positive for SSRT2 and SOX-10, and negative for CK7. Punch biopsy revealed malignant epithelioid cells positive for SOX10 and pan melanoma (HMB-45, Melan-A, tyrosinase), while negative for H3K27me3 and CK7 (Figure 2).
    keywords: dural; mass; melanoma; metastatic
       cache: skin-653.pdf
  plain text: skin-653.txt

        item: #1128 of 1356
          id: skin-655
      author: Shahid, Azib; Iftikhar, Fatima; Glaser, Katherine; Fernandez, Anthony
       title: A Case Report of Chilblain Lupus Erythematosus in a Young Male with Literature Review
        date: 2020-01-28
       words: 2700
      flesch: 46
     summary: Nailfold capillaroscopy typically reveals changes in proximal nailfold capillary morphology, with enlarged and tortuous capillary loops being a common finding.4,5 Chilblain lesions may also be accompanied by discoid or subacute cutaneous lupus erythematosus lesions. These include: Major criteria: 1) Acral skin lesions associated with cold temperature 2) Evidence of lupus erythematosus in skin lesions on histopathology or direct immunofluorescence Minor criteria: 1) Coexistence of systemic lupus erythematosus or other skin lesions of discoid lupus erythematosus 2) Response to anti-lupus erythematosus therapy 3) Negative results of cryoglobulin and cold agglutinin studies.
    keywords: chilblain; chle; erythematosus; lesions; lupus; patients; skin
       cache: skin-655.pdf
  plain text: skin-655.txt

        item: #1129 of 1356
          id: skin-656
      author: Ambur, Austin B; Newman, Andrew; Barr, Jason; Lam, Travis
       title: Persistent Chloracne in a Tank Mechanic
        date: 2020-05-08
       words: 787
      flesch: 52
     summary: Skin diseases associated with Agent Orange and other organochlorine exposures. The most commonly recommended treatment regimen includes removing the source of dioxin exposure and symptomatic care.2 Although there have been reports that isotretinoin, dermabrasion, and light electrodessication may be beneficial in the treatment of chloracne, the condition remains to be mostly treatment- resistant.3 We present a case of chloracne to highlight the unique clinical characteristics and bring awareness to the difficulty of treatment.
    keywords: chloracne; dioxin; skin
       cache: skin-656.pdf
  plain text: skin-656.txt

        item: #1130 of 1356
          id: skin-658
      author: Bartholomew, Erin K.; McHugh, Mackenzi R.; O'Connor, Megan C.
       title: Wes Anderson's "Exceedingly Lovely" Face
        date: 2020-01-28
       words: 418
      flesch: 58
     summary: This congenital vascular disease commonly includes vascular malformations in the brain and eyes; Agatha may have succumbed to a seizure with poor vascular perfusion to her cerebral cortex. Nevertheless, Agatha charms viewers and protagonist Zero with her shy kindness; her slight, albeit grandiose facial imperfection making her even more human.
    keywords: agatha; birthmark
       cache: skin-658.pdf
  plain text: skin-658.txt

        item: #1131 of 1356
          id: skin-659
      author: LaCour, Matthew; Croley, Julie Amthor; Wilson, Janice
       title: Generalized Lichen Nitidus in a Middle-Aged Adult
        date: 2020-03-08
       words: 744
      flesch: 46
     summary: In the majority of affected patients, LN is associated with spontaneous resolution after a few months to years, but clinical course of the generalized form is unpredictable.3 Generalized cases are infrequently noted, with the majority of reported cases affecting children.4 Due to the rarity of presentation of generalized LN in adults, skin biopsies were essential in confirming the diagnosis. Patients are typically asymptomatic, though pruritus can occur.1 An uncommon case of generalized LN is reported in a middle-aged adult emphasizing an approach to diagnosis and treatment.
    keywords: lichen; nitidus
       cache: skin-659.pdf
  plain text: skin-659.txt

        item: #1132 of 1356
          id: skin-660
      author: Gupta, Naeha; Kamrani, Payvand; Lountzis, Nektarios; McClain, Richard
       title: Case Report of Reactive Angioendotheliomatosis
        date: 2020-03-08
       words: 1851
      flesch: 38
     summary: This hypersensitivity response leads to deposition of immunoglobulins in capillaries in the skin leading to thrombi, ensuing local hypoxia and, again, subsequent angiogenesis.1-3 On histopathology, RAE demonstrates a benign intraluminal proliferation of endothelial cells that may occlude the vascular lumen.4–6 In addition, the vessels are usually dilated.4 The upper subcutaneous fat might demonstrate vascular occlusion with cells and fibrin.2 Furthermore, association with underlying systemic infections suggest that RAE can represent a hypersensitivity response of endothelial cells to foreign antigens.1
    keywords: angioendotheliomatosis; cell; endothelial; intravascular; patient; rae
       cache: skin-660.pdf
  plain text: skin-660.txt

        item: #1133 of 1356
          id: skin-662
      author: Vender MD FRCPC, Ronald
       title: Transitioning Between Biologics
        date: 2019-12-02
       words: 3084
      flesch: 52
     summary: An overlap of biologic therapy or bridging with standard systemics may also be considered. Smith, C., Jabbar‐Lopez, Z., Yiu, Z., et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis.
    keywords: biologic; dermatol; patients; psoriasis; transitioning; treatment
       cache: skin-662.pdf
  plain text: skin-662.txt

        item: #1134 of 1356
          id: skin-663
      author: Berman, Brian; Ceilley, Roger; Cockerell, Clay; Ferris, Laura; High, Whitney A; Lebwohl, Mark; Nestor, Mark S; Rosen, Theodore; Litchman, Graham H; Prado, Giselle; Svoboda, Ryan M; Rigel, Darrell S
       title: Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment
        date: 2019-09-13
       words: 6935
      flesch: 46
     summary: The purpose was to identify common scenarios in which utilization of GEP tests might be considered so that the existing literature could be assessed for evidence supporting or refuting their use in each situation. In addition, in SKIN September 2019 Volume 3 Issue 5 Copyright 2019 The National Society for Cutaneous Medicine 291 298 many situations, GEP tests are now covered by Medicare and other insurance plans, and assistance from industry is often available, capping the associated costs and facilitating the accessibility of these assays to patients in need.
    keywords: consensus; et al; evidence; expression; gene; gene expression; gep; medicine; melanoma; patients; recommendations; test
       cache: skin-663.pdf
  plain text: skin-663.txt

        item: #1135 of 1356
          id: skin-666
      author: Novice, Taylor Shea; Glazer, Alex
       title: Spontaneous Resolution of Asymptomatic Papules on the Face of a Two-Year-Old
        date: 2020-01-28
       words: 745
      flesch: 40
     summary: Cells are typically negative for CD1a, S100, and CD207 and devoid of Bierbeck granules.2 The differential diagnosis includes juvenile xanthogranulomas (JXG), generalized eruptive histiocytomas, and urticaria pigmentosa.3 BCH is considered to belong to the spectrum of non-Langerhans cell histiocytosis, which share overlapping clinical, histologic and ultrastructural characteristics.4 Key Words: Histiocytic disorders; Lumps/Bumps; Benign cephalic histiocytosis; benign histiocytosis; histiocytoses; spontaneous resolution; multiple papules; cephalic papules Conflict of Interest Disclosures: Benign cephalic histiocytosis (BCH) is considered one of the rare, self-resolving non-Langerhans cell histiocytoses that occurs in infants and young children.
    keywords: histiocytosis; lesions; papules
       cache: skin-666.pdf
  plain text: skin-666.txt

        item: #1136 of 1356
          id: skin-667
      author: Genece, Jordan; Chu, Justin; Liu, Stephanie; Shihab, Nahla; Ungar, Jonathan
       title: Granulomatous Cheilitis: A Case Report
        date: 2020-03-08
       words: 1422
      flesch: 43
     summary: The inflammation is generally painless and may be intermittent initially, but tends to persist over time.1 Due to the inconsistency of the presentation of symptoms over time and the difficulty in isolating an underlying mechanism a final diagnosis of granulomatous cheilitis may only be rendered after a few years.4 Granulomatous cheilitis is considered a rare entity, with only a few cases reported in the literature.2 We report a case of biopsy proven granulomatous cheilitis in a young Caucasian man INTRODUCTION Introduction: Granulomatous cheilitis is a rare condition, with an unknown etiological pathway, resulting in inflammation of the lips. A skin biopsy from his right side of upper mucosa lip revealed collections of histiocytes in the dermis and slight spongiosis that are consistent with granulomatous cheilitis (Figure 3).
    keywords: cheilitis; lip; medicine; swelling; triamcinolone
       cache: skin-667.pdf
  plain text: skin-667.txt

        item: #1137 of 1356
          id: skin-668
      author: Maxfield, Luke J; Tanner, Laura S; Schwartz, Chelsea
       title: Extensive Palisaded Neutrophilic Granulomatous Dermatitis with Systemic Lupus Erythematosus
        date: 2020-05-08
       words: 1623
      flesch: 29
     summary: We also review similar clinical and microscopic disease entities with a summative comparison of neutrophilic dermatoses in patients with autoimmune connective tissue diseases. Neutrophilic dermatoses and associated autoimmune and connective tissue diseases10 Neutrophilic Dermatoses Clinical Findings Histopathologic Findings Associated Systemic Conditions Palisaded neutrophilic granulomatous dermatitis • Erythematous papules, plaques, and nodules • Minimal tenderness Sparse perivascular infiltrate with neutrophils, lymphocytes, and histiocytes RA SLE SS IBD Sweet’s syndrome • Erythematous papules, plaques, and nodules • Fever • Malaise • Neutrophilia • Tender Diffuse neutrophilic infiltrate Papillary dermal edema Minimal to absent leukocytoclastic vasculitis RA SLE IBD Pyoderma gangrenosum • Ulcerative lesions with violaceous undermined borders Non-specific SLE RA Juvenile RA IBD Rheumatoid neutrophilic dermatitis • Urticarial papules, plaques, and
    keywords: dermatitis; lesions; lupus; neutrophilic; nodules; pngd; sle
       cache: skin-668.pdf
  plain text: skin-668.txt

        item: #1138 of 1356
          id: skin-67
      author: Svoboda, Ryan M; Franco, Abigail I; Rigel, Darrell S
       title: Comparing Electrical Impedance Spectroscopy to Traditional Clinical Adjunctive Tools in the Detection of Melanoma
        date: 2017-10-27
       words: 395
      flesch: 37
     summary: Despite adjuncts such as dermoscopy, clinical detection remains challenging • Electrical impedance spectroscopy (EIS) (Nevisense, SciBase AB, Stockholm, Sweden) has been shown to have potential as a diagnostic aid for the detection of melanoma • To compare the results of EIS to clinical detection algorithms in biopsy-proven melanoma lesions • To determine the correlation between EIS score and pathologic staging • Only biopsy-positive lesions were included in the data analysis • There were few advanced lesions • There appears to be a moderate positive correlation between increasing EIS score and advancing tumor stage •
    keywords: eis; melanoma
       cache: skin-67.pdf
  plain text: skin-67.txt

        item: #1139 of 1356
          id: skin-670
      author: Gu, Yuhan David; Reynolds, Hoyt Harris; Kissel, Rebecca; Elewski, Boni E
       title: Secukinumab and Latex Allergies: Don't trust your EMR
        date: 2020-01-28
       words: 853
      flesch: 44
     summary: As new therapies and delivery systems are developed, it is imperative that electronic medical systems are updated to reflect potential reactions resulting from the delivery system itself. However, these systems may not always incorporate potential allergens that are specific to the route of administration.
    keywords: latex; patient; secukinumab; systems
       cache: skin-670.pdf
  plain text: skin-670.txt

        item: #1140 of 1356
          id: skin-672
      author: Avila, Christina; Milani-Nejad, Nima; Carr, David
       title: Superficial Acral Fibromyxoma with Ossification on the Fingertip
        date: 2020-05-08
       words: 817
      flesch: 51
     summary: SKIN May 2020 Volume 4 Issue 3 Copyright 2020 The National Society for Cutaneous Medicine 294 SHORT COMMUNICATIONS Superficial Acral Fibromyxoma with Ossification on the Fingertip Christina Avila, MPH1, Nima Milani-Nejad, MD, PhD2, David R. Carr, MD2 1The Ohio State University College of Medicine, Columbus, OH 2The Ohio State University Department of Internal Medicine, Division of Dermatology, Columbus, OH Superficial acral fibromyxomas (SAFM) are soft tissue tumors with a predilection for the extremities that often involve the nail bed. 2012;36(6):789-98 4. Prescott RJ, Husain EA, Abdellaoui A, et al. Superficial acral fibromyxoma: A clinicopathological study of new 41 cases from the U.K.: Should myxoma (NOS) and fibroma (NOS) continue as part of 21st-century reporting?
    keywords: fibromyxoma; medicine; safm
       cache: skin-672.pdf
  plain text: skin-672.txt

        item: #1141 of 1356
          id: skin-673
      author: Tsatalis, John
       title: Christina M. Jenkins: Weaving the History of Artificial Hair Extensions
        date: 2020-05-08
       words: 464
      flesch: 52
     summary: Today, enhancements like bonding, singeing, and access to hair of different color and texture have created more natural appearing products, while the well-publicized risk of central centrifugal cicatricial alopecia has created a movement toward improved safety profiles for hair weaves. In 1952, an African American woman named Christina Jenkins solved this millennium old problem with the invention of “HairWeeve”.
    keywords: hair; jenkins
       cache: skin-673.pdf
  plain text: skin-673.txt

        item: #1142 of 1356
          id: skin-675
      author: Guda, Anisha; Browning, John
       title: Letter to the Editor: Commentary on "Stigmatizing attitudes towards persons with psoriasis among laypersons and medical students"
        date: 2020-03-08
       words: 676
      flesch: 39
     summary: They call for educational campaigns and advertisements that could mitigate the negative opinions of laypersons towards viewing psoriatic lesions while also minimizing stereotypes and myths.1 To further investigate the potential utility of educational campaigns, we searched for psoriasis social awareness events that had been organized in the past. The National Society for Cutaneous Medicine 187 COMPELLING COMMENTS Letter to the Editor: Commentary on “Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students” Anisha Guda BS1, John Browning MD2 1UT Health San Antonio Long School of Medicine, San Antonio, TX 2Adjunct Associate Professor, Pediatrics and Dermatology, UT Health San Antonio, San Antonio, TX To the Editor: We read with great interest the article by Pearl et al in which the prevalence and predictors of stigmatizing attitudes among medical students and laypersons was determined.1 They found that laypersons view psoriasis as contagious and not a serious disease while medical students had less stigmatizing attitudes.
    keywords: attitudes; awareness; psoriasis
       cache: skin-675.pdf
  plain text: skin-675.txt

        item: #1143 of 1356
          id: skin-676
      author: Obayomi, Aderonke O; Vick, Garrett; Charbonnet, Tamela
       title: TNF-α Antagonist Induced Bullous Pemphigoid
        date: 2020-03-08
       words: 718
      flesch: 50
     summary: Despite reduction in the activity of bullous lesions, her psoriasis was noted to flare with an increase in affected body surface area to 25 percent. Urticarial plaque with overlying bullae on the patient’s right leg.
    keywords: patient; pemphigoid
       cache: skin-676.pdf
  plain text: skin-676.txt

        item: #1144 of 1356
          id: skin-677
      author: Auchus, Alexander; Brodell, Robert T; Nahar, Vinayak K; Ward, Kimberley HM
       title: Avoiding the Hazards of Ultraviolet Light in the Adolescent Population
        date: 2020-05-08
       words: 4642
      flesch: 56
     summary: SKIN May 2020 Volume 4 Issue 3 Copyright 2020 The National Society for Cutaneous Medicine 189 IN-DEPTH REVIEWS Avoiding the Hazards of Ultraviolet Light in the Adolescent Population Alexander Auchus1, Robert T. Brodell, MD2, Vinayak K. Nahar, MD, MS, PhD, FRSPH2,3, Kimberley H.M. Ward, MD2 1Department of Psychology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 2Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS 3Department of Preventive Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS Ultraviolet (UV) light in the UVB and UVA ranges has been demonstrated to cause acute sunburn and chronic skin problems including wrinkles, brown spots (solar lentigines), sallowness, precancerous lesions including actinic keratoses, and skin cancer (basal cell carcinoma, squamous cell carcinoma, and melanoma).1-4 In fact, in 2009, UV-emitting tanning devices were classified as “carcinogenic to humans” (Group 1) by the World Health Organization’s International Agency for Research on Cancer.5 Skin damage is increased with the strength of the UV light during mid-day (10am-2pm), cloudless days, higher altitudes, and the duration of exposure. While not everyone exposed to significant amounts of UV light will develop skin cancer, the lifetime risk of basal cell carcinoma in Caucasian individuals is around 30%.7 Most importantly, one severe sunburn in a lifetime has been shown to increase an individual’s risk of developing potentially life-threatening malignant melanoma.8,9 Protection from the hazards of UV light remains the most important modifiable risk factor for skin cancer.
    keywords: agents; dermatology; journal; medicine; protection; skin; sunscreen; tanning; uvb
       cache: skin-677.pdf
  plain text: skin-677.txt

        item: #1145 of 1356
          id: skin-68
      author: Svoboda, Ryan M; Zuckerman, Joshua D; Rigel, Darrell S
       title: Pilot Study Assessing the Efficacy of a Novel Topical Adhesive for Dermatologic Excisional Wound Closure
        date: 2017-10-27
       words: 323
      flesch: -27
     summary: PowerPoint Presentation Pilot study assessing the efficacy of a novel topical adhesive for dermatologic excisional wound closure Ryan M. Svoboda, MD MS1, Joshua D. Zuckerman, MD2, Darrell S. Rigel, MD MS3* Background Objective Methods Results Limitations Conclusions 1National Society for Cutaneous Medicine, New York, NY 2Schweiger Dermatology, New York, NY 3Ronald O. Perelman Dept. of Dermatology, NYU Medical Center, New York, NY • The topical adhesive, 2-octyl cyanoacrylate, has been used as an alternative to suture or staple closure of the skin in a variety of procedures • While the use of adhesive carries potential benefits in terms of ease of application, prior reports of allergic contact dermatitis and burns from exothermic reactions have presented a potential barrier to usage • To investigate the feasibility of using a novel formulation of 2-octyl cyanoacrylate (Actabond-Bergen Medical Products, Inc., Morris Plains, NJ) for skin closure after surgical excision of cutaneous lesions *1 patient lost to follow-up **< 1mm skin edge separation, treated conservatively • The results of office-based cutaneous surgical excisions using a novel formulation of 2-octyl cyanoacrylate for skin closure were examined in 9 consecutive patients (10 lesions) • Surgical sites were photographed: • Pre-operatively • Intraoperatively (open wound, prior to adhesive application, following adhesive application) • Two-weeks post-operatively • At follow-up, patient satisfaction was assessed and all incisions were examined for: • Cosmetic result • Signs of infection • Small sample size in this pilot series • No comparison group •
    keywords: cyanoacrylate; octyl
       cache: skin-68.pdf
  plain text: skin-68.txt

        item: #1146 of 1356
          id: skin-680
      author: Fisher, Kaylee; Meister, Harry; Shihab, Nahla; Lebwohl, Mark
       title: Psoriasis with End Stage Renal Disease Successfully Treated with Ustekinumab: A Case Report
        date: 2020-07-12
       words: 1016
      flesch: 53
     summary: This suggests that ustekinumab may be a safe therapeutic choice for severe plaque psoriasis in individuals with renal dysfunction.8 The use of ustekinumab to treat psoriasis may be a therapeutic option for patients who have renal dysfunction and may not require renal dose-adjustments. In this report we detail a case of severe plaque psoriasis complicated with end-stage renal disease (ESRD), successfully treated with ustekinumab without need for dose adjustment.
    keywords: disease; kidney; patient; psoriasis; ustekinumab
       cache: skin-680.pdf
  plain text: skin-680.txt

        item: #1147 of 1356
          id: skin-681
      author: Nazarian, Roya S.; Vyas, Nikki S.; Evans, John; Phelps, Robert G.
       title: Hyperpigmentation Associated with the Use of Topical Cidofovir for Treatment of Trichodysplasia Spinulosa in an Immunosuppressed Adult: Case Report and Review of the Literature
        date: 2020-03-08
       words: 2132
      flesch: 46
     summary: Multiple treatments exist including oral acitretin, valganciclovir, lefludomide, topical cidofovir, physical extraction, and modification of immunosuppressive medications. We describe the case of a 52-year old female with a painful midfacial eruption and alopecia of the bilateral eyebrows ultimately diagnosed with TS and treated with topical cidofovir 3%.
    keywords: case; cidofovir; skin; spinulosa; topical; trichodysplasia
       cache: skin-681.pdf
  plain text: skin-681.txt

        item: #1148 of 1356
          id: skin-683
      author: Bhatia, Kyle R; Brodell, Robert T; Bhatia, Ashish C; Mockbee, Chelsea S
       title: Interdigital Tinea: The Forerunner of Infectious Eczematoid Dermatitis
        date: 2020-07-12
       words: 1697
      flesch: 52
     summary: Weinstein A, Berman B. Topical treatment of common superficial tinea infections. The National Society for Cutaneous Medicine 355 antibiotic resistance, which can be attributed to dermatophyte production of penicillin-like and streptomycin-like antibiotic substances.4,5 Clinical presentation of intertriginous tinea pedis infection is highly variable.
    keywords: case; ied; infection; patient; pedis; tinea
       cache: skin-683.pdf
  plain text: skin-683.txt

        item: #1149 of 1356
          id: skin-684
      author: Litchman DO, MS, Graham H; Svoboda, Ryan M; Rigel, Darrell S
       title: Is Absorption of Sunscreen Truly a Problem? A Careful Review Suggests it is Not.
        date: 2019-09-13
       words: 930
      flesch: 54
     summary: This is especially critical because multiple studies have shown that skin cancer risk is mitigated by avoiding and blocking ultraviolet (UV) radiation, the primary purpose of sunscreen usage. Higher SPF sunscreens have been demonstrated to be more protective in real- world settings.6
    keywords: cancer; new; skin; sunscreen
       cache: skin-684.pdf
  plain text: skin-684.txt

        item: #1150 of 1356
          id: skin-686
      author: Heibel, Haley Danielle; Cockerell, Clay J.
       title: Clinician-Dermatopathologist Communication via the Requisition Form in the Era of Electronic Medical Records: A Review of the Literature
        date: 2020-01-28
       words: 3452
      flesch: 31
     summary: Communication between clinicians and dermatopathologists may be improved through institution of standards for SBRFs by professional groups, required clinical elements on the SBRF, and the development of a consistent and efficient system to collect, deliver, and communicate clinical information to dermatopathologists.10 Electronic SBRFs may be improved by the inclusion of checklists with required fields and clear descriptions to allow for greater ease in extracting information by the dermatopathologist.10 After the implementation of templated electronic SBRFs, Maley et al13 found an increased amount of pertinent clinical information on the SBRF for specimens with a final diagnosis of melanoma and that electronic SBRFs were significantly more likely than handwritten SBRFs to include the type of biopsy specimen, a larger number of differential diagnoses, a recorded diameter of the lesion, and a greater proportion of the lesion removed in the biopsy specimen. Microsoft Word - 3. 686 Proof done.docx SKIN January 2020 Volume 4 Issue 1 Copyright 2020 The National Society for Cutaneous Medicine 15 IN-DEPTH REVIEWS Clinician-Dermatopathologist Communication via the Requisition Form in the Era of Electronic Medical Records: A Review of the Literature Haley D. Heibel, MD,1 Clay J. Cockerell, MD, MBA2 1SUNY Downstate Health Sciences University, Brooklyn, NY, USA 2Cockerell Dermatopathology, Dallas, TX, USA Background: There are shortcomings in the quality and accuracy of clinical information on skin biopsy requisition forms (SBRFs).
    keywords: biopsy; dermatopathologists; diagnosis; emr; information; requisition; sbrf; skin
       cache: skin-686.pdf
  plain text: skin-686.txt

        item: #1151 of 1356
          id: skin-69
      author: Svoboda, Ryan M; Glazer, Alex M; Rigel, Darrell S
       title: 31-Gene Expression Profile Assessing Metastatic Risk in Melanoma Patients: Issues Impacting Patient Selection
        date: 2017-10-27
       words: 520
      flesch: 13
     summary: The impact of the results of this test on clinical decision making has been studied, but little is known about which clinical factors impact dermatologists’ decision to utilize the test • To determine which factors impact the decision to utilize the 31- GEP test for metastatic risk stratification in CMM patients *Disclosures: Dr. Rigel serves as a consultant to and on the advisory board for Castle Biosciences. Despite the fact that 2/3rds of CMM patients who develop metastases initially have a negative SLNBx, negative SLNBx status does not seem to be a significant stimulus to ordering the test Percentage of Dermatologists Who Would Order 31-GEP Test in Different Clinical Scenarios *statistically significant **p-value comparing proportion who would order test at baseline and in presence of ulceration or SLN negative status for given thickness Breslow Thickness 0.26 mm 0.50 mm 0.76 mm 2.1 mm p-value* Non-ulcerated 22% 78% 61% 74% <0.001 Ulcerated 67% 87% 80% 72% <0.001 Percent of Sample Who Would Use 31-GEP Test to Predict Metastatic Risk in Malignant Melanoma *Using chi-squared test to compare the proportion who would order the 31-GEP test at each Breslow thickness
    keywords: test
       cache: skin-69.pdf
  plain text: skin-69.txt

        item: #1152 of 1356
          id: skin-690
      author: none
       title: A Survey Based Study on the Sun Safety Knowledge of Students Attending Public Schools in San Antonio, TX
        date: 2020-01-28
       words: 1144
      flesch: 62
     summary: According to the World Health Organization, the majority of sun exposure occurs before the age of 18.1 Because children spend much of their time outdoors, teachers should ensure students have enough knowledge to protect themselves from the sun. According to the World Health Organization, the majority of sun exposure occurs before the age of 18.
    keywords: antonio; students; sun
       cache: skin-690.pdf
  plain text: skin-690.txt

        item: #1153 of 1356
          id: skin-70
      author: Bernstein, Daniel; Giddings, Sara; Khorasani, Hooman
       title: Mohs Micrographic Surgery Peripheral Margin Control Prior to En Bloc Tumor Resection: A Report of Three Cases
        date: 2018-01-02
       words: 1437
      flesch: 50
     summary: Case 3: 73-year-old male with multiply recurrent SCC of the right lower extremity treated with MMS peripheral margin control followed by central tumor extirpation and reconstruction. Conclusions: MMS peripheral margin control followed by central tumor extirpation and defect reconstruction at a later date in the operating room is an option for deeply invasive, large and aggressive NMSC.
    keywords: control; margin; mms; tumor
       cache: skin-70.pdf
  plain text: skin-70.txt

        item: #1154 of 1356
          id: skin-704
      author: Khan, Umair; Kaushik, Shivani; Anvekar, Rina
       title: Recent Advances in Systemic Therapy for Malignant Melanoma
        date: 2020-01-28
       words: 5677
      flesch: 51
     summary: Although the exact mechanism of ACT’s antitumor activity is not fully understood, it may include suppression of Tregs or changes in the TME cytokine profile that eliminates host immunosuppression.22 T cells are primed against cancer cells by in vitro stimulation using neo-antigens that include cancer- antigenic peptides and tumor cells. Immunotherapy helps CTLs perform two tasks in order to eradicate tumor cells: recognizing the presence of tumor cells and INTRODUCTION Malignant melanoma is a major contributor of skin cancer related mortality with increasing incidence and resistance to therapy.
    keywords: braf; cancer; cells; et al; inhibitors; ipilimumab; melanoma; patients; pd-1; phase; response; skin; survival; therapy; trials; tumor
       cache: skin-704.pdf
  plain text: skin-704.txt

        item: #1155 of 1356
          id: skin-706
      author: Orlowski, Timothy Jay; Hatch, Michael M; Pavlidakey, Peter; Kissel, Rebecca; Graham, Lauren V
       title: Pediatric Inflammatory Epidermolysis Bullosa Acquisita in a Patient with Oculocutaneous Albinism
        date: 2020-03-08
       words: 930
      flesch: 46
     summary: UV radiation can cause damage to the BMZ and increase the transcriptional expression of type VII collagen antibodies in dermal fibroblasts.4,5 We hypothesize that due to his history of OCA, our patient’s increased sensitivity to solar radiation led to the exposure of BMZ antigens and development of type VII collagen autoantibodies. Management of epidermolysis bullosa acquisita.
    keywords: acquisita; bullosa; epidermolysis; patient
       cache: skin-706.pdf
  plain text: skin-706.txt

        item: #1156 of 1356
          id: skin-709
      author: Khederlou, Hamid; Najmi, Zahra; Mohammadi, Narges; Atrak, Shahla; Ghaffari, Nader
       title: Successful Treatment of Generalized Pustular Psoriasis of Pregnancy with Oral Cyclosporine
        date: 2020-05-08
       words: 1756
      flesch: 18
     summary: Pustular psoriasis can be localized or widespread, similar to our case in this study.10,11 GPPP is characterized by macroscopic pustules and is the most difficult variant of generalized pustular psoriasis to treat. SKIN May 2020 Volume 4 Issue 3 Copyright 2020 The National Society for Cutaneous Medicine 252 RESIDENT COMPETITION RESEARCH ARTICLES Successful Treatment of Generalized Pustular Psoriasis of Pregnancy with Oral Cyclosporine Zahra Najmi, MD,1 Ali Sayyadinejad, MD,2 Narges Mohammadi, MD,3 Shahla Atrak, MD,1 Nader Ghaffari, MD,4 Hamid Khederlou, MD5 1Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran 2Department of Dermatology, Zanjan University of Medical Sciences, Zanjan, Iran 3Student Research Center, Zanjan University of Medical Sciences, Zanjan, Iran 4MD, Anatomical and Clinical Pathologist, Booali Laboratory, Zanjan, Iran 5Resident of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran Generalized pustular psoriasis of pregnancy (GPPP) or impetigo herpetiformis is a rare and severe dermatosis which usually occurs during the third trimester of pregnancy.1,2
    keywords: case; cyclosporine; dermatol; impetigo; pregnancy; psoriasis; pustules; zanjan
       cache: skin-709.pdf
  plain text: skin-709.txt

        item: #1157 of 1356
          id: skin-710
      author: Martinez, Aidan; Han, Joseph; Shihab, Nahla; Lebwohl, Mark
       title: Successful Treatment of Granuloma Annulare with Certolizumab
        date: 2020-05-08
       words: 1020
      flesch: 32
     summary: We present the first case of a patient with generalized GA who failed topical treatment, phototherapy, and adalimumab, but was able to achieve complete resolution with certolizumab. This form is usually self- limited, treatment is primarily indicated for cosmetic reasons and associated impact on self-image and quality of life.2 A less common type is generalized GA, which can be diagnosed by the presence of generalized skin-colored plaque and papules varying in sizes.3 Unlike the localized form, generalized GA is often pruritic.
    keywords: annulare; certolizumab; granuloma
       cache: skin-710.pdf
  plain text: skin-710.txt

        item: #1158 of 1356
          id: skin-713
      author: Bembry, Raina; Malakouti, Navid; Maiberger, Mary
       title: Hypersensitivity Reactions Secondary to Dupilumab in Two Patients with Moderate to Severe Atopic Dermatitis
        date: 2020-07-12
       words: 1369
      flesch: 42
     summary: Here we decribe two cases of patients with moderate to severe atopic dermatitis who developed an acute hypersensitivity reaction within hours of their second dose of dupilumab. Guidelines of care for the management of atopic dermatitis.
    keywords: atopic; dermatitis; dupilumab; patients
       cache: skin-713.pdf
  plain text: skin-713.txt

        item: #1159 of 1356
          id: skin-714
      author: Simmons, Brian J; Chapman, M Shane; Linos, Konstantinos
       title: Imiquimod-Induced Cutaneous Lupus-like Reaction: A Potential Histologic Pitfall Highlighting the Importance of Clinico-pathologic Correlation
        date: 2020-05-08
       words: 710
      flesch: 44
     summary: Overall, imiquimod is thought to induce lupus erythematous-like microscopic findings via local upregulation of interferon alpha and/or direct pro-apoptotic activity via B-cell lymphoma 2(Bcl-2) with subsequent activation of caspases.2 To date, there are 3 cases in the literature addressing this phenomenon in patients aged 75 to 91 years old for the treatment of actinic keratosis and lentigo maligna.2,3 However, with better long term efficacy data the use of imiquimod for the treatment of residual MIS will continue to increase making the potential prevalence of a lupus-erythematous like reaction more common. Although controversial, the use of imiquimod for the treatment of primary melanoma in-situ (MIS) and residual MIS after surgical excisions has become more common.
    keywords: imiquimod; lupus; mis
       cache: skin-714.pdf
  plain text: skin-714.txt

        item: #1160 of 1356
          id: skin-718
      author: Omorodion, Itohan H; Flowers, Richard H; Cropley, Thomas G
       title: A 65-Year-Old Male with a Large Plaque of Retiform Purpura with Impending Necrosis on the Right Lower Abdomen
        date: 2020-07-12
       words: 792
      flesch: 45
     summary: In extreme cases, surgical debridement may be indicated.1,3,4 NS is mainly attributed to improper injection technique and the risk of recurrence is low, so it is not a contraindication for continuing therapy.1,4 NS may be avoided by using Z-track injections, long needles, auto-injectors, performing aspirations prior to injection, and injecting in regions with less blood vessels.3 Nicolau Syndrome (NS) is a rare but highly distinctive adverse reaction to intramuscular, intra-articular, or subcutaneous injections which can lead to ischemic necrosis of the skin, muscle, and adipose tissue.1,2 NS has been reported following injections of various medications, including nonsteroidal anti- inflammatory drugs, antibiotics, glucocorticoids, and anesthetics.2,3 In this report, the patient experienced NS after self- injecting GA after approximately 8 years of prior GA therapy.
    keywords: injection
       cache: skin-718.pdf
  plain text: skin-718.txt

        item: #1161 of 1356
          id: skin-719
      author: Juhasz, Margit; Chen, Siwei; Khosrovi-Eghbal, Arash; Ekelem, Chloe; Landaverde, Yessica; Baldi, Pierre; Mesinkovska, Natasha Atanaskova
       title: Characterizing the Skin and Gut Microbiome of Alopecia Areata Patients
        date: 2020-01-28
       words: 3225
      flesch: 42
     summary: The objective of this study was to characterize the skin and gut microbiome of AA patients, and compare microbial composition to healthy individuals. Specific to dermatology and hair biology, recent animal studies suggest that the gut microbiome may play a role in the development of AA.2,3 With mounting evidence of the microbiome’s importance in various inflammatory disorders, we hypothesize that the skin and gut microbiome of AA patients differ significantly from healthy controls.
    keywords: alopecia; controls; disease; fungal; gut; irvine; microbiome; patients; scalp; skin
       cache: skin-719.pdf
  plain text: skin-719.txt

        item: #1162 of 1356
          id: skin-720
      author: Khan, Umair; Shihab, Nahla; Phelps, Robert G; Lebwohl, Mark
       title: Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab
        date: 2020-03-08
       words: 1555
      flesch: 48
     summary: In a selection of published cases, type I PRP patients displayed a 50% treatment response rate to methotrexate alone9. PRP can also present with additional cutaneous features such as nails that are thickened, discolored, and ridged, whereas psoriasis patients display nail changes such as nail pitting, the oil drop sign, and distal onycholysis.
    keywords: patient; pilaris; pityriasis; prp; rubra; treatment
       cache: skin-720.pdf
  plain text: skin-720.txt

        item: #1163 of 1356
          id: skin-721
      author: Karri, Padmavathi V; Charles, Datonye O; Bui, Brina V
       title: To Our Brown Skin Girls
        date: 2020-07-12
       words: 449
      flesch: 60
     summary: The alarming number of skin lighteners and bleaching treatments in Asian and African cultures are proof of skin color hierarchy.1,2 In 2017, the global skin- lightening industry was worth several billions with as much as 61% of women in India use skin-lightening cream and 77% in Nigeria.1–3 Instead of pointing fingers at those choosing to lighten their complexion, we must instead bring awareness and change to the society that discriminates against darker skin. Popular Instagram hashtags to celebrate dark skin are “melaninpoppin”, “melaninqueen”, and “blackgirlmagic” with over 20 million tags.
    keywords: 2020; brown; skin
       cache: skin-721.pdf
  plain text: skin-721.txt

        item: #1164 of 1356
          id: skin-722
      author: Kurta, Anastasia O; Weinstock, Leonard B; Semchyshyn, Natalie
       title: Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone
        date: 2020-05-08
       words: 1385
      flesch: 55
     summary: After two months of LDN therapy, she reported moderate improvement in EM symptoms with reduced pain flares in her feet. MCAS is a chronic multi-system disease of abnormal mast cell activation that leads to inflammatory and allergic illness.
    keywords: cell; dose; ldn; mast; pain
       cache: skin-722.pdf
  plain text: skin-722.txt

        item: #1165 of 1356
          id: skin-724
      author: Thibodeaux, Quinn; Fried, Rick; Goldenberg, Gary; Han, George; Hsu, Sylvia; Kircik, Leon; Knuckles, Melissa; Lebwohl, Mark; Litchman, Graham; Murina, Andrea; Rivera-Oyola, Ryan; Weinberg, Jeffrey; Wu, Jashin J; Koo, John
       title: Expert Panel Discussion among Psoriasis and Psychodermatology Specialists: How Best to Manage Depressed Psoriasis Patients with Brodalumab
        date: 2019-12-02
       words: 2937
      flesch: 43
     summary: Despite the inclusion of patients with psychiatric disorders and SIB risk factors, rates of serious psychiatric adverse events in the brodalumab clinical trials are comparable to the rates reported for other psoriasis treatments.9 10. It is also recommended that dermatologists tailor their treatment of depressed patients with psoriasis to include agents that are highly effective and rapidly acting.
    keywords: brodalumab; depression; dermatology; novartis; patients; pharma; psoriasis; treatment
       cache: skin-724.pdf
  plain text: skin-724.txt

        item: #1166 of 1356
          id: skin-73
      author: Curtis, Jeffrey R; Elewaut, Dirk; Chen, Su; Hojnik, Maja; Naveh, Navit; Anderson, Jaclyn K
       title: Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications
        date: 2017-10-27
       words: 2206
      flesch: 46
     summary: bAll ADA pati ents in all interventi onal studies of PsA, non-PsA pSpA, nr-axSpA, and AS. bAll ADA pati ents in all interventi onal studies of PsA, non-PsA pSpA, nr-axSpA, and AS.
    keywords: ents; ibd; pati
       cache: skin-73.pdf
  plain text: skin-73.txt

        item: #1167 of 1356
          id: skin-730
      author: Elliott, Russell; Lawrence, Gary; Hazot, Yohan; Margulis, Lenny; Stakias, Vassilis; Stuart, Iain
       title: Ex Vivo Assessment of FMX101 & FMX103 Human Skin Permeation and Penetration
        date: 2019-11-09
       words: 1209
      flesch: 26
     summary: Ex vivo assessment of drug delivery across human skin to the sebaceous appendages assessed using a flow-through diffusion cell • The flow-through diffusion cell (Figure 1) was used to assess drug delivery across human skin and to the sebaceous appendages •����Human�skin�from�a�single�donor�was�initially�stored�at�−80⁰�C� and thawed at room temperature. Development of a suitable receptor solution and extraction diluent for ex vivo drug permeation and penetration experiments in human skin • Three receptor solutions were assessed for their ability to minimize degradation of minocycline during ex vivo permeation and penetration • 165 mM sodium acetate pH 5.0 with 0.01% Brij-O20 • 50 mM MgCl2 in 115 mM sodium acetate pH 5.0 with 0.01% Brij-O20 • 35 mM EDTA in 130 mM sodium acetate pH 5.0 with 0.01% Brij-O20 • Three different diluents were assessed for their suitability as extraction fluids for the recovery of minocycline from the surface of the skin, the skin layers (epidermis and dermis), and from a single drop of 2-octyl cyanoacrylate glue (SurgiSeal®) • 90/9/1 acetonitrile/water/formic acid • 90/9/1 methanol/water/formic acid • 25 mM MgCl2 in 90/9/1 methanol/water/formic acid) • Method development tests determined 35 mM EDTA in 130 mM sodium acetate pH 5.0 with 0.01% Brij-O20 was suitable as the receptor solution and that 90/9/1 methanol/ water/formic acid should be used as the extraction solvent Skin Penetration and Permeation • Foam samples were collapsed in a glass container an approximately 10 mg of the collapsed foam was dosed onto the skin (n=10) • Flow was set at 10 µl/min and the formulation was allowed to penetrate through the skin for 12 hours • Subsequently, two treatment paradigms were implemented: 1. Sebaceous Appendage Intact: Five skin samples were cleaned�and�heated�at�60°C�(140°F)�for�2�minutes�in�order� to manually separate the dermis from the epidermis 2. Sebaceous Appendage Separation:
    keywords: minocycline; penetration; skin
       cache: skin-730.pdf
  plain text: skin-730.txt

        item: #1168 of 1356
          id: skin-731
      author: Del Rosso, James Q; Hartman, Corey L; Lewis, Caitlin; Schreiber, Rhonda
       title: Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris
        date: 2019-11-09
       words: 1974
      flesch: 57
     summary: Foam vehicle formulations received the highest ranking by far, with 56% of respondents rating it as “most preferred”. It is well known that topical vehicle formulation can significantly alter drug delivery and therefore impact safety, efficacy and tolerability.3 In recent years aqueous-based foam formulations have become a preferred vehicle in treating skin disease as their favorable tolerability and cosmetic elegance have led to positive patient preference, increasing the likelihood that adherence to treatment regimens including these foam vehicles will also improve.
    keywords: foam; satisfaction; tazarotene; treatment; use; week
       cache: skin-731.pdf
  plain text: skin-731.txt

        item: #1169 of 1356
          id: skin-732
      author: Han, George; Armstrong, April W; Desai, Seemal R; Guenin, Eric
       title: Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population
        date: 2019-11-09
       words: 1244
      flesch: 59
     summary: Percent Reduction in Lesion Counts A. Inflammatory Lesions -80% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 LS M e a n P e rc e n t R e d u ct io n -59% -44% -35% -22% -24% -42% Tretinoin 0.05% Lotion (n=36) Vehicle (n=33) B. Noninflammatory Lesions -25% -7% -35% -9% -51% -24% -80% -60% -40% -20% 0% Baseline Week 4 Week 8 Week 12 LS M e a n P e rc e n t R e d u ct io n Tretinoin 0.05% Lotion (n=36) Vehicle (n=33) *P=0.012 vs vehicle.
    keywords: vehicle; week
       cache: skin-732.pdf
  plain text: skin-732.txt

        item: #1170 of 1356
          id: skin-733
      author: Bhatia, Neal; Kircik, Leon H; Shamban, Ava; Bhatt, Varsha; Pillai, Radhakrishnan; Guenin, Eric
       title: A Randomized, Observer‑Blind, Split‑Face Study to Assess Compatibility of Facial Foundation Makeup with Tretinoin 0.05% Lotion and Skin Texture After Application
        date: 2019-11-09
       words: 1292
      flesch: 42
     summary: My makeup foundation has a natural-looking appearance My makeup foundation appears to have an even full coverage My skin appears to be smooth with my makeup foundation applied With my makeup foundation, my skin tone appears to be even Treated: post-makeup application Untreated: post-makeup application Treated: at hour six Untreated: at hour six B. Participant Satisfaction Items Treated: at hour six 4: Strongly Agree 3: Agree Somewhat 2: Disagree Somewhat 1: Strongly Disagree I feel satis�ed with applying this treatment under my foundation makeup It was easy to apply my foundation makeup after thetreatment I feel con�dent wearing foundation makeup after applying the treatment I feel I can add the treatment to my everyday routine before applying foundation makeup Treated: post-makeup application P a rt ic ip a n t R a ti n g , M e a n S co re ± S D *P<0.05 vs untreated post-makeup application. Per participant ratings, even/full coverage and skin smoothness were significantly better on the treated side than on the untreated side immediately after foundation application (P=0.03 and P=0.01, respectively; Figure 2A) •
    keywords: application; foundation; makeup; skin
       cache: skin-733.pdf
  plain text: skin-733.txt

        item: #1171 of 1356
          id: skin-734
      author: St. Surin-Lord, Sharleen; Werschler, William Philip; Guenin, Eric
       title: Acne-Related Quality of Life: Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female Patients with Moderate-to-Severe Disease
        date: 2019-11-09
       words: 914
      flesch: 41
     summary: Compared with other dermatologic conditions, acne is associated with greater negative psychosocial impacts, particularly with feelings of despair and distress2 ◾ Acne-related QoL has been shown to be worse in women, possibly because of differences in perceptions regarding self-appearance and cosmetic concerns2 ◾ CONCLUSION ◾ Tretinoin 0.05% lotion was significantly more effective than its vehicle in achieving improvements in QoL, especially in female participants ◾ Improvements seen in each QoL domain were mirrored by a significant improvement in participant satisfaction REFERENCES 1.
    keywords: acne; qol; role
       cache: skin-734.pdf
  plain text: skin-734.txt

        item: #1172 of 1356
          id: skin-735
      author: Woolery-Lloyd, Heather C; Harper, Julie C; Guenin, Eric
       title: Acne-Related Quality of Life: Correlation Between Acne Symptom Scores and Other Domains Following Treatment with Tretinoin 0.05% Lotion
        date: 2019-11-09
       words: 1099
      flesch: 52
     summary: At Week 12, correlations were similar (0.66, 0.67, and 0.61, respectively) with clear improvements seen with tretinoin treatment (Figures 1, 2, and 3 [higher scores for each domain vs baseline]) FIGURE 1: Correlation Between Acne Symptoms and Self-Perception at Baseline and Week 12 in Patients Treated With Tretinoin 0.05% Lotion (ITT population; Improvement B. Week 12 correlation=0.69 correlation=0.66 Higher scores for each domain reflect improved health-related QoL. ITT, intent-to-treat. FIGURE 2: Correlation Between Acne Symptoms and Role-Emotional at Baseline and Week 12 in Patients Treated With Tretinoin 0.05% Lotion (ITT population;
    keywords: acne; symptoms
       cache: skin-735.pdf
  plain text: skin-735.txt

        item: #1173 of 1356
          id: skin-736
      author: Draelos, Zoe; Cook-Bolden, Fran; Green, Lawrence; Guenin, Eric; Martin, Gina; Pillai, Radhakrishnan
       title: Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial
        date: 2019-11-09
       words: 961
      flesch: 49
     summary: Participants aged 12 years and older were randomized (2:2:1:1) to receive double-blind treatment with tazarotene 0.045% lotion, tazarotene 0.1% cream, lotion vehicle, or cream vehicle ◾ ◾ Per SSA ratings, the percentage of participants who reported having 90-100% clear skin was similar between tazarotene lotion and cream and greater than vehicle (Figure 3) FIGURE 2.
    keywords: cream; lotion; tazarotene
       cache: skin-736.pdf
  plain text: skin-736.txt

        item: #1174 of 1356
          id: skin-737
      author: Gold, Linda Stein; Zeichner, Joshua; Alikunju, Shanavas; Gautam, Anirudh; Shenoy, Srinivas; Singh, Preeti; Sidgiddi, Srinivas
       title: DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea
        date: 2019-11-09
       words: 501
      flesch: 61
     summary: Subjects were randomized to receive DFD-29 (minocycline HCl) 40 mg extended release (ER) capsules, DFD-29, 20 mg ER capsules, Oraycea® (doxycycline HCl) At week 16 the median reduction in total RosaQoL was 11 points in DFD-29 (40 mg), 8 points in DFD-29 (20 mg), 3 points in doxycycline (40 mg) and 1 point in the placebo group (Fig.1). 
    keywords: dfd-29
       cache: skin-737.pdf
  plain text: skin-737.txt

        item: #1175 of 1356
          id: skin-738
      author: Tsianakas, Athanasios; Bhatia, Neal; Alikunju, Shanavas; Gautam, Anirudh; Shenoy, Srinivas; Singh, Preeti; Sidgiddi, Srinivas
       title: DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea
        date: 2019-11-09
       words: 724
      flesch: 53
     summary: The mean reduction in total inflammatory lesion count from Baseline was 19.2 lesions in DFD-29 (40 mg), 12.6 lesions in DFD-29 (20 mg), 10.5 lesions in doxycycline (40 mg) and 7.3 lesions in placebo groups (Fig.2). * # @ 0 10 20 30 40 50 60 70 80 90 100 IGA(0/1) DFD-29 40mg, n=53 DFD-29 20mg, n=47 Doxycycline 40mg,n=48 Placebo, n=52 % S u b je c ts a c h ie v in g I G A s u c c e s s 66.4 33.3 31.9 11.5 * # @ * *Statistical significance reported vs placebo, # Statistical significance reported vs Doxycycline, @ Statistical significance reported vs DFD-29 20mg
    keywords: dfd-29; doxycycline
       cache: skin-738.pdf
  plain text: skin-738.txt

        item: #1176 of 1356
          id: skin-739
      author: Thaci, D; Papp, K; Gordon, K; Morita, A; Gooderham, M; Foley, P; Alemano, E; Kisa, R; Elbez, Y; Ren, H; Banerjee, S
       title: An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study
        date: 2019-11-09
       words: 2369
      flesch: 61
     summary: For patients with DLQI overall scores 2 at baseline, scores of 0/1 to individual questions on the 10-question DLQI form (each scored 0–3) were analyzed. Analysis of DLQI score • The proportion of patients achieving DLQI overall score 0/1, indicative of no impact on the patient’s health-related QoL,10 over time to Week 12 was calculated.
    keywords: bid; bms-986165; dlqi; pasi; score
       cache: skin-739.pdf
  plain text: skin-739.txt

        item: #1177 of 1356
          id: skin-74
      author: Garg, Amit; van der Zee, Hessel H; Geng, Ziqian; Mulder, Gerit D
       title: Impact of Baseline Smoking Status and Body Mass Index in Patients with Hidradenitis Suppurativa Treated with Adalimumab or Placebo in Phase 2 or 3 Studies
        date: 2017-10-27
       words: 1788
      flesch: 63
     summary: Ziqian Geng,3 Gerit D Mulder3 1Department of Dermatology, Hofstra Northwell School of Medicine, Hempstead, New York, USA; 2Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands; 3AbbVie Inc., North Chicago, Illinois, USA Presented at the Fall Clinical Dermatology Conference - 36th Anniversary • Las Vega, Nevada • October 12 – 15, 2017 INTRODUCTION • Patients with HS who received treatment with ADA had a greater clinical response than patients who received placebo, irrespective of baseline smoking status or BMI – The clinical response observed with ADA was not affected by smoking status or BMI – Patients may not have appropriately declared themselves as smokers, which may have affected the proportion of smokers who achieved clinical response • Achievement of HiSCR in Patients with BMI < 30 and BMI ≥ 30 Who Received ADA †P <
    keywords: ada; patients; placebo
       cache: skin-74.pdf
  plain text: skin-74.txt

        item: #1178 of 1356
          id: skin-740
      author: Girgis, IG; Chimalakonda, A; Jones III, JP; Dockens, R; Marchisin, D; Darbenzio, R; Singhal, S; Throup, J; Banerjee, S
       title: Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjects
        date: 2019-11-09
       words: 2398
      flesch: 66
     summary: To determine the effect of BMS-986165 plasma concentrations on the QT interval corrected for heart rate (HR) using Fridericia’s method (QTcF), and on other 12-lead ECG-derived endpoints, in healthy subjects. The relationship between BMS-986165 plasma concentration and QTcF was adequately described by a linear mixed-effects model (Figure 3).
    keywords: bms-986165; dose; set; subjects; qtcf
       cache: skin-740.pdf
  plain text: skin-740.txt

        item: #1179 of 1356
          id: skin-741
      author: Gordon, K; Papp, K; Gooderman, M; Thaci, D; Foley, P; Morita, A; Kundu, S; Kisa, R; Napoli, A; Banerjee, S
       title: Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial
        date: 2019-11-09
       words: 4787
      flesch: 73
     summary: ○ By PASI score (20, 20; Figure 2B): ∙ Response rates for the subgroup of patients with PASI scores 20 were similar to those for patients with PASI scores 20. • BSA (20%, 20%, to indicate less/more severe disease8).
    keywords: bid; mg bid; pasi; spga; years
       cache: skin-741.pdf
  plain text: skin-741.txt

        item: #1180 of 1356
          id: skin-742
      author: Lebwohl, Mark; Del Rosso, James; Hong, Chih-ho; Tallman, Anna M; Kircik, Leon
       title: Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study
        date: 2019-11-09
       words: 2052
      flesch: 56
     summary: [vehicle BID] and 5% [vehicle QD]) and were maintained for 4 weeks after the end-of-study treatment in all active treatment groups except for the 0.5% BID group2 PGA Response Rates by Baseline % BSA Affected ■ PGA response rates at Week 12 were higher in tapinarof cream groups than vehicle groups, regardless of baseline % BSA affected (Figure 2) – 1 to <10% BSA affected (n=102): 67% (1% BID), 60% (1% QD), 33% (0.5% BID), and 35% (0.5% QD) vs 13% (vehicle BID) and 6% (vehicle QD) – ≥10% BSA affected (n=39): INTRODUCTION ■ Psoriasis is a chronic, immune-mediated disease characterized by scaly, erythematous, and pruritic plaques that can be painful and disfiguring1 ■ Although multiple options are available for the treatment of plaque psoriasis, there is a need for effective topical therapies that can be used without body surface area (BSA) restrictions or concerns for the duration of treatment ■ Tapinarof cream is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for the treatment of psoriasis (ClinicalTrials.gov ID: NCT03956355) and atopic dermatitis ■ This previously conducted phase 2b dose-finding study (ClinicalTrials.gov ID: NCT02564042) was designed to assess the efficacy and safety of tapinarof cream in subjects with plaque psoriasis2,3 ■ Factors related to disease characteristics and skin type may influence clinical outcomes in psoriasis4,5 ■ This post-hoc analysis was conducted to explore whether the efficacy and safety of tapinarof cream varied across subgroups by baseline disease characteristics and skin type OBJECTIVE ■ To evaluate the efficacy and safety of tapinarof through post-hoc analysis from a phase 2b study in subjects with plaque psoriasis stratified by baseline disease characteristics, including % BSA affected, duration of psoriasis, and Fitzpatrick skin type METHODS Study Design ■ In this multicenter (United States, Canada, and Japan), phase 2b, double-blind, vehicle- controlled randomized study, adult subjects with psoriasis were randomized 1:1:1:1:1:1 to receive tapinarof cream 0.5% or 1% once (QD) or twice daily (BID) or vehicle QD or BID for 12 weeks and followed up for 4 more weeks (Figure 1) Figure 1.
    keywords: bid; pga; tapinarof; vehicle
       cache: skin-742.pdf
  plain text: skin-742.txt

        item: #1181 of 1356
          id: skin-743
      author: Gold, Linda Stein; Bhatia, Neal; Tallman, Anna M; Rubenstein, David
       title: Secondary Efficacy Outcomes from a Phase 2b, Randomized Dose-Finding Study of Tapinarof Cream for the Treatment of Plaque Psoriasis
        date: 2019-11-09
       words: 2276
      flesch: 51
     summary: [vehicle BID] and 5% [vehicle QD]) and were maintained for 4 weeks after the end of study treatment in all active treatment groups except for the 0.5% BID group3 PGA Scores ■ Mean improvements in PGA scores (SD) from baseline at Week 12 were significantly higher in all tapinarof cream treatment groups compared with the vehicle groups: – ≥4 ■ Incidence, frequency, and nature of adverse events (AEs) and serious AEs were collected from the start of study treatment until the end of study visit at Week 16 – Investigators assessed the overall degree of application-site irritation using a scale from 0=no irritation to 4=very severe at each study visit – Subject-reported tolerability on a 5-point scale from 0=none to 4=strong/severe was used to assess the presence and degree of application-site burning/stinging and itching within 2 hours following application of tapinarof or vehicle ■ P values for differences between tapinarof cream groups and the corresponding vehicle group for PASI response rates were calculated post hoc using Barnard’s and Fisher’s exact tests.
    keywords: bid; tapinarof; vehicle; week
       cache: skin-743.pdf
  plain text: skin-743.txt

        item: #1182 of 1356
          id: skin-744
      author: Griffiths, C.E.M.; Papp, K.A.; Song, M; Miller, M; You, Y; Shen, Y-K; Han, C; Blauvelt, A
       title: Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial
        date: 2019-11-09
       words: 1700
      flesch: 56
     summary: Week 172 Week 204Week 100 Week 124 P er ce nt ag e of P at ie nt s 445 436 431 420 404 396264 262 259 255 250 244n = Guselkumab Adalimumab→Guselkumab *Patients with baseline DLQI score >1. Weeks 76-204: Guselkumab – includes patients randomized to guselkumab at baseline and to placebo who crossed over and were treated with guselkumab at Week 16; Adalimumab→Guselkumab – includes patients randomized to adalimumab at baseline and crossed over and were treated with guselkumab at or after Week 52. Table 1. mg administered by subcutaneous (SC) injection at Weeks 0, 4, and 12, then every 8 weeks (q8wk) — Placebo at Weeks 0, 4, and 12, followed by guselkumab 100 mg SC at Weeks 16 and 20, then q8wk — Adalimumab 80 mg SC at Week 0, 40 mg at Week 1, then 40 mg q2wk through Week 47 — Starting at Week 52, all patients received open-label guselkumab treatment through Week 204 ■ Efficacy assessments included proportions of patients achieving Psoriasis Area and Severity Index (PASI) 90, PASI 100, Investigator’s Global Assessment (IGA) score of cleared (0) or minimal (1), and IGA score of 0 ■ Patient-reported outcomes included proportions of patients achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 (no effect on a patient’s health-related quality of life) and Psoriasis Symptoms and Signs Diary (PSSD) summary scores of 0 (no symptoms or signs of psoriasis) ■ Efficacy was analyzed using prespecified treatment failure rules (TFR), nonresponder imputation (NRI), and As Observed (OBS) methodology — For TFR, patients who discontinued due to lack of efficacy, worsening of psoriasis, or use of a protocol-prohibited psoriasis treatment were considered nonresponders — For NRI, patients with missing efficacy data (regardless of the reason) after application of TFR were counted as nonresponders — For OBS, only patient data from each visit were used; missing data were not imputed ■ Data for patients randomized to guselkumab and for those originally randomized to placebo who then crossed over to guselkumab at Week 16 were combined (guselkumab group) and presented in this analysis Figure 1.
    keywords: guselkumab; patients; tfr; week
       cache: skin-744.pdf
  plain text: skin-744.txt

        item: #1183 of 1356
          id: skin-745
      author: Herbert, Adelaide A; Glaab, Debbie; Schreiber, Rhonda
       title: A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis.
        date: 2019-11-09
       words: 1841
      flesch: 60
     summary: There was no relationship seen between urinary calcium/creatinine ratio and %BSA treated or age. However, response rates (% of subjects with an ISGA score of 0 or 1 for body or scalp at week 8) were consistent with that observed in the double-blind, vehicle controlled Phase III studies in adults.
    keywords: calcipotriene; day; foam; psoriasis; subjects
       cache: skin-745.pdf
  plain text: skin-745.txt

        item: #1184 of 1356
          id: skin-746
      author: Kerdel, Francisco; Don, Christina; Block, Renata; Lewis, Caitlin; Schreiber, Rhonda
       title: Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis
        date: 2019-11-09
       words: 1521
      flesch: 59
     summary: The severity of patients’ psoriasis was described as % of Body Surface Area (%BSA), where less than 3% can be considered mild, 3-10% moderate, and >11% as severe. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
    keywords: foam; patient; psoriasis; treatment
       cache: skin-746.pdf
  plain text: skin-746.txt

        item: #1185 of 1356
          id: skin-747
      author: Prussick, Ronald; Lebwohl, Mark; Gunn, Nadege; Harris, Susan; Vittitow, Jason; Jacobson, Abby; Israel, Robert J
       title: Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease
        date: 2019-11-09
       words: 1895
      flesch: 59
     summary: CRP level, mg/L Mean (SD) n=587 -1.2 (13.1) n=255 -0.7 (5.4) n=341 -0.3 (11.7) Baseline AST/ALT ratio ≥1.4 Baseline CRP level, mg/L Mean (SD) n=178 6.6 (12.6) Given the potential role chronic low-grade systemic inflammation may play in the relationship between psoriasis and NAFLD,7,8 a post hoc exploratory analysis was conducted to examine changes in C-reactive protein (CRP), a systemic marker of chronic inflammation,10 in patients with psoriasis and early indicators of NAFLD who were treated with brodalumab OBJECTIVE • Post hoc analysis to examine changes in CRP levels in patients with psoriasis with an aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) ratio suggestive of liver fibrosis or who had decreases in liver test parameters while taking brodalumab in clinical trials METHODS • Exploratory analysis of data pooled from 4 randomized, double-blind, placebo-controlled trials11-13 • Included patients who received ≥1 dose of subcutaneous brodalumab 210 mg every 2 weeks, ustekinumab per the US indicated dosing regimen14 (in 2 trials13), or placebo • Patients were subgrouped post hoc (ie, not prespecified outcomes) by various indicators to determine liver disease (eg, baseline AST/ALT ratio [≥0.9 suggestive of mild to more advanced fibrosis15,16] and maximum postbaseline AST and ALT grade decreases during treatment [based on common terminology criteria for adverse events])
    keywords: alt; ast; baseline; crp; mean; patients
       cache: skin-747.pdf
  plain text: skin-747.txt

        item: #1186 of 1356
          id: skin-748
      author: Gottlieb, Alice; Menter, Alan; Yamauchi, Paul; Han, George; Pillai, Radhakrishnan; Lin, Tina; Jacobson, Abby
       title: Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies
        date: 2019-11-09
       words: 1348
      flesch: 56
     summary: CONCLUSION • Skin clearance rates were maintained through week 120 in patients regardless of PsA history • Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis:
    keywords: brodalumab; history; patients; psa
       cache: skin-748.pdf
  plain text: skin-748.txt

        item: #1187 of 1356
          id: skin-749
      author: Lebwohl, Mark; Green, Lawrence; Bettencourt, Miriam; Fretzin, Scott; Jacobson, Abby
       title: Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics
        date: 2019-11-09
       words: 1204
      flesch: 55
     summary: Among patients whose disease did not respond to 1, 2, or ≥3 prior biologics, skin clearance rates were comparable from weeks 52 to 120 in those achieving PASI 75 (Figure 2A), PASI 90 (Figure 2B), and PASI 100 (Figure 2C) • At week 120, observed PASI 75 response rates were 82.1%, 84.3%, and 93.2% in patients whose disease did not respond to 1, 2, or ≥3 prior biologics, respectively – PASI 90 response rates were 64.1%, 74.5%, and 79.7%, respectively – PASI 100 response rates were 50.0%, 54.9%, and 54.2%, respectively Safety • Across all years, exposure-adjusted TEAE rates per 100 patient- years in patients receiving brodalumab whose disease did not respond to 1, 2, or ≥3
    keywords: biologics; brodalumab; patients
       cache: skin-749.pdf
  plain text: skin-749.txt

        item: #1188 of 1356
          id: skin-75
      author: Gottlieb, Alice B; Elewski, Boni E; Okun, Martin M; Bagel, Jerry; Poulin, Yves; Gu, Yihua; Geng, Ziqian; Williams, David A; Valdecantos, Wendell C
       title: Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial
        date: 2017-10-27
       words: 2577
      flesch: 58
     summary: 2003;49:206-12. REFERENCES • For psoriasis patients with concomitant nail disease who received 40 mg ADA every-other-week treatment for 26 weeks in Period A, treatment response was maintained from entry to Period B through week 52. • Patients receiving PBO in Period A, who switched to 40 mg ADA every-other-week treatment in Period B, eventually reached a similar response at week 52, to those receiving continuous ADA treatment.
    keywords: ada; patients; pbo; period; population; psoriasis; week
       cache: skin-75.pdf
  plain text: skin-75.txt

        item: #1189 of 1356
          id: skin-750
      author: Bhatia, Neal D; Desai, Seemal R; Teller, Craig; Jacobson, Abby
       title: Maintenance and Improvement of Skin Clearance Response With Brodalumab Among Patients With Moderate-to-Severe Psoriasis
        date: 2019-11-09
       words: 757
      flesch: 55
     summary: Seemal R. Desai,2 Craig Teller,3 Abby Jacobson4 1Therapeutics Clinical Research, San Diego, CA; 2Innovative Dermatology, PA, Plano, TX, The University of Texas Southwestern Medical Center, Dallas, TX; 3Bellaire Dermatology, Bellaire, TX; 4Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ 39th Annual Fall Clinical Dermatology Conference® for Dermatologists • October 17-20, 2019 • Las Vegas, NV INTRODUCTION • Brodalumab is a human anti–interleukin-17 receptor A monoclonal antibody that is efficacious in treating moderate-to-severe psoriasis1 • Maintenance of skin clearance among patients receiving brodalumab 210 mg subcutaneously every 2 weeks (Q2W) stratified by categories of psoriasis area and severity index (PASI) response at 12 weeks was previously assessed in two phase 3 studies (AMAGINE-2/-3) of adults with moderate- to-severe plaque psoriasis2 OBJECTIVE • To evaluate skin clearance response with brodalumab 210 mg Q2W through week 52 in the phase 3, double-blind, randomized, placebo- controlled AMAGINE-1 trial METHODS • Patients in AMAGINE-1 were initially randomized to brodalumab 210 mg Q2W or placebo for 12 weeks3 • After 12 weeks, those receiving brodalumab 210 mg Q2W who achieved static physician’s global assessment score of 0 or 1 (sPGA 0/1) were re-randomized to brodalumab 210 mg Q2W or placebo • Beginning at week 16, patients re-randomized to placebo who had return of disease, defined as sPGA ≥3, qualified for retreatment with their induction dose of brodalumab • 128 patients from AMAGINE-1 who received continuous brodalumab 210 mg Q2W through week 52 were included in this post hoc analysis comprising – 83 patients who were re-randomized to brodalumab 210 mg Q2W – 45 non–re-randomized patients who received brodalumab 210 mg Q2W after inadequate sPGA response • Skin clearance was monitored by categories of PASI response using nonresponder imputation RESULTS Week 12 PASI Responses • At week 12, among 128 patients who received continuous brodalumab 210 mg Q2W, 63% achieved PASI 90% improvement (PASI 90) or greater (37% achieved PASI 100 and 26% achieved PASI 90 to <100; Table 1) PASI Responses at Weeks 16, 28, and 52 • Among patients achieving PASI 100 at week 12, >75% maintained PASI 100 at weeks 16 and 28 – 81% maintained PASI 100 at week 16 – 77% maintained PASI 100 at week 28 • Among patients achieving PASI 100 at week 12, 79% maintained PASI 100 through week 52 • Notably, most patients (64%) who achieved PASI 90 to <100 at week 12 either improved to PASI 100 (49%) or maintained the same level of clearance (15%; Figure 1) at week 52 • Of patients who achieved PASI 75 to <90 at week 12, 43% experienced improvement at week 52 (19% improved to PASI 100 and 24% improved to PASI 90 to <100) PASI Response at Week 12 in AMAGINE-1 3 6 9 15 49 18 Responses at week 52 among week 12 PASI 90 to <100 responders, % PASI <50 PASI 50 to <75 PASI 75 to <90 PASI 90 to <100 PASI
    keywords: pasi; week
       cache: skin-750.pdf
  plain text: skin-750.txt

        item: #1190 of 1356
          id: skin-751
      author: Armstrong, April; Blauvelt, Andrew; Drew, Scott; Ho, Roger; Jacobson, Abby
       title: Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies of Brodalumab
        date: 2019-11-09
       words: 860
      flesch: 55
     summary: Ho,4 Abby Jacobson5 1University of Southern California, Los Angeles, CA; 2Oregon Medical Research Center, Portland, OR; 3OhioHealth, Marion, OH; 4 The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY; 5Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ 39th Annual Fall Clinical Dermatology Conference® for Dermatologists • October 17-20, 2019 • Las Vegas, NV INTRODUCTION • Complete skin clearance is an important treatment goal for patients with psoriasis1 • Evidence shows that complete skin clearance is associated with several benefits over almost-clear skin, including improved quality of life1 • Brodalumab is a human anti–interleukin-17 receptor A monoclonal antibody that is efficacious in treating moderate-to-severe psoriasis2-4 • In the phase 3 brodalumab trials AMAGINE-1, -2, and -3, 42%, 44%, and 37% of patients receiving brodalumab 210 mg every 2 weeks (Q2W), respectively, achieved a psoriasis area and severity index score of 100 (PASI 100) at week 122,3 OBJECTIVE • To explore whether patients with psoriasis achieving complete skin clearance experienced greater improvements in quality of life than those achieving a good but less-than-complete response METHODS • Data for this post hoc analysis were pooled from the nonplacebo groups of the 12-week induction phases of three phase 3 clinical trials (AMAGINE-1/-2/-3) of brodalumab in patients with moderate-to-severe plaque psoriasis • Patients included in the analysis were treated with brodalumab (140 or 210 mg) or ustekinumab (45 or 90 mg) and had achieved complete skin clearance, defined as 100% improvement in PASI score (PASI 100), or good but incomplete skin clearance, defined as PASI 90 to <100 • Patient-reported outcomes were used to evaluate quality of life (Figure 1), stratified by complete or good but incomplete skin clearance RESULTS • At week 12, mean (standard deviation [SD]) hospital anxiety and depression scale anxiety and depression scores were numerically lower for patients achieving PASI 100 (anxiety, 4.75 CONCLUSIONS • Achievement of complete skin clearance (PASI 100) was associated with greater numeric improvements in quality-of-life measures than achievement of a good but less-than-complete response in patients with moderate-to-severe plaque psoriasis •
    keywords: clearance; pasi; skin
       cache: skin-751.pdf
  plain text: skin-751.txt

        item: #1191 of 1356
          id: skin-752
      author: Ehst, Benjamin; Han, George; Guenthner, Scott; Eads, Kimberly; Jacobson, Abby
       title: Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration 
        date: 2019-11-09
       words: 1127
      flesch: 52
     summary: In this post hoc analysis, skin clearance was assessed by 75% and 100% improvement in psoriasis area and severity index from baseline (PASI 75 and PASI 100, respectively) responses for patients who received any dose of brodalumab during the study and those who received continuous brodalumab 210 mg Q2W through week 120 • Patients were stratified by psoriasis duration at baseline (<10 years and ≥10 years) • Safety was summarized by exposure-adjusted rates of treatment- emergent adverse events (TEAEs) for patients in both groups RESULTS Efficacy • Overall, 72.8% of patients receiving any dose of brodalumab (N=3625) and 70.8% receiving continuous brodalumab 210 mg Q2W (N=339) had disease duration ≥10 years •
    keywords: disease; duration; years
       cache: skin-752.pdf
  plain text: skin-752.txt

        item: #1192 of 1356
          id: skin-753
      author: Lebwohl, Mark; Blauvelt, Andrew; Menter, Alan; Papp, Kim; Jacobson, Abby
       title: Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab
        date: 2019-11-09
       words: 1436
      flesch: 63
     summary: [12.2] years; 90% white) entered the OLE; 107 patients had an efficacy evaluation at week 264 • Median duration of brodalumab exposure was 264 (interquartile range, 200-274) weeks Efficacy • Efficacy with brodalumab was maintained from week 12 up to week 264, with PASI 75 responses consistently ≥80% and PASI 100 responses consistently ≥40% (Figure 1) – There was a decrease in response at week 264 (final study visit), when patients had been off treatment for ≥6 weeks Patient-reported outcomes • The percentage of patients receiving brodalumab who had a DLQI score of 0 or 1 was 83.9% at week 12 and 68.4% at week 264 (Figure 2) • A greater percentage of patients with PASI 100 responses had a DLQI score of 0 or 1 at week 264 (96.4% [27 of 28 patients]) than those with PASI 90 to <100 responses (85.7% [6 of 7 patients]) or PASI 75 to <90 responses (40.0% [2 of 5 patients]; Figure 3) Safety • aAt week 264, patients had been off treatment for ≥6 weeks.
    keywords: brodalumab; pasi; patients; week
       cache: skin-753.pdf
  plain text: skin-753.txt

        item: #1193 of 1356
          id: skin-754
      author: Tanghetti, Emil A; Gold, Linda Stein; Del Rosso, James Q; Weiss, Stefan; Lin, Tina; Angel, Arturo; Pillai, Radhakrishnan
       title: Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology
        date: 2019-11-09
       words: 1364
      flesch: 37
     summary: Dermal Levels Following 24 Hours of Topical Exposure to Halobetasol/ Tazarotene Lotion Versus Halobetasol 0.05% Cream (A) or Tazarotene 0.1% Cream (B) 0% 8% 7% 6% 5% 4% 3% 2% 1% 0% 25% 20% 15% 10% 5% HP 0.01%/TAZ 0.045% Lotion Halobetasol Cream, 0.05% HP 0.01%/TAZ 0.09% Lotion Tazarotene Cream, 0.1% A. Halobetasol Dermal Levels (N=10) P e rc e n t o f A p p lie d D o se ( M e a n ) Epidermis Dermis Receptor B. Tazarotene Dermal Levels (N=10) HP, halobetasol propionate; TAZ, tazarotene. ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics | Presented at the Fall Clinical Dermatology Conference • October 17-20, 2019 • Las Vegas, NV SYNOPSIS ◾ Halobetasol propionate (HP) and tazarotene (TAZ) are both effective treatments for psoriasis but are limited by labelling restrictions or potential for adverse events ◾
    keywords: cream; lotion; taz
       cache: skin-754.pdf
  plain text: skin-754.txt

        item: #1194 of 1356
          id: skin-755
      author: Alexis, Andrew F; Yamauchi, Paul S; Lin, Tina; Martin, Gina
       title: Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
        date: 2019-11-09
       words: 1037
      flesch: 51
     summary: -60% -30% -40% -50% -20% -10% 10% 0% 20% Study Visit (Weeks) M e a n P e rc e n t C h a n g e F ro m B a se lin e 0 2 4 6 8 12 Treatment Posttreatment *P=0.016 vs vehicle; * Mild 11 (14.5) 4 (11.1) Moderate 12 (15.8) 3 (8.3) Severe 3 (3.9) 1 (2.8) Relationship to study drug Related 14 (18.4) 3 (8.3) Unrelated 12 (15.8) 5 (13.9) Treatment‑Related TEAEs reported in ≥2% of participants Contact dermatitis 3 (3.9) 0 Skin atrophy 3 (3.9) 0 Burning sensation 2 (2.6) 1 (2.8) Pruritis 1 (1.3) 1 (2.8) Psoriasis 0 1 (2.8) HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%; SAE, serious adverse event; TEAE, treatment‑emergent adverse event.
    keywords: taz; vehicle
       cache: skin-755.pdf
  plain text: skin-755.txt

        item: #1195 of 1356
          id: skin-756
      author: Lebwohl, Mark G; Sugarman, Jeffrey L; Gold, Linda Stein; Lin, Tina; Martin, Gina
       title: Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
        date: 2019-11-09
       words: 1176
      flesch: 52
     summary: ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics | Presented at the Fall Clinical Dermatology Conference • October 17-20, 2019 • Las Vegas, NV SYNOPSIS ◾ Psoriasis is a chronic, immune-mediated disease that can have frequent exacerbations and remissions1,2 ◾ The use of topical therapy is a key component in the management of almost all psoriasis patients3 ◾ 21.7) Severe 1 (2.6) 1 (4.3) Relationship to study drug Related 8 (21.1) 3 (13.0) Unrelated 10 (26.3) 5 (21.7) Treatment-related TEAEs reported in ≥2% of participants Application site pain 3 (7.9) 0 Pruritis 2 (5.3) 1 (4.3) Contact dermatitis 2 (5.3) 0 Rash 1 (2.6) 0 Skin atrophy 1 (2.6) 0 Skin lesion 1 (2.6) 0 Telangiectasia 1 (2.6) 0 Wound secretion 1 (2.6) 0 Skin irritation 0
    keywords: participants; taz; vehicle
       cache: skin-756.pdf
  plain text: skin-756.txt

        item: #1196 of 1356
          id: skin-757
      author: Glick, Brad; Lain, Edward; Lin, Tina; Israel, Robert
       title: Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)
        date: 2019-11-09
       words: 1309
      flesch: 61
     summary: -50% -40% -30% -20% -10% 0% Apremilast (n=148) Placebo (n=73) Week 16 0% 10% 20% 30% 40% 50% HP/TAZ (n=100) Vehicle (n=63) P e rc e n ta g e o f P ar ti ci p an ts Week 8 33.0% 35.1% 9.5% 12.3% B. Percentage of Patients with ≥75% Reduction in IGAxBSAa or PGAxBSAb (ITT Populations) ◾ The percentage of participants with a ≥75% reduction from baseline IGAxBSA at Week 8 was significantly higher following treatment with HP/TAZ lotion (33.0%) compared with vehicle (9.5%; P<0.001; Figure 2 and Figure 3B) FIGURE 2: Percentage of Patients With ≥75% Reduction From Baseline in IGAxBSA (ITT Population) 0% 15% 10% 5% 20% 25% 30% 35% 40% 45% 50% Study Visit (Weeks) P e rc e n ta g e o f P a rt ic ip a n ts Baseline 2 4 6 8 12 Treatment Posttreatment HP/TAZ (n=100)
    keywords: taz; vehicle
       cache: skin-757.pdf
  plain text: skin-757.txt

        item: #1197 of 1356
          id: skin-758
      author: Gold, Lina Stein; Lebwohl, Mark G; Bhatia, Neal; Lin, Tina; Pillai, Radhakrishnan
       title: Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion
        date: 2019-11-09
       words: 1369
      flesch: 54
     summary: Maintained Body Surface Area (BSA) From Week 8 to End of Study With HP/TAZ ≤5% BSA ≤3% BSA 49.3% 77.5% 39.7% 71.5% 0% 20% 40% 60% 80% 100% Subjects Participating for At Least 6 Months (n=390) Subjects Participating for At Least 1 Year (n=138) P e rc e n ta g e o f P a rt ic ip a n ts HP/TAZ, halobetasol propionate 0.01%/tazarotene 0.045%. For individuals participating for at least 1 year, 77.5% maintained a BSA level of ≤5% and 49.3% maintained a BSA level of ≤3% during the study (Figure 4) FIGURE 4.
    keywords: success; taz; treatment; weeks
       cache: skin-758.pdf
  plain text: skin-758.txt

        item: #1198 of 1356
          id: skin-759
      author: Bhatia, Neal; Vlahovic, Tracey C; Green, Lawrence; Martin, Gina; Lin, Tina
       title: Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities
        date: 2019-11-09
       words: 1466
      flesch: 55
     summary: ◾ A clinically meaningful effect in overall psoriasis treatment (IGAxBSA-75) was achieved by 37.7% of participants treated with HP 0.01% lotion compared with 7.2% treated with vehicle (P<0.001; Figure 5) FIGURE 5: Achievement of ≥50% (IGAxBSA-50) and ≥75% (IGAxBSA-75) Reduction in IGAxBSA by Week 8 0% 30% 20% 10% 40% 50% 60% Halobetasol propionate 0.01% lotion P er ce nt ag e o f P ar ti ci p an ts Vehicle IGAxBSA-50 IGAxBSA-75 **P≤0.001 versus vehicle. ◾ Mean percent reduction from baseline to Week 8 in IGAxBSA score was also significantly greater with HP treatment (-50.5%) than with vehicle (-13.8%; P<0.001)
    keywords: lotion; plaque; psoriasis; treatment; vehicle
       cache: skin-759.pdf
  plain text: skin-759.txt

        item: #1199 of 1356
          id: skin-76
      author: none
       title: Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial
        date: 2017-10-27
       words: 1742
      flesch: 63
     summary: /c Infection Serious infection TB (active or latent) n= 76 70 75 12 15 19 13 11 8 63 52 47 3 1 2 2 2 3 • Lymphoma was reported by one patient (ADAew/pbo/ew), non-melanoma skin cancer (NMSC) was reported by one patient (ADAew/pbo/ew), and malignancy other than lymphoma or NMSC, by 2 patients (one ADAew/eow/ew and one ADAew/pbo/ew). Baseline Patient Characteristics, PIONEER OLE ADAew/ew/ew N=88 ADAew/eow/ew N=90 ADAew/pbo/ew N=92 n % n % n %
    keywords: adaew; patients; week
       cache: skin-76.pdf
  plain text: skin-76.txt

        item: #1200 of 1356
          id: skin-760
      author: Lebwohl, Mark; Kircik, Leon; Reich, Kristian; Munjal, Sugar; Shenoy, Srinivas; Mrowietz, Ulrich
       title: PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial
        date: 2019-11-09
       words: 609
      flesch: 69
     summary: At week 24 , PASI-75 was achieved by 44.3%, 47.2% and 39.7% patients in PPC-06 600 mg BID, 400 mg BID and 400 mg QD groups, respectively, compared to 20% in the placebo group (p=0.004, 0.002 and 0.004 for the PPC-06 600 mg BID, 400 mg BID and 400 mg QD groups, respectively) (Fig.1).  DRL Publication # 885 Results *Statistical significance reported with placebo 0 10 20 30 40 50 60 70 80 90 100 PASI 75 IGA (0/1) Co-Primary outcomes PPC-06 600mg BID, n=101 PPC-06 400mg BID, n=102 PPC-06 400mg QD, n=101 Placebo, n=102 % S u b je c ts a c h ie v in g c o -p ri m a ry e n d p o in ts 44.4 * 47.2 39.7 20 44.3 41.4 35.7 22 * * * * *
    keywords: bid
       cache: skin-760.pdf
  plain text: skin-760.txt

        item: #1201 of 1356
          id: skin-761
      author: Blauvelt, Andrew; Papp, Kim A; Merola, Joseph F; Gottlieb, Alice B; Cross, Nancy; Madden, Cindy; Peterson, Luke; Cioffi, Christopher; Griffiths, Christopher EM
       title: Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study
        date: 2019-11-09
       words: 2165
      flesch: 40
     summary: At the start of BE ABLE 2 (Week 12), across all treatment groups, 133 of 217 patients (61.3%) were PASI90 responders ● Of these 133 BE ABLE 1 responders, 125 (94.0%) had scalp psoriasis and 80 (60.2%) had nail psoriasis at baseline (Week 0) SCALP AND NAIL OUTCOMES ● Bimekizumab treatment provided considerable improvements in both scalp and nail psoriasis – The proportion of patients with scalp psoriasis at baseline who achieved resolution increased rapidly with bimekizumab treatment; responses were generally maintained up to Week 60 (Figure 2A) – The percentage of BE ABLE 1 responders with nail psoriasis at baseline achieving resolution increased over time across all bimekizumab dose groups, reaching 73–89% at Week 60 (Figure 2B) responders remained on the same dose up to Week 60, except for those previously randomized to bimekizumab 480 mg, who received 320 mg from Week 128 (Figure 1) ● Presence of scalp or nail psoriasis at baseline (Week 0) was defined as a Psoriasis Scalp Severity Index (PSSI) score >0 or a modified Nail Psoriasis Severity Index (mNAPSI) score of >0, respectively ● The following outcomes were assessed in Week 12 responders: – Resolution of scalp psoriasis (defined as PSSI of 0) – Resolution of nail psoriasis (defined as mNAPSI of 0) – Complete skin clearance (defined as a score of 0 on both absolute PASI and the Investigator’s Global Assessment [IGA]) – Dermatology Life Quality Index (DLQI) of 0 or 1 (representing no impact of psoriasis on health- related QoL) ● Non-responder imputation and observed data are presented Results PATIENTS ●
    keywords: bimekizumab; nail; pharma; psoriasis; responders; week
       cache: skin-761.pdf
  plain text: skin-761.txt

        item: #1202 of 1356
          id: skin-762
      author: Papp, Kim A; Merola, Joseph F; Gottlieb, Alice B; Griffiths, Christopher EM; Harris, Kristina K; Cross, Nancy; Peterson, Luke; Cioffi, Christopher; Blauvelt, Andrew
       title: Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study
        date: 2019-11-09
       words: 2147
      flesch: 39
     summary: KA Papp reports consultant honoraria from AbbVie, Akros, Amgen, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, LEO, Merck (MSD), Merck- Serono, Mitsubishi Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Aventis/Genzyme, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health; speaker fees from AbbVie, Amgen, Astellas, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, LEO, Merck (MSD), Novartis, Pfizer, Sanofi Aventis/Genzyme, Sun Pharma, Valeant/Bausch Health; investigator grants from AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, LEO, MedImmune, Merck (MSD), Merck-Serono, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Aventis/Genzyme, Sun Pharma, Takeda, UCB Pharma, Valeant/Bausch Health; advisory board honoraria from AbbVie, Amgen, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dow Pharma, Eli Lilly, Galderma, Janssen, Merck (MSD), Novartis, Pfizer, Regeneron, Sanofi Aventis/Genzyme, Sun Pharma, UCB Pharma, Valeant/Bausch Health; and other fees from AbbVie, Akros, Amgen, Anacor, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck (MSD), Merck-Serono, Novartis, Pfizer, Regeneron, Sanofi Aventis/Genzyme, Sun Pharma, Valeant/Bausch Health. JF Merola reports consultant honoraria from AbbVie, Almirall, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Samumed, Sanofi Regeneron, Sun Pharma, UCB Pharma;
    keywords: bimekizumab; dlqi; pharma; responders; week
       cache: skin-762.pdf
  plain text: skin-762.txt

        item: #1203 of 1356
          id: skin-763
      author: Gordon, K; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A; Thaci, D; Leonardi, C; Poulin, Y; Boehnlein, M; Kavanagh, S; Arendt, C; Reich, K
       title: Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2019-11-09
       words: 2152
      flesch: 52
     summary: Investigator (Research grants) from AbbVie; Baxter; Boehringer Ingelheim Pharma; Celgene; Centocor/Janssen; Eli Lilly; EMD Serono; GSK; Leo Pharma; MedImmune; Merck; Novartis; Pfizer; Regeneron; Takeda; UCB Pharma. MB, CA: Employees of UCB Pharma; SK: Employee of UCB Pharma; Consulting fees from AveXis, Colorado Prevention Center, DiaMedica, PureTech, UCB Pharma, Zosano; KR: Advisor and/or paid speaker for and/or participated in clinical trials sponsored by: Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Biopepis, Sanofi, Takeda, UCB Pharma, Valeant, Xenoport. RBW: Grants and/or honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, Xenoport.
    keywords: czp; pasi; pharma; q2w; treatment; weeks
       cache: skin-763.pdf
  plain text: skin-763.txt

        item: #1204 of 1356
          id: skin-764
      author: Gordon, K; Warren, R.B.; Gottlieb, A.B.; Blauvelt, A.; Thaci, D; Leonardi, C; Poulin, Y; Boehnlein, M; Kavanagh, S; Arendt, C; Reich, K
       title: Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2019-11-09
       words: 2012
      flesch: 55
     summary: Investigator (Research grants) from AbbVie; Baxter; Boehringer Ingelheim Pharma; Celgene; Centocor/Janssen; Eli Lilly; EMD Serono; GSK; Leo Pharma; MedImmune; Merck; Novartis; Pfizer; Regeneron; Takeda; UCB Pharma; MB, CA: Employees of UCB Pharma; SK: Employee of UCB Pharma; Consulting fees from AveXis, Colorado Prevention Center, DiaMedica, PureTech, UCB Pharma, Zosano; KR: Advisor and/or paid speaker for and/or participated in clinical trials sponsored by: Abbvie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Biopepis, Sanofi, Takeda, UCB Pharma, Valeant, Xenoport. Author Disclosures KG: Honoraria and or research support from: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol- Myers Squibb, Celgene, Dermira Inc., Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; RBW: Grants and/or honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, Xenoport; ABG: Research/Educational Grants: Janssen, Incyte, Eli Lilly, Novartis, Allergan and LEO Pharma.
    keywords: czp; mg q2w; patients; pharma; q2w; week
       cache: skin-764.pdf
  plain text: skin-764.txt

        item: #1205 of 1356
          id: skin-765
      author: Gottlieb, A.B.; Thaci, D; Leonardi, C; Poulin, Y; Kavanagh, S; Boehnlein, M; Reich, K
       title: Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials
        date: 2019-11-09
       words: 1935
      flesch: 56
     summary: • CZP demonstrated similar efficacy in treating nail disease in PSO patients with and without concomitant PsA. • Week 48 nail disease outcomes in PSO patients with and without PsA treated with CZP in CIMPASI-1/CIMPASI-2 and CIMPACT Observed case data are reported for all patients with PSO who had nail disease at baseline (mNAPSI >0) treated with CZP (dose combined: CZP 400 mg or 200 mg Q2W following a 400 mg loading dose at Weeks 0, 2, 4) through 48 weeks in CIMPASI-1/2 and CIMPACT, and for the subpopulations of patients with and without self-reported PsA (+PsA/−PsA).
    keywords: czp; patients; psa; pso
       cache: skin-765.pdf
  plain text: skin-765.txt

        item: #1206 of 1356
          id: skin-766
      author: Blauvelt, A; Strober, B; Langley, R; Kavanagh, S; Arendt, C; Boehnlein, M; Lebwohl, M; Reich, K
       title: Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
        date: 2019-11-09
       words: 2155
      flesch: 53
     summary: Consulting honoraria and clinical investigator: AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira Inc., Eli Lilly, Galderma, Genentech/ Roche, GSK, Janssen, LEO Pharma, Meiji, Merck, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, Vidac. Speaker’s fees: Eli Lilly, Janssen, Regeneron, Sanofi Genzyme; BS: Consulting fees and/or other honoraria: AbbVie, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Dermira Inc., Janssen, Eli Lilly, LEO Pharma, Medac, Menlo Therapeutics, Novartis, Pfizer, GSK, UCB Pharma, Sun Pharma, Ortho Dermatologics/ Valeant, Regeneron, Sanofi Genzyme; CORRONA Psoriasis Registry; Grant Support to the University of Connecticut for Fellowship Program (payments to the University of Connecticut, not BS): AbbVie, Janssen; RL: Consulting fees and/or other honoraria: AbbVie, Amgen, Boehringer Ingelheim International GmbH, Centocor, Pfizer, Janssen, LEO Pharma, Eli Lilly, Valeant; SK, CA, MB: Employees of UCB Pharma; ML: Consultant for Allergan, Aqua, LEO Pharma, Promius.
    keywords: aes; czp; mg q2w; pasi; pharma; q2w
       cache: skin-766.pdf
  plain text: skin-766.txt

        item: #1207 of 1356
          id: skin-767
      author: van de Kerkhof, P; Pinter, A; Boehnlein, M; Kavanagh, S; Crowley, J.J.
       title: Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2
        date: 2019-11-09
       words: 1878
      flesch: 60
     summary: CONCLUSIONS • Rapid improvements in psoriasis of the head and neck region were seen as early as Week 2 of CZP treatment. In this post-hoc analysis, we report CZP efficacy for the head and neck region over 48 weeks.
    keywords: czp; head; pasi; patients; q2w
       cache: skin-767.pdf
  plain text: skin-767.txt

        item: #1208 of 1356
          id: skin-768
      author: Guttman-Yassky, E; Blauvelt, A; Eichenfield, L.F.; Paller, A; Armstrong, A; Drew, J; Gopalan, R; Simpson, E
       title: Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study
        date: 2019-11-09
       words: 3339
      flesch: 56
     summary: • Safety analyses used the safety population (those randomized who received ≥1 dose of study drug) • Missing data through Week 16 were imputed using Markov chain Monte Carlo (MCMC) multiple imputation, with no imputation for missing pruritus data (prespecified) – Data for patients requiring topical rescue were included if available; data for those requiring systemic rescue were considered missing from the time of withdrawal – A post hoc analysis was performed for pruritus, whereby missing data were imputed using MCMC imputation • Statistical comparisons were performed between LEB and placebo (and not between LEB groups) RESULTS • mg Q4W, 250 mg Q4W, 250 mg Q2W versus 0% of placebo-treated patients, respectively • A similar rate of herpes infections was reported in LEB groups versus placebo: 2.7%, 5.0%, 2.7% of LEB 125
    keywords: baseline; leb; mg q4w; patients; placebo; q2w; q4w leb; week
       cache: skin-768.pdf
  plain text: skin-768.txt

        item: #1209 of 1356
          id: skin-769
      author: McKenzie, Shanice Alyssa; Patel, Nirali; Harview, Christina L; Truong, Allison K; Chen, Lucia Y; Grogan, Tristan R; Shi, Vivian Y; Bennett, Richard G; Hsiao, Jennifer Lin
       title: Weight Gain Over Time in Hidradenitis Suppurativa Patients: Trends and Implications
        date: 2020-03-08
       words: 2168
      flesch: 59
     summary: However, little is documented about weight gain over time in HS patients. Since obesity is thought to increase HS severity, weight management should be stressed in HS patients early on before weight gain occurs.
    keywords: bmi; gain; hidradenitis; patients; school; weight
       cache: skin-769.pdf
  plain text: skin-769.txt

        item: #1210 of 1356
          id: skin-77
      author: Papp, Kim A; Blauvelt, Andrew; Flack, Mary; Gu, Yihua; Thompson, Elizabeth HZ
       title: Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab
        date: 2017-10-27
       words: 2111
      flesch: 57
     summary: EFFICACY • At OLE entry, PASI 90 response rates for patients previously treated with 18 mg, 90 mg, or 180 mg risankizumab or ustekinumab were 0% (0/22), 53.6% (15/28), 51.5% (17/33), and 14.8% (4/27), respectively, reflecting residual benefit from study drug in the parent study (Figure 2). • At OLE entry, PASI 100 response rates for patients previously treated with 18 mg, 90 mg, or 180 mg risankizumab or ustekinumab were 0% (0/22), 39.3% (11/28), 30.3% (10/33), and 3.7% (1/27), respectively, and increased to 27.3% (6/22), 46.4% (13/28), 39.4% (12/33), and 48.1% (13/27), respectively, at week 24 of the OLE (Figure 3).
    keywords: ole; risankizumab; week
       cache: skin-77.pdf
  plain text: skin-77.txt

        item: #1211 of 1356
          id: skin-770
      author: Weidinger, Stephan; Tollenaere, Maxim A.X.; Drerup, Katharina; Litman, Thomas; Norsgaard, Hanne
       title: Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro
        date: 2019-11-09
       words: 1801
      flesch: 48
     summary: Study design In silico bioinformatics analysis of RNA-sequencing data2 to examine the correlation between IL13 expression and AD disease biomarkers Validate correlations in vitro using disease-relevant cell cultures Can IL-13-driven expression of AD disease biomarkers be reverted by tralokinumab? IL13 expression strongly correlates with key AD disease biomarkers: A) Positive correlation between IL13 expression and infl ammatory mediators and B) Negative correlation between IL13 expression and skin barrier markers 2 7 6 5 4 3 A B IL13 –5 –4 –3 –2 –1 0 1 2 C C L2 2 IL13 –6 210–1–2–3–4–5 C C L2 2 7 6 5 4 3 IL13 –4 210–1–2–3 C C L1 7 7 –5 –3 –1 1 3 5 Pearson r=0.79 Pearson r=0.69 IL13 –4 210–1–2–3 N TR K 1 5 –7 –5 –3 –1 1 3 Pearson r=0.82 IL13 –4 210–1–2–3 FL G 2 14 9 10 11 12 13 Pearson r=-0.61 IL13 –4 210–1–2–3 EL O V L6 7 4 5 6 Pearson r=-0.73 IL13 –4 210–1–2–3 FL G 16 10 11 12 13 14 15 Pearson r=-0.55 IL13 –4 210–1–2–3 LO R 10 5 6 7 8 9 Pearson r=-0.59 Pearson r=0.81 Graph axes represent Log2 (CPM) values.
    keywords: expression
       cache: skin-770.pdf
  plain text: skin-770.txt

        item: #1212 of 1356
          id: skin-772
      author: Arrowitz, CE; Jiang, LI; Hino, PD; Babcock, MJ; Weber, TM
       title: A Comparison of Efficacy among Therapeutic Moisturizing Creams
        date: 2019-11-09
       words: 1227
      flesch: 41
     summary: Skin hydration improvement at Day 10, and 5 days after completion of treatment (regression Day 5) Skin hydration measured using a Corneometer 0 1 2 3 4 5 6 Baseline Day 10 R Day 5 Baseline Day 10 R Day 5 Baseline Day 10 R Day 5 Baseline Day 10 R Day 5 Baseline Day 10 R Day 5 Baseline Day 10 R Day 5 0 1 2 3 4 5 6A. Dryness B. Roughness C li n ic a l g ra d in g s co re C li n ic a l g ra d in g s co re a a a a a a aa 0 1 2 3 4 5 6 MCA MCB MCA MCC C. Flaking C li n ic a l g ra d in g s co re a,b a a,b a 0 1 2 3 4 5 6 0 1 2 3 4 5 6 D. Dryness E. Roughness Study 1 Study 2 C li n ic a l g ra d in g s co re C li n ic a l g ra d in g s co re a a a a,b a a a a 0 1 2 3 4 5 6 F. Flaking C li n ic a l g ra d in g s co re a a a,b a ap<0.001 vs baseline; bp≤0.01 vs MCB ap≤0.001 vs baseline; bp≤0.01 vs MCC Figure 3. Treatments applied daily (10 days) Treatment discontinued Baseline Day 10 R Day 5Assessments Table 1.
    keywords: day
       cache: skin-772.pdf
  plain text: skin-772.txt

        item: #1213 of 1356
          id: skin-773
      author: Draelos, Zoe Diane; Hall, Steven B; Munsick, Carey
       title: A 14 Day, Single Blind, Controlled Study to Assess the Qualitative Improvement in Skin Moisturization and Desquamation of 15% Lactic Acid Moisturizer with Ceramides (LAMC) Treatment in Healthy Female Subjects
        date: 2019-11-09
       words: 730
      flesch: 54
     summary: CONCLUSIONS • LAMC provided a statistically significant and clinically meaningful improvement in moisturization and desquamation as evidenced by D-SQUAME®, Dry Skin Scale, and Subject Self-Assessments in the population studied. Lactic Acid Moisturizer with Ceramides (LAMC) contains ceramides, humectants and lactic acid that work in combination to moisturize dry skin and induce desquamation.
    keywords: day; skin
       cache: skin-773.pdf
  plain text: skin-773.txt

        item: #1214 of 1356
          id: skin-774
      author: Moore, Angela Yen; Moore, Stephen
       title: Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination
        date: 2019-11-09
       words: 1607
      flesch: 60
     summary: • After PDT with red light illumination, 8% (9/114) of patients experienced irritation in 5% (9/176) of PDT treatments (Figure 1). • Irritation may be mitigated by stringent adherence to a specific PDT post-care regimen using sunblock and healing creams every 2 hours during waking hours for 48 hours after PDT treatment.
    keywords: irritation; light; pdt; sessions
       cache: skin-774.pdf
  plain text: skin-774.txt

        item: #1215 of 1356
          id: skin-775
      author: Dirschka, T; Ulrich, M; Reinhold, U; Dominicus, R; Aschoff, R; Szeimies, R.M.
       title: Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial
        date: 2019-11-09
       words: 958
      flesch: 41
     summary: [%] Impaired [%] 40.8 18.4 20.420.4 18.4 8.2 16.3 57.1 Total lesion clearance per patient‘s side - 12 weeks after the last PDT BF-200 ALA Placebo lesion preparation (including degreasing, roughening of the skin) application of BF-200 ALA or placebo light-tight dressing; 3 h removal of remaining gel, illumination with narrowband red light source potential second PDT treatment FU 1 year assessment after 12 weeks Due to ALA PDT‘s mode of action, AEs are mainly local application site reactions such as erythema, pain, edema, and irritation which are transient and self-limiting, normally within 1-2 weeks. BF-200 ALA Placebo 0 50 100 150 C o m p le te ly c le a re d l e s io n s
    keywords: ala; bf-200; placebo
       cache: skin-775.pdf
  plain text: skin-775.txt

        item: #1216 of 1356
          id: skin-776
      author: Laquer, V; Bruce, S; Schlesinger, T; Zeitouni, N; Torres, A; Cohen, J; Tu, J; Hanke, W; Goldman, M; Ozog, D; Markowitz, O; Gold, M; Nestor, M; Berman, B; Munavalli, G; Pariser, D
       title: A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT)
        date: 2019-11-09
       words: 1549
      flesch: 54
     summary: 7 PDT with BF-200 ALA for BCC treatment in the EU lesion preparation (including degreasing, roughening of the skin) application of BF-200 ALA or vehicle light-tight dressing; 3 h removal of remaining gel, illumination with narrowband red light source second PDT 1 week apart potential second PDT cycle FU1-4 12 months- 5 years assessment after 12 weeks NCT03573401 This approval was primarily based on a single pivotal study that demonstrated the efficacy and safety of BF-200 ALA PDT in conjunction with a narrowband red light source (~635 nm; 37 J/cm ) for the treatment of non-aggressive superficial 2 and/or nodular BCC with a thickness of <2 mm.
    keywords: ala; bf-200; clinical; pdt; treatment; visit; weeks
       cache: skin-776.pdf
  plain text: skin-776.txt

        item: #1217 of 1356
          id: skin-778
      author: Migden, Michael R; Schlesinger, Todd E; Schmults, Chrysalyne D; Dinehart, Scott M; Ferris, Robert L; Freeman, Morganna; Guild, Valerie; Koyfman, Shlomo; Pavlick, Anna C; Wolf, Gregory T; Rabinowits, Guilherme; Swanson, Neil
       title: Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma
        date: 2019-11-09
       words: 2212
      flesch: 26
     summary: Given the approval of cemiplimab, the curative confidence and morbidity of definitive, single modality radiation therapy should be considered, discussed with the patient, and weighed against systemic options such as immunotherapy Immunotherapy in the management of advanced CSCC Consensus • Cemiplimab is the only FDA approved therapy for use in patients with LA or metastatic CSCC who are not candidates for curative surgery or curative radiation. Key abstracts from congresses were also included (e.g. from American Society of Clinical Oncology, the European Academy of Dermatology and Venereology, the American Academy of Dermatology, and the Society for Investigative Dermatology) 5471 references were identified and screened 161 references were used to develop final recommendations Considerations for the Management of Advanced CSCC SELECT CONSENSUS STATEMENTS AND KEY RECOMMENDATIONS Radiation therapy for advanced CSCC may be considered in the following settings Consensus • Adjuvant radiation therapy may be considered in patients with uncertain surgical margins (e.g. multifocal or large caliber nerve invasion, or lymphovascular invasion) or with a recurrent tumor.
    keywords: advisory; consensus; cscc; patients; pharmaceuticals; radiation; regeneron; therapy
       cache: skin-778.pdf
  plain text: skin-778.txt

        item: #1218 of 1356
          id: skin-779
      author: Litchman, Graham; Caruso, Hilary; Cook, Robert; Rigel, Darrell
       title: Recurrence prediction in cutaneous melanoma with 31-gene expression profiling and sentinel lymph node biopsy
        date: 2019-11-09
       words: 916
      flesch: 77
     summary: GEP SLN GEP and SLN RFS n=1479 n=867 n=1479 Sensitivity 76% (71-80%) 57% (51-63%) 86% (82-90%) Sensitivity and NPV of 31-GEP and SLNB in a model assuming use of 31-GEP to guide SLNB decisions GEP SLN GEP and SLN RFS n=1479 n=842 n=1479 Sensitivity 76% (71-80%) 56% (50-62%) 84% (79-88%) NPV 92% (90-94%) 79% (75-82%) 94% (93-95%) DMFS n=1223 n=842 n=1223 Sensitivity 76% (70-82%) 61% (53-68%) 86% (80-90%) NPV 93% (91-95%) 86% (83-89%) 95% (94-97%) MSS n=1157 n=609 n=1157 Sensitivity 86% (77-92%) 72% (60-82%) 94% (97-98%) NPV 98% (97-99%) 96% (95-98%) 99% (98-100%)
    keywords: gep; patients
       cache: skin-779.pdf
  plain text: skin-779.txt

        item: #1219 of 1356
          id: skin-78
      author: Strober, Bruce; Papp, Kim A; Flack, Mary; Gu, Yihua; Thompson, Elizabeth HZ; Valdecantos, Wendell C
       title: Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis
        date: 2017-10-27
       words: 1498
      flesch: 54
     summary: OBJECTIVE • The objective of this analysis was to examine the distribution of PASI responses in patients from the phase 2 trial treated with risankizumab versus ustekinumab. MATERIALS & METHODS RESULTS CONCLUSIONS • The proportions of patients achieving different levels of PASI responses were assessed at weeks 12 and 16 in an intent-to-treat population.
    keywords: pasi; patients; risankizumab; week
       cache: skin-78.pdf
  plain text: skin-78.txt

        item: #1220 of 1356
          id: skin-780
      author: Brouha, Brook; Ferris, Laura K; Skelsey, Maral K; Peck, Gary; Yao, Zuxu; Jansen, Burkhard
       title: Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma
        date: 2019-11-09
       words: 1419
      flesch: 56
     summary: • PLA positive lesions are biopsied as intended in 97.53% of cases. • PLA negative lesions are monitored clinically and not biopsied in 99.94% of cases.
    keywords: cases; lesions; pla; test
       cache: skin-780.pdf
  plain text: skin-780.txt

        item: #1221 of 1356
          id: skin-781
      author: Schadendorf, Dirk; Dummer, Reinhard; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandala, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Mortier, Laurent; Robert, Caroline; Schachter, Jacob; Ortmann, Christine-Elke; de Jong, Egbert; Gasal, Edward; Kefford, Richard; Kirkwood, John M; Long, Georgina V
       title: Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo
        date: 2019-11-09
       words: 3796
      flesch: 57
     summary: Kaplan- Meier analysis of RFS based on age (< median or ≥ median) demonstrated improved RFS in patients treated with dabrafenib + trametinib vs placebo regardless of age (Figure 2) – Age < 51 years: Median RFS was not reached in the dabrafenib + trametinib arm vs 20.1 months in the placebo arm (HR, 0.51 • Kaplan-Meier analysis demonstrated that dabrafenib + trametinib improved RFS vs placebo regardless of patients’ sex (Figure 3) – Female patients: Median RFS was not reached in the dabrafenib + trametinib arm vs 25.5 months in the placebo arm (HR, 0.56 [95% CI, 0.42-0.75]) – Male patients: Median RFS was not reached in the dabrafenib + trametinib arm vs 13.8 months in the placebo arm (HR, 0.45
    keywords: arm; dabrafenib; months; placebo; rfs; trametinib
       cache: skin-781.pdf
  plain text: skin-781.txt

        item: #1222 of 1356
          id: skin-782
      author: Kirsch, Brandon; DuBois, Janet; Chadha, Deepak
       title: A Multi-Center, Open-Label Study to Assess Pharmacokinetics (PK), Safety and Tolerability of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, ≥9 to 
        date: 2019-11-09
       words: 1259
      flesch: 56
     summary: Severe 12 (48.0%) Very Severe 4 (16.0%) 0 1 2 3 4 Day 1 Day 8 H D S M -A x S co re Study Day HDSM-Ax Scores 0% 10% 20% 30% 40% 50% 60% None Mild Moderate Severe Very Severe P e rc e n t R e sp o n se s Severity PGI-S Responses Day 1 Day 8 SB GEL, 15% (N=25) Subjects with TEAEs 3 (12.0%) Number of TEAEs 4 Dry Eye 1 (4.0%, mild) Vision Blurred 1 (4.0%, moderate) Influenza 1 (4.0%, moderate) Urinary Hesitation 1 (4.0%, mild) Subjects with SAEs 0 Arch Dermatol Res. 2016; 308:743-749. References 0 2 4 6 8 10 12 14 16 D ay 1 , 0 h D ay 1 , 1 h D ay 1 , 4 h D ay 1 , 8 h D ay 1 , 2 4h D ay 8 , 2 4h S o fp ir o n iu m S am p le C o n ce n tr at io n (n g /m L) Collection Day, Nominal Hour Sofpironium Concentrations 0 2 4 6 8 10 12 14 16 D ay 1 , 0 h D ay 1 , 1 h D ay 1 , 4 h D ay 1 , 8 h D ay 1 , 2 4h D ay 8 , 2 4h B B I- 4 0 1 0 C o n ce n tr at io n (n g /m L) Collection Day, Nominal Hour BBI-4010 Concentrations
    keywords: day; severity; sofpironium
       cache: skin-782.pdf
  plain text: skin-782.txt

        item: #1223 of 1356
          id: skin-783
      author: Pariser, D.M.; Lain, E.L.; Mamelok, R; Drew, J; Mould, D.R.
       title: Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Healthy Volunteers and Patients with Primary Axillary Hyperhidrosis
        date: 2019-11-09
       words: 3150
      flesch: 30
     summary: In both studies, intensive blood sampling occurred on Days 1-2 and, for one study also on Days 15-16; additional sampling occurred in subsequent weeks • PK data from these phase 2 studies informed a population PK model (NONMEM version 7.2.0 Icon PLC, Dublin, Ireland) from which exposure metrics were used to assess the relationship between topical glycopyrronium PK and anticholinergic-related AEs or efficacy Figure 1. For adults receiving oral glycopyrrolate 1, 2, and 3 mg, respectively, mean ± SD PK parameters were Cmax 0.15 ± 0.12, 0.23 ± 0.11, and 0.38 ± 0.19 ng/mL, and AUC0-24 2.12 ± 1.47, 3.50 ± 1.50, and 5.50 ± 2.19 h*ng/mL ± SD (Table 2) Table 2.
    keywords: days; glycopyrronium; patients; phase; study; topical
       cache: skin-783.pdf
  plain text: skin-783.txt

        item: #1224 of 1356
          id: skin-784
      author: Bhatia, Neal
       title: Measuring the Predictive Value of Serological Quantification of Cytokines with the Onset of Influenza-Like Signs and Symptoms Induced by Imiquimod 3.75% Cream: Results of a Single Center, Open-Label, Proof of Concept Trial
        date: 2019-11-09
       words: 925
      flesch: 62
     summary: No Systemic Symptoms Systemic Symptoms V1 V2 V3 V4 V5 V1 V2 V3 V4 V5 SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT SS LSR EL CYT CONCLUSION • Treatment on the face led to more incidence of flu like symptoms in younger patients • Elevations in pro-inflammatory cytokines did not appear to predict the development of either sys- temic symptoms or local skin reactions. • Frequency of symptoms indicative of an influenza-like response, in- cluding, fever, headache, fatigue, malaise, gastrointestinal symptoms, dizziness, myalgia, and arthralgia.
    keywords: cyt; il-13
       cache: skin-784.pdf
  plain text: skin-784.txt

        item: #1225 of 1356
          id: skin-785
      author: Madan, Sumit; Kumar, Sudershan; Segal, Jeanett
       title: Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized-Isotretinoin 32-mg Formulation and Lidose-Isotretinoin 40 mg in Fed and Fasted Conditions: 2 Open-label, Randomized Crossover Studies in Healthy Adult Participants
        date: 2019-11-09
       words: 2539
      flesch: 15
     summary: ACCUTANE® (isotretinoin capsules) PI. ABSORICA® (isotretinoin capsules) PI.
    keywords: fed; isotretinoin; lidose; state
       cache: skin-785.pdf
  plain text: skin-785.txt

        item: #1226 of 1356
          id: skin-787
      author: Geizhals, Solomon; Lebwohl, Mark G
       title: The Successful Treatment of Multiple Cutaneous Malignancies with HPV Vaccination: Case Report
        date: 2020-03-08
       words: 1348
      flesch: 46
     summary: The National Society for Cutaneous Medicine 150 vaginal, vulvar, and some oropharyngeal cancers, but not against β-HPV types.6-7 Although the β-HPV subtype has been viewed as the main culprit in cutaneous malignancy pathogenesis, nevertheless, some patients that received the more limited quadrivalent vaccine reduced new SCC development in immunocompetent patients without known HPV infection.8 The data supporting the use of intratumoral vaccine injections in eliciting immune responses capable of eradicating tumor cells12 coupled with the evidence showing a strong relationship between HPV and non-melanotic skin cancers led us to treat and now report a 2nd case in which a patient’s multiple cutaneous malignancies were successfully treated with the HPV vaccine.
    keywords: cell; hpv; skin; vaccine
       cache: skin-787.pdf
  plain text: skin-787.txt

        item: #1227 of 1356
          id: skin-789
      author: Singer, Sarina; Shihab, Nahla; Lebwohl, Mark
       title: Cyclosporine for Severe Drug Eruption in a Psoriasis Patient
        date: 2020-07-12
       words: 844
      flesch: 46
     summary: The principal management of drug eruption is to withdraw the offending drugs and provide supportive care. We suspected that his new rash represented drug eruption, suggested discontinuation of doxycycline, and prescribed cyclosporine 250 mg by mouth twice a day.
    keywords: cyclosporine; drug; eruption
       cache: skin-789.pdf
  plain text: skin-789.txt

        item: #1228 of 1356
          id: skin-79
      author: Thaci, Diamant; Menter, Alan; Wu, Jashin J; Arikan, Dilek; Kupper, Hartmut; Bereswill, Mareike; Valdecantos, Wendell C
       title: Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry
        date: 2017-10-27
       words: 3226
      flesch: 62
     summary: Proportion of Patients Achieving PGA “Clear” or “Minimal” Over Years 1–8 (All-Rx and New-Rx Patient Populations: as Observed) 12 24 36 48 60 72 84 96 0 20 40 60 80 100 Registry Participation, months P a ti e n ts ,% 57.0 58.7 59.1 62.6 61.9 63.8 65.5 45.0 n= Na= New-Rx (N=2554)All-Rx (N=6045) 52.8 55.5 56.3 59.5 59.9 63.2 64.2 50.0 2635 4624 983 1862 2376 4048 881 1588 2090 3537 767 1363 1994 3185 724 1216 1496 2415 571 953 1114 1745 425 673 428 653 217 338 9 20 8 16 Na=number of patients with non-missing PGA data at the respective visit; All-Rx=all-treated patient population. This included AEs collected in the registry, collected retroactively before registry entry, and from feeder studies for patients rolling over from preregistry feeder clinical trials.
    keywords: ada; exposure; patients; population; registry
       cache: skin-79.pdf
  plain text: skin-79.txt

        item: #1229 of 1356
          id: skin-790
      author: Zufall, Alina G; Li, Rung-chi; Zlotoff, Barrett J; Lawrence, Monica G; Flowers, Richard H
       title: Eosinophilic Annular Erythema- Successful Treatment with Dupilumab
        date: 2020-05-08
       words: 1456
      flesch: 46
     summary: Eosinophilic annular erythema treated with dupilumab. 2013;27(8):973-979. doi:10.1111/j.1468- 3083.2012.04616.x 2. Kahofer P, Grabmaier E, Aberer E. Treatment of eosinophilic annular erythema with chloroquine.
    keywords: dermatol; eae; eosinophilic; erythema; patient
       cache: skin-790.pdf
  plain text: skin-790.txt

        item: #1230 of 1356
          id: skin-792
      author: Agrawal, Shruti; Tomecki, Kenneth J
       title: Dermatology and Vaccines: A Call to Arms
        date: 2020-01-28
       words: 1470
      flesch: 49
     summary: In addition to serving as a preventive tool, HPV vaccination may be an effective treatment for warts, basal cell carcinoma, and squamous cell carcinoma.5 The Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for teenagers 11 to 12 years old – two doses at 6-12 months apart. Despite its benefits, overall acceptance of HPV vaccination has been modest at best, possibly due to lack of widespread availability of accurate information, a false perception that only sexually active adolescents should receive the vaccine, social stigma, financial barriers, and the need for multiple doses.6 Some physicians present the HPV vaccine as “optional,” instead of firmly and clearly framing the vaccine as a non-negotiable tool to prevent disease.
    keywords: anti; hpv; measles; vaccination; vaccine
       cache: skin-792.pdf
  plain text: skin-792.txt

        item: #1231 of 1356
          id: skin-793
      author: Shihab, Nahla; Tyutyunik, Michael; Lebwohl, Mark
       title: Psoriasis in Pregnancy: A Review
        date: 2020-03-08
       words: 2120
      flesch: 47
     summary: The treatment of psoriasis is varied depending on the disease severity, comorbidities, and patient preference.2,3 In the case of pregnancy, treatment of psoriasis can also be challenging. The treatment of psoriasis in pregnancy can be challenging, mainly because there is only a few evidence-based studies.
    keywords: cells; dermatol; medicine; pregnancy; pregnant; psoriasis; skin; treatment
       cache: skin-793.pdf
  plain text: skin-793.txt

        item: #1232 of 1356
          id: skin-795
      author: Brady, Joshua M; Kashlan, Reem; Moossavi, Meena
       title: Hermann Pinkus – Influencing an Entire Generation of Dermatopathologists
        date: 2020-07-12
       words: 483
      flesch: 45
     summary: Microsoft Word - July 2020 - DH 795 - proof - returned.docx SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 391 DERMATOLOGIC HISTORY Hermann Pinkus – Influencing an Entire Generation of Dermatopathologists Joshua M. Brady, BS,1 Reem Kashlan, MPH,1 Meena Moossavi, MD, MPH1 1Wayne State University, Detroit, MI Hermann Pinkus was born in Berlin, Germany on November 18, 1905. Hermann and his father, like many other Jewish physicians in the 1930’s, were displaced from Germany due to the Nazi regime.1 Hermann Pinkus graduated from the University of Berlin in 1929 and completed a majority of his training in Breslau, Germany.
    keywords: hermann; pinkus
       cache: skin-795.pdf
  plain text: skin-795.txt

        item: #1233 of 1356
          id: skin-796
      author: Yi, Lauren G; Forrester, Vernon J; Timko, Michael P; Wilson, Barbara B
       title: Plant Stellate Trichomes: Strange Contaminants Appearing in KOH Preparations
        date: 2020-03-08
       words: 586
      flesch: 50
     summary: The National Society for Cutaneous Medicine 185 SHORT COMMUNICATIONS Plant Stellate Trichomes: Strange Contaminants Appearing in KOH Preparations Lauren G. Yi BS1, Vernon J. Forrester MD2, Michael P. Timko PhD3, Barbara B. Wilson MD2 1University of Virginia School of Medicine, Charlottesville, VA 2Department of Dermatology, University of Virginia, Charlottesville, VA 3Department of Biology, University of Virginia, Charlottesville, VA We have observed stellate structures under microscopy on potassium hydroxide preparations of skin scrapings. Typical appearance as seen on a potassium hydroxide preparation without skin scrapings (40X).
    keywords: skin; structures; trichomes
       cache: skin-796.pdf
  plain text: skin-796.txt

        item: #1234 of 1356
          id: skin-797
      author: Kashlan, Reem; Brady, Joshua M; Moossavi, Meena
       title: Ken Hashimoto – A Pioneer in Dermatological Electron Microscopy
        date: 2020-07-12
       words: 498
      flesch: 35
     summary: Hashimoto, a Fulbright scholar, received his medical degree from Niigata University Medical School and dermatological training at the University of Maryland and Massachusetts General Hospital.1 Hashimoto subsequently established and was chair of the Dermatology program at Wright State University before coming to Wayne State University (WSU) in 1980.1,2 Hashimoto held his position as Professor and Chairman of WSU until his retirement in 2000, becoming the first and only Japanese national to head an American dermatological department at that time.1 Hashimoto’s proficiency with the electron microscope and extensive knowledge of histochemistry was vital to the understanding of many diseases. Microsoft Word - July 2020 - DH 797 - Proof - final.docx SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 393 DERMATOLOGIC HISTORY Ken Hashimoto – A Pioneer in Dermatological Electron Microscopy Reem Kashlan, MPH1, Joshua M. Brady, BS1, Meena Moossavi, MD, MPH1 1Wayne State University School of Medicine Ken Hashimoto was born in Niigata, Japan on June 19, 1931.
    keywords: dermatology; hashimoto; university
       cache: skin-797.pdf
  plain text: skin-797.txt

        item: #1235 of 1356
          id: skin-798
      author: Prezzano, James C; Richardson, Christopher T; Scott, Glynis A; Ibrahim, Sherrif F
       title: Extensive Primary Anetoderma Refractory to Erbium YAG Fractionally Ablative Laser
        date: 2020-05-08
       words: 1109
      flesch: 50
     summary: A 10,600-nm CO2 laser using the pinhole method was used successfully to treat lesions on the ear of an eight-year-old boy with secondary anetoderma following juvenile xanthogranuloma.5 Anetoderma secondary to a severe sun burn was successfully treated with 595-nm pulsed-dye laser combined with 1550-nm non-ablative fractionated laser.6 Patients with secondary anetoderma and anetoderma limited to a relatively small body surface area may be more amenable to laser treatment than patients with extensive involvement.
    keywords: anetoderma; laser; primary; treatment
       cache: skin-798.pdf
  plain text: skin-798.txt

        item: #1236 of 1356
          id: skin-8
      author: Haslam, Samuel P.; Ikpeama, Chinelo; Wilkerson, Michael G.
       title: Penile Mondor's Disease: Two Rare Cases
        date: 2017-06-28
       words: 991
      flesch: 64
     summary: PMD was again suspected, and the patient was advised to abstain from sexual activity until the pain and elevated area resolved. Patients may complain of continuous or throbbing pain and pain exacerbated by erection and sexual activity.
    keywords: disease; penile; pmd
       cache: skin-8.pdf
  plain text: skin-8.txt

        item: #1237 of 1356
          id: skin-800
      author: Vebman, Jonathan Ilai; Choy, Alexa; Yao, Christopher
       title: Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis
        date: 2020-03-08
       words: 2852
      flesch: 52
     summary: Our goals were to analyze and present literature on prevalence of various psoriatic comorbidities, and provide an estimate of what percent of psoriasis patients might have or develop Myocardial/cardiovascular/heart disease, stroke, diabetes, obesity, hypertension, or metabolic syndrome. This paper reviews the literature on the prevalence of specific psoriasis co- morbidities and summarizes published findings on the frequency of each of these conditions in psoriasis patients.
    keywords: cardiovascular; disease; metabolic; patients; prevalence; psoriasis; study
       cache: skin-800.pdf
  plain text: skin-800.txt

        item: #1238 of 1356
          id: skin-801
      author: Gottlieb, AB; Gisondi, P; Eells, J; Peterson, L; Kavanaugh, A
       title: Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study
        date: 2020-01-28
       words: 1585
      flesch: 59
     summary: CONCLUSIONS • Of patients with PsA who initially responded to CZP treatment and achieved an MDA response at Week 24 and completed treatment to Week 216, >85% maintained this clinical response after four years of treatment. Data are pooled for patients treated with CZP 200 mg Q2W and CZP 400 mg Q4W. aMDA plus BSA ≤3% responses are reported in patients who had BSA ≥3% at baseline.
    keywords: czp; mda; patients; week
       cache: skin-801.pdf
  plain text: skin-801.txt

        item: #1239 of 1356
          id: skin-803
      author: Silverberg, JI; Beck, L; Boguniewicz, M; Lin, T; Evans, AM; Patel, DS; Rush, T; Swensen, AR
       title: Study of Adult Atopic Dermatitis and Comorbidities in the US Department of Defense Healthcare System
        date: 2020-01-28
       words: 1164
      flesch: 50
     summary: Comorbidities of Interest During the 1-year Baseline Period Prior to Index in AD patients in the DoD database 2.4% 2.4% 0.6% 11.7% 1.0% 11.3% 7.2% 17.0% 12.3% 0.5% 22.7% 2.1% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% RA Psoriasis Lupus Infections IBD Depression Conjunctivitis Cataracts Asthma Alopecia areata Allergic Rhinitis ADHD C o m o rb id it ie s Disclosures This study was sponsored by LEO Pharma.. The 1-year US prevalence of adult AD was 7.2%-10.2% in 2010- 20121 
    keywords: data; dod; health
       cache: skin-803.pdf
  plain text: skin-803.txt

        item: #1240 of 1356
          id: skin-804
      author: Wu, JJ; Hansen, JB; Patel, DS; Jensen, NN; Veverka, KA; Swensen, AR
       title: Calcipotriene Plus Betamethasone Dipropionate (0.005%/0.064%) foam vs halobetasol propionate and tazarotene (0.01%/0.045%) Lotion: Matching-Adjusted Indirect Comparison & US Cost-Per-Responder Analysis
        date: 2020-01-28
       words: 1790
      flesch: 58
     summary: After reweighting of patients and anchoring to vehicle effect, significantly more Cal/BD foam patients demonstrated greater difference in treatment success relative to vehicle after 4 weeks than did HP/TAZ lotion patients after 8 weeks (51.4% vs 30.7%; treatment difference=20.7%; P<.001) (Table 2)  Halobetasol propionate and tazarotene (0.01%/0.045%, HP/TAZ) lotion is a fixed-combination, once-daily topical treatment of plaque psoriasis in adults.2 Study Design 
    keywords: cal; foam; lotion
       cache: skin-804.pdf
  plain text: skin-804.txt

        item: #1241 of 1356
          id: skin-805
      author: Hull, M; Gillard, KK; Peterson-Brandt, J; Klein, SZ
       title: Treatment Patterns and Depression and Anxiety among Patients Newly Identified with Hyperhidrosis in a Real-World Database Representing US Commercial Health Plan Members
        date: 2020-01-28
       words: 2087
      flesch: 38
     summary: Methods Patient Selection • Commercial health plan members with ≥2 hyperhidrosis diagnosis codes and/or antiperspirant prescription claims were identified from January 2010 through November 2017 from the Optum Research Database, a de-identified research database that contains commercial and Medicare Advantage claims, containing both medical and pharmacy information from 1993 to current and covering over 60 million lives. – Depression was defined as ≥1 medical claim with a diagnosis code for depression in any position and/or
    keywords: anxiety; depression; hyperhidrosis; index; patients; period
       cache: skin-805.pdf
  plain text: skin-805.txt

        item: #1242 of 1356
          id: skin-806
      author: Werth, VP; Joly, P; Mimouni, D; Maverakis, E; Lahane, P; Gearhart, L; Pordeli, P; Chen, DM
       title: A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
        date: 2020-01-28
       words: 2463
      flesch: 41
     summary: bursitis infective (1 patient) and abdominal pain (1 patient) – SAEs related to MMF were, in 1 patient each, pneumonia and influenza (same patient), herpes zoster, urinary retention, chronic obstructive pulmonary disease and skin ulcer Infusion-Related Reactions • IRRs in the rituximab arm occurred primarily at the 1st infusion and frequency decreased with subsequent infusions – 17.9% (1st infusion), 4.5% (2nd infusion), 3% (3rd infusion) and 3% (4th infusion) • IRRs were Grade 1 or 2 in 11 of 15 patients • 3 rituximab patients experienced serious (life-threatening) IRRs that led to discontinuation of infusions and withdrawal from treatment – 2 patients (1st infusion), 1 patient (2nd infusion) – All serious IRRs resolved with symptomatic treatment • IRRs in PV patients were consistent with those seen in patients in other autoimmune indications, both in clinical trials and in the post-marketing setting Infections • A Phase III, Randomized, Double-Blind, Controlled Study (PEMPHIX) to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris Victoria P. Werth,1 Pascal Joly,2
    keywords: arm; day; disease; mmf; patients; rituximab
       cache: skin-806.pdf
  plain text: skin-806.txt

        item: #1243 of 1356
          id: skin-807
      author: Farberg, AS; Hall, MA; Douglas, L; Covington, KR; Kurley, SJ; Cook, RW; Dinehart, SM
       title: Integrating the 40-Gene Expression Profile (40-GEP) Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
        date: 2020-01-28
       words: 1671
      flesch: 51
     summary: Messina and Zager Mount Sinai: Dr. Khorasani Northwestern University: Dr. Yoo Oakview Dermatology: Dr. Trotter OHSU: Dr. Bar Pariser Derm: Dr. Pariser Penn State: Dr. Neves Porter Adventist: Dr. Campana SFVAHCS: Dr. Arron Skin Cancer Specialists: Dr. Griego St. Louis University: Dr. Ramona The Indiana Skin Cancer Center: Dr. Michael Thomas Jefferson University: Dr. Curry University of Pennsylvania: Dr. Newman University of California, San Francisco: Dr. Arron University of Missouri: Drs. Class 2B 25 44.0% 60.0% M e ta s ta s is -F re e S u rv iv a l p<0.0001 Class 1 Class 2A Class 2B 100% 80% 60% 40% 20% 0% 0 1 2 3 4 5 Years Feature of Modeling Cohort (% of Cohort)
    keywords: class; gep; management; nccn; patients; risk; university
       cache: skin-807.pdf
  plain text: skin-807.txt

        item: #1244 of 1356
          id: skin-808
      author: Thorpe, R; Caruso, HG; Covington, KR; Brodland, D; Zitelli, J
       title: Development and validation of a nomogram incorporating the 31-GEP test and clinicopathologic factors for accurate prediction of recurrence risk in patients with cutaneous melanoma
        date: 2020-01-28
       words: 824
      flesch: 68
     summary: The 31-gene expression profile (31-GEP) test is an independent significant predictor of 5-year risk of recurrence and distant metastasis.1-7 • 31-GEP results classify tumor biology as lowest-risk (Class 1A), low-risk (Class 1B), high-risk (Class 2A), and highest-risk (Class 2B): Development and validation of a nomogram incorporating the 31-GEP test and clinicopathologic factors for accurate prediction of recurrence risk in patients with cutaneous melanoma Thorpe, R.1; Caruso, H.G.2; Covington, K.R.2; Brodland, D.3; Zitelli, J.3 1. A logistic regression model was fitted on clinical and pathological data to determine relative predictive value for recurrence risk.
    keywords: class; recurrence; risk
       cache: skin-808.pdf
  plain text: skin-808.txt

        item: #1245 of 1356
          id: skin-809
      author: Blauvelt, A; Paul, C; van de Kerkhof, P; Warren, RB; Gottlieb, AB; Langley, RG; Brock, F; Arendt, C; Boehnlein, M; Lebwohl, M; Reich, K
       title: Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies
        date: 2020-01-28
       words: 2667
      flesch: 54
     summary: Incidence of TEAEs • At Week 144, the IR of TEAEs and serious TEAEs was comparable between CZP dose groups (Table 2). Table 1. Pooled demographics and baseline characteristics for patients who received ≥1 dose CZP through Weeks 0–144 aPatients who received both CZP 200 mg Q2W and CZP 400 mg Q2W are only included once in the population count for the ‘All CZP’ group; bCZP 200 mg Q2W patients received a loading dose of CZP 400 mg at Weeks 0, 2, and 4 or Weeks 16, 18, and 20.
    keywords: czp; mg q2w; pharma; q2w; teaes; weeks
       cache: skin-809.pdf
  plain text: skin-809.txt

        item: #1246 of 1356
          id: skin-81
      author: Zouboulis, Christos C; Okun, Martin M; Gniadecki, Robert; Foley, Peter A; Lynde, Charles; Weisman, Jamie; Karunaratne, Piyalal; Williams, David A
       title: Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)
        date: 2017-10-27
       words: 1507
      flesch: 51
     summary: • Results are reported as “study weeks,” which consist of PIONEER + OLE weeks, shown consecutively. a. Weeks include PIONEER I or II + the OLE, listed consecutively.
    keywords: abbvie; patients; pioneer; week
       cache: skin-81.pdf
  plain text: skin-81.txt

        item: #1247 of 1356
          id: skin-810
      author: Pona, A; Cline, A; Kolli, SS; Feldman, SR
       title: Demographics, Adherence, and Satisfaction of Home UV Phototherapy in Psoriasis
        date: 2020-01-28
       words: 766
      flesch: 51
     summary: The phototherapy system was also used to remotely monitor patient treatments, collecting treatment records and adherence data. Review of home phototherapy.
    keywords: adherence; phototherapy; treatment
       cache: skin-810.pdf
  plain text: skin-810.txt

        item: #1248 of 1356
          id: skin-811
      author: Moore, A; Green, L; Bruce, S; Sadick, N; Tschen, E; Werschler, P; Dhawan, S; Forsha, D; Gold, M; Guenthner, S; Kempers, S; Kircik, L; Parish, J; Rendon, M; Rich, P; Stein-Gold, L; Tyring, S; Weiss, R; Nasir, A; Schmitz, C; Boodhoo, T; Kaoukhov, A; Berk, D; Cook-Bolden, F; Grada, Ayman
       title: Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials
        date: 2020-01-28
       words: 693
      flesch: 59
     summary: Truncal Acne: % of Patients with IGA success at WK 12 Slide Number 1 PowerPoint Presentation Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials Angela Moore, MD; Lawrence Green, MD2, Suzanne Bruce, MD; Neil Sadick, MD; Eduardo Tschen, MD, MBA; Philip Werschler, MD, FAAD, FAACS; Sunil Dhawan, MD; Douglas Forsha, MD; Michael Gold, MD, FAAD; Scott Guenthner, MD; Steve Kempers, MD; Leon Kircik, MD; Jennifer Parish, MD; Marta Rendon, MD; Phoebe Rich, MD; Linda Stein-Gold, MD; Stephen Tyring, MD, PhD; Robert Weiss, MD, FAAD; Adnan Nasir, MD; Carsten Schmitz, MD, PhD; Terry Boodhoo, MS; Alexandre Kaoukhov, MD; David Berk, MD; Fran Cook-Bolden, MD; Ayman Grada, MD, MS Email: ayman.grada@Almirall.com Introduction 
    keywords: sarecycline
       cache: skin-811.pdf
  plain text: skin-811.txt

        item: #1249 of 1356
          id: skin-813
      author: Gottlieb, A; Lebwohl, M; Armstrong, A; Israel, RJ; Jacobson, A
       title: Malignancy Events in Patients With a History of Cancer in Clinical Studies of Brodalumab
        date: 2020-01-28
       words: 974
      flesch: 54
     summary: Of patients with history of malignancy who received continuous ustekinumab, 2 adjudicated malignancy events (both basal cell carcinoma) occurred through 52 weeks, which were also classified as nonmelanoma skin cancer AEs • A limitation of this study was the relatively low number of patients included in the analysis Acknowledgments: Abby Jacobson4 1Icahn School of Medicine at Mount Sinai, New York, NY; 2University of Southern California, Los Angeles, CA; 3Bausch Health US, LLC, Bridgewater, NJ; 4Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ 2020 Winter Clinical Dermatology Conference - Hawaii® • January 17-22, 2020 • Kohala Coast, HI INTRODUCTION • Brodalumab is a fully human anti–interleukin-17 receptor A monoclonal antibody efficacious for the treatment of adults with moderate-to-severe plaque psoriasis • In a previous analysis, rates of malignancy among brodalumab-treated patients in clinical studies of psoriasis were generally low, and there was no increase in malignancy events with brodalumab compared with ustekinumab through 52 weeks1 OBJECTIVE •
    keywords: brodalumab; malignancy; patients
       cache: skin-813.pdf
  plain text: skin-813.txt

        item: #1250 of 1356
          id: skin-814
      author: Lebwohl, M; Leonardi, C; Wu, JJ; Yamauchi, P; Rawnsley, N; Merchant, M; Jacobson, A
       title: One-Year Pharmacovigilance Update of Brodalumab
        date: 2020-01-28
       words: 852
      flesch: 40
     summary: Few patients receiving brodalumab reported depression, and none reported serious fungal infections, suicide attempts, or completed suicides © 2020. One-Year Pharmacovigilance Update of Brodalumab Mark Lebwohl,1 Craig Leonardi,2 Jashin J. Wu,3 Paul Yamauchi,4 Nicole Rawnsley,5 Mohammed Merchant,6 Binu Alexander,6 Abby Jacobson5 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Saint Louis University School of Medicine, St Louis, MO; 3Dermatology Research and Education Foundation, Irvine, CA; 4Dermatology Institute & Skin Care Center, Santa Monica, CA; 5Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ; 6Bausch Health US, LLC, Bridgewater, NJ 2020 Winter Clinical Dermatology Conference - Hawaii® • January 17-22, 2020 • Kohala Coast, HI SYNOPSIS • Efficacy and safety of brodalumab, a fully human anti–interleukin-17 receptor A monoclonal antibody, have been demonstrated in one phase 2 and three phase 3 trials (AMAGINE-1/-2/-3)1-3 • There are limited data on the effects of brodalumab treatment in a real-world setting OBJECTIVE • To report an update of brodalumab 1-year pharmacovigilance in the United States (August 15, 2017–August 14, 2018) METHODS • Observational data were collected for US patients who received brodalumab (N=826) and reported an adverse event (AE) through routine pharmacovigilance reporting from healthcare providers and patients • AEs were categorized by Medical Dictionary for Regulatory Activities preferred term and system organ class, seriousness, and (company-determined) causality • Brodalumab exposure was estimated by first shipment date to last dose date plus 55 days (ie, 5 half-lives of brodalumab) • AEs were summarized with descriptive statistics and as exposure-adjusted rates per patient-year (PY) •
    keywords: brodalumab; events; reports
       cache: skin-814.pdf
  plain text: skin-814.txt

        item: #1251 of 1356
          id: skin-815
      author: Baldwin, H; Green, L; Kircik, L; Guenin, E
       title: Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males with Moderate-to-Severe Acne
        date: 2020-01-28
       words: 1525
      flesch: 64
     summary: + , *# ** *) M e a n P e rc e n t C h a n g e F ro m B a se lin e Females Baseline Week 2 Week 4 Week 8 Week 12 -17.6% -25.9% -39.7% -54.1% -6.9% -22.0% -33.1% -49.9% -5.4% -4.6% -24.0% -28.2% -70% -60% -50% -40% -30% -20% -10% 0% # * ) ( ' & %
    keywords: lotion; tazarotene; week
       cache: skin-815.pdf
  plain text: skin-815.txt

        item: #1252 of 1356
          id: skin-816
      author: Han, G; Armstrong, AW; Desai, SR; Guenin, E
       title: Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Asians
        date: 2020-01-28
       words: 1401
      flesch: 54
     summary: -70% -60% -50% -40% -30% -20% -10% 0% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e Asian Participants Tretinoin 0.05% Lotion (n=36) In�ammatory Lesions -27.9% -40.7% -52.1% -24.7% -33.2% -41.0% -70% -60% -50% -40% -30% -20% -10% 0% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e All Participants Tretinoin 0.05% Lotion (n=819)
    keywords: asian; participants; week
       cache: skin-816.pdf
  plain text: skin-816.txt

        item: #1253 of 1356
          id: skin-817
      author: Stein-Gold, L; Pariser, DM; Guenin, E
       title: Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability
        date: 2020-01-28
       words: 1548
      flesch: 60
     summary: In�ammatory Lesions -27.4% -28.1% -24.1% -34.6% -36.3%Vehicle: -44.6% Week 8 -37.9% -46.7% -36.4% -50.3% -49.7% #( -55.3% Week 12 -45.2% -55.8% -46.6% -63.5% -56.7% 13-19 y (n=173) 20-29 y (n=163) 30+ y (n=80) #( -70% -50% -30% -10% -21.3% Week 4 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e B. Nonin�ammatory Lesions -17.0% -25.6% -18.2% -27.6% LS Mean Percent Reduction from Baseline in Inflammatory (A) and Noninflammatory (B) Lesion Counts by Age Group and Visit (ITT Population, Pooled) #( -70% -50% -30% -10% -30.5% Week 4 LS M e a n P e rc e n t C h a n g e F ro m B a se lin e A.
    keywords: age; vehicle; week
       cache: skin-817.pdf
  plain text: skin-817.txt

        item: #1254 of 1356
          id: skin-818
      author: Lain, E; Day, D; Harper, JC; Guenin, E
       title: Efficacy of a Novel Tretinoin 0.05% Lotion in the Treatment of Moderate-to-Severe Acne by Gender and Race: Pooled Analysis of Two Phase 3 Studies
        date: 2020-01-28
       words: 1512
      flesch: 65
     summary: -30.2% -46.1% -56.9% -27.1% -38.7% -47.1% -70% -60% -50% -40% -30% -20% -10% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e Females Tretinoin 0.05% Lotion (n=433) In�ammatory Lesions B. Nonin�ammatory Lesions -26.0% -39.2% -53.4% -21.8% -30.2% -39.4% -70% -60% -50% -40% -30% -20% -10% 0% LS M e a n P e rc e n t C h a n g e F ro m B a se lin e Males Baseline Week 4 Week 8 Week 12 Tretinoin 0.05% Lotion (n=386) Vehicle Lotion (n=345)
    keywords: vehicle; week
       cache: skin-818.pdf
  plain text: skin-818.txt

        item: #1255 of 1356
          id: skin-819
      author: Draelos, Z; Cook-Bolden, F; Green, L; Guenin, E; Martin, G; Pillai, R
       title: Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial
        date: 2020-01-28
       words: 1161
      flesch: 46
     summary: ◾ Per SSA ratings, the percentage of participants who reported having 90-100% clear skin was similar between tazarotene lotion and cream and greater than vehicle (Figure 3) Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene Participants aged 12 years and older were randomized (2:2:1:1) to receive double-blind treatment with tazarotene 0.045% lotion, tazarotene 0.1% cream, lotion vehicle, or cream vehicle ◾
    keywords: acne; cream; lotion; tazarotene
       cache: skin-819.pdf
  plain text: skin-819.txt

        item: #1256 of 1356
          id: skin-82
      author: Draelos, Zoe D; Kempers, Steven E; Smith, Stacy R; Wilson, David C; Powala, Christopher V; Bradshaw, Mark; Estes, Esther; Shanler, Stuart D
       title: Safety and Efficacy of A-101 Hydrogen Peroxide Topical Solution in Adults with Seborrheic Keratosis: Results from the Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
        date: 2017-10-27
       words: 1281
      flesch: 63
     summary: Figure 1: Clearance of all 4 SK Lesions (A) and Clearance of at Least 3 of 4 SK Lesions (B) 0 2 1 3 4 5 6 7 8 9 10 Day 106 0 A B 0 Day 106 P at ie n ts , % 0 6 8 10 12 14 4 2 16 P at ie n ts , % 4.0% 13.5% P < 0.001 P < 0.0001 Vehicle A-101 40% 0 20 10 30 40 50 60 70 Le si on s, % 0 30 20 10 40 50 60 70 Le si on s, %48% 64% 10% 15% A B Day 106 Day 106 Vehicle A-101 40% P < 0.001P < 0.0001 Figure 2: Mean Per-Patient Percentage of Lesions (A) or Facial Lesions (B) Judged to be Clear/Near Clear (PLA ≤ 1) Safety • A noninvasive, well-tolerated, topical agent for the removal of SK lesions is an important unmet need.
    keywords: a-101; lesions; patients; vehicle
       cache: skin-82.pdf
  plain text: skin-82.txt

        item: #1257 of 1356
          id: skin-820
      author: Cook-Bolden, F; Soung, J; Guenthner, ST; Bumpass, B; Lin, T
       title: Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
        date: 2020-01-28
       words: 1280
      flesch: 53
     summary: Mean Percent Reduction in Overall Affected Body Surface Area (BSA) by Study Visit in Female and Male Participants (ITT Population, Pooled) 0% 10% 20% -10% -20% -30% -40% -50% 0 2 4 6 8 12 0% 10% 20% -10% -20% -30% -40% -50% 0 2 4 6 8 12 P e rc e n t C h a n g e f ro m B a se li n e Female Participants Treatment Posttreatment -8.2% -17.7% -28.6% -5.6% -27.2% 2.1% -3.9% -8.6% -35.6% -4.6% P e rc e n t C h a n g e f ro m B a se li n e Male Participants Treatment Posttreatment -0.1% This analysis included 177 female participants (HP lotion, n=113; vehicle, n=64) and 253 male participants (HP lotion, n=172; vehicle, n=81) ◾
    keywords: lotion; vehicle
       cache: skin-820.pdf
  plain text: skin-820.txt

        item: #1258 of 1356
          id: skin-821
      author: Desai, SR; Glick, B; Del Rosso, JQ; Lin, T
       title: Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
        date: 2020-01-28
       words: 1338
      flesch: 51
     summary: Mean Percent Reduction in Overall Affected Body Surface Area (BSA) by Study Visit in Hispanic Participants (ITT Population, Pooled) -10% 0% 10% -20% -30% -40% 0 2 4 6 8 12 P e rc e n t C h a n g e F ro m B a se li n e Treatment Posttreatment -4.9% -14.6% -23.3% -26.0% [primary endpoint]) • Treatment success (≥2-grade improvement from baseline) in each individual sign of psoriasis (erythema, plaque elevation, and scaling) at the target lesion • Improvements from baseline in overall BSA • Reductions of ≥50% and ≥75% from baseline in IGAxBSA (IGAxBSA-50, IGAxBSA-75) ◾ Safety and treatment-emergent adverse events (TEAEs) were evaluated throughout the study RESULTS ◾
    keywords: lotion; treatment; vehicle
       cache: skin-821.pdf
  plain text: skin-821.txt

        item: #1259 of 1356
          id: skin-822
      author: Stein-Gold, L; Elewski, B; Draelos, Z; Lin, T
       title: Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis
        date: 2020-01-28
       words: 1291
      flesch: 55
     summary: -29.7% -34.2% -36.8% -3.1% -3.9% -9.3% -8.7% -2.6 Vehicle (n=45) Treatment Posttreatment P e rc e n t C h a n g e fr o m B a se lin e -7.3% -18.0%
    keywords: taz; vehicle
       cache: skin-822.pdf
  plain text: skin-822.txt

        item: #1260 of 1356
          id: skin-823
      author: Tyring, SK; Kircik, LH; Yamauchi, PS; Anbalagan, N; Lin, T
       title: Efficacy and Safety of Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Moderate to Severe Plaque Psoriasis of the Lower Extremities
        date: 2020-01-28
       words: 1587
      flesch: 56
     summary: Mean Percent Reduction in IGAxBSA Composite by Study Visit in Participants With a Target Lesion on the Leg (ITT Population, Pooled) -10% 0% 10% -20% -30% -50% -40% -60% 0 2 4 6 8 12 P e rc e n t C h a n g e f ro m B a se li n e Treatment Posttreatment -24.1% -35.7% -43.5% -47.2% (12.9) Severe 13 (9.0) 4 (5.7) Relationship to study drug Related 34 (23.6) 7 (10.0) Unrelated 18 (12.5) 9 (12.9) Treatment-related TEAEs reported in ≥2% of participants Contact dermatitis 11 (9.0) 0 Skin atrophy 4 (2.8) 0 Folliculitis 4 (2.8) 0 Excoriation 3 (2.1) 0 Pruritis 2 (1.4) 2 (2.9) Skin burning sensation 2 (1.4) 2 (2.9) Burning sensation (nervous system disorders) 2 (1.4) 2 (2.9) AE, adverse event; HP/TAZ, halobetasol propionate 0.01% and tazarotene 0.045%; SAE, serious adverse event; TEAE, treatment- emergent adverse event.
    keywords: taz; vehicle
       cache: skin-823.pdf
  plain text: skin-823.txt

        item: #1261 of 1356
          id: skin-824
      author: Tanghetti, EA; Stein-Gold, L; Del Rosso, JQ; Weiss, S; Lin, T; Angel, A; Pillai, R
       title: Novel Lotion Formulation Using Polymeric Emulsion Technology for Improved Skin Moisturization and Drug Permeation in Patients With Psoriasis
        date: 2020-01-28
       words: 1286
      flesch: 43
     summary: CONCLUSIONS ◾ Lotion formulations for the treatment of psoriasis and acne have been developed that utilize an innovative polymeric emulsion technology and an optimal selection of solvents, emollients, and humectants ◾ The vehicle lotion formulation is non‑greasy, aesthetically pleasing, and provides enhanced barrier to the skin ◾ ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC | Presented at Winter Clinical Dermatology Conference 2020 • January 17-22, 2020 • Kohala Coast, HI SYNPOSIS ◾
    keywords: cream; hours; lotion
       cache: skin-824.pdf
  plain text: skin-824.txt

        item: #1262 of 1356
          id: skin-825
      author: Eichenfield, LF; Elewski, B; Sugarman, JL; Rosen, T; Gupta, A; Pillai, R; Lin, T
       title: Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients
        date: 2020-01-28
       words: 1487
      flesch: 56
     summary: Participants were aged 6 – 16 years with culture-positive mild-to-severe onychomycosis affecting ≥20% of at least 1 great toenail ◾ ACKNOWLEDGEMENTS: Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC | Presented at Winter Clinical Dermatology Conference 2020 • January 17-22, 2020 • Kohala Coast, HI SYNOPSIS ◾ Onychomycosis—a chronic fungal nail infection—can occur in children, ranging in prevalence from 0.35% – 5.5% worldwide1 ◾
    keywords: cure; efinaconazole; population
       cache: skin-825.pdf
  plain text: skin-825.txt

        item: #1263 of 1356
          id: skin-826
      author: Lebwohl, MG; Sugarman, J; Pariser, DM; Bagel, J; Lin, T; Israel, R
       title: Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study
        date: 2020-01-28
       words: 1510
      flesch: 48
     summary: Select local signs/symptoms showed marked improvements in severity of itching, dryness, and burning/stinging over the study course; greatest improvement was for itching (Figure 2) ◾ Incidence of treatment-emergent Grade 3 local skin reactions was 22.2% for itching, 6.9% for dryness, and 9.8% for burning/stinging ◾ Incidence of other local skin reactions are shown in Figure 3 • Incidence peaked at 2.3% for skin atrophy (week 8), 2.7% for folliculitis (week 8), and 1.5% for striae and telangiectasias (week 28) ◾ Local skin reactions most frequently reported as AEs were application site folliculitis (14 participants [2.5%]; 1 discontinued) and application site atrophy (4 participants [0.7%]; 1 discontinued); no participant reported striae or telangiectasias AEs ◾ At week 8, treatment was stopped for participants that achieved treatment success; those who did not reach treatment success were treated for 4 additional weeks •
    keywords: baseline; treatment; week
       cache: skin-826.pdf
  plain text: skin-826.txt

        item: #1264 of 1356
          id: skin-827
      author: Green, L; Armstrong, A; Teller, CF; Bell, S; Lin, T
       title: Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction
        date: 2020-01-28
       words: 1117
      flesch: 49
     summary: Of individuals who did not achieve sufficient response to topical treatment, over half would have continued to use their topical treatment over starting a systemic/biologic if the topical had been more effective ◾ These survey results suggest that patients are extensively using topical treatments to control their psoriasis, and that topical treatments, if more effective, would be preferred by most patients over systemic or biologic treatments REFERENCES 1. Of the 92 participants that had previously used topical treatment and were currently taking a biologic or systemic treatment, most (n=73) were also still using topical treatment.
    keywords: psoriasis; treatment
       cache: skin-827.pdf
  plain text: skin-827.txt

        item: #1265 of 1356
          id: skin-828
      author: Maxi, Margaret Coleman; Byrne, Joel; Martin, Ardenne; Martin, Pamela
       title: Merkel Cell Carcinoma Presenting as an Indurated Plaque
        date: 2020-10-27
       words: 1952
      flesch: 56
     summary: Merkel cell carcinoma: changing incidence trends. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, Nghiem P. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.
    keywords: carcinoma; cases; cell; chest; journal; mcc; merkel; patients; presentation
       cache: skin-828.pdf
  plain text: skin-828.txt

        item: #1266 of 1356
          id: skin-829
      author: Choy, Alexa Haley; Vebman, Jonathan; Yao, Christopher
       title: Biologic Prescribing Patterns Among Mount Sinai Psoriasis Patients: Results of a Retrospective Chart Review
        date: 2020-03-08
       words: 2624
      flesch: 44
     summary: Objective: The purpose of the study is to understand biologic prescribing patterns among Mount Sinai psoriasis patients and assess its relationship to insurance policy, which may limit treatment access. Two of the most commonly cited prescribing barriers included patient insurance restrictions (79.0%) and out-of-pocket costs (71.7%).12 Thus, the purpose of this study is to understand biologic prescribing patterns among Mount Sinai psoriasis patients and assess its relationship to insurance policy, which may limit treatment access.
    keywords: biologic; insurance; patients; psoriasis
       cache: skin-829.pdf
  plain text: skin-829.txt

        item: #1267 of 1356
          id: skin-83
      author: Glinos, George D; Pastar, Irena; Tomic-Canic, Marjana; Stone, Rivka C
       title: Mislocalization of Adherens Junction- Associated Proteins in a Patient with Darier Disease
        date: 2018-04-30
       words: 2121
      flesch: 41
     summary: Perilesional (non-acantholytic) portions of DD skin partially recapitulated the normal phenotype. In fact, the loss of membranous localization of desmosomal attachment plaque proteins (e.g. desmoplakins, plakophilin, plakoglobin) as well as desmosomal cadherins (desmoglein 1/3, desmocollin 1) has been well-described in acantholytic portions of histologic sections from DD skin biopsies 5,7,8 , with normal localization maintained in perilesional skin 5 as well as relative maintenance of tight junctions 8 .
    keywords: catenin; darier; disease; proteins; skin; staining
       cache: skin-83.pdf
  plain text: skin-83.txt

        item: #1268 of 1356
          id: skin-830
      author: Adelman, Madeline; Veenstra, Jesse; Wollner, Ira; McGoey, Joseph
       title: Why is My Skin Turning Black? A Rare Side Effect of Capecitabine
        date: 2020-05-08
       words: 1533
      flesch: 43
     summary: This case supports that capecitabine can cause hyperpigmentation independent of HFS, and thus, should be evaluated as a separate entity of HFS if other symptoms are lacking. The patient was counseled that this type of hyperpigmentation is a potential side effect of capecitabine therapy and would likely persist while he is on medication.
    keywords: capecitabine; case; hfs; hyperpigmentation; skin
       cache: skin-830.pdf
  plain text: skin-830.txt

        item: #1269 of 1356
          id: skin-832
      author: Reynolds, Matthew T; Dinehart, Scott M; Anderson, Katlyn R; Gorelick, Joe
       title: Treatment of Recalcitrant Prurigo Nodularis with Dupilumab
        date: 2020-05-08
       words: 1875
      flesch: 48
     summary: Recently, reports of PN patients treated with alternative non-FDA indicated agents, namely dupilumab (Dupixent) have gained attention. The peak pruritus numerical rating scale (NRSi) was used to evaluate patients at weeks 0 and 4. Results: Dupilumab therapy results in a dramatic reduction in NRSi scores by week 4 and that result continues throughout the duration of therapy.
    keywords: dupilumab; nrsi; patients; score; treatment; week
       cache: skin-832.pdf
  plain text: skin-832.txt

        item: #1270 of 1356
          id: skin-833
      author: Kamrani, Payvand; Giesey, Rachel; Christensen, Luisa; Korman, Neil; Delost, Gregory
       title: Unique presentation of Urticaria Pigmentosa as a subcutaneous mass
        date: 2020-05-08
       words: 821
      flesch: 43
     summary: Klein NJ, Misseldine S. Anesthetic considerations in pediatric mastocytosis: a review. Systemic tests are rarely needed but can be deemed useful if there is a concern of systemic mastocytosis involvement such as diarrhea, gastric ulcers, flushing reactions, headaches, and failure to thrive.5 These tests include a CBC with differential, complete chemistry panel, and serum tryptase level which would be elevated in systemic mastocytosis but negative in cutaneous mastocytosis.1 UP that begins after age 10 usually persists and can be associated with systemic disease.
    keywords: mass; mastocytosis; medicine; skin
       cache: skin-833.pdf
  plain text: skin-833.txt

        item: #1271 of 1356
          id: skin-834
      author: Jackson Cullison, Stephanie Renae; Jansen, Burkhard; Yao, Zuxu; Ferris, Laura K
       title: Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses
        date: 2020-03-08
       words: 2449
      flesch: 44
     summary: The National Society for Cutaneous Medicine 124 ORIGINAL RESEARCH Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses Stephanie R. Jackson, MD PhD1, Burkhard Jansen, MD2, Zuxu Yao, PhD2, and Laura K. Ferris, MD PhD1 1Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 2DermTech, Inc., La Jolla, CA Importance: Strategies to non-invasively detect cutaneous melanoma generally focus on differentiating melanoma from non-melanoma lesions. The histopathologic diagnoses were established by three dermatopathologists who agreed on the diagnoses of non-melanoma excluding SDN (n=50, nevi with no, mild, or moderate atypia as well as non-melanocytic lesions) or INTRODUCTION METHODS SKIN March 2020
    keywords: lesions; melanoma; mutations; non; pla; sdn; tert
       cache: skin-834.pdf
  plain text: skin-834.txt

        item: #1272 of 1356
          id: skin-835
      author: Paul, Joan; Dagrosa, Alicia T.; Chen, Youdinghuan; Gangar, Pamela; Ressler, Daniel; Chapman, M. Shane
       title: Photodynamic Therapy with δ-Aminolevulinic Acid and Blue Light for the Treatment of Actinic Cheilitis
        date: 2020-07-12
       words: 1695
      flesch: 48
     summary: Post- treatment investigator assessments of swelling, erythema, flaking/scaling, crusting, vesiculation/pustulation, and INTRODUCTION METHODS SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 359 erosion/ulceration were graded on a scale of 0 to 4 (none, mild, moderate, severe). Microsoft Word - July 2020 - BAR 835 - proof - returned.docx SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 357 BRIEF ARTICLES Photodynamic Therapy with δ-Aminolevulinic Acid and Blue Light for the Treatment of Actinic Cheilitis Joan Paul, MD, MPH1, Alicia T. Dagrosa, MD, MBA2, Youdinghuan Chen, PhD3, Pamela Gangar, MD4, Daniel R. Ressler5, M. Shane Chapman, MD, MBA2 1The Permanente Medical Group, Department of Dermatology, Oakland, CA 2Dartmouth-Hitchcock Medical Center, Department of Dermatology, Lebanon, NH 3Dartmouth Geisel School of Medicine, Department of Epidemiology, Hanover, NH 4University of Arizona, Department of Pediatrics, Tucson, AZ 5Dartmouth-Hitchcock Medical Center, Clinical Research Unit, Lebanon, NH Background: Actinic cheilitis is a common precancerous disorder of the lower lip caused by ultraviolet radiation.
    keywords: actinic; cheilitis; improvement; study; subjects; treatment
       cache: skin-835.pdf
  plain text: skin-835.txt

        item: #1273 of 1356
          id: skin-837
      author: Rosen, Ted
       title: Dermatologists' Management Approach to Sexually Transmitted Disease
        date: 2020-03-08
       words: 2080
      flesch: 37
     summary: Clinicians must also report STD cases diagnosed in the private or academic setting to public health authorities, as required by state law. Furthermore, it is crucial to remember that STD diagnosis or verification often requires a multi-faceted approach.
    keywords: disease; genital; herpes; medicine; std; syphilis; treatment
       cache: skin-837.pdf
  plain text: skin-837.txt

        item: #1274 of 1356
          id: skin-838
      author: Maghfour, Jalal; Gill, Frances; Olson, Justin; Murina, Andrea
       title: Association Between Housing Instability and Severity of Psoriasis and Psoriatic Arthritis: A Cross-Sectional Study
        date: 2020-07-12
       words: 3000
      flesch: 55
     summary: Housing instability was found to be a source of chronic stress and several studies linked housing instability to adverse health outcomes.6 In 2013, over one in four renters paid more than half their income in rent. Housing unstable psoriasis participants had a higher average BSA than housing stable psoriasis participants (14% vs 7.1%).
    keywords: bsa; cdapsa; housing; instability; participants; patients; psa; psoriasis
       cache: skin-838.pdf
  plain text: skin-838.txt

        item: #1275 of 1356
          id: skin-86
      author: Dayan, Steven; Ogilvie, Patricia; Rivkin, Alexander Z; Yoelin, Steven G; Garcia, Julie K; Ferrusi, Ilia L
       title: OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study
        date: 2017-10-27
       words: 2123
      flesch: 58
     summary: The primary endpoint—proportion of subjects achieving ≥2-grade improvement from baseline on day 30 in investigator and subject Facial Wrinkle Scale with photonumeric guide (FWS) scores of FHL severity at maximum eyebrow elevation—was met (61.4% with onabotulinumtoxinA vs 0% with placebo; P<0.0001) OBJECTIVE • To present results from a 12-month, phase 3 study on the effects of onabotulinumtoxinA on patient-reported satisfaction and to assess impacts of treatment METHODS Patients • Neurotoxin-naive males and females aged ≥18 years with both: ─ Moderate to severe FHL at maximum eyebrow elevation (as assessed by both investigator and subject using the FWS on study day 1, before treatment) ─ The study comprised a 6-month double-blind, placebo-controlled, parallel- group treatment period (days 1–180) followed by a 6-month open-label treatment period (days 180–360) (Figure 1) • Eligible subjects were randomized (3:1) to receive a single treatment consisting of onabotulinumtoxinA 40 U (20 U in FHL and 20 U in GL) or placebo administered at 10 injection sites (Figure 2) ─ OnabotulinumtoxinA 4U or placebo was given in 0.1 mL at each injection site • Following the double-blind period, subjects could receive up to 2 open-label treatments with onabotulinumtoxinA using the same 10 injection sites, with ≥84 days between treatment cycles • Follow-up assessments were made at weeks 1 and 2 after each study treatment; all subjects also had follow-up visits every 30 days from study day 30 through day 360 Figure 1.
    keywords: day; onabotulinumtoxina; placebo; study; subjects; treatment
       cache: skin-86.pdf
  plain text: skin-86.txt

        item: #1276 of 1356
          id: skin-861
      author: Guda, Anisha; Kowalewski, Catherine; Osswald, Sandra; Usatine, Richard
       title: The Impact of Psoriasis on the Quality of Life of Patients in San Antonio, TX
        date: 2020-07-12
       words: 1824
      flesch: 55
     summary: Conclusion: Acutely, psoriasis patients are impacted psychologically and are frustrated with their disease. They found that psoriasis patients had a lower levels of self-confidence and experienced difficulties with social functioning compared to individuals without chronic disease.
    keywords: disease; life; patients; psoriasis; quality
       cache: skin-861.pdf
  plain text: skin-861.txt

        item: #1277 of 1356
          id: skin-862
      author: Stashower, Julian; Belote, Katherine; Zlotoff, Barrett
       title: Delusions of Parasitosis Influenced by Crowdsourcing Diagnostic Platform CrowdMed
        date: 2020-08-26
       words: 559
      flesch: 46
     summary: Patients on CrowdMed distribute cash awards to contributors that they feel helped the most, which may motivate contributors not to provide correct information, but information that patients will like. CrowdMed is a popular subscription-based crowdsourcing platform that reports having dealt with thousands of patients.
    keywords: crowdmed; patients
       cache: skin-862.pdf
  plain text: skin-862.txt

        item: #1278 of 1356
          id: skin-866
      author: Graham, Kathleen R; Rohr, Bethany R; Marks, Victor J
       title: Blistering Rash over Broken Ribs
        date: 2020-08-29
       words: 1203
      flesch: 55
     summary: We present a case of a 55-year-old man with fracture blisters found in a previously undocumented location. Differential included fracture blisters, Varicella zoster virus, Herpes simplex virus, bullous pemphigoid, bullous arthropod.
    keywords: blisters; bullae; fracture; patient; trauma
       cache: skin-866.pdf
  plain text: skin-866.txt

        item: #1279 of 1356
          id: skin-867
      author: Hands, Jacob M; Moy, Lawrence
       title: A Review of Exogenous Factors Implicated in the Induction of Cutaneous Melanoma
        date: 2020-05-08
       words: 11075
      flesch: 47
     summary: The authors write that increased cutaneous melanoma risk may be resultant from excess PAHs, arsenic, among other carcinogenic substances that penetrate personal protective equipment (PPE).122 While it is difficult to prove –– without confound –– the effects ascribed to PAHs in occupational cohorts, their role in the pathogenesis of cutaneous melanoma appears likely. A variety of loci have been found that significantly increased cutaneous melanoma risk, independent of solar exposure.
    keywords: cancer; exposure; factors; incidence; induction; melanoma; melanoma induction; melanoma risk; radiation; review; risk; role; skin; uva; uvb; uvr
       cache: skin-867.pdf
  plain text: skin-867.txt

        item: #1280 of 1356
          id: skin-868
      author: Jimenez, Antonio; Hoyer, Paige; Wilkerson, Michael
       title: An Atypical Presentation of Pemphigus Vegetans in the Umbilicus
        date: 2020-08-26
       words: 1585
      flesch: 44
     summary: Pemphigus vegetans is a rare variant of pemphigus and presents as oral ulcerations with associated verrucous lesions in intertriginous or flexural areas. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study.
    keywords: disease; pemphigus; presentation; vegetans; vulgaris
       cache: skin-868.pdf
  plain text: skin-868.txt

        item: #1281 of 1356
          id: skin-869
      author: Jimenez, Antonio Roberto; Hoyer, Paige; Wilkerson, Michael
       title: Aseptic Syphilitic Meningitis in an HIV-Negative Patient with Concomitant Primary and Secondary Syphilis
        date: 2020-07-12
       words: 1674
      flesch: 47
     summary: ASM is less common in immunocompetent patients and may not always be considered in the differential diagnosis of patients presenting with primary or secondary syphilis. Neurosyphilis is typically considered a tertiary manifestation of syphilis; however, ASM typically occurs within six months of exposure and may be concurrent with the rash of secondary syphilis.
    keywords: asm; neurosyphilis; patient; rash; syphilis
       cache: skin-869.pdf
  plain text: skin-869.txt

        item: #1282 of 1356
          id: skin-87
      author: Dayan, Steven; Rivkin, Alexander; Sykes, Jonathan M; Teller, Craig F; Weinkle, Susan H; Shumate, Garrett T; Gallagher, Conor J
       title: Pan-facial Treatment Positively and Significantly Impacts Social Perception
        date: 2017-10-27
       words: 1220
      flesch: 33
     summary: Despite this trend, no studies have evaluated the impact of pan-facial aesthetic treatment on social perception • Objective: To evaluate how the social perception of each HARMONYTM subject is impacted following pan-facial treatment BACKGROUND • Pan-facial treatment positively and significantly impacted how HARMONYTM subjects were perceived by society ─ Subjects were perceived as being more socially adept, successful at attracting others, attractive, friendly, successful, healthy, approachable, educated, financially successful, hirable and younger • Respondents believe that attractiveness is important and facial aesthetic treatments are socially acceptable CONCLUSIONS Group 2: Paired Images • Respondents preferred the after treatment photo for all positive traits Trait X % of subjects were considered MORE (trait) following pan-facial treatment Attractive 80 % Someone with good social skills 80 % Intelligent Survey Methodology • Baseline and primary endpoint (Month 4) images from HARMONYTM were pooled (84 subjects) ─ Of the 93 HARMONYTM subjects who completed pan-facial treatment, 9 subjects were excluded from this analysis due to inconsistencies unrelated to treatment between the before and after images (e.g. presence of makeup, lipstick, or changes in hair color).
    keywords: attractiveness; harmonytm; subjects; treatment
       cache: skin-87.pdf
  plain text: skin-87.txt

        item: #1283 of 1356
          id: skin-873
      author: Guda, Anisha; Vandergriff, Travis; Mauskar, Melissa
       title: A Survey Based Study on Maintenance of Certification Programs during Grand Rounds at UT Southwestern Medical Center
        date: 2020-07-12
       words: 1221
      flesch: 44
     summary: Survey Results on Likert Scale Regarding MOC Grand Rounds at UTSW quizzes, case challenges, and questions of the week.1 Most academic medical centers have regular clinical conferences (Grand Rounds) where both faculty and residents discuss difficult cases. A five-question survey was developed and piloted by the authors and emailed to dermatologists who attended MOC Grand Rounds at UTSW Medical Center.
    keywords: dermatologists; moc; rounds
       cache: skin-873.pdf
  plain text: skin-873.txt

        item: #1284 of 1356
          id: skin-878
      author: Litchman, Graham H; Prado, Giselle; Teplitz, Rebeca W; Rigel, Darrell
       title: A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis
        date: 2020-05-08
       words: 5739
      flesch: 60
     summary: 9 Gene Brunner et al. first published a retrospective cohort of archival melanomas (n=135) where gene signature was correlated with OS.11 Gene signature predicted OS independently of AJCC staging (HR=3.83; p=0.0004). Gene signatures reported in the literature.
    keywords: expression; gene; gep; melanoma; patients; prognostic; risk; search; signature; studies; survival
       cache: skin-878.pdf
  plain text: skin-878.txt

        item: #1285 of 1356
          id: skin-879
      author: none
       title: Enhancing Patient Compliance for Usage of Laundry Detergents Free of Dyes and Perfumes: Potential Impact of Better Cleaning Performance
        date: 2020-05-08
       words: 3850
      flesch: 50
     summary: In the US and Canada respectively, 80% and 97% of dermatologist recommend the use of free detergents for their patients with sensitive skin. A segment of commercially marketed laundry detergents, commonly known as free detergents, have been formulated without dyes and perfumes to accommodate skin sensitivities.
    keywords: cleaning; consumer; detergents; fabrics; free; laundry; performance; skin; stain; tpfg; washing
       cache: skin-879.pdf
  plain text: skin-879.txt

        item: #1286 of 1356
          id: skin-88
      author: Dayan, Steven; Yoelin, Steven G; De Boulle, Koenraad; Ferrusi, Ilia L
       title: The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies
        date: 2017-10-27
       words: 2324
      flesch: 44
     summary: The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies Steven Dayan, MD1; Steven G. Yoelin, MD2; Koenraad De Boulle, MD3; Ilia L. Ferrusi, PhD4 1DeNova Research, Chicago, IL, USA; 2Medical Associates Inc., Newport Beach, CA, USA; 3Aalst Dermatology Clinic, Aalst, Belgium; 4Allergan plc, Irvine, CA, USA Scan to obtain PDF of poster INTRODUCTION • Facial lines or wrinkles are a common sign of aging, developing slowly over time due to repeated contraction of underlying facial muscles1-3 • In the upper face, 3 types of facial lines are common: lateral canthal lines (crow’s feet lines; CFL), caused by smiling or squinting; horizontal frontalis lines (forehead lines; FHL), caused by raising of the eyebrows; and glabellar lines (GL), caused by frowning1 • With age, these upper facial lines (UFL) tend to become static and visible, even when facial muscles are at rest1 • The development of UFL can influence self-perception and may have a variety of psychological impacts3-5 OBJECTIVE • To determine the psychological impact of CFL and FHL individually and of the 3 UFL areas combined • To evaluate whether the 11-item Facial Line Outcomes (FLO-11) Questionnaire3 is an adequate measure to assess CFL, FHL, and UFL psychological impacts METHODS Subjects • Two qualitative research studies (Figure 1) were conducted in adults with moderate or severe UFL (ie, CFL, FHL, and GL) at maximum contraction, as measured using the investigator-rated Facial Wrinkle Scale with photonumeric guide (FWS; 0=none; Study Designs Study 1 Study 2 Concept elicitation interview: open-ended questions about psychological impacts of CFL Subjects complete the FLO-11 questionnaire Targeted questions about relevancy of FLO-11 items and FLO-11 overall for assessing psychological impacts of CFL Concept elicitation interview: open-ended questions about impacts of FHL (n=20) or UFL (n=20); subjects were also asked to define the psychological impacta Targeted questions about relevancy of FLO-11 items and FLO-11 overall for assessing psychological impacts of FHL or UFL Subjects aged ≥18 years with moderate or severe CFL at maximum contraction (n=41) Subjects aged 18–65 years with moderate or severe FHL only (n=9) or with moderate or severe UFL (CFL, FHL, and GL) at maximum contraction (n=20) aEleven subjects in addition to the 9 subjects with FHL only completed interviews about the impact of FHL. CFL, crow’s feet lines; FHL, forehead lines; GL, glabellar lines; UFL, upper facial lines.
    keywords: cfl; feeling; fhl; impacts; lines
       cache: skin-88.pdf
  plain text: skin-88.txt

        item: #1287 of 1356
          id: skin-880
      author: Kamrani, Payvand; Schaeffer, Madeline; Altman, David
       title: Recurrence of Primary Cutaneous Anaplastic Large Cell Lymphoma at a New Location After Wide Surgical Excision 
        date: 2020-10-27
       words: 1617
      flesch: 50
     summary: Coexistence of CD30‐positive anaplastic large cell lymphoma and mycosis fungoides. Patients may present clinically with solitary or multifocal papules and/or nodules usually affecting the upper half of the body, which may enlarge and ulcerate over time.4 Roughly 10% of cases may present with multifocal cutaneous disease in multiple anatomic regions at the time of diagnosis.7 Before a diagnosis of PALCL can be made, systemic anaplastic large cell lymphoma with secondary skin involvement must first be ruled out with imaging.
    keywords: cd30; cell; excision; figure; lymphoma; pcalcl
       cache: skin-880.pdf
  plain text: skin-880.txt

        item: #1288 of 1356
          id: skin-882
      author: Robinson, June K; Jansen, Burkhard
       title: Caring for Melanoma Survivors with Self-Detected Concerning Moles During COVID-19 Restricted Physician Access: a Cohort Study
        date: 2020-05-08
       words: 1700
      flesch: 53
     summary: Sample 3§ M 7 x 9 Leg ND ND N Sample 4§ M 7 x 7 Scalp ND ND N Sample 5 F 7 x 8 Back ND ND N Sample 6 F 6 x 11 Back ND ND N Sample 7* F 7 x 7 Back ND ND N B) Randomly selected physician collected PLA control samples received during the same time period^ Sample # Sex Lesion Size (mm) Lesion Location LINC PRAME PLA Control 1 M 10 x 10 Back ND ND N Control 2 F 9 x 10 Ankle QNS QNS QNS Control 3 F 10 x 7 Back ND D P Control 4 F 6 x 7 Leg ND ND N Control 5 F 11 x 12 Back ND ND N Control Comparison of mole self-sampling specimens with physician provided samples A) PLA patient self-sampling under the remote supervision of a licensed healthcare professional Sample # Sex Lesion Size (mm) Lesion Location LINC PRAME PLA Sample 1 M 5 x 5 Hip ND ND N Sample 2* F 5 x 5 Shoulder ND ND N
    keywords: control; melanoma; physician; self; skin
       cache: skin-882.pdf
  plain text: skin-882.txt

        item: #1289 of 1356
          id: skin-889
      author: Jafari, Alexander; Murina, Andrea
       title: Virtual Continuity Clinics: A Hybrid Approach to Longitudinal Patient-Dermatologist Relationships in the Wake of COVID-19
        date: 2020-07-12
       words: 1043
      flesch: 37
     summary: While both groups preferred in-person consultations over telemedicine visits, satisfaction with teledermatology still remained high and mainly differed based on the format offered (e.g. store-and-forward versus live-interactive sessions).5 During the current COVID-19 pandemic, teledermatology may emerge as a suitable alternative for establishing longitudinal care for patients. The implementation of virtual continuity clinics in dermatology via telehealth during the COVID-19 pandemic may highlight its merits in GME training.
    keywords: care; continuity; patient; resident
       cache: skin-889.pdf
  plain text: skin-889.txt

        item: #1290 of 1356
          id: skin-89
      author: Dayan, Steven; Ogilvie, Patricia; Rivkin, Alexander Z; Yoelin, Steven G; Garcia, Julie; Ferrusi, Ilia L
       title: Simultaneous Treatment of Moderate-to-Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines wtih OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study
        date: 2017-10-27
       words: 2457
      flesch: 58
     summary: • Eligible subjects were randomized (2:2:1) to receive one of the following treatments: ─ OnabotulinumtoxinA 64 U (20 U in FHL, 20 U in GL, and 24 U in CFL) ─ OnabotulinumtoxinA 40 U (20 U in FHL, 20 U in GL, and placebo in CFL) ─ Placebo • OnabotulinumtoxinA 4 U or placebo was given as 0.1 mL at 16 injection sites (Figure 2) • Following the double-blind period, subjects entered the open-label treatment period, during which they could receive up to 2 onabotulinumtoxinA 64 U treatments using the same 16-injection site paradigm, with at least 84 days separating treatment cycles • Follow-up assessments were made at weeks 1 and 2 after each study treatment; all subjects also had follow-up visits every 30 days starting on study day 30 though day 360 Figure 2. Injection Sites for Treatment of Forehead Lines, Glabellar Lines, and Crow’s Feet Lines Forehead Glabellar Crow’s feet lines Patient-Reported Outcome (PRO) Measures • Subjects completed the Facial Line Satisfaction Questionnaire (FLSQ) and the 11-item Facial Line Outcomes Questionnaire (FLO-11) at baseline, on days 7, 14, and 30, then every 30 days through day 360 • Both PRO instruments were developed, validated, and implemented in accordance with US Food and Drug Administration guidance10,11 • FLSQ (11 questions at baseline and 13 questions at follow-up) is designed to assess treatment satisfaction and appearance-related impacts associated with facial lines in the FHL, GL, and/or CFL areas from the subject’s perspective ─ FLSQ Item 5 assesses the subjects’ satisfaction with treatment of their facial lines ─ FLSQ Impact Domain measures appearance-related and emotional impacts of treatment, including appearance-related age, anger, tiredness, emotional unhappiness, and negative self-esteem • FLO-11 assesses psychological and appearance-related impacts associated with facial lines in the forehead, glabellar, and crow’s feet areas, from the subjects’ perspective ─ FLO-11 Item 4 evaluates whether subjects feel that they look older than their actual age Statistical Analysis • FLSQ Item 5, FLSQ Impact Domain, and FLO-11 Item 4 were included as key secondary efficacy endpoints as they reflect the subject’s perception of treatment effects and drive retreatment decisions ─ Proportion of subjects mostly satisfied or very satisfied on FLSQ Item 5 (primary time point: day 60) ─
    keywords: day; fhl; lines; onabotulinumtoxina; placebo; treatment
       cache: skin-89.pdf
  plain text: skin-89.txt

        item: #1291 of 1356
          id: skin-895
      author: Kolli, Hiren; Moy, Ronald
       title: Indurated and Puckered Skin on the Lateral Thighs
        date: 2020-10-27
       words: 1353
      flesch: 54
     summary: 74% of patients had some clinical improvement, including 2 with near clearance.7 Treatment of sclerodermatous GVHD with ultraviolet A1 (340– 400 nm) without psoralen with standard immunosuppression was shown to achieve a complete response in 3 of 5 patients and a partial response in 2 patients.8 In a series of 12 patients with sclerodermatous GVHD alone or with concomitant lichenoid change, all responded favorably to extracorporeal photopheresis.
    keywords: chronic; cutaneous; disease; gvhd; sclerodermatous
       cache: skin-895.pdf
  plain text: skin-895.txt

        item: #1292 of 1356
          id: skin-9
      author: Haslam, Samuel P; Woolridge, Katelyn F; Wilkerson, Michael G
       title: A Rare Transition from Pemphigus Vulgaris to Pemphigus Foliaceus Following Rituximab Therapy Confirmed by Antidesmoglein ELISA 
        date: 2017-06-28
       words: 1134
      flesch: 46
     summary: 6. Levy-Sitbon C, Reguiai Z, Durlach A et al. Transition from pemphigus vulgaris to pemphigus foliaceus: a case report. Rapid transition from pemphigus vulgaris to pemphigus foliaceus.
    keywords: elisa; pemphigus; transition
       cache: skin-9.pdf
  plain text: skin-9.txt

        item: #1293 of 1356
          id: skin-901
      author: Apple, Aurel; Lin, Ann; Kim, Angela; Rozenberg, Suzanne; Kushner, Rachel
       title: Palmoplantar Pityriasis Rosea
        date: 2020-10-27
       words: 1415
      flesch: 47
     summary: Different variants of palmoplantar PR have been reported, the first being Bukhari who called for palmoplantar involvement to be included among the known variant forms of PR.6 Lesions of secondary syphilis may appear similarly to palmoplantar PR but would also be associated with systemic symptoms such as genital-mucosal involvement and lymphadenopathy.7 We ruled out syphilis with a non-reactive rapid plasma reagin (RPR) test. We describe a 48-year-old male who presented following a traumatic motor vehicle accident with an atypical presentation of palmoplantar PR which mimicked secondary syphilis.
    keywords: palmoplantar; patient; pityriasis; rosea
       cache: skin-901.pdf
  plain text: skin-901.txt

        item: #1294 of 1356
          id: skin-902
      author: Schaffenburg, William; Davis, Joshua; Logemann, Nicholas; Simpson, Meagan
       title: Complete Histologic Response of Regionally Metastatic Melanoma Treated with Intralesional Interleukin 2, Topical Retinoid and Imiquimod
        date: 2020-10-27
       words: 1103
      flesch: 33
     summary: The regimen per Shi et al. resulted in leukoderma, ulceration and irritation to the area as intended.1 With daily application of topical treatment, plus biweekly IL-2 injections, the local metastases slowly regressed over the next six weeks (Figure 1). Histological examination of punch biopsies before treatment showed dermal nodules of heavily pigmented, malignant melanocytes.
    keywords: figure; melanoma; national; therapy; treatment
       cache: skin-902.pdf
  plain text: skin-902.txt

        item: #1295 of 1356
          id: skin-905
      author: Katamanin, Olivia; Glazer MD, Alex M
       title: Dermatologists' Perceptions and Use of Electronic Health Record Systems
        date: 2020-08-29
       words: 1030
      flesch: 43
     summary: Interventions to improve EHR should focus on improving workflow efficiency and maximizing the amount of time dermatologists can spend with patients. Further studies are needed to weigh the benefits of EHR, investigate the amount of time dermatologists spend using EHR, and to classify specific ways EHR can become more user friendly.
    keywords: dermatologists; ehr; time
       cache: skin-905.pdf
  plain text: skin-905.txt

        item: #1296 of 1356
          id: skin-908
      author: Cockerell, Clay J; Heibel, Haley D; Workman, Ashleigh
       title: Considerations for Dermatologic Patient Care during COVID-19
        date: 2020-07-12
       words: 851
      flesch: 35
     summary: Here, we discuss our experience of diagnosing multiple metastatic cutaneous cancers during the COVID-19 era and consider how perceived and existing barriers for patients receiving dermatologic care in the pandemic may have led to the progression of cancer. Unintended consequences of dermatologic patients seeking care from other facilities include utilization of resources reserved for COVID-19 patients and inappropriate diagnosis and treatment, leading to further spread of COVID-19.
    keywords: covid-19; dermatologists; patients
       cache: skin-908.pdf
  plain text: skin-908.txt

        item: #1297 of 1356
          id: skin-909
      author: Shiu, Valerie; Brown, Margaret; Bambekova, Pavela; Yeh, Jenny; Brogan, Jaqueline; Kowalewski, Catherine
       title: 755-nm Alexandrite Laser for the Treatment of Non-Facial Superficial and Nodular Basal Cell Carcinoma
        date: 2020-10-27
       words: 1403
      flesch: 49
     summary: It is important to note that scar outcomes following the 755-nm Alexandrite laser treatment of the BCC sites were not better than treating BCC sites with electrodesiccation and curettage (ED&C), and therefore the patient and the provider METHODS RESULTS DISCUSSION SKIN November 2020 Volume 4 Issue 6 Copyright 2020 The National Society for Cutaneous Medicine 550 Table 1. Treatment sites were re- biopsied approximately six weeks later.
    keywords: bcc; eschar; scar; treatment
       cache: skin-909.pdf
  plain text: skin-909.txt

        item: #1298 of 1356
          id: skin-910
      author: Mititelu, Roxana; Flores-Echaiz, Claudia; Kanna, Manish
       title: Toluidine blue for extramammary Paget’s disease in Mohs micrographic surgery
        date: 2021-01-01
       words: 923
      flesch: 45
     summary: Furthermore, immunohistochemical stains are often not employed in the settings of MMS due to significant start-up costs, long incubation times, difficulty with antibody reagent consistency and staining reproducibility.2 The presence of mucin in Paget cells lends itself to be visualized with special stains other than H&E, including Alcian blue, PAS, mucicarmine, and Toluidine blue.3 We present a case of EMPD treated with MMS using Toluidine blue. Conclusion: Toluidine blue is a fast, user-friendly dye that can be used intraoperatively during MMS as to detect Paget cells and thus to determine the appropriate negative margin.
    keywords: empd; mms; paget
       cache: skin-910.pdf
  plain text: skin-910.txt

        item: #1299 of 1356
          id: skin-914
      author: Laggis, Caroline W; Secrest, Aaron M; Agyei, Martin; Simister, Sam; Davis, Andrea N; Dickerson, Ty; Rhoads, Jamie LW
       title: The Impact of Skin Disease on Quality of Life in Rural Communities of Ghana
        date: 2020-08-26
       words: 3677
      flesch: 49
     summary: The Impact of Skin Disease on Quality of Life in Rural Communities of Ghana Caroline W. Laggis, MD1, Aaron M. Secrest, MD, PhD1,2, Martin Agyei, MD3, Sam Simister, BS4, Andera N. Davis, PhD5, Ty Dickerson, MD, MPH4, Jamie L.W. Rhoads, MD, MS1 1Department of Dermatology, University of Utah, Salt Lake City, UT, USA 2Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA 3Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana 4School of Medicine, University of Utah, Salt Lake City, UT, USA 5Department of Geography, University of Utah, Salt Lake City, UT, USA The 2015 Global Burden of Disease (GBD) reported that skin and subcutaneous disorders are the fourth leading cause of non-fatal disease burden worldwide, with dermatitis causing the greatest burden.1 The GBD provides valuable insight into the burden of skin disease over time and by ABSTRACT Background: Skin disease is the fourth-leading cause of non-fatal disability worldwide. This suggests that better dermatologic education and availability of physician assistants would likely meaningfully decrease skin disease burden in these rural communities.
    keywords: burden; dermatology; disease; dlqi; ghana; life; participants; qol; quality; rural; skin
       cache: skin-914.pdf
  plain text: skin-914.txt

        item: #1300 of 1356
          id: skin-916
      author: Wilson, Claire; Roman, Brandon; Ashack, Kurt; Aronson, Iris K
       title: Anti-SAE1 Antibodies and Dermatomyositis: A Case Series of Three Patients 
        date: 2020-10-27
       words: 1944
      flesch: 46
     summary: 4. Muro Y, Sugiura K , Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Furthermore, two of our three patients were ANA positive, with one patient demonstrating anti-histone antibodies, and another with anti-ssDNA antibodies, findings not described in the literature with respect to this specific subset of DM patients.
    keywords: anti; case; dermatomyositis; findings; patients
       cache: skin-916.pdf
  plain text: skin-916.txt

        item: #1301 of 1356
          id: skin-92
      author: Makino, Elizabeth; Tan, Priscilla; Mehta, Rahul C
       title: Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage
        date: 2017-10-27
       words: 1178
      flesch: 51
     summary: Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage Elizabeth T. Makino, BS CCRA MBA; Priscilla Tan, BA; Rahul C. Mehta, PhD Research & Development SkinMedica, an Allergan Company, Irvine, CA, USA Presented at the Fall Clinical Dermatology Conference Series, October 12-15, 2017, Las Vegas, NV, USA BACKGROUND Photodamaged skin is characterized by the presence of fine/coarse lines, mottled pigmentation, among other changes to facial skin. OBJECTIVE To assess and compare the efficacy and tolerability of different facial treatments designed to improve photodamaged facial skin.
    keywords: lines; skin; tns; week
       cache: skin-92.pdf
  plain text: skin-92.txt

        item: #1302 of 1356
          id: skin-923
      author: Bernett, Courtney Nicole; Hignett, Emma; Kwong, Pearl
       title: Management and Referral Patterns in Pediatric Atopic Dermatitis: A Survey of Pediatric Healthcare Professionals
        date: 2020-08-29
       words: 4105
      flesch: 45
     summary: Similarly, we also assessed which therapies PHPs trial in AD patients prior to referral to an allergist for more extensive testing and this data is reflected in Table 6. Although the sample size of participants in the study was small (28), the surveyed PHPs had considerable experience (average years in practice = 21.75), most were physicians, and they managed a fair volume of AD patients, giving further merit to our study.
    keywords: allergy; atopic; dermatitis; food; management; patients; phps; referral; survey; testing
       cache: skin-923.pdf
  plain text: skin-923.txt

        item: #1303 of 1356
          id: skin-924
      author: Urban, Katelyn; Giesey, Rachel Lynn; Delost, Maria; Delost, Gregory Raymond
       title: An Update on the Global Burden and Socioeconomics of Scabies: A Cross-Sectional Analysis from the Global Burden of Disease Study 2017
        date: 2020-10-27
       words: 2898
      flesch: 48
     summary: The individual countries with highest scabies burden were Papua New Guinea (age-standardized DALYs 148.2), Solomon Islands (140.5), Kiribati (139.9), Timor-Leste (138.2) and the Maldives (134.9). A positive linear relationship exists between scabies burden and burden of rheumatic fever and bacterial skin disease.
    keywords: age; burden; countries; dalys; disease; gbd; scabies; skin
       cache: skin-924.pdf
  plain text: skin-924.txt

        item: #1304 of 1356
          id: skin-925
      author: Cline, Abigail; Gomolin, Tamar; Safai, Bijan
       title: Factors Influencing Patient Satisfaction in Dermatology
        date: 2020-10-27
       words: 2049
      flesch: 43
     summary: Patient satisfaction scores are one of the most accessible markers insurance companies ABSTRACT Background: Patient satisfaction is a proxy for healthcare quality, with physicians evaluated and reimbursed based on patient satisfaction scores. The field of dermatology recognizes the importance of patient satisfaction, with the American Board of Dermatology encouraging the collection of patient satisfaction survey data during the Maintenance of Certification process.2 Despite the growing research in patients’ perceptions of their visits, factors that enhance patient satisfaction remain unclear.
    keywords: dermatology; factors; patient; respondents; satisfaction
       cache: skin-925.pdf
  plain text: skin-925.txt

        item: #1305 of 1356
          id: skin-928
      author: Vangipuram, Ramya; Nguyen, Harrison; Tyring, Stephen
       title: What is the True Etiology of “Recurrent Shingles”?
        date: 2021-01-01
       words: 2429
      flesch: 50
     summary: Results: 44 patients (56%) had evidence of herpes simplex virus infection. 43 patients (56%) had evidence of herpes simplex virus infection (Table 1).
    keywords: herpes; infection; patients; shingles; simplex; virus; zoster
       cache: skin-928.pdf
  plain text: skin-928.txt

        item: #1306 of 1356
          id: skin-929
      author: Bhatia, Neal
       title: Dermatology and Virtual Realities with Industry: “It’s Not Your Father’s Pharma Anymore”
        date: 2020-07-12
       words: 1916
      flesch: 50
     summary: Advisory board meetings, speaker training meetings for promotional education, and investigator meetings for clinical trials have all been conducted virtually. Everyone in pharma, from drug reps to medical science liaisons to executives have been under stay-at-home policies, including digital sales tools and virtual meetings for face-to-face visits.
    keywords: dermatology; industry; meetings; pharma; reps
       cache: skin-929.pdf
  plain text: skin-929.txt

        item: #1307 of 1356
          id: skin-93
      author: Makino, Elizabeth T; Tan, Priscilla; Mehta, Rahul
       title: Immediate and Long-Term Efficacy of a Two-Step Topical Hyaluronic Acid Lip Treatment
        date: 2017-10-27
       words: 1324
      flesch: 43
     summary: o Subjects presented with mean scores of 3.11 for lip scaling (dryness) and 4.14 for overall lip condition. • Must have mild to severe lip condition (lip texture/visual roughness and lines/wrinkles) with a score of 3 or higher on the modified Griffiths’ scale.
    keywords: baseline; lip; week
       cache: skin-93.pdf
  plain text: skin-93.txt

        item: #1308 of 1356
          id: skin-930
      author: Litchman, Graham H; Marson, Justin W; Svoboda, Ryan M; Rigel, Darrel S
       title: Integrating Electrical Impedance Spectroscopy into Clinical Decisions for Pigmented Skin Lesions Improves Diagnostic Accuracy: A Multitiered Study
        date: 2020-08-30
       words: 3346
      flesch: 59
     summary: Conclusions: The integration of EIS technology into the PSL biopsy decision was demonstrated to be effective in significantly enhancing clinician NNB and more accurate PSL biopsy selection. Reductions in NNB were observed across all three clinician levels (Table 1) after incorporating EIS technology into their biopsy decisions, with decreases of 14.8%, 16.8%, and 16.0% for residents, midlevels, and practicing dermatologists, respectively.
    keywords: 0.001; biopsies; biopsy; eis; lesions; melanomas; psls
       cache: skin-930.pdf
  plain text: skin-930.txt

        item: #1309 of 1356
          id: skin-931
      author: Christensen, Luisa Fernanda; Carr, David; Hill, Sheena; Ramser, Elizabeth; Perez, Jaime Abraham; Bordeaux, Jeremy
       title: Sentinel Lymph Node Predictors in Melanoma of Breslow Thickness 0.8-1.0 mm
        date: 2020-08-26
       words: 3650
      flesch: 59
     summary: Wong SL, Faries MB, Kennedy EB, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Munsch C, Lauwers-Cances V, Lamant L, et al.
    keywords: lymph; melanoma; node; patients; sentinel; slnb; thickness
       cache: skin-931.pdf
  plain text: skin-931.txt

        item: #1310 of 1356
          id: skin-932
      author: Wanner, Brian; Cusick, Austin; Kapil, Jyoti; D'Addario, Stephen
       title: TP53 Mutated Metastatic Basal Cell Carcinoma Responsive to Sonidegib
        date: 2021-01-01
       words: 1552
      flesch: 48
     summary: Distant metastasis, however, can occur, and has a reported prevalence of less than 0.55% of all BCC cases.2 Tumor genetics play a significant role in the prognosis and subsequent treatment of metastatic BCC. Surveillance chest computed tomography revealed new bilateral pulmonary nodules and a subsequent biopsy showed metastatic BCC.
    keywords: bcc; carcinoma; case; cell; metastatic; skin
       cache: skin-932.pdf
  plain text: skin-932.txt

        item: #1311 of 1356
          id: skin-933
      author: Huang, Amy; Glick, Sharon
       title: Integrating Metagenomics into Personalized Medicine in Dermatology
        date: 2020-10-27
       words: 1370
      flesch: 32
     summary: These systems include the skin and gut microbiomes. Mehta H, Goulet PO, Mashiko S, et al.
    keywords: gut; microbiome; response; skin
       cache: skin-933.pdf
  plain text: skin-933.txt

        item: #1312 of 1356
          id: skin-935
      author: Weisert, Elise M; Hinds III, Ethan D
       title: Letter to the Editor: Commentary on “Avoiding the Hazards of Ultraviolet Light in the Adolescent Population”
        date: 2020-08-26
       words: 766
      flesch: 44
     summary: Many devices now also have settings to disable blue light in favor of yellow light, which were created to combat blue light-induced insomnia in users.5 Standard UVA/UVB protecting sunscreens appear to have inadequate effects on the ROS produced by visible light, suggesting the need for fortification with topical antioxidants, which protect against oxidative SKIN September 2020 Volume 4 Issue 5 Copyright 2020 The National Society for Cutaneous Medicine 487 stress to the melanocytes.3,6 Providing education to this young patient population about the possible benefits of utilizing a topical antioxidant serum on the face and neck when they apply daily sunscreen offers an opportunity for protection against skin cancers, as well as protection from premature aging and hyperpigmentation. An emerging body of literature suggests that visible light exposure (400-700 nm) may also contribute to premature aging of the skin and hyperpigmentation.2 Studies show these effects are secondary to the production of reactive oxygen species (ROS).3 Penetration of visible light into the dermis generates ROS that upregulate proinflammatory cytokines and matrix metalloproteinases, causing skin inflammation that contributes to photoaging and collagen breakdown, respectively.3 Though the sun is the largest producer of visible light, artificial sources of light also emit radiation, including televisions, LED light, fluorescent light, and screens such as cell phones, computers, and tablets.4 Their peak emission lies in the blue spectrum (400-490 nm).4 As the use of technology, especially smartphones and tablets, continues to propagate, adolescents receive more radiation than ever from electronic devices, even from camera flashes.4 The risk may even include children, who increasingly utilize electronics for games, school, and communication.
    keywords: aging; light; medicine; skin
       cache: skin-935.pdf
  plain text: skin-935.txt

        item: #1313 of 1356
          id: skin-936
      author: Bhatia, Neal
       title: Photodynamic Therapy in 2020: Lights in the Darkness
        date: 2020-07-12
       words: 3651
      flesch: 44
     summary: The first major study published in 2008 compared the efficacy and tolerability of daylight PDT to red light PDT both using MAL, based on the continuous and sustained activation of protoporphyrin IX by SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 315 daylight as compared to the concentrated activation by red light. The labelled indication for 20% ALA with blue light calls for an incubation of 14 hours, meaning treat the day before and stay SKIN July 2020 Volume 4 Issue 4 Copyright 2020 The National Society for Cutaneous Medicine 314 indoors to avoid activating the light.4 Ironically, these treatments were indicative of how daylight PDT was conducted, given that the patients who had ALA applied the day before would immediately start reacting once they went outdoors to come back to the clinic for the light treatment.
    keywords: ala; daylight; keratoses; light; patients; pdt; skin; study; therapy; treatment
       cache: skin-936.pdf
  plain text: skin-936.txt

        item: #1314 of 1356
          id: skin-937
      author: Rigel, Darrell S; Ceilley, Roger I; Litchman, Graham H; Cockerell, Clay J
       title: Gene Expression Profile Testing in Skin Cancer Prognosis: The Data is Clear – It’s Time to Get On Board
        date: 2020-07-12
       words: 2395
      flesch: 51
     summary: They ignore multiple prospective trials that have demonstrated efficacy and wrongly suggest that prospective randomized controlled trials are needed for validation when these are not required (or even possible to perform for prognostic tests as there is no way to interpret a control Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML, Molecular risk prediction in cutaneous melanoma: a metaanalysis of the 31-gene expression profile prognostic test in 1,479 patients, Journal of the American Academy of Dermatology (2020), doi.org/10.1016/j.jaad.2020.03.053.
    keywords: dermatol; expression; gene; gep; melanoma; risk; skin; studies; test
       cache: skin-937.pdf
  plain text: skin-937.txt

        item: #1315 of 1356
          id: skin-938
      author: Auchus, Alexander; Brodell, Robert T; Nahar, Vinayak K; Ward, Kimberley HM
       title: Commentary in Response: Commentary on “Avoiding the Hazards of Ultraviolet Light in the Adolescent Population”
        date: 2020-08-29
       words: 375
      flesch: 33
     summary: Microsoft Word - September 2020 - CAN 938 - proof.docx SKIN September 2020 Volume 4 Issue 5 Copyright 2020 The National Society for Cutaneous Medicine 488 COMMENTARY & NOTES Commentary in Response: Commentary on “Avoiding the Hazards of Ultraviolet Light in the Adolescent Population” Alexander Auchus1, Robert T. Brodell, MD2, Vinayak K. Nahar MD, MS, PhD, FRSPH2,3, Kimberley H.M. Ward, MD2 1Department of Psychology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 2Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS 3Department of Preventive Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS Funding: None Corresponding Author: Vinayak K. Nahar, MD, PhD, MS, FRSPH Department of Dermatology School of Medicine University of Mississippi Medical Center 2500 North State Street – L216 Jackson,
    keywords: medical; medicine
       cache: skin-938.pdf
  plain text: skin-938.txt

        item: #1316 of 1356
          id: skin-94
      author: Kaminer, Michael; Cohen, Joel L; Narurkar, Vic; Shamban, Ava; Werschler, Phil; Shumate, Garrett T; Gallagher, Conor J
       title: Maximizing Pan-Facial Aesthetic Outcomes; Findings and Recommendations from the HARMONY Study
        date: 2017-10-27
       words: 1435
      flesch: 41
     summary: (75%) Marionette Lines Total Ultra XC + Ultra Plus XC 1.2 (50%) 1.1 (75%) Ultra XC 0.3 (10%) 0.5 (40%) Ultra Plus XC 1.1 (53%) 0.8 (75%) Location HIGHEST SITES % of sub that rec’d both products (% rec’d both products in same visit) LOWEST SITES % of sub that rec’d both products (% rec’d both products in same visit) Nasolabial Fold 17.6 (11.8) 15.8 (5.3) Marionette Lines 20.0 (10.0) 53.3 (53.3) Oral Commissures 5.3 (0.0) 55.6 (33.3) Radial Cheek 0.0 (0.0) 50.0 (50.0) Perioral 6.7 (0.0) 27.2 (18.2) • Highest improvement was achieved when using only one product per location Product HIGHEST SITES Mean volume injected per subject (% of subjects treated) LOWEST SITES Mean volume injected per subject (% of subjects treated) (75%) Overall Midface Total V1-V4 2.7 (100%) 2.9 (90%) Ultra XC & Ultra Plus XC Ultra XC & Ultra Plus XC Layering Use of Touch-Ups Location Product HIGHEST SITES Mean volume injected per subject (% of subjects treated) LOWEST SITES Mean volume injected per subject (% of subjects treated) Radial Cheek Total Ultra XC + Ultra Plus XC 0.0 (0%) 0.8 (30%) Ultra XC 0.0 (0%) 0.5 (30%)
    keywords: sites; ultra
       cache: skin-94.pdf
  plain text: skin-94.txt

        item: #1317 of 1356
          id: skin-940
      author: Dhaliwal, Parneet; Ibad, Sidra; Losak, Diana; Cockerell, Clay
       title: A Case of Granulomatous Hypersensitivity Reactions to a Dermal Filler Precipitated by PD-1 Checkpoint Inhibitor Therapy
        date: 2021-01-01
       words: 1824
      flesch: 42
     summary: Some of the known adverse reactions to PD-1 inhibitors include morbilliform eruptions, erythematous plaques, bullous dermatoses, psoriasiform dermatitis and now, granulomatous inflammation at sites of prior dermal filler injections. The National Society for Cutaneous Medicine 44 sarcoidosis.9 However, that case was not related to filler injections.
    keywords: checkpoint; dermal; filler; nivolumab; patient; reaction; skin
       cache: skin-940.pdf
  plain text: skin-940.txt

        item: #1318 of 1356
          id: skin-947
      author: Chadha, Simran Arinder; Shastry, Jennifer; Sunshine, Joel; Choi, Jennifer; Guggina, Lauren
       title: Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature
        date: 2020-10-27
       words: 2520
      flesch: 33
     summary: The National Society for Cutaneous Medicine 585 BRIEF ARTICLES Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature Simran A. Chadha, BS1, Jennifer L. Shastry, MD2, Joel C. Sunshine, MD2, Jennifer Choi, MD2*, Lauren Guggina, MD2* 1Northwestern University, Feinberg School of Medicine, Chicago, IL 2Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL *These authors contributed equally Phosphoinositide 3-kinase (PI3K) inhibitors are novel small molecule targeted inhibitors approved for the treatment of multiple hematologic malignancies, namely relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and breast cancer.1,2 Isoform-specific PI3K inhibitors are a subclass of this broader category, consisting of agents targeting the p110- isoform (alpelisib and taselisib), the p110- isoform (idelalisib), and the p110- and p110- isoforms (duvelisib).3 The specificity of these molecular targets allows for higher dosage while limiting toxicity; however, cutaneous, endocrine, and gastrointestinal toxicities are common. Previously Reported Cutaneous Toxicities of PI3K Inhibitors Age/ Sex Malignancy PI3K inhibitor Time to reaction Morphology Histopathology Reaction type Treatment of cutaneous eruption PI3K therapy outcome Successful re- challenge (if interrupted)?
    keywords: case; corticosteroids; duvelisib; eruption; inhibitors; pi3k; plaques; skin
       cache: skin-947.pdf
  plain text: skin-947.txt

        item: #1319 of 1356
          id: skin-948
      author: Kolb, Logan; Hignett, Emma; Kwong, Pearl
       title: Autosensitization due to Pediculosis Capitis (a “Pediculid”) in a 16-Year Old Female: A Case Report
        date: 2020-08-26
       words: 851
      flesch: 45
     summary: Practitioners should be aware of these current trends, evolving treatments, and the presence of id reactions related to pediculosis. The decision to treat with ivermectin was made because the patient refused to cut her hair and believed that current topical treatments were “toxic”.
    keywords: capitis; figure; patient; pediculosis
       cache: skin-948.pdf
  plain text: skin-948.txt

        item: #1320 of 1356
          id: skin-949
      author: Ugwu, Nelson; Kibbi, Nour
       title: Successful Treatment of Multiple Post-Operative Keratoacanthomas with Topical 5-Fluorouracil
        date: 2021-01-01
       words: 1985
      flesch: 57
     summary: Alternative non-surgical treatments also carried significant limitations. 1/3 continued 5- topical FU Goette et al 19829 14 66 (44-80) 6M, 8F head (2), neck (2), upper extremity (5), lower extremity (3), chest (1), shoulder (1) solitary lesions sporadic 20% 5FU ointment, 2-3 times daily for 2-4 weeks, (-) or (+) occlusion None 14/14 at 1- 7 weeks 1-7 weeks none Gray et al 199912 2 74 (68-80) 2M head (2), neck (2), forearm and hand (5), lower leg (3), chest (1), shoulder (1) solitary lesions sporadic 5% 5FU cream daily without occlusion for 4-8 weeks none 1/2 at 8 weeks 8 weeks 1 patient underwent biopsy with electrodessicatio n at 4 weeks after PR Thompson et al 201411 10 74.4 (52-92) 9F, 1M lower extremity (5) and head (5) solitary lesions sporadic short-contact (1 hr) topical 5% 5-fluorouracil cream twice daily until resolution none 9/10 at 4-6 weeks 4-6 weeks 1 patient underwent Mohs surgery after 1 week of 5-FU Silva et al 20197 1 64
    keywords: extremity; fluorouracil; kas; topical; treatment; weeks
       cache: skin-949.pdf
  plain text: skin-949.txt

        item: #1321 of 1356
          id: skin-95
      author: Makino, Elizabeth T; Tan, Priscilla; Mehta, Rahul C
       title: Clinical Efficacy and Tolerability of a Topical HQ-Free Serum on Females with self-Reported Pregnancy-Induced Facial Melasma
        date: 2017-10-27
       words: 1059
      flesch: 50
     summary: • LYT2 was well-tolerated with tolerability scores remaining similar to baseline scores. • Highly rated by subjects for self-perceived efficacy and product texture/attributes with a significant proportion of subjects agreeing to favorable responses by week 12.
    keywords: baseline; melasma; skin; subjects
       cache: skin-95.pdf
  plain text: skin-95.txt

        item: #1322 of 1356
          id: skin-951
      author: Thomley, Meredith E; Preda-Naumescu, Ana; Boyd, Carter J; Mayo, Tiffany
       title: Analyzing the Relationship Between Altmetric Score and Literature Citations in the Dermatology Literature
        date: 2020-10-27
       words: 3553
      flesch: 49
     summary: Journal Year Twitter Created Correlation Coefficient between number of citations and Altmetric score (2013) P-value (2013) Correlation Coefficient between number of citations and Altmetric score (2016) P-value (2016) Journal of Investigative Dermatology 2012 0.02 0.95 0.93 <0.0001 Pigment Cell & Melanoma Research n/a 0.11 0.77 0.005 0.99 Journal of the American Academy of Dermatology 2015 0.0006 0.99 0.80 0.006 JAMA Dermatology 2019 0.58 0.08 -0.29 0.42 Acta Dermato- Venereologica 2011 0.89 0.0005 -0.11 0.75 Experimental Dermatology 2016 -0.15 0.69 0.73 0.02 British Journal of Dermatology 2013 0.47 0.17 -0.17 0.63 Contact Dermatitis 2019 -0.18 0.63 -0.28 0.42 Journal of Dermatological Science n/a 0.59 0.073 0.84 0.0002 Journal of the European Academy of Dermatology and Venereology 2019 -0.28 0.44 0.24 0.50 Wound Repair and Regeneration n/a -0.23 0.51 0.54 0.11 American Journal of Clinical Dermatology n/a -0.006 0.99 0.28 0.44 Dermatologic Surgery n/a -0.01 0.97 -0.20 0.57 Seminars in Cutaneous Medicine and Surgery 2017 0.98 <0.0001 n/a n/a Journal of Dermatology n/a -0.06 0.87 0.72 0.02 suggests that citation count and journal impact factor are not entirely explained by article Altmetric Attention score. The total Altmetric Attention score for the 2016 cohort of articles was 60.3% higher than in 2013, whereas article citation counts were 51.4% lower in 2016 than 2013.
    keywords: altmetric; article; citation; dermatology; impact; journal; score
       cache: skin-951.pdf
  plain text: skin-951.txt

        item: #1323 of 1356
          id: skin-952
      author: Oduguwa, Emmanuella; Tahseen, Danyal
       title: Falling in Hair Love Comes Naturally
        date: 2020-08-29
       words: 557
      flesch: 40
     summary: Although there is heightened awareness for natural hair, Black women report dissatisfaction with the degree of knowledge that physicians specializing in hair have about the complexity of Afro-textured hair.3 Dermatologists play an integral role in Black women’s journey to disentangle social stigmas and clinically treat indications that impose barriers to maintaining natural hair styles. The retro-curvature of the bulb and elliptical shaft in Afro-textured hair contrast to the straight shape of hair follicles common among Caucasians.1 Although wearing Afro-textured hair in natural styles, such as afros, protects hair from potentially harmful chemical treatments, social stigmas discourage natural styles.1,2 An example of discrimination against Afro-ethnic hair in popular media occurred in 2015, when a fashion critic compared Black actress Zendaya’s dreadlocks to the smell of marijuana.
    keywords: afro; hair; women
       cache: skin-952.pdf
  plain text: skin-952.txt

        item: #1324 of 1356
          id: skin-953
      author: Gomolin, Tamar A; Cline, Abigail; Russo, Marian
       title: Maskne: Exacerbation or Eruption of Acne During the COVID-19 Pandemic
        date: 2020-08-29
       words: 855
      flesch: 42
     summary: The widespread use of face masks may be a contributing factor to acne mechanica and folliculitis mechanica, where stopping the mechanical insult is essential to treatment. However, if ‘maskne’ persists despite the above regimen, lesions may represent acne mechanica rather than folliculitis mechanica.
    keywords: acne; mask; mechanica; skin
       cache: skin-953.pdf
  plain text: skin-953.txt

        item: #1325 of 1356
          id: skin-954
      author: Tan, Llewelyn Yi Chang; Tan, Chee Hian; Lim, Joel Hua Liang
       title: Cutaneous scalp metastases from a left hallux subungual melanoma: An instructive case of scalp nodules
        date: 2021-01-01
       words: 1767
      flesch: 50
     summary: Skin melanoma has also been reported to spread to the scalp1. There are 4 major subtypes of cutaneous melanoma and they include superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna melanoma (LMM) and acral lentiginous melanoma (ALM).
    keywords: figure; melanoma; nodules; scalp; skin
       cache: skin-954.pdf
  plain text: skin-954.txt

        item: #1326 of 1356
          id: skin-956
      author: Ezekwe, Nneamaka; Huynh, Thy; Brodell, Robert
       title: Distinguishing Features: Linear Rashing is Not Always Koebnerization
        date: 2021-01-01
       words: 1150
      flesch: 32
     summary: Issue 10, pages 1282-1284) linear cutaneous sarcoidosis from linear psoriasis. Routine histological examination distinguishes cutaneous sarcoidosis from psoriasis.
    keywords: agents; linear; psoriasis; sarcoidosis; scars
       cache: skin-956.pdf
  plain text: skin-956.txt

        item: #1327 of 1356
          id: skin-958
      author: Gupta, Rohit; Martin, Jennifer; Wasko, Carina
       title: Mycobacterium Kansasii Infection Overlying Tattoo Pigment in an Immunocompromised Patient
        date: 2020-10-27
       words: 1494
      flesch: 37
     summary: They are thought to originate from mycobacterial contamination of tattoo equipment or the tattoo pigment, or bacterial inoculation of breaks in the skin surface caused by the tattooing process, and they can occur in both healthy and immunocompromised individuals.4 We describe a case of M. kansasii infection occurring over long-standing black tattoo pigment in an HIV-positive patient. Mycobacterium kansasii infection presenting as cellulitis in a patient with systemic lupus erythematosus.
    keywords: cutaneous; infection; kansasii; mycobacterium; patient; tattoo
       cache: skin-958.pdf
  plain text: skin-958.txt

        item: #1328 of 1356
          id: skin-959
      author: Levin, Nicole; Gray, Taylor; Farsi, Maheera; Dorton, David; Miller, Richard
       title: Topical Zinc May Augment Post-Operative Wound Healing, Including Following Mohs Micrographic Surgery: A Review of the Literature
        date: 2020-09-01
       words: 4774
      flesch: 53
     summary: Furthermore, no complications occurred in the zinc oxide group; however, 6 complications were noted in the group receiving standard wound care, including infection, wound dehiscence, postoperative bleeding, pain, and excessive swelling.23 Currently a clinical trial is in progress which will compare scar outcomes following dermatologic surgery when treated with topical zinc oxide versus petrolatum.38 This split-scar study will treat half of the incision with zinc oxide and half with petrolatum. Donor sites were located on the upper thigh and demonstrated complete epithelialization more rapidly when treated with zinc oxide (8.7 days vs 10.7 days).33
    keywords: care; compression; group; healing; oxide; patients; skin; studies; study; sulfate; topical; use; wound; zinc; zinc oxide
       cache: skin-959.pdf
  plain text: skin-959.txt

        item: #1329 of 1356
          id: skin-962
      author: none
       title: Onychomadesis as a Manifestation of Coxsackievirus A6 in an Adult
        date: 2020-10-27
       words: 877
      flesch: 49
     summary: Wei, S.-H., et al., An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. CVA6 has been shown to affect both children and adults and is associated with a more profound disease course that includes fever, sore throat, malaise, herpangina, a vesicular or maculopapular rash, and onychomadesis; a temporary cessation of nail growth that can lead to proximal separation of the nail plate from the nail matrix.1 A 32-year-old woman was referred to dermatology clinic for a painful rash of the hands and soles of four days duration, associated with malaise and subjective fevers.
    keywords: cva6; hfmd; onychomadesis
       cache: skin-962.pdf
  plain text: skin-962.txt

        item: #1330 of 1356
          id: skin-964
      author: Siller Jr., Alfredo; Jebain, Joseph; Amer, Yomna; Haley, Christopher T.; Chen, Leon; Tyring, Stephen K.
       title: Painful Retiform Purpura with Cutaneous Necrosis
        date: 2020-10-27
       words: 1433
      flesch: 38
     summary: The purpura often become necrotic and may develop bullae and abscesses.1,4 Fever, oral sores, fatigue, and dyspnea are also common manifestations.6 The differential diagnosis for levamisole- induced vasculitis includes leukocytoclastic vasculitis, drug reaction, cryoglobulinemia, idiopathic thrombocytopenic purpura, granulomatosis with polyangiitis, Churg- Strauss syndrome, and polyarteritis nodosa.2,6 Histologic findings for levamisole- induced vasculitis are not disease specific but may include leukocytoclastic vasculitis, thrombosis, and panniculitis.2,6 Diagnosis is therefore made through laboratory values and clinical history. The majority of patients with levamisole- induced vasculitis are positive for p-ANCA, while c-ANCA positivity has been reported in about 50% of patients.3,4,7 Anti–double- stranded DNA and lupus anticoagulant studies may also be positive.2 The anti- human elastase antibody is a sensitive and specific test to cocaine-induce lesions8 which can be helpful to distinguish levamisole-induced vasculitis from ANCA- associated vasculitis.2
    keywords: anca; cocaine; levamisole; purpura; use; vasculitis
       cache: skin-964.pdf
  plain text: skin-964.txt

        item: #1331 of 1356
          id: skin-969
      author: Phan, Michael; Phan, Jonathan
       title: Norman Orentreich: Father of Hair Modern Transplantation
        date: 2020-08-29
       words: 451
      flesch: 47
     summary: Dr. Orentreich also incorporated the use of intralesional corticosteroid to prevent hypertrophic and keloidal scarring and dermabrasion to treat elevated grafts.3 Microsoft Word - September 2020 - DH 969 - proof.docx SKIN September 2020 Volume 4 Issue 5 Copyright 2020 The National Society for Cutaneous Medicine 489 DERMATOLOGIC HISTORY Norman Orentreich: Father of Modern Hair Transplantation Michael Phan BS1, Jonathan Phan MS1 1University of Texas Medical Branch, School of Medicine, Galveston TX Norman Orentreich, MD is universally regarded as the father of modern hair transplantation.
    keywords: hair; orentreich
       cache: skin-969.pdf
  plain text: skin-969.txt

        item: #1332 of 1356
          id: skin-971
      author: Kou, Leon; Zhong, Lily; Danesh, Sid
       title: Primary Cutaneous Mucinous Carcinoma of the Nasal Bridge
        date: 2020-10-27
       words: 1597
      flesch: 53
     summary: Primary mucinous carcinoma with direct histopathologic evidence of lymphatic invasion. Mucinous carcinoma is a malignant tumor with a low rate of metastasis, but high rate of recurrence.
    keywords: carcinoma; case; lesion; metastasis; pcmc; skin
       cache: skin-971.pdf
  plain text: skin-971.txt

        item: #1333 of 1356
          id: skin-974
      author: Schaefer, Max A; Dhandha, Maulik M; Karnes, Jonathan B
       title: “They Won’t Let Me Return to Work.” A Carpenter Diagnosed with Porphyria Cutanea Tarda
        date: 2021-01-01
       words: 1338
      flesch: 46
     summary: Significant improvement of skin eruption following therapeutic intervention with phlebotomy, hydroxychloroquine, photo protection, alcohol cessation, and curative hepatitis C treatment. referred to gastroenterology for treatment of hepatitis C, to hematology for phlebotomy, and dermatology to help guide therapy with hydroxychloroquine. This case of a carpenter diagnosed with PCT not only illustrates a classic case but also the opportunity to achieve significant response to therapy in a motivated patient particularly with improved access to direct-acting antivirals (DAA) for hepatitis C treatment.
    keywords: nmol; patient; pct; skin
       cache: skin-974.pdf
  plain text: skin-974.txt

        item: #1334 of 1356
          id: skin-975
      author: Potluri, Venkat Sumanth; Youssef, Ronnie; Fertig, Raymond; Dhaliwal, Parneet
       title: A Case of ALK-Negative Anaplastic Large Cell Lymphoma Presenting as a Solitary Cutaneous Nodule
        date: 2021-01-01
       words: 1762
      flesch: 48
     summary: ALCL by any other name: the many facets of anaplastic large cell lymphoma. Anaplastic large cell lymphoma, ALK-negative.
    keywords: alcl; alk; anaplastic; cell; lymphoma
       cache: skin-975.pdf
  plain text: skin-975.txt

        item: #1335 of 1356
          id: skin-976
      author: Strober, Bruce; Gottlieb, Alice; Tha?i, Diamant; Puig, Luis; Colombo, Matthew J; Kundu, Sundeep; Kisa, Renata; Banerjee, Subhashis
       title: An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
        date: 2020-09-02
       words: 1922
      flesch: 41
     summary: This analysis suggests that BMS-986165 elicits a rapid response and is efficacious in achieving an absolute PASI of ≤2 in approximately 50% of patients and an absolute PASI ≤1 in approximately 30% of patients with moderate to severe plaque psoriasis — As mentioned earlier, an absolute PASI of ≤2 has been shown to be clinically meaningful for clinical and HRQoL outcomes2 — Mean percentage change from baseline in absolute PASI at Week 12 was approximately 80% in BMS-986165–treated patients • Five ongoing Phase 3 trials in plaque psoriasis (NCT03624127, NCT03611751, NCT04167462, NCT03924427, and NCT04036435) involving BMS-986165 treatment will evaluate this further over a longer duration and in larger patient cohorts • PASI ≤2 has the potential to be an alternative therapeutic goal to percent PASI improvements and sPGA scores for patients with moderate to severe plaque psoriasis Introduction • Plaque psoriasis is a debilitating, chronic, immune-mediated skin disorder that impairs patients’ health- related quality of life (HRQoL) and productivity1 • Treatment outcomes for plaque psoriasis based on the absolute Psoriasis Area and Severity Index (PASI) are indicative of an individual patient’s disease severity at the time of analysis2 — Absolute PASI may be more clinically meaningful than percentage change in PASI from baseline captured by scores such as PASI 75 (≥75% reduction from baseline PASI)2 — Although a consensus therapeutic target has yet to be defined, a recent analysis reported that attainment of an absolute PASI of ≤2 translates to meaningful improvements in clinical and HRQoL outcomes2 • Previous studies have demonstrated that an absolute PASI ≤2 correlates with PASI 90 (≥90% improvement from baseline PASI), static Physician’s Global Assessment (sPGA) score of 0/1 (range, 0–5; higher scores indicate greater disease severity), and Dermatology Life Quality Index (DLQI) of 0/1 (range, 0–30; higher scores indicate worse HRQoL)2 • BMS-986165 is an oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2), an intracellular enzyme involved in key cytokine signaling pathways in plaque psoriasis pathogenesis3 — In a Phase 2, double-blind, randomized trial in patients with moderate to severe plaque psoriasis (NCT02931838), 67%–75% of patients treated with BMS-986165 at doses of 3 or 6 mg twice daily (BID) or 12 mg once daily (QD) achieved PASI 75 at Week 12 (primary endpoint) vs 7% with placebo (P<0.001)3 — BMS-986165 had a favorable safety and tolerability profile, and was associated with low rates of treatment discontinuation3 Objective • This post hoc analysis of the Phase 2 trial compared the efficacy of BMS-986165 vs placebo based on absolute PASI over time up to Week 12 Methods Inclusion criteria • Adults with body mass index of 18–40 kg/m2 • Moderate to severe plaque psoriasis for ≥6 months affecting ≥10% of body surface area — PASI ≥12 (range, 0–72; higher scores indicate greater disease severity) — sPGA ≥3 • Eligible for phototherapy or systemic therapy Exclusion criteria • Diagnosis of nonplaque psoriasis or other immune-mediated condition requiring concomitant systemic immunosuppressant therapy • History or evidence of specific infections (eg, HIV or hepatitis B or C infection) or risk of tuberculosis • Previous lack of response to any therapeutic agent targeting the TYK2 pathway (eg, interleukin-12/-23 pathways) Absolute PASI at Week 12 Patients achieving PASI threshold, % (intent-to-treat population) Absolute PASI Placebo (n=45
    keywords: absolute; bid; bms-986165; pasi; psoriasis
       cache: skin-976.pdf
  plain text: skin-976.txt

        item: #1336 of 1356
          id: skin-977
      author: Gordon, Kenneth; Papp, Kim; Gooderham, Melinda; Morita, Akimichi; Foley, Peter; Tha?i, Diamant; Kundu, Sundeep; Kisa, Renata; Wei, Lan; Banergee, Subhashis
       title: BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients
        date: 2020-09-02
       words: 2420
      flesch: 54
     summary: Other laboratory parameters were measured but are not presented here • Mean (standard deviation [SD]), median (interquartile range), or median (range) absolute values for laboratory parameters are reported for the placebo group and the most clinically effective BMS-986165 doses (ie, doses ≥3 For patients with LDL-C values available, no increase was observed over 12 weeks of treatment (data not shown) • Increases in CPK observed at 12 weeks in the placebo and BMS-986165 groups were asymptomatic, mostly Grade 1 or 2, and were observed in 12/44 (27%) patients who received placebo and 57/221 (26%) who received BMS-986165 Table 1.
    keywords: bid; bms-986165; mg bid; n=45; pharma; week
       cache: skin-977.pdf
  plain text: skin-977.txt

        item: #1337 of 1356
          id: skin-978
      author: Gottlieb, Alice B; Strober, Bruce; Tha?i, Diamant; Gordon, Kenneth; Kundu, Sundeep; Kisa, Renata; Wei, Lan; Banerjee, Subhashis; Merola, Joseph
       title: BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI
        date: 2020-09-02
       words: 2250
      flesch: 59
     summary: The treatment period was 12 weeks, with an additional 30-day off-treatment follow-up period for safety12 Efficacy assessments and outcomes • Key efficacy assessments included PASI, sPGA, BSA, and the Dermatology Life Quality Index (DLQI) questionnaire — The primary endpoint was PASI 75 at Week 12 • Percentage mean change from baseline to Week 12 in sPGA×BSA and PASI score was assessed for the placebo group and all BMS-986165 dose groups • Spearman correlation coefficients were used to assess the relationship between sPGA×BSA and PASI or DLQI scores at Week 12, as well as between percentage change from baseline in sPGA×BSA and PASI or DLQI scores at Week 12 for all treatment groups. Percentage mean change from baseline by visit in (A) sPGA×BSA and (B) PASI score in patients with moderate to severe plaque psoriasis treated with BMS-986165 or placebo (N=267) A M e an ( SE ) ch an ge f ro m b as e li n e , % 0 -20 -40 -60 -80 -100 Baseline B M e an ( SE ) ch an ge f ro m b as e li n e , % 0 -20 -40 -60 -80 -100 Baseline Percentage mean change from baseline in sPGA×BSA Percentage mean change from baseline in PASI score Week 1 Week 2 Week 4 Week 8 Week 12 Week 1 Week 2 Week 4 Week 8 Week 12 Placebo (n=45)
    keywords: baseline; bms-986165; change; pasi; spga×bsa; week
       cache: skin-978.pdf
  plain text: skin-978.txt

        item: #1338 of 1356
          id: skin-98
      author: Schneider, Katie H; Goberdhan, Lisa T; Makino, Elizabeth T; Mehta, Rahul C
       title: Combining In-Office Chemical Peel Procedures with Topical Therapy of a Comprehensive Pigmentation Control Product for Multi-Ethnic Subjects with Moderate-to-Severe Facial Hyperpigmentation
        date: 2017-10-27
       words: 814
      flesch: 40
     summary: Combining in-office chemical peel procedures with topical therapy of a comprehensive pigmentation control product for multi-ethnic subjects with moderate to severe facial hyperpigmentation Katie H. Schneider, BS, CRA; Lisa T. Goberdhan, BA; Elizabeth T. Makino, BS, CCRA, MBA; Rahul C. Mehta, PhD Research & Development SkinMedica, an Allergan Company, Irvine, CA, USA Presented at the Fall Clinical Dermatology Conference Series, October 12-15, 2017, Las Vegas, NV, USA BACKGROUND Skin discoloration is a common concern with limited treatment options for multi-ethnic patients due to the increased risk of Post Inflammatory Hyperpigmentation (PIH). Female subject, Age 36, Fitz III Left to Right: Baseline & Week 12 after 3 VP treatments, and 9 weeks of twice daily use of LYT2 Improvements observed in overall hyperpigmentation and overall photodamage at week 4 through week 12 with statistically significant improvements observed at weeks 8 and 12 (p<0.03; student’s paired t-test).
    keywords: hyperpigmentation; subjects; week
       cache: skin-98.pdf
  plain text: skin-98.txt

        item: #1339 of 1356
          id: skin-980
      author: Lebwohl, Mark; Lacour, Jean-Philippe; Liljedahl, Monika; Lynde, Charles; M?rch, Marie H; Tha?i, Diamant; Warren, Richard B
       title: Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial
        date: 2020-09-02
       words: 1696
      flesch: 59
     summary: This Phase III, multicenter trial included a 4-week open-label lead-in phase in adult patients with: ─ Trunk and/or limb psoriasis, involving 2–30% of body surface area (BSA); physician’s global assessment (PGA) of disease severity ≥’mild’; modified psoriasis area and severity index (m- PASI) ≥2. Poster #12797Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: results of a Phase III, multicentre, randomized, 52-week, vehicle-controlled trial Mark Lebwohl1, Jean-Philippe Lacour2, Monika Liljedahl3, Charles Lynde4,5, Marie Holst Mørch3, Diamant Thaçi6 and Richard B Warren7 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Department of Dermatology, University Hospital of Nice, Nice, France; 3LEO Pharma A/S, Ballerup, Denmark; 4Lynde Dermatology, Probity Medical Research, Markham, ON, Canada; 5Department of Medicine, University of Toronto, Toronto, ON, Canada; 6Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany; 7Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, University of Manchester, Manchester, UK Materials and Methods Introduction 
    keywords: aes; foam; patient; phase; treatment
       cache: skin-980.pdf
  plain text: skin-980.txt

        item: #1340 of 1356
          id: skin-981
      author: Lebwohl, Mark; Lacour, Jean-Philippe; Liljedahl, Monika; Lynde, Charles; M?rch, Marie H; Tha?i, Diamant; Warren, Richard B
       title: Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial
        date: 2020-09-02
       words: 1586
      flesch: 62
     summary: Conclusions  Proactive management with Cal/BD foam was superior in prolonging time to first relapse, reducing number of relapses and increasing days in remission versus vehicle-controlled reactive management. Mean age of randomized patients was 52.2 years; 91% of patients were white and 68% male.
    keywords: foam; patients; phase; relapse
       cache: skin-981.pdf
  plain text: skin-981.txt

        item: #1341 of 1356
          id: skin-982
      author: Kerdel, Francisco; Don, Christina; Block, Renata; Lewis, Caitlin; Schreiber, Rhonda
       title: Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis
        date: 2020-09-02
       words: 1521
      flesch: 59
     summary: The severity of patients’ psoriasis was described as % of Body Surface Area (%BSA), where less than 3% can be considered mild, 3-10% moderate, and >11% as severe. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
    keywords: foam; patient; psoriasis; treatment
       cache: skin-982.pdf
  plain text: skin-982.txt

        item: #1342 of 1356
          id: skin-984
      author: Herbert, Adelaide A; Glaab, Debbie; Schreiber, Rhonda
       title: A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis
        date: 2020-09-02
       words: 1841
      flesch: 60
     summary: However, response rates (% of subjects with an ISGA score of 0 or 1 for body or scalp at week 8) were consistent with that observed in the double-blind, vehicle controlled Phase III studies in adults. Patient Tolerability of tazarotene foam, 0.1%, and Impact on Patient Compliance A multicenter, open-label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis.
    keywords: calcipotriene; day; foam; psoriasis; subjects
       cache: skin-984.pdf
  plain text: skin-984.txt

        item: #1343 of 1356
          id: skin-985
      author: Selmer, Johan; Vestbjerg, Birgitte; Pr?stegaard, Morten; Gold, Linda Stein
       title: Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris
        date: 2020-09-02
       words: 1196
      flesch: 53
     summary: CAL/BDP topical suspension (n=338) 2 week follow- up Figure 3: Primary efficacy variable: % PGA Treatment SuccessINTRODUCTION: MC2-01 cream is a novel topical treatment of psoriasis containing the active ingredients calcipotriene and betamethasone dipropionate (0.005% / 0.064% w/w, CAL/BDP). The secondary efficacy endpoint of non-inferiority of % change in mPASI from baseline to Week 8 of MC2-01 cream versus CAL/BDP TS at Week 8 was also met.
    keywords: bdp; cal; cream; mc2
       cache: skin-985.pdf
  plain text: skin-985.txt

        item: #1344 of 1356
          id: skin-986
      author: Gold, Linda Stein; Weiss, Jonathan S; Green, Lawrence; Kircik, Leon; Miller, Lauren; Jacobson, Abby; Harris, Susan
       title: Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%
        date: 2020-09-02
       words: 1432
      flesch: 54
     summary: Body Surface Area at Treatment Successa (Safety Population) 0% 20% 40% 60% 80% 100% P e rc e n ta g e o f P ar ti ci p an ts 91.2% 75.2% 55.7% 35.5% ≤5% ≤3% ≤2% ≤1% 74.5% 59.8% 46.1% 33.3% ≤5% ≤3% ≤2% ≤1% Body Surface Area Body Surface Area Overall Study Population: Baseline BSA 3–12%b (n=318)
    keywords: baseline; bsa; taz; treatment
       cache: skin-986.pdf
  plain text: skin-986.txt

        item: #1345 of 1356
          id: skin-987
      author: Lebwohl, Mark G; Sugarman, Jeffrey; Pariser, David M; Bagel, Jerry; Trickett, Cynthia; Jacobson, Abby; Israel, Robert
       title: Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study
        date: 2020-09-02
       words: 1527
      flesch: 49
     summary: Select local signs/symptoms showed marked improvements in severity of itching, dryness, and burning/stinging over the study course; greatest improvement was for itching (Figure 2) ◾ Incidence of treatment-emergent Grade 3 local skin reactions was 22.2% for itching, 6.9% for dryness, and 9.8% for burning/stinging ◾ Incidence of other local skin reactions are shown in Figure 3 • Incidence peaked at 2.3% for skin atrophy (week 8), 2.7% for folliculitis (week 8), and 1.5% for striae and telangiectasias (week 28) ◾ Local skin reactions most frequently reported as AEs were application site folliculitis (14 participants [2.5%]; 1 discontinued) and application site atrophy (4 participants [0.7%]; 1 discontinued); no participant reported striae or telangiectasias AEs ◾ At week 8, treatment was stopped for participants that achieved treatment success; those who did not reach treatment success were treated for 4 additional weeks •
    keywords: baseline; dermatologics; treatment; week
       cache: skin-987.pdf
  plain text: skin-987.txt

        item: #1346 of 1356
          id: skin-988
      author: Langley, Richard G; Crowley, Jeffrey; Gooderham, Melinda; Papp, Kim A; Korman, Neil J; Spelman, Lynda; Igarashi, Atsuyuki; Ohtsuki, Mamitaro; Gupta, Aditya K; Yamauchi, Paul; Parno, Jeffrey; Mendelsohn, Alan M; Rozzo, Stephen J; Eads, Kimberly
       title: Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2
        date: 2020-09-02
       words: 4545
      flesch: 28
     summary: The efficacy analysis was concluded at week 208 for reSURFACE 1 (extension week 144; 2210.8 total patient years) and week 196 for reSURFACE 2 (2768.3 total patient years) Efficacy Figure 2. reSURFACE 1 week 64 results of PASI 75/90/100 responses for A) tildrakizumab 100 mg, B) tildrakizumab 200 mg, and C) PGA response; and reSURFACE 2 week 52 results of PASI 75/90/100 The patient flow from randomization through the extension study for reSURFACE 1 and reSURFACE 2 is shown in Figure 1 Table 1.
    keywords: mg n; pasi; resurface; til
       cache: skin-988.pdf
  plain text: skin-988.txt

        item: #1347 of 1356
          id: skin-989
      author: Cantrell, Wendy; Lee, Patricia; Mendelsohn, Alan M; Parno, Jeff; Rozzo, Stephen J; Liao, Wilson
       title: Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1
        date: 2020-09-02
       words: 2339
      flesch: 36
     summary: At week 28, tildrakizumab nonresponders (those who did not achieve PASI ≥50) discontinued treatment ○ Tildrakizumab responders (PASI ≥75) and partial responders (PASI ≥50 and <75) continued the study — In Part 3 (weeks 28–64), patients who had received tildrakizumab from the start of the study were rerandomized to placebo, tildrakizumab 100 mg, or tildrakizumab 200 mg based on their level of response to treatment; patients received tildrakizumab every 12 weeks or placebo every 4 weeks — After rerandomization to placebo, treatment was reinitiated if patients experienced a relapse (a reduction in maximum PASI response by ≥50%) or a rebound (>125% worsening of PASI scores from baseline values) No Tier 1 AEs were reported in patients who were rerandomized to placebo at week 28 and relapsed either on placebo or tildrakizumab 100 mg CONCLUSIONS • In Part 3 of the reSURFACE 1 trial (weeks 28–64), tildrakizumab 100 mg had a durable response profile — A large proportion (46%) of tildrakizumab 100 mg responders did not relapse after rerandomization to placebo for 48 weeks after receiving their last dose of drug •
    keywords: pasi; patients; tildrakizumab
       cache: skin-989.pdf
  plain text: skin-989.txt

        item: #1348 of 1356
          id: skin-990
      author: Papp, Kim A; Yeung, Jensen; Shear, Neil; Albrecht, Lorne; Lynde, Charles; Zhang, Jingchuan; Zhao, Yang; Parno, Jeff; Mendelsohn, Alan M; Gooderham, Melinda
       title: Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab
        date: 2020-09-02
       words: 2415
      flesch: 52
     summary: W28 PASI 75–89 W28 PASI 50–74 LTE Start (reSURFACE1) Number of patients: W28 PASI 100 W28 PASI 90–99 W28 PASI 75–89 W28 PASI 50–74 91 131 79 34 91 131 79 34 91 131 79 34 81 117 63 22 82 121 63 26 85 122 70 27 84 127 70 33 83 127 75 33 86 125 76 33 86 129 78 34 89 130 79 34 91 130 78 34 90 131 78 34 91 131 79 34 90 129 78 34 89 128 75 33 91 131 79 34 91 131 79 34 91 130 79 34 91 131 79 34 start (reSURFACE 2) start (reSURFACE 1) W28 PASI 75–89 W28 PASI 50–74 LTE Start (reSURFACE1) Number of patients: W28 PASI 100 W28 PASI 90–99 W28 PASI 75–89 W28 PASI 50–74 91 131 79 34 91 131 79 34 91 131 79 34 81 117 63 22 82 121 63 26 85 122 70 27 84 127 70 33 83 127 75 33 86 125 76 33 86 129 78 34 89 130 79 34 91 130 78 34 90 131 78 34 91 131 79 34 90 129 78 34 89 128 75 33 91 131 79 34 91 131 79 34 91 130 79 34 91 131 79 34 start (reSURFACE 2) start (reSURFACE 1)
    keywords: patients; resurface; start; w28 pasi; week
       cache: skin-990.pdf
  plain text: skin-990.txt

        item: #1349 of 1356
          id: skin-991
      author: Lebwohl, Mark G; Mehta, Nehal N; Gottlieb, Alice B; Mendelsohn, Alan M
       title: Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies
        date: 2020-09-02
       words: 3582
      flesch: 50
     summary: Metabolic syndrome (MetS) is a combination of common cardiometabolic abnormalities associated with an increased risk of cardiovascular disease and diabetes1 and has higher prevalence in patients with moderate to severe psoriasis compared with the overall population2-4 • In patients with psoriasis treated with anti-tumor necrosis factor or anti–interleukin (IL)-17 agents, MetS may reduce the absolute Psoriasis Area and Severity Index (PASI) response and long-term drug survival5-7 • Tildrakizumab—a high-affinity, humanized, immunoglobulin G1κ, anti–IL-23p19 monoclonal antibody—is approved in the US, Europe, and Australia for treatment of moderate to severe plaque psoriasis — The efficacy of tildrakizumab was demonstrated in 2 phase 3 clinical studies, reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754)8 — Treatment with tildrakizumab significantly increased the proportion of patients with ≥75%, ≥90%, and 100% improvement in PASI scores (PASI 75, PASI 90, and PASI 100, respectively) and Physician’s Global Assessment 0/1 response rates compared with placebo8 • Previously, we evaluated tildrakizumab efficacy in patients meeting National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria9 for MetS (including diminished high-density lipoprotein cholesterol and elevated blood pressure, body mass index [BMI], triglycerides, and glucose) after 1 year of treatment — MetS has a minimal effect on tildrakizumab efficacy10 and safety11 and there are no increases in cardiac events or worsening of diabetes in patients with MetS following 1 year of tildrakizumab treatment12 OBJECTIVE • To update the efficacy of tildrakizumab in psoriasis patients with vs without MetS with up to 3 years (148 weeks) of follow-up in reSURFACE 1 and reSURFACE 2 METHODS Study design • 35.6 ± 6.1 27.3 ± 5.3 37.6 ± 9.8 Body surface area, % 29.4 ± 16.7 32.2 ± 16.6 32.6 ± 19.5 30.1 ± 19.4 34.1 ± 18.4 30.3 ± 18.9 31.4 ± 17.2 27.6 ± 12.9 Disease duration, y 17.2 ± 12.6 16.2 ± 12.3 16.6 ± 11.5 16.7 ± 12.9 16.1 ± 10.6 15.2 ± 11.2 18.0 ± 13.5 20.1 ± 14.8 Baseline PASI score 19.9 ± 7.1 20.5 ± 7.1 21.5 ± 9.3 20.6 ± 9.7 19.6 ± 6.9 20.8 ± 8.8 19.5 ± 7.2 19.2 ± 6.3 Baseline PGA score 3.3 ± 0.6 3.4 ± 0.6 3.4 ± 0.6 3.5 ± 0.6 3.3 ± 0.5 3.4 ± 0.6 3.3 ± 0.6b 3.4 ± 0.6 CV disorders, n (%) 14 (14.3) 17 (65.4) 31 (27.4) 16 (47.1) 29 (17.1) 17 (38.6) 27 (20.8) 16 (53.3) Diabetes, n (%) 8 (8.2) 8 (30.8) 11 (9.7) 8 (23.5) 5 (2.9) 7 (15.9) 11 (8.5) 7 (23.3) Psoriatic arthritis, n (%) 16 (16.3) 5 (19.2) 19 (16.8) 9 (26.5) 24 (14.1) 11 (25.0) 17 (13.1) 4 (13.3) Response to >1 traditional systemic medicine, n (%)c
    keywords: mets
       cache: skin-991.pdf
  plain text: skin-991.txt

        item: #1350 of 1356
          id: skin-992
      author: Mease, Philip J; Chohan, Saima; Garcia Fructuoso, Ferran J; Gottlieb, Alice B; Chou, Richard C; Mendelsohn, Alan M; Luggen, Michael E
       title: Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
        date: 2020-09-02
       words: 2966
      flesch: 45
     summary: Demographics and baseline clinical disease characteristics TIL 200 mg Q4W (n = 78) TIL 200 mg Q12W (n = 79) TIL 100 mg Q12W (n = 77) TIL 20 mg Q12W (n = 78) PBO (n = 79) Age, years, mean ± SD 50.1 ± 13.3 49.3 ± 11.2 49.2 ± 11.9 47.2 ± 13.4 48.1 ± 13.3 Female, n (%) 46 (59.0) 37 (46.8) 47 (61.0) 41 (52.6) 44 (55.7) Race, n (%) White Black or African American Other 76 (97.4) 0 2 (2.6) 78 (98.7) 0 1 (1.3) 75 (97.4) 1 (1.3) 1 (1.3) 75 (96.2) 1 (1.3) 2 (2.6) 74 (93.7) 3 (3.8) 2 (2.5) Weight, kg, mean ± SD 85.1 ± 19.7 87.1 ± 19.5 83.6 ± 18.9 85.1 ± 18.1 85.3 ± 20.2 BMI, kg/m2, mean ± SD 30.1 ± 6.5 30.2 ± 6.5 29.5 ± 6.8 29.4 ± 5.2 29.5 ± 6.0 Duration of PsA, years, mean ± SD 6.9 ± 7.3 6.8 ± 6.3 6.3 ± 7.2 6.6 ± 6.7 7.3 ± 8.0 Enthesitis score (LEI >0), mean ± SD 3.1 ± 1.7 2.8 ± 1.7 3.2 ± 1.8 3.1 ± 1.7 2.8 ± 1.8 BSA, (%), mean ± SD 11.9 ± 16.0 9.0 ± 12.4 12.8 ± 16.0 10.4 ± 14.1 8.2 ± 12.2 BSA ≥3%, n (%) 53 (67.9) 44 (55.7) 54 (70.1) 41 (52.6) 42 (53.2) PASI, mean ± SDb 7.6 ± 9.8 6.2 ± 7.4 8.8 ± 9.5 6.6 ± 7.0 5.0 ± 6.5 HAQ score, mean ± SD 1.0 ± 0.6 1.0 ± 0.6 1.0 ± 0.7 1.1 ± 0.6 1.2 ± 0.6
    keywords: mg q12w; pbo; q12w til; q4w; til; weeks
       cache: skin-992.pdf
  plain text: skin-992.txt

        item: #1351 of 1356
          id: skin-993
      author: Gordon, K; Warren, R B; Gottlieb, A B; Blauvelt, A; Tha?i, D; Leonardi, C; Poulin, Y; Boehnlein, M; Kavanagh, S; Arendt, C; Reich, K
       title: Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
        date: 2020-09-02
       words: 1971
      flesch: 54
     summary: Consulting honoraria and clinical investigator: AbbVie, Aclaris, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira Inc., Eli Lilly, Genentech/Roche, GSK, Janssen, LEO Pharma, Meiji, Merck, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharma, Sun Pharma, UCB Pharma, Valeant, Vidac. Investigator (Research grants) from AbbVie, Baxter, Boehringer Ingelheim, Celgene, Centocor/Janssen, Eli Lilly, EMD Serono, GSK; LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Takeda, UCB Pharma; MB, CA: Employees of UCB Pharma; SK: Employee of UCB Pharma.
    keywords: czp; mg q2w; pasi; patients; pharma; q2w
       cache: skin-993.pdf
  plain text: skin-993.txt

        item: #1352 of 1356
          id: skin-994
      author: Gordon, K; Warren, R B; Gottlieb, A B; Blauvelt, A; Tha?i, D; Poulin, Y; Boehnlein, M; Brock, F; Arendt, C; Reich, K
       title: Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)
        date: 2020-09-02
       words: 2046
      flesch: 49
     summary: Author Disclosures KG: Honoraria and/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol- Myers Squibb, Celgene, Dermira Inc., Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; RBW: Research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Bristol- Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, UCB Pharma; ABG: Current consulting/advisory board agreements with AbbVie, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Incyte, Janssen, Leo Pharma, Novartis, Sun Pharma, UCB Pharma, XBiotech; Research and educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB Pharma, XBiotech; AB: Served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Allergan, Almirall, Athenex, Boehringer Ingelheim, Bristol- Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, FLX Bio, Forte, Galderma, Janssen, Leo, Novartis, Ortho, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie; DT: Honoraria for participation on ad boards, as a speaker or for consultancy from AbbVie, Almiral, Amgen, Boehringer Ingelheim, Celgene, Dignity, Dr. Reddy’s Laboratories, Galapagos, GSK, Janssen, Leo Pharma, Morphosis, MSD, Lilly, Novartis, Pfizer, Sandoz-Hexal, Pfizer, Regeneron/Sanofi, UCB Pharma; Research grants from Celgene and Novartis; YP: Investigator (research grants) from AbbVie, Baxter, Boehringer Ingelheim, Celgene, Centocor/Janssen, Eli Lilly, EMD Serono, GSK, Leo Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Takeda, and UCB Pharma; Speaker (honoraria) from AbbVie, Celgene, Janssen, Eli Lilly, Leo Pharma, Novartis, Regeneron, and Sanofi Genzyme; MB, FB, CA: Employees of UCB Pharma; KR: AbbVie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Takeda, UCB Pharma, Valeant and Xenoport. The authors acknowledge Susanne Wiegratz, UCB Pharma, Monheim, Germany for publication coordination and Joe Dixon, PhD, Costello Medical, Cambridge, UK for medical writing and editorial assistance.
    keywords: czp; pasi; q2w
       cache: skin-994.pdf
  plain text: skin-994.txt

        item: #1353 of 1356
          id: skin-995
      author: Blauvelt, A; Paul, C; van de Kerkhof, P; Warren, R B; Gottlieb, A B; Langley, R G; Brock, F; Arendt, C; Boehnlein, M; Lebwohl, M; Reich, K
       title: Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies
        date: 2020-09-02
       words: 2693
      flesch: 54
     summary: Author Disclosures AB: AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira Inc., Eli Lilly, FLX Bio, Forte, Galderma, Janssen, LEO Pharma, Novartis, Ortho, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, UCB Pharma; CP: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira Inc., Eli Lilly, GSK, Janssen, LEO Pharma, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, UCB Pharma; PvdK: AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, Novartis; RBW: AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Avillion, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, Xenoport; ABG: AbbVie, Allergan, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira Inc., Dr. Reddy’s Laboratories, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB Pharma, Valeant, XBiotech (no personal compensation); RGL: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, UCB Pharma, Valeant; FB, CA, MB: Employees of UCB Pharma; ML: Allergan, Aqua, LEO Pharma, Promius; Employee of Mount Sinai which received funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/AstraZeneca, Novartis, Pfizer, Valeant, Vidac; KR:
    keywords: czp; mg q2w; pharma; q2w; teaes; weeks
       cache: skin-995.pdf
  plain text: skin-995.txt

        item: #1354 of 1356
          id: skin-996
      author: Moore, Angela; Bruce, Suzanne; Sadick, Neil; Tschen, Eduardo; Werschler, Philip; Dhawan, Sunil; Farsha, Douglas; Gold, Michael; Guenthner, Scott; Kempers, Steve; Kircik, Leon; Parish, Jennifer; Rendon, Marta; Rich, Phoebe; Stein-Gold, Linda; Tyring, Stephen; Weiss, Robert; Nasir, Adnan; Schmitz, Carsten; Boodhoo, Terry; Kaoukhov, Alexandre; Berk, David; Cook-Bolden, Fran; Grada, Ayman
       title: Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials
        date: 2020-09-02
       words: 710
      flesch: 59
     summary: 3 WEEK 12 Vestibular, phototoxic, vulvovaginal candidiasis, and mycotic infections ≤1.1% in sarecycline treated patients. Truncal Acne: % of Patients with IGA success at WK 12 Slide Number 1
    keywords: sarecycline
       cache: skin-996.pdf
  plain text: skin-996.txt

        item: #1355 of 1356
          id: skin-997
      author: Pariser, David M; Green, Lawrence J; Lain, Edward L; Schmitz, Carsten; Chinigo, Amy S; McNames, Brian; Berk, David R; Hoffman, Jamison; Grada, Ayman
       title: Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris
        date: 2020-09-02
       words: 1303
      flesch: 48
     summary: Overall summary of patients with adverse events (safety population) • Sarecycline is a novel, narrow-spectrum, once-daily, oral tetracycline-class antibiotic indicated for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne1 • Poor tolerability and bacterial resistance concerns may limit the use of broad-spectrum tetracycline antibiotics for the treatment of acne1 Background • To evaluate the long-term safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study1 • Additionally, a Phase I, single-center, randomized, double-blind, placebo-controlled, crossover study conducted to evaluate the potential of sarecycline to cause phototoxicity1 Objective Open-label Safety Evaluation • Patients aged 9-years of age or older with moderate-to-severe acne who completed one of two prior Phase III, double-blind, placebo- controlled, 12-week trials in which they received sarecycline 1.5mg/kg/ day or placebo were included 1,2 • Primary assessment was the safety of sarecycline treatment over one year as measured by adverse events (AEs), vital signs, electrocardiograms (ECGs), clinical laboratory tests, and physical examinations Treatment periods were separated by at least nine days •
    keywords: patients; placebo; sarecycline; study; treatment
       cache: skin-997.pdf
  plain text: skin-997.txt

        item: #1356 of 1356
          id: skin-998
      author: Gold, Linda Stein; Del Rosso, James Q; Kircik, Leon; Bhatia, Neal D; Hooper, Deirdre; Nahm, Walter; Stuart, Iain
       title: Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea
        date: 2020-09-02
       words: 2618
      flesch: 47
     summary: Study 11 Randomized (N=751) Completed DB study (FMX103 1.5%) n=437 Completed DB study (Vehicle) n=232 Entered OL study n=140 (32%) Entered OL study n=77 (24%) Study 12 Randomized (N=771) Completed DB study (FMX103 1.5%) n=479 Completed DB study (Vehicle) n=239 Entered OL study n=192 (40%) Entered OL study n=95 (40%) Study design Week 52Baseline Key Inclusion Criteria for DB Study • Males and nonpregnant females ≥18 years • Moderate-to-severe facial papulopustular rosacea (IGA score of 3 or 4) • >15 to ≤75 facial papules and pustules, excluding lesions involving eyes and scalp; ≤2 nodules on the face • Presence or history of facial erythema or flushing Co-Primary Efficacy Endpoints • Absolute change in the inflammatory lesion count at Week 52 compared to DB baseline • IGA Success Rate (dichotomized as yes/no) at Week 52, where success was defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from DB baseline Secondary Efficacy Endpoints • The absolute and percent change from DB baseline in inflammatory lesion count at Weeks 16, 22, 28, 34, 40, 46, and 52 of the OL study • The dichotomized IGA Success Rate at Weeks 16, 22, 28, 34, 40, and 46 • The Subject Satisfaction Questionnaire (SSQ) at Week 52 Week 12 FMX103 1.5% (505 enrolled, 504 in safety population, 410 completed) Double-blind, vehicle-controlled (N=1522) Open-Label (FX2016-13) for subjects who completed the DB study Visit every 6 weeks Vehicle Foam (n=256) FMX103 1.5% (n=495) Vehicle Foam (n=257) FMX103 1.5% (n=514) S tu dy 1 1 S tu dy 1 2 IGA, Investigator’s Global Assessment; DB, double-blind study; OL, open-label study; OTC, over-the-counter. Results Subject Disposition and Double-Blind Baseline Demographics • As shown in Figure 2, 504 subjects who completed the DB study (Study 11: N=217; Study 12: N=287) comprised the All Treated (Safety) population in the OL extension study (Study 13) Figure 2.
    keywords: fmx103; rosacea; study; subjects; treatment; vehicle; week
       cache: skin-998.pdf
  plain text: skin-998.txt